

Program and Information

CROI 2017

Conference on Retroviruses
and Opportunistic Infections



SEATTLE, WASHINGTON
February 13-16, 2017

CONTENTS

CROI FOUNDATION	2
IAS–USA	2
CROI 2017 PROGRAM COMMITTEE	3
Scientific Program Committee	3
Community Liaison Subcommittee	5
EXTERNAL REVIEWERS	6
SCHOLARSHIP AWARDEES	8
Young Investigator Awardees	8
International Investigator Awardees	13
Community Educator Awardees	13
CONTINUING MEDICAL EDUCATION	15
GENERAL INFORMATION	17
Overview	17
Americans With Disabilities Act	17
Commercial Support	17
Emergency Services	17
Embargo Policies and Social Media	18
Welcome Reception	18
Meals	18
Overflow Accommodations for Oral Sessions	19
USB Flash Drive	19
Mobile App	19
Website	19
Webcasts	20
Affiliated Activities Policy	20
Wi-Fi Access at the Conference	20
Conference Badges	20
Child Care	21
Conference Etiquette	21
CROI HOTELS	21
CONFERENCE SERVICES	22
ABSTRACT PROCESS	26
ORAL SESSIONS (including Preconference Sessions)	28
POSTER SESSIONS, BY DAY	73
POSTER SESSIONS, BY CATEGORY	212
DISCLOSURE OF FINANCIAL RELATIONSHIPS WITH COMMERCIAL CONCERNS	216
INDEX OF STUDIES RELATED TO RESEARCH IN WOMEN	227
AUTHOR INDEX	232
CONFERENCE SCHEDULE OVERVIEW	INSIDE BACK COVER
CONVENTION CENTER FLOOR PLANS	BACK COVER
AREA MAP	BACK COVER

CROI FOUNDATION

The CROI Foundation operates exclusively for the charitable and educational purpose of organizing, promoting, and presenting the Conference on Retroviruses and Opportunistic Infections (CROI).

Roles and Responsibilities of the CROI Foundation Volunteer Board of Directors

- Works closely with the CROI Scientific Program Committee (CROI PC) and the CROI Secretariat to accomplish the mission of CROI
- Approves nominations for members of the CROI PC and the CROI PC Chair and Vice Chairs
- Ensures that the CROI PC is responsible for the scientific program content of CROI
- Enters into and oversees the partner agreement with the CROI Secretariat
- Has the sole and absolute discretion to veto any policies, procedures, or actions taken or proposed to be taken by the CROI PC or the CROI Secretariat that would pose a substantial risk of preventing the Foundation at any time from qualifying or continuing to qualify as a 501(c)(3) organization or that might cause the loss of such qualification
- Oversees the long-term financial and administrative integrity of CROI

CROI Foundation Board of Directors

Constance A. Benson, MD

President

University of California San Diego
San Diego, CA, United States

John M. Coffin, PhD

Secretary-Treasurer

Tufts University
Boston, MA, United States

Elaine J. Abrams, MD

ICAP at Columbia University
New York, NY, United States

Susan P. Buchbinder, MD

San Francisco Department
of Public Health
San Francisco, CA, United States

Judith S. Currier, MD, MSc

University of California Los Angeles
Los Angeles, CA, United States

Kevin M. De Cock, MD

Centers for Disease Control and Prevention
Nairobi, Kenya

Scott M. Hammer, MD

Columbia University Medical Center/
New York—Presbyterian Hospital
New York, NY, United States

Richard A. Koup, MD

Vaccine Research Center, National
Institute of Allergy and
Infectious Diseases

National Institutes of Health
Bethesda, MD, United States

John W. Mellors, MD

University of Pittsburgh
Pittsburgh, PA, United States

Julie M. Overbaugh, PhD

Fred Hutchinson Cancer Research Center
Seattle, WA, United States

Robert T. Schooley, MD

University of California San Diego
La Jolla, CA, United States

IAS—USA

The International Antiviral Society—USA is a 501(c)(3) not-for-profit professional education organization. The IAS—USA partners with the CROI Foundation to organize CROI. The mission of the IAS—USA is to improve the prevention, treatment, care, and quality of life for people with or at risk of HIV, hepatitis C virus, or other viral infections through high-quality, relevant, balanced, and needs-oriented education and information for practitioners and scientists who are actively involved in medical care and research.

Executive Director: Donna M. Jacobsen

Address: 425 California Street, Suite 1450

San Francisco, CA 94104-2120

Phone: 415-544-9400

Website: www.iasusa.org



CROI 2017 PROGRAM COMMITTEE

The Scientific Program Committee (PC) is a team of experts in their given field who volunteer to organize the scientific program for CROI. Members are selected based on their area of scientific expertise and their commitment to the mission of the conference. Initial terms are up to 3 years; subsequent terms are based on previous participation and interest level. Members are nominated by the PC and approved by the CROI Foundation Board of Directors. The PC members are responsible for identifying topics and speakers that will ensure innovative programming; strategic planning; abstract review and program development; or organizing, conducting, or convening workshops, symposia, and special sessions.

Scientific Program Committee



Susan P. Buchbinder, MD
CROI 2017 Chair
San Francisco Department
of Public Health
San Francisco, CA
United States



Judith S. Currier, MD, MSc
CROI 2017 Vice Chair
University of California
Los Angeles
Los Angeles, CA
United States



Richard A. Koup, MD
CROI 2017 Vice Chair
Vaccine Research Center
National Institute of Allergy and Infectious Diseases
National Institutes of Health
Bethesda, MD, United States



Elaine J. Abrams, MD
ICAP at Columbia University
New York, NY, United States



Connie L. Celum, MD, MPH*
University of Washington
Seattle, WA, United States



Adaora Adimora, MD*
University of North Carolina
at Chapel Hill
Chapel Hill, NC, United States



Richard E. Chaisson, MD
The Johns Hopkins University
Baltimore, MD, United States



Galit Alter, PhD
Ragon Institute of MGH, MIT
and Harvard
Cambridge, MA
United States



Nicolas Chomont, PhD*
Université de Montréal
Montreal, Canada



Constance A. Benson, MD
University of California
San Diego
San Diego, CA, United States



John M. Coffin, PhD
Tufts University
Boston, MA, United States



Paul Bieniasz, PhD*
The Rockefeller University
New York, NY, United States



Kevin M. De Cock, MD
Centers for Disease Control
and Prevention
Nairobi, Kenya



Wafaa M. El-Sadr, MD, MPH
ICAP at Columbia University
New York, NY, United States



Joseph J. Eron, Jr, MD*
University of North Carolina
at Chapel Hill
Chapel Hill, NC, United States



Courtney V. Fletcher, PharmD
University of Nebraska
Medical Center
Omaha, NE, United States



Huldrych F. Günthard, MD
University Hospital Zurich
Zurich, Switzerland



Timothy Hallett, PhD
Imperial College London
London, United Kingdom



Scott M. Hammer, MD
Columbia University Medical
Center/New York-
Presbyterian Hospital
New York, NY, United States



Diane V. Havlir, MD
University of California
San Francisco
San Francisco, CA
United States



Sharon L. Hillier, PhD
Magee-Womens Hospital
University of Pittsburgh
Medical Center
Pittsburgh, PA, United States



James A. Hoxie, MD
University of Pennsylvania
Philadelphia, PA
United States



Peter W. Hunt, MD
University of California
San Francisco
San Francisco, CA
United States



Harold W. Jaffe, MD
Centers for Disease Control
and Prevention (retired)
Atlanta, GA, United States



Ilesh V. Jani, MD, PhD
Instituto Nacional de Saude
Maputo, Mozambique



Frank Kirchhoff, PhD
Ulm University
Medical Center
Ulm, Germany



Dennis L. Kolson, MD, PhD
University of Pennsylvania
Philadelphia, PA
United States



Hermione Lyall, MD
Imperial College Healthcare
National Health
Service Trust
London, United Kingdom



James A. McIntyre, MBChB, FRCOG
Anova Health Institute
Johannesburg, South Africa



John W. Mellors, MD
University of Pittsburgh
Pittsburgh, PA, United States



Ronald T. Mitsuyasu, MD
University of California
Los Angeles
Los Angeles, CA
United States



Nelly R. Mugo, MBChB, MPH*
Kenya Medical
Research Institute
Nairobi, Kenya



Landon Myer, MD, PhD*
University of Cape Town
Cape Town, South Africa



Julie M. Overbaugh, PhD
Fred Hutchinson Cancer
Research Center
Seattle, WA, United States



Andrew N. Phillips, PhD
University College London
London, United Kingdom



Peter Reiss, MD, PhD
Amsterdam Institute
for Global Health
and Development
Amsterdam, Netherlands



Annette H. Sohn, MD*
TREAT Asia
Bangkok, Thailand



Douglas D. Richman, MD
University of California
San Diego; Veterans Affairs
San Diego Healthcare
System
San Diego, CA, United States



Serena S. Spudich, MD, MA
Yale University
New Haven, CT, United States



Jürgen K. Rockstroh, MD
University of Bonn
Bonn, Germany



Wesley I. Sundquist, PhD
University of Utah
Salt Lake City, UT,
United States



Robert T. Schooley, MD
University of California
San Diego
La Jolla, CA, United States



David L. Thomas, MD
The Johns Hopkins University
Baltimore, MD, United States



Guido Silvestri, MD
Emory University
Atlanta, GA, United States



Alexandra Trkola, PhD
University of Zurich
Zurich, Switzerland

Community Liaison Subcommittee

The Community Liaison Subcommittee is a group of community educators and advocates that provides feedback to the PC about the content and structure of the scientific program in general and specifically related to scientific topics of interest to the HIV/AIDS-affected community.



Mark Hubbard
Tennessee Association of
People With AIDS
Nashville, TN, United States



**Morenike Ukpog, FWACS,
MBA, BChD**
Obafemi Awolowo University
Ile-Ife, Nigeria



Jeff Taylor
Committee Lead
AIDS Treatment
Activists Coalition
Palm Springs, CA
United States



Lisa Diane White, MPH*
SisterLove, Inc.
Atlanta, GA, United States

*Joined the Scientific Program Committee or Community Liaison Subcommittee in 2016

The CROI Foundation wishes to thank for their service the following individuals who rotated off the Scientific Program Committee in 2016: Bruce J. Brew, Ellen G. Chadwick, Mario Stevenson, and Amalio Telenti; and from the Community Liaison Subcommittee: Steven F. Wakefield.

EXTERNAL REVIEWERS

We gratefully acknowledge the contributions of the following, who served as volunteer external reviewers of abstracts for CROI 2017.

Edward P. Acosta, PharmD

University of Alabama at Birmingham
Birmingham, AL, United States

Peter L. Anderson, PharmD

University of Colorado
Aurora, CO, United States

Till Baernighausen, MD, PhD, ScD, MSc

Institute of Public Health,
Heidelberg University
Heidelberg, Germany

John M. Blandford, PhD

Centers for Disease Control
and Prevention
Atlanta, GA, United States

Marta Boffito, MD, PhD

Chelsea and Westminster NHS
Foundation Trust
London, United Kingdom

Jacob Bor, PhD

Boston University
Boston, MA, United States

William Borkowsky, MD

New York University
New York, NY, United States

Bruce J. Brew, MD, MBBS

University of New South Wales
Sydney, Australia

Todd T. Brown, MD, PhD

The Johns Hopkins University
Baltimore, MD, United States

Corey Casper, MD

Fred Hutchinson Cancer Research Center
Seattle, WA, United States

Ellen G. Chadwick, MD

Ann & Robert H. Lurie Children's Hospital
of Chicago
Chicago, IL, United States

David B. Clifford, MD

Washington University
St. Louis, MO, United States

David Evans, PhD

University of Wisconsin Madison
Madison, WI, United States

Charles W. Flexner, MD

The Johns Hopkins University
Baltimore, MD, United States

Patricia M. Flynn, MD

St. Jude Children's Research Hospital
Memphis, TN, United States

Jennifer Furin, MD, PhD

Case Western Reserve University
Cleveland, OH, United States

Dana H. Gabuzda, MD

Dana Farber Cancer Institute,
Harvard Medical School
Boston, MA, United States

Monica Gandhi, MD, MPH

University of California San Francisco
San Francisco, CA, United States

Gerardo Garcia-Lerma, PhD

Centers for Disease Control
and Prevention
Atlanta, GA, United States

Carlo Giaquinto, MD

University of Padova
Padova, Italy

Beatrice H. Hahn, MD

University of Pennsylvania
Philadelphia, PA, United States

James G. Hakim, MD

University of Zimbabwe
Harare, Zimbabwe

P. Richard Harrigan, MD

British Columbia Centre for Excellence
in HIV/AIDS
Vancouver, Canada

Priscilla Hsue, MD

University of California San Francisco
San Francisco, CA, United States

Angela Kashuba, PharmD

University of North Carolina
at Chapel Hill
Chapel Hill, NC, United States

Susan E. Krown, MD

AIDS Malignancy Consortium
New York, NY, United States

Raphael J. Landovitz, MD

University of California Los Angeles
Los Angeles, CA, United States

Bruno Ledergerber, PhD

University of Zurich
Zurich, Switzerland

Scott L. Letendre, MD

University of California San Diego
San Diego, CA, United States

Sharon R. Lewin, MD

University of Melbourne
Melbourne, Australia

Annie F. Luetkemeyer, MD

University of California San Francisco
San Francisco, CA, United States

Patrick W. G. Mallon, PhD, MBBS

University College Dublin
Dublin, Ireland

Natasha Martin, DPhil

University of California San Diego
San Diego, CA, United States

Grace A. McComsey, MD

Case Western Reserve University
Cleveland, OH, United States

Jonathan Mermin, MD, MPH

Centers for Disease Control
and Prevention
Atlanta, GA, United States

Victor Musiime, PhD, MBChB

Makerere University College of
Health Sciences
Kampala, Uganda

Susanna Naggie, MD, MHS

Duke University
Durham, NC, United States

Jean-Michel Pawlotsky, MD, PhD

Henri Mondor University Hospital
Creteil, France

Martina Penazzato, MD, PhD

World Health Organization
Geneva, Switzerland

Paul Revill, MSc

University of York
York, United Kingdom

Lesley Scott, MD

National Health Laboratory Service
Johannesburg, South Africa

Kenneth E. Sherman, MD

University of Cincinnati
Cincinnati, OH, United States

James H. Stein, MD

University of Wisconsin
Madison, WI, United States

Mario Stevenson, PhD

University of Miami
Miami, FL, United States

Amalio Telenti, MD, PhD

J. Craig Ventner Institute
La Jolla, CA, United States

Timothy Wilkin, MD

Weill Cornell Medicine
New York, NY, United States

David L. Wyles, MD

Denver Health, University of Colorado
Denver, CO, United States

Robert Yarchoan, MD

National Cancer Institute
Bethesda, MD, United States

Clement Zeh, PhD, MPH

Centers for Disease Control
and Prevention
Atlanta, GA, United States

SCHOLARSHIP AWARDEES

CROI is committed to supporting young and early career investigators working in HIV research to help them further their education and to network with other researchers in the field. Young Investigator Scholarship awardees are presenting authors on accepted abstracts and have been highly recommended by their mentors.

In addition, CROI offers scholarships to international researchers and community educators working in resource-limited countries who would otherwise be unable to attend CROI. Through their applications and letters of recommendation, these awardees have shown that they will greatly benefit from the opportunity to participate in CROI.

Young Investigator Awardees

Hadega Aamer

Seattle Children's Research Institute

Hosiana Abewe

University of California San Diego

Rana Abutaima

University of Liverpool

Emily Adland

The University of Oxford

Erika Ahlgren

Sahlgrenska Academy
University of Gothenburg

Giuseppe Ancona

University of Milan

Nisha Andany

Women's College Research Institute

Elizabeth M. Anderson

National Cancer Institute

Suvaporn Anugulruengkitt

Chulalongkorn University

Marília L. Araújo

Universidade de São Paulo

Nadine Bachmann

University Hospital Zurich

Anani D. Badje

l'Institut National de la
Santé et de la Recherche Médicale

Francesca Bai

University of Milan

Samuel Bailin

Vanderbilt University Medical Center

Kayode Balogun

University Health Network

Riddhima Banga

Centre Hospitalier Universitaire Vaudois

Ariola Bardhi

Albert Einstein College of Medicine

Joshua A. Barocas

Massachusetts General Hospital

Lisa Bebell

Massachusetts General Hospital

Angela Bengtson

University of North Carolina
at Chapel Hill

Priya Bhagwat

University of California Los Angeles

Elisa Biliotti

Sapienza University of Rome

Anne Boerekamps

Erasmus University Medical Center

Pauline Bollen

Radboud University Medical Center

Michal Bonar

Case Western Reserve University

Kobus Bosman

University Medical Center Utrecht

Giorgio Bozzi

National Institutes of Health

Kirsty Brittain

University of Cape Town

Jordan Broekhuis

University of Nebraska Medical Center

Kristina M. Brooks

Clinical Center
National Institutes of Health

Maria C. Brühl

Sahlgrenska University Hospital

Marcus Buggert

University of Pennsylvania

Supanee Buranapraditkun

Chulalongkorn University

Zahid A. Butt

University of British Columbia

Valentina Cambiano

University College London

Elvira S. Cannizzo

University of Milan

Adam Capoferri

The Johns Hopkins University

Itziar Carrasco GarciaPuerta de Hierro Research Institute and
University Hospital**Heather Carryl**

Howard University

Valeria Cento

University of Rome Tor Vergata

Antoine Chaillon

University of California San Diego

Austin W. H. Chan

Duke University

Phillip Chan

SEARCH

The Thai Red Cross AIDS Research Center

Johanna Chapin-Bardales

Emory University

Glen Chew

University of Hawaii

Meredith Clement

Duke University Medical Center

Lauren F. Collins

Duke University

Sarah Dabydeen

University of California San Diego

Raghubendra S. Dagur

University of Nebraska Medical Center

Jennifer M. Dan

University of California San Diego

Michelle L. D'Antoni

University of Hawaii

Mirela D'arc

Universidade Federal do Rio de Janeiro

Thibaut DavyUniversity of North Carolina
at Chapel Hill**Lesley R. de Armas**

University of Miami

Davide De Francesco

University College London

Carolina De La FlorUniversity of Texas Southwestern
Medical Center**Heloise M. Delagreverie**

Hôpital Saint Louis

Anne Derache

Africa Health Research Institute

Belete A. Desimmie

National Cancer Institute

Amy K. Dickey

Massachusetts General Hospital

Maartje Dijkstra

Public Health Service Amsterdam

Adam Dingens

Fred Hutchinson Cancer Research Center

Horacio A. Duarte

University of Washington

Vanessa El Kamari

Case Western Reserve University

Ceri Evans

Queen Mary University of London

Michelli Faria de Oliveira

University of California San Diego

Carolina Fernández McPhee

Instituto de Investigación Sanitaria

Gregorio Marañón

University Hospital Gregorio Marañón

Nina C. Flerin

Albert Einstein College of Medicine

J. Morgan Freiman

Boston Medical Center

Pierre Gantner

Hôpitaux Universitaires de Strasbourg

Erin I. Garcia

University of Washington

Claudia García-Morales

National Institute of

Respiratory Diseases

Esther Gathogo

King's College London

Alexander J. Gill

University of Pennsylvania

Leila B. Giron

Federal University of Sao Paulo

Aleksandr Gorin

University of California Los Angeles

Louise Greathead

Imperial College London

Sharon A. Greene

University of Washington

Diane Gu

University of California Los Angeles

Akshay Gupta

The Johns Hopkins University

Ahmad Haeri Mazanderani

National Institute for

Communicable Diseases

Gustaf O. Hammarlund

Sahlgrenska Academy

University of Gothenburg

Nathan Hanan

University of California San Diego

Said Hassounah

Lady Davis Institute, McGill AIDS Centre

Jason M. Hataye

National Institutes of Health

Tiffany Hensley-McBain

University of Washington

Lucas E. Hermans

University Medical Center Utrecht

Sabine HermansAmsterdam Institute for Global Health
and Development**Linn Hermansson**Sahlgrenska Academy
University of Gothenburg**Raul Ulises Hernandez-Ramirez**

Yale University

Bonnie HienerThe Westmead Institute for
Medical Research**Simone H. Hijlkema**

Erasmus University Medical Center

Akarin HiransuthikulHIV-NAT, The Thai Red Cross AIDS
Research Centre**Admire Hlupeni**

University of Zimbabwe

Martin Hoenig

University of California San Diego

Malon Van den Hof

Academic Medical Center

Elske Hoornenborg

Public Health Service Amsterdam

Szuhan Huang

George Washington University

Brandon M. Imp

Robert Wood Johnson Medical School

Sergio Ita

University of California San Diego

Watsamon Jantarabenjakul

Chulalongkorn University

Mathew L. Jones

University of Oxford

Claus Kadelka

University of Zurich

Mariah M. Kalmin

The George Washington University

Justin A. Kaplan

National Cancer Institute

Samantha Kaplan

Yale University

Harpreet Kaur

Cleveland Clinic Foundation

Christine Kelly

University College Dublin

Jérôme Kervevanl'Institut National de la
Santé et de la Recherche Médicale**Moliehi Khaketla**

University of British Columbia

Zahra Kiani

McGill University

Ditte M. Kirkegaard-Klitbo

Hvidovre Hospital

Astrid R. Krarup

Aarhus University Hospital

Stefanie KroezeAmsterdam Institute for Global Health
and Development**Steven Lada**

University of California San Diego

Camille Lange

National Institutes of Health

Leah T. Le

Yale University

Lorna Leal

Hospital Clinic de Barcelona

Guinevere Q. Lee

Ragon Institute of MGH, MIT and Harvard

Louise LeyreUniversity of Montreal Hospital
Research Centre**Andrea Lisco**

National Institutes of Health

Yang Liu

National Cancer Institute

Sarah Lofgren

University of Minnesota

Claire Loiseaul'Institut National de la
Santé et de la Recherche Médicale**Francesca Lombardi**

Catholic University of Sacred Heart

Briana Lynch

National Institutes of Health

Christine E. MacBrayne

University of Colorado

João I. Mamede

Northwestern University

Maura ManionNational Institute of Allergy and
Infectious Diseases**Madeleine C. P. Mankowski**

The Johns Hopkins University

Jennifer Manne-Goehler

Beth Israel Deaconess Medical Center

Alyssa R. Martin

The Johns Hopkins University

Enrique Martin-GayoRagon Institute of MGH, MIT
and Harvard**Tafireyi Marukutira**

Macfarlane Burnet Institute

Michela Masetti

University of Milan

Aviva Mattingly

National Institutes of Health

Rodrigo Matus NicodemusVaccine Research Center
National Institute of Allergy and
Infectious Diseases
National Institutes of Health**Allison M. McFall**

The Johns Hopkins University

Vanessa McMahan

University of Washington

Luz M. Medrano

Institute of Health Carlos III

Natasha Mehta

University of California San Francisco

Caroline MelhadoUniversity of North Carolina at
Chapel Hill**Esther Merlini**

University of Milan

Kate Michel

Georgetown University

Brooks I. Mitchell

University of Hawaii

Julie Mitchell

US Military HIV Research Program

Aaloke Mody

University of California San Francisco

Michalina A. Montano

University of Washington

Rocio Montejano

Hospital Universitario La Paz

Caitlin A. Moran

Emory University

Sara Moron-Lopez

IrsiCaixa

Sikhulile MoyoBotswana Harvard AIDS
Institute Partnership**Andrew Musick**

National Cancer Institute

Shalena Naidoo

Stellenbosch University

Megan Neary

University of Liverpool

Anne M. Neilan

Massachusetts General Hospital

Kristin N. Nelson

Emory University

Mariia Novikova

National Cancer Institute

Piotr Nowak

Karolinska Institute

Jane A. O'Halloran

University College Dublin

Oluwasolape M. Olawore

The Johns Hopkins University

Lorenzo Onorato

Second University of Naples

Edmund Osei-Kuffour

Heinrich-Heine-University Hospital

Laurence Palk

University of California Los Angeles

Nandagopal PaneerselvamYR Gaitonde Center for AIDS Research
and Education**Nivedha Panneer**Centers for Disease Control
and Prevention**Alexander Pasternak**

Academic Medical Center

Chansavath Phetsouphanh

University of Oxford

Tamsin Phillips

University of Cape Town

Jillian Pintye

University of Washington

Marilia R. Pinzone

University of Pennsylvania

Timothy Plitnik

University of Miami

Joan T. PriceUniversity of North Carolina
at Chapel Hill**Christina Psomas**

University Hospital of Montpellier

Maria Pujantell

IrsiCaixa

Sarah Rasmussen

The Johns Hopkins University

Ludy Registre

Boston University School of Medicine

Michael J. A. Reid

University of California San Francisco

Lindsey Reif

Columbia University

Chiara Resnati

University of Milan

Lara Rheinemann

University of Utah

Owain Roberts

University of Liverpool

Cristina Rodriguez-Hart

The Johns Hopkins University

Anna Joy Rogers

University of Alabama at Birmingham

Julia K. Rohr

Harvard University

Casper Rokx

Erasmus University Medical Center

Charlotte-Paige M. Rolle
Emory University

Miriam Rosas Umbert
IrsiCaixa

Jonathan Ross
Montefiore Medical Center
Albert Einstein College of Medicine

Kathryn Rough
Harvard University

Sahar Saeed
McGill University

Kate Salters
Simon Fraser University

Ryan Sanford
Montreal Neurological Institute

Antonella Santoro
University of Modena and Reggio Emilia

Luca Sardo
University of the Sciences

Elisabeth Schaffer
University of North Carolina
at Chapel Hill

Stein Schalkwijk
Radboud University Medical Center

Gundolf Schuettfort
University Hospital Frankfurt

Jordan A. Schwartz
University of Toronto

Sergio Serrano-Villar
Hospital Universitario Ramón y Cajal

Monisha Sharma
University of Washington

Katie Sharp
University of California Los Angeles

Leah Shepherd
University College London

Rupak Shivakoti
The Johns Hopkins University

Francesco R. Simonetti
The Johns Hopkins University

Mariya V. Sivay
The Johns Hopkins University

Robert S. Smith
Washington University in St. Louis

Victoria P. Strouvelle
University of Zurich

Hang Su
University of Nebraska Medical Center

Diya Surie
University of Washington

Andrew Timmons
The Johns Hopkins Hospital

Jessie Torgersen
University of Pennsylvania

Matthew Triplette
University of Washington

Mattia Trunfio
University of Torino

Rachel Van Duyn
National Cancer Institute

Clara E. Van Ommen
University of British Columbia

Rosan van Zoest
Amsterdam Institute for Global Health
and Development

Rebecca Veenhuis
The Johns Hopkins University

Jennifer Velloza
University of Washington

Vinicius A. Vieira
University of São Paulo

Victor Virlogeux
l'Institut National de la
Santé et de la Recherche Médicale

Thomas Vollbrecht
Veterans Medical Research Foundation

Alinda Vos
University Medical Center Utrecht

Elizabeth Wahome
KEMRI Wellcome Trust

Tomas Raul Wiche Salinas
Hospital Research Centre
University of Montreal

Ingeborg Wijting
Erasmus University Medical Center

Anni Winckelmann
Aarhus University Hospital

Joanne R. Winter
University College London

Chun-Shu Wong
National Institutes of Health

Emily Woolnough
Alfred Hospital

Vincent Wu
University of Washington

Guangai Xue
National Cancer Institute

Jingyan Yang
Columbia University

Gonzalo Yebra
University of Edinburgh

Zhe Yuan
University of Nebraska-Lincoln

Brian C. Zanoni
Massachusetts General Hospital

Jennifer M. Zerbato
University of Pittsburgh

Alexander S. Zevin
University of Washington

Tian Zhou
University of Nebraska Medical Center

Jason Zucker
Columbia University Medical Center

International Investigator Awardees

Andrew M. Abaasa
MRC/UVRI Uganda
Research Unit on AIDS

Gbolahan Ajibola
Botswana Harvard AIDS Research
Institute Partnership

Stable Besa
Zambart

Sergio M. de Almeida
Universidade Federal do Paraná

Paolo Denti
University of Cape Town

Kostyantyn Dumchev
Ukrainian Institute on
Public Health Policy

Trupti I. Gilada
Unison Medicare and Research Center

Ashraf Grimwood
Kheth'Impilo

Cheryl J. Hendrickson
University of the Witwatersrand

Arvind Kaimal
Infectious Diseases Institute

Atupele P. Kapito-Tembo
University of Malawi College of Medicine

Margaret P. Kasaro
University of North Carolina

Agnes Kiragga
Makerere University

Zachary A. Kwen
Kenya Medical Research Institute

Kwana Lechiile
Botswana-UPenn Partnership
University of Pennsylvania

Tshepo B. Leeme
Botswana-UPenn Partnership
University of Pennsylvania

Maia Lesosky
University of Cape Town

Sekai C. Mathabire
Epicentre

Lydia Nakiyingi
Infectious Diseases Institute

Mastula Nanfuka
The Support Organisation

McNeil Ngongondo
University of North Carolina
Project-Malawi

Thanh T. Nguyen
Oxford University

Thu T. M. Nguyen
Oxford University

Harriet Nuwagaba-Biribonwoha
ICAP at Columbia University

Moussa Seydi
Centre Hospitalier Universitaire de Fann

Tavitiya Sudjaritruk
Chiang Mai University

Gaëlle F. Tchouwa
Virology Laboratory IMPM-IRD, Centre
de Recherche Sur les Maladies
Emergentes et Reemergentes

Community Educator Awardees

Giorgio Barbareschi
European AIDS Treatment Group

Tamás Bereczky
European AIDS Treatment Group

Aisuluu Bolotbaeva
Central Asian HIV Foundation

Giulio M. Corbelli
AVAC

Michael Dorosh
Treatment Education Network

Florita C. Durueke
New HIV Vaccine and Microbicides
Advocacy Society

Angel L. Hernández
University of Puerto Rico

Andrew H. Kaytes
Christie's Place

Tapiwanashe Kujinga
Pan-African Treatment Access Movement

Michael Meulbroek
Asociación para el Trasplante de Organos
a Seropositivos

Kennedy Mupeli
Centre for Youth of Hope

Lillian K. Mworeko
Makerere University Kampala

Robert Newells

AIDS Project of the East Bay

Adeolu O. Ogunrombi

University of Liverpool

Godfrey O. Okumu

Impact Research and
Development Organization

Simon O. Ondiek

Nyanza Reproductive Health Society

David A. Palm

University of North Carolina
at Chapel Hill

Julia M. Patterson

University Hospital AIDS Clinical
Research Site
Case Western Reserve University

Elias Phiri

Addington Afro Ethnic Health
Promotion Group

Ferran Pujol Roca

Projecte dels NOMS-Hispanosida

Jorge Saz Berges

Joves Positius

Cissy Ssuuna

Children's Foundation
Baylor College of Medicine

Moses N. Supercharger

Joint Clinical Research Centre

Manuel A. Venegas

University of Washington

Ntando Yola

Desmond Tutu HIV Foundation

CONTINUING MEDICAL EDUCATION

Accreditation Statement

The International Antiviral Society—USA (IAS—USA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The IAS—USA designates this live activity for a maximum of **17.25 AMA PRA Category 1 Credits™**. Physicians should claim only the credit commensurate with the extent of their participation in the activity.



Objectives

After participating in CROI, learners will be able to:

- Describe results of basic science research on HIV transmission and infection and advances toward a cure
- List the most recent findings from trials related to the clinical aspects of HIV infection and its complications, including relevant coinfections and comorbidities, and implications of these data for treatment strategies
- Describe current epidemiologic data on the prevalence of HIV infection and the biobehavioral approaches to prevention

Statement of Need

Since HIV was identified, the scientific response to the global pandemic has been a coordinated effort among basic researchers, clinical investigators, health care providers, epidemiologists, and community leaders to move information and potential treatment options from research to clinical trials and out to affected communities as quickly as possible. CROI was founded in 1993 by researchers working in the field of HIV/AIDS and its complications, as a science-focused forum for exchanging current research findings among their international peers. CROI continues to focus on scientific exchange, providing an environment in which basic science researchers, translational researchers, clinical investigators, epidemiologists, and public health experts meet to present and discuss the latest research into different facets of HIV and its complications, as well as selected other emerging infections.

CME Credit Information

Physicians (MD, DO, and international equivalents) are eligible to receive CME credit for participation in CROI. CME credits can be claimed for plenary lectures, symposia, opening session lectures, and special sessions. CME credits cannot be claimed for oral abstract sessions, themed discussion sessions, or poster sessions. For physician attendees whose certificate is through the American Board of Internal Medicine (ABIM), Maintenance of Certification (MOC) points are available for participation in CROI. Other researchers, practitioners, and clinicians can receive a Certificate of Participation verifying their attendance, as required by the American Medical Association (AMA).

ABIM MOC Points



Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to **17.25** MOC points in the American Board of Internal Medicine (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Claiming CME Credits, ABIM MOC Points, or a Certificate of Participation

During the conference, daily evaluations will be e-mailed to all CROI participants to the e-mail account **used to register for the conference**. On the final day of the conference, all CROI participants will receive a final e-mail that will contain their registration confirmation number and a link to the overall CROI evaluation. In addition, a secure web page has been created on the CROI website. The links to the daily and final evaluation can be found at www.croiconference.org/electronic-materials. You will need your email address and registration ID to access this page. To obtain CME credits, ABIM MOC points, or a Certificate of Participation for CROI, this final evaluation must be completed by March 31, 2017. Once the evaluation is submitted, participants will receive the link to claim and print their certificate.

To determine the number of CME credits, ABIM MOC points, or hours of participation that can be claimed, calculate time spent attending the conference, including opening and plenary lectures, workshops, and symposia. For example, if you attended 2 plenary talks (8:30 AM to 9:30 AM), and a symposium (4:00 PM to 6:00 PM), you would have a total of 3 hours to apply toward CME credits or ABIM MOC points (if applicable) for that day. At the end of CROI, please add the total hours you attended for your certificate. You may claim a maximum of **17.25 AMA PRA Category 1 Credits™** and **17.25** ABIM MOC points for this activity.

ABIM MOC points will only be awarded after the successful completion of the evaluation component demonstrating knowledge gained at all meetings through a series of multiple choice questions. ABIM MOC points are intended for internal medicine physicians, in the United States, who are maintaining their ABIM Board Certification.

A CME/ABIM MOC hour worksheet can be found at www.croiconference.org/sites/default/files/uploads/croi2017-cmeworksheet.pdf

Disclosure of Financial Relationships

It is the policy of the IAS—USA to ensure balance, independence, objectivity, and scientific rigor in all its educational activities. All faculty members (speakers, presenters, etc) participating in IAS—USA-sponsored activities are required to disclose to the program audience any financial interests within the past 12 months that could be perceived to influence, or give the appearance of potentially influencing, the written or oral presentation. (The ACCME defines a financial interest as an interest in any amount.) The information is intended to make the IAS—USA audience aware of author and contributor interests and commitments with commercial companies or other entities, enabling the audience members to form their own judgments about such associations.

Each author or contributor is required to complete this financial disclosure declaration. In accordance with IAS—USA policy, the IAS—USA will identify and resolve ahead of time any possible conflicts of interest that may influence CME activities with regard to exposition or conclusion. Disclosure information will be included with the Program and Abstracts eBook on the web.

Drug and Product Disclaimer

This activity may contain information about the investigational uses of drugs or products that are not approved by the US Food and Drug Administration. Please consult full prescribing information before using any medication or product mentioned in this activity.

GENERAL INFORMATION

Overview

CROI was established in 1993 to provide a forum for basic scientists and clinical investigators to present, discuss, and critique their investigations into the epidemiology and biology of human retroviruses and associated diseases. The synergy of basic science and clinical investigation has been a major contributor to the success of the meeting. CROI is the preeminent HIV research meeting in the world and includes up to 4000 HIV research and care leaders internationally. The goal of the conference is to help researchers translate their laboratory and clinical findings into tangible progress against the HIV pandemic. CROI has facilitated the presentation of important discoveries in the field, thereby accelerating progress in HIV and AIDS research.

Americans With Disabilities Act

CROI endeavors to comply fully with the legal requirements of the Americans With Disabilities Act (ADA). If you require assistance on-site, please visit the Seattle Visitor Center and Concierge Services in the Upper Pike Street Lobby during the conference.

Commercial Support

CROI is largely supported by participant registration fees. Please note, CROI registration fees cover all attendee meals (including the welcome reception) and travel expenses for selected invited participants (eg, speakers, leaders, moderators, and CROI PC), as well as selected meeting materials and other conference expenses.

In addition, CROI seeks grants from commercial companies, particularly from companies with competing products. These companies have no input in or control over the selection of faculty or content of the presentations. Commercial support is used to cover some of the costs of the convention center, audiovisual services, and other conference services.

CROI 2017 received grant support commitments from the following commercial companies:

PLATINUM SUPPORTERS

Merck

ViiV Healthcare

GOLD SUPPORTERS

Bristol-Myers Squibb

Gilead Sciences, Inc

Janssen Therapeutics

SILVER SUPPORTER

AbbVie

Emergency Services

In the event of a medical emergency, please contact Security Control immediately. You may contact Security Control by dialing 5127 from any house phone located in the Washington State Convention Center (WSCC). In addition, there are red “hot line” phones located around the WSCC. These phones ring directly into the Security Control office.

IAS—USA staff or any uniformed WSCC personnel with a 2-way radio can also assist you in an emergency. Contacting Security Control will greatly **minimize** response time in the event an emergency medical unit needs to report to the WSCC. Security personnel can quickly assess the situation and bring emergency personnel directly to the individual in need. For this reason, WSCC requests that our clients and guests NOT contact 911 directly.

Embargo Policies and Social Media

The research presented at CROI 2017 is embargoed until the conclusion of the session in which it is presented. For example, if a study is presented from 1:45 PM to 2:00 PM as part of a session that ends at 2:45 PM, the embargo on that study lifts at 2:45 PM. Embargoes on poster presentations lift at the conclusion of the session in which the poster is presented. If a study to be presented at CROI 2017 is included in an official CROI press conference and that press conference takes place before the official presentation of the study at the conference, the embargo lifts at the conclusion of the press conference in which the study is featured.

CROI embargo policies apply to any public dissemination of research information presented at the conference, including electronic publications (eg, blogs) or social media (eg, Facebook, Twitter). No public dissemination of research information from the conference is permitted prior to the lifting of the conference embargo. Individuals or organizations that violate the conference embargo policy may have their conference credentials revoked and may forfeit the opportunity to participate in future conferences.

Welcome Reception

All registered CROI attendees are invited to join us for a Welcome Reception immediately following the Opening Session on Monday evening. The reception will be held at the Convention Center.

This unique Welcome Reception will offer attendees the opportunity to network with colleagues. Light hors d'oeuvres will be served. Each attendee will be given 2 drink tickets with their registration materials to be used for alcoholic or nonalcoholic beverages.

Meals

Morning coffee and light continental breakfast will be available to conference registrants from 7:30 AM to 8:30 AM, Tuesday, Wednesday, and Thursday, in the 4AB Auditorium. An afternoon snack break will be available at 2:30 PM in the Poster Hall. Attendees are on their own for all other meals, including lunch and dinner, each day. Below is a list of food service options located in the WSCC or within a short walking distance.

Food Service at the Convention Center

820 Pike Street – Pan Asian Cuisine	Subway Sandwiches
Crêpes Voilà	Taco Del Mar
Cyber Dogs – Internet Café	The Juicy Café
Espresso Caffé Dior	Tully's Coffee
Goldberg's Deli	Wild Rye Café Bakery

Restaurants Within 4 Blocks of the Convention Center

Blueacre Seafood	1700 7th Ave	206-659-0737	blueacreseafood.com
Blue C Sushi	1510 7th Ave	206-467-4022	bluesushi.com
Café Yumm!	717 Pine St	206-624-9866	cafeyum.com
Daily Grill	629 Pike St	206-624-8400	dailygrill.com
Dragonfish Asian Café	722 Pine St	206-467-7777	dragonfishcafe.com
FareStart	700 Virginia St	206-267-7606	farestart.org
Gameworks	1511 7th Ave	206-521-0951	gameworks.com
Gordon Biersch Brewery Restaurant	600 Pine St, Ste 401	206-405-2707	gordonbiersch.com
Il Fornaio	600 Pine St, Ste 132	206-264-0994	ilfornaio.com
MOD Superfast Pizza	1302 6th Ave	206-332-0200	modsuperfast.com
Morton's Steakhouse	1511 6th Ave	206-223-2751	mortons.com
NYC Hyatt Deli Market	1520 7th Ave	206-682-7011	
Palomino	6th and Union	206-623-1300	r-u-i.co

Restaurants within 4 Blocks of the Convention Center (continued)

Pike Place Chowder	600 Pine St, Ste 404	206-838-5680	
Potbelly Sandwich Shop	1429 4th Ave	206-623-0099	potbelly.com
RN74	1425 4th Ave	206-456-7474	michaelmina.net
Rock Bottom Restaurant	1333 5th Ave	206-623-3070	rockbottom.com
Ruth's Chris Steak House	727 Pine St	206-624-8524	ruthschris.com
Soup's On!	1420 5th Ave	206-625-9976	soupsonusa.com
Sullivan's Steakhouse	612 Union St	206-494-4442	sullivansteakhouse.com
Tango Restaurant & Lounge	1100 Pike St	206-583-0382	tangorestaurant.com
Tap House Grill	1506 6th Ave	206-816-3314	taphousegrill.com
Thai Ginger	600 Pine St	206-749-9100	www.thaiginger.com
The Capital Grille	1301 4th Ave	206-382-0900	thecapitalgrille.com
The Cheesecake Factory	700 Pike St	206-652-5400	thecheesecakefactory.com
Toss'd Custom Salads	1420 5th Ave	206-682-6700	
Veggie Grill	1427 4th Ave	206-624-1332	veggiegrill.com

Overflow Accommodations for Oral Sessions

There is a simultaneous overflow area located in the Atrium Lobby. There are 6 screens, and each will be live streaming one of the 6 concurrent oral sessions (Oral Abstracts, Themed Discussions, or Symposia). Headsets with an audio switch will be available for easy transitioning between the concurrent sessions.

Overflow monitors for individual session rooms will become available as needed. CROI staff will direct you to these locations.

USB Flash Drive

Any registrant who purchased a **USB flash drive** with the Abstract eBook preloaded onto it will receive it in their welcome packet at registration. Abstracts can also be found in the **Abstract eBook** and searchable database on the CROI website after the session in which the abstract is presented.

Mobile App:

The CROI 2017 mobile App has many features to enhance your conference experience:

- View abstracts
- Find information about speakers and other CROI attendees
- Create a personal calendar of the sessions you plan to attend
- E-mail session notes
- Receive the latest changes to the CROI program
- View electronic posters



The mobile App is compatible with iOS and Android devices. Search "CROI 2017" in your mobile device App store. Access is restricted to registered attendees only. Your log-in information and password will be provided with your registration materials.

Website

For additional information about the conference and to access electronic materials please visit the website at www.CROIconference.org.

The final Abstract eBook (flip book and PDF versions) will be available for public download following the conference. Abstracts from CROI 2017 can be viewed and downloaded in the searchable database during the conference. Abstracts and electronic posters from CROI 2014, 2015, 2016 are available at www.croiconference.org/abstracts/search-abstracts/

Webcasts

Plenaries, symposia, scientific overviews, oral abstract sessions, and themed discussions are available as webcasts. Webcasts are also available as streaming video for the Apple iPad and iPhone.

Visit www.CROIconference.org or www.CROIwebcasts.org to access the CROI webcasts. Webcasts will be available within 24 hours of the end of the relevant session.

Affiliated Activities Policy

The goal of CROI is to promote meaningful, high-level scientific interchange of ideas and debate in order to find better ways to prevent, treat, and cure HIV/AIDS. In keeping with this goal, organizations (commercial companies and their agents, not-for-profit groups, government agencies, etc) have been approved to host Affiliated Activities occurring outside CROI session times. Affiliated Activities are not sponsored by, endorsed by, or supported by the IAS–USA, the CROI Foundation, or CROI 2017.

If an affiliated activity is found to have violated the Guidelines for Affiliated Activities, the sponsoring organization, the supporting organization, and the organizer of the meeting may be prohibited from holding an Affiliated Activity at future CROI conferences and may have their current registration revoked. Noncompliance may be subject to fines and damages, and could negatively impact the registration status and attendance of those attending an unapproved affiliated activity.

If you have organized a meeting or activity that includes CROI attendees, as described in the Affiliated Activity guidelines, and have not completed the Affiliated Activity application, please see an IAS–USA staff member in the IAS–USA office (room 603) for assistance.

In the spirit of CROI and the goal of promoting scientific collaboration among colleagues, if you are invited to or are attending a meeting or activity that you feel may not have been approved by CROI, please contact an IAS–USA staff member in the IAS–USA office.

Wi-Fi Access at the Conference

Complimentary Wi-Fi access is provided at the WSCC. Network information is as follows:

Network name: **CROI2017**

The Wi-Fi password will change daily to prevent devices from automatically connecting to the network. Limiting the number of concurrent devices will assist in maximizing the internet speeds for those devices actively in use. The password for each day of the conference are listed below, and are NOT case sensitive.

Monday password: **Monday2017**

Tuesday password: **Tuesday2017**

Wednesday password: **Wednesday2017**

Thursday password: **Thursday2017**

If you are having issues with Wi-Fi access, please contact an IAS–USA staff member. Additional Internet hotspots not located in the session rooms are listed in the Convention Center map on the back of the Program.

Conference Badges

Badge pickup is available at the registration lobby; please bring government-issued photo identification that clearly shows your name. You must wear your name badge to gain entry to all official meeting activities, including the poster sessions. **DO NOT LOSE YOUR BADGE. Payment of US \$850 will be required to replace a lost badge.**

Child Care

Children are not permitted entry into any meeting room, including the poster area. If you should require child care, please contact the concierge of your hotel or the Visitor Information Center on Level 1 at the WSCC.

Conference Etiquette

In consideration of the work of presenters at CROI, and the CROI copyright policy, attendees should not photograph posters, record parts of talks, or post other people's data. Please ensure all cell phones and pagers are off or are set on SILENT mode. No photography is permitted in session rooms.

CROI HOTELS

Conference attendees are required to stay in one of the official conference hotels. The few exceptions to this include registrants who live in the Seattle area (ie, within a 50-mile radius of the WSCC) and registrants who are sharing a room with an approved CROI attendee with accommodations booked via the CROI housing system. Please inform the Conference Secretariat if you have inadvertently booked a hotel stay outside of the CROI housing system.

CROI 2017 hotels are listed below.

Crowne Plaza Seattle Downtown

1113 6th Avenue
Seattle, WA 98101
PH: 206-464-1980

The Fairmont Olympic Hotel

411 University Street
Seattle, WA 98101
PH: 206-621-1700

Grand Hyatt Seattle

721 Pine Street
Seattle, WA 98101
PH: 206-774-1234

Hilton Garden Inn

1821 Boren Avenue
Seattle, WA 98101
PH: 206-467-7770

Hilton Seattle

1301 6th Avenue
Seattle, WA 98101
PH: 206-624-0500

Mayflower Park Hotel

405 Olive Way
Seattle, WA 98101
PH: 206-623-8700

Motif Seattle

1415 5th Avenue
Seattle, WA 98101
PH: 206-971-8000

Hyatt at Olive 8

1635 8th Avenue
Seattle, WA 98101
PH: 206-685-1234

Renaissance Seattle Hotel

515 Madison Street
Seattle, WA 98104
PH: 206-583-0300

Sheraton Seattle Hotel

1400 6th Avenue
Seattle, WA 98101
PH: 206-621-9000

W Seattle

1112 4th Avenue
Seattle, WA 98101
PH: 206-264-6000

The Westin Seattle

1900 5th Avenue
Seattle, WA 98101
PH: 206-728-1000

CONFERENCE SERVICES

General Information

Services	Location	Hours
Seattle Visitor Center and Concierge Services	Upper Pike St. Lobby Level 1	Monday to Friday 9:00 AM – 5:00 PM
Bag and Coat Check	Hall 4C-3, 4 Level 4	Monday: 8:00 AM – 10:30 PM Tuesday: 7:30 AM – 8:00 PM Wednesday and Thursday: 7:30 AM – 6:30 PM
Cyber Cafe	4D Skybridge Level 4	Sunday: 3:00 AM – 5:00 PM Monday to Wednesday: 7:30 AM – 7:00 PM Thursday: 7:30 AM – 6:00 PM
Media Center	Room 400 Level 4	Monday: 10:00 AM – 7:00 PM Tuesday to Thursday: 8:00 AM – 6:30 PM
Badge Pickup	Hall 4C-3, 4 Level 4	Sunday: 3:00 PM – 5:00 PM
Attendee Services		Monday: 8:00 AM – 7:00 PM
Housing Information		Tuesday: 7:00 AM – 6:00 PM
Scholarship Badge Pickup		Wednesday: 8:00 AM – 6:00 PM
Media Badge Pickup		Thursday: 8:00 AM – 6:00 PM
Speaker Ready Room	Room 620 Level 6	Sunday: 3:00 PM – 6:00 PM Monday to Thursday: 6:00 AM – 6:00 PM
Personal Considerations Room	Room 507 Level 5	Sunday: 3:00 PM – 6:00 PM Monday: 9:00 AM – 7:00 PM Tuesday: 8:00 AM – 6:00 PM Wednesday: 8:00 AM – 6:00 PM Thursday: 8:00 AM – 6:00 PM
New Mother's Room	Room 416 Level 4	Sunday: 3:00 PM – 6:00 PM Monday: 9:00 AM – 7:00 PM Tuesday: 8:00 AM – 6:00 PM Wednesday: 8:00 AM – 6:00 PM Thursday: 8:00 AM – 6:00 PM

CONFERENCE SERVICES

Notes

Full-service concierge assistance, including maps, guides, tickets, restaurant reservations, tours, ground transportation, and personal services is available.

Bag and coat check are free of charge.

Computers with Internet access are available for webcasts and abstract searches.

There is no on-site press registration. Registered press can pick up press kits and obtain location for press conferences at this location.

Badges and conference materials can be picked up at this location.

Oral abstract, invited, and themed discussion session speakers must drop off presentations at least 24 hours before their presentation.

Poster presenters must submit an electronic version of their poster for placement on the CROI website by February 7, 2017.

The Personal Considerations Room is a room set aside for those who require a short-term private space for personal health needs. Use of this room is available on a first-come, first-served basis.

The New Mother's Room is a room set aside for nursing mothers who require a short-term private room. Use of this room is available on a first-come, first-served basis.



ABSTRACT PROCESS

Scientific Categories

- A. Virology
- B. Molecular Epidemiology and HIV/SIV Evolution
- C. Pathogenesis: Human Studies and Animal Models
- D. Host Immune Responses to Infection, Vaccines, and Immunotherapy
- E. HIV Reservoirs, Latency, and All Curative Strategies Including Therapeutic Vaccines and Gene Therapy
- F. Neuropathogenesis and CNS HIV Complications
- G. Clinical Pharmacology
- H. Antiretroviral Therapy: Pre-Clinical and Randomized Trials
- I. Antiretroviral Therapy: Efficacy and Effectiveness Studies
- J. HIV Drug Resistance
- K. HIV Diagnostics
- L. Hepatitis Viruses and Liver Complications
- M. Malignancies
- N. Cardiovascular Complications of HIV Infection and Antiretroviral Therapy
- O. Other Complications of HIV Infection and Antiretroviral Therapy
- P. Tuberculosis and Other Opportunistic Infections
- Q. Maternal/Fetal HIV
- R. Pediatrics and Adolescents
- S. Epidemiology
- T. Prevention Interventions
- U. Prevention Scale-Up
- V. Contraceptive and Reproductive Health in Women
- W. Implementation and Scale-Up of Treatment and Care
- X. Population and Cost Modeling
- Y. Emerging Viruses: Zika Virus

Abstract Content

Author names, institutions, abstract titles, and abstracts in the Program and Abstracts eBook are generally presented as submitted by the corresponding author.

Abstract Review Process

The PC and a panel of volunteer external reviewers reviewed approximately 2000 submitted abstracts. Each abstract was reviewed by 5 to 10 reviewers selected for each abstract category based upon their individual expertise.

PC members and external experts in the field reviewed the abstracts for the quality and originality of the work and scored them numerically. All reviewers were instructed to abstain from scoring any abstract on which they are an author or coauthor, have a financial or personal conflict of interest, or do not have the appropriate expertise to evaluate. Scores ranged from 1 (definite oral presentation) to 5 (rejected).

Scores for each abstract were averaged and the standard deviation was calculated to assess variability. If variability was high, outlier scores are identified and censored. Abstracts with high variability in scores were discussed individually during a series of conference calls. Abstracts were accepted for oral presentations, for poster presentations, or rejected. Late-breaking abstract reviews included an assessment of the late-breaking nature of the work (versus just being a late submission).

Common Reasons for Abstract Rejection


- Information is not new enough
- Methodology is inadequate or insufficient to support conclusions
- Background does not summarize the hypothesis
- Submission is poorly written
- Abstract is duplicative of other submissions
- Abstract is not appropriate for CROI
- Controls are absent or inadequate
- Statistical evaluation is inadequate or absent
- Summary of essential results is inadequate or absent
- Data are inadequate or insufficient to support conclusions
- Submission reports clinical trial and data from unplanned analysis or incomplete or ongoing studies
- Format does not follow guidelines (eg, section[s] missing, more than 1 graphic, table, or figure submitted)

Statistics for Abstracts

General abstract submitted	1751
General abstracts accepted	948
General oral abstracts	80
General poster abstracts	868
Late-breaking abstracts submitted	159
Late-breaking abstracts accepted	53
Late-breaking oral abstracts	16
Late-breaking poster abstracts	37
Total abstracts submitted	1910
Total abstract accepted	1001

All Authors on Accepted Abstracts

Region	N	Percent
Africa	265	14
Asia	99	5.2
Australia	35	1.8
Europe	432	22.5
Latin and South America	29	1.5
North America	1050	55



PRECONFERENCE SESSIONS

MONDAY, FEBRUARY 13, 2017

Workshop W1: PROGRAM COMMITTEE WORKSHOP FOR NEW INVESTIGATORS AND TRAINEES

Ballroom 6AB

9:00 AM-12:15 PM

Target Audience: This workshop is directed toward new trainees (eg, undergraduate students, graduate students, postdoctoral fellows, and physician fellows) and new investigators (both international and domestic). It is open to all CROI attendees, however.

Level of Knowledge: It is assumed that participants have been conducting active research in the field for less than 3 years.

Conveners

John W. Mellors, *Univ of Pittsburgh, Pittsburgh, PA, USA*

Serena S. Spudich, *Yale Univ, New Haven, CT, USA*



1 PROGRAM COMMITTEE WORKSHOP FOR NEW INVESTIGATORS AND TRAINEES



MOLECULAR VIROLOGY: ADVANCES IN THE UNDERSTANDING OF HIV-1

Paul Bieniasz, *Howard Hughes Medical Center, New York, NY, USA*



ADVANCES IN ANTIBODIES

Richard A. Koup, *VRC, NIAID, NIH, Bethesda, MD, USA*



ADVANCES IN HIV PREVENTION: NEW BIOMEDICAL AND BEHAVIORAL APPROACHES

James A. McIntyre, *Anova Health Institute, Johannesburg, South Africa*



HIV COMPLICATIONS: PERSISTENT THREAT OR A PROBLEM OF THE PAST?

Judith S. Currier, *Univ of California Los Angeles, Los Angeles, CA, USA*



HIV RESERVOIRS: OBSTACLES TO AN HIV CURE

Nicolas Chomont, *Univ de Montréal, Montreal, QC, Canada*

LUNCH AND MARTIN DELANEY PRESENTATION, FROM LAB TO LICENSURE: THE IMPORTANCE OF GOOD PARTICIPATORY PRACTICE IN RESEARCH

Room 6 AB

12:15 PM - 1:45 PM

Description: The Martin Delaney Presentation is held annually during the workshops for Young Investigators, International Investigators, and Community Educators in honor of pioneering HIV/AIDS activist Martin Delaney (1945–2009). It recognizes the important contributions of community advocacy and engagement in research.

Target Audience: This session is directed toward new trainees (eg, undergraduate students, graduate students, postdoctoral fellows, and physician fellows) and new investigators. Attendance is mandatory for all scholarship recipients. It is open to all CROI attendees.

Level of Knowledge: It is assumed that participants have been conducting active research in the field for less than 1 year.

Objectives: After attending this presentation, participants will be able to:

- List the 6 fundamental principles of Good Participatory Practice (GPP)
- Explain the importance of GPP and describe several practical ways it can be implemented in current and future biomedical HIV treatment and prevention trials
- Explain why GPP principles are important and how they can be applied in future HIV cure research

Moderator

Mark Hubbard, *Tennessee Association of People with AIDS, Nashville, TN, USA*



2 FROM LAB TO LICENSURE: THE IMPORTANCE OF GOOD PARTICIPATORY PRACTICE IN RESEARCH



HISTORY AND PRINCIPLES OF GOOD PARTICIPATORY PRACTICE GUIDELINES

Stacey Hannah, *AIDS Vaccine Advocacy Coalition, New York, NY, USA*



GPP AS A GUIDE TO BIOMEDICAL HIV PREVENTION TRIAL DESIGN AND IMPLEMENTATION

Deborah Baron, *Wits RHI, Johannesburg, South Africa*



APPLYING GPP PRINCIPLES TO CURE RESEARCH

David Evans, *Project Inform, San Francisco, CA, USA*

Workshop W2: CLINICAL TRIAL DESIGN AND ANALYSIS**Room 6 C****2:15 PM - 4:00 PM**

Target Audience: This session is directed to clinicians and scientists who are interested in designing or interpreting clinical and epidemiologic studies.

Level of Knowledge: It is assumed that participants are familiar with the basic design of randomized and observational clinical trials and basic HIV epidemiology.

Objectives: At completion of the session, participants will be able to:

- Provide examples of different study designs to assess efficacy of new prevention methods in the era of preexposure prophylaxis (PrEP)
- Describe approaches to designing and evaluating implementation science trials
- Evaluate strengths and limitations of respondent-driven sampling as a method for recruiting and understanding under-studied populations

Conveners

Susan P. Buchbinder, *San Francisco Dept of PH, San Francisco, CA, USA*

Richard Chaisson, *The Johns Hopkins Univ, Baltimore, MD, USA*

**3 PREVENTION TRIAL DESIGN IN THE ERA OF PREP**

Deborah J. Donnell, *Fred Hutchinson Cancer Rsr Center, Seattle, WA, USA*

**4 IMPLEMENTATION SCIENCE TRIALS: DO THE RULES OF RCTS APPLY?**

James R. Hargreaves, *London Sch of Hygiene and Trop Med, London, United Kingdom*

**5 RESPONDENT DRIVEN SAMPLING & OTHER METHODS FOR RECRUITING HARD TO REACH POPULATIONS**

Carl A. Latkin, *The Johns Hopkins Univ, Baltimore, MD, USA*

**Workshop W3: FRONTIERS IN LABORATORY SCIENCE****Room 611-614****2:15 PM - 4:00 PM**

Target Audience: This session is directed to students, researchers and clinicians who are interested in learning about the application of hot new technologies aimed at profiling the immune response to infection and the intracellular molecular mechanisms exploited by HIV during cellular infection.

Level of Knowledge: It is assumed that the participants are familiar with basic immunology and virology.

Objectives:

- Describe how the CRISPR/Cas9 system may be exploited to explore the molecular mechanisms underlying HIV infection
- Describe the role of RNA structure in HIV infection and latency
- Describe how high-dimensional time-of-flight mass spectrometry may be used to explore single cell immune profile dynamics during infection


Conveners

Galit Alter, *Ragon Institute of MGH, MIT and Harvard, Cambridge, MA, USA*

Frank Kirchhoff, *Ulm Univ Medical Center, Ulm, Germany*

**6 HIGH-THROUGHPUT GENOME ENGINEERING IN PRIMARY CD4+ T CELLS**

Judd F. Hultquist, *Univ of California San Francisco, San Francisco, CA, USA*



7 IDENTIFYING AND PROFILING VIRUS-SPECIFIC T CELLS USING MASS CYTOMETRY

Evan William Newell, *Singapore Immunol Network, Singapore, Singapore*



8 QUANTIFYING HIV-1 MRNA STRUCTURE AND TRANSLATION EFFICIENCY IN CELLS

Silvi Rouskin, *Whitehead Institute, Cambridge, MA, USA*



Workshop W4: INTERACTIVE CASE-BASED WORKSHOP ON HEPATITIS C Room 6 E 2:15 PM - 4:00 PM

Target Audience: This session is directed to persons interested in the management of hepatitis C virus (HCV) infection.

Level of Knowledge: It is assumed that participants are familiar with the general principles of HCV treatment and the medications used.

Objectives: At completion of the session, participants will be able to:

- Recognize the limitations of current approaches to fibrosis staging
- Develop a framework for selection of HCV therapy
- Recognize common situations where resistance testing is indicated
- Recognize and manage common drug interactions with coinfection
- Recognize how treatment approaches differ for persons with cirrhosis

Conveners

Susanna Naggie, *Duke Univ, Durham, NC, USA*

David Wyles, *Denver Health, Denver, CO, USA*



9 SESSION DESCRIPTION: INTERACTIVE CASE-BASED WORKSHOP ON HEPATITIS C



APPROACHES TO STAGING AND TREATMENT OF EARLY STAGE HCV

John D. Scott, *Univ of Washington, Seattle, WA, USA*



EFFECT OF RAVs ON DAA TREATMENT AND RE-TREATMENT OF PTS WITH CHRONIC HCV INFECTION

Alessandra Mangia, *Ospedale Casa Sollievo della Sofferenza, San Giovanni Rotondo, Italy*



COMMON DRUG INTERACTIONS WITH HIV/HCV COINFECTION

Debika Bhattacharya, *Univ of California Los Angeles, Los Angeles, CA, USA*



CIRRHOSIS ISSUES

Sanjay Bhagani, *Royal Free Hosp, London, United Kingdom*

OPENING SESSION

Auditorium - 4 AB

5:00 PM - 7:00 PM

Session Hosts

Susan P. Buchbinder, *San Francisco Dept of PH,
CROI 2017 Chair* *San Francisco, CA, USA*



Judith S. Currier, *Univ of California Los Angeles,
CROI 2017 Vice Chair* *Los Angeles, CA, USA*



Richard A. Koup, *VRC, NIAID, NIH,
CROI 2017 Vice Chair* *Bethesda, MD, USA*



Preconference Sessions • Monday

Bernard Fields Lecture

The Bernard Fields Lecture, named in tribute to the exemplary work of the esteemed microbiologist and virologist Bernard Fields, is given during the Opening Session, usually by a basic scientist recognized for his or her important and relevant contributions to the fields of virology and viral pathogenesis.

10 INSIGHTS INTO HIV PREVENTION, PATHOGENESIS AND TREATMENT FROM NONHUMAN PRIMATE MODELS

Jeffrey D. Lifson, *Frederick National Laboratory for Cancer Research, Frederick, MD, USA*



N'Galy-Mann Lecture

The N'Galy-Mann Lecture recognizes an HIV/AIDS researcher for his or her important and relevant work in the fields of epidemiology or clinical research. The Lecture is named in honor of Drs Bosenge N'Galy and Jonathan Mann for their crucial, pioneering work in HIV science in Africa.

11 HIV/AIDS RESEARCH IN ZIMBABWE: PROVIDING THE EVIDENCE FOR QUALITY CARE

James G. Hakim, *University of Zimbabwe, Harare, Zimbabwe*



CROI Foundation Special Event

Musical performance by Zimbabwean human rights activist **Oliver Mtukudzi** and his band, the **Black Spirits**.



TUESDAY, FEBRUARY 14, 2017

Plenary PL-1: TUESDAY PLENARY SESSION**Auditorium - 4 AB****8:30 AM - 9:30 AM****12 THE EMERGING POTENTIAL FOR HIV CURE FOR INFANTS, CHILDREN, AND ADULTS**

8:30

Jintanat Ananworanich, *US Military HIV Rsr Prog, USA and The Thai Red Cross AIDS Rsr Cntr, Thailand***13 ADVANCES IN CELLULAR THERAPY IN CANCER AND HIV**

9:00

Carl H. June, *Univ of Pennsylvania, Philadelphia, PA, USA***Oral Abstract O-1: GETTING HIV THROUGH THE CELL****Room 611-614****10:00 AM - 12:00 PM****Oral Abstract Moderators****Jaisri Lingappa**, *Univ of Washington, Seattle, WA, USA***John M. Coffin**, *Tufts Univ, Boston, MA, USA***14LB QUATERNARY CONFIGURATION OF THE FUNCTIONAL CD4-BINDING SITE IN THE HIV-1 ENV TRIMER**

10:00

Qingbo Liu¹, **Priyamvada Acharya**¹, **Michael Dolan**¹, **Peng Zhang**¹, **Aliaksandr Druz**¹, **William Rice**², **Bridget Carragher**², **Clinton Potter**², **Peter D. Kwong**¹, **Paolo Lusso**³¹NIH, Bethesda, MD, USA, ²New York Structural Bio Cntr, New York, NY, USA, ³NIAID, Bethesda, MD, USA**15 EARLY CYTOPLASMIC UNCOATING IS NECESSARY FOR INFECTIVITY OF HIV-1**

10:15

João I. Mamede, **Gianguido C. Cianci**, **Meegan R. Anderson**, **Thomas Hope**
*Northwestern Univ, Chicago, IL, USA***16 ECCENTRIC VIRAL GENOMIC RNA AND INTEGRASE ARE PREMATURELY DEGRADED IN TARGET CELLS**

10:45

Michaela Madison¹, **Dana Q. Lawson**¹, **Jennifer Elliott**¹, **Ayse N. Ozanturk**², **Pratibha Chowdary Koneru**³, **James R. Fuchs**³, **Mamuka Kvaratskhelia**³, **Sebla B. Kutluay**¹¹Washington Univ in St. Louis, St. Louis, MO, USA, ²Bilkent Univ, Ankara, Turkey, ³Ohio State Univ, Columbus, OH, USA**17 DYNAMICS OF NUCLEAR ENVELOPE ASSOCIATION AND NUCLEAR IMPORT OF HIV-1 COMPLEXES**

11:00

Ryan C. Burdick, **Jianbo Chen**, **Jaya Sastri**, **Wei-Shau Hu**, **Vinay K. Pathak**
*NCI, Frederick, MD, USA***18 CYPA REGULATES HIV-1 ACCESS TO AN FG-GUIDED NUCLEAR ENTRY PATHWAY**

11:15

Guangai Xue¹, **Vineet KewalRamani**¹, **Shih Lin Goh**², **Hyun Jae Yu**¹, **Anna Gres**³, **KyeongEun Lee**¹, **Stefan G. Sarafianos**³, **Jeremy Luban**²¹NCI, Frederick, MD, USA, ²Univ of Massachusetts, Worcester, MA, USA, ³Univ of Missouri, Columbia, MO, USA**19 A COMPREHENSIVE CRISPR SCREEN IDENTIFIES NOVEL HIV RESTRICTION FACTORS**

11:30

Molly Ohainle, **Louisa Pendergast**, **Jolien Vermeire**, **Michael Emerman**
Fred Hutchinson Cancer Rsr Cntr, Seattle, WA, USA

20 **A RETROTRANPOSED ESCRT-III FACTOR BLOCKS HIV-1 BUDDING WITHOUT INDUCING CYTOTOXICITY**

11:30

Lara Rheinemann, Diane Downhour, Gaelle Mercenne, Alesia McKeown, John McCullough, Wes Sundquist, Nels Elde

Univ of Utah, Salt Lake City, UT, USA

21 **DESIGNED PROTEINS INDUCE THE FORMATION OF NANOCAGE-CONTAINING EXTRACELLULAR VESICLES**

11:45

Joerg Votteler¹, Cassie Ogohara², Sue Yi², Yang Hsia², Una Nattermann², David M Belnap¹, Neil P King², Wes Sundquist¹

¹*Univ of Utah, Salt Lake City, UT, USA*, ²*Univ of Washington, Seattle, WA, USA*

Oral Abstract O-2: CRITICAL ISSUES IN WOMEN'S HEALTH, MTCT, AND HIV TREATMENT IN CHILDREN

Room 606-609

10:00 AM - 12:00 PM

Oral Abstract Moderators

Mary Glenn Fowler, *The Johns Hopkins Univ, Baltimore, MD, USA*

Paolo Rossi, *Children Hosp Bambino Gesù, Rome, Italy*

22 **RANDOMIZED TRIAL OF LEEP VS CRYOTHERAPY TO TREAT CIN2/3 IN HIV-INFECTED WOMEN**

10:00

Sharon A. Greene¹, Evans Nyongesa-Malava¹, Barbra A. Richardson¹, Grace John-Stewart¹, Hugo De Vuyst², Nelly Yatich¹, Catherine Kiptinness¹, Sameh Sakr³, Nelly Mugo⁴, Michael H. Chung¹

¹*Univ of Washington, Seattle, WA, USA*, ²*Intl Agency for Rsr on Cancer, Lyon, France*, ³*Coptic Hosp, Nairobi, Kenya*, ⁴*KEMRI, Nairobi, Kenya*

23 **NATURAL HISTORY OF CERVICAL INTRAEPITHELIAL NEOPLASIA-2 AMONG HIV-INFECTED WOMEN**

10:15

Christine Colie¹, L. Stewart Massad², Cuiwei Wang¹, **Kate Michel**¹, Gysamber D'Souza³, Joel Palefsky⁴, Howard Minkoff⁵, Howard D. Strickler⁶, Seble Kassaye¹

¹*Georgetown Univ, Washington, DC, USA*, ²*Washington Univ, St. Louis, MO, USA*, ³*The Johns Hopkins Univ, Baltimore, MD, USA*, ⁴*Univ of California San Francisco, San Francisco, CA, USA*, ⁵*Maimonides Med Cntr, Brooklyn, NY, USA*, ⁶*Albert Einstein Coll of Med, Bronx, NY, USA*

24 **INTEGRATION OF POSTNATAL SERVICES IMPROVES MCH AND ART OUTCOMES: A RANDOMISED TRIAL**

10:30

Landon Myer¹, Tamsin Phillips¹, Allison Zerbe², Kirsty Brittain¹, Stanzi M. Le Roux¹, Robert Remien³, Claude A. Mellins³, James A. McIntyre⁴, Elaine J. Abrams², for the Maternal Child Health - Antiretroviral Therapy (MCH-ART) study

¹*Univ of Cape Town, Cape Town, South Africa*, ²*Columbia Univ, New York, NY, USA*, ³*New York State Psychiatric Inst, New York, NY, USA*, ⁴*Anova Hlth Inst, Johannesburg, South Africa*

25 **ADVERSE BIRTH OUTCOMES DIFFER BY ART REGIMEN FROM CONCEPTION IN BOTSWANA**

10:45

Rebecca Zash¹, Denise Jacobson², Modiegi Diseko³, Gloria Mayondi³, Mompoti Mmalane³, Chipo Petlo⁴, Max Essex², Shahin Lockman⁵, Joseph Makhema³, Roger L. Shapiro²

¹*Beth Israel Deaconess Med Cntr, Boston, MA, USA*, ²*Harvard Univ, Boston, USA*, ³*Botswana Harvard AIDS Inst Partnership, Gaborone, Botswana*, ⁴*Ministry of Hlth, Botswana, Gaborone, Botswana*, ⁵*Brigham and Women's Hosp, Boston, MA, USA*

- 26**
11:00 **EFFECT OF POINT-OF-CARE TESTING ON ANTIRETROVIRAL-THERAPY INITIATION RATES IN INFANTS**
Ilesh Jani¹, Bindiya Meggi¹, Osvaldo Loquiha², Ocean Tobaiwa², Chishamiso Mudenyanga², Dadirayi Mutsaka², Nedio Mabunda¹, Adolfo Vubil¹, Lara Vojnov², Trevor Peter²
¹Instituto Nacional de Saude, Maputo, Mozambique, ²Clinton Hlth Access Initiative, Maputo, Mozambique
- 27**
11:15 **TREATMENT OF ACUTE HIV INFECTION IN NEONATES**
Louise Kuhn¹, Karl Technau², Renate Strehlau², Stephanie Shiau¹, Faezah Patel², Gayle G. Sherman³, Caroline Tiemessen³, Grace M. Aldrovandi⁴, Ashraf Coovadia², Elaine J. Abrams⁵
¹Columbia Univ, New York, NY, USA, ²Empilweni Service and Rsr Unit, Johannesburg, South Africa, ³Natl Inst of Communicable Diseases, Johannesburg, South Africa, ⁴Univ of California Los Angeles, Los Angeles, CA, USA, ⁵ICAP at Columbia Univ, New York, NY, USA
- 28**
11:30 **RAPID DECLINE OF TOTAL HIV DNA IN CHILDREN STARTING ART WITHIN 8 DAYS OF BIRTH**
Kirsten A. Veldsman¹, Jean Maritz², Shahieda Isaacs¹, Mary Grace K. Katusiime¹, Heleen la Grange¹, Anita Janse van Rensburg¹, Barbara Laughton², John Mellors³, Mark Cotton², Gert U. van Zyl¹
¹Stellenbosch Univ, Parow, South Africa, ²Stellenbosch Univ, Cape Town, South Africa, ³Univ of Pittsburgh, Pittsburgh, PA, USA
- 29LB**
11:45 **LOPINA VIR/RITONAVIR 1:1 SUPER-BOOSTING OVERCOMES RIFAMPICIN INTERACTIONS IN CHILDREN**
Helena Rabie¹, **Paolo Denti**², Janice Lee³, Mhleli Masango⁴, Ashraf Coovadia⁴, Sandy Pillay⁵, Afaaf Liberty⁴, Helen McIlleron², Mark Cotton¹, Marc Lallemand³
¹Stellenbosch Univ, Cape Town, South Africa, ²Univ of Cape Town, Cape Town, South Africa, ³Drug for Neglected Diseases Initiative, Geneva, Switzerland, ⁴Univ of the Witwatersrand, Johannesburg, South Africa, ⁵Enhancing Care Foundation, Wentworth Hosp, Durban, South Africa

Oral Abstract O-3: HIDING IN PLAIN SIGHT: DISCOVERING THE UNDIAGNOSED AND UNDERTREATED HIV EPIDEMIC
Room 6 E **10:00 AM - 12:00 PM**

Oral Abstract Moderators

Carlos del Rio, Emory Univ, Atlanta, GA, USA

Aleny Couto, Ministry of Health, Maputo, Mozambique

30 10:00 **HIV INCIDENCE, PREVALENCE, AND UNDIAGNOSED INFECTIONS IN MEN WHO HAVE SEX WITH MEN**

Sonia Singh, Ruiguang Song, Anna S. Johnson, Eugene McCray, Irene Hall
CDC, Atlanta, GA, USA

31 10:15 **VIRAL-LOAD DYNAMICS AMONG PERSONS WITH DIAGNOSED HIV: UNITED STATES, 2014**

Nicole Crepaz¹, Tian Tang², Gary Marks¹, Irene Hall¹
¹CDC, Atlanta, GA, USA, ²ICF Intl, Atlanta, GA, USA

32 TIME SPENT WITH HIV VIRAL LOAD >1500 COPIES/ML AMONG PATIENTS IN HIV CARE, 2000-2014

10:45

Kate Buchacz¹, Maria Mendoza¹, Carl Armon², Frank J. Palella³, Charles Rose¹, Ellen Tedaldi⁴, Richard Novak⁵, Lytt Gardner¹, for the the HIV Outpatient Study

¹CDC, Atlanta, GA, USA, ²Cerner Corp, Kansas City, MO, USA, ³Northwestern Univ, Chicago, IL, USA, ⁴Temple Univ, Philadelphia, PA, USA, ⁵Univ of Illinois, Chicago, IL, USA

33 A RANDOMIZED TRIAL OF NOVEL STRATEGIES TO INCENTIVIZE HIV TESTING AMONG MEN IN UGANDA

10:45

Gabriel Chamie¹, Elisabeth Schaffer², Alex Ndyabakira³, Devy Emperor¹, Dalsone Kwarisiima⁴, Diane V. Havlir¹, James Kahn¹, Moses R. Kamya⁵, Harsha Thirumurthy²

¹Univ of California San Francisco, San Francisco, CA, USA, ²Univ of North Carolina at Chapel Hill, Chapel Hill, NC, USA, ³Makerere Univ and Univ of California San Francisco Rsr Collab, Mbarara, Uganda, ⁴Makerere Univ Joint AIDS Prog, Kampala, Uganda, ⁵Makerere Univ Coll of Hlth Scis, Kampala, Uganda

34LB COMBINATION HIV PREVENTION AND HIV INCIDENCE IN RAKAI, UGANDA

11:00

Mary K. Grabowski¹, Gertrude Nakigozi², Fred Nalugoda², Thomas Quinn¹, Godfrey Kigozi², Ronald H. Gray¹, David Serwadda³, Maria Wawer¹, Steven J. Reynolds⁴, Larry W. Chang¹

¹The Johns Hopkins Univ, Baltimore, MD, USA, ²Rakai Health Sciences Prog, Kalisizo, Uganda, ³Makerere Univ, Kampala, Uganda, ⁴NIAID, Washington, DC, USA

35 NAMIBIA PILOTS SENTINEL POPULATION SURVEILLANCE OF HIV INCIDENCE AND VIRAL SUPPRESSION

11:15

Tuli Nakanyala¹, Andrew D. Maher², Nicholus Mutenda¹, Karen M. Banda², Anna Jonas³, Charity Ntema⁴, Ndapewa Hamunime¹, David W. Lowrance⁵, Sadhna V. Patel⁵, Willi McFarland²

¹Ministry of Hlth and Social Services, Windhoek, Namibia, ²Univ of California San Francisco, San Francisco, CA, USA, ³US CDC, Windhoek, Namibia, ⁴Development Aid from People to People, Windhoek, Namibia, ⁵CDC, Atlanta, GA, USA

36 SOCIAL NETWORKS AND HIV PREVALENCE IN KENYA IN THE SEARCH STUDY

11:30

Wenjing Zheng¹, Norton Sang², Gabriel Chamie³, Laura B. Balzer⁴, Craig Cohen³, Tamara D. Clark³, Edwin D. Charlebois³, Moses R. Kamya⁵, Diane V. Havlir³, Maya L. Petersen¹

¹Univ of California Berkeley, Berkeley, CA, USA, ²Kenya Med Rsr Inst, Nairobi, Kenya, ³Univ of California San Francisco, San Francisco, CA, USA, ⁴Harvard Univ, Boston, MA, USA, ⁵Makerere Univ Coll of Hlth Scis, Kampala, Uganda

37 HIGH RATE OF DISEASE PROGRESSION IN UNTREATED HIV-2 INFECTION

11:45

Joakim Esbjörnsson¹, Fredrik Månsson², Anders Kvist³, Zacarias J. da Silva⁴, Jacob Lindman³, Angelica Palm³, Marianne Jansson³, Patrik Medstrand³, Hans Norrgren³, for the SWEGUB CORE Group

¹Univ of Oxford, Oxford, UK, ²Lund Univ, Malmö, Sweden, ³Lund Univ, Lund, Sweden, ⁴LNSP, Bissau, Guinea-Bissau

Oral Abstract O-4: NEW HIV DRUGS, FORMULATIONS, COMBINATIONS, AND RESISTANCE

Room 6 AB

10:00 AM - 12:00 PM

Oral Abstract Moderators

Sally Hodder, *West Virginia Clinical and Translational Science Inst, Morgantown, WV, USA*

Yazdan Yazdanpanah, *Inserm, IAME, Paris, France*

38 DISCOVERY OF NOVEL POTENT HIV CAPSID INHIBITORS WITH LONG-ACTING POTENTIAL

10:00

Winston C. Tse, John O. Link, Andrew Mulato, Anita Niedziela-Majka, William Rowe, John R. Somoza, Armando G. Villasenor, Stephen R. Yant, Jennifer R. Zhang, Jim Zheng

Gilead Scis, Inc, Foster City, CA, USA

39 HUMAN CONFIRMATION OF ORAL DOSE REDUCTION POTENTIAL OF NANOPARTICLE ARV FORMULATIONS

10:15

Andrew Owen¹, Steve Rannard¹, Akil Jackson², Laura Dickinson¹, Marco Giardiello¹, Marco Siccardi¹, Paul Domanico³, Melynda Watkins³, Yao Cheng⁴, Marta Boffito⁵

¹Univ of Liverpool, Liverpool, UK, ²Chelsea and Westminster Hosp, London, UK,

³Clinton Hlth Access Initiative, Boston, MA, USA, ⁴Med Patent Pool, Geneva,

Switzerland, ⁵Chelsea and Westminster NHS Fndn Trust, London, UK

40 CLINICAL PHARMACOLOGY OF THE HIV INTEGRASE STRAND TRANSFER INHIBITOR BICTEGRAVIR

10:30

Heather Zhang, **Joseph M. Custodio**, Xuelian Wei, Hui Wang, Amanda Vu, John Ling, Hal Martin, Erin Quirk, Brian P. Kearney

Gilead Sci, Foster City, CA, USA

41 RANDOMIZED TRIAL OF BICTEGRAVIR OR DOLUTEGRAVIR WITH FTC/TAF FOR INITIAL HIV THERAPY

10:45

Paul E. Sax¹, Edwin DeJesus², Gordon Crofoot³, Douglas Ward⁴, Paul Benson⁵, Xuelian Wei⁶, Kirsten L. White⁶, Hal Martin⁶, Andrew Cheng⁶, Erin Quirk⁶

¹Brigham and Women's Hosp, Boston, MA, USA, ²Orlando Immunol Cntr,

Orlando, FL, USA, ³The Crofoot Rsr Cntr, Houston, TX, USA, ⁴Dupont Circle

Physicians Group, Washington, DC, USA, ⁵Be Well Med Cntr, Berkley, MI, USA,

⁶Gilead Scis, Inc, Foster City, CA, USA

42 PATHWAYS OF RESISTANCE IN SUBJECTS FAILING DOLUTEGRAVIR MONOTHERAPY

11:00

José L. Blanco¹, Celia Oldenbuettel², Réjean Thomas³, Josep Mallolas¹, Eva Wolf⁴, Bluma Brenner⁵, Christoph D. Spinner⁶, Mark A. Wainberg⁵, Esteban Martinez¹, for the Redo Group

¹Hosp Clinic Barcelona, Barcelona, Spain, ²MVZ Karlsplatz, HIV Rsr and Clinical

Care Cntr, München, Germany, ³Clinique Médicale l'Actuel, Montreal, QC,

Canada, ⁴MUC Rsr, Munich, Germany, ⁵McGill Univ, Montreal, Quebec, Canada,

⁶Univ Hosp Klinikum Rechts der Isar, Munich, Germany

43 PREVALENCE AND IMPACT OF PRETREATMENT DRUG RESISTANCE IN THE ANRS 12249 TASP TRIAL

11:15

Anne Derache¹, Collins C. Iwuji², Siva Danaviah¹, Anne-Geneviève Marcelin³, Vincent Calvez³, Tulio de Oliveira⁴, François Dabis⁵, Deenan Pillay¹, for the ANRS 12249 Treatment as Prevention

¹Africa Hlth Rsr Inst, Mtubatuba, South Africa, ²Univ Coll London, London, UK,

³Pitie-Salpetriere Hosp, Paris, France, ⁴Univ of KwaZulu-Natal, Durban, South

Africa, ⁵Univ de Bordeaux, Bordeaux, France

44LB PHASE III SWORD 1&2: SWITCH TO DTG+RPV MAINTAINS 10:30 VIROLOGIC SUPPRESSION THROUGH 48 WKS

Josep M. Llibre¹, Chien-Ching Hung², Cynthia Brinson³, Francesco Castelli⁴, Pierre-Marie Girard⁵, Lesley Kahl⁶, Elizabeth Blair⁷, Brian Wynn⁸, Kati Vandermeulen⁹, Michael Aboud⁷

¹Univ Hosp Germans Trias, Badalona, Barcelona, Spain, ²Natl Taiwan Univ Hosp, Taipei, Taiwan, ³Central Texas Clinical Rsr, Austin, TX, USA, ⁴ASST Spedali Civili di Brescia, Brescia, Italy, ⁵Saint-Antoine Hosp, Paris, France, ⁶ViiV Hlthcare, Brentford, Middlesex, UK, ⁷ViiV Hlthcare, Rsr Triangle Park, NC, USA, ⁸ViiV Hlthcare, Collegeville, PA, USA, ⁹Janssen, Beerse, Belgium

45LB DORAVIRINE IS NON-INFERIOR TO DARUNAVIR/R IN PHASE 3 11:45 TREATMENT-NAÏVE TRIAL AT WEEK 48

Jean-Michel Molina¹, **Kathleen Squires**², Paul E. Sax³, Pedro Cahn⁴, Johan Lombaard⁵, Edwin DeJesus⁶, Xia Xu⁷, Bach-Yen T. Nguyen⁷, George Hanna⁷, Carey Hwang⁷

¹Hosp St Louis, Paris, France, ²Thomas Jefferson University, Philadelphia, PA, USA, ³Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA, ⁴Fundación Huesped, Buenos Aires, Argentina, ⁵Joshua Research, Bloemfontein, South Africa, ⁶Orlando Immunology Center, Orlando, FL, USA, ⁷Merck & Co, Inc, Kenilworth, NJ, USA

Themed Discussion TD-1: CD8 T CELLS: WHERE AND HOW THEY KILL Room 615-617 1:30 PM - 2:30 PM

Themed Discussion Leader

Nicole Frahm, FHCRC, Seattle, WA, USA

266 LYMPH NODE HIV-SPECIFIC CXCR5+ CTLs ARE ASSOCIATED WITH ENHANCED VIRAL CONTROL

Zaza Ndhlovu¹, Funsho Ogunshola², Omolara Baiyegunhi², Nikoshia Mewala², Amber Moodley², Krista Dong¹, Thumbi Ndung'u², Bruce D. Walker¹

¹Ragon Inst of MGH, MIT and Harvard, Cambridge, MA, USA, ²Univ of KwaZulu Natal, Durban, South Africa

267 RESIDENT MEMORY CD8+ T CELLS FORM THE FRONT-LINE DEFENSE IN HIV-INFECTED LYMPH NODES

Marcus Buggert¹, Lalit Beura², Son Nguyen¹, David Canaday³, Ali Naji⁴, Constantinos Petrovas⁵, Gustavo Reyes-Terán⁶, Steven G. Deeks⁷, David Masopust², Michael R. Betts¹

¹Univ of Pennsylvania, Philadelphia, PA, USA, ²Univ of Minnesota, Minneapolis, MN, USA, ³Case Western Reserve Univ, Cleveland, OH, USA, ⁴Hosp of the Univ of Pennsylvania, Philadelphia, PA, USA, ⁵NIH, Bethesda, MD, USA, ⁶Rsr Cntr in Infectious Diseases, Mexico City, Mexico, ⁷Univ of California San Francisco, San Francisco, CA, USA

268 HIV-1 ESCAPE FROM CD8+ CYTOTOXIC T-LYMPHOCYTES DEFINED AT CLONAL RESOLUTION

Aleksandr Gorin, Yushen Du, Ren Sun, Otto Yang
Univ of California Los Angeles, Los Angeles, CA, USA

269 INVESTIGATING THE ROLE OF TCR STRUCTURE IN FUNCTIONAL ACTIVITY OF HIV-SPECIFIC CTLs

Nina C. Flerin¹, Tynisha Glover¹, Huabiao Chen², Jianhua Zheng¹, Harris Goldstein¹

¹Albert Einstein Coll of Med, Bronx, NY, USA, ²Ragon Inst of Massachusetts General Hosp, Cambridge, MA, USA

270 HIV-SPECIFIC CD8 T CELLS IN PERSONS TREATED IN FIEBIG I ACUTE INFECTION WHO STOP ART

Hiroshi Takata¹, Donn Colby², Eugene Kroon², Suteeraporn Pinyakorn¹, Nelson L. Michael³, Merlin L. Robb¹, Jintana Intasan², Jintanat Ananworanich⁴, Lydie Trautmann¹, for the RV411 and RV254/SEARCH010 Study Groups

¹Walter Reed Army Inst of Rsr, Silver Spring, MD, USA, ²SEARCH, The Thai Red Cross AIDS Rsr Cntr, Bangkok, Thailand, ³Walter Reed Army Inst of Rsr, Silver Spring, MD, USA, ⁴US Military HIV Rsr Prog, Silver Springs, MD, USA

Themed Discussion TD-2: VIRUS AND CELL RNA IN HIV REPLICATION Room 611-614 1:30 PM - 2:30 PM

Themed Discussion Leader

Kate Bishop, *The Francis Crick Inst, London, UK*

161 UBP43 (USP18) ABROGATES SAMHD1-MEDIATED RESTRICTION OF HIV-1

Edmund Osei-Kuffour¹, Kerstin Schott², Dieter Häussinger¹, Philipp A. Lang¹, Karl S. Lang³, Renate König⁴, Carsten Münk¹

¹Heinrich Heine Univ Hosp, Düsseldorf, Germany, ²Paul Ehrlich Institut, Fed Inst for Vaccines and BioMeds, Düsseldorf, Germany, ³Univ Hosp, Essen, Düsseldorf, Germany, ⁴Paul Ehrlich Institut, Langen, Germany

162 LNCRNA DISCOVERY IN THE HIV REPLICATION CYCLE ADDS A NEW LAYER IN HIV-HOST INTERPLAY

Wim Trypsteen¹, Pejman Mohammadi², Clarissa Van Hecke¹, Pieter Mestdag¹, Steve Lefever¹, Pieter De Bleser³, Jo Vandesompele¹, Angela Ciuffi², Ward De Spiegelaere¹, Linos Vandekerckhove¹

¹Ghent Univ, Ghent, Belgium, ²Univ of Lausanne, Lausanne, Switzerland, ³Inflammation Rsr Cntr, Flanders Inst of BioTech, Ghent, Belgium

163 SPLICING IN A PANEL OF HIV-1 TRANSMITTED/FOUNDER VIRUSES

Ann Emery, Ronald Swanstrom

Univ of North Carolina at Chapel Hill, Chapel Hill, NC, USA

164 THE ROLES OF 5 CONSERVED LENTIVIRAL RNA STRUCTURES IN HIV-1 REPLICATION

Yang Liu¹, Olga A. Nikolaitchik¹, Belete A. Desimmie¹, Vinay K. Pathak¹, Kevin M. Weeks², Wei-Shau Hu¹

¹NCI, Frederick, MD, USA ²Univ of North Carolina at Chapel Hill, Chapel Hill, NC, USA

165 EXPONENTIAL GROWTH OF HIV DEPENDENT ON BURST SIZE BREAKTHROUGH OF THE ALLEE THRESHOLD

Jason M. Hataye¹, Joseph P. Casazza¹, David R. Ambrozak¹, Takuya Yamamoto², Daniel Douek³, Alan S. Perelson⁴, Richard A. Koup³

¹NIH, Bethesda, MD, USA, ²Osaka Univ, Sukta, Osaka, Japan, ³NIAID, Bethesda, MD, USA, ⁴Los Alamos Natl Lab, Los Alamos, NM, USA

Themed Discussion TD-3: HIV, MIGRATION, AND ACCESS TO CARE

Room 606-609

1:30 PM - 2:30 PM

Themed Discussion Leader

Andrea Howard, *Columbia Univ, New York, NY, USA*

1015 MIGRATION, GENDER, AND HIV INCIDENCE IN RAKAI, UGANDA

Oluwasolape M. Olawore¹, Aaron Tobian², Fred Nalugoda², Ronald H. Gray¹, Maria Wawer¹, Robert Ssekubugu², John Santelli³, Larry W. Chang², David Serwadda⁴, Kate Grabowski¹

¹The Johns Hopkins Univ, Baltimore, MD, USA, ²Rakai Hlth Scis Prog, Kalisizo, Uganda, ³Columbia Univ, New York, NY, USA, ⁴Makerere Univ, Kampala, Uganda

1016 OUTCOMES ALONG THE HIV CARE CONTINUUM AMONG UNDOCUMENTED IMMIGRANTS IN CLINICAL CARE

Jonathan Ross, Uriel Felsen, Chinazo Cunningham, Viraj V. Patel, David B. Hanna

Albert Einstein Coll of Med, Bronx, NY, USA

1017 IMMIGRANTS AND BOTSWANA'S ART PROGRAM: POTENTIAL BARRIERS TO EPIDEMIC CONTROL

Tafireyi Marukutira¹, Mary Grace Alwano¹, Stephanie Behel², Joseph N. Jarvis¹, Unoda Chakalisa³, Kathleen Powis⁴, William Bapati⁵, Gene Ussery⁶, Refeletswe Lebelonyane⁷, Pamela J. Bachanas²

¹US CDC, Gaborone, Botswana, ²CDC, Atlanta, GA, USA, ³Botswana Harvard Partnership, Gaborone, Botswana, ⁴Harvard Univ, Boston, MA, USA, ⁵Tebelopele Voluntary Counseling and Testing Cntr, Gaborone, Botswana, ⁶Northrop Grumman Corporation, Atlanta, GA, USA, ⁷Botswana Ministry of Hlth, Gaborone, Botswana

1018 CASCADE OF CARE OF HIV SEROCONVERTERS IN THE CONTEXT OF UNIVERSAL "TEST AND TREAT"

Joseph Larmarange¹, Mamadou H. Diallo¹, Collins C. Iwuji², Joanna Orne-Gliemann³, Nuala McGrath⁴, Mélanie Plazy³, Frank Tanser⁵, Rodolphe Thiébaud⁶, Deenan Pillay⁵, François Dabis⁶

¹IRD, Paris, France, ²Univ Coll London, UK, London, UK, ³INSERM, Bordeaux, France, ⁴Univ of Southampton, Southampton, UK, ⁵Africa Hlth Rsr Inst, Mtubatuba, South Africa, ⁶Univ de Bordeaux, Bordeaux, France

Themed Discussion TD-4: OBESITY AND FATTY LIVER DISEASE

Room 6 C

1:30 PM - 2:30 PM

Themed Discussion Leader

John Koethe, MD, *Vanderbilt University Medical Center, Nashville, TN, USA*

693 BODY MASS INDEX AND THE RISK OF SERIOUS NON-AIDS EVENTS: THE D:A:D STUDY

Amit C. Achhra¹, Caroline Sabin², Lene Ryom³, Antonella d'Arminio Monforte⁴, Stephane de Wit⁵, Andrew Phillips², Christian Pradier⁶, Jens D. Lundgren⁷, Matthew Law¹, for the the DAD Study Group

¹Kirby Inst, Sydney, Australia, ²Univ Coll London, London, UK, ³CHIP, Copenhagen, Denmark, ⁴Univ of Milan, Milan, Italy, ⁵Univ Libre de Bruxelles, Brussels, Belgium, ⁶Nice Univ Hosp, Nice, France, ⁷Univ of Copenhagen, Copenhagen, Denmark

- 694 RANDOMIZED TRIAL OF BEHAVIORAL WEIGHT LOSS FOR HIV-INFECTED PATIENTS**
Katie Becofsky¹, Edward J. Wing², Jeanne McCaffery³, Matthew Boudreau³, Rena R. Wing³
¹Univ of Massachusetts Amherst, Amherst, MA, USA, ²Brown Univ, Providence, RI, USA, ³The Miriam Hosp, Providence, RI, USA
- 695 PREDICTORS OF SEVERE WEIGHT/BODY MASS INDEX GAIN FOLLOWING ANTIRETROVIRAL INITIATION**
Priya Bhagwat¹, Igbo Ofotokun², Grace A. McComsey³, Todd Brown⁴, Carlee Moser⁵, Catherine A. Sugar¹, Judith S. Currier¹
¹Univ of California Los Angeles, Los Angeles, CA, USA, ²Emory Univ, Atlanta, GA, USA, ³Case Western Reserve Univ, Cleveland, OH, USA, ⁴The Johns Hopkins Univ, Baltimore, MD, USA, ⁵Harvard Univ, Boston, MA, USA
- 696 RALTEGRAVIR SWITCH AND BIOMARKERS OF LIVER STEATOSIS AND METABOLIC SYNDROME IN WOMEN**
David Reynoso¹, Anoma Somasunderam¹, Maitreyee Nigalye¹, Judith S. Currier², Netanya S. Utay¹, **Jordan E. Lake**³
¹Univ of Texas Med Branch at Galveston, Galveston, TX, USA, ²Univ of California Los Angeles, Los Angeles, CA, USA, ³Univ Texas Houston, Houston, TX, USA
- 697 CHANGES IN LIVER STEATOSIS AFTER SWITCHING EFVIRENZ TO RALTEGRAVIR: THE STERAL STUDY**
Juan Macías¹, Dolores Merino², Francisco Téllez³, Federico Pulido⁴, Juan González-García⁵, Manuel Márquez⁶, Antonio Rivero⁷, María Mancebo¹, Juan A. Pineda¹, for the RIS-HEP09
¹Hosp Univ de Valme, Sevilla, Spain, ²Complejo Hospario Univ de Huelva, Huelva, Spain, ³Hosp Univ de Puerto Real, Cádiz, Spain, ⁴Hosp 12 de Octubre, Madrid, Spain, ⁵Hosp Univ La Paz, Madrid, Spain, ⁶Hosp Virgen de la Victoria, Málaga, Spain, ⁷Hosp Univ Reina Sofía, Cordoba, Spain

Themed Discussion TD-5: PREP WITHOUT BORDERS: NEW DELIVERY OPTIONS

Room 6 E

1:30 PM - 2:30 PM

Themed Discussion Leader

Aaron Siegler, Emory Univ, Atlanta, GA, USA

- 961 FEASIBILITY OF A PHARMACIST-RUN HIV PREP CLINIC IN A COMMUNITY PHARMACY SETTING**
Elyse Tung¹, Annalisa Thomas¹, Allyson Eichner¹, Peter Shalit²
¹Kelley-Ross Pharm, Seattle, WA, USA, ²Univ of Washington, Seattle, WA, USA
- 962 ASSESSING THE EFFICACY AND FEASIBILITY OF A RETAIL PHARMACY-BASED HIV TESTING PROGRAM**
Bryan C. Collins, Heather W. Bronson, Elaine G. Martin
Virginia Dept of Hlth, Richmond, VA, USA
- 963 MIDWEST PHARMACISTS' KNOWLEDGE OF & WILLINGNESS TO PROVIDE PREEXPOSURE PROPHYLAXIS**
Jordan Broekhuis, Kimberly K. Scarsi, Harlan Sayles, Donald Klepser, Joshua Havens, Susan Swindells, Sara H. Bares
Univ of Nebraska, Omaha, NE, USA
- 964 TEXT MESSAGING IS ASSOCIATED WITH IMPROVED RETENTION IN A CLINIC-BASED PREP PROGRAM**
Christine M. Khosropour¹, Richard T. Lester², Matthew R. Golden¹, Julia C. Dombrowski¹
¹Univ of Washington, Seattle, WA, USA, ²Univ of British Columbia, Vancouver, British Columbia, Canada

965 **BRIEF BEHAVIORAL INTERVENTION INCREASES PREP DRUG LEVELS IN A REAL-WORLD SETTING**

Sarit A. Golub¹, Stephanie Pena², Amy Hilley³, John Pachankis⁴, Asa Radix²
¹City Univ of New York, New York, NY, USA, ²Callen-Lorde Community Hlth Cntr, New York, NY, USA, ³Hunter HIV/AIDS Rsr Team, New York, NY, USA, ⁴Yale Univ, New Haven, CT, USA

Symposium S-1 VISIONS OF HIV CURE
Room 6 E

4:00 PM - 6:00 PM

Target Audience: This session is directed to clinicians and scientists who are interested in understanding the mechanisms of HIV persistence during antiretroviral therapy and the novel strategies developed to cure HIV infection or at least reduce the size of the viral reservoir.

Level of Knowledge: It is assumed that the participants are familiar with the concept of viral reservoirs, HIV latency and cure strategies.

Objectives: At the completion of the session, participants will be able to:

- Describe the methods used to identify and quantify persistently infected cells during antiretroviral therapy
- Evaluate the potential of novel curative strategies
- Describe the mechanism by which an immune intervention (vaccine, immune checkpoint blockers) may reduce the size of the viral reservoir

Conveners

R. Brad Jones, *George Washington Univ, Washington, DC, USA*

Sharon Lewin, *Univ of Melbourne, Melbourne, Australia*



46 **VISUALIZING PERSISTENT HIV IN CLINICAL SAMPLES**

4:00

Daniel E. Kaufmann, *Univ of Montreal, Montreal, QC, Canada*



47 **CHARACTERIZING HIV EXPRESSION IN VIVO**

4:30

Mary F. Kearney, *NCI, NIH, Frederick, MD, USA*



48 **IMMUNE-BASED INTERVENTIONS TARGETING INFLAMMATION AND VIRAL PERSISTENCE**

5:00

Mirko Paiardini, *Emory Univ Sch of Med, Atlanta, GA, USA*



49 **THERAPEUTIC VACCINATION FOR HIV/SIV: WHAT WILL IT TAKE FOR CURE?**

5:30

Louis J. Picker, *Oregon Hlth & Sci Univ, Beaverton, OR, USA*



Symposium S-2 MULTIDRUG-RESISTANT TB (MDR-TB): THE GOOD, THE BAD, AND THE UGLY

Room 606-609

4:00 PM - 6:00 PM

Target Audience: This session is directed to clinicians and researchers interested in the pathogenesis, clinical manifestations, diagnosis, treatment and prevention of tuberculosis (TB) and its complications, including HIV and TB co-infection.

Level of knowledge: It is assumed that participants are familiar with basic TB biology, epidemiology, clinical features and treatment.

Objectives: At the completion of the session, participants will be able to:

- Describe the epidemiology of and factors associated with transmission of multidrug resistant TB (MDR-TB)
- Identify appropriate regimens utilizing new and investigational drugs for treatment of MDR-TB, including the challenges associated with their use in children
- Assess the role of new and existing technologies for diagnosis of MDR-TB

Conveners

Constance Benson, *Univ of California San Diego, San Diego, CA, USA*

Roxana Rustomjee, *NIAID, NIH, DHHS, Rockville, MD, USA*



50 MDR-TB EPIDEMIOLOGY AND TRANSMISSION DYNAMICS

4:00

N. Sarita Shah, *CDC, Atlanta, GA, USA*



51 EMERGING TREATMENT ISSUES IN MDR-TB

4:30

Francesca Conradie, *Univ of the Witwatersrand, Johannesburg, South Africa*



52 NEW DIAGNOSTIC TECHNOLOGIES FOR MDR-TB

5:00

Catharina C. Boehme, *Fndn for Innovative New Diagnostics (FIND), Geneva, Switzerland*



53 THE CHALLENGES OF TREATING MDR-TB IN CHILDREN

5:30

H. Simon Schaaf, *Stellenbosch Univ, Cape Town, South Africa*



Oral Sessions • Tuesday

Symposium S-3 STRANGERS IN THE NIGHT: CHALLENGES AND OPPORTUNITIES IN STI CONTROL

Room 6 C

4:00 PM - 6:00 PM

Target audience: This session is directed to clinicians and scientists who are interested in understanding the prevention and management of sexually transmitted infections, and their relationship to HIV.

Level of knowledge: It is assumed that the participants are familiar with basic HIV and STI epidemiology.

Objectives:

At the completion of the session, participants will be able to:

- Describe the role of the vaginal microbiome in susceptibility of HIV acquisition
- Discuss strategies for prevention of sexually transmitted infections
- Identify the promise of point of care tests for sexually transmitted infections

Conveners

Deborah Money, *Univ of British Columbia, Vancouver, BC, Canada*

Arlene Sena, *Univ of North Carolina at Chapel Hill, Chapel Hill, NC, USA*



54 VAGINAL MICROBIOME AND SUSCEPTIBILITY TO HIV

4:00 **R. Scott McClelland**, *Univ of Washington, Seattle, WA, USA*



55 ANTIBIOTIC PROPHYLAXIS FOR STIs: PROMISES OR PERILS

4:30

Jean-Michel Molina, *Univ of Paris Diderot, Paris, France*



56 SYPHILIS IN THE ERA OF TREATMENT AS PREVENTION AND PRE-EXPOSURE PROPHYLAXIS

5:00

Matthew R. Golden, *Univ of Washington, Seattle, WA, USA*



57 SCALE-UP OF POINT-OF-CARE TESTS FOR SEXUALLY TRANSMISSIBLE INFECTIONS

5:30

Rebecca J. Guy, *Kirby Inst, Univ of New South Wales, Sydney, Australia*



WEDNESDAY, FEBRUARY 15, 2017

Plenary PL-2 WEDNESDAY PLENARY SESSION**Auditorium - 4 AB****8:30 AM - 9:30 AM****58 (PREVENTING) THE COMING EPIDEMIC: HIV IN YOUTH**

8:30

Shannon L. Hader, CDC, Atlanta, GA, USA**59 ANTIVIRAL VACCINE DEVELOPMENT FROM A (AIDS) TO Z (ZIKA)**

9:00

Barney S. Graham, NIAID, VRC, NIH, Bethesda, MD, USA**Oral Abstract O-5 ROLE OF HOST AND IMMUNE FACTORS IN HIV INFECTION****Room 611-614****10:00 AM - 12:00 PM****Oral Abstract Moderators****Michael Betts**, Univ of Pennsylvania, Philadelphia, PA, USA**Irini Sereti**, NIAID, Bethesda, MD, USA**60 IMMUNE CORRELATES OF HIV ACQUISITION**

10:00

Krystelle Nganou Makamdop¹, Slim Fourati², Jianfei Hu¹, Amy Ransier¹, Farida Laboune¹, Rafick-Pierre Sekaly², Daniel Douek¹¹NIAID, Bethesda, MD, USA, ²Case Western Reserve Univ, Cleveland, OH, USA**61 MARKED CHANGES IN CELLULAR BUT NOT VIRUS TRANSCRIPTOME IN CD4-LOW HIV-INFECTED CELLS**

10:15

Joseph P. Casazza¹, Eli Boritz², David R. Ambrozak², Amy R. Henry², Farida Laboune², Sam Darko², Jianfei Hu², Christine Grech², Daniel Douek², Richard A. Koup²¹NIH, Bethesda, MD, USA, ²VRC, NIAID, Bethesda, MD, USA**62LB SINGLE CELL TRANSCRIPTIONAL PROFILING REVEALS A NOVEL POPULATION OF MUCOSAL TFH CELLS**

10:30

Andrew R. Rahmberg¹, Premeela A. Rajakumar¹, James M. Billingsley², Surinder P. Gill¹, R. Paul Johnson¹¹Emory Univ, Atlanta, GA, USA, ²Yerkes Natl Primate Rsr Cntr, Decatur, GA, USA**63 HIGH HIV PERMISSIVITY OF T FOLLICULAR REGULATORY CELLS IS RELATED TO Ki67 EXPRESSION**

10:45

Shannon Miller¹, Brodie Miles¹, Joy Folkvord², Amie Meditz³, Martin McCarter¹, Mario Santiago¹, David N. Levy⁴, Samantha MaWhinney¹, **Elizabeth Connick**²¹Univ of Colorado Denver, Aurora, CO, USA, ²Univ of Arizona, Tucson, AZ, USA,³Boulder Community Hosp, Boulder, CO, USA, ⁴New York Univ Coll of Dentistry, New York, NY, USA**64LB VIRION INCORPORATION OF INTEGRIN $\alpha 4\beta 7$: IMPLICATIONS FOR HIV-1 PATHOGENESIS**

11:00

Christina Guzzo, David Ichikawa, Chung Park, Cathy Rehm, Claudia Cicala, James Arthos, Anthony S. Fauci, John Kehrl, Paolo Lusso

NIAID, Bethesda, MD, USA

65 **DEFINING THE NATURE OF CD8+ T-CELL RESPONSES IN LYMPH NODES OF HIV ELITE CONTROLLER**

11:15

Son Nguyen¹, Marcus Buggert¹, Ali Naji², Perla Del Río-Estrada³, Gustavo Reyes-Terán³, Steven G. Deeks⁴, Michael R. Betts¹

¹Univ of Pennsylvania, Philadelphia, PA, USA, ²Hosp of the Univ of Pennsylvania, Philadelphia, PA, USA, ³Rsr Cntr in Infectious Diseases, Mexico City, Mexico, ⁴Univ of California San Francisco, San Francisco, CA, USA

66 **HIV-SPECIFIC BINDING ANTIBODY PROFILES ASSOCIATED WITH BROADLY NEUTRALIZING ACTIVITY**

11:30

Claus Kadelka, Thomas Liechti, Hanna Ebner, Peter Rusert, Roger Kouyos, Huldrych F. Günthard, Alexandra Trkola

Univ of Zurich, Zurich, Switzerland

67 **THE IMPACT OF HIV-GENETICS ON IMPRINTING ANTIBODY RESPONSES: THE SWISS 4.5K SCREEN**

11:45

Roger Kouyos, Peter Rusert, Claus Kadelka, Alex Marzel, Thomas Liechti, Merle Schanz, Hanna Ebner, Huldrych F. Günthard, Alexandra Trkola, for the Swiss HIV Cohort Study

Univ of Zurich, Zurich, Switzerland

Oral Abstract O-6 CNS RESERVOIRS, NEUROPATHOGENESIS, AND HOST FACTORS

Room 606-609

10:00 AM - 12:00 PM

Oral Abstract Moderators

Ignacio Pérez-Valero, Hospital La Paz, Madrid, Spain

Ronald Swanstrom, University of North Carolina, Chapel Hill, NC, USA

68 **INTENSITY OF SUPPRESSION LINKED WITH SHIFTING COMPARTMENTALIZATION OF CNS HIV DNA**

10:00

Benjamin B. Gelman¹, Joshua G. Lisinicchia¹, Lalita D. Singh¹, Vipulkumar N. Patel¹, Alexander J. Gill², Colleen E. Kovacsics², Dennis L. Kolson²

¹Univ of Texas Med Branch, Galveston, TX, USA, ²Univ of Pennsylvania, Philadelphia, PA, USA

69 **CNS PARENCHYMA AND CHOROID PLEXUS, NOT CSF, ARE VIRAL RESERVOIRS IN MONKEYS WITH AIDS**

10:15

Jaclyn Mallard¹, Brittany Rife², Emily Papazian¹, Arianna Noggle¹, David J. Nolan², Marco Salemi², Kenneth C. Williams¹

¹Boston Coll, Chestnut Hill, MA, USA, ²Univ of Florida, Gainesville, FL, USA

70 **EARLY MACROPHAGE-INDEPENDENT INFLAMMATION AND SHIV-RNA IN CNS IN A RHESUS SHIV MODEL**

10:30

Denise C. Hsu¹, Piyanate Sunyakumthorn², Matthew Wegner², Jacob D. Estes³, Claire Deleage³, Robert J. O'Connell², Victor Valcour⁴, Serena Spudich⁵, Nelson L. Michael⁶, **Sandhya Vasan**¹

¹US Military HIV Rsr Prog, Bangkok, Thailand, ²Armed Forces Rsr Inst of Med Scis, Bangkok, Thailand, ³Frederick Natl Lab for Cancer Rsr, Leidos Biomed Rsr Inc, Frederick, MD, USA, ⁴Univ of California San Francisco, San Francisco, CA, USA, ⁵Yale Univ, New Haven, CT, USA, ⁶US Military HIV Rsr Prog, Silver Spring, MD, USA

71

10:45

DEEP SEQUENCING REVEALS RARE CNS COMPARTMENTALIZATION IN ACUTE HIV-1 INFECTION

Rujipas Sirijatuphat¹, James L. Fletcher², Eric Sanders-Buell³, Jintanat Ananworanich³, Nelson L. Michael³, Victor Valcour⁴, Sodsai Tovanabutra³, Gustavo Kijak³, Serena Spudich⁵, for the RV254/SEARCH 010 Team and MHRP Viral Sequencing Core

¹Mahidol Univ, Bangkok, Thailand, ²South East Asia Rsr Collab with Hawaii (SEARCH), Bangkok, Thailand, ³US Military HIV Rsr Prog, Silver Spring, MD, USA, ⁴Univ of California San Francisco, San Francisco, USA, ⁵Yale Univ, New Haven, CT, USA

72

11:00

CD4/CD8 RATIO ASSOCIATES WITH NEUROPSYCHOLOGIC PERFORMANCE DURING EARLY HIV INFECTION

Leah T. Le¹, Kevin Robertson², Brinda Emu¹, Richard W. Price³, Magnus Gisslén⁴, Henrik Zetterberg⁴, Roxane Fabre⁵, Christian Pradier⁵, Serena Spudich¹, Matteo Vassallo⁶

¹Yale Univ, New Haven, CT, USA, ²Univ of North Carolina at Chapel Hill, Chapel Hill, NC, USA, ³Univ of California San Francisco, San Francisco, CA, USA, ⁴Sahlgrenska Academy at the Univ of Gothenburg, Gothenburg, Sweden, ⁵Univ de Nice-Sophia Antipolis, Nice, France, ⁶Cntr Hosp de Cannes, Cannes, France

73

11:15

ASYMPTOMATIC HIV-1 CSF ESCAPE IS UNCOMMON AND IS NOT ASSOCIATED WITH NEURONAL DAMAGE

Sarah Beth Joseph¹, Laura P. Kincer¹, Natalie M. Bowman¹, Henrik Zetterberg², Magnus Gisslén², Kevin Robertson¹, Serena Spudich³, Joseph J. Eron¹, Richard W. Price⁴, Ronald Swanstrom¹

¹Univ of North Carolina Chapel Hill, Chapel Hill, NC, USA, ²Sahlgrenska Academy at the Univ of Gothenburg, Gothenburg, Sweden, ³Yale Univ, New Haven, CT, USA, ⁴Univ of California San Francisco, San Francisco, CA, USA

74

11:30

GENETIC VARIATION IN EIF2AK3 IS ASSOCIATED WITH NEUROCOGNITIVE IMPAIRMENT IN HIV

Scott Letendre¹, Cagla Akay-Espinoza², Ajay Bharti¹, Peilin Jia³, Asha R. Kallianpur⁴, Donald Franklin¹, Gerard D. Schellenberg², Robert K. Heaton⁵, Igor Grant⁵, Kelly L. Jordan-Sciutto²

¹Univ of California San Diego, San Diego, CA, USA, ²Univ of Pennsylvania, Philadelphia, PA, USA, ³Univ of Texas Houston, Houston, TX, USA, ⁴Cleveland Clinic Lerner Coll of Med, Cleveland, OH, USA, ⁵Univ of California San Diego, La Jolla, CA, USA

75

11:45

CEREBRAL SMALL-VESSEL DISEASE IN HIV-INFECTED PATIENTS WELL CONTROLLED ON CART

Antoine Moulignier¹, Julien Savatovsky¹, Ophélie Godin², Nadia Valin³, François-Xavier Lescure⁴, Roland Tubiana⁵, Ana Canestri⁶, Cédric Lamirel¹, **Dominique Costagliola**², for the MICROBREAK ANRS study group

¹Fndn Ophtalmologique Adolphe de Rothschild, Paris, France, ²Univ Paris 06, Paris, France, ³Saint Antoine Hosp, Paris, France, ⁴Bichat Hosp, Paris, France, ⁵Pitié-Salpêtrière Hosp, Paris, France, ⁶Tenon Hosp, Paris, France

Oral Abstract O-7 TB AND OTHER OPPORTUNISTIC INFECTIONS**Room 6 C****10:00 AM - 12:00 PM****Oral Abstract Moderators****Haileyesus Getahun**, *World Health Organization, Geneva, Switzerland***Richard Hafner**, *NIAID, NIH, Bethesda, MD, USA***76LB A MULTICENTER DIAGNOSTIC ACCURACY STUDY OF THE XPERT ULTRA FOR TUBERCULOSIS DIAGNOSIS**

10:00

Samuel G. Schumacher¹, Pamela Nabeta¹, **Catharina C. Boehme**¹, Jerrold Ellner², David Alland³, Susan E. Dorman⁴, Claudia M. Denkinger¹, for the TB Clinical Diagnostics Research Consortium and FIND Trial Consortium

¹FIND, Geneva, Switzerland, ²Boston Med Cntr, Boston, MA, USA, ³Univ of Med and Dentistry of New Jersey, Newark, NJ, USA, ⁴The Johns Hopkins Univ, Baltimore, MD, USA

77 WHOLE-GENOME SEQUENCING AND SPATIAL ANALYSIS OF XDR TB TRANSMISSION IN SOUTH AFRICA

10:15

Kristin N. Nelson¹, Neel R. Gandhi¹, Sara C. Auld¹, James C. Brust², Barun Mathema³, Nazir Ismail⁴, Pravi Moodley⁵, Angela Campbell¹, Salim Allana¹, N. Sarita Shah⁶

¹Emory Univ, Atlanta, GA, USA, ²Albert Einstein Coll of Med, Bronx, NY, USA, ³Columbia Univ, New York, NY, USA, ⁴NICD, Johannesburg, South Africa, ⁵Univ of KwaZulu-Natal, Durban, South Africa, ⁶CDC, Atlanta, GA, USA

78 SIX-MONTH IPT REDUCES MORTALITY INDEPENDENTLY OF ART IN AFRICAN ADULTS WITH HIGH CD4

10:30

Anani D. Badje¹, Raoul Moh², Delphine Gabillard¹, Calixte Guehi³, Mathieu Kabran², Hervé Menan², André Inwoley², Christine Danel¹, Serge Eholie⁴, Xavier Anglaret¹

¹INSERM, Bordeaux, France, ²Prog PAC-CI, ANRS Rsr site, Abidjan, Cote d'Ivoire, ³INSERM, Abidjan, Cote d'Ivoire, ⁴Service des Maladies Infectieuses et Tropes, Abidjan, Cote d'Ivoire

79 THE ESSENTIALITY OF INH DURING THE FIRST 14 DAYS OF TB THERAPY: THE A5307 EBA TRIAL

10:45

Andreas H. Diacon¹, Sachiko Miyahara², Xin Sun², Richard Hafner³, **Florian von Groote-Bidlingmaier**⁴, Courtney Fletcher⁵, Evelyn Hogg⁶, Rodney Dawson⁷, Susan Swindells⁵, William Bishai⁸

¹Stellenbosch Univ, Cape Town, South Africa, ²Harvard Univ, Boston, MA, USA, ³NIH, Bethesda, MD, USA, ⁴TASK Applied Sci, Cape Town, South Africa, ⁵Univ of Nebraska Med Cntr, Omaha, NE, USA, ⁶Social & Scientific Systems, Silver Spring, MD, USA, ⁷Univ of Cape Town, Mowbray, South Africa, ⁸The Johns Hopkins Univ, Baltimore, MD, USA

80LB THE NIX-TB TRIAL OF PRETOMANID, BEDAQUILINE AND LINEZOLID TO TREAT XDR-TB

11:00

Francesca Conradie¹, Andreas H. Diacon², Daniel Everitt³, Carl Mendel³, Christo van Niekerk⁴, Pauline Howell⁵, Kyla Comins⁶, Mel Spigelman³

¹Univ of the Witwatersrand, Johannesburg, SA, ²Stellenbosch Univ, Cape Town, SA, ³Global Alliance for TB Drug Development, New York, NY, USA, ⁴Global Alliance for TB Drug Development, Pretoria, SA, ⁵Clinical HIV Rsr Unit, Johannesburg, SA, ⁶TASK Applied Science, Belville, SA

81LB RANDOMIZED CONTROLLED TRIAL OF PREDNISONE FOR PREVENTION OF PARADOXICAL TB-IRIS

11:15

Graeme Meintjes¹, Cari Stek², Liz Blumenthal¹, Friedrich Thienemann¹, Charlotte Schutz¹, Jozefien Buyze², Gary Maartens¹, Robert Wilkinson³, Lutgarde Lynen², for the PredART Trial Team

¹Univ of Cape Town, Cape Town, South Africa, ²Inst of Tropical Med, Antwerp, Belgium, ³Imperial Coll, London, UK

- 82**
11:30 **AMBITION-CM: HIGH-DOSE LIPOSOMAL AMPHOTERICIN FOR HIV-RELATED CRYPTOCOCCAL MENINGITIS**
Joseph N. Jarvis¹, Tshepo B. Leeme², Awilly A. Chofle³, Gabriella Bidwell³, Mooketsi Molefi⁴, Katlego Tsholo², Nametso Lekwape², Charles Muthoga², Síle Molloy⁵, Thomas S. Harrison⁵
¹CDC Botswana, Gaborone, Botswana, ²Botswana–UPenn Partnership, Gaborone, Botswana, ³Natl Inst of Med Rsr, Mwanza, Tanzania, ⁴Univ of Botswana, Gaborone, Botswana, ⁵St. George's Univ of London, London, UK
- 83**
11:45 **A RANDOMISED CONTROLLED TRIAL OF INDUCTION THERAPY OF TALAROMYCES MARNEFFI INFECTION**
Thuy Le¹, Nguyen V. Kinh², Nguyen Le Nhu Tung³, Thanh Thuy Pham Thi⁴, Pham T. Phuc⁵, Doan T. Hanh⁶, Jeremy Day¹, Guy Thwaites¹, Marcel Wolbers¹, for the IVAP Investigators
¹Oxford Univ Clinical Rsr Unit in Vietnam, Ho Chi Minh, Vietnam, ²Natl Hosp for Trop Diseases, Hanoi, Vietnam, ³Hosp for Trop Diseases, Ho Chi Minh City, Vietnam, ⁴Bach Mai Hosp, Hanoi, Vietnam, ⁵Viet Tiep Hosp, Hai Phong, Vietnam, ⁶Uong Bi Hosp, Quang Ninh, Vietnam

Oral Abstract O-8 COMMON BEDFELLOWS: PREP, STIs, AND THE MICROBIOME

Room 6 AB

10:00 AM - 12:00 PM

Oral Abstract Moderators

Gita Ramjee, South African Medical Research Council, Tygerberg, South Africa
Hyman Scott, Bridge HIV, San Francisco, CA, USA

- 84**
10:00 **RESISTANCE EMERGENCE IN MACAQUES ADMINISTERED CABOTEGRAVIR LA DURING ACUTE INFECTION**
Jessica Radzio¹, Olivia Council¹, Mian-er Cong¹, James Mitchell¹, Shanon Ellis¹, Wei Huang², William Spreen³, Walid Heneine¹, **Gerardo Garcia-Lerma**¹
¹CDC, Atlanta, GA, USA, ²Monogram BioScis, San Francisco, CA, USA, ³ViiV Hlthcare, Rsr Triangle Park, NC, USA
- 85**
10:15 **DAILY ORAL PREP IS EFFECTIVE AMONG WOMEN WITH ABNORMAL VAGINAL MICROBIOTA**
Renee Heffron¹, R. Scott McClelland¹, Jennifer Balkus², Connie L. Celum¹, Craig Cohen³, Nelly Mugo⁴, Elizabeth A. Bukusi⁴, Deborah J. Donnell², Jared Baeten¹, for the Partners PrEP Study Team
¹Univ of Washington, Seattle, WA, USA, ²Fred Hutchinson Cancer Rsr Cntr, Seattle, WA, USA, ³Univ of California San Francisco, San Francisco, CA, USA, ⁴Kenya Med Rsr Inst, Nairobi, Kenya
- 86LB**
10:30 **IMPACT OF VAGINAL MICROBIOTA ON GENITAL TISSUE AND PLASMA CONCENTRATIONS OF TENOFOVIR**
Sharon L. Hillier¹, Leslie A. Meyn¹, Katherine Bunge², Michele Austin³, Bernard J. Moncla¹, Charlene S. Dezzutti¹, Jill Schwartz⁴, Mark A. Marzinke⁵, Craig Hendrix⁵, Lisa C. Rohan¹
¹Univ of Pittsburgh, Pittsburgh, PA, USA, ²Magee-Womens Hospital of UPMC, Pittsburgh, PA, USA, ³Magee-Womens Rsr Inst, Pittsburgh, PA, USA, ⁴CONRAD, Arlington, VA, USA, ⁵Johns Hopkins Univ, Baltimore, MD, USA

87 ABUNDANCE OF PENILE ANAEROBES, IL-8, AND THE RISK OF HIV ACQUISITION, RAKAI, UGANDA

10:45

Cindy M. Liu¹, Jessica Prodder², Aaron Tobian², Rupert Kaul³, Alison Abraham², Godfrey Kigozi⁴, Fred Nalugoda⁴, David Serwadda⁵, **Lance Price¹**, Ronald H. Gray²

¹George Washington Univ, Washington, DC, USA, ²Johns Hopkins Univ, Baltimore, MD, USA, ³Univ of Toronto, Toronto, Ontario, Canada, ⁴Rakai Hlth Scis Prog, Kalisizo, Uganda, ⁵Makerere Univ, Kampala, Uganda

88 DAPIVRINE RING USE DOES NOT DIMINISH THE EFFECTIVENESS OF HORMONAL CONTRACEPTION

11:00

Jennifer Balkus¹, Thesla Palanee-Phillips², Samantha Siva³, Clemensia Nakabiito⁴, Gonasangrie Nair⁵, Samuel Kabwigu⁴, Ishana Harkoo⁶, Catherine Chappell⁷, Lydia Soto-Torres⁸, Jared Baeten⁹

¹Fred Hutchinson Cancer Rsr Cntr, Seattle, WA, USA, ²Wits Reproductive Hlth and HIV Inst, Johannesburg, South Africa, ³South African Med Rsr Council, Durban, South Africa, ⁴Makerere Univ-Johns Hopkins Univ Rsr Collab, Kampala, Uganda, ⁵Emavundleni Rsr Cntr, Cape Town, South Africa, ⁶CAPRISA, Durban, South Africa, ⁷Magee-Womens Hosp of UPMC, Pittsburgh, PA, USA, ⁸NIH, Bethesda, MD, USA, ⁹Univ of Washington, Seattle, WA, USA

89 STD PARTNER SERVICES TO MONITOR AND PROMOTE PREP USE AMONG MEN WHO HAVE SEX WITH MEN

11:15

David A. Katz¹, Julia C. Dombrowski¹, Teal Bell², Matthew R. Golden¹

¹Univ of Washington, Seattle, WA, USA, ²Washington State Dept of Hlth, Olympia, WA, USA

90 CHALLENGES OF TRANSLATING PREP INTEREST INTO UPTAKE AMONG YOUNG BLACK MSM IN ATLANTA

11:30

Charlotte-Paige M. Rolle¹, Aaron S. Siegler¹, Travis Sanchez¹, Nicole Luisi¹, Scott R. Cutro², Carlos del Rio¹, Patrick Sullivan¹, Eli Rosenberg¹, Colleen F. Kelley¹

¹Emory Univ, Atlanta, GA, USA, ²Kaiser Permanente, Atlanta, GA, USA

91LB ON DEMAND POST EXPOSURE PROPHYLAXIS WITH DOXYCYCLINE FOR MSM ENROLLED IN A PREP TRIAL

11:45

Jean-Michel Molina¹, Isabelle Charreau², Christian Chidiac³, Gilles Pialoux⁴, Eric Cua⁵, Constance Delaugerre¹, Catherine Capitant², Daniela Rojas-Castro⁶, Laurence Meyer⁷, for the ANRS IPERGAY Study Group

¹St. Louis, Hosp, Paris, France, ²INSERM, Villejuif, France, ³Univ of Lyon, Lyon, France, ⁴Tenon Hosp, Paris, France, ⁵CHU de Nice, Nice, France, ⁶AIDES, Pantin, France, ⁷AP-HP, Le Kremlin-Bicetre, France

Themed Discussion TD-6 INTRACELLULAR AND TISSUE PHARMACOLOGY

Room 615-617

1:30 PM - 2:30 PM

Themed Discussion Leader

Catia Marzolini, Univ Hosp Basel, Basel, Switzerland

404 LEDIPASVIR/SOFOSBUVIR RAISES TENOFOVIR DIPHOSPHATE CONCENTRATIONS IN RED CELLS

Christine MacBrayne¹, Daniel S. Fierer², Kristen M. Marks³, Peter L. Anderson¹, Lane R. Bushman¹, Kimberly M. Hollabaugh⁴, Michael D. Hughes⁴, Raymond T. Chung⁵, Susanna Naggie⁶, Jennifer J. Kiser¹

¹Univ of Colorado, Aurora, CO, USA, ²Icahn Sch of Med at Mt Sinai, New York, NY, USA, ³Weill Cornell Med, New York, NY, USA, ⁴Harvard Univ, Boston, MA, USA, ⁵MGH, Boston, USA, ⁶Duke Univ, Durham, NC, USA

405 TENOFOVIR DIPHOSPHATE ARISING FROM TAF IS QUANTIFIABLE IN DRIED BLOOD SPOTS

Jose Castillo-Mancilla, Ryan P. Coyle, Jia-Hua Zheng, Lucas Ellison, Laura Roon, Jordan Fey, Lane Bushman, Jennifer J. Kiser, Peter Anderson
Univ of Colorado, Aurora, CO, USA

406 EXTRA/INTRA-CELLULAR NUCLEOSIDE/TIDE SEMEN PHARMACOLOGY: IMPLICATIONS FOR ERADICATION

Julie B. Dumond, Stephen A. Greene, Heather M. Asher Prince, Jingxian Chen, Brian Maas, Craig Sykes, Amanda Schauer, Cynthia L. Gay, Angela Kashuba, Myron S. Cohen
Univ of North Carolina at Chapel Hill, Chapel Hill, NC, USA

407 INTEGRASE AND PROTEASE INHIBITOR CONCENTRATIONS IN LYMPHOID VS GI TISSUES

Sulggi Lee¹, Hiroyu Hatano¹, Angela Kashuba², Mackenzie L. Cottrell², Teri Liegler¹, Sophie Stephenson¹, Ma Somsouk¹, Peter W. Hunt¹, Steven G. Deeks¹, Radojka M. Savic¹
¹*Univ of California San Francisco, San Francisco, CA, USA*, ²*Univ of North Carolina at Chapel Hill, Chapel Hill, NC, USA*

408 PLASMA AND INTRACELLULAR PK OF TENOFOVIR IN PATIENTS SWITCHED FROM TDF TO TAF

Anthony Podany, Sara H. Bares, Joshua Havens, Ravi Dyavar Shetty, Jennifer O'Neill, Sarah Lee, Courtney Fletcher, Susan Swindells, Kimberly K. Scarsi
Univ of Nebraska, Omaha, NE, USA

**Themed Discussion TD-7 CNS TREATMENT STRATEGIES:
 RISK AND BENEFITS**
Room 611-614**1:30 PM - 2:30 PM****Themed Discussion Leader**

Ned Sacktor, MD, *The Johns Hopkins Univ, Baltimore, MD, USA*

380 CAN WE AFFORD TO WAIT? ART AND THE CNS

Kevin Robertson¹, Javier R. Lama², Christopher D. Pilcher³, Jessica Rios², Peter Brandes², Eduardo Ruiz², Eline Appelmans⁴, Serena Spudich⁵, Ann Duerr⁴, for the SABES Team

¹*Univ of North Carolina at Chapel Hill, Chapel Hill, NC, USA*, ²*Asociacion Civil Impacta Salud y Educacion, Lima, Peru*, ³*Univ of California San Francisco, San Francisco, CA, USA*, ⁴*Fred Hutchinson Cancer Rsr Cntr, Seattle, WA, USA*, ⁵*Yale Univ, New Haven, CT, USA*

350 COGNITIVE TRAJECTORIES OVER 4 YEARS AMONG HIV+ WOMEN WITH OPTIMAL VIRAL SUPPRESSION

Leah H. Rubin¹, Gayle Springer², Pauline M. Maki¹, Kathryn Anastos³, Deborah Gustafson⁴, Maria Villacres⁵, Drenna Waldrop-Valverde⁶, David Vance⁷, Hector Bolivar⁸, Victor Valcour⁹

¹*Univ of Illinois at Chicago, Chicago, IL, USA*, ²*The Johns Hopkins Univ, Baltimore, MD, USA*, ³*Albert Einstein Coll of Med, Bronx, NY, USA*, ⁴*SUNY Downstate Med Cntr, Brooklyn, NY, USA*, ⁵*Univ of Southern California, Los Angeles, CA, USA*, ⁶*Emory Univ, Atlanta, GA, USA*, ⁷*Univ of Alabama at Birmingham, Birmingham, AL, USA*, ⁸*Univ of Miami, Miami, FL, USA*, ⁹*Univ of California San Francisco, San Francisco, CA, USA*

381 **CENICRIVIROC IMPROVES NEUROCOGNITION AND REDUCES MONOCYTE ACTIVATION IN TREATED HIV**

Lishomwa C. Ndhlovu¹, **Michelle L. D'Antoni**¹, Robert Paul², Kalpana J. Kallianpur¹, Laurent Fischer³, Eric Lefebvre³, Star Seyedkazemi³, Beau K. Nakamoto¹, Debra Ogata-Arakaki¹, Cecilia Shikuma¹

¹Univ of Hawaii, Honolulu, HI, USA, ²Univ of Missouri—St. Louis, St. Louis, MO, USA, ³Tobira Therapeutics, Inc, South San Francisco, CA, USA

382 **CSF INFLAMMATORY MARKERS AFTER ADDING MARAVIROC TO MONOTHERAPY DARUNAVIR/RITONAVIR**

Tristan Barber¹, Arkaitz Imaz², Marta Boffito¹, Daniel Podzamczar², Anton Pozniak¹, Rosa Fortuny², Nicholas Davies¹, Jordi Niubo², Sundhiya Mandalia³, Brian Gazzard¹

¹Chelsea and Westminster NHS Fdn Trust, London, UK, ²Hosp Univ de Bellvitge, Barcelona, Spain, ³Imperial Coll London, London, UK

384 **EXTENSIVE EFAVIRENZ METABOLISM IS ASSOCIATED WITH GREATER CNS TOXICITY**

Marijana Vujkovic¹, Scarlett Bellamy², Athena Zuppa¹, Marc Gastonguay³, Xiaoyan Han⁴, Mosepele Mosepele⁵, Gregory Bisson⁴, Richard Aplenc¹, **Robert Gross**⁴

¹Children's Hosp of Philadelphia, Philadelphia, PA, USA, ²Drexel Univ, Philadelphia, PA, USA, ³Metrum Rsr Group, Tariffville, CT, USA, ⁴Univ of Pennsylvania, Philadelphia, PA, USA, ⁵Univ of Botswana, Gaborone, Botswana

Themed Discussion TD-8 SCREENING FOR HSIL:

ALTERNATIVES TO CYTOLOGY

Room 606-609

1:30 PM - 2:30 PM

Themed Discussion Leader

Timothy Wilkin, MD, Weill Cornell Medicine, New York, NY, USA

592 **MULTITEST SCREENING STRATEGIES ADD VALUE FOR PREDICTING BIOPSY-PROVEN HSIL FOR MSM**

Dorothy J. Wiley¹, Hilary K. Hsu¹, Matthew G. Moran¹, Jenny Brook¹, David Elashoff¹, Martha Ganer¹, Stephen Young², David Morris³, Otoniel Martínez-Maza¹, Ronald T. Mitsuyasu¹

¹Univ of California Los Angeles, Los Angeles, CA, USA, ²Tricore Reference Labs, Albuquerque, NM, USA, ³Desert AIDS Proj, Palm Springs, CA, USA

596 **IMPACT OF ART COVERAGE AND SCREENING ON ANAL CANCER IN HIV+ MEN WHO HAVE SEX WITH MEN**

Nello Blaser¹, Barbara Bertisch¹, Manuel Koller¹, Marcel Stoeckle², Matthias Cavassini³, Roger Kouyos⁴, Janne Estill¹, Matthias Egger¹, **Olivia Keiser**¹, for the Swiss HIV Cohort Study

¹Univ of Bern, Bern, Switzerland, ²Univ Hosp Basel, Basel, Switzerland, ³Univ of Lausanne, Lausanne, Switzerland, ⁴Univ of Zurich, Zurich, Switzerland

594 **MULTIPLE HPV INFECTIONS AND ANAL PRECANCEROUS LESIONS IN HIV-INFECTED MEN**

Shu-Hsing Cheng¹, Chien-Yu Cheng¹, Chi-Chao Wang¹, Fang-Yeh Chu², Yu-Mei Hsueh³

¹Taoyuan General Hosp, Taoyuan, Taiwan, ²Far Eastern Memorial Hosp, New Taipei, Taiwan, ³Taipei Med Univ, Taipei, Taiwan

595 SCREENING FOR PRECANCEROUS ANAL LESIONS WITH P16/KI67 DUAL STAIN CYTOLOGY IN HIV

Sergio Serrano-Villar¹, Beatriz Hernández-Novoa², Amparo de Benito¹, Jorge Romero³, Antonio Ocampo⁴, Laura Pérez-Martínez⁵, Mar Masia⁶, Elena Sendagorta⁷, Gonzalo Sanz⁸, José Antonio Pérez-Molina¹

¹Hosp Univ Ramón y Cajal, Madrid, Spain, ²Brystol-Myers-Squibb, Madrid, Spain, ³Centro Sandoval, Madrid, Spain, ⁴Hosp Xeral de Vigo, Vigo, Pontevedra, ⁵Hosp San Pedro, Logroño, Spain, ⁶Hosp General Univ de Elche, Elche, Spain, ⁷Hosp Univ La Paz, Madrid, Spain, ⁸Hosp Clínico San Carlos, Madrid, Spain

Themed Discussion TD-9 HIV SELF-TESTING: KNOW YOURSELF Room 6 C

1:30 PM - 2:30 PM

Themed Discussion Leader

Joanne Stekler, MD, Univ of Washington, Seattle, WA, USA

891 HIV SELF-TEST (HIVST) AWARENESS, EXPOSURE, AND USE, NEW YORK CITY, 2015–2016

Paul M. Salcuni, Zoe R. Edelstein, Demetre C. Daskalakis, Julie Myers
New York City DHMH, Queens, NY, USA

893 PEER-LED ORAL HIV-SELF TESTING FINDS UNDIAGNOSED HIV AMONG MSM IN MALINDI, KENYA

Elisabeth M. van der Elst¹, Mahmoud Shally¹, Clifford Oduor¹, Oscar Chirro¹, Fauz Ibrahim², Bernadette Kombo¹, Susan M. Graham³, **Eduard Sanders**⁴
¹KEMRI Wellcome Trust Rsr Prog, Kilifi, Kenya, ²Kilifi County Dept of Hlth, Kilifi, Kenya, ³Univ of Washington, Seattle, WA, USA, ⁴Kenya Med Rsr Inst, Kilifi, Kenya

894 ROLE OF PARTNER VIOLENCE IN WOMEN'S ABILITY TO DISTRIBUTE SELF-TESTS TO MALE PARTNERS

Elisabeth Schaffer¹, Kawango Agot², Harsha Thirumurthy¹
¹Univ of North Carolina at Chapel Hill, Chapel Hill, NC, USA, ²Impact Rsr and Development Org, Kisumu City, Kenya

895 INFORMING HIV SELF-TESTING SERVICES IN MALAWI USING DISCRETE CHOICE EXPERIMENTS

Pitchaya Indravudh¹, Marc D'Elbee², Moses Kumwenda¹, Augustine Choko³, Doreen Sakala¹, Thokozani Kalua⁴, Cheryl Johnson⁵, Karin Hatzold⁶, Liz Corbett³, Fern Terris-Prestholt²

¹Malawi–Liverpool–Wellcome Trust Clinical Rsr Prog, Blantyre, Malawi, ²London Sch of Hygiene & Trop Med, London, UK, ³London Sch of Hygiene & Trop Med, Blantyre, Malawi, ⁴Malawi Dept of HIV and AIDS, Lilongwe, Malawi, ⁵WHO, Geneva, Switzerland, ⁶Pop Services Intl, Harare, Zimbabwe

896 PROVIDING USER SUPPORT FOR HIV SELF-TESTING BEYOND INSTRUCTIONS-FOR-USE IN MALAWI

Pitchaya Indravudh¹, Moses Kumwenda¹, Melissa Neuman², Blessings Chisunkha¹, Karin Hatzold³, Chiwawa Nkhoma⁴, Thokozani Kalua⁵, Cheryl Johnson⁶, Miriam Taegtmeier⁷, Liz Corbett⁸

¹Malawi–Liverpool–Wellcome Trust Clinical Rsr Prog, Blantyre, Malawi, ²London Sch of Hygiene & Trop Med, London, UK, ³Pop Services Intl, Harare, Zimbabwe, ⁴Pop Services Intl, Blantyre, Malawi, ⁵Malawi Dept of HIV and AIDS, Lilongwe, Malawi, ⁶WHO, Geneva, Switzerland, ⁷Liverpool Sch of Trop Med, Liverpool, UK, ⁸London Sch of Hygiene & Trop Med, Blantyre, Malawi

Themed Discussion TD-10 HIV PERSISTENCE: CLONES, CLONES, AND MORE CLONES

Room 6 AB

1:30 PM - 2:30 PM

Themed Discussion Leader

Thor Wagner, *University of Washington/Seattle Children's, Seattle, WA, USA*

292 CLONAL EXPANSION OF GENOME-INTACT HIV-1 IN FUNCTIONALLY POLARIZED T-CELL SUBSETS

Guinevere Q. Lee¹, Nina Orlova¹, Erik Serrao², Xiaoming Sun¹, Navin F. Chowdhury¹, Eric Rosenberg³, Alan N. Engelman², Xu G. Yu¹, Mathias Lichterfeld⁴

¹Ragon Inst of MGH, MIT and Harvard, Cambridge, MA, USA, ²Dana-Farber Cancer Inst, Boston, MA, USA, ³Massachusetts General Hosp, Boston, MA, USA, ⁴Brigham and Women's Hosp, Boston, MA, USA

293 INTACT PROVIRUSES ARE UNEQUALLY DISTRIBUTED IN T CELL SUBSETS DURING ART

Bonnie Hiener¹, Bethany A. Horsburgh¹, John-Sebastian Eden², Kirston Barton¹, Eunok Lee¹, Steven G. Deeks³, Jeffery Milush³, Nicolas Chomont⁴, Rémi Fromentin⁴, Sarah Palmer¹

¹The Westmead Inst for Med Rsr, Westmead, Australia, ²The Univ of Sydney, Sydney, Australia, ³Univ of California San Francisco, San Francisco, CA, USA, ⁴Univ de Montréal, Montreal, QC, Canada

294 A SMALL FRACTION OF PROVIRUSES IN EXPANDED CLONES EXPRESS UNSPLICED HIV RNA IN VIVO

Andrew Musick¹, Jonathan Spindler¹, Brandon Keele², Michael J. Bale¹, Wei Shao², Ann Wiegand¹, John Mellors³, John Coffin⁴, Frank Maldarelli¹, Mary F. Kearney¹

¹NCI, Frederick, MD, USA, ²Leidos Biomed, Inc, Frederick, MD, USA, ³Univ of Pittsburgh, Pittsburgh, PA, USA, ⁴Tufts Univ, Boston, MA, USA

295 PROLIFERATION OF CD4+ T CELLS CONTAINING REPLICATION-COMPETENT HIV-1

Zheng Wang, Ya-Chi Ho, Janet Siliciano, Robert Siliciano
Johns Hopkins Univ, Baltimore, MD, USA

296 CYTOTOXIC T LYMPHOCYTES MAY SHAPE THE HIV-1 PROVIRAL LANDSCAPE

R. Brad Jones¹, Mihaela Pertea², Katherine Bruner², Ross Pollack², Adam Capoferri², Robert Siliciano², Ya-Chi Ho²

¹The George Washington Univ, Washington, DC, USA, ²The Johns Hopkins Univ, Baltimore, MD, USA

Themed Discussion TD-11 INTEGRATION OF SCREENING AND TREATMENT OF NCD INTO HIV CARE IN RESOURCE LIMITED SETTINGS

Room 6 E

1:30 PM - 2:30 PM

Themed Discussion Leader

Matthias Egger, MD, *Inst of Social and Preventive Medicine, Univ of Bern, Bern, Switzerland*

637 INTEGRATING CARDIOVASCULAR DISEASE RISK-FACTOR SCREENING IN HIV SERVICES IN SWAZILAND

Miriam Rabkin¹, Anton M. Palma¹, Margaret L. McNairy¹, Samkelo Simelane², Averie B. Gachuhi¹, Raymond A. Bitchong³, Harriet Nuwagaba-Biribonwoha¹, Pido Bongomin², Velephi Okello⁴, Wafaa M. El-Sadr¹

¹ICAP at Columbia Univ, New York, NY, USA, ²ICAP Swaziland, Mbabane, Swaziland, ³Raleigh Fitkin Memorial Hosp, Manzini, Swaziland, ⁴Swaziland Ministry of Hlth, Mbabane, Swaziland

638 COMPOSITE "HIV/ HYPERTENSION/ DIABETES CONTROL" OUTCOME IN SEARCH CHRONIC CARE MODEL

Dalsone Kwariisima¹, Jeanna Wallenta², James Ayieko³, Florence Mwangwa⁴, Asiphas Owaraganise⁴, Tamara D. Clark², Edwin D. Charlebois², Maya L. Petersen⁵, Diane V. Havlir², Moses R. Kamya⁶

¹Makerere Univ Joint AIDS Prog, Kampala, Uganda, ²Univ of California San Francisco, San Francisco, CA, USA, ³Kenya Med Rsr Inst, Nairobi, Kenya, ⁴Infectious Diseases Rsr Collab, Kampala, Uganda, ⁵Univ of California Berkeley, Berkeley, CA, USA, ⁶Makerere Univ Coll of Hlth Scis, Kampala, Uganda

639 THE ART ADVANTAGE: HEALTHCARE UTILIZATION FOR DIABETES & HYPERTENSION IN SOUTH AFRICA

Jennifer Manne-Goehler¹, Livia Montana², Xavier Gomez-Olive³, Guy Harling⁴, Ryan Wagner⁵, Alisha Wade⁶, Julia K. Rohr², Stephen Tollman⁷, Till Baernighausen⁸, Thomas Gaziano⁹

¹Beth Israel Deaconess Med Cntr, Boston, MA, USA, ²Harvard Univ, Cambridge, MA, USA, ³Tintswalo Hosp, Acornhoek, South Africa, ⁴Harvard Univ, Boston, MA, USA, ⁵Univ of the Witwatersrand, Acornhoek, South Africa, ⁶MRC/Wits Rural Pub Hlth and Hlth Transitions Rsr Unit, Johannesburg, South Africa, ⁷Univ of Witwatersrand, Johannesburg, South Africa, ⁸Heidelberg Univ, Heidelberg, Germany, ⁹Brigham and Women's Hosp, Boston, MA, USA

640 CARDIOVASCULAR RISK ASSESSMENT IN A SUB-SAHARAN AFRICA HIV CLINICAL COHORT

Mosepele Mosepele¹, Linda C. Hemphill², Tommy Palai¹, Isaac Nkele³, Kara Bennett⁴, Shahin Lockman⁵, Virginia Triant²

¹Univ of Botswana, Gaborone, Botswana, ²Massachusetts General Hosp, Boston, MA, USA, ³Botswana—Harvard AIDS Partnership, Gaborone, Botswana, ⁴Bennett Statistical Consulting Inc, New York, NY, USA, ⁵Harvard Univ, Boston, MA, USA

641 HIV AND IMMUNE ACTIVATION ARE RISK FACTORS FOR ENDOTHELIAL DAMAGE IN ADULT MALAWIANS

Christine Kelly¹, Henry Mwandumba², Rob Heyderman³, Raphael Kamng'ona², Mishek Chammudzi², Irene Sheha², Jane E. Mallewa⁴, Sarah Walker³, Nigel Klein³, Saye Khoo⁵

¹Univ Coll Dublin, Dublin, Ireland, ²Malawi Liverpool Wellcome Clinical Rsr Prog, Blantyre, Malawi, ³Univ Coll London, London, UK, ⁴Univ of Malawi, Blantyre, Malawi, ⁵Univ of Liverpool Inst of Translational Med, Liverpool, UK

Symposium S-4 CREATING AND DESTROYING HIV CAPSIDS**Room 611-614****4:00 PM - 6:00 PM**

Target audience: This session is directed to clinicians and scientists who are interested in the assembly of HIV-1 particles and mature capsids, viral genome packaging and recognition of the mature HIV-1 capsid by the TRIM5alpha antiviral protein.

Level of knowledge: It is assumed that participants are familiar with basic concepts in HIV-1 particle assembly and structure.

Objectives: At the completion of the session, participants will be able to:

- Describe how HIV-1 Gag assembles into immature particles and then transitions to a mature infectious form
- Describe how variation in HIV-1 genomic RNA structure facilitates packaging of viral RNA into virions
- Describe how RNA interactions with integrase are required for the correct maturation of virions
- Describe how the TRIM5alpha protein recognizes the mature HIV-1 capsid

Conveners

Sebla Kutluay, *Washington Univ in St. Louis, St Louis, MO, USA*

Victoria D'Souza, *Harvard Univ, Cambridge, MA, USA*

**92 THE FATES AND FOLDS OF HIV-1 RNA**

4:00

Alice Telesnitsky, *Univ of Michigan, Ann Arbor, MI, USA*

**93 STRUCTURE AND FUNCTION OF IMMATURE AND MATURE HIV CAPSIDS**

4:30

Hans-Georg Kräusslich, *Heidelberg Univ, Heidelberg, Germany*

**94 A ROLE OF HIV-1 INTEGRASE IN ENCAPSIDATION OF THE VIRAL RNA GENOME**

5:00

Mamuka Kvaratskhelia, *The Ohio State Univ, Columbus, OH, USA*

**95 TRIM5ALPHA RECOGNITION OF THE HIV CAPSID**

5:30

Barbie K. Ganser-Pornillos, *Univ of Virginia, Charlottesville, VA, USA*



Symposium S-5 HEPATITIS/LIVER

Room 6 E

4:00 PM - 6:00 PM

Target audience: This session is directed to investigators and clinicians who are interested in the epidemiology, basic science, public health impact, and future trends in hepatitis B and hepatitis C therapy.

Level of knowledge: It is assumed that participants are familiar with the general principles of hepatitis B and hepatitis C virology and treatment.

Objectives:

- To identify the limitations and the potential for virologic and immunologic approaches to the cure of HBV infection
- To compare the approach to preventing vertical transmission of HIV to HBV
- To appreciate the opportunities and challenges to achieving the UN HCV elimination goals
- To understand the prevalence of fatty liver disease and recognize the difference between steatosis and steatohepatitis

Conveners

Marion G. Peters, *Univ of California San Francisco, San Francisco, CA, USA*

Massimo Puoti, *ASST GOM Niguarda, Milan, Italy*



96 HEPATITIS B: PROGRESS AND PROSPECTS IN HEPATITIS B VIRUS CURE

4:00

Patrick Kennedy, *Queen Mary Univ London, London, United Kingdom*



97 MANAGEMENT OF CHRONIC HEPATITIS B DURING PREGNANCY

4:30

Mindie H. Nguyen, *Stanford Univ Med Cntr, Palo Alto, CA, USA*



98 HEPATITIS C VIRUS: GONE BY 2030?

5:00

John W. Ward, *CDC, Atlanta, GA, USA*



99 FATTY LIVER DISEASE: A GROWING CONCERN

5:30

Rohit Loomba, *Univ of California San Diego, La Jolla, CA*



Symposium S-6 THE FIRST AGE: INFANTS ON THE WORLD STAGE

Room 606-609

4:00 PM - 6:00 PM

Target Audience: This session is directed to clinicians and scientists who are interested in understanding the impact of HIV and ART on newborns and infants

Level of Knowledge: It is assumed that the participants are familiar with the basic concepts of HIV acquisition, prevention, and treatment in infants and newborns

Objectives: At the completion of the session, participants will be able to:

- Describe the impact of HIV and ART on pregnancy outcomes among women with HIV infection
- Discuss the short- and long-term outcomes of ART-exposure in uninfected infants and children born to women with HIV
- Review approaches to early diagnosis of HIV in newborns and infants
- Describe experiences with, and outcomes of, early ART in HIV infected infants

Conveners

Mutsa Bwakura-Dangarembizi, *Univ of Zimbabwe, Harare, Zimbabwe*

Thanyawee Puthanakit, *Chulalongkorn Univ, Bangkok, Thailand*



100 MTCT: EVOLVING EPIDEMIOLOGY AND PREGNANCY OUTCOMES

4:00

Roger L. Shapiro, *Harvard Schl of Pub Hlth, Boston, MA, USA*



101 THE ART AND SCIENCE OF INFANT DIAGNOSIS

4:30

Martina Penazzato, *WHO, Geneva, Switzerland*



102 THE HIV-EXPOSED AND UNINFECTED CHILD: WHAT'S TO WORRY?

5:00

Claire Thorne, *Univ College London, London, United Kingdom*



103 THE TREATMENT OF NEWBORNS AND INFANTS LIVING WITH HIV

5:30

Elizabeth Maleche Obimbo, *Univ of Nairobi, Nairobi, Kenya*



Symposium S-7 GETTING TO THE THIRD 90

Room 6 C

4:00 PM - 6:00 PM

Target Audience: This session is directed to clinicians and scientists who are interested in understanding progress and challenges in maximizing the percentage of people on antiretroviral therapy who have viral load suppression, particularly in low and middle income settings, and how global targets for viral suppression can be achieved in the future.

Level of Knowledge: It is assumed that the participants are familiar with effects of antiretroviral treatment on HIV viral load, the basic concepts of viral load measurement, and the influences of adherence and drug resistance.

Objectives: At the completion of the session, participants will be able to:

- Describe the issues related to implementation of monitoring of ART in low and middle income settings
- Describe challenges in achieving the target of 90% virally suppressed

Conveners

Laura Broyles, *Centers for Disease Control and Prevention, Atlanta, GA, USA*



Velephi Okello, *Swaziland Ministry of Health, Mbabane, Swaziland*



104 ACTING OR NOT ACTING ON VIRAL LOAD

4:00

Steven J. Reynolds, *NIAID, NIH, Washington, DC, USA*



105 MEASURING VIRAL LOAD: INNOVATIONS AND TAKING TO SCALE

4:30

Rosanna W. Peeling, *London Sch of Hygiene and Trop Medicine, London, United Kingdom*



106 USING TECHNOLOGY TO IMPROVE ADHERENCE

5:00

Richard T. Lester, *Univ of British Columbia, Vancouver, Canada*



107 REACHING KEY AND VULNERABLE POPULATIONS TO ACHIEVE THE THIRD 90

5:30

Ruanne V. Barnabas, *Univ of Washington, Seattle, USA*



THURSDAY, FEBRUARY 16, 2017

Plenary PL-3 THURSDAY PLENARY SESSION**Auditorium - 4 AB****8:30 AM - 9:30 AM****108 IF YOU CAN MAKE IT THERE: ENDING THE HIV EPIDEMIC IN NEW YORK**

8:30

Demetre C. Daskalakis, NYC DHMH, New York, NY, USA**109 HTLV-1: THE OTHER HUMAN RETROVIRUS**

9:00

Charles R. Bangham, Imperial Coll London, London, UK**Oral Abstract O-10 IMPROVING THE HIV CARE CASCADE****Room 6 C****10:00 AM - 12:00 PM****Oral Abstract Moderators****Loice Achieng**, Univ of Nairobi, Nairobi, Kenya**Valdilea Veloso**, Oswaldo Cruz Foundation - Fiocruz, Rio de Janeiro, Brazil**110 A COMBINATION INTERVENTION STRATEGY FOR HIV LINKAGE AND RETENTION IN MOZAMBIQUE**

10:00

Batya Elul¹, Matthew R. Lamb¹, Maria Lahuerta¹, Fatima Abacassamo², Laurence Ahoua³, Stephanie Kujawski¹, Maria Tomo², Ilesh Jani⁴¹Columbia Univ, New York, NY, USA, ²Cntr for Collab in Hlth, Maputo City, Mozambique, ³ICAP at Columbia Univ, Maputo City, Mozambique, ⁴Inst Nacional de Saude, Maputo, Mozambique**111 PEER NAVIGATION ENHANCES HIV CARE RETENTION: AN RCT IN SOUTH AFRICAN PRIMARY CLINICS**

10:15

Wayne T. Steward¹, Emily Agnew¹, Julia DeKadt², Hailey Gilmore¹, Mary-Jane Rathagana², Jessica Grignon³, Starley B. Shade¹, John Tumbo⁴, Scott Barnhart³, Sheri A Lippman¹¹Univ of California San Francisco, San Francisco, CA, USA, ²Intl Training and Educ Cntr for Hlth—South Africa, Pretoria, South Africa, ³Univ of Washington, Seattle, WA, USA, ⁴Rustenburg Sub-District Office, Rustenburg, South Africa**112 COST-EFFECTIVENESS OF POLICY OPTIONS WHEN PRETREATMENT NNRTI DRUG RESISTANCE IS HIGH**

10:30

Andrew Phillips¹, Valentina Cambiano¹, Michael Jordan², Fumiyo Nakagawa¹, Marco Vitoria³, Meg Doherty³, Paul Revill⁴, Elliot Raizes⁵, Silvia Bertagnolio⁴, for the Working Group on Modelling Drug Resistance in Sub-Saharan Africa¹Univ Coll London, London, UK, ²Tufts Univ, Boston, MA, USA, ³WHO, Geneva, Switzerland, ⁴Univ of York, York, UK, ⁵CDC, Atlanta, GA, USA**113 INCREASED RISK OF CART FAILURE AFTER LOW-LEVEL VIREMIA UNDER WHO GUIDELINES**

10:45

Lucas E. Hermans¹, Michelle A. Moorhouse², Sergio Carmona², Diederick Grobbee³, Laura Marije Hofstra³, Douglas D. Richman⁴, Hugo Tempelman⁵, Willem D. Venter², Annemarie Wensing³, for the Ndlovu Research Consortium¹Univ Med Cntr Utrecht, Utrecht, Netherlands, ²Univ of Witwatersrand, Johannesburg, South Africa, ³Univ Med Cntr Utrecht, Utrecht, Netherlands, ⁴Univ of California San Diego, San Diego, California, USA, ⁵Ndlovu Care Group, Groblersdal, South Africa

114LB REAL PROGRESS IN THE HIV EPIDEMIC: PHIA FINDINGS FROM ZIMBABWE, MALAWI, AND ZAMBIA

11:00

Jessica E. Justman¹, David Hoos¹, Graham Kalton², Rose Nyirenda³, Crispin Moyo⁴, Owen Mugurungi⁵, Andrew Voetsch⁶, Hetal Patel⁶, Laura Porter⁶, for the PHIA Project Teams for Malawi, Zambia and Zimbabwe

¹ICAP at Columbia Univ, New York, NY, USA, ²Westat, Inc., Rockville, MD, USA, ³Government of Malawi Ministry of Hlth, Lilongwe, Malawi, ⁴Government of Zambia Ministry of Hlth, Lusaka, Zambia, ⁵Ministry of Hlth and Child Welfare, Zimbabwe, Harare, Zimbabwe, ⁶CDC, Atlanta, GA, USA

115 STRATEGIES TO ACHIEVE 90-90-90: MODELING INSIGHTS FROM ZIMBABWE

11:15

Jack Olney, Jeffrey Eaton, Ellen McRobie, Timothy B. Hallett
Imperial Coll London, London, UK

116 HIV CASCADE OF CARE INTERVENTIONS IN KENYA: CLINICAL IMPACT AND COST-EFFECTIVENESS

11:30

Liem Binh Luong Nguyen¹, Yazdan Yazdanpanah¹, David Maman², Stephen Wanjala³, Alexandra Vandenbulcke⁴, Elisabeth Szumilin⁴, William Hennequin⁴, Robert Parker⁵, Pierre Mendiherat⁴, Kenneth Freedberg⁵

¹INSERM, Paris, France, ²Epicentre, Cape Town, South Africa, ³MSF, Nairobi, Kenya, ⁴MSF, Paris, France, ⁵Massachusetts General Hosp, Boston, MA, USA

117 A RANDOMIZED TRIAL OF READY-TO-USE SUPPLEMENTARY FOOD AT ART INITIATION IN AFRICA

11:45

Jane E. Mallewa¹, Alexander J. Szubert², Jay Berkley³, Sanele Nkomani⁴, Abraham Siika⁵, Peter Mugenyi⁵, Andrew Prendergast⁶, Sarah Walker², Diana Gibb², for the REALITY Trial Team

¹Malawi—Liverpool—Wellcome Trust Clinical Rsr Prog, Blantyre, Malawi, ²Univ Coll London, London, UK, ³KEMRI Wellcome Trust Rsr Prog, Kilifi, Kenya, ⁴Univ of Zimbabwe Clinical Rsr Cntr, Harare, Zimbabwe, ⁵Moi Univ, Eldoret, Kenya, ⁶Queen Mary Univ of London, London, UK

Oral Abstract O-11 HIV PERSISTENCE AND REACTIVATION

Room 6 E

10:00 AM - 12:00 PM

Oral Abstract Moderators

Ann Chahroudi, Emory University School of Medicine, Atlanta, GA, USA

Davey Smith, Univ of California, San Diego, La Jolla, CA, USA

118 TLR7 AGONIST GS-9620 INCREASES IMMUNE-MEDIATED CLEARANCE OF HIV-INFECTED CELLS

10:00

Alivelu Irrinki¹, Angela Tsai¹, Jasmine Kaur¹, Jay Lalezari², Tomas Cihlar¹, George Kukolj¹, Derek D. Sloan³, **Jeffrey Murry**¹

¹Gilead Scis, Inc, Foster City, CA, USA, ²Quest Clinical Rsr, San Francisco, CA, USA, ³Agenovir, South San Francisco, CA, USA

119LB VIRAL CONTROL INDUCED BY HIVCONSV VACCINES & ROMIDEPSIN IN EARLY TREATED INDIVIDUALS

10:15

Beatriz Mothe¹, José Moltó², Christian Manzardo³, Josep Coll¹, Maria C. Puertas¹, Javier Martinez-Picado¹, Tomas Hanke⁴, Bonaventura Clotet¹, Christian Brander¹, for the BCN02-Romi Study Group

¹IrsiCaixa AIDS Rsr Inst, Badalona, Spain, ²Fundació Lluita Contra la Sida, Badalona, Spain, ³Univ of Barcelona, Barcelona, Spain, ⁴The Jenner Inst, Oxford, UK

120 NO EVIDENCE OF ONGOING HIV REPLICATION AFTER 7 YEARS ON ART

10:30

Mary Grace K. Katusiime¹, Gert U. van Zyl¹, Ann Wiegand², Elias K. Halvas³, Valerie F. Boltz², Barbara Laughton¹, Susan Engelbrecht¹, Mark Cotton¹, John W. Mellors³, **Mary F. Kearney**²

¹Stellenbosch Univ, Parow, South Africa, ²NCI, Frederick, MD, USA, ³Univ of Pittsburgh, Pittsburgh, PA, USA

121 A PROPORTION OF LATENT HIV IS MISSED BY ASSAYING ONLY RESTING CD4 T CELLS

10:45

Anthony R. Cillo, **Michele Sobolewski**, Taylor Buckley, John Bui, Joshua C. Cyktor, John W. Mellors

Univ of Pittsburgh, Pittsburgh, PA, USA

122 CTLs PARE DEFECTIVE HIV PROVIRUSES WITHOUT IMPACTING INFECTIOUS LATENT RESERVOIRS

11:00

Szuhan Huang¹, Allison S. Thomas², Sara Karandish¹, Dora Chan¹, Adam Ward¹, Ya-Chi Ho³, Erika Benko⁴, Colin Kovacs⁵, R. Brad Jones¹

¹The George Washington Univ, Washington, DC, USA, ²Boston Univ, Boston, MA, USA, ³The Johns Hopkins Univ, Baltimore, MD, USA, ⁴Maple Leaf Med Clinic, Toronto, Ontario, Canada, ⁵Univ of Toronto, Toronto, Ontario, Canada

123 DEVELOPMENT OF A PKC AGONIST DERIVED FROM INGENOL FOR HIV LATENCY DISRUPTION IN VIVO

11:15

Jessica Brehm¹, Vincent Tai¹, David Irlbeck¹, Robert Ferris¹, Nancie Archin², Matt Kanke², Jean-Pierre Routy³, David M. Margolis², Jun Tang¹, David Favre¹

¹GlaxoSmithKline, Durham, NC, USA, ²Univ of North Carolina at Chapel Hill, Chapel Hill, NC, USA, ³McGill Univ Hlth Cntr, Glen Site, Montréal, QC, Canada

124 HIV RNA REBOUND POSTINTERRUPTION IN PERSONS SUPPRESSED IN FIEBIG I ACUTE HIV

11:30

Donn Colby¹, Nicolas Chomont², Eugene Kroon¹, Louise Leyre², Suteeraporn Pinyakorn³, Nelson L. Michael³, Merlin L. Robb³, Nittaya Phanuphak¹, **Jintanat Ananworanich**³, for the RV411 and RV254/SEARCH010 Study Groups

¹SEARCH, The Thai Red Cross AIDS Rsr Cntr, Bangkok, Thailand, ²Cntr de Rsr du Cntr Hosp de l'Univ de Montréal, Montréal, QC, Canada, ³US Military HIV Rsr Prog, Bethesda, MD, USA

125 EARLY DETECTION OF HIV REBOUND BY INNATE SENSORS POST ART INTERRUPTION

11:45

Julie Mitchell¹, Eugene Kroon², Khunthalee Benjapornpong², Suteeraporn Pinyakorn¹, Praphan Phanunphak³, Sharon R. Lewin⁴, Jintanat Ananworanich¹, Mark de Souza², Lydie Trautmann¹, for the Search 019 Study Group

¹Henry M. Jackson Fndn, Silver Spring, MD, USA, ²SEARCH, The Thai Red Cross AIDS Rsr Cntr, Bangkok, Thailand, ³Henry M. Jackson Fndn, Bethesda, MD, USA, ⁴Doherty Inst for Infection and Immunity, Melbourne, Australia

Oral Abstract 0-12 INFLAMMATION AND AGE-RELATED COMPLICATIONS

Room 6 AB

10:00 AM - 12:00 PM

Oral Abstract Moderators

Jason Baker, *HCMC / Univ of Minnesota, Minneapolis, MN, USA*

Heidi Crane, *Univ of Washington, Seattle, WA, USA*

126 IL- β INHIBITION SIGNIFICANTLY REDUCES ATHEROSCLEROTIC INFLAMMATION IN TREATED HIV

10:00

Priscilla Hsue¹, Steven G. Deeks¹, Amorina E. Ishai², Sophia Hur¹, Danny Li¹, Felicia Stermen³, Jay Lalezari⁴, Adam Rupert⁵, Peter Ganz¹, Ahmed Tawakol²

¹Univ of California San Francisco, San Francisco, CA, USA, ²Massachusetts General Hosp, Boston, MA, USA, ³California Pacific Med Cntr, San Francisco, CA, USA, ⁴Quest Clinical Rsr, San Francisco, CA, USA, ⁵Natl Inst of Hlth, Frederick, MD, USA

127 HYPERBILIRUBINEMIA PREVENTS CARDIOVASCULAR DISEASE FOR HIV+ AND HIV- INDIVIDUALS

10:15

Vincent C. Marconi¹, Kaku So-Armah², Janet Tate³, Joseph Lim⁴, Vincent Lo Re⁵, Adeel A. Butt⁶, Matthew B. Goetz⁷, Maria Rodriguez-Barradas⁸, Amy Justice³, Matthew Freiberg⁹

¹Emory Univ, Atlanta, GA, USA, ²Boston Univ, Boston, MA, USA, ³VA Connecticut Hlthcare System, West Haven, CT, USA, ⁴Yale Univ, New Haven, CT, USA, ⁵Univ of Pennsylvania, Philadelphia, PA, USA, ⁶Weill Cornell Med Coll, New York, NY, USA, ⁷VA Greater Los Angeles Hlth Care System, Los Angeles, CA, USA, ⁸Baylor Coll of Med, Houston, TX, USA, ⁹Vanderbilt Univ, Nashville, TN, USA

128LB ASSOCIATION BETWEEN CARDIOVASCULAR DISEASE & CONTEMPORARILY USED PROTEASE INHIBITORS

10:30

Lene Ryom¹, Jens D. Lundgren², Wafaa M. El-Sadr³, Peter Reiss⁴, Andrew Phillips⁵, Ole Kirk⁶, Rainer Weber⁷, Caroline Sabin⁵, Amanda Mocroft⁸, for the D:A:D Study Group

¹CHIP, Copenhagen, Denmark, ²Univ of Copenhagen, Copenhagen, Denmark, ³ICAP at Columbia Univ, New York, NY, USA, ⁴Stichting HIV Monitoring and Academic Med Cntr Amsterdam, Amsterdam, Netherlands, ⁵Univ Coll London, London, UK, ⁶Rigshosp, Copenhagen, Denmark, ⁷Univ of Zurich, Zurich, Switzerland, ⁸Univ Coll London, London, UK

129 CARDIOVASCULAR PREVENTION POLICY IN HIV: RECOMMENDATIONS FROM A MODELING STUDY

10:45

Rosan van Zoest¹, Mikaela Smit², Brooke Nichols³, Ilonca Vaartjes⁴, Colette Smit⁵, Marc van der Valk⁶, Ferdinand Wit⁵, Timothy B. Hallett², Peter Reiss⁵, for the Netherlands ATHENA Observational HIV Cohort

¹Amsterdam Inst for Global Hlth and Development and Academic Med Cntr, Amsterdam, Netherlands, ²Imperial Coll London, London, UK, ³Erasmus Univ Med Cntr, Rotterdam, Netherlands, ⁴Univ Med Cntr Utrecht, Utrecht, Netherlands, ⁵Stichting HIV Monitoring, Amsterdam, Netherlands, ⁶Academic Med Cntr, Amsterdam, Netherlands

130 IMPACT OF SMOKING, HYPERTENSION & CHOLESTEROL ON MYOCARDIAL INFARCTION IN HIV+ ADULTS

11:00

Keri N. Althoff¹, Frank J. Palella², Kelly Gebo¹, Stephen J. Gange¹, Charles Rabkin³, Jennifer E. Thorne⁴, Micheal A. Horberg⁵, Daniel B. Klein⁶, Mari Kitahata⁷, Richard D. Moore⁸

¹The Johns Hopkins Univ, Baltimore, MD, USA, ²Northwestern Univ, Chicago, IL, USA, ³NCI, Rockville, MD, USA, ⁴Kaiser Permanente Mid-Atlantic States, Rockville, MD, USA, ⁵Kaiser Hosp, San Leandro, CA, USA, ⁶Univ of Washington, Seattle, WA, USA

131 CESSATION OF CIGARETTE SMOKING AND THE IMPACT ON CANCER INCIDENCE IN THE D:A:D STUDY

11:15

Leah Shepherd¹, Lene Ryom², Kathy Petoumenos³, Camilla Ingrid Hatleberg², Antonella d'Arminio Monforte⁴, Fabrice Bonnet⁵, Peter Reiss⁶, Jens D. Lundgren², Amanda Mocroft¹, for the D:A:D study group

¹Univ Coll London, London, UK, ²CHIP, Copenhagen, Denmark, ³Kirby Inst, Sydney, Australia, ⁴Univ of Milan, Milan, Italy, ⁵CHU de Bordeaux, Bordeaux, France, ⁶Stichting HIV Monitoring and Academic Med Cntr, Amsterdam, Netherlands

132 BONE DENSITY AND TRABECULAR BONE SCORE IMPROVE FRACTURE PREDICTION IN HIV+ WOMEN

11:30

Jingyan Yang¹, Anjali Sharma², Josh Aschheim³, Kathryn Anastos², Mardge H. Cohen⁴, Elizabeth T. Golub⁵, Deborah Gustafson⁶, Daniel Merenstein⁷, Phyllis Tien⁸, Michael T. Yin¹

¹Columbia Univ Med Cntr, New York, NY, USA, ²Albert Einstein Coll of Med, Bronx, NY, USA, ³Arcadia Hlth, New York, USA, ⁴John H. Stroger Jr. Hosp of Cook County, Chicago, IL, USA, ⁵The Johns Hopkins Univ, Baltimore, MD, USA, ⁶SUNY Downstate Med Cntr, Brooklyn, NY, USA, ⁷Georgetown Univ, Washington, DC, USA, ⁸Univ of California San Francisco, San Francisco, CA, USA

133 FRAILTY PROGRESSION AND RECOVERY AMONG PERSONS AGING WITH HIV AND SUBSTANCE USE

11:45

Damani A. Piggott, Karen Bandeen-Roche, Shruti H. Mehta, Todd Brown, Huanle Yang, Jeremy D. Walston, Sean X. Leng, Gregory D. Kirk

The Johns Hopkins Univ, Baltimore, MD, USA

Oral Abstract O-9 HEPATITIS C: PROBLEMS AND PROGRESS

Room 606-609

10:00 AM - 12:00 PM

Oral Abstract Moderators

Juan Berenguer, Hospital General Universitario Gregorio Marañón, Madrid, Spain

Annie Luetkemeyer, Univ of California San Francisco, San Francisco, CA, USA

134 INCIDENCE OF HEPATITIS C AMONG HIV-INFECTED MEN WHO HAVE SEX WITH MEN, 2000–2015

10:00

Antoine Chaillon¹, Christy M. Anderson¹, Thomas C. Martin¹, Edward R. Cachay¹, David L. Wyles², Davey M. Smith¹, Susan J. Little¹, Richard S. Garfein¹, Natasha Martin¹

¹Univ of California San Diego, San Diego, CA, ²Denver Health, Denver, CO, USA

135 MODELING HIV-HCV EPIDEMIOLOGY IN THE DAA ERA: THE ROAD TO ERADICATION

10:15

Victor Virlogeux¹, Laurent Cotte², Pascal Pugliese³, Isabelle Poizot-Martin⁴, Marc-Antoine Valantin⁵, Lise Cuzin⁶, Jacques Reynes⁷, Eric Billaud⁸, Thomas Huleux⁹, for the DataAIDS Study Group

¹INSERM, Lyon, France, ²Hospices Civils de Lyon, Lyon, France, ³CHU de Nice, Nice, France, ⁴Assistance Publique—Hôpitaux de Marseille, Marseille, France, ⁵Assistance Publique—Hôpitaux de Paris, Paris, France, ⁶CHU Toulouse, Toulouse, France, ⁷CHU de Montpellier, Montpellier, France, ⁸CHU de Nantes, Nantes, France, ⁹Cntr Hosp de Tourcoing, Tourcoing, France

136 UNRESTRICTED DAA ACCESS IN THE NETHERLANDS: RAPID THERAPY UPTAKE IN HIV+HCV+ PATIENTS

10:30

Anne Boerekamps¹, Astrid Newsum², Colette Smit³, Peter Reiss⁴, Clemens Richter⁵, Marc van der Valk⁶, Joop Arends⁷, Kees Brinkman⁸, Bart Rijnders¹, for the Netherlands ATHENA HIV observational cohort and the NVHB-SHM Hepatitis Working Group

¹Erasmus Univ Med Cntr, Rotterdam, Netherlands, ²Pub Hlth Service of Amsterdam and Academic Med Cntr, Amsterdam, Netherlands, ³Stichting HIV Monitoring, Amsterdam, Netherlands, ⁴Stichting HIV Monitoring and Academic Med Cntr, Amsterdam, Netherlands, ⁵Rijnstate Hosp, Arnhem, Netherlands, ⁶Academic Med Cntr, Amsterdam, Netherlands, ⁷Univ Med Cntr Utrecht, Utrecht, Netherlands, ⁸OLVG, Amsterdam, Netherlands

137LB SUBSTANTIAL DECLINE IN ACUTE HCV INFECTIONS AMONG DUTCH HIV+MSM AFTER DAA ROLL OUT

10:45

Anne Boerekamps¹, Guido van den Berk², Fanny Lauw³, Eliane Leyten⁴, Joop Arends⁵, Marjo Kasteren⁶, Mark Claassen⁷, Charles Boucher¹, **Bart Rijnders**¹, for the Dutch Acute HCV in HIV (DAHHS) study group

¹Erasmus Univ Med Cntr, Rotterdam, Netherlands, ²OLVG, Amsterdam, Netherlands, ³Slotervaart MC, Amsterdam, Netherlands, ⁴MC Haaglanden, The Hague, Netherlands, ⁵Univ Medl Cntr Utrecht, Utrecht, Netherlands, ⁶St. Elizabeth Ziekenhuis, Tilburg, Netherlands, ⁷Rijnstate Hosp, Arnhem, Netherlands

138 CORRELATION OF RENAL BIOMARKERS AND TENOFOVIR AUC IN THE ION-4 STUDY COHORT

11:00

Austin W. Chan¹, Larry Park¹, Lauren F. Collins¹, Curtis Cooper², Michael Saag³, Douglas Dieterich⁴, Mark Sulkowski⁵, Susanna Naggie¹, for the ION-4 Study Group

¹Duke Univ, Durham, NC, USA, ²Ottawa General Rsr Inst, Ottawa, Ontario, ³Univ of Alabama at Birmingham, Birmingham, AL, USA, ⁴Icahn Sch of Med at Mt Sinai, New York, NY, USA, ⁵The Johns Hopkins Univ, Baltimore, MD, USA

139 HEPATOCELLULAR CARCINOMA AFTER SVR WITH IFN-FREE REGIMENS IN HIV/HCV COINFECTION

11:15

Nicolás Merchante¹, Boris Revollo², Francisco Rodríguez-Arrondo³, Esperanza Merino⁴, Maria J. Galindo⁵, Marta Montero⁶, Antonio Rivero-Juárez⁷, Marcial Delgado-Fernández⁸, Maria J. Rios-Villegas⁹, Juan A. Pineda¹

¹Hosp Univ de Valme, Sevilla, Spain, ²Hosp German Trias i Pujol, Badalona, Spain, ³Hosp Univ de Donostia, San Sebastián, Spain, ⁴Hosp General Univ de Alicante, Alicante, Spain, ⁵Hosp Clínico de Valencia, Valencia, Spain, ⁶Hosp Univ y Politécnico La Fe, Valencia, Spain, ⁷Hosp Univ Reina Sofía, Córdoba, Spain, ⁸Hosp Regional Univ de Málaga, Málaga, Spain, ⁹Hosp Univ Virgen Macarena, Sevilla, Spain

140 IDENTIFICATION OF HCV INTER-SUBTYPE RECOMBINANT STRAINS WITH BREAKPOINTS IN NS5A

11:30

Sugin Cai, Alicia Newton, Wei Huang, Jeannette Whitcomb
Monogram BioScis, South San Francisco, CA, USA

141 SYNERGY BETWEEN COMBINATIONS OF ANTI-HCV BROADLY NEUTRALIZING MONOCLONAL ANTIBODIES

11:45

Madeleine C. Mankowski¹, Andrew I. Flyak², Stuart C. Ray³, James E. Crowe², Justin R. Bailey³

¹Johns Hopkins Univ, Severna Park, MD, USA, ²Vanderbilt Univ, Nashville, TN, USA, ³Johns Hopkins Univ, Baltimore, MD, USA

Themed Discussion TD-12 THE IMPOSSIBLE DREAM: POPULATION PERSPECTIVES ON 90:90:90 IN ADOLESCENTS AND YOUNG ADULTS

Room 615-617

1:30 PM - 2:30 PM

Themed Discussion Leader

Mary-Ann Davies, *University of Cape Town Faculty of Health Sciences, Cape Town, South Africa*

834 COMMUNITY INTERVENTION IMPROVES ADOLESCENT HIV STATUS KNOWLEDGE:HPTN 071 STUDY ZAMBIA

Kwame Shanaube¹, Mwate J. Chaila¹, David Macleod², Ab Schaap¹, Sian Floyd², Conred Jani¹, Graeme Hoddinott³, Richard Hayes², Sarah Fidler⁴, Helen Ayles⁵

¹Zambart, Lusaka, Zambia, ²London Sch of Hygiene and Trop Med, London, UK, ³Univ of Stellenbosch, Cape Town, South Africa, ⁴Imperial Coll London, London, UK, ⁵London Sch of Hygiene and Trop Med, Lusaka, Zambia

835 A NOVEL MODEL OF COMMUNITY COHORT CARE FOR HIV-INFECTED ADOLESCENTS IMPROVES OUTCOMES

Lindsey Reif¹, Rachel Bertrand², Vanessa Rivera³, Bernadette Josphe², Benedict Anglade², Jean W. Pape³, Daniel Fitzgerald³, Margaret McNairy³

¹Columbia Univ, New York, NY, USA, ²GHEKIO, Port-au-Prince, Haiti, ³Weill Cornell Med, New York, NY, USA

836 LOCAL SOCIAL NETWORKS PREDICT RETENTION & SUPPRESSION IN YOUNG WOMEN IN SEARCH TRIAL

Lillian Brown¹, Wenjing Zheng², James Ayieko³, Asiphas Owaraganise⁴, Florence Mwangwa⁴, Tamara D. Clark¹, Edwin D. Charlebois¹, Moses R. Kamy⁵, Diane V. Havlir¹, Maya L. Petersen²

¹Univ of California San Francisco, San Francisco, CA, USA, ²Univ of California Berkeley, Berkeley, CA, USA, ³Kenya Med Rsr Inst, Nairobi, Kenya, ⁴Infectious Diseases Rsr Collab, Kampala, Uganda, ⁵Makerere Univ, Kampala, Uganda

837 TEENAGE PREGNANCY: A CRITICAL BARRIER TO RETENTION ON ANTIRETROVIRAL THERAPY

Harriet Nuwagaba-Biribonwoha¹, Agnes Kiragga², Constantin Yiannoutsos³, Beverly Musick³, Kara K. Wools-Kaloustian³, Elaine J. Abrams¹, Batya Elul⁴, for the International Epidemiologic Databases to Evaluate AIDS (IeDEA) East Africa Collaboration

¹ICAP at Columbia Univ, New York, NY, USA, ²Makerere Univ, Kampala, Uganda, ³Indiana Univ, Indianapolis, IN, USA, ⁴Columbia Univ, New York, NY, USA

838 IMPACT OF SUBSTANCE USE, MENTAL HEALTH, AND AGE ON RETENTION AND VIRAL SUPPRESSION

Brian C. Zanoni¹, Sara Lammert¹, Jessica Haberer¹, Gregory K. Robbins¹, Heidi M. Crane², Michael J. Mugavero³, Katerina Christopoulos⁴, Kenneth H. Mayer⁵

¹Massachusetts General Hosp, Boston, MA, USA, ²Univ of Washington, Seattle, WA, USA, ³Univ of Alabama at Birmingham, Birmingham, AL, USA, ⁴Univ of California San Francisco, San Francisco, CA, USA, ⁵Fenway Hlth, Boston, MA, USA

Themed Discussion TD-13 HOT FLASHES: HORMONAL CONTRACEPTION AND HIV RISK

Room 611-614

1:30 PM - 2:30 PM

Themed Discussion Leader

Laneta Dorflinger, *Contraceptive Technology Innovation, FHI360, Durham, NC, USA*

944 DEPOT MEDROXYPROGESTERONE ACETATE INCREASES HIV-1 REPLICATION IN MUCOSAL TISSUE

Charlene S. Dezzutti¹, Seo Young Park¹, Ingrid Macio², Kenneth Marks³, Sidney Lawlor³, Catherine Chappell⁴, Katherine Bunge⁴

¹Univ of Pittsburgh, Pittsburgh, PA, USA, ²Univ of Pittsburgh Med Cntr, Pittsburgh, PA, USA, ³Magee-Womens Rsr Inst, Pittsburgh, PA, USA, ⁴Magee-Womens Hosp of UPMC, Pittsburgh, PA, USA

943 CHANGES IN GENITAL-TRACT HIV TARGET CELLS WITH THREE PROGESTIN-BASED CONTRACEPTIVES

Lisa B. Haddad¹, Alison S. Kohlmeier², Richard Haaland², Nakita Brown¹, David Lupo², Christina Mehta¹, Anandi N. Sheth¹, Kehmia Titanji¹, Clyde Hart², Igbo Ofotokun¹

¹Emory Univ, Atlanta, GA, USA, ²CDC, Atlanta, GA, USA

945 ZIM-CHIC: IMPACT OF CONTRACEPTIVE INITIATION ON IMMUNE CELLS IN THE CERVIX AND PBMCS

Sharon L. Achilles¹, Feliz Mhlanga², Leslie A. Meyn¹, Kevin A. Stoner³, Allen T. Matubu², Zvavahera M. Chirenje², Sharon L. Hillier¹

¹Univ of Pittsburgh, Pittsburgh, PA, USA, ²Univ of Zimbabwe, Harare, Zimbabwe, ³Magee-Womens Rsr Inst, Pittsburgh, PA, USA

946 HIV GENITAL-TRACT SHEDDING WHILE ON PROGESTIN CONTRACEPTION

Julie A. Nelson¹, Jeff Wiener², Jennifer H. Tang¹, Lameck Chinula³, Stacey Hurst², Gerald Tegha³, Albans Msika³, Mina C. Hosseinipour³, Lisa B. Haddad⁴, Athena Kourtis²

¹Univ of North Carolina at Chapel Hill, Chapel Hill, NC, USA, ²CDC, Atlanta, GA, USA, ³Univ of North Carolina Proj—Malawi, Lilongwe, Malawi, ⁴Emory Univ, Atlanta, GA, USA

947 HORMONAL CONTRACEPTION DOES NOT AFFECT ART EFFECTIVENESS OR GENITAL HIV SHEDDING

Rena Patel¹, Jared Baeten¹, Renee Heffron¹, Ting Hong¹, Nicole Davis², Kavita Nanda³, Robert Coombs¹, Elizabeth A. Bukusi⁴, Athena Kourtis², Nelly Mugo⁵

¹Univ of Washington, Seattle, WA, USA, ²CDC, Atlanta, GA, USA, ³FHI 360, Durham, NC, USA, ⁴Kenya Med Rsr Inst, Nairobi, Kenya, ⁵KEMRI, Nairobi, Kenya

Themed Discussion TD-14 HIV AND SUBSTANCE ABUSE: DOUBLE TROUBLE

Room 606-609

1:30 PM - 2:30 PM

Themed Discussion Leader

Steven Shoptaw, *Univ of California Los Angeles, Los Angeles, CA, USA*

869 "HOOKED ON PAINKILLERS" PRIOR TO FIRST INJECTION AMONG PWID IN 16 U.S. CITIES

Dita Broz¹, Maria Zlotorzynska², Michael Spiller¹, Gabriela Paz-Bailey¹, for the NHBS Study Group

¹CDC, Atlanta, GA, USA, ²Emory Univ, Atlanta, GA, USA

870 OPIOID SUBSTITUTION THERAPY AND INITIATION INTO INJECTION DRUG USE IN SAN DIEGO, CA

Maria Luisa Mittal¹, Devesh Vashishtha¹, Xiaoying Sun¹, Sonia Jain¹, Richard S. Garfein², Steffanie A. Strathdee², Dan Werb¹

¹Univ of California San Diego, La Jolla, CA, USA, ²Univ of California San Diego, San Diego, CA, USA

871 CHANGES IN PRESCRIPTION OPIOID, METH, AND COCAINE USE AMONG MSM IN 20 US CITIES

Brooke Hoots, Dita Broz, Lina Nerlander, Gabriela Paz-Bailey

CDC, Atlanta, GA, USA

872 CHANGING PATTERN OF CRYSTAL METH USE IN BLACK & WHITE MSM, WASHINGTON, DC, 2008–2014

Irene Kuo¹, Rudy Patrick¹, Jenevieve Opoku², Anthony Rawls¹, Many Magnus¹, James Peterson¹, Michael Kharfen², Alan Greenberg¹

¹The George Washington Univ, Washington, DC, USA, ²District of Columbia Dept of Hlth, Washington, DC, USA

873 INCREASING METHAMPHETAMINE USE AMONG NON-MSM WHO INJECT DRUGS IN KING COUNTY, WA

Sara N. Glick¹, Richard Burt², Kim Kummer¹, Joe Tinsley², Caleb Banta-Green¹, Matthew R. Golden¹

¹Univ of Washington, Seattle, WA, USA, ²Pub Hlth - Seattle & King County, Seattle, WA, USA

Themed Discussion TD-15 I WANT A NEW DRUG

Room 6 C

1:30 PM - 2:30 PM

Themed Discussion Leader

Karl Salzwedel, National Institutes of Health, Bethesda, MD, USA

433 NOVEL HIV PI WITH HIGH RESISTANCE BARRIER AND POTENTIAL FOR UNBOOSTED QD ORAL DOSING

John O. Link, Darryl Kato, Michael Moore, Andrew Mulato, Bernard Murray, Judy Mwangi, Nathan D. Shapiro, George Stepan, Yujin Wang, Zheng-Yu Yang

Gilead Scis, Inc, Foster City, CA, USA

434 NOVEL NON-CATALYTIC SITE INTEGRASE INHIBITOR WITH IMPROVED RESISTANCE PROFILE

Michael L. Mitchell, Mini Balakrishnan, Gediminas Brizgys, Ruby Cai, Eric Lansdon, Andrew Mulato, Mark Osier, Jianhong Wang, Helen Yu, Roman Sakowicz

Gilead Scis, Inc, Foster City, CA, USA

435 MK-8591 CONCENTRATIONS AT SITES OF HIV TRANSMISSION AND REPLICATION

Jay Grobler, Carolyn McHale, Carol Freddo, Dan Dreyer, Li Sun, Marissa Vavrek, Sheila Breidinger, Kerry Fillgrove, Daria Hazuda, Ming-Tain Lai

Merck & Co, Inc, West Point, PA, USA

436 GS-9131 IS A NOVEL NRTI WITH ACTIVITY AGAINST NRTI-RESISTANT HIV-1

Kirsten L. White, Nicolas Margot, Kirsten Stray, Helen Yu, George Stepan, Constantine Boojamra, Richard Mackman, Adrian Ray, Michael D. Miller, Tomas Cihlar

Gilead Scis, Inc, Foster City, CA, USA

437 PRO140 SINGLE-AGENT MAINTENANCE THERAPY FOR HIV-1 INFECTION: A 2-YEAR UPDATE

Jay Lalezari¹, **Kush Dhody**², Ula Kowalczyk¹, Kazem Kazempour², Nader Pourhassan³, Paul J. Maddon⁴

¹Quest Clinical Rsr, San Francisco, CA, USA, ²Amarex Clinical Rsr, LLC, Germantown, MD, USA, ³CytoDyn, Inc, Vancouver, WA, USA, ⁴Maddon Advisors LLC, Scarsdale, NY, USA

Themed Discussion TD-16 HOW DOES THE MICROBIOME AFFECT HIV INFECTION?**Room 6 E****1:30 PM - 2:30 PM****Themed Discussion Leader**

Cara Wilson, MD, Univ of Colorado-Anschutz Medical Campus, Aurora, CO, USA

207 IMPACT OF MSM-ASSOCIATED MICROBIOTA ON IMMUNE ACTIVATION AND IN VITRO HIV INFECTION

Sam Li, Abigail Armstrong, Charles P. Neff, Catherine Lozupone, Brent E. Palmer

Univ of Colorado, Aurora, CO, USA

208 FECAL MICROBIOTA FROM HIV-INFECTED SUBJECTS INCREASES IMMUNE ACTIVATION AND INFECTION

Charles P. Neff, Sam Li, Abigail Armstrong, Catherine Lozupone, Brent E. Palmer

Univ of Colorado, Aurora, CO, USA

209 MARAVIROC INHIBITS HIV TARGET T-CELL TRAFFICKING INTO THE FEMALE GENITAL LUMEN

Alison S. Kohlmeier¹, Sean McMaster², Jessica Radzio¹, Mian-er Cong¹, Chuong Dinh¹, Amy Martin¹, Jacob E. Kohlmeier², Gerardo Garcia-Lerma¹

¹CDC, Atlanta, GA, USA, ²Emory Univ, Atlanta, GA, USA

210 INVESTIGATING THE EFFECT OF PH ON CERVICOVAGINAL MUCUS BARRIER PROPERTIES TO HIV

Julie K. Shade, Thuy Hoang, Kevin Delong, Justin Hanes, Richard Cone, Laura Ensign

The Johns Hopkins Univ, Baltimore, MD, USA

Themed Discussion TD-17 EMERGING VIRUSES: THE ZIKA VIRUS**Room 6 AB****1:30 PM - 2:30 PM****Themed Discussion Leader**

Robert T. Schooley, Univ of California San Diego, La Jolla, CA, USA

1054 CHARACTERIZATION OF MORE THAN 10,000 ZIKA VIRUS TEST RESULTS IN THE US

Joseph M. Volpe¹, Dajie Luo¹, Arren Fisher¹, Mindy Nye², Barbara Body², Marcia Eisenberg¹

¹LabCorp, Durham, NC, USA, ²LabCorp, Burlington, NC, USA

1055LB ZIKA VIRUS PERSISTENCE IN BODY FLUIDS

Gabriela Paz-Bailey¹, Eli Rosenberg², Katherine Doyle¹, Jorge Munoz-Jordan¹, Gilberto Santiago¹, Liore Klein³, Janice Perez¹, Stephen Waterman¹, Luisa Alvarado⁴, Tyler Sharp¹

¹CDC, Atlanta, GA, USA, ²Emory Univ, Atlanta, GA, USA, ³Caduceus Healthcare, Inc, Ponce, PR, USA, ⁴Ponce Univ, Ponce, PR, USA

1056LB NEUROLOGIC CONSEQUENCES OF POSTNATAL ZIKA VIRUS INFECTION IN INFANTS

Maud Mavigner¹, Justin O'Neal², Siddhartha Bhaumik¹, Jakob Habib¹, Cameron Robinson¹, Maria Alvarado³, Xiaodong Zhang³, Jens Wrannert¹, Mehul Suthar², Ann Chahroudi¹

¹Emory Univ, Atlanta, GA, USA, ²Emory Vaccine Center, Atlanta, GA, USA,

³Yerkes Natl Primate Rsr Cntr, Atlanta, GA, USA

1057LB ZIKA VIRUS PROTECTION BY A SINGLE LOW-DOSE NUCLEOSIDE-MODIFIED mRNA VACCINATION

Michael J. Hogan¹, Norbert Pardi¹, Rebecca S. Pelc², Hanne Anderson³, Charles McGee⁴, Michael J. Hope⁵, Mark G. Lewis³, Theodore C. Pierson², Barton F. Haynes⁴, Drew Weissman¹

¹Univ of Pennsylvania, Philadelphia, PA, USA, ²NIAID, Bethesda, MD, USA,

³Bioqual, Inc, Rockville, MD, USA, ⁴Duke Univ, Durham, NC, USA, ⁵Acutas Therapeutics, Vancouver, BC, Canada

Symposium S-8 PATHS INTERTWINED: BROADLY NEUTRALIZING ANTIBODIES AND THE HIV-1 ENVELOPE TRIMER

Room 606-609

4:00 PM - 6:00 PM

Target Audience: This session is directed to clinicians and scientists who are interested in understanding how broadly neutralizing antibody responses in HIV-1 infection develop, how they may be harnessed for preventive vaccines, and exploited for HIV cure.

Level of Knowledge: It is assumed that the participants are familiar with the basic principles of how antibodies function.

Objectives:

- Describe how broadly neutralizing antibodies are stimulated during infection and following vaccination
- Describe the structural properties of broadly neutralizing antibodies and their interaction with the HIV Envelope
- Describe the potential of exploiting broadly neutralizing antibodies for functional cure

Conveners

Nicole Doria-Rose, National Institutes of Health, Bethesda, MD, USA

Gabriella Scarlatti, Global HIV Vaccine Enterprise, New York, NY, USA



142 NEUTRALIZING ANTIBODY DEVELOPMENT DURING HIV-1 INFECTION

4:00

Penelope Moore, Univ of the Witwatersrand, Johannesburg, South Africa



143 IMMUNOGEN DESIGN TO INDUCE HIV NEUTRALIZING ANTIBODIES

4:30

William R. Schief, Scripps Rsr Inst, La Jolla, CA, USA



144 STRUCTURAL STUDIES OF HIV NEUTRALIZING ANTIBODIES

5:00

Andrew B. Ward, Scripps Rsr Inst, La Jolla, CA, USA



145 CLINICAL STUDIES WITH BROADLY NEUTRALIZING ANTIBODIES

5:30

Michel Nussenzweig, Rockefeller Univ, New York, NY, USA



Symposium S-9 MODERN ART Room 6 E

4:00 PM - 6:00 PM

Target Audience: This session is directed to clinicians and scientists who are interested in understanding contemporary antiretroviral therapy and HIV drug resistance

Level of Knowledge: It is assumed that the participants are familiar with the principles of HIV drug resistance and antiretroviral therapy

Objectives: At the completion of the session, participants will be able to:

- Describe trends in transmitted HIV drug resistance and resistance emergence on ART
- Compare strategies for simplification of antiretroviral therapy in patients suppressed on therapy
- Summarize the challenges in developing an initial antiretroviral regimen for the global HIV epidemic

Conveners

Ying-Ru Lo, *World Health Organization, Geneva, Switzerland*

Paul E. Sax, *Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA*



0146 HIV-1 DRUG RESISTANCE IN RESOURCE-LIMITED SETTINGS

4:00

Ravindra K. Gupta, *Univ College London, London, UK*



0147 LONG-ACTING ANTIRETROVIRAL THERAPY: A SHOT IN THE DARK OR A PARADIGM SHIFT?

4:30

Charles W. Flexner, *The Johns Hopkins Univ, Baltimore, MD, USA*



148 SIMPLE ART: MORE COMPLEX THAN THOUGHT

5:00

Jose R. Arribas, *Hospital La Paz, Madrid, Spain*



149 TOWARD AN IDEAL ANTIRETROVIRAL REGIMEN FOR THE GLOBAL EPIDEMIC

5:30

Beatriz Grinsztejn, *Oswaldo Cruz Foundation - Fiocruz, Rio de Janeiro, Brazil*



Symposium S-10 LEVERAGING THE PLATFORM: RESPONDING TO NONCOMMUNICABLE DISEASES

Room 6 C

4:00 PM - 6:00 PM

Target Audience: This session is directed to clinicians and scientists who are interested in understanding the potential for synergies between global efforts to reduce premature mortality from noncommunicable diseases and global efforts to improve the quality and length of life of people living with HIV.

Level of Knowledge: It is assumed that participants are familiar with basic clinical management of HIV and a range of noncommunicable diseases, including prevention, care and treatment. Some familiarity with health care systems in low resource settings will enhance the value of this session.

Objectives: At the completion of the session, participants will be able to:

- Understand the global burden of noncommunicable diseases associated with HIV
- Understand the use of HIV treatment infrastructure to address noncommunicable diseases
- Understand the benefits and challenges of integrating services for HIV and noncommunicable diseases at different levels of the health system

Conveners

Peter Godfrey-Faussett, UNAIDS, Geneva, Switzerland

Irene Mukui, National AIDS and STI Control Program, Nairobi, Kenya



150 OVERVIEW OF THE GLOBAL BURDEN OF NONCOMMUNICABLE DISEASES IN HIV INFECTION

4:00

Pragna Patel, CDC, Atlanta, GA, USA



151 CARDIOVASCULAR DISEASE AMONGST PEOPLE LIVING WITH HIV IN AFRICA

4:30

Gerald Yonga, Aga Khan Univ, Nairobi, Kenya



152 CAN WE LEVERAGE HIV PLATFORMS FOR PREVENTION OF CERVICAL CANCER IN LMICs IN SSA?

5:00

Doreen Ramogola-Masire, Univ of Botswana-Univ of Pennsylvania Collaboration, Gaborone, Botswana



153 MINIMIZING MORBIDITY: INTEGRATING CARE FOR DEPRESSION & HIV IN LOW RESOURCE SETTINGS

5:30

Pamela Collins, NIMH, Bethesda, MD, USA



POSTER SESSIONS BY DAY

TUESDAY, FEBRUARY 14, 2017

Poster P-A1: VIROLOGY TRAFFICKING
Poster Hall - 4 EF

2:30 PM - 4:00 PM

- 154 PHENOTYPING AND SORTING OF INDIVIDUAL FREE INFECTIOUS HIV PARTICLES BY FLOW CYTOMETRY**
Michał Bonar, John Tilton
Case Western Reserve Univ, Cleveland, OH, USA
- 155 SINGLE VIRUS IMAGING OF HIV-1 WITH FLUORESCENTLY LABELED CA**
 Zeger Debyser, Irena Zurnic, Lieve Dirix, Veerle Lemmens, Veerle Lemmens, Susana Rocha, Johan Hofkens, Jelle Hendrix, **Frauke Christ**
Katholieke Univ Leuven, Leuven, Belgium
- 156 CHARACTERIZING CELLULAR FACTORS INVOLVED IN HIV-1 GAG TRAFFICKING TO ASSEMBLY SITES**
Rachel Van Duyne, Philip R. Tedbury, Eric O. Freed
NCI, Frederick, MD, USA
- 157 HIV-1 RESISTANCE TO KF116 REVEALS INTEGRASE'S ROLE DURING POLYPROTEIN PROCESSING**
Ashley C. Hoyte¹, Augusta V. Jamin², Pratibha Chowdary Koneru¹, Stephanie Rebensburg¹, Jason Anderson¹, Matthew Kobe¹, Emma N. Ivanauskas¹, James R. Fuchs³, Alan N. Engelman², Mamuka Kvaratskhelia¹
¹The Ohio State Univ, Columbus, OH, USA, ²Dana-Farber Cancer Inst, Boston, MA, USA, ³The Ohio State Univ, Columbus, OH, USA
- 158 ROLE OF MA TRIMERIZATION IN HIV-1 ENVELOPE GLYCOPROTEIN INCORPORATION**
Mariia Novikova, Philip R. Tedbury, Eric O. Freed
NCI, Frederick, MD, USA
- 159 PRODUCTION OF HIV-1 PROTEINS FROM "DEFECTIVE" HIV-1 PROVIRUS**
Hiromi Imamichi¹, Joseph Adelsberger², H. Clifford Lane¹
¹NIAID, Bethesda, MD, USA, ²Leidos Biomed Rsr, Inc, Frederick, MD, USA
- 160LB NUCLEAR PORE HETEROGENEITY AFFECTS HIV-1 INFECTION AND THE ANTIVIRAL ACTIVITY OF MX2**
Melissa Kane¹, Stephanie Rebensburg², Matthew Takata¹, Trinity Zang¹, Masahiro Yamashita³, Mamuka Kvaratskhelia², Paul Bieniasz⁴
¹The Rockefeller Univ, New York, NY, USA, ²The Ohio State Univ, Columbus, OH, USA, ³Aaron Diamond AIDS Rsr Cntr, New York, NY, USA, ⁴Howard Hughes Med Cntr, New York, NY, USA

Poster Sessions • Tuesday

Poster P-B1: UNDERSTANDING NETWORKS AND LINKED INFECTIONS: FROM LOCAL TO GLOBAL

Poster Hall - 4 EF

2:30 PM - 4:00 PM

182 IDENTIFICATION OF MAJOR ROUTES OF HIV TRANSMISSION THROUGHOUT MESOAMERICA

Antoine Chaillon¹, Joel O. Wertheim¹, Santiago Avila-Rios², Ann M. Dennis³, Claudia García-Morales², Carlos Mejía-Villatoro⁴, Elsa Y. Palou⁵, Gustavo Reyes-Terán⁶, Sanjay R. Mehta¹, for the The Mesoamerican Project Group

¹Univ of California, San Diego, San Diego, CA, USA, ²Natl Inst of Respiratory Diseases, Mexico City, Mexico, ³Univ of North Carolina at Chapel Hill, Chapel Hill, NC, USA, ⁴Roosevelt Hosp, Guatemala City, Guatemala, ⁵Hosp Escuela Univ, Tegucigalpa, Honduras, ⁶Rsr Cntr in Infectious Diseases, Mexico City, Mexico

183 REVEALING THE MOLECULAR EPIDEMIOLOGY OF THE COLOGNE, GERMANY, HIV EPIDEMIC

Melanie Stecher¹, **Martin Hoenigl**², Joerg Janne Vehreschild¹, Clara Lehmann³, Gerd Fätkenheuer³, Rolf Kaiser¹, Sanjay R. Mehta², Antoine Chaillon²

¹Univ of Cologne, Cologne, Germany, ²Univ of California San Diego, San Diego, CA, USA, ³Cologne Univ Hosp, Cologne, Germany

184 STRUCTURE OF HIV-1C TRANSMISSION NETWORK IN SOUTHERN BOTSWANA, 2016

Vlad Novitsky¹, Sikhulile Moyo², Melissa Zahralban-Steele¹, Baitshepi Mokaleng², Dorcas Maruapula², Mary F. McLane¹, Kathleen Wirth¹, Lisa A. Mills³, Simani Gaseitsiwe², Max Essex¹

¹Harvard Univ, Boston, MA, USA, ²Botswana Harvard AIDs Rsr Inst Partnership, Gaborone, Botswana, ³CDC Botswana, Gaborone, Botswana

185 PHYLOGENETICS OF A RECENT HIV OUTBREAK AMONG PEOPLE WHO INJECT DRUGS IN SCOTLAND

Manon Ragonnet-Cronin¹, Celia Jackson², Amanda Bradley-Stewart², Celia Aitken², Andrew McAuley³, Norah Palmateer³, David Goldberg³, Catriona Milosevic², Andrew Leigh Brown¹

¹Univ of Edinburgh, Edinburgh, UK, ²NHS Greater Glasgow and Clyde, Glasgow, UK, ³Hlth Protection Scotland, Glasgow, UK

186 NONDISCLOSED MSM LINK TOGETHER IN HIV TRANSMISSION NETWORKS

Manon Ragonnet-Cronin¹, Stéphane Hué², Anna Tostevin³, Anton Pozniak⁴, Tracy Fawcett⁵, Alison E. Brown⁶, David Dunn³, Andrew Leigh Brown¹, for the UK HIV Drug Resistance Database

¹Univ of Edinburgh, Edinburgh, UK, ²London Sch of Hygiene & Tropical Med, London, UK, ³Univ Coll London, London, UK, ⁴Chelsea and Westminster NHS Fndn Trust, London, UK, ⁵Leeds Teaching Hosps NHS Trust, Leeds, UK, ⁶Pub Hlth England, London, UK

187 MATING THE EFFECT OF COMPLETENESS OF HIV SEQUENCING DATA ON TRANSMISSION NETWORKS

Sharoda Dasgupta¹, Anne Marie France¹, Mary-Grace Brandt², M Cheryl B. Ocfemia¹, Tianchi Zhang¹, Nivedha Panneer¹, Angela Hernandez¹, Alexandra Oster¹

¹CDC, Atlanta, GA, USA, ²Michigan Dept of Community Hlth, Detroit, MI, USA

188 TEMPORAL CHANGES IN HIV TRANSMISSION PATTERNS AMONG YOUNG MEN WHO HAVE SEX WITH MEN

Nivedha Panneer¹, Y. O. Whiteside², Anne Marie France², Joel O. Wertheim³, Alexandra Oster²

¹Oak Ridge Inst for Sci and Educ, Atlanta, GA, USA, ²CDC, Atlanta, GA, USA,

³Univ of California San Diego, San Diego, CA, USA

189 PHYLODYNAMIC ANALYSIS AIDS PARTNER SERVICES BY IDENTIFYING UNREPORTED TRANSMISSION

Ellsworth Campbell¹, Anupama Shankar¹, Emily Westheimer², Cynthia L. Gay³, Stephanie E. Cohen⁴, Jin-Fen Li¹, Jeffrey A. Johnson¹, Philip J. Peters¹, William M. Switzer¹

¹CDC, Atlanta, GA, USA, ²New York City DHMH, New York, NY, USA, ³Univ of North Carolina at Chapel Hill, Chapel Hill, NC, USA, ⁴San Francisco Dept of Pub Hlth, San Francisco, CA, USA

190 NEUTRALIZING ANTIBODIES IN HUMANS INFECTED WITH ZONOTIC SIMIAN FOAMY VIRUSES

Caroline Lambert, Julie Gouzil, Léa Richard, Réjane Rua, Edouard Betsem, Antoine Gessain, **Florence Buseyne**

Inst Pasteur, Paris, France

Poster P-C4: ANIMAL MODELS OF HIV INFECTION**Poster Hall - 4 EF****2:30 PM - 4:00 PM****216 ANTIBIOTICS DISRUPT GASTROINTESTINAL BACTERIA AND HOST IMMUNITY IN RHESUS MACAQUES**

Alexander S. Zevin, Jennifer A. Manuzak, Tiffany Hensley-McBain, Ryan Cheu, Charlene Miller, Jacob Modesitt, Jeremy Smedley, Nichole Klatt
Univ of Washington, Seattle, WA, USA

217 ALCOHOL CONSUMPTION INCREASES SIV FOUNDER VIRUS DIVERSITY TO ALTER DISEASE COURSE

Spencer Robichaux, Angela M. Amedee
Louisiana State Univ, New Orleans, LA, USA

218 GORILLA ENTERIC VIROME DYNAMICS IN ASSOCIATION WITH SIV INFECTION

Mirela D'arc¹, Carolina Furtado², Juliana D. Siqueira², Ahidjo Ayoub³, Martine Peeters³, Marcelo A. Soares²

¹Univ Fed do Rio de Janeiro, Rio de Janeiro, Brazil, ²Inst Nacional de Câncer, Rio de Janeiro, Brazil, ³IRD, Montpellier, France

219 EARLY HIV-1 DETECTION IN HUMANIZED MICE

Hang Su, Prasanta Dash, Larisa Y. Poluektova, Santhi Gorantla, Howard E. Gendelman

Univ of Nebraska, Omaha, NE, USA

220 AN ENGINEERED RNA VIRUS CAUSES ACUTE AIDS IN HUMAN CD4,CCR5 TRANSGENIC MICE

Rachel A. Liberatore, Emily J. Mastrocola, Elena Cassella, Jessie Willen, Fabian Schmidt, Dennis Voronin, Trinity Zang, Theodora Hatzioannou, **Paul Bieniasz**

The Rockefeller Univ, New York, NY, USA

Poster P-C5: EFFECT OF ANTIRETROVIRAL THERAPY ON HIV DISEASE AND RECOVERY**Poster Hall - 4 EF****2:30 PM - 4:00 PM****221 RAPID T FOLLICULAR HELPER CELL RECONSTITUTION IN LYMPH NODES AFTER ART INITIATION**

Chun-Shu Wong¹, Afroditi Boulougoura¹, Angela Kibiy², Jeremy Davis³, Stefania Pittaluga³, Maura Manion¹, Andrea Lisco¹, Virginia Sheikh⁴, JoAnn Mican¹, Irini Sereti¹

¹NIAID, Bethesda, MD, USA, ²Leidos Biomed Rsr, Bethesda, MD, USA, ³NCI, Bethesda, MD, USA, ⁴FDA, Silver Spring, MD, USA

222 INFLAMMASOME AND PYROPTOSIS ARE INVOLVED IN THE LACK OF IMMUNE RESPONSE DURING CART

Michela Masetti¹, Massimiliano Fabbiani², Mara Biasini¹, Antonio Muscatello², Nicola Squillace², Elisa Colella², Mario Clerici³, Andrea Gori², Daria Trabattoni¹, Alessandra Bandera²

¹Univ of Milan, Milan, Italy, ²San Gerardo Hosp, Monza, Italy, ³Univ of Milan, Segrate, Milan, Italy

223 INCREASED IL-18/IL-1B RATIO BLUNTS CCL20 PRODUCTION AND TH17 GUT HOMING DURING CART

Claire Loiseau¹, Mary Requena², Anne Laure Iscache¹, Michelle Cazabat², Nicolas Carrere², Bertrand Suc², Bruno Marchou², Jacques Izopet², Pierre Delobel²

¹INSERM, Toulouse, France, ²CHU Toulouse, Toulouse, France

224 GENITAL HIV SHEDDING WHEN ANTIRETROVIRAL THERAPY (ART) SUPPRESSES PLASMA HIV RNA

Marta E. Bull¹, Caroline Mitchell², Corey Williams³, Jaime Soria⁴, Eduardo Ticona⁵, Eduardo Ticona⁵, Alberto M. La Rosa⁶, Joan Dragavon¹, Robert Coombs¹, Lisa Frenkel¹

¹Univ of Washington, Seattle, WA, USA, ²Massachusetts General Hosp, Boston, MA, USA, ³Seattle Children's Rsr Inst, Seattle, WA, USA, ⁴Hosp Nacional Dos de Mayo, Lima, Peru, ⁵Hosp Dos de Mayo, Lima, Peru, ⁶Asociación Civil Impacta Salud y Educación, Lima, Peru

225 PREDICTORS OF IMMUNE RECOVERY AFTER ART IN VERY ADVANCED DISEASE

Pablo F. Belaunzaran-Zamudio¹, Alejandro Olmedo¹, Irini Sereti², Yanink Caro-Vega¹, Adam Rupert³, Alondra López¹, Ian Sanne⁴, Juan Sierra-Madero¹, Michael M. Lederman⁵

¹Instituto Nacional de Ciencias Medicas y Nutrición Salvador Zuirán, Mexico, Mexico, ²NIAID, Bethesda, MD, USA, ³Leidos Biomed Rsr, Inc, Frederick, VA, USA, ⁴Univ of the Witwatersrand, Johannesburg, South Africa, ⁵Case Western Reserve Univ, Cleveland, OH, USA

226 PARADOXICAL CD4 DECLINE ON ART: A NOVEL, RARE, AND PERPLEXING IMMUNOLOGIC OUTCOME

Andrea Lisco¹, Itzhak Levy², Jason Brophy³, Claire Deleage⁴, Chun-Shu Wong¹, Adam Rupert⁵, Caryn G. Morse⁶, Shanna Chan⁷, Jacob D. Estes⁴, Irini Sereti¹

¹NIAID, Bethesda, MD, USA, ²Academic Med Cntr Hosp, Tel Aviv, Israel, ³Children's Hosp of Eastern Ontario, Ottawa, Canada, ⁴Frederick Natl Lab for Cancer Rsr, Frederick, USA, ⁵Leidos Biomed Rsr, Inc, Frederick, MD, USA, ⁶NIH, Bethesda, MD, USA, ⁷Winnipeg Regional Hlth Authority, Manitoba, Canada

227 EFFECT OF EXOGENOUS INTERFERON ALPHA ON HIV VIRAL POPULATIONS IN VIVO

Giorgio Bozzi¹, Wei Shao², Robin L. Dewar², Vinay K. Pathak¹, Belete A. Desimmie¹, Ryan C. Burdick¹, Sara Jones³, Claudia Balotta⁴, Mary E. Wright⁵, Frank Maldarelli¹

¹NCI, Frederick, MD, USA, ²Leidos Biomed Rsr, Inc, Frederick, MD, USA, ³Leidos Biomed Rsr, Inc, Bethesda, MD, USA, ⁴Univ of Milan, Milan, Italy, ⁵NIAID, Bethesda, MD, USA

Poster P-D1: HIV-SPECIFIC ANTIBODIES AND HOW TO INDUCE THEM

Poster Hall - 4 EF

2:30 PM - 4:00 PM

242 A BROAD POLYCLONAL RESPONSE IS MEDIATED BY SUPERINFECTION WITH 2 DISTINCT VIRUSES

Bingjie Wang¹, Katherine L. Williams¹, Valerie Cortez¹, James A. Williams², Kelly K. Lee², R. Scott McClelland², Julie Overbaugh¹

¹Fred Hutchinson Cancer Rsr Cntr, Seattle, WA, USA, ²Univ of Washington, Seattle, WA, USA

243 HIGH-RESOLUTION MAPPING OF AN ENV EPIOTOPE BY COMPREHENSIVE ESCAPE MUTANT SELECTION

Adam Dingens, Hugh Haddox, Julie Overbaugh, Jesse Bloom

Fred Hutchinson Cancer Rsr Cntr, Seattle, WA, USA

244 INITIAL HIV DIVERSITY & NEUTRALIZING ANTIBODY DEVELOPMENT IN PEOPLE WHO INJECT DRUGS

Andrew D. Redd¹, Nicole Doria-Rose², Matthew Seivers³, Stephen Schmidt¹, Oliver Laeyendecker¹, Stephen Porcella⁴, Gregory D. Kirk³, John R. Mascola⁵, Shruti H. Mehta³, Thomas C. Quinn¹

¹NIAID, Bethesda, MD, USA, ²NIH, Bethesda, MD, USA, ³The Johns Hopkins Univ, Baltimore, MD, USA, ⁴NIAID, Hamilton, MT, USA, ⁵Vaccine Rsr Cntr, Bethesda, MD, USA

245 ELITE NEUTRALIZATION AND UNIQUE EPIOTOPE SPECIFICITY OF A VIREMIC NONPROGRESSOR

Nandagopal Paneerselvam¹, Chinnambedu Ravichandran Swathirajan¹, Sunil S. Solomon¹, Jayantha Bhattacharya², Bimal K. Chakrabarti², Rajat Goyal³, Aylur K. Srikrishnan¹, Kailapuri G. Murugavel¹

¹YRG CARE, Chennai, India, ²HIV Vaccine Translational Rsr Lab, Faridabad, India, ³Intl AIDS Vaccine Initiative, New York, NY, USA

246 USING EMPIRIC SATURATION MUTAGENESIS TO IDENTIFY NOVEL ENV TRIMERS FOR VACCINES

Maria Jose Duenas Decamp¹, Li Jiang², Dan Bolon¹, Paul Clapham¹

¹Univ of Massachusetts, Worcester, MA, USA, ²Harvard Univ, Boston, MA, USA

247 OLEANOLIC ACID DERIVATIVE OKS3-019 AS A NOVEL BIFUNCTIONAL HIV-1 ENTRY INHIBITOR

Shigeyoshi Harada¹, Kasumi Ogihara², Yuta Hikichi¹, Tetsuro Matano¹, Tetsuo Narumi², Kazuhisa Yoshimura¹

¹Natl Inst of Infectious Diseases, Shinjuku-ku, Tokyo, Japan, ²Shizuoka Univ, Hamamatsu, Shizuoka, Japan

248 GP41 ANTIGENIC RECOGNITION AND RESPONSE IN HIV-NEGATIVE MEN WHO HAVE SEX WITH MEN

Katie McFaul, Jia Guo, Elizabeth Atkins, Xiao-Ning Xu, Peter Kelleher, for the Centre for Immunology and Vaccinology

Imperial Coll London, London, UK

249 B-CELL RESPONSES POST-ART INTERRUPTION IN PERSONS TREATED IN FIEBIG I

Supranee Buranapraditkun¹, Donn Colby², Suwanna Pattamasavin², Suteeraporn Pinyakorn³, Rapee Trichaviroj⁴, Nelson L. Michael⁵, Merlin L. Robb³, Jintanat Ananworanich³, Lydie Trautmann³, for the RV411 and RV254/SEARCH010 study groups

¹Henry M. Jackson Fndn for the Advancement of Military Med, Bethesda, MD, USA, ²SEARCH, The Thai Red Cross AIDS Rsr Cntr, Bangkok, Thailand, ³US Military HIV Rsr Prog, Bethesda, MD, USA, ⁴Armed Forces Rsr Inst of Med Sci, Bangkok, Thailand, ⁵Walter Reed Army Inst of Rsr, Silver Spring, MD, USA

250 DC FUNCTIONALITY DISTINGUISHES HIV-1 CONTROLLERS WITH NEUTRALIZING ANTIBODY BREADTH

Enrique Martin-Gayo¹, Zhengyu Ouyang¹, Dhohyung Kim¹, Kellie E. Kolb², Bruce D. Walker¹, Alex K Shalek², Xu G. Yu¹

¹Ragon Inst of MGH, MIT and Harvard, Cambridge, MA, USA, ²MIT Inst for Med Engineering & Sci (IMES), Cambridge, MA, USA

Poster P-E1: PERSISTENT VIREMIA AND IMMUNITY ON ART

Poster Hall - 4 EF

2:30 PM - 4:00 PM

277 RESIDUAL LOW-LEVEL VIREMIA ON ART NOT ASSOCIATED WITH LOWER SYSTEMIC EXPOSURE TO ARVs

Monica Gandhi¹, Andrei Stefanescu², Ronald Bosch², Rajesh T. Gandhi³, Joshua C. Cyktor⁴, Howard Horng¹, Joseph J. Eron⁵, John W. Mellors⁴, Deborah McMahon⁴

¹Univ of California San Francisco, San Francisco, CA, USA, ²Harvard Univ, Boston, MA, USA, ³Massachusetts General Hosp, Boston, MA, USA, ⁴Univ of Pittsburgh, Pittsburgh, PA, USA, ⁵Univ of North Carolina at Chapel Hill, Chapel Hill, NC, USA

278 ANTIGP41 TITERS REFLECT RESIDUAL REPLICATION IN VIROLOGICALLY SUPPRESSED ART PATIENTS

Heloise M. Delagreverie¹, Maxime Grudé², Sidonie Lambert³, François Raffi⁴, Catherine Lepout⁵, Cécile Goujard⁶, Lorraine Plessis⁷, Christine Katlama⁸, Francis Barin⁹, Constance Delaugerre¹⁰

¹Hôpital Saint Louis, PARIS, France, ²INSERM, Paris, France, ³Institut Pierre Louis d'Epidémiologie et de Santé, Paris, France, ⁴CHU Hotel-Dieu Nantes, Nantes, France, ⁵Hôpital Bichat, Paris, France, ⁶AP-HP, Le Kremlin-Bicêtre, France, ⁷INSERM, Villejuif, France, ⁸Pierre and Marie Curie Univ, Paris, France, ⁹INSERM, Tours, France, ¹⁰Hôpital Saint Louis, Paris, France

279 ANTIBODY LEVELS CORRELATE WITH THE INFECTED CELL POPULATION IN HIV PATIENTS ON ART

Sheila Keating¹, Christina Lalama², Ronald Bosch², Deborah McMahon³, Joshua Cyktor³, John Mellors³, Joseph J. Eron⁴, Rajesh T. Gandhi⁵, Michael P. Busch¹, for the ACTG 5321 team

¹Blood Systems Rsr Inst, San Francisco, CA, USA, ²Harvard Univ, Boston, MA, USA, ³Univ of Pittsburgh, Pittsburgh, PA, USA, ⁴Univ of North Carolina at Chapel Hill, Chapel Hill, NC, USA, ⁵Massachusetts General Hosp and Ragon Inst, Boston, MA, USA

280 PERSISTENT IMMUNE ACTIVATION DESPITE ART: THE "DIE IS CAST" BEFORE ART INITIATION

Rajesh T. Gandhi¹, Deborah McMahon², Ronald Bosch³, Christina Lalama³, Bernard Macatangay², Joshua Cyktor², Ann Collier⁴, Charles Rinaldo², Joseph J. Eron⁵, John Mellors²

¹Massachusetts General Hosp and Ragon Inst, Boston, MA, USA, ²Univ of Pittsburgh, Pittsburgh, PA, USA, ³Harvard Univ, Boston, MA, USA, ⁴Univ of Washington, Seattle, WA, USA, ⁵Univ of North Carolina at Chapel Hill, Chapel Hill, NC, USA

281 SEX-BASED DIFFERENCES IN HIV RESERVOIR ACTIVITY AND RESIDUAL IMMUNE ACTIVATION

Eileen Scully¹, Monica Gandhi², Rowena Johnston³, Rob Gorelick⁴, Jeffrey D. Lifson⁵, Sharon R. Lewin⁶, Jonathan Karn⁷, Nicolas Chomont⁸, Peter Bacchetti², Steven G. Deeks²

¹The Johns Hopkins Univ, Baltimore, MD, USA, ²Univ of California San Francisco, San Francisco, CA, USA, ³amfAR, New York, NY, USA, ⁴Leidos Biomed Rsr, Inc, Frederick, MD, USA, ⁵Frederick Natl Lab, Frederick, MD, USA, ⁶Univ of Melbourne, Melbourne, Australia, ⁷Case Western Reserve Univ, Cleveland, OH, USA, ⁸Univ de Montréal, Montréal, QC, Canada

Poster P-E5: PARSING PERSISTENT PROVIRUSES

Poster Hall - 4 EF

2:30 PM - 4:00 PM

300 NOVEL ASSAY TO MEASURE INTEGRATED HIV DNA IN PBMC FROM ART-SUPPRESSED PERSONS

Steven Lada¹, Jake VanBelzan², Caroline Ignacio¹, Matthew Strain¹, Una O'Doherty², Douglas D. Richman¹

¹Univ of California San Diego, La Jolla, CA, USA, ²Univ of Pennsylvania, Philadelphia, PA, USA

301 PARALLEL NEXTGEN FULL-LENGTH HIV PROVIRAL DNA SEQUENCE AND INTEGRATION SITE ANALYSIS

Mathew L. Jones, Emanuele Marchi, Jacob Hurst, Nicola Robinson, John Frater

Univ of Oxford, Oxford, UK

302 HIV-1 INTEGRATION SITES ANALYSIS REVEALS DIFFERENT COMPARTMENTS OF THE HIV RESERVOIR

Eva Malatinkova¹, Wei Wang², Stephanie Laufs², Ward De Spiegelaere¹, Ning Wu², Saira Afzal², Raffaele Fronza², Sabine Kinloch-de Loes³, Manfred Schmidt², **Linos Vandekerckhove**¹

¹HIV Cure Rsr Cntr, Ghent Univ, Ghent, Belgium, ²German Cancer Rsr Cntr and Natl Cntr for Tumor Diseases, Heidelberg, Germany, ³Royal Free Hosp, London, UK

303 ENRICHMENT OF DEFECTIVE PROVIRUSES LACKING TAT-REV DURING LONG-TERM ART

Francesco R. Simonetti¹, Paolo Cattaneo¹, Alessia Lai¹, Elizabeth M. Anderson², Stefano Rusconi¹, Melissa Tosiano³, John Mellors³, Frank Maldarelli², Massimo Galli⁴, Claudia Balotta¹

¹Univ of Milan, Milan Italy, ²NCI, Frederick, MD, USA, ³Univ of Pittsburgh, Pittsburgh, PA, USA, ⁴Luigi Sacco Univ Hosp, Milan, Italy

304 HIV INTEGRATION SITE/ORIENTATION CONFER SELECTIVE ADVANTAGE FOR PERSISTENCE ON ART

Hadega Aamer¹, Malika Aid², Sherry McLaughlin¹, Thomas R. Sibley³, Evan J. Silberman³, Wenjie Deng³, Paul Edlefsen⁴, Rafick-Pierre Sekaly⁵, Lisa Frenkel³, James Mullins³

¹Seattle Children's Rsr Inst, Seattle, WA, USA, ²Harvard Univ, Boston, USA, ³Univ of Washington, Seattle, WA, USA, ⁴Fred Hutchinson Cancer Rsr Cntr, Seattle, WA, USA, ⁵Case Western Reserve Univ, Cleveland, OH, USA

305 ROMIDEPSIN-INDUCED HIV-1 VIREMIA IS OLIGOCLONAL WITH LIMITED DELETERIOUS MUTATIONS

Anni Winckelmann¹, Kirston Barton², Bonnie Hiener², Timothy E. Schlub³, Wei Shao⁴, Thomas A. Rasmussen¹, Lars Østergaard¹, Ole S. Søgaard¹, Martin Tolstrup¹, Sarah Palmer²

¹Aarhus Univ Hosp, Aarhus, Denmark, ²Univ of Sydney, Westmead, Australia, ³Univ of Sydney, Camperdown, New South Wales, Australia, ⁴Leidos Biomed Rsr, Inc, Frederick, MD, USA

Poster P-E7: EFFECT OF TRANSPLANTATION ON THE HIV RESERVOIR

Poster Hall - 4 EF

2:30 PM - 4:00 PM

317 INDUCIBLE HIV-1 LATENT RESERVOIR INCREASES AFTER HIV+ OR HIV- SOLID ORGAN TRANSPLANT

Alyssa R. Martin¹, Andrew D. Redd², Gregory Laird¹, Robert Siliciano¹, Diane Brown¹, Darin Ostrander¹, Thomas Quinn¹, Dorry Segev¹, Aaron Tobian¹, Christine Durand¹

¹The Johns Hopkins Univ, Baltimore, MD, USA, ²NIAID, Bethesda, MD, USA

318 PERSISTENCE OF A MINORITY HIV VARIANT DESPITE ALLOBMT WITH COMPLETE DONOR CHIMERISM

Adam Capoferri¹, Andrew D. Redd², Daniel I. Rosenbloom³, Roberto Ramirez², Subul Beg¹, Andrew Timmons⁴, Christopher Gocke¹, Robert Siliciano¹, Richard Ambinder¹, Christine Durand¹

¹The Johns Hopkins Univ, Baltimore, MD, USA, ²NIAID, Bethesda, MD, USA, ³Columbia Univ, New York, NY, USA, ⁴Johns Hopkins Hosp, Baltimore, MD, USA

319 TWO HUNDRED EIGHTY-EIGHT-DAY DRUG-FREE REMISSION FROM HIV REBOUND BY ALLOGENEIC PBSCT

Nathan Cummins¹, Stacey Rizza¹, Jason Baker², Nicolas Chomont³, Tae-Wook Chun⁴, Mathias Lichterfeld⁵, Douglas D. Richman⁶, Timothy Schacker⁷, Joseph D. Yao¹, Andrew Badley¹

¹Mayo Clinic, Rochester, MN, USA, ²Univ of Minnesota, Minneapolis, MN, USA, ³Univ de Montréal, Montreal, QC, Canada, ⁴NIH, Bethesda, MD, USA, ⁵Massachusetts General Hosp, Boston, MA, USA, ⁶Univ of California San Diego, La Jolla, CA, USA, ⁷Univ of Minnesota, Minneapolis, MN, USA

320 PERSISTENCE OF HIV DNA IN TISSUES EARLY AFTER TRANSPLANTATION WITH CCR5Δ32 STEM CELLS

Kobus Bosman¹, Monique Nijhuis¹, Anke Bruns¹, Maria Salgado², Gero Hütter³, Lodewijk Brosens¹, Javier Martinez-Picado⁴, Jürgen Kuball¹, Annemarie Wensing¹, for the IciStem consortium

¹Univ Med Cntr Utrecht, Utrecht, Netherlands, ²AIDS Rsr Inst IrsiCaixa, Badalona, Spain, ³Cellex, Dresden, Germany, ⁴ICREA, Barcelona, Spain

321 IMMUNE DYSREGULATION DICTATES SHIV REBOUND AFTER STEM-CELL TRANSPLANT IN MACAQUES

Christopher Peterson¹, Clarisse Benne², Patricia Polacino³, Keith Jerome¹, Shiu-Lok Hu⁴, Nichole Klatt⁴, Stephen DeRosa¹, Rafick-Pierre Sekaly², Hans-Peter Kiem¹

¹Fred Hutchinson Cancer Rsr Cntr, Seattle, WA, USA, ²Case Western Reserve Univ, Cleveland, OH, USA, ³Washington Natl Primate Rsr Cntr, Seattle, WA, USA, ⁴Univ of Washington, Seattle, WA, USA

322 CONTROL OF PATHOGENIC SHIV INFECTION IN TRANSPLANTED MACAQUES

Christopher Peterson¹, Kevin G. Haworth¹, Bryan P. Burke², Patricia Polacino³, Shiu-Lok Hu⁴, Brandon Keele⁵, Jeffrey S. Bartlett², Geoff P. Symonds², Hans-Peter Kiem¹

¹Fred Hutchinson Cancer Rsr Cntr, Seattle, WA, USA, ²Calimmune, Inc, Pasadena, CA, USA, ³Washington Natl Primate Rsr Cntr, Seattle, WA, USA, ⁴Univ of Washington, Seattle, WA, USA, ⁵NCI, Frederick, MD, USA

Poster P-F5 VIROLOGY/BASIC NEUROSCIENCE

Poster Hall - 4 EF

2:30 PM - 4:00 PM

373 PROGRESSIVE HIPPOCAMPAL NEURONAL LOSS IN PEDIATRIC SIV INFECTION

Heather Carryl¹, Koen Van Rompay², Kristina De Paris³, Mark W. Burke¹

¹Howard Univ, Washington, DC, USA, ²Univ of California Davis, Davis, CA, USA, ³Univ of North Carolina at Chapel Hill, Chapel Hill, NC, USA

374 HIV GENE VARIANTS ALTERING CORECEPTOR BINDING & DRUG RESISTANCE PREDICT CNS PHENOTYPES

Debashis Sahoo, **Sarah Dabydeen**, Kumud K. Singh
Univ of California San Diego, La Jolla, CA, USA

375 IFN γ -INDUCED PROTEASOMAL DEGRADATION OF ASTROCYTIC HO-1 IN HIV NEUROPATHOGENESIS

Alexander J. Gill¹, Colleen E. Kovacsics¹, Suren A. Ambegaokar², Benjamin B. Gelman³, Dennis L. Kolson¹

¹Univ of Pennsylvania, Philadelphia, PA, USA, ²Ohio Wesleyan Univ, Delaware, OH, USA, ³Univ of Texas Med Branch, Galveston, TX, USA

376 IFN- β REDUCES MACROPHAGE HEME OXYGENASE-1 EXPRESSION: ROLE IN HIV NEUROPATHOGENESIS

Fiorella P. Rossi¹, **Alexander J. Gill**¹, Rolando Garza², Dennis L. Kolson¹

¹Univ of Pennsylvania, Philadelphia, PA, USA, ²Univ of Texas at San Antonio, San Antonio, TX, USA

377 CNS IRON STATUS IS ASSOCIATED WITH NEUROCOGNITIVE FUNCTION OVER TIME IN HIV+ ADULTS

Harpreet Kaur¹, William S. Bush², Scott Letendre³, Ronald J. Ellis³, Robert K. Heaton³, Stephanie M. Patton⁴, James R. Connor⁴, David C. Samuels⁵, Todd Hulgand⁵, Asha R. Kallianpur¹

¹Cleveland Clinic, Cleveland, OH, USA, ²Case Western Reserve Univ, Cleveland, OH, USA, ³Univ of California San Diego, San Diego, CA, USA, ⁴Penn State, Hershey, PA, USA, ⁵Vanderbilt Univ, Nashville, TN, USA

378 DIFFERENTIAL IN VITRO NEUROTOXICITY OF ANTIRETROVIRAL DRUGS

Cagla Akay-Espinoza¹, Anna L. Stern¹, Rebecca I. Nara¹, Nina Panvelker¹, Jean Li¹, Kelly L. Jordan-Sciutto¹

¹Univ of Pennsylvania, Philadelphia, PA, USA

379 DISCORDANT HIV RNA IN OLFACTORY MUCOSA OF HIV-POSITIVE PATIENTS

Andrea Calcagno¹, Tiziano Allice², Luca Bertero¹, Mattia Trunfio¹, Maria Enrica Amasio³, Daniele Imperiale³, Valeria Ghisetti², Giovanni Di Perri¹, Paola Cassoni¹, Stefano Bonora¹

¹Univ of Torino, Torino, Italy, ²Ospedale Amedeo di Savoia, Torino, Italy, ³Ospedale Maria Vittoria, Torino, Italy

Poster P-F6 INTERVENTION-FOCUSED

Poster Hall - 4 EF

2:30 PM - 4:00 PM

380 CAN WE AFFORD TO WAIT? ART AND THE CNS

Kevin Robertson¹, Javier R. Lama², Christopher D. Pilcher³, Jessica Rios², Peter Brandes², Eduardo Ruiz², Eline Appelmanns⁴, Serena Spudich⁵, Ann Duerr⁴, for the SABES Team

¹Univ of North Carolina at Chapel Hill, Chapel Hill, NC, USA, ²Asociacion Civil Impacta Salud y Educacion, Lima, Peru, ³Univ of California San Francisco, San Francisco, CA, USA, ⁴Fred Hutchinson Cancer Rsr Cntr, Seattle, WA, USA, ⁵Yale Univ, New Haven, CT, USA

381 CENICRIVIROC IMPROVES NEUROCOGNITION AND REDUCES MONOCYTE ACTIVATION IN TREATED HIV

Lishomwa C. Ndhlovu¹, **Michelle L. D'Antoni**¹, Robert Paul², Kalpana J. Kallianpur¹, Laurent Fischer³, Eric Lefebvre³, Star Seyedkazemi³, Beau K. Nakamoto¹, Debra Ogata-Arakaki¹, Cecilia Shikuma¹

¹Univ of Hawaii, Honolulu, HI, USA, ²Univ of Missouri—St. Louis, St. Louis, MO, USA, ³Tobira Therapeutics, Inc, South San Francisco, CA, USA

382 CSF INFLAMMATORY MARKERS AFTER ADDING MARAVIROC TO MONOTHERAPY DARUNAVIR/RITONAVIR

Tristan Barber¹, Arkaitz Imaz², Marta Boffito¹, Daniel Podzamczar², Anton Pozniak¹, Rosa Fortuny², Nicholas Davies¹, Jordi Niubo², Sundhiya Mandalia³, Brian Gazzard¹

¹Chelsea and Westminster NHS Fndn Trust, London, UK, ²Hosp Univ de Bellvitge, Barcelona, Spain, ³Imperial Coll London, London, UK

Poster P-F7 HOST AND VIRAL BIOMARKERS

Poster Hall - 4 EF

2:30 PM - 4:00 PM

383 CSF LEVELS OF THE GLIAL MARKER YKL-40 STRONGLY ASSOCIATED WITH NEURONAL INJURY IN HIV

Linn Hermansson¹, Markus Axelsson¹, Kaj Blennow², Dietmar Fuchs³, Lars Hagberg¹, Jan Lycke¹, Henrik Zetterberg¹, Magnus Gisslén¹

¹Sahlgrenska Academy at the Univ of Gothenburg, Gothenburg, Sweden, ²Sahlgrenska Univ Hosp, Gothenburg, Sweden, ³Innsbruck Med Univ, Innsbruck, Austria

384 EXTENSIVE EFAVIRENZ METABOLISM IS ASSOCIATED WITH GREATER CNS TOXICITY

Marijana Vujkovic¹, Scarlett Bellamy², Athena Zuppa¹, Marc Gastonguay³, Xiaoyan Han⁴, Mosepele Mosepele⁵, Gregory Bisson⁴, Richard Aplenc¹, **Robert Gross**⁴

¹Children's Hosp of Philadelphia, Philadelphia, PA, USA, ²Drexel Univ, Philadelphia, PA, USA, ³Metrum Rsr Group, Tariffville, CT, USA, ⁴Univ of Pennsylvania, Philadelphia, PA, USA, ⁵Univ of Botswana, Gaborone, Botswana

385 EXHAUSTED T CELLS AND INFLAMMATORY MONOCYTES ARE LINKED TO BRAIN ATROPHY IN HIV

Brooks I. Mitchell¹, Glen Chew¹, Kalpana J. Kallianpur¹, Mary Margaret Byron¹, Robert Paul², Beau K. Nakamoto¹, Dominic Chow¹, Scott A. Souza¹, Cecilia Shikuma¹, Lishomwa C. Ndhlovu¹

¹Univ of Hawaii, Honolulu, HI, USA, ²Univ of Missouri—St. Louis, St. Louis, MO, USA

- 386 CSF AND SERUM BIOMARKERS OF NEURONAL INJURY AND AGING IN HIV-INFECTED PARTICIPANTS**
Sergio M. de Almeida¹, Clea E. Ribeiro¹, Indianara Rotta¹, Mauro Piovesan¹, Sonia M. Raboni¹, Scott Letendre², Bin Tang², Florin Vaida², Ronald J. Ellis²
¹Univ Fed do Paraná, Curitiba, Brazil, ²Univ of California San Diego, San Diego, CA, USA
- 387 CSF S100B AND CX3CR1 MONOCYTES IN ACUTE HIV INFECTION PREDICT PUTAMEN ATROPHY**
 Lishomwa C. Ndhlovu¹, **Kalpana J. Kallianpur**¹, Eugene Kroon², Thep Chalermchai³, Khunthalee Benjapornpong⁴, Shelly J. Krebs⁵, Serena Spudich⁶, Jintanat Ananworanich⁵, Victor Valcour⁷, for the RV254/SEARCH010 Study Group
¹Univ of Hawaii, Honolulu, HI, USA, ²SEARCH, The Thai Red Cross AIDS Rsr Cntr, Bangkok, Thailand, ³SEARCH, Bangkok, Thailand, ⁴Thai Red Cross AIDS Rsr Cntr, Bangkok, Thailand, ⁵US Military HIV Rsr Prog, Silver Spring, MD, USA, ⁶Yale Univ, New Haven, CT, USA, ⁷Univ of California San Francisco, San Francisco, CA, USA
- 388 TELOMERE LENGTH: NEUROCOGNITIVE BIOMARKER IN HIV-1-INFECTED SUBJECTS**
Marília L. Araújo¹, Maria Rita. P Gascón², Raquel Paiva³, Bárbara Santana³, Rodrigo Calado³, Wellington Duarte¹, Luiz A. Fonseca¹, Augusto César P. Oliveira², Jorge Casseb¹
¹Univ de São Paulo, São Paulo, Brazil, ²Inst de Infectologia Emílio Ribas, São Paulo, Brazil, ³Univ de São Paulo Ribeirão Preto, Ribeirão Preto, Brazil
- 389 CEREBROSPINAL FLUID CONCENTRATION OF THE SYNAPTIC MARKER NEUROGRANIN IN HIV**
Maria C. Brühl¹, Aylin Yilmaz², Lars Hagberg², Dietmar Fuchs³, Kaj Blennow¹, Henrik Zetterberg², Richard W. Price⁴, Magnus Gisslén²
¹Sahlgrenska Univ Hosp, Gothenburg, Sweden, ²Sahlgrenska Academy at the Univ of Gothenburg, Gothenburg, Sweden, ³Innsbruck Med Univ, Innsbruck, Austria, ⁴San Francisco General Hosp, San Francisco, CA, USA
- 390 THE HUMAN GUT MICROBIOME AND HIV-ASSOCIATED NEUROCOGNITIVE DISORDERS**
Josue Perez-Santiago¹, Sara Gianella², Ajay Bharti¹, Debralee Cookson¹, Robert K. Heaton², Igor Grant², Scott Letendre¹, Scott N. Peterson³
¹Univ of California San Diego, San Diego, CA, USA, ²Univ of California San Diego, La Jolla, CA, USA, ³Sanford Burnham Prebys Med Discovery Inst, La Jolla, CA, USA
- 391 HIV ANTIBODIES IN CSF AND SERUM IN UNTREATED AND TREATED INFECTION**
Magnus Gisslén¹, Richard W. Price², Serena Spudich³, Lars Hagberg¹, Steven G. Deeks², Peter Burbelo⁴
¹Sahlgrenska Academy at the Univ of Gothenburg, Gothenburg, Sweden, ²Univ of California San Francisco, San Francisco, CA, USA, ³Yale Univ, New Haven, CT, USA, ⁴NIDCR, Bethesda, MD, USA
- 392 NUCLEAR-MITOCHONDRIAL INTERACTIONS AND NEUROCOGNITIVE IMPAIRMENT IN HIV+ ADULTS**
 Sandra P. Smieszek¹, Asha R. Kallianpur², David C. Samuels³, Donald Franklin⁴, Robert K. Heaton⁵, Scott Letendre⁴, Ronald J. Ellis⁴, Todd Hulgán³, **William S. Bush**¹
¹Case Western Reserve Univ, Cleveland, OH, USA, ²Cleveland Clinic Lerner Coll of Med, Cleveland, OH, USA, ³Vanderbilt Univ, Nashville, TN, USA, ⁴Univ of California San Diego, San Diego, CA, USA, ⁵Univ of California San Diego, La Jolla, CA, USA

393 GENETICALLY PREDICTED GENE EXPRESSION AND HIV-ASSOCIATED NEUROCOGNITIVE DISORDER

Sandra Smieszek¹, William S. Bush¹, Todd Hulgán², David C. Samuels², Donald Franklin³, Robert K. Heaton⁴, Scott Letendre³, Ronald J. Ellis³, Asha R. Kallianpur⁵

¹Case Western Reserve Univ, Cleveland, OH, USA, ²Vanderbilt Univ, Nashville, TN, USA, ³Univ of California San Diego, San Diego, CA, USA, ⁴Univ of California San Diego, La Jolla, CA, USA, ⁵Cleveland Clinic Lerner Coll of Med, Cleveland, OH, USA

Poster P-G1 INTRACELLULAR AND TISSUE PHARMACOLOGY

Poster Hall - 4 EF

2:30 PM - 4:00 PM

404 LEDIPASVIR/SOFOSBUVIR RAISES TENOFOVIR DIPHOSPHATE CONCENTRATIONS IN RED CELLS

Christine MacBrayne¹, Daniel S. Fierer², Kristen M. Marks³, Peter L. Anderson¹, Lane R. Bushman¹, Kimberly M. Hollabaugh⁴, Michael D. Hughes⁴, Raymond T. Chung⁵, Susanna Naggie⁶, Jennifer J. Kiser¹

¹Univ of Colorado, Aurora, CO, USA, ²Icahn Sch of Med at Mt Sinai, New York, NY, USA, ³Weill Cornell Med, New York, NY, USA, ⁴Harvard Univ, Boston, MA, USA, ⁵MGH, Boston, USA, ⁶Duke Univ, Durham, NC, USA

405 TENOFOVIR DIPHOSPHATE ARISING FROM TAF IS QUANTIFIABLE IN DRIED BLOOD SPOTS

Jose Castillo-Mancilla, Ryan P. Coyle, Jia-Hua Zheng, Lucas Ellison, Laura Roon, Jordan Fey, Lane Bushman, Jennifer J. Kiser, Peter Anderson

Univ of Colorado, Aurora, CO, USA

406 EXTRA/INTRA-CELLULAR NUCLEOSIDE/TIDE SEMEN PHARMACOLOGY: IMPLICATIONS FOR ERADICATION

Julie B. Dumond, Stephen A. Greene, Heather M. Asher Prince, Jingxian Chen, Brian Maas, Craig Sykes, Amanda Schauer, Cynthia L. Gay, Angela Kashuba, Myron S. Cohen

Univ of North Carolina at Chapel Hill, Chapel Hill, NC, USA

407 INTEGRASE AND PROTEASE INHIBITOR CONCENTRATIONS IN LYMPHOID VS GI TISSUES

Sulggi Lee¹, Hiroyu Hatano¹, Angela Kashuba², Mackenzie L. Cottrell², Teri Liegler¹, Sophie Stephenson¹, Ma Somsouk¹, Peter W. Hunt¹, Steven G. Deeks¹, Radojka M. Savic¹

¹Univ of California San Francisco, San Francisco, CA, USA, ²Univ of North Carolina at Chapel Hill, Chapel Hill, NC, USA

408 PLASMA AND INTRACELLULAR PK OF TENOFOVIR IN PATIENTS SWITCHED FROM TDF TO TAF

Anthony Podany, Sara H. Bares, Joshua Havens, Ravi Dyavar Shetty, Jennifer O'Neill, Sarah Lee, Courtney Fletcher, Susan Swindells, Kimberly K. Scarsi

Univ of Nebraska, Omaha, NE, USA

Poster P-G3 PHARMACOKINETICS AND PHARMACOGENETICS: NEW AND EXISTING DRUGS AND FORMULATIONS

Poster Hall - 4 EF

2:30 PM - 4:00 PM

- 415 PHARMACOKINETICS ANALYSIS OF VRC01, A BROADLY NEUTRALIZING HIV-1 MONOCLONAL ANTIBODY**
Yunda Huang¹, Lily Zhang¹, Nicole Grunenber¹, Robert Bailor², Abby Isaacs¹, Julie Ledgerwood³, Kelly Seaton⁴, Kenneth Mayer⁵, Larry Corey¹, Peter Gilbert¹
¹Fred Hutchinson Cancer Rsr Cntr, Seattle, WA, USA, ²NIAID, Gaithersburg, MD, USA, ³NIAID, Bethesda, MD, USA, ⁴Duke Human Vaccine Inst, Durham, NC, USA, ⁵The Fenway Inst, Boston, MA, USA
- 416 EFFECT OF CYP3A4*22 ON ORAL RILPIVIRINE PLASMA CONCENTRATIONS**
Rana Abutaima¹, Marta Boffito², Andrea Calcagno³, Jessica Cusato³, Antonio D'Avolio³, Laura Else¹, Chris Higgs², Saye Khoo¹, Marco Siccardi¹, Andrew Owen¹
¹Univ of Liverpool, Liverpool, UK, ²St. Stephen's AIDS Trust, Chelsea and Westminster Hosp, London, UK, ³Univ of Turin, Turin, Italy
- 417 EFFECT OF CYP3A5 GENOTYPE ON THE PK OF MARAVIROC AND METABOLITES IN HEALTHY SUBJECTS**
Manoli Vourvahis¹, Sunil Nepal², Annie Fang¹, Gwendolyn Fate³, Linda S. Wood³, Jean-Claude Marshall³, Andrew Clark⁴, Jayvant Heera³
¹Pfizer, New York, NY, USA, ²Pfizer, Biostatistics, Collville, PA, USA, ³Pfizer, Groton, CT, USA, ⁴ViiV Hlthcare, London, UK
- 418 ABCG2 RS2231142 INFLUENCES TFV CONCENTRATIONS IN PLASMA AND URINE**
Margherita Bracchi¹, **Megan Neary**², Nicole Pagani¹, Laura Else², Saye Khoo², Zaheer Abbas¹, David Hawkins¹, Graeme Moyle¹, Andrew Owen², Marta Boffito³
¹Chelsea and Westminster Hosp, London, UK, ²Univ of Liverpool, Liverpool, UK, ³Chelsea and Westminster NHS Fndn Trust, London, UK
- 419 TFV-DP IN DRIED BLOOD SPOTS (DBS) FOLLOWING DIRECTLY OBSERVED THERAPY: DOT-DBS STUDY**
Peter Anderson¹, Albert Y. Liu², Jose Castillo-Mancilla¹, Sharon Seifert¹, Cricket McHugh¹, Theresa Wagner², Susan Buchbinder², Lane Bushman¹, Jennifer J. Kiser¹, Samantha MaWhinney¹
¹Univ of Colorado Denver, Aurora, CO, USA, ²San Francisco Dept of Pub Hlth, San Francisco, CA, USA
- 420 IN VITRO AND IN VIVO EVALUATION OF BIODEGRADABLE IMPLANT CONTAINING TAF FOR HIV PREP**
Phillip G. Durham¹, Greg Gatto¹, Leah Johnson¹, Mark A. Marzinke², Stephanie Swarner¹, Ginger Rothrock¹, Tejal Desai³, Ian McGowan⁴, Ida Washington⁵, Ariane van der Straten⁶
¹RTI Intl, Durham, NC, USA, ²The Johns Hopkins Univ, Baltimore, MD, USA, ³Univ of California San Francisco, San Francisco, CA, USA, ⁴Univ of Pittsburgh, Pittsburgh, PA, ⁵Magee-Womens Rsr Inst, Pittsburgh, PA, USA, ⁶RTI Intl, San Francisco, CA, USA

421LB HPTN 076: TMC278 LA SAFE, TOLERABLE, AND ACCEPTABLE FOR HIV PRE-EXPOSURE PROPHYLAXIS

Linda-Gail Bekker¹, Shuying S. Li², Betsy Tolley³, Mark A. Marzinke⁴, Nyaradzo Mgodi⁵, Jessica E. Justman⁶, Shobha Swaminathan⁷, Adeola Adeyeye⁸, Jennifer H. Farrior³, Nirupama Sista³

¹Univ of Cape Town, Cape Town, South Africa, ²FRCHC, Seattle, WA, USA, ³FHI 360, Durham, NC, USA, ⁴Johns Hopkins Univ, Baltimore, MD, USA, ⁵Univ of Zimbabwe, Harare, Zimbabwe, ⁶ICAP at Columbia Univ, New York, NY, USA, ⁷Rutgers Univ, Newark, NJ, USA, ⁸NIH, Rockville, MD, USA

422LB TRANSCUTANEOUS REFILLABLE NANOFLUIDIC IMPLANT FOR CONSTANT DELIVERY OF HIV PREP

Corrine Xuan Chua¹, Priya Jain¹, Ming Hu², Peter L. Anderson³, Jason T. Kimata⁴, Jagannadha Sastry⁵, Roberto Arduino⁵, **Alessandro Grattoni**¹

¹Houston Methodist Rsr Inst, Houston, TX, USA, ²Univ of Houston, Houston, TX, USA, ³Univ of Colorado Denver, Aurora, CO, USA, ⁴Baylor Coll of Med, Houston, TX, USA, ⁵Univ of Texas, Houston, TX, USA

Poster P-H2 ANTIRETROVIRAL CLINICAL TRIALS
Poster Hall - 4 EF
2:30 PM - 4:00 PM**441 WITHDRAWN****442 LONG-TERM SAFETY AND EFFICACY OF CAB AND RPV AS 2-DRUG ORAL MAINTENANCE THERAPY**

David A. Margolis¹, Cynthia Brinson², Graham H. Smith³, Joseph J. Eron⁴, Gary J. Richmond⁵, Roger P. LeBlanc⁶, Peter E. Williams⁷, William Spreen¹, Kenneth Sutton⁸, Britt S. Stancil⁹

¹ViiV Hlthcare, Rsr Triangle Park, NC, USA, ²Central Texas Clinical Rsr, Austin, TX, USA, ³Maple Leaf Med Clinic, Toronto, Ontario, Canada, ⁴Univ of North Carolina at Chapel Hill, Chapel Hill, NC, USA, ⁵Gary J Richmond MD PA, Ft Lauderdale, FL, USA, ⁶Clinique OPUS, Montréal, Québec, Canada, ⁷Janssen Rsr and Development, Beerse, Belgium, ⁸ViiV Hlthcare, Raleigh, NC, USA, ⁹PAREXEL Intl, Durham, NC, USA

443 EFFICACY & SAFETY OF SWITCHING TO EVG/COBI/FTC/TAF IN VIROLOGICALLY SUPPRESSED WOMEN

Sally Hodder¹, Kathleen Squires², Cissy Kityo³, Debbie Hagins⁴, Anchalee Avihingsanon⁵, Yulia Plotnikova⁶, Shuping Jiang⁷, Rima Kulkarni⁷, Andrew Cheng⁷, Huyen Cao⁷

¹West Virginia Clinical and Translational Sci Inst, Morgantown, WV, USA, ²Thomas Jefferson Univ, Philadelphia, PA, USA, ³Joint Clinical Rsr Cntr, Kampala, Uganda, ⁴Chatham CARE Cntr, Savannah, GA, USA, ⁵HIV-NAT, Thai Red Cross AIDS Rsr Cntr, Bangkok, Thailand, ⁶Irkutsk Regional Cntr for Prevention and Control of AIDS and Infectious Diseases, Irkutsk, Russian Federation, ⁷Gilead Scis, Inc, Foster City, CA, USA

444 THE FDA SNAPSHOT ALGORITHM MAY OVERESTIMATE THE EFFICACY OF INITIAL ART

Stephen J. Kerr¹, Andrew Carr²

¹The Thai Red Cross AIDS Rsr Cntr, Bangkok, Thailand, ²St. Vincent's Hosp, Sydney, Australia

445 CELLULAR HIV-1 DNA LEVELS AFTER 96 WEEKS OF SWITCH TO ATV/R +3TC IN THE ATLAS-M TRIAL

Francesca Lombardi¹, Simone Belmonti¹, Eugenia Quiros-Roldan², Alessandra Latini³, Chiara Picarelli¹, Arianna Emiliozzi¹, Massimiliano Fabbiani⁴, Roberto Cauda¹, Andrea De Luca⁵, for the AtLaS-M study group
¹Catholic Univ of Sacred Heart, Rome, Italy, ²Spedali Civili di Brescia, Brescia, Italy, ³Istituto S. Galliciano Inst (IRCCS), Rome, Italy, ⁴Univ of Milan, Milan, Italy, ⁵Siena Univ Hosp, Siena, Italy

446 DYNAMICS OF VIRAL LOAD AND CYTOKINES WHEN ART IS INITIATED SOON AFTER HIV ACQUISITION

Trupti I. Gilada¹, Javier R. Lama², Rachel A. Bender Ignacio³, Ricardo Alfaro², Carmela Ganoza², Angela K. Ulrich⁴, Socorro M. Harb³, Rogelio M. Valdez⁴, Robert Coombs³, Ann Duerr⁴
¹Unison Medicare and Rsr Cntr, Mumbai, India, ²Asociacion Civil Impacta Salud y Educacion, Lima, Peru, ³Univ of Washington, Seattle, WA, USA, ⁴Fred Hutchinson Cancer Rsr Cntr, Seattle, WA, USA

447 VALACYCLOVIR DOES NOT ATTENUATE CD4 COUNT DECLINE IN CART-UNTREATED HIV INFECTION

Darrell H. Tan¹, Janet M. Raboud², Leah Szadkowski³, Beatriz Grinsztejn⁴, Jose Valdez Madruga⁵, Pedro Cahn⁶, Simon Barton⁷, Amanda Clarke⁸, Wendy Zubyk⁹, Sharon Walmsley¹⁰
¹St. Michael's Hosp, Toronto, Ontario, Canada, ²Univ of Toronto, Toronto, Ontario, Canada, ³Toronto General Rsr Inst, Toronto, Ontario, Canada, ⁴Inst Nacional de Infectologia (INI-Fiocruz), Rio de Janeiro, Brazil, ⁵Centro de Referência e Treinamento em DST/AIDS-SP, Sao Paulo, Brazil, ⁶Fundación Huesped, Buenos Aires, Argentina, ⁷St. Stephen's AIDS Trust, London, UK, ⁸Brighton & Sussex Univ Hosps NHS Trust, Brighton, UK, ⁹Canadian HIV Trials Network, Vancouver, British Columbia, Canada, ¹⁰Univ of Toronto, Toronto, Ontario, Canada

448 RALTEGRAVIR/EMTRICITABINE/TENOFOVIR IN HIV-2 INFECTION (ANRS 159 VIH-2 PILOT TRIAL)

Sophie Matheron¹, Diane Descamps¹, Sébastien Gallien², Amel Besseghir³, Roland Tubiana⁴, Florence Damond¹, Fideline Collin³, Françoise Brun-Vezinet¹, Genevieve Chene³, for the ANRS 159 VIH2 trial Study Group
¹Hopital Bichat-Claude Bernard, AP-HP, Paris, France, ²Hopital Saint Louis, AP-HP, Paris, France, ³INSERM, Bordeaux, France, ⁴Hopital Pitié-Salpêtrière, AP-HP, Paris, France

449LB LONG-ACTING IBALIZUMAB IN PATIENTS WITH MULTI-DRUG RESISTANT HIV-1: A 24-WEEK STUDY

Stanley Lewis¹, Jeffery Fessel², **Brinda Emu**³, Shannon Schrader⁴, Princy Kumar⁵, Gary J. Richmond⁶, Steven Weinheimer¹, Christian Marsolais⁷
¹TaiMed Biologics USA, Irvine, CA, USA, ²Kaiser Permanent Med Cntr, San Francisco, CA, USA, ³Yale Univ, New Haven, CT, USA, ⁴Schrader Clinic, Houston, TX, USA, ⁵Georgetown Univ, Washington, DC, ⁶Gary J Richmond MD PA, Ft Lauderdale, FL, USA, ⁷Theratechnologies, Inc, Montreal, Canada

450LB A PHASE 2 OPEN-LABEL TRIAL OF ANTIBODY UB-421 MONOTHERAPY AS A SUBSTITUTE FOR HAART

Chang-Yi Wang¹, **Wingwai Wong**², Hung-Chin Tsai³, Yen-Hsu Chen⁴, Mei-June Liao⁵, Shugene Lynn⁶, for the United BioPharma UB-421 Clinical and Research Team
¹United Biomed, Inc, Hauppauge, NY, USA, ²Taipei Veterans General Hosp, Taipei, Taiwan, ³Kaohsiung Veterans General Hosp, Kaohsiung, Taiwan, ⁴Kaohsiung Med Univ and Hosp, Kaohsiung, Taiwan, ⁵United Biopharma, Inc, Hsinchu, Taiwan, ⁶UBI Asia, Hsinchu, Taiwan

451LB DOLUTEGRAVIR AS MAINTENANCE MONOTHERAPY FOR HIV-1: A RANDOMIZED CLINICAL TRIAL

Ingeborg Wijting¹, Casper Rokx¹, Charles Boucher¹, Dorine de Vries - Sluijs¹, Karin Schurink¹, Elroy Andrinopoulou¹, Eric van Gorp¹, Wouter Bierman², Bart Rijnders¹, for the DOMONO study-group

¹Erasmus Univ Med Cntr Rotterdam, Rotterdam, Netherlands, ²Univ Med Cntr Groningen, Groningen, Netherlands

452LB ELSULFAVIRINE AS COMPARED TO EFAVIRENZ IN COMBINATION WITH TDF/FTC: 48-WEEK STUDY

Robert Murphy¹, Alexey V. Kravchenko², Elena Orlova-Morozova³, Firaya Nagimova⁴, Oleg Kozirev⁵, Tatyana Shimonava⁶, Marina Deulina², Natalia Vostokova⁷, Olga Zozulya⁷, Vadim Bichko⁸

¹Northwestern Univ, Chicago, IL, USA, ²Russia AIDS Federal Cntr, Moscow, Russian Federation, ³Moscow Region AIDS Cntr, Moscow, Russian Federation, ⁴Republic Tartarstan AIDS Cntr, Kazan, Russian Federation, ⁵Volgograd Region AIDS Cntr, Volgograd, Russian Federation, ⁶Moscow City AIDS Cntr, Moscow, Russian Federation, ⁷IPHARMA Moscow, Moscow, Russian Federation, ⁸Viriom, Inc, San Diego, CA, USA

Poster P-11 ART: SAFETY AND PRESCRIBING OVER THE LONG TERM**Poster Hall - 4 EF****2:30 PM - 4:00 PM****453 SIGNIFICANT EFFICACY & LONG-TERM SAFETY DIFFERENCE WITH TAF-BASED STR IN NAÏVE ADULTS**

Jose R. Arribas¹, Melanie Thompson², Paul E. Sax³, Bernhard Haas⁴, Cheryl McDonald⁵, David Wohl⁶, Edwin DeJesus⁷, Amanda Clarke⁸, Moupali Das⁹, Scott McCallister⁹

¹Hosp Univ La Paz, Madrid, Spain, ²AIDS Rsr Consortium of Atlanta, Atlanta, GA, USA, ³Brigham and Women's Hosp, Boston, MA, USA, ⁴Hosp Graz West, Graz, Austria, ⁵Tarrant County Infectious Disease Associates, Fort Worth, TX, USA, ⁶Univ of North Carolina at Chapel Hill, Chapel Hill, NC, USA, ⁷Orlando Immunol Cntr, Orlando, FL, USA, ⁸Brighton & Sussex Univ Hosps NHS Trust, Brighton, UK, ⁹Gilead Scis, Inc, Foster City, CA, USA

454 PATTERNS OF EFAVIRENZ USE AS FIRST-LINE THERAPY IN THE UNITED STATES: 1999–2015

Angela Bengtson¹, Brian W. Pence¹, Ellen F. Eaton², Jessie K. Edwards¹, Joseph J. Eron¹, W. C. Mathews³, Katie Mollan¹, Richard D. Moore⁴, Connall O'Cleirigh⁵, Michael J. Mugavero²

¹Univ of North Carolina at Chapel Hill, Chapel Hill, NC, USA, ²Univ of Alabama at Birmingham, Birmingham, AL, USA, ³Univ of California San Diego, San Diego, CA, USA, ⁴Johns Hopkins, Baltimore, MD, USA, ⁵Massachusetts General Hosp, Boston, MA, USA

455 ART INITIATION, REGARDLESS OF COMPOSITION, IMPROVES PATIENT-REPORTED DEPRESSION

Ellen Eaton, Ashutosh Tamhane, Michael J. Mugavero
Univ of Alabama at Birmingham, Birmingham, AL, USA

456 THE CLINICAL AND ECONOMIC IMPACT OF DOLUTEGRAVIR-BASED FIRST-LINE ART IN INDIA

Amy Zheng¹, Nagalingeswaran Kumarasamy², Mingshu Huang¹, A. David Paltiel³, Kenneth H. Mayer⁴, Bharat Bhushan Rewari⁵, Rochelle P. Walensky¹, Kenneth Freedberg¹

¹Massachusetts General Hosp, Boston, MA, USA, ²YR Gaitonde Cntr for AIDS Rsr and Educ, Chennai, India, ³Yale Univ, New Haven, CT, USA, ⁴Fenway Hlth, Boston, MA, USA, ⁵WHO, New Delhi, India

Poster P-12 MAINTENANCE: SECOND- AND THIRD-LINE THERAPY

Poster Hall - 4 EF2:30 PM - 4:00 PM

457 QUALITY OF LIFE IMPROVEMENT DURING SECOND-LINE THERAPY IN RESOURCE-LIMITED SETTINGS

Thiago S. Torres¹, Linda J. Harrison¹, Alberto M. La Rosa², Lu Zheng¹, Sandra W. Cardoso³, Selvamuthu Poongulali⁴, McNeil Ngongondo⁵, Ann Collier⁶, Michael D. Hughes¹, for the AIDS Clinical Trials Group (ACTG) A5273 Study Group

¹Harvard Univ, Boston, MA, USA, ²Asociación Civil Impacta Salud y Educación, Lima, Peru, ³Inst Nacional de Infectologia (INI/Fiocruz), Rio de Janeiro, Brazil, ⁴YRG CARE Med Centre, Chennai, India, ⁵UNC-Proj Malawi, Lilongwe, Malawi, ⁶Univ of Washington, Seattle, WA, USA

458 PROMISING RESULTS OF DOLUTEGRAVIR + LAMIVUDINE MAINTENANCE IN ANRS 167 LAMIDOL TRIAL

Veronique Joly¹, Charles Burdet², Roland Landman³, François Raffi⁴, Christine Katlama⁵, André Cabié⁶, Aida Benalycherif³, Gilles Peytavin¹, Diane Descamps¹, Yazdan Yazdanpanah²

¹Hôpital Bichat, Paris, France, ²INSERM, Paris, France, ³IMEA, Paris, France, ⁴CHU Hotel-Dieu Nantes, Nantes, France, ⁵Pierre and Marie Curie Univ, Paris, France, ⁶CHU Fort de France, Fort de France, Martinique, France

459 ADVERSE DRUG REACTIONS AMONG PATIENTS RECEIVING SECOND-LINE ART IN SOUTH AFRICA

Dorina Onoya¹, Kamban Hirasen¹, Lawrence Long¹, Matthew Fox²

¹Univ of the Witwatersrand, Johannesburg, South Africa, ²Boston Univ, Boston, MA, USA

460 LONG-TERM EFFICACY OF DOLUTEGRAVIR 50 MG BID IN INI-RESISTANT FAILING HIV-1 SUBJECTS

Antonella Castagna¹, Micol Ferrara², Laura Galli³, Laura Comi⁴, Gaetana Sterrantino⁵, Giovanni Cenderello⁶, Mauro Zaccarelli⁷, Emanuele Focà⁸, Andrea Roncadori⁹, Adriano Lazzarin¹⁰

¹Univ Vita-Salute San Raffaele, Milan, Italy, ²Univ di Torino, Torino, Italy, ³Ospedale San Raffaele, Milano, Italy, ⁴Azienda Ospedaliera Papa Giovanni XXIII, Bergamo, Italy, ⁵Azienda Ospedaliero Univ Careggi, Firenze, Italy, ⁶Galliera Hosp, Genoa, Italy, ⁷Natl Inst for Infectious Diseases, Rome, Italy, ⁸ASST Spedali Civili di Brescia, Brescia, Italy, ⁹CINECA, Casalecchio di Reno, Italy, ¹⁰San Raffaele Vita-Salute Univ, Milan, Italy

Poster P-J3 INTEGRASE STRAND TRANSFER INHIBITOR RESISTANCE

Poster Hall - 4 EF 2:30 PM - 4:00 PM

495 EVOLUTION OF ARCHIVED HIV-1 QUASISPECIES IN INDIVIDUALS TREATED WITH DOLUTEGRAVIR

Pierre Gantner¹, Guinevere Q. Lee², David Rey¹, Thibault Mesplede³, Marialuisa Partisani¹, Geneviève Beck-Wirth⁴, Jean-Pierre Faller⁵, Martin Martinot⁶, Mark Wainberg³, Samira Fafi-Kremer¹

¹Hôpitaux Univ de Strasbourg, Strasbourg, France, ²BC Cntr for Excellence in HIV/AIDS, Vancouver, British Columbia, Canada, ³McGill Univ, Montreal, Quebec, Canada, ⁴Groupe Hosp Régional—Mulhouse Sud Alsace, Mulhouse, France, ⁵Hôpital Nord Franche Comté, Belfort, France, ⁶Hôpital Civil de Colmar, Colmar, France

- 496 IMPACT OF CLINICALLY OBSERVED INTEGRASE MUTATIONS ON DOLUTEGRAVIR RESISTANCE**
Atsuko Hachiya, Masaaki Nakashima, Yoko Ido, Urara Shigemi, Masakazu Matsuda, Reiko Okazaki, Junji Imamura, Yoshiyuki Yokomaku, Yasumasa Iwatani
Natl Hosp Org Nagoya Med Cntr, Nagoya, Japan
- 497 BICTEGRAVIR DISSOCIATION HALF-LIFE FROM HIV-1 G140S+Q148H INTEGRASE/DNA COMPLEXES**
Kirsten L. White, Anita Niedziela-Majka, Nikolai Novikov, Michael D. Miller, Haolun Jin, Scott E. Lazerwith, Manuel Tsiang
Gilead Scis, Inc, Foster City, CA, USA
- 498 PHENOTYPIC SUSCEPTIBILITY OF SIV AND HIV-1 VARIANTS TO BICTEGRAVIR, A NOVEL INSTI**
Said Hassounah, Thibault Mesplede, Bonnie Spira, Nathan Osman, Mark A. Wainberg
McGill Univ, Montréal, Quebec, Canada
- 499 A HIGH-LEVEL RESISTANCE TO INTEGRASE INHIBITORS SELECTED OUTSIDE INTEGRASE HIV-1 GENE**
 Isabelle Malet¹, Frédéric Subra², Charlotte Charpentier³, Gilles Collin⁴, Diane Descamps⁴, Vincent Calvez¹, Anne-Geneviève Marcelin¹, **Olivier Delelis**²
¹Pitie-Salpetriere Hosp, Paris, France, ²Ecole Normale Supérieure de Cachan, Cachan, France, ³INSERM, Paris, France, ⁴Bichat Hosp, Paris, France
- 500LB EMERGENCE OF INTEGRASE RESISTANCE MUTATIONS DURING INITIAL THERAPY WITH TDF/FTC/DTG**
Jennifer A. Fulcher¹, Yushen Du¹, Ren Sun¹, Raphael J. Landovitz²
¹Univ of California Los Angeles, Los Angeles, CA, USA, ²UCLA Cntr for Clinical AIDS Rsr & Educ, Los Angeles, CA, USA

Poster P-J4 REVERSE TRANSCRIPTASE INHIBITOR RESISTANCE

Poster Hall - 4 EF

2:30 PM - 4:00 PM

- 501 CROSS-RESISTANCE PROFILES OF THE NNRTIS IN DEVELOPMENT TO PREVENT HIV-1 INFECTION**
Nicholas S. Giacobbi, Nicolas Sluis-Cremer
Univ of Pittsburgh, Pittsburgh, PA, USA
- 502 DRUG RESISTANCE AFTER CESSATION OF EFAVIRENZ-BASED ANTIRETROVIRAL TREATMENT**
Gbolahan Ajibola¹, Christopher Rowley², Kathleen M. Powis³, Sikhulile Moyo¹, Jean Leidner⁴, Kara Bennett⁵, Florence Chilisa¹, Joseph Makhema¹, Roger L. Shapiro², Shahin Lockman²
¹Botswana Harvard AIDS Inst Partnership, Gaborone, Botswana, ²Harvard Univ, Boston, MA, USA, ³Massachusetts General Hosp, Boston, MA, USA, ⁴Goodtables Consulting, Oklahoma, OK, USA, ⁵Bennett Statistical Consulting Inc, New York, NY, USA
- 503 4'-MODIFIED NRTIS' POTENT ANTI-HIV ACTIVITY STEMS FROM STRONG RT ACTIVE-SITE BINDING**
Kenji Maeda¹, Yuki Takamatsu², Debananda Das², Satoru Kohgo³, Shinichiro Hattori¹, Hironori Hayashi¹, Kouki Matsuda¹, Stefan G. Sarafianos⁴, Hiroaki Mitsuya²
¹Natl Cntr for Global Hlth and Med Rsr Inst, Shinjuku, Tokyo, Japan ²NIH, Bethesda, MD, USA, ³Sojo Univ, Kumamoto, Japan, ⁴Univ of Missouri, Columbia, MO, USA

504LB RISING TRANSMITTED RESISTANCE FORCES ABANDONMENT OF WHO RECOMMENDED THERAPY IN ARUBA

Laura Marije Hofstra¹, Elena Sánchez Rivas², Monique Nijhuis¹, Eduan Wilkinson³, Karina Kelly², Tania Mudrikova¹, Rob Schuurman¹, Tulio de Oliveira³, Jaclyn De Kort², Annemarie Wensing¹

¹Univ Med Cntr Utrecht, Utrecht, Netherlands, ²Dr. Horacio E. Oduber Hosp, Oranjestad, Aruba, ³Univ of KwaZulu-Natal, Durban, South Africa

Poster P-J5 RESISTANCE TO PROTEASE AND MATURATION INHIBITORS

Poster Hall - 4 EF

2:30 PM - 4:00 PM

505 LOW HIV-1 RESISTANCE IN SUBJECTS USING DARUNAVIR ONCE-DAILY REGIMENS ACROSS STUDIES

Erkki Lathouwers¹, Eric Y. Wong², Donghan Luo², Sareh Seyedkazemi², Sandra De Meyer¹, Kimberley Brown²

¹Janssen Infectious Diseases BVBA, Beerse, Belgium, ²Janssen Scientific Affairs, LLC, Titusville, NJ, USA

506 EVOLUTION OF GAG AND GP41 IN PATIENTS RECEIVING FIRST-LINE PI AND NNRTI REGIMENS

Justen Manasa¹, Vici Varghese¹, Soo-Yon Rhee¹, Jeffery Fessel², Karen S. Jang¹, Elizabeth White¹, David Katzenstein¹, Robert Shafer¹

¹Stanford Univ, Stanford, CA, USA, ²Kaiser Permanent Med Cntr, San Francisco, CA, USA

507 RESISTANCE TO POTENT AND BROADLY ACTIVE HIV-1 MATURATION INHIBITORS

Justin A. Kaplan¹, Emiko Urano¹, Sherimay Ablan¹, Nishani Kuruppu¹, David Martin², T.J. Nitz², Ritu Gaur³, Carl Wild², Eric Freed¹

¹NCI, Frederick, MD, USA, ²DFH Pharma, Inc, Gaithersburg, MD, USA, ³South Asian Univ, Akbar Bhawan, Chanakyapuri, New Delhi, India

Poster P-K1 HIV DETECTION AND REGENCY METHODS

Poster Hall - 4 EF

2:30 PM - 4:00 PM

508 CLINICAL VALIDATION OF A NOVEL DIAGNOSTIC HIV-2 TOTAL NUCLEIC ACID QUALITATIVE ASSAY

Ming Chang¹, Audrey J. Wong¹, Dana Raugi¹, Robert Smith¹, Jose Ortega¹, Selly Ba², Moussa Seydi², Geoffrey Gottlieb¹, Robert Coombs¹, for the University of Washington-Dakar HIV-2 Study Group

¹Univ of Washington, Seattle, WA, USA, ²CHU de Fann, Dakar, Senegal

509 EVALUATION OF FDA-APPROVED RAPID HIV TESTS FOR LABORATORY DIAGNOSIS OF HIV INFECTION

Kevin P. Delaney, Steven Ethridge, Hongwei Jia, Silvina Masciotra, Laura Wesolowski

CDC, Atlanta, GA, USA

510 PERFORMANCE OF DRIED BLOOD SPOTS AS A SAMPLE TYPE FOR HIV AG/AB COMBO ASSAY

Vera Holzmayer, Kelly Collier, Jill Fuhrman, Mary Rodgers, Gavin Cloherty
Abbott Labs, Abbott Park, IL, USA

511 REGENCY STAGING OF HIV INFECTIONS THROUGH ROUTINE DIAGNOSTIC TESTING

Eduard Grebe¹, Alex Welte¹, Jake Hall², Michael P. Busch³, Shelley Facente⁴, Sheila Keating², Kara Marson⁴, Christopher D. Pilcher⁴, **Gary Murphy²**, for the CEPHIA

¹Stellenbosch Univ, Stellenbosch, South Africa, ²Pub Hlth England, London, UK, ³Blood Systems Rsr Inst, San Francisco, CA, USA, ⁴Univ of California San Francisco, San Francisco, USA

512 DEVELOPMENT OF A HIGH-THROUGHPUT MULTIPLEX ASSAY FOR MEASURING HIV INCIDENCE

Martin Stengelin¹, Daisy Roy¹, Sudeep Kumar¹, Kara Marson², Steven G. Deeks², Gary Murphy³, Michael P. Busch⁴, **Christopher D. Pilcher²**

¹Meso Scale Diagnostics, LLC, Rockville, MD, USA, ²Univ of California San Francisco, San Francisco, CA, USA, ³Pub Hlth England, London, UK, ⁴Blood Systems Rsr Inst, San Francisco, CA, USA

513 IDENTIFYING RECENT HIV INFECTIONS: AN INDIVIDUALIZED ASSESSMENT OF RISK

Jaythoon Hassan¹, Joanne Moran¹, Kate O'Donnell², Gary Murphy³, Derval Igoe², Cillian De Gascun¹, for the Monitoring Recently Acquired HIV Infection Group

¹Univ Coll Dublin, Dublin, Ireland, ²Hlth Protection Surveillance Cntr, Dublin, Ireland, ³Pub Hlth England, London, UK

514 THE HIV GENOMIC INCIDENCE ASSAY MEETS FRR AND MDRI PERFORMANCE STANDARDS

Sung Yong Park¹, Tanzy Love², Kathryn Anastos³, Jack DeHovitz⁴, Chenglong Liu⁵, Kord Kober⁶, Mardge Cohen⁷, Wendy Mack¹, Elizabeth T. Golub⁸, **Ha Youn Lee¹**

¹Univ Southern California, Los Angeles, CA, USA, ²Univ of Rochester, Rochester, NY, USA, ³Albert Einstein Coll of Med, Bronx, NY, USA, ⁴SUNY Downstate Med Cntr, Brooklyn, NY, USA, ⁵Georgetown Univ, Washington, DC, USA, ⁶Univ of California San Francisco, San Francisco, CA, USA, ⁷Stroger Hosp, Chicago, IL, USA, ⁸Johns Hopkins Univ, Baltimore, MD, USA

Poster P-L1 HCV TRANSMISSION: THE CASCADE IS NOT RUNNING DRY
Poster Hall - 4 EF
2:30 PM - 4:00 PM
515 DURATION OF ACUTE HEPATITIS C INFECTION AND IMPLICATIONS FOR INCIDENCE ESTIMATION

Eshan Patel¹, Anna Eisenberg², Jeffrey Quinn¹, Thomas C. Quinn³, Aaron Tobian¹, Oliver Laeyendecker²

¹Johns Hopkins Univ, Baltimore, MD, USA, ²NIAID, Baltimore, MD, USA, ³NIAID, Bethesda, MD, USA

516 HEPATITIS C VIRUS GENOTYPE AND IG-G AVIDITY RESPONSE DURING RECENT INFECTION

Veronica Bruce¹, Eshan Patel², Andrea Cox², Shruti H. Mehta², Denali Boon², Jacob Konikoff², David Thomas², Thomas C. Quinn³, Kimberly Page¹, Oliver Laeyendecker³

¹Univ of New Mexico, Albuquerque, NM, USA, ²The Johns Hopkins Univ, Baltimore, MD, USA, ³NIAID, Bethesda, MD, USA

517 IDENTIFICATION OF RISK FACTORS FOR HEPATITIS-C TESTING IN NON-BIRTH COHORT PATIENTS

Amanda E. Smart¹, Alexander Geboy², Peter Basch², Whitney Nichols², Alexander Zeymo², Idene Perez², Maria Hafeez², Ilan Fleisher², Stephen Fernandez², Dawn Fishbein²

¹Georgetown Univ, Washington, DC, USA ²MedStar Hlth Rsr Inst, Hyattsville, MD, USA

- 518 ESTABLISHING EPIDEMIOLOGICAL LINKAGE WITHIN HCV NETWORKS USING GENETIC DISTANCE**
Rebecca Rose¹, Susanna Lamers², Guido Massaccesi³, William Osburn³, Stuart C. Ray³, Andrea Cox³, Oliver Laeyendecker⁴
¹BioInfoExperts, Norfolk, VA, USA, ²BioInfoExperts, Thibodaux, LA, USA, ³Johns Hopkins Univ, Baltimore, MD, USA, ⁴NIAID, Baltimore, MD, USA
- 519 HIGH PREVALENCE OF HEPATITIS-C VIRUS AMONG HIV NEGATIVE MSM IN AMSTERDAM PREP PROJECT**
Elske Hoornenborg¹, Maria Prins¹, Roel C.A. Achterbergh¹, Maarten F. Schim van der Loeff¹, Udi Davidovich¹, Arjan Hogewoning¹, Henry J.C. de Vries¹, Janke Schinkel², Thijs J.W. van der Laar³, for the Amsterdam PrEP Project team in the HIV Transmission Elimination Amsterdam Consortium (H-team)
¹Pub Hlth Service Amsterdam, Amsterdam, Netherlands, ²Academic Med Cntr, Amsterdam Zuidoost, Netherlands, ³Stichting Sanquin Bloedvoorziening, Amsterdam, Netherlands
- 520 HIGH CLUSTERING OF ACUTE HCV INFECTIONS AMONG HIV-POSITIVE MEN WHO HAVE SEX WITH MEN**
Eve Todesco¹, Nesrine Day², Corinne Amiel³, Veronique Schneider⁴, Georges Kreplak², Laurent Roudière¹, Stéphane Hué⁵, Christine Katlama¹, Anne-Geneviève Marcelin¹, Marc-Antoine Valentin¹
¹Pitié-Salpêtrière Hosp, Paris, France, ²Cerballiance Lab, Paris, France, ³INSERM, Paris, France, ⁴Tenon Hosp, Paris, France, ⁵London Sch of Hygiene & Tropical Med, London, UK
- 521 SYSTEMATIC HCV-RNA SCREEN IN HIV+ MSM REVEALS HIGH NUMBERS OF POTENTIAL TRANSMITTERS**
Dominique L. Braun¹, Roger Kouyos¹, Benjamin H. Hampel¹, Christina Grube¹, Huldrych F. Günthard¹, Jürg Böni², Jan S. Fehr¹, for the Swiss HIV Cohort Study
¹Univ Hosp Zurich, Zurich, Switzerland, ²Univ of Zurich, Zurich, Switzerland
- 522 HCV IN DEMOCRATIC REPUBLIC OF THE CONGO: THE 2013–2014 DEMOGRAPHIC AND HEALTH SURVEY**
Gavin Cloherty¹, **Vera Holzmayer**¹, Jacques Pepin², Eric H. Frost², Michael Fried³, Anto Tshetu⁴, Franck Fwamba⁵, Jérémie Muwanga⁵, Steven R. Meshnick³, Jonathan Parr³
¹Abbott Labs, Abbott Park, IL, USA, ²Univ of Sherbrooke, Sherbrooke, Quebec, Canada, ³Univ of North Carolina at Chapel Hill, Chapel Hill, NC, USA, ⁴Univ of Kinshasa, Kinshasa, Democratic Republic of the Congo, ⁵Natl AIDS Control Prog (PNLS), Kinshasa, Democratic Republic of the Congo
- 523 LOW HCV PREVALENCE AMONG HIV+ INDIVIDUALS IN SUB-SAHARAN AFRICA**
Anne Loarec¹, Lucas Molfino², Kizito Walter³, Winnie Muyindike⁴, Valentina Carneio¹, Isabelle Andrieux-Meyer⁵, Suna Balkan⁶, Yvonne Nzomukunda³, David Maman⁷, Juliet Mwanga-Amumpaire⁸
¹MSF, Epicentre, Paris, France, ²MSF, Maputo, Mozambique, ³MSF, Nairobi, Kenya, ⁴Mbarara Univ of Sci and Tech, Mbarara, Uganda, ⁵MSF, Geneva, Switzerland, ⁶MSF, Paris, France, ⁷Epicentre, Cape Town, South Africa, ⁸MSF, Epicentre, Mbarara, Uganda
- 524 EFFECT OF OST AND PSYCHOTHERAPY ON HIV RISK AMONG HCV INFECTED INDIVIDUALS**
Zahid A. Butt¹, Nabin Shrestha¹, Naveed Z. Janjua², for the The BC-HTC Team
¹Univ of British Columbia, Vancouver, British Columbia, Canada, ²BC Cntr for Disease Control, Vancouver, British Columbia, Canada

Poster P-L2 PROGRESSION OF LIVER DISEASE IN THE HCV-INFECTED POPULATION**Poster Hall - 4 EF****2:30 PM - 4:00 PM****525 PROGRESSION OF LIVER FIBROSIS IN HIV-MONOINFECTED ADULTS WITH ELEVATED TRANSAMINASES**

Rebecca Krakora¹, Mary McLaughlin², David E. Kleiner³, Nina Kvaratskhelia¹, Raissa Canales Santos⁴, Colleen Hadigan², Joseph A. Kovacs¹, Theo Heller⁴, **Caryn G. Morse¹**

¹NIH, Bethesda, MD, USA, ²NIAID, Bethesda, MD, USA, ³NCI, Bethesda, MD, USA,

⁴NIDDK, Bethesda, MD, USA

526 GUT EPITHELIAL DAMAGE, IMMUNE ACTIVATION & LIVER FIBROSIS IN HIV AND HCV INFECTION

Michael J. Reid¹, Yifei Ma¹, Rebecca Scherzer¹, Jennifer Price¹, Audrey French², Michael Plankey³, Carl Grunfeld¹, Phyllis Tien¹

¹Univ of California San Francisco, San Francisco, CA, USA ²Rush Univ, Chicago, IL, USA, ³Georgetown Univ, Washington, DC, USA

527 VERTICALLY HIV/HCV- VS HCV-INFECTED CHILDREN: HCV TREATMENT & PROGRESSION TO FIBROSIS

Carolina Fernández McPhee¹, Talía Sainz², Loreto Hierro³, Antoni Noguera-Julian⁴, María José Mellado², Marta Montero⁵, María Isabel González-Tomé⁶, Paloma Jara³, Carmen Díaz³, María Luisa Navarro¹

¹Univ Hosp Gregorio Marañón, Madrid, Spain, ²Hosp La Paz and IdiPAZ, Madrid, Spain, ³Univ Hosp La Paz, Madrid, Spain, ⁴Univ de Barcelona, Barcelona, Spain, ⁵Hosp Univ y Politécnico La Fe, Valencia, Spain, ⁶Univ Hosp 12 de Octubre, Madrid, Spain

528 THE ASSOCIATION BETWEEN HCV AND COMORBID CONDITIONS IN 2 LARGE PATIENT COHORTS

Sarah E. Rowan¹, Joshua Durfee¹, David C. Tabano², Suzanne Dirksen¹, Edward Havranek¹, Aimee Truesdale¹, Arthur Davidson¹

¹Denver Hlth and Hosp Authority, Denver, CO, USA, ²Kaiser Permanente Colorado, Denver, CO, USA

529 CAUSE & PREDICTORS OF MORTALITY IN AN HIV/HEPATITIS-C-COINFECTED COHORT IN SCOTLAND

Rebecca Metcalfe¹, Gordon Proctor², Joe Schofield³, Emma Thomson²

¹Brownlee Cntr for Infectious Diseases, NHS Greater Glasgow and Clyde, Glasgow, UK, ²Univ of Glasgow, Glasgow, UK, ³Pub Hlth Protection Unit, NHS Greater Glasgow and Clyde, Glasgow, UK

530 ADAR1 SNPS INVOLVED IN SEVERITY OF LIVER DISEASE IN HIV/HCV-COINFECTED PATIENTS

Luz M. Medrano¹, Amanda Fernández-Rodríguez¹, Juan Berenguer², María Á. Jimenez-Sousa¹, Teresa Aldámiz-Echevarría², Francisco Tejerina², Cristina Diez², Lorena Vigón¹, Salvador Resino¹, for the Institute of Health Carlos III (ISCIII)

¹Inst of Hlth Carlos III, Madrid, Spain, ²Hosp Gregorio Marañón, Madrid, Spain

531 CB2-RR VARIANT, LINKED TO LIVER DAMAGE IN HIV/HCV CASES, MAY FAVOR HIV ACQUISITION

Caterina Sagnelli¹, Marco Merli², Caterina Uberti-Foppa², Giulia Bellini¹, Hamid Hasson², Nicola Coppola¹, Adriano Lazzarin², Evangelista Sagnelli¹, Francesca Rossi¹

¹Second Univ of Naples, Naples, Italy, ²San Raffaele Scientific Inst, Milan, Italy

532 PNPLA3_RS738409 VARIANT INFLUENCES PROGRESSION TO CIRRHOSIS IN HIV/HCV COINFECTION

Luis M. Real¹, Juan Macías¹, María Mancebo¹, Mario Frías², Giovanni Dolci³, Francisco Téllez⁴, Dolores Merino⁵, Giovanni Guaraldi³, Antonio Rivero-Juárez², Juan A. Pineda¹

¹Hosp Univ de Valme, Sevilla, Spain, ²Hosp Univ Reina Sofía, Córdoba, Spain, ³Univ of Modena and Reggio Emilia, Modena, Italy, ⁴Hosp de La Línea, La Línea de la Concepción, Spain, ⁵Complejo Hospario Univ de Huelva, Huelva, Spain

533 FIB-4 CUTOFFS FOR PREDICTION OF LIVER-RELATED EVENTS IN HIV/HCV COINFECTION

Leire Pérez Latorre¹, Marisa Montes², Miguel A. Von Wichmann³, Manuel Crespo⁴, Marta Montero⁵, Carmen Quereda⁶, María J. Téllez⁷, José M. Bellón¹, Juan González-García², **Juan Berenguer**¹

¹Hosp General Univ Gregorio Marañón, Madrid, Spain, ²Hosp Univ La Paz, Madrid, Spain, ³Hosp Univ Donostia, San Sebastián, Spain, ⁴Complejo Hospario Univ de Vigo, Vigo, Pontevedra, Spain, ⁵Hosp Univ y Politécnico La Fe, Valencia, Spain, ⁶Hosp Ramon y Cajal, Madrid, Spain, ⁷Hosp Clínico de San Carlos, Madrid, Spain

Poster P-L3 HCV: PROGRESSION TO CIRRHOSIS AND HEPATOCELLULAR CARCINOMA

Poster Hall - 4 EF

2:30 PM - 4:00 PM

534 EFFECTIVENESS OF DAAs IN HIV/HCV-COINFECTED PATIENTS WITH DECOMPENSATED CIRRHOSIS

Juan Berenguer¹, Lourdes Domínguez-Domínguez², Ángela Gil-Martín³, Carmen Quereda⁴, Teresa Aldámiz-Echevarría¹, Ignacio Santos⁵, Pablo Ryan⁶, Gabriel Gaspar⁷, Inma Jarrin⁸, Juan Gonzalez-Garcia⁹

¹Gregorio Marañon Hosp, Madrid, Spain, ²Hosp Univ 12 de Octubre, Madrid, Spain, ³Servicio Madrileño de Salud, Madrid, Spain, ⁴Hosp Ramon y Cajal, Madrid, Spain, ⁵Hosp Univ de La Princesa, Madrid, Spain, ⁶Infanta Leonor Hosp, Madrid, Spain, ⁷Hosp Univ de Getafe, Getafe, 28905, ⁸Inst of Hlth Carlos III, Madrid, Spain, ⁹Hosp Univ La Paz, Madrid, Spain

535 EFFICACY AND SAFETY OF DAAs IN CIRRHOTIC HCV/HIV COINFECTED PATIENTS

Jordi Navarro¹, Montse Laguno², Helem Haydee Vilchez³, Josep M. Guardiola⁴, Jose A. Carrion⁵, Luis Force⁶, Mireia Cairó⁷, Carmen Cifuentes⁸, Manuel Crespo⁹, for the Catalano-Balear Study Group

¹Hosp Univ Vall d'Hebron, Barcelona, Spain, ²Hosp Clínic i Provincial de Barcelona, Barcelona, Spain, ³Hosp Univ de Son Espases, Palma de Mallorca, Spain, ⁴Hosp de la Santa Creu i Sant Pau, Barcelona, Spain, ⁵Hosp del Mar, Barcelona, Spain, ⁶Hosp de Mataró, Mataró, Spain, ⁷Hosp Univ Mútua de Terrassa, Terrassa, Spain, ⁸Hosp de Son Llàtzer, Palma de Mallorca, Spain, ⁹Hosp Univ de la Vall d'Hebron, Barcelona, Spain

536 INFLUENCE OF HIV ON CHANGES IN LIVER FUNCTION IN CIRRHOSIS AFTER ANTI-HCV TREATMENT

Juan Macías¹, Luis E. Morano-Amado², Francisca Cuenca-Lopez³, Dolores Merino⁴, Manuel Márquez⁵, Karin Neukam¹, Maria J. Rios-Villegas⁶, Francisco Téllez⁷, Juan A. Pineda¹

¹Hosp Univ de Valme, Sevilla, Spain, ²Hosp Univ Alvaro Cunqueiro, Vigo, Spain, ³Hosp Univ Reina Sofía, Córdoba, Spain, ⁴Complejo Hospario Univ de Huelva, Huelva, Spain, ⁵Hosp Virgen de la Victoria, Málaga, Spain, ⁶Hosp Univ Virgen Macarena, Sevilla, Spain, ⁷Hosp de La Línea, La Línea de la Concepción, Spain

537 LIVER MICRORNA HSA-MIR-125A-5P MAY EXERT AN ONCOSUPPRESSOR EFFECT ON HCC

Lorenzo Onorato¹, Giorgio de Stefano², Valentina Lodice², Nunzia Farella², Nicoletta Potenza³, Evangelista Sagnelli¹, Aniello Russo³, Carmine Minichini¹, Mario Starace¹, Nicola Coppola¹

¹Second Univ of Naples, Naples, Italy, ²AORN dei Colli, PO Cotugno, Naples, Italy, ³Second Univ of Naples, Caserta, Italy

538 REAL-LIFE TREATMENT RATES FOR HEPATOCELLULAR CARCINOMA IN HIV-INFECTED PATIENTS

Nicolás Merchante¹, Francisco Rodríguez-Arrondo², Esperanza Merino³, Boris Revollo⁴, Sofia Ibarra⁵, Miguel García-Deltoro⁶, Francisco Téllez⁷, Joseba Portu⁸, Alberto Romero-Palacios⁹, Juan A. Pineda¹

¹Hosp Univ de Valme, Sevilla, Spain, ²Hosp Univ de Donostia, San Sebastián, Spain, ³Hosp General Univ de Alicante, Alicante, Spain, ⁴Hosp German Trias i Pujol, Badalona, Spain, ⁵Hosp de Basurto, Basurto, Spain, ⁶Hosp General de Valencia, Valencia, Spain, ⁷Hosp de La Línea, La Línea de la Concepción, Spain, ⁸Hosp de Txagorritxu, Vitoria, Spain, ⁹Hosp de Puerto Real, Puerto Real, Spain

539 PREDICTORS OF HEPATOCELLULAR CARCINOMA IN HIV/HCV COINFECTED PATIENTS WITH CIRRHOSIS

Aaron P. Thrift, Kathryn E. Royse, Christine Hartman, Jennifer R. Kramer, Elizabeth Chiao

Baylor Coll of Med, Houston, TX

540 IFN-FREE THERAPY IS EFFECTIVE AND SAFE FOR HCV RECURRENCE IN LT HCV/HIV COINFECTION

Christian Manzardo¹, Maria Carlota Londoño¹, Ana Moreno², Lluís Castells³, Victoria Aguilera⁴, Jose R. Fernandez⁵, Jorge Calvo-Pulido⁶, Judith Peñafiel¹, Antoni Rimola¹, Jose M. Miro¹

¹Univ of Barcelona, Barcelona, Spain, ²Hosp Ramon y Cajal, Madrid, Spain, ³Hosp Univ Vall d'Hebron, Barcelona, Spain, ⁴Hosp Univ La Fe, Valencia, Spain, ⁵Hosp Univ de Cruces, Barakaldo, Spain, ⁶Hosp 12 de Octubre, Madrid, Spain

541 RISK FACTORS OF ACUTE REJECTION AFTER LIVER TRANSPLANTATION IN HIV+/HCV+ PATIENTS

Christian Manzardo¹, Sandra Silva Arrieta², Antonio Rafecas³, Sandra Franco², Santos del Campo⁴, Elisa Cordero⁵, Judith Peñafiel¹, Antoni Rimola¹, Christian Brander², Jose M. Miro¹

¹Univ of Barcelona, Barcelona, Spain, ²IrsiCaixa Inst for AIDS Rsr, Badalona, Spain, ³L'Hosp de Llobregat, Spain, ⁴Hosp Ramon y Cajal, Madrid, Spain, ⁵Univ of Sevilla, Sevilla, Spain

542LB HCC DEVELOPMENT IN HCV PATIENTS AFTER DAA: THE EXPERIENCE OF THE SCOLTA PROJECT

Barbara Menzaghi¹, Carlo Magni², Laura A. Nicolini³, Giovanni Cenderello⁴, Vito Fiore⁵, Maria Gussio⁶, Roberto Gulminetti⁷, Francesca Vichi⁸, Paolo Bonfanti⁹

¹Busto Arsizio Hosp, Busto Arsizio, Italy, ²ASST Fatebenefratelli, Milan, Italy, ³Univ of Genova, Genova, Italy, ⁴Galliera Hosp, Genoa, Italy, ⁵Unit of Infectious Diseases, Sassari, Italy, ⁶Garibaldi Hosp, Catania, Italy, ⁷IRCCS Policlinico San Matteo Fndn Univ of Pavia, Pavia, Italy, ⁸S. Maria Annunziata Hosp, Milan, Italy, ⁹A. Manzoni Hospital, Lecco, Italy

Poster P-M1 ANAL CANCER: SCREENING AND HPV**Poster Hall - 4 EF****2:30 PM - 4:00 PM**

- 591 MULTIPLE-TEST SCREENING STRATEGIES IMPROVE BIOPSY-PROVEN HSIL-DETECTION IN HIV+ WOMEN**
Dorothy J. Wiley¹, Elizabeth Chiao², Jeanette Lee³, Ashish A. Deshmukh⁴, Scott B. Cantor⁵, Joel Palefsky⁶, Elizabeth A. Stier⁷
¹Univ of California Los Angeles, Los Angeles, CA, USA, ²Baylor Coll of Med, Houston, TX, USA, ³Univ of Arkansas for Med Scis, Little Rock, AR, USA, ⁴Univ of Florida, Gainesville, FL, USA, ⁵Univ of Texas MD Anderson Cancer Cntr, Houston, TX, USA, ⁶Univ of California San Francisco, San Francisco, CA, USA, ⁷Boston Univ, Boston, MA, USA
- 592 SCREENING STRATEGIES ADD VALUE FOR PREDICTING BIOPSY-PROVEN HSIL FOR MSM**
Dorothy J. Wiley¹, Hilary K. Hsu¹, Matthew G. Moran¹, Jenny Brook¹, David Elashoff¹, Martha Ganser¹, Stephen Young², David Morris³, Otoniel Martínez-Maza¹, Ronald T. Mitsuyasu¹
¹Univ of California Los Angeles, Los Angeles, CA, USA, ²Tricore Reference Labs, Albuquerque, NM, USA, ³Desert AIDS Proj, Palm Springs, CA, USA
- 593 ANAL HIGH-RISK HPV ASSOCIATIONS WITH SERUM CYTOKINES/CHEMOKINES AND FREE TESTOSTERONE**
Dorothy J. Wiley¹, Hilary K. Hsu², Sitram Vangala³, David Elashoff³, Xiang Lu³, Todd Brown⁴, Gysamber D'Souza², Elizabeth Breen³, Stephen Young³, Nancy Joste¹
¹Univ of California Los Angeles, Los Angeles, CA, USA, ²The Johns Hopkins Univ, Baltimore, MD, USA, ³Tricore Reference Labs, Albuquerque, NM, USA, ⁴Univ of New Mexico Hlth Scis Cntr, Albuquerque, NM, USA
- 594 MULTIPLE HPV INFECTIONS AND ANAL PRECANCEROUS LESIONS IN HIV-INFECTED MEN**
Shu-Hsing Cheng¹, Chien-Yu Cheng¹, Chi-Chao Wang¹, Fang-Yeh Chu², Yu-Mei Hsueh³
¹Taoyuan General Hosp, Taoyuan, Taiwan, ²Far Eastern Memorial Hosp, New Taipei, Taiwan, ³Taipei Med Univ, Taipei, Taiwan
- 595 SCREENING FOR PRECANCEROUS ANAL LESIONS WITH P16/KI67 DUAL STAIN CYTOLOGY IN HIV**
Sergio Serrano-Villar¹, Beatriz Hernández-Novoa², Amparo de Benito¹, Jorge Romero³, Antonio Ocampo⁴, Laura Pérez-Martínez⁵, Mar Masia⁶, Elena Sendagorta⁷, Gonzalo Sanz⁸, José Antonio Pérez-Molina¹
¹Hosp Univ Ramón y Cajal, Madrid, Spain, ²Brystol-Myers-Squibb, Madrid, Spain, ³Centro Sandoval, Madrid, Spain, ⁴Hosp Xeral de Vigo, Vigo, Pontevedra, ⁵Hosp San Pedro, Logroño, Spain, ⁶Hosp General Univ de Elche, Elche, Spain, ⁷Hosp Univ La Paz, Madrid, Spain, ⁸Hosp Clínico San Carlos, Madrid, Spain
- 596 IMPACT OF ART COVERAGE AND SCREENING ON ANAL CANCER IN HIV+ MEN WHO HAVE SEX WITH MEN**
Nello Blaser¹, Barbara Bertisch¹, Manuel Koller¹, Marcel Stoeckle², Matthias Cavassini³, Roger Kouyou⁴, Janne Estill¹, Matthias Egger¹, **Olivia Keiser¹**, for the Swiss HIV Cohort Study
¹Univ of Bern, Bern, Switzerland, ²Univ Hosp Basel, Basel, Switzerland, ³Univ of Lausanne, Lausanne, Switzerland, ⁴Univ of Zurich, Zurich, Switzerland
- 597 PREVALENCE OF HPV TYPES COVERED BY CURRENT VACCINES IN HIV-INFECTED MEN, SUN STUDY**
Pragna Patel¹, Tim Bush¹, Lois Conley¹, Elizabeth Unger¹, Teresa Darragh², Keith Henry³, Jerome Escota⁴, Joel Palefsky², John T. Brooks¹, Erna M. Kojic⁵
¹CDC, Atlanta, GA, USA, ²Univ of California San Francisco, San Francisco, CA, USA, ³Hennepin County Med Cntr, Minneapolis, MN, USA, ⁴Washington Univ, St. Louis, MO, USA, ⁵Brown Univ, Providence, RI, USA

Poster P-N5 INFLAMMATION, BIOMARKERS, AND RISK FACTORS FOR VASCULAR DISEASE

Poster Hall - 4 EF

2:30 PM - 4:00 PM

623 ASSOCIATION OF INFLAMMATION AND COAGULATION WITH CLINICAL RISK IN THE START TRIAL

Jason Baker, Shweta Sharma, Birgit Grund, for the INSIGHT START (Strategic Timing of AntiRetroviral Treatment) Study Group
Univ of Minnesota, Minneapolis, MN, USA

624 HIV VIRAL BURDEN ASSOCIATED WITH SUBCLINICAL CORONARY ARTERY DISEASE IN HIV+ MEN

Sabina Haberlen¹, Ruibin Wang¹, Frank J. Palella², Lisa Jacobson¹, Todd Brown¹, Mallory Witt³, Kathryn Berlach⁴, Matthew Budoff⁵, Alison Abraham¹, Wendy Post¹

¹The Johns Hopkins Univ, Baltimore, MD, USA, ²Northwestern Univ, Chicago, IL, USA, ³Los Angeles Biomed Rsr Inst at Harbor-UCLA Med Cntr, Torrance, CA, USA, ⁴Univ of Pittsburgh, Pittsburgh, PA, USA, ⁵Harbor-UCLA Med Cntr, Torrance, CA, USA

625 HIGHER CARNITINE LEVELS ARE ASSOCIATED WITH SUBSEQUENT MYOCARDIAL INFARCTIONS IN HIV

Arjun Sinha¹, Peter W. Hunt¹, Jeffrey N. Martin¹, Yifei Ma¹, Heidi M. Crane², Daniel Drozd², Peter Ganz¹, Stanley Hazen³, **Priscilla Hsue**¹

¹Univ of California San Francisco, San Francisco, CA, USA, ²Univ of Washington, Seattle, WA, USA, ³Cleveland Clinic, Cleveland, OH, USA

626 VACS INDEX IS SUPERIOR TO NADIR CD4 COUNT FOR PREDICTING AMI AND MORTALITY

Christopher Rentsch¹, Janet Tate¹, Vincent C. Marconi², Matthew Budoff³, Adeel A. Butt⁴, Matthew Freiberg⁵, Matthew Goetz⁶, Maria Rodriguez-Barradas⁷, David Rimland⁸, Amy Justice⁹

¹VA Connecticut Hlthcare System, West Haven, CT, USA, ²Emory Univ, Atlanta, GA, USA, ³Harbor-UCLA Med Cntr, Torrance, CA, USA, ⁴Weill Cornell Med Coll, New York, NY, USA, ⁵Vanderbilt Univ, Nashville, TN, USA, ⁶VA Greater Los Angeles Hlth Care System, Los Angeles, CA, USA, ⁷Baylor Coll of Med, Houston, TX, USA, ⁸Atlanta VA Med Cntr, Decatur, GA, USA, ⁹VA Connecticut Hlthcare System, West Haven, CT, USA

627 EPICARDIAL FAT, IMMUNE ACTIVATION, AND CORONARY PLAQUE AMONG HIV+ AND HIV- WOMEN

Suman Srinivasa¹, Michael Lu¹, Kathleen V. Fitch¹, Travis R. Hallett¹, Tricia H. Burdo², Janet Lo¹, Sara E. Looby¹, Udo Hoffmann¹, Steven K. Grinspoon¹, Markella V. Zanni¹

¹Massachusetts General Hosp, Boston, MA, USA, ²Temple Univ, Philadelphia, PA, USA

628 DIVERGENT EFFECTS OF HIV AND SMOKING ON AORTIC INFLAMMATION

Chris T. Longenecker¹, Claire E. Sullivan², Justin T. Morrison², Corri Lynn O. Hileman¹, David A. Zidar¹, Robert Gilkeson¹, James O'Donnell¹, Grace A. McComsey¹

¹Case Western Reserve Univ, Cleveland, OH, USA, ²Univ Hosps of Cleveland Med Cntr, Cleveland, OH, USA

629 CRP PREDICTS SUBCLINICAL CVD PROGRESSION IN HIV- BUT NOT HIV+ WOMEN

Caitlin A. Moran¹, Aswani Vunnavu¹, Anandi N. Sheth¹, Christina Mehta¹, Phyllis Tien², Michael Plankey³, Elizabeth T. Golub⁴, Arshed Quyyumi¹, Robert C. Kaplan⁵, Igbo Ofotokun¹

¹Emory Univ, Atlanta, GA, USA, ²Univ of California San Francisco, San Francisco, CA, USA, ³Georgetown Univ, Washington, DC, USA, ⁴The Johns Hopkins Univ, Baltimore, MD, USA, ⁵Albert Einstein Coll of Med, Bronx, NY, USA

630 SERUM ST2 IS AN INDEPENDENT PREDICTOR OF ALL-CAUSE MORTALITY IN HIV-INFECTED PATIENTS

Rodolphe Thiébaud¹, Sophie Hue², Fabien LeMarec¹, Jean Daniel Lelievre², Michel Dupon³, Emile Foucat², Isabelle Pellegrin³, Christine Lacabaratz², Fabrice Bonnet³, Yves Levy²

¹INSERM, Bordeaux, France, ²INSERM, Créteil, France, ³CHU de Bordeaux, Bordeaux, France

631 A LOWER CD COUNT PREDICTS MOST CAUSES OF DEATH EXCEPT CARDIOVASCULAR DEATHS

Gisela Leierer¹, Armin Rieger², Brigitte Schmied³, Mario Sarcletti¹, Maria Geit⁴, Bernhard Haas⁵, Ninon Taylor⁶, Michaela Rappold¹, Bruno Ledergerber⁷, **Robert Zangerle**¹

¹Med Univ of Innsbruck, Innsbruck, Austria, ²Med Univ of Vienna, Vienna, Austria, ³Otto-Wagner Hosp, Vienna, Austria, ⁴Kepler Univ Hosp Linz, Linz, Austria, ⁵General Hosp Graz South-West, Graz, Austria, ⁶Paracelsus Med Univ, Salzburg, Austria, ⁷Univ of Zurich, Zurich, Switzerland

632 ASSOCIATIONS BETWEEN HIV CONTROLLER STATUS AND SUBCLINICAL CAROTID ATHEROSCLEROSIS

Rebecca McKibben¹, David B Hanna², Sabina Haberen³, Robert C Kaplan², Frank J Palella⁴, Elizabeth T Golub¹, Peter Bacchetti⁵, Ruth Greenblatt⁵, Todd Brown⁶, Wendy Post¹

¹Johns Hopkins Univ, Baltimore, MD, USA, ²Albert Einstein Coll of Med, Bronx, NY, USA, ³Johns Hopkins Bloomberg SPH, Baltimore, MD, USA, ⁴Northwestern Univ, Chicago, IL, USA, ⁵Univ of California, San Francisco, San Francisco, CA, USA, ⁶Johns Hopkins Univ, Baltimore, MD, USA

633 ASSOCIATION BETWEEN CARDIOVASCULAR EVENTS AND HIV-SPECIFIC RISK FACTORS

Stefan Esser¹, Norbert H. Brockmeyer², Martin Hower³, Volker Holzendorf⁴, Christina Schulze⁵, Marina Arendt⁵, Till Neumann⁶, Nico Reinsch⁷, for the HIV HEART Study Group

¹Univ Hosp Duisburg-Essen, Essen, Germany, ²Ruhr-Univ Bochum, Bochum, Germany, ³City Hosp Dortmund, Dortmund, Germany, ⁴Univ Leipzig, Leipzig, Germany, ⁵Univ Hosp Essen, Essen, Germany, ⁶Cardiologic Outpatient Clinic Staibach, Bochum, Germany, ⁷Alfried Krupp Hosp, Essen, Germany

634 IMPAIRED ANTIVASCULAR CONTRACTION OF PERIVASCULAR ADIPOSE TISSUE IN HIV INDIVIDUALS

Dan Wang, Cheng Wang, Cuiwei Wang, Chenglong Liu, Jennifer Verbesey, Philena Sun, Seble Kassay, Mary Young, Christopher Wilcox, for the Hypertension, Kidney and Vascular Research Center and DC Women's Interagency HIV Study

Georgetown Univ, Washington, DC, USA

635LB NOVEL IMAGING STRATEGY SHOWS HIGH-LEVEL AORTIC CD206+ MACROPHAGE INFILTRATION IN HIV

Markella V. Zanni¹, **Mabel Toribio**¹, Moses Q. Wilks¹, Michael T. Lu¹, Tricia H. Burdo², Fred Cope³, Udo Hoffmann¹, Kenneth C. Williams⁴, Georges El-Fakhri¹, Steven K. Grinspoon¹

¹Massachusetts General Hosp, Boston, MA, USA, ²Temple Univ, Philadelphia, PA, USA, ³Navidea Biopharmaceuticals, Dublin, OH, USA, ⁴Boston Coll, Chestnut Hill, MA, USA

636LB GUT MICROBIOTA, TRYPTOPHAN CATABOLISM AND ATHEROSCLEROSIS IN HIV INFECTION

Qibin Qi¹, Simin Hua¹, David B. Hanna¹, Clary Clish², Jason Lazar³, Wendy Post⁴, Kathryn Anastos¹, Robert Burk¹, Robert C. Kaplan¹

¹Albert Einstein Coll of Med, Bronx, NY, USA, ²Broad Inst of MIT and Harvard, Cambridge, MA, USA, ³SUNY Downstate Med Cntr, Brooklyn, NY, USA, ⁴Johns Hopkins Univ, Baltimore, MD, USA

Poster P-N6 INTEGRATION OF SCREENING AND TREATMENT OF NCD INTO HIV CARE IN RESOURCE-LIMITED SETTINGS

Poster Hall - 4 EF

2:30 PM - 4:00 PM

637 INTEGRATING CARDIOVASCULAR DISEASE RISK-FACTOR SCREENING IN HIV SERVICES IN SWAZILAND

Miriam Rabkin¹, Anton M. Palma¹, Margaret L. McNairy¹, Samkelo Simelane², Averie B. Gachuhi¹, Raymond A. Bitchong³, Harriet Nuwagaba-Biribonwoha¹, Pido Bongomin², Velephi Okello⁴, Wafaa M. El-Sadr¹

¹ICAP at Columbia Univ, New York, NY, USA, ²ICAP Swaziland, Mbabane, Swaziland, ³Raleigh Fitkin Memorial Hosp, Manzini, Swaziland, ⁴Swaziland Ministry of Hlth, Mbabane, Swaziland

638 COMPOSITE "HIV/ HYPERTENSION/ DIABETES CONTROL" OUTCOME IN SEARCH CHRONIC CARE MODEL

Dalsone Kwariisima¹, Jeanna Wallenta², James Ayieko³, Florence Mwangwa⁴, Asiphah Owaraganise⁴, Tamara D. Clark², Edwin D. Charlebois², Maya L. Petersen⁵, Diane V. Havlir², Moses R. Kamya⁶

¹Makerere Univ Joint AIDS Prog, Kampala, Uganda, ²Univ of California San Francisco, San Francisco, CA, USA, ³Kenya Med Rsr Inst, Nairobi, Kenya, ⁴Infectious Diseases Rsr Collab, Kampala, Uganda, ⁵Univ of California Berkeley, Berkeley, CA, USA, ⁶Makerere Univ Coll of Hlth Scis, Kampala, Uganda

639 THE ART ADVANTAGE: HEALTHCARE UTILIZATION FOR DIABETES & HYPERTENSION IN SOUTH AFRICA

Jennifer Manne-Goehler¹, Livia Montana², Xavier Gomez-Olive³, Guy Harling⁴, Ryan Wagner⁵, Alisha Wade⁶, Julia K. Rohr², Stephen Tollman⁷, Till Baernighausen⁸, Thomas Gaziano⁹

¹Beth Israel Deaconess Med Cntr, Boston, MA, USA, ²Harvard Univ, Cambridge, MA, USA, ³Tintswalo Hosp, Acornhoek, South Africa, ⁴Harvard Univ, Boston, MA, USA, ⁵Univ of the Witwatersrand, Acornhoek, South Africa, ⁶MRC/Wits Rural Pub Hlth and Hlth Transitions Rsr Unit, Johannesburg, South Africa, ⁷Univ of Witwatersrand, Johannesburg, South Africa, ⁸Heidelberg Univ, Heidelberg, Germany, ⁹Brigham and Women's Hosp, Boston, MA, USA

640 CARDIOVASCULAR RISK ASSESSMENT IN A SUB-SAHARAN AFRICA HIV CLINICAL COHORT

Mosepele Mosepele¹, Linda C. Hemphill², Tommy Palai¹, Isaac Nkele³, Kara Bennett⁴, Shahin Lockman⁵, Virginia Triant²

¹Univ of Botswana, Gaborone, Botswana, ²Massachusetts General Hosp, Boston, MA, USA, ³Botswana-Harvard AIDS Partnership, Gaborone, Botswana, ⁴Bennett Statistical Consulting Inc, New York, NY, USA, ⁵Harvard Univ, Boston, MA, USA

641 HIV AND IMMUNE ACTIVATION ARE RISK FACTORS FOR ENDOTHELIAL DAMAGE IN ADULT MALAWIANS

Christine Kelly¹, Henry Mwandumba², Rob Heyderman³, Raphael Kamng'ona², Mishek Chammudzi², Irene Sheha², Jane E. Mallewa⁴, Sarah Walker³, Nigel Klein³, Saye Khoo⁵

¹Univ Coll Dublin, Dublin, Ireland, ²Malawi Liverpool Wellcome Clinical Rsr Prog, Blantyre, Malawi, ³Univ Coll London, London, UK, ⁴Univ of Malawi, Blantyre, Malawi, ⁵Univ of Liverpool Inst of Translational Med, Liverpool, UK

642 INCREASING PREVALENCE OF HYPERTENSION AMONG HIV-POSITIVE ADULTS IN SENEGAL, 1994–2015

Noelle A. Benzekri¹, Papa Salif Sow², **Moussa Seydi**², Stephen E. Hawes¹, Geoffrey Gottlieb¹

¹Univ of Washington, Seattle, WA, ²CHU de Fann, Dakar, Senegal

Poster P-01 IMMUNOLOGIC PREDICTORS OF MORBIDITY AND MORTALITY

Poster Hall - 4 EF

2:30 PM - 4:00 PM

643 MITOCHONDRIAL D-LOOP SNPs ASSOCIATED WITH AGE-RELATED COMORBIDITIES IN HIV PATIENTS

Rumi Minami, Soichiro Takahama, Yasunori Koga, Masahiro Yamamoto
Natl Hosp Org, Kyushu Med Cntr, Fukuoka, Japan

644 IMMUNOLOGIC AND VIROLOGIC MEASURES AND MORTALITY AFTER NCD IN HIV+ ADULTS

Jessica L. Castilho, Megan M. Turner, Bryan E. Shepherd, John R. Koethe, Sally S. Bebawy, Carmen E. Bofill, Stephen P. Raffanti, Timothy R. Sterling
Vanderbilt Univ, Nashville, TN, USA

645 VITAMIN D METABOLITES AND MORTALITY RISK AMONG HAART-TREATED HIV-INFECTED MEN

Long Zhang¹, Todd Brown¹, Joseph B. Margolick¹, Sabina Haberlen¹, Mallory Witt², Frank J. Palella³, Lawrence Kingsley⁴, Andrew Hoofnagle⁵, Lisa Jacobson¹, Alison Abraham¹

¹The Johns Hopkins Univ, Baltimore, MD, USA, ²Los Angeles Biomed Rsr Inst at Harbor—UCLA Med Cntr, Torrance, CA, USA, ³Northwestern Univ, Chicago, IL, USA, ⁴Univ of Pittsburgh, Pittsburgh, PA, USA, ⁵Univ of Washington, Seattle, WA, USA

646 LONGITUDINAL HIV VIRAL TRAJECTORIES AND COMORBIDITIES IN THE WIHS

Seble Kassaye¹, Cuiwei Wang², Jeff Collmann³, Tracey Wilson⁴, Kathryn Anastos⁵, Mardge H. Cohen⁶, Ruth Greenblatt⁷, Joel Milam⁶, Stephen J. Gange⁷, Michael Plankey¹

¹Georgetown Univ, Washington, DC, USA, ²SUNY Downstate Med Cntr, Brooklyn, NY, USA, ³Albert Einstein Coll of Med, Bronx, NY, USA, ⁴John H. Stroger Jr. Hosp of Cook County, Chicago, IL, USA, ⁵Univ of California San Francisco, San Francisco, CA, USA, ⁶Univ of Southern California, Los Angeles, CA, USA, ⁷The Johns Hopkins Univ, Baltimore, MD, USA

647 OXIDATIVE STRESS PREDICTS SERIOUS NON-AIDS EVENTS IN HIV-INFECTED PATIENTS

Mar Masia¹, Sergio Padilla², Marta Fernández², Xavier Barber³, Santiago Moreno⁴, Jose A. Iribarren⁵, Joaquin Portilla⁶, Alejandro Peña⁷, Francesc Vidal⁷, Félix Gutiérrez²

¹Hosp General Univ de Elche, Elche, Spain, ²Univ Miguel Hernández, Elche, Spain, ³Hosp Ramon y Cajal, Madrid, Spain, ⁴Hosp Donostia, San Sebastián, Spain, ⁵Hosp General Univ de Alicante, Alicante, Spain, ⁶Hosp Univ San Cecilio, Granada, Spain, ⁷Hosp Univ de Tarragona Joan XXIII, Tarragona, Spain

648 INFLAMMATION BIOMARKERS PREDICT CLINICAL TREATMENT FAILURE IN HIV-INFECTED ADULTS

Rupak Shivakoti¹, Nikhil Gupte², Sandy Pillay³, Cynthia Riviere⁴, Sandra W. Cardoso⁵, Ashwin Balagopal¹, Richard Semba¹, Thomas Campbell⁶, Amita Gupta¹, for the NWCS 319 and ACTG 5175 PEARLS Study Team

¹The Johns Hopkins Univ, Baltimore, MD, USA, ²BJGMC Clinical Trials Unit, Pune, India, ³Durban Univ of Tech, Durban, South Africa, ⁴Les Cntrs GHESKIO, Port-Au-Prince, Haiti, ⁵Inst Nacional de Infectologia (INI/Fiocruz), Rio de Janeiro, Brazil, ⁶Univ of Colorado Denver, Aurora, CO, USA

Poster P-02 ART TOXICITY

Poster Hall - 4 EF

2:30 PM - 4:00 PM

649 ART EFFECTS ON RENAL AND BONE HEALTH IN LIFELONG HIV SURVIVORS

Aviva Mattingly¹, Sara Jones², Aylin Unsal¹, Julia Purdy³, James Reynolds³, Jeffrey Kopp⁴, Rohan Hazra⁵, Colleen Hadigan¹

¹NIAD, Bethesda, MD, USA, ²Liedos Biomed Rsr Inc, Frederick, MD, USA, ³NIH, Bethesda, MD, USA, ⁴NIDDK, Bethesda, MD, USA, ⁵NICHD, Bethesda, MD, USA

650 FACTORS ASSOCIATED WITH RAPID EGFR DECLINE IN PATIENTS RECEIVING TDF AND/OR ATV

Lisa Hamzah¹, Sophie Jose², Rachael Jones³, Deborah Williams⁴, David Chadwick⁵, Andrew Phillips², Caroline Sabin², Frank Post⁶

¹King's Coll Hosp, London, UK, ²Univ Coll London, London, UK, ³Chelsea and Westminster NHS Fndn Trust, London, UK, ⁴Brighton and Sussex Univ Hosps, Brighton, UK, ⁵South Tees Hosps NHS Fndn Trust, Middlesbrough, UK, ⁶King's Coll Hosp NHS Fndn Trust, London, UK

651 DISCONTINUATION OF DTG, EVG/C, AND RAL DUE TO TOXICITY IN A PROSPECTIVE COHORT

Josep M. Llibre¹, Anna Esteve², Jose M. Miro³, Gracia Mateo⁴, Adrià Curran⁵, Daniel Podzamczar⁶, Melchor Riera⁷, Francesc Homar⁸, Luis Force⁹, for the the PISCIS Cohort Study Group

¹Univ Hosp Germans Trias, Barcelona, Spain, ²Cntr d'Estudis Epidemiològics Sobre les ITS i Sida de Catalunya, Barcelona, Spain, ³Univ of Barcelona, Barcelona, Spain, ⁴Hosp Sant Pau, Barcelona, Spain, ⁵Hosp Vall d'Hebró, Barcelona, Spain, ⁶Hosp Univ de Bellvitge, Barcelona, Spain, ⁷Hosp Univ Son Espases, Palma de Mallorca, Spain, ⁸Hosp Son Llàtzer, Palma de Mallorca, Spain, ⁹Hosp de Mataró, Mataró, Spain

652 IMPACT OF TENOFOVIR DIFUMARATE ON TELOMERE LENGTH OF AVIREMIC HIV-INFECTED PATIENTS

Rocio Montejano¹, Natalia Stella-Ascariz¹, Susana Monge², Jose I. Bernardino¹, Ignacio Pérez-Valero¹, Laura Pintado³, Marisa Montes¹, Jesus Mingorance¹, Rosario Perona³, Jose R. Arribas¹

¹Inst de Investigación Hosp Univ La Paz, Madrid, Spain, ²Univ de Alcalá de Henares, Madrid, Spain, ³Inst of Biomed Rsr "Alberto Sols," Madrid, Spain

653 **DARUNAVIR/R USE AND INCIDENT CHRONIC KIDNEY DISEASE IN HIV-POSITIVE PERSONS**

Lene Ryom¹, Jens D. Lundgren¹, Peter Reiss², Ole Kirk¹, Matthew Law³, Michael Ross⁴, Philippe Morlat⁵, Christoph A. Fux⁶, Amanda Mocroft⁷, for the D:A:D Study Group

¹CHIP, Rigshosp, Copenhagen, Denmark, ²Stichting HIV Monitoring and Academic Med Cntr Amsterdam, Amsterdam, Netherlands, ³Kirby Inst, Sydney, Australia, ⁴Mt Sinai Sch of Med, New York, NY, USA, ⁵CHU Bordeaux, Bordeaux, France, ⁶Clinic for Infectious Diseases and Hosp Hygiene, Kantonsspital Aarau, Aarau, Switzerland, ⁷Univ Coll London, London, UK

Poster P-P1 TB PREVENTION

Poster Hall - 4 EF

2:30 PM - 4:00 PM

705 **CO-TRIMOXAZOLE PROPHYLAXIS DECREASES TUBERCULOSIS RISK AMONG ASIAN PATIENTS WITH HIV**

Wen-Wei Ku¹, Awachana Jiamsakul², Kedar Joshi³, Mark Kristoffer Ungos Pasayan⁴, Alvina Widhani⁵, Romanee Chaiwarith⁶, Sasisopin Kiertiburanakul⁷, Kiat Ruxrungtham⁸, Ly Penh Sun⁹, Wingwai Wong¹

¹Taipei Veterans General Hosp, Taipei, Taiwan, ²Kirby Inst, Sydney, Australia, ³Inst of Infectious Diseases, Pune, India, ⁴Rsr Inst for Trop Med, Manila, Philippines, ⁵Cipto Mangunkusumo Hospital, Univ of Indonesia, Jakarta, Indonesia, ⁶Rsr Inst for Hlth Scis, Chiang Mai Univ, Chiang Mai, Thailand, ⁷Mahidol Univ, Bangkok, Thailand, ⁸HIV-NAT, Thai Red Cross AIDS Rsr Cntr, Bangkok, Thailand, ⁹Univ of Hlth Scis, Phnom Penh, Cambodia

706 **ISONIAZID PREVENTIVE THERAPY INITIATION, COMPLETION, & RETENTION IN CARE IN ETHIOPIA**

Andrea Howard¹, Katharine Yuengling¹, Yael Hirsch-Moverman¹, Suzue Saito¹, Tsigereda Gadisa², Wafaa M. El-Sadr¹, Zenebe Melaku³

¹ICAP at Columbia Univ, New York, NY, USA ²ICAP at Columbia Univ, Maseru, Lesotho, ³ICAP at Columbia Univ, Addis Ababa, Ethiopia

707 **IPT COVERAGE IN NURSE-LED SCREENING OF CHILD TUBERCULOSIS CONTACTS**

Nicole Salazar-Austin¹, Silvia Cohn¹, Grace Barnes¹, Molefi Tladi², Katlego Matlaoleng², Neil Martinson², Richard Chaisson¹

¹The Johns Hopkins Univ, Baltimore, MD, USA, ²Perinatal HIV Rsr Unit, Soweto, South Africa

708 **PROVISION OF IPT TO PEOPLE LIVING WITH HIV IN SWAZILAND: A RETROSPECTIVE COHORT STUDY**

Munyaradzi Pasipamire¹, Batsabile Simelane², Kikanda Kindandi³, Arnold Mafukidze², Marianne Calnan², Samson Haumba²

¹Ministry of Hlth—Swaziland Natl AIDS Prog, Mbabane, Swaziland, ²URC Swaziland, Mbabane, Swaziland, ³Ministry of Hlth, Mbabane, Swaziland

709 **DOES THE BENEFIT OF IPT FOR PERSONS WITH HIV WHO CONSUME ALCOHOL OUTWEIGH THE RISK?**

J. Morgan Freiman¹, Winnie Muyindike², Karen Jacobson³, C. Robert Horsburgh³, Jerrold Ellner¹, Judith Hahn⁴, Benjamin Linas³

¹Boston Med Cntr, Boston, MA, USA, ²Mbarara Univ of Sci and Tech, Mbarara, Uganda, ³Boston Univ, Boston, MA, USA, ⁴Univ of California San Francisco, San Francisco, CA, USA

710 HEPATOTOXICITY DURING IPT AND ART IN SEVERELY IMMUNOSUPPRESSED PEOPLE

McNeil Ngongondo¹, Sachiko Miyahara², Michael D. Hughes², Xin Sun², Amita Gupta³, Johnstone Kumwenda⁴, Thiago S. Torres⁵, Gregory Bisson⁶, Mina C. Hosseinipour¹, for the Adult AIDS Clinical Trials Group A5274 (REMEMBER) Study Team

¹UNC Proj-Malawi, Lilongwe, Malawi, ²Harvard Univ, Boston, MA, USA, ³The Johns Hopkins Univ, Baltimore, MD, USA, ⁴Coll of Med-Johns Hopkins Rsr Proj, Blantyre, Malawi, ⁵Inst Nacional de Infectologia (INI-Fiocruz), Rio de Janeiro, Brazil, ⁶Univ of Pennsylvania, Philadelphia, PA, USA

Poster P-P2 TB PATHOGENESIS AND DIAGNOSIS Poster Hall - 4 EF

2:30 PM - 4:00 PM

711 THE SENSITIVITY OF QUANTIFERON-TB GOLD PLUS IS NOT AFFECTED BY HIV STATUS

L. Telisinghe¹, M. Amofa-Sekyi², K. Maluzi², D. Kaluba-Milimo², M. Cheeba-Lengwe², K. Chiwele², B. Kosloff², S. Floyd³, S. L. Bailey³, H. Ayles⁴

¹Univ of Bristol, Bristol, UK, ²Zambart, Lusaka, Zambia, ³London Sch of Hygiene and Trop Med, London, UK, ⁴London Sch of Hygiene and Trop Med, Lusaka, Zambia

712 LOOP-MEDIATED ISOTHERMAL AMPLIFICATION ASSAY TO DIAGNOSE TUBERCULOSIS IN RURAL UGANDA

Lydia Nakiyingi¹, Prossy Nakanwagi², Tifu Agaba¹, Mark Mugenyi³, Frank Mubiru¹, Moses L. Joloba⁴, Yukari C. Manabe⁵

¹Infectious Diseases Inst, Kampala, Uganda, ²Baylor Coll of Med Children's Fndn, Kampala, Uganda, ³Kiboga Hosp, Kiboga, Uganda, ⁴Makerere Univ, Kampala, Uganda, ⁵The Johns Hopkins Univ, Baltimore, MD, USA

713 THE DIAGNOSIS OF EXTRAPULMONARY TUBERCULOSIS BY GENEXPERT MTB/RIF ASSAY IN ETHIOPIA

Mulualem Tadesse¹, Dossegnaw Aragaw¹, Alemayehu Bekele¹

¹Jimma Univ, Jimma, Ethiopia

714 EXTRAPULMONARY TB AT ART PROGRAMS IN LOWER-INCOME COUNTRIES: DIAGNOSTICS AND OUTCOMES

Kathrin Zürcher¹, Marie Ballif¹, Sasisopin Kiartiburanakul², Marcel Yotebieng³, Beatriz Grinsztejn⁴, Denna Michael⁵, Henri Chenal⁶, Matthias Egger¹, April C. Pettit⁷, Lukas Fenner¹

¹Inst of Social and Preventive Med, Univ of Bern, Bern, Switzerland, ²Mahidol Univ, Bangkok, Thailand, ³The Ohio State Univ, Columbus, OH, USA, ⁴Inst Nacional de Infectologia (INI-Fiocruz), Rio de Janeiro, Brazil, ⁵Natl Inst for Med Rsr, Kisesa HDSS, Mwanza, Tanzania, United Republic of, ⁶CIRBA, Abidjan, Côte d'Ivoire, ⁷Vanderbilt Univ, Nashville, TN, USA

715LB LOW-LEVEL M. TB GENOTYPIC HETERORESISTANCE PREDICTS PHENOTYPIC DRUG RESISTANCE

John Z. Metcalfe¹, Elizabeth Streicher², Christopher Allender³, Darrin Lemmer³, Rebecca Colman⁴, Grant Theron², Rob Warren², David M. Engelthaler³

¹Univ of California San Francisco, San Francisco, CA, USA, ²Stellenbosch Univ, Tygerberg, South Africa, ³Translational Genomics Rsr Inst, Flagstaff, AZ, USA, ⁴Univ of California San Diego, San Diego, CA, USA

716LB HUMAN AND MOUSE HEMATOPOIETIC STEM CELLS ARE A DEPOT FOR DORMANT M. TUBERCULOSIS

Julia Tornack¹, Stephen Reece¹, **Wolfgang Bauer**², Alexis Vogelzang¹, Silke Banderma¹, Ulrike Zedler¹, Georg Stingl², Stefan Kaufmann¹, Fritz Melchers¹

¹Max Planck Inst for Infection Bio, Berlin, Germany, ²Med Univ of Vienna, Vienna, Austria

Poster P-P3 TB TREATMENT, OUTCOMES, AND MORTALITY

Poster Hall - 4 EF

2:30 PM - 4:00 PM

717 RISK FACTORS FOR DEATH IN ADVANCED HIV-INFECTED ADULTS IN AN EMPIRIC TB THERAPY TRIAL

Gregory Bisson¹, Ritesh Ramchandani², Sachiko Miyahara², Xin Sun², Jing Bao³, Amita Gupta⁴, Mina C. Hosseinipour⁵, Johnstone Kumwenda⁶, for the Adult AIDS Clinical Trials Group A5274 (REMEMBER) Study Team

¹Univ of Pennsylvania, Philadelphia, PA, USA, ²Harvard Univ, Boston, MA, USA, ³NIH, Bethesda, MD, USA, ⁴Johns Hopkins Univ, Baltimore, MD, USA, ⁵Univ of North Carolina Proj—Malawi, Lilongwe, Malawi, ⁶Malawi Coll of Med—Johns Hopkins Univ Rsr Proj, Blantyre, Malawi

718 DOES TIME TO ART INITIATION IMPACT EARLY RESPONSES TO DR-TB TREATMENT?

Erika K. Mohr¹, Johnny Daniels¹, Odelia Muller¹, Bongani Chabalala¹, Jennifer Hughes¹, Virginia de Azevedo², Amir Shroufi³, Sarah Jane Steele³, Gabriella Ferlazzo³, Laura Trivino Duran¹

¹MSF, Khayelitsha, Cape Town, South Africa, ²City of Cape Town Dept of Hlth, Cape Town, South Africa, ³MSF, Cape Town, South Africa

719 HIV-RELATED TB TREATMENT INTERMITTENCY IN THE CONTINUATION PHASE AND MORTALITY

Brenda Crabtree-Ramírez¹, Cathy Jenkins², Bryan E. Shepherd², Karu Jayathilake², Valdilea Veloso³, Eduardo Gotuzzo⁴, Claudia P. Cortes⁵, Denis Padgett⁶, Catherine McGowan², Timothy R. Sterling²

¹Inst Nacional de Ciencias Médicas y Nutrición, Salvador Zubirán, Mexico, Mexico, ²Vanderbilt Univ, Nashville, TN, USA, ³Oswaldo Cruz Fndn—Fiocruz, Rio de Janeiro, Brazil, ⁴Univ Peruana Cayetano Heredia, Lima, Peru, ⁵Univ of Chile, Santiago, Chile, ⁶Hosp Seguro Social, Tegucigalpa, Honduras

720 IMPACT OF INH ADHERENCE ON TB INCIDENCE AND MORTALITY BY WEEK 96 IN ACTG 5274 TRIAL

Amita Gupta¹, Xin Sun², Sachiko Miyahara², Mitch Matoga³, Deborah Langat⁴, Cynthia Riviere⁵, Gregory Bisson⁶, Johnstone Kumwenda⁷, Mina C. Hosseinipour³, for the ACTG A5274/REMEMBER Study Team

¹Johns Hopkins Univ, Baltimore, MD, USA, ²Harvard Univ, Boston, MA, USA, ³Univ of North Carolina Proj—Malawi, Lilongwe, Malawi, ⁴KEMRI/Walter Reed Proj, Kericho, Kenya, ⁵Les Cntrs GHESKIO, Port-Au-Prince, Haiti, ⁶Univ of Pennsylvania, Philadelphia, PA, USA, ⁷Malawi Coll of Med—Johns Hopkins Univ Rsr Proj, Blantyre, Malawi

721 WITHDRAWN

722 OUTCOMES ACROSS THE TUBERCULOSIS TREATMENT CASCADE AMONG ADOLESCENTS IN HAITI

Lindsey Reif¹, Rachel Bertrand², Eric Kutscher³, Vanessa Rivera³, Pierrot Julma², Serena Koenig⁴, Jean W. Pape³, Daniel Fitzgerald³, Margaret McNairy³

¹Columbia Univ, New York, NY, USA, ²GHEKIO, Port-au-Prince, Haiti, ³Weill Cornell Med, New York, NY, USA, ⁴Harvard Univ, Boston, MA, USA

723LB WITHDRAWN

724LB EFFICACY OF BEDAQUILINE, PRETOMANID, MOXIFLOXACIN & PZA (BPAMZ) AGAINST DS- & MDR-TB

Rodney Dawson¹, **Kendra Harris²**, Almari Conradie², Divan Burger³, Stephen Murray⁴, Carl Mendel², Mel Spigelman²

¹Univ of Cape Town, Mowbray, South Africa, ²Global Alliance for TB Drug Development, New York, NY, USA, ³QuintilesIMS, Bloemfontein, South Africa, ⁴Mallinckrodt Pharmaceuticals, Bedminster, NJ, USA

Poster P-Q2 THE PMTCT CASCADE: TRANSMISSION, TESTING, AND VIRAL SUPPRESSION

Poster Hall - 4 EF

2:30 PM - 4:00 PM

761 MOTHER-TO-CHILD TRANSMISSION OF HIV IN KENYA: A MULTIYEAR NATIONAL EVALUATION

Lucy Ng'ang'a¹, Christine J. McGrath², Agnes Langat¹, Jillian Pintye³, Mary Schmitz¹, Abraham Katana¹, Rose Wafula⁴, John Kinuthia⁵, Grace John-Stewart³, Kevin De Cock¹

¹US CDC, Nairobi, Kenya, ²Univ of Texas Med Branch, Galveston, TX, USA, ³Univ of Washington, Seattle, WA, USA, ⁴Natl AIDS and STD Control Prog, Ministry of Hlth, Nairobi, Kenya, ⁵Kenyatta Natl Hosp, Nairobi, Kenya

762 MISSED OPPORTUNITIES FOR REPEAT HIV TESTING AND EARLY ART INITIATION IN PREGNANCY

Anna Joy Rogers¹, Eliud Akama², Elly Weke³, Justin Blackburn¹, George Owino⁴, Elizabeth A. Bukusi³, Patrick Oyaro², Zachary A. Kwen², Craig Cohen⁵, Janet M. Turan¹

¹Univ of Alabama at Birmingham, Birmingham, AL, USA, ²Kenya Med Rsr Inst, Kisumu, Kenya, ³Kenya Med Rsr Inst, Nairobi, Kenya, ⁴Kenya Med Rsr Inst, Rongo, Kenya, ⁵Univ of California San Francisco, San Francisco, CA, USA

763 LOW HIV INCIDENCE IN SOUTH AFRICAN PREGNANT WOMEN RECEIVING A PREVENTION INTERVENTION

Geoffrey Fatti¹, **Ashraf Grimwood¹**, Bon Egbujie¹, Eula Mothibi¹, Najma Shaikh¹, Debra Jackson², Brian Eley³

¹Kheth'Impilo, Cape Town, South Africa, ²UNICEF, New York, NY, USA, ³Univ of Cape Town, Cape Town, South Africa

764 HIV INCIDENCE, CASCADE, AND TESTING AMONG MOTHERS IN WESTERN KENYA

Alliance Nikuze¹, Stephen Wanjala², Jihane Ben-Farhat¹, Willis Omwoyo³, Laura Oyiengo⁴, Elisabeth Szumilin⁵, Leon Salumu⁵, Alexandra Vandenbulcke⁵, Valarie S. Opollo⁶, **David Maman⁷**

¹Epicentre, Paris, France, ²MSF, Nairobi, Kenya, ³Ministry of Hlth, Homa Bay, Kenya, ⁴Natl AIDS/STI Control Prog, Nairobi, Kenya, ⁵MSF France, Paris, France, ⁶Kenya Med Rsr Inst, Kisumu, Kenya, ⁷Epicentre, Cape Town, South Africa

- 765 DETECTION OF HIV IN BREAST MILK AMONG PREGNANT/ POSTPARTUM WOMEN WITH RECENT HIV**
Alison L Drake¹, John Kinuthia², Daniel Matemo², Barbra A. Richardson¹, Sandy Emery³, Vrascha Chohan¹, Julie Overbaugh³, Grace John-Stewart¹
¹Univ of Washington, Seattle, WA, USA, ²Kenyatta Natl Hosp, Nairobi, Kenya, ³Fred Hutchinson Cancer Rsr Cntr, Seattle, WA, USA
- 766 UPTAKE AND RETENTION IN CARE OF PREGNANT WOMEN STARTING OPTION B+ IN MAPUTO**
Esmeralda Karajeane¹, Dulce Bila¹, Orvalho Augusto², Maria Lain¹, Basilio Muianga¹, Chadreque Muluana³, Nello Macuacua¹, Victorino Chavane¹, Paula Vaz¹
¹Fundação Ariel Glaser Contra o Sida Pediátrico, Maputo, Mozambique, ²Univ Eduardo Mondlane, Maputo, Mozambique, ³Direcção Provincial de Saude de Maputo, Maputo Provincia, Mozambique
- 767 STRATEGIES FOR VIRAL-LOAD MONITORING DURING PREGNANCY IN RESOURCE-LIMITED SETTINGS**
Maia Lesosky¹, Elaine J. Abrams², Nei-Yuan M. Hsiao³, Landon Myer¹, for the Maternal Child Health - Antiretroviral Therapy (MCH-ART) study
¹Univ of Cape Town, Cape Town, South Africa, ²Columbia Univ, New York, NY, USA, ³NHLS, Cape Town, South Africa
- 768 VIRAL SUPPRESSION AMONG HIV+ PREGNANT WOMEN ENTERING ANTENATAL CARE ON ART IN UGANDA**
Catherine A. Koss¹, Paul Natureeba², Deborah Cohan¹, Teddy Ochieng², Theodore Ruel¹, Miriam Nakalembe³, Tamara D. Clark¹, Edwin D. Charlebois¹, Moses R. Kamya³, Diane V. Havlir¹
¹Univ of California San Francisco, San Francisco, CA, USA, ²Makerere Univ—Univ of California San Francisco Rsr Collab, Kampala, Uganda, ³Makerere Univ Coll of Hlth Scis, Kampala, Uganda
- 769 MEASURES OF ENGAGEMENT IN ROUTINE HIV CARE TO PREDICT ELEVATED VIRAL LOAD ON ART**
Tamsin Phillips¹, Allison Zerbe², Agnes Ronan¹, Nei-Yuan M. Hsiao³, Greg Petro¹, James A. McIntyre⁴, Andrew Bouille¹, Elaine J. Abrams², Landon Myer¹, for the Maternal Child Health - Antiretroviral Therapy (MCH-ART) study
¹Univ of Cape Town, Cape Town, South Africa, ²ICAP at Columbia Univ, New York, NY, USA, ³Natl Hlth Lab Service, Cape Town, South Africa, ⁴Anova Hlth Inst, Johannesburg, South Africa
- 770 SELF-REPORT AND DRY BLOOD SPOTS AS MARKERS OF ANTIRETROVIRAL ADHERENCE IN PREGNANCY**
Maria L. Alcaide¹, Shandir Ramlagan², Violeta Rodriguez¹, Ryan Cook³, Karl Peltzer², Stephen Weiss¹, Deborah Jones¹
¹Univ of Miami, Miami, USA, ²HIV/AIDS, STIs, and TB Rsr Prog, Pretoria, South Africa, ³Univ of California Los Angeles, Los Angeles, CA, USA
- 771 UNINTENDED PREGNANCY PREDICTS SUBSEQUENT RAISED VIRAL LOAD IN THE POSTNATAL PERIOD**
Kirsty Brittain¹, Tamsin Phillips¹, Allison Zerbe², Agnes Ronan¹, Greg Petro¹, Nei-Yuan M. Hsiao³, James A. McIntyre⁴, Elaine J. Abrams⁵, Landon Myer¹, for the Maternal Child Health - Antiretroviral Therapy (MCH-ART) Study
¹Univ of Cape Town, Cape Town, South Africa, ²Columbia Univ, New York, NY, USA, ³NHLS, Cape Town, South Africa, ⁴Anova Hlth Inst, Johannesburg, South Africa, ⁵ICAP at Columbia Univ, New York, NY, USA

Poster P-Q4 OUTCOMES OF HIV AND ARV-EXPOSED INFANTS

Poster Hall - 4 EF

2:30 PM - 4:00 PM

780 MITOCHONDRIAL DNA CONTENT IN HIV-EXPOSED UNINFECTED INFANTS IN CAMEROON

Jennifer Jao¹, Kathleen M. Powis², Brian Kirmse³, Chunli Yu¹, Fanny Epie⁴, Elaine J. Abrams⁵, Derek LeRoith¹, Mitchell Geffner⁶, Irwin J. Kurland⁷, Helene C. Cote⁸

¹Icahn Sch of Med at Mt Sinai, New York, NY, USA, ²Massachusetts General Hosp, Boston, MA, USA, ³Univ of Mississippi, Jackson, MS, USA, ⁴Cameroon Baptist Convention Hlth Services, Bamenda, Cameroon, ⁵Columbia Univ, New York, NY, USA, ⁶Univ of Southern California, Los Angeles, CA, USA, ⁷Albert Einstein Coll of Med, Bronx, NY, USA, ⁸Univ of British Columbia, Vancouver, Canada

781 LOPINAVIR/RITONAVIR INITIATED AT 7 DAYS OF LIFE IMPAIRS INFANT GROWTH

Nicolas Nagot¹, Thorkild Tylleskär², Chipeco Kankasa³, Nicolas MEDA⁴, James Tumwine⁵, Mandisa Singata⁶, Marianne Peries¹, Philippe Van de Perre¹, Stephane Blanche⁷, for the ANRS 12174 Trial Group

¹INSERM, Montpellier, France, ²Univ of Bergen, Bergen, Norway, ³Univ Teaching Hosp, Lusaka, Zambia, ⁴Cntr MURAZ, Bobo-Doulasso, Burkina Faso, ⁵Univ of Makerere, Kampala, Uganda, ⁶Univ of Fort Hare, East London, South Africa, ⁷Necker Hosp, Paris, France

782 GROWTH OUTCOMES OF HIV-EXPOSED UNINFECTED CHILDREN BY BIRTH PERIOD IN MALAWI

Malango T. Msukwa¹, Andreas Haas², Lyson Tenthani¹, Cristina B. Hofer², Janne Estill², Frank M. Chimbwandira³, Adrian Spoerri², Joep J. van Oosterhout⁴, Olivia Keiser², for the Umoyo Study Group

¹Univ of Bern, Lilongwe, Malawi, ²Univ of Bern, Bern, Switzerland, ³Ministry of Hlth, Lilongwe 3, Malawi, ⁴Dignitas Intl, Zomba, Malawi

783 GROWTH IN INFANTS EXPOSED TO EFV AND TDF THROUGH BREASTMILK: MALAWI PMTCT OPTION B+

Atupele P. Kapito-Tembo¹, Austin Wesevich², Andy Bauleni¹, Mina C. Hosseinipour², Dennis Ongubo², Queen Dube³, Amanda Corbett⁴, Don Mathanga¹, Victor Mwapasa¹, Sam Phiri⁵

¹Univ of Malawi, Blantyre, Malawi, ²Univ of North Carolina Proj—Malawi, Lilongwe, Malawi, ³Ministry of Hlth Queen Elizabeth Central Hosp, Blantyre, Malawi, ⁴Univ of North Carolina at Chapel Hill, Chapel Hill, NC, USA, ⁵Lighthouse Trust, Lilongwe, Malawi

784 PREDICTORS OF NEURODEVELOPMENT IN CHILDREN OF HIV-INFECTED AND -UNINFECTED WOMEN

Jean Leidner¹, Paige L. Williams², Gloria Mayondi³, Penny Holding⁴, Adam Cassidy⁵, Joseph Makhema³, Chipso Petlo⁶, Charlotte Mdluli³, Shahin Lockman², Betsy Kammerer⁵

¹Goodtables Consulting, Oklahoma, OK, USA, ²Harvard Univ, Boston, MA, USA, ³Botswana Harvard AIDS Inst Partnership, Gaborone, Botswana, ⁴Independent Consultant, Nairobi, Kenya, ⁵Boston Children's Hosp, Boston, MA, USA, ⁶Ministry of Hlth, Botswana, Gaborone, Botswana

785 B-CELL SUBSETS PROFILE AND VACCINE RESPONSE IN HIV-EXPOSED UNINFECTED (HEU) CHILDREN

Laurence Raymond Marchand¹, Catherine Gravel¹, Armelle Le Champion², Marc Boucher², Normand Lapointe², Valerie Lamarre², Fatima Kakkar², Helene C. Cote³, Hugo Soudeyns¹, for the CIHR Team on Cellular Aging and HIV Comorbidities in Women and Children (CARMA)

¹CHU Sainte Justine, Montreal, Canada, ²Univ of Montreal, Montreal, Canada, ³Univ of British Columbia, Vancouver, Canada

786 INFLAMMATORY RESPONSES ASSOCIATED WITH CMV AND MATERNAL HIV IN ZIMBABWEAN INFANTS

Ceri Evans¹, Bernard Chasekwa², Sandra Rukobo², Margaret Ghova², Kuda Mutasa², Robert Ntozini², Jean Humphrey², Andrew Prendergast¹

¹Queen Mary Univ of London, London, UK, ²Zvitambo Inst for Maternal and Child Hlth Rsr, Harare, Zimbabwe

787 MATERNAL ART ASSOCIATED WITH IMPROVED PROTECTIVE TRANSPLACENTAL ANTIBODY TRANSFER

Scott Dryden-Peterson¹, Elize de Bruyn², Gloria Mayondi³, Betsy Kammerer⁴, Jean Leidner⁵, Roger L. Shapiro⁶, Haruna Jibril⁷, Shabir Madhi², Shahin Lockman⁶

¹Brigham and Women's Hosp, Boston, MA, USA, ²Respiratory and Meningeal Pathogens Rsr Unit, Soweto, South Africa, ³Botswana Harvard AIDS Inst Partnership, Gaborone, Botswana, ⁴Boston Children's Hosp, Boston, MA, USA, ⁵Goodtables Consulting, Norman, OK, USA, ⁶Harvard Univ, Boston, MA, USA, ⁷Botswana Ministry of Hlth, Gaborone, Botswana

Poster P-R5 COMORBIDITIES AND COMPLICATIONS IN CHILDREN AND YOUTH

Poster Hall - 4 EF

2:30 PM - 4:00 PM

818 TREATMENT OUTCOMES OF KAPOSI SARCOMA IN HIV-1-INFECTED CHILDREN IN MOZAMBIQUE

Faizana Amodo¹, Yolanda Cachomba², Dalila Rego¹, Orvalho Augusto², Dulce Bila³, Paula Vaz³

¹Hosp Central de Maputo, Maputo, Mozambique, ²Univ Eduardo Mondlane, Maputo, Mozambique, ³Fundação Ariel Glaser Contra o Sida Pediátrico, Maputo, Mozambique

819 DURABLE GAINS IN BONE MASS AMONG SOUTH AFRICAN CHILDREN SWITCHING TO EFAVIRENZ

Stephen M. Arpad¹, Stephanie Shiao¹, Renate Strehlau², Faeezah Patel², Ndileka Mbete², Louise Kuhn¹, Ashraf Coovadia², Michael T. Yin¹

¹Columbia Univ, New York, NY, USA, ²Empilweni Service and Rsr Unit, Johannesburg, South Africa

820 EFFECTS OF CALCIUM AND VITAMIN D SUPPLEMENTATION ON BONE HEALTH IN HIV-INFECTED YOUTH

Tavitiya Sudjaritruk¹, Linda Aupibul¹, Torsak Bunupuradah², Suparat Kanjanavanit³, Tawalchaya Chotecharoentanan¹, Sineenart Taejaroenkul¹, Pradthana Ounchanum⁴, Piyarat Suntarattiwong⁵, Thanyawee Puthanakit⁶, for the CAL-D Study Group

¹Chiang Mai Univ, Chiang Mai, Thailand, ²HIV Netherlands Australia Thailand Rsr Collab (HIV-NAT), ³Nakornping Hosp, Chiang Mai, Thailand, ⁴Chiang Rai Prachanukroh Hosp, Chiang Rai, Thailand, ⁵Queen Sirikit Natl Inst of Child Hlth, Bangkok, Thailand, ⁶Chulalongkorn Univ, Bangkok, Thailand

821 METABOLIC PROFILES OF ADULTS VERTICALLY INFECTED WITH HIV AND THE GENERAL POPULATION

Elise Arrivé¹, **Jean-Paul Viard**², Elisa Arezes³, Ferial Ayat³, Benoit Salanave⁴, Sophie Matheron⁵, Véronique Reliquet⁶, Corinne Vigouroux⁷, Josiane Warszawski³, for the ANRS C019 COVERTE Study Group

¹Univ of Bordeaux, Bordeaux, France, ²Hôtel-Dieu de Paris, Paris, France, ³INSERM, Le Kremlin-Bicêtre, France, ⁴Equipe de Surveillance et d'Epidémiologie Nutritionnelle/Agence Natl de Santé Publique, Bobigny, France, ⁵Bichat-Claude Bernard Hosp, Paris, France, ⁶CHU Hôtel Dieu, Nantes, France, ⁷INSERM, Paris, France

- 822 EFFECTS OF VITAMIN D SUPPLEMENTATION ON CAROTID INTIMA-MEDIA THICKNESS IN HIV+ YOUTH**
Allison R. Eckard¹, Paolo Raggi², Mary Ann O’Riordan³, Julia C. Rosebush⁴, Danielle Labbato³, Ann Chahroudi⁴, Joshua H. Ruff⁴, Chris T. Longenecker³, Vin Tangpricha⁴, Grace A. McComsey³
¹Med Univ of South Carolina, Charleston, SC, USA, ²Mazankowski Alberta Heart Inst, Edmonton, Canada, ³Case Western Reserve Univ, Cleveland, OH, USA, ⁴Emory Univ, Atlanta, GA, USA
- 823 DOES PREMATURE VASCULAR STIFFNESS SLOWLY IMPROVE FOLLOWING EARLY ART? DATA FROM CHER**
Steve Innes¹, Mark Cotton¹, Kennedy N. Ot wombe², Barbara Laughton¹, Sara H Browne³
¹Stellenbosch Univ, Cape Town, South Africa, ²Univ of the Witwatersrand, Johannesburg, South Africa, ³Univ of California San Diego, San Diego, CA, USA
- 824 SVCAM AND MCP-1 INVOLVED IN PREMATURE ARTERIAL-WALL STIFFNESS IN PREPUBERTAL CHILDREN**
Steve Innes¹, Richard Glashoff¹, Shalena Naidoo¹, Kennedy N. Ot wombe², Barbara Laughton¹, Maile Karris³, Mark Cotton¹, Sara H Browne³
¹Stellenbosch Univ, Cape Town, South Africa, ²Univ of the Witwatersrand, Johannesburg, South Africa, ³Univ of California San Diego, San Diego, CA
- 825 VASCULAR HEALTH AND CEREBRAL BLOOD FLOW IN PERINATALLY HIV-INFECTED CHILDREN**
Charlotte Blokhuis¹, Sophie Cohen¹, Henriëtte J. Scherpbier¹, Henk-Jan M. Mutsaerts², Joost C. Meijers³, Neeltje A. Kootstra², Peter Reiss⁴, Ferdinand Wit⁴, Charlotte E. Teunissen⁵, Dasja Pajkrt¹
¹Emma Children’s Hosp/Academic Med Cntr, Amsterdam, Netherlands, ²Academic Med Cntr, Amsterdam, Netherlands, ³Sanquin Rsr, Amsterdam, Netherlands, ⁴Stichting HIV Monitoring and Academic Med Cntr, Amsterdam, Netherlands, ⁵VU Univ Med Cntr, Amsterdam, Netherlands
- 826 NEUROPSYCHOLOGICAL OUTCOMES IN A TWO YEAR AFRICAN-BASED PEDIATRIC OBSERVATIONAL STUDY**
Michael J. Boivin¹, Miriam Chernoff², Barbara Laughton³, Mutsa Bwakura-Dangarembizi⁴, Portia Kamthunzi⁵, Linda Barlow-Mosha⁶, Avy Violari⁷, Mark Cotton³, Paul Palumbo⁸, for the IMPAACT P1104s Study Team
¹Michigan State Univ, East Lansing, MI, USA, ²Harvard Univ, Boston, MA, USA, ³Stellenbosch Univ, Cape Town, South Africa, ⁴Univ of Zimbabwe, Harare, Zimbabwe, ⁵Univ of North Carolina Proj–Malawi, Lilongwe, Malawi, ⁶Makerere Univ–Johns Hopkins Univ Rsr Collab, Kampala, Uganda, ⁷Univ of the Witwatersrand, Johannesburg, South Africa, ⁸Dartmouth-Hitchcock Med Cntr, Lebanon, NH, USA
- 827 PLASMA HEME OXYGENASE-1 IS ASSOCIATED WITH COGNITIVE DECLINE IN CHILDREN WITH HIV**
David Bearden¹, Alexander J. Gill², Paige L. Williams³, Dennis L. Kolson², Laura Schankel⁴, Allison Agwu⁵, Russell B. Van Dyke⁶, Steven D. Douglas⁴, for the Pediatric HIV/AIDS Cohort Study (PHACS) network and the IMPAACT 219C Study Team
¹Univ of Rochester, Rochester, NY, USA, ²Univ of Pennsylvania, Philadelphia, PA, USA, ³Harvard Univ, Boston, MA, USA, ⁴Children’s Hosp of Philadelphia, Philadelphia, PA, USA, ⁵The Johns Hopkins Univ, Baltimore, MD, USA, ⁶Tulane Univ, Metairie, LA, USA

828 BIOMARKERS OF COGNITIVE DECLINE IN PERINATALLY INFECTED CHILDREN WITH HIV

David Bearden¹, Alexander J. Gill², Paige L. Williams³, Dennis L. Kolson², Laura Schankel⁴, Allison Agwu⁵, Russell B. Van Dyke⁶, Steven D. Douglas⁴, for the The Pediatric HIV/AIDS Cohort Study (PHACS) network and the IMPAACT 219C study team

¹Univ of Rochester, Rochester, NY, USA, ²Univ of Pennsylvania, Philadelphia, PA, USA, ³Harvard Univ, Boston, MA, USA, ⁴Children's Hosp of Philadelphia, Philadelphia, PA, USA, ⁵The Johns Hopkins Univ, Baltimore, MD, USA, ⁶Tulane Univ, Metairie, LA, USA

829 MONOCYTES MAY BE ANTIVIRAL TARGETS TO LIMIT PEDIATRIC HIV-RELATED CNS MANIFESTATIONS

Erica L. Johnson, Dominika Swieboda, Christina Gavegnano, Rana Chakraborty, Raymond F. Schinazi

Emory Univ, Atlanta, GA, USA

830 CENTRAL NERVOUS SYSTEM PENETRATION OF ANTIRETROVIRAL THERAPY IN HIV-INFECTED CHILDREN

Malon V. Hof¹, Charlotte Blokhuis², Sophie Cohen², Henriëtte J. Scherpbier², Ferdinand Wit³, Marcel Pistorius¹, Neeltje A. Kootstra¹, Charlotte E. Teunissen⁴, Ron Mathot¹, Dasja Pajkrt²

¹Academic Med Cntr, Amsterdam, Netherlands, ²Emma Children's Hosp/ Academic Med Cntr, Amsterdam, Netherlands, ³Stichting HIV Monitoring and Academic Med Cntr, Amsterdam, Netherlands, ⁴VU Univ Med Cntr, Amsterdam, Netherlands

Poster P-S5 MEASURING HIV INCIDENCE AND PREVALENCE**Poster Hall - 4 EF****2:30 PM - 4:00 PM****876 ASSESSING UTILITY OF HIV INCIDENCE ASSAYS IN ESTIMATING INDIVIDUAL INFECTION TIMES**

Christopher D. Pilcher¹, Shelley Facente¹, Eduard Grebe², Sheila Keating³, Reshma Kassanjee⁴, Matt A. Price⁵, Michael P. Busch³, Gary Murphy⁶, Alex Welte², Travis C. Porco¹

¹Univ of California San Francisco, San Francisco, CA, USA, ²Stellenbosch Univ, Stellenbosch, South Africa, ³Blood Systems Rsr Inst, San Francisco, CA, USA, ⁴Univ of Cape Town, Cape Town, South Africa, ⁵Intl AIDS Vaccine Initiative, New York, NY, USA, ⁶Pub Hlth England, London, UK

877 A MULTIPLEX ASSAY FOR MONITORING RECENT HIV-1 TRANSMISSION IN LOCALIZED OUTBREAKS

Kelly Curtis, Ellsworth Campbell, Krystin A. Price, William M. Switzer
CDC, Atlanta, GA, USA

878 INFERENCE OF HIV-1 INFECTION DATES IN AN OUTBREAK USING ANTIBODY-BASED RECENCY ASSAYS

Ellsworth Campbell¹, Kelly Curtis¹, Krystin A. Price¹, Debra Hanson¹, Sara J. Blosser², Joan Duwve³, Pam Pontones², Philip J. Peters¹, William M. Switzer¹

¹CDC, Atlanta, GA, USA, ²Indiana State Hlth Dept, Indianapolis, IN, USA, ³Indiana Univ, Indianapolis, IN, USA

879 IDENTIFICATION AND VALIDATION OF AN INCIDENCE-TESTING ALGORITHM FOR HIV-1 SUBTYPE C

Oliver Laeyendecker¹, Jacob Konikoff², Douglas Morrison³, Ronald Brookmeyer³, Jing Wang⁴, Connie L. Celum⁵, Charles S. Morrison⁶, Quarraisha Abdool Karim⁷, Audrey Pettifor⁸, Susan H. Eshleman⁹

¹NIAID, NIH, Baltimore, MD, USA, ²The Johns Hopkins Univ, Baltimore, MD, USA, ³Univ of California Los Angeles, Los Angeles, CA, USA, ⁴Fred Hutchinson Cancer Rsr Cntr, Seattle, WA, USA, ⁵Univ of Washington, Seattle, WA, USA, ⁶FHI 360, Durham, NC, USA, ⁷CAPRISA, Durban, South Africa, ⁸Univ of North Carolina at Chapel Hill, Chapel Hill, NC, USA, ⁹The Johns Hopkins Univ, Baltimore, MD, USA

880 VALIDATION OF LIMITING ANTIGEN AVIDITY ASSAY TO ESTIMATE HIV INCIDENCE IN EAST AFRICA

Oliver Laeyendecker¹, Ronald H. Gray², Kate Grabowski², Steven Reynolds¹, Anthony Ndyabo³, Joseph Ssekasanvu², Gilad Bismut², Maria Wawer², David Serwadda⁴, Thomas C. Quinn¹

¹NIAID, Baltimore, MD, USA, ²The Johns Hopkins Univ, Baltimore, MD, USA, ³Rakai Hlth Scis Prog, Kalisizo, Uganda, ⁴Makerere Univ, Kampala, Uganda

881 MISCLASSIFICATION RATE OF HIV ANTIBODY AVIDITY ASSAYS IN INDIVIDUALS FROM CAMEROON

Briana Lynch¹, Eshan Patel², Colleen R. Courtney³, Aubin J. Nanack³, Thomas Quinn², Oliver Laeyendecker⁴, Phillipe N. Nyambi³, Ralf Duerr³, Andrew D. Redd⁵, for the Medical Diagnostic Center, Yaoundé, Cameroon

¹NIH, Bethesda, MD, USA, ²The Johns Hopkins Univ, Baltimore, MD, USA, ³New York Univ, New York, NY, USA, ⁴NIAID, Baltimore, MD, USA, ⁵NIAID, Bethesda, MD, USA

882 WITHDRAWN

883 HIGH HIV INCIDENCE AMONG PWID AND MSM ATTENDING INTEGRATED CARE CENTERS IN INDIA

Allison M. McFall¹, Sunil S. Solomon¹, Gregory M. Lucas¹, Aylur K. Srikrishnan², Muniratnam S. Kumar², Santhanam Anand², Canjeevaram K. Vasudevan², David D. Celentano¹, Shruti H. Mehta¹

¹The Johns Hopkins Univ, Baltimore, MD, USA, ²YR Gaitonde Cntr for AIDS Rsr and Educ, Chennai, India

884 TRENDS IN HIV INCIDENCE AMONG PWID, MSM AND CSW USING PREVENTION SERVICES IN UKRAINE

Kostyantyn Dumchev¹, Olga Varetska², Yana Sazonova², Pavlo Smyrnov²

¹Ukrainian Inst on Pub Hlth Policy, Kyiv, Ukraine, ²Alliance for Pub Hlth, Kyiv, Ukraine

885 IMPROVED EVALUATION OF HIV PREVALENCE ADJUSTING FOR INFORMATIVE NONPARTICIPATION

Linbo Wang¹, Erik VanWidenfelt², Chloe Auletta-Young¹, Nealia Khan¹, Etienne Kadima², Unoda Chakalisa², Tendani Gaolathe², Eric Tchetgen Tchetgen¹, Kathleen Wirth¹

¹Harvard Univ, Boston, MA, ²Botswana Harvard AIDS Inst Partnership, Gaborone, Botswana

Poster P-S7 HIV SELF TESTING: KNOW YOURSELF**Poster Hall - 4 EF****2:30 PM - 4:00 PM**

- 891 HIV SELF-TEST (HIVST) AWARENESS, EXPOSURE, AND USE, NEW YORK CITY, 2015–2016**
Paul M. Salcuni, Zoe R. Edelstein, Demetre C. Daskalakis, Julie Myers
New York City DHMH, Queens, NY, USA
- 892 ETEST: A “SMART” HOME HIV TESTING SYSTEM ENABLING REAL-TIME FOLLOW-UP AFTER TESTING**
Tyler B. Wray¹, Philip A. Chan², Don Operario¹, Erik Simpanen¹
¹*Brown Univ, Providence, RI, USA*, ²*The Miriam Hosp, Providence, RI, USA*
- 893 PEER-LED ORAL HIV-SELF TESTING FINDS UNDIAGNOSED HIV AMONG MSM IN MALINDI, KENYA**
 Elisabeth M. van der Elst¹, Mahmoud Shally¹, Clifford Oduor¹, Oscar Chirro¹, Fauz Ibrahim², Bernadette Kombo¹, Susan M. Graham³, **Eduard Sanders**⁴
¹*KEMRI Wellcome Trust Rsr Prog, Kilifi, Kenya*, ²*Kilifi County Dept of Hlth, Kilifi, Kenya*, ³*Univ of Washington, Seattle, WA, USA*, ⁴*Kenya Med Rsr Inst, Kilifi, Kenya*
- 894 ROLE OF PARTNER VIOLENCE IN WOMEN’S ABILITY TO DISTRIBUTE SELF-TESTS TO MALE PARTNERS**
Elisabeth Schaffer¹, Kawango Agot², Harsha Thirumurthy¹
¹*Univ of North Carolina at Chapel Hill, Chapel Hill, NC, USA*, ²*Impact Rsr and Development Org, Kisumu City, Kenya*
- 895 INFORMING HIV SELF-TESTING SERVICES IN MALAWI USING DISCRETE CHOICE EXPERIMENTS**
Pitchaya Indravudh¹, Marc D’Elbee², Moses Kumwenda¹, Augustine Choko³, Doreen Sakala¹, Thokozani Kalua⁴, Cheryl Johnson⁵, Karin Hatzold⁶, Liz Corbett³, Fern Terris-Prestholt²
¹*Malawi–Liverpool–Wellcome Trust Clinical Rsr Prog, Blantyre, Malawi*, ²*London Sch of Hygiene & Trop Med, London, UK*, ³*London Sch of Hygiene & Trop Med, Blantyre, Malawi*, ⁴*Malawi Dept of HIV and AIDS, Lilongwe, Malawi*, ⁵*WHO, Geneva, Switzerland*, ⁶*Pop Services Intl, Harare, Zimbabwe*
- 896 PROVIDING USER SUPPORT FOR HIV SELF-TESTING BEYOND INSTRUCTIONS-FOR-USE IN MALAWI**
Pitchaya Indravudh¹, Moses Kumwenda¹, Melissa Neuman², Blessings Chisunkha¹, Karin Hatzold³, Chiwawa Nkhoma⁴, Thokozani Kalua⁵, Cheryl Johnson⁶, Miriam Taegtmeyer⁷, Liz Corbett⁸
¹*Malawi–Liverpool–Wellcome Trust Clinical Rsr Prog, Blantyre, Malawi*, ²*London Sch of Hygiene & Trop Med, London, UK*, ³*Pop Services Intl, Harare, Zimbabwe*, ⁴*Pop Services Intl, Blantyre, Malawi*, ⁵*Malawi Dept of HIV and AIDS, Lilongwe, Malawi*, ⁶*WHO, Geneva, Switzerland*, ⁷*Liverpool Sch of Trop Med, Liverpool, UK*, ⁸*London Sch of Hygiene & Trop Med, Blantyre, Malawi*
- 897 ACCEPTABILITY OF SELF-COLLECTED RECTAL SWABS FOR HIV EXPOSURE TESTING AMONG MSM/TGW**
Hong Van Tieu¹, Maria Lemos², Michele Andrasik², Ira Fleming², Vijay Nandi¹, Geneva Ortiz¹, Debbie Lucy¹, Martin Musuruana³, Julie McElrath², Beryl A. Koblin¹
¹*New York Blood Cntr, New York, NY, USA*, ²*Fred Hutchinson Cancer Rsr Cntr, Seattle, WA, USA*, ³*Univ of Illinois, Peoria, IL, USA*
- 898 FEASIBILITY AND REACH OF A HOME-TEST GIVEAWAY IN NEW YORK CITY, 2015–2016**
Zoe R. Edelstein¹, Paul M. Salcuni¹, Benjamin Tsoi¹, Paul Kobra¹, Adriana Andaluz¹, David A Katz², Demetre C. Daskalakis¹, Julie Myers¹
¹*New York City DHMH, Queens, NY, USA*, ²*Univ of Washington, Seattle, WA, USA*

Poster P-S8 MEASURING THE US HIV EPIDEMIC

Poster Hall - 4 EF

2:30 PM - 4:00 PM

899 STATE-LEVEL ESTIMATES OF HIV INCIDENCE, PREVALENCE, AND UNDIAGNOSED INFECTIONS

Anna S. Johnson, Ruiguang Song, Irene Hall
CDC, Atlanta, GA, USA

900 ESTIMATING THE UNDIAGNOSED FRACTION: A COMPARISON OF NEW METHODS

Jeanette Birnbaum¹, Jason Carr², Martina Morris¹
¹*Univ of Washington, Seattle, WA, USA*, ²*Washington State Dept of Hlth, Olympia, USA*

901 HIV TESTING MOTIVATIONS OF US MEN WHO HAVE SEX WITH MEN IN A NATIONAL ONLINE SURVEY

David A. Katz¹, Patrick Sullivan², Robert C. Sineath², Jennie McKenney², Maria Zlotorzynska², Susan Cassels³, Joanne Stekler¹
¹*Univ of Washington, Seattle, WA, USA*, ²*Emory Univ, Atlanta, GA, USA*, ³*Univ of California Santa Barbara, Santa Barbara, CA, USA*

902 INCREASES IN HIV TESTING FREQUENCY AMONG MEN WHO HAVE SEX WITH MEN, UNITED STATES

Qian An, Ruiguang Song, Teresa Finlayson, Cyprian Wejnert, Gabriela Paz-Bailey
CDC, Atlanta, GA, USA

903 UNDIAGNOSED HIV AND HCV IN A NEW YORK CITY EMERGENCY ROOM, 2015

Lucia V. Torian¹, Uriel Felsen², Qiang Xia³, Eric Rude³, Herbert Rose⁴, Angelica Bocour³, Gary J. Williams⁵, Bob F. Bridgforth⁵, Lisa A. Forgiione³, Barry S. Zingman⁴
¹*New York City DHMH, New York, NY, USA*, ²*Albert Einstein Coll of Med, Bronx, NY, USA*, ³*New York City DHMH, Long Island City, NY, USA*, ⁴*Montefiore Med Cntr, Bronx, NY, USA*, ⁵*Quest Diagnostics, San Clemente, CA, USA*

904 EXAMINATION OF UNRECOGNIZED AND MISREPORTED HIV STATUS IN BALTIMORE MSM AND PWID

Danielle German¹, Kate Shearer¹, Colin Flynn², Carl A. Latkin¹, Oliver Laeyendecker³, Thomas Quinn¹, William Clarke¹
¹*The Johns Hopkins Univ, Baltimore, MD, USA*, ²*Maryland DHMH, Baltimore, MD, USA*, ³*NIAID, Baltimore, MD, USA*

905 SPATIAL VARIATION ALONG THE HIV CARE CONTINUUM IN WASHINGTON, DC, 2014–2015

Arpi Terzian¹, Naji Younes¹, Jenevieve Opoku², Johnathan Hubbard¹, Rena R. Jones³, Princy Kumar¹, Amanda D. Castel¹, for the The DC Cohort Executive Committee
¹*The George Washington Univ, Washington, DC, USA*, ²*District of Columbia Dept of Hlth, Washington, DC, USA*, ³*NCI, Bethesda, MD, USA*

906 TRENDS AND DISPARITIES IN ART USE AMONG PERSONS WITH HIV IN SAN FRANCISCO, 2006–2015

Ling Hsu¹, Sandy Schwarcz¹, Susan Scheer¹
¹*San Francisco Dept of Pub Hlth, San Francisco, CA, USA*

907 CARE CONSTANCY AND VIRAL SUPPRESSION AMONG ADULTS IN HIV CLINICAL CARE, UNITED STATES

Heather Bradley, Kate Buchacz, Yunfeng Tie, Oluwatosin Olaiya, R. L. Shouse
CDC, Atlanta, GA, USA

908 BEYOND THE STATIC HIV CONTINUUM: CAPTURING THE DYNAMIC PROCESS OF RETENTION

Hana Lee¹, Xiaotian Wu¹, Michael J. Mugavero², Stephen R. Cole³, Bryan Lau⁴, **Becky L. Genberg**¹, Joseph Hogan¹

¹Brown Univ, Providence, RI, USA, ²Univ of Alabama at Birmingham, Birmingham, AL, USA, ³Univ of North Carolina at Chapel Hill, Chapel Hill, NC, USA, ⁴The Johns Hopkins Univ, Baltimore, MD, USA

909 ASSOCIATION BETWEEN 4 MEASURES OF RETENTION IN CARE AND VIROLOGIC FAILURE

Mariah M. Kalmin, Amanda D. Castel, Alan Greenberg, Heather Young, Heather Hoffman, for the DC Cohort Executive Committee

George Washington Univ, Washington, DC, USA

910 USING SURVEILLANCE DATA TO MEASURE PROGRESS ALONG THE HIV CARE CONTINUUM

Nancy A. Hessol¹, Ling Hsu², Sharon Pipkin², Susan Scheer²

¹Univ of California San Francisco, San Francisco, CA, USA, ²San Francisco Dept of Pub Hlth, San Francisco, CA, USA

Poster P-S9 FACTORS INFLUENCING HIV OUTCOMES

Poster Hall - 4 EF

2:30 PM - 4:00 PM

911 IMPROVED HIV CARE OUTCOMES FOR INMATES REFERRED TO COMMUNITY PROGRAMS IN PHILADELPHIA

Makeda Carroll¹, Tanner Nassau¹, Melissa Miller¹, Cody Poerio², Hannah Zellman³, Bruce Herdman⁴, Coleman Terrell¹, Kathleen Brady¹

¹Philadelphia Dept of Pub Hlth, Philadelphia, PA, USA, ²Action Wellness, Philadelphia, PA, USA, ³Philadelphia FIGHT, Philadelphia, PA, USA, ⁴Philadelphia Prison System, Philadelphia, PA, USA

912 HEALTH LITERACY AND DEMOGRAPHIC DISPARITIES IN HIV-1 VIRAL SUPPRESSION

Peter F Rebeiro¹, Tristan McPherson², Kathryn Goggins¹, Megan M. Turner¹, Sally S. Bebawy¹, Lauren Brinkley-Rubinstein³, Anna K. Person¹, Timothy R. Sterling¹, Sunil Kripalani¹, April C. Pettit¹

¹Vanderbilt Univ, Nashville, TN, USA, ²Columbia Univ, New York, NY, USA, ³Univ of North Carolina at Chapel Hill, Chapel Hill, NC, USA

913 FOOD INSECURITY AND HIV TREATMENT OUTCOMES IN THE WOMEN'S INTERAGENCY HIV STUDY

Sheri Weiser¹, Lila A. Sheira¹, Kartika Palar¹, Tracey Wilson², Lisa Metsch³, Adaora Adimora⁴, Igbo Ofotokun⁵, Eryka Wentz⁶, Phyllis Tien¹, Edward A. Frongillo⁷

¹Univ of California San Francisco, San Francisco, CA, USA, ²SUNY Downstate Med Cntr, Brooklyn, NY, USA, ³Columbia Univ, New York, NY, USA, ⁴Univ of North Carolina at Chapel Hill, Chapel Hill, NC, USA, ⁵Emory Univ, Atlanta, GA, USA, ⁶The Johns Hopkins Univ, Baltimore, MD, USA, ⁷Univ of South Carolina, Columbia, SC, USA

914 HIV STATUS AWARENESS AND ART COVERAGE AMONG FEMALE SEX WORKERS IN JUBA, SOUTH SUDAN

Avi Hakim³, Victoria Achut¹, Alfred Okiria², Alex Bolo³, Jennifer Wesson⁴, Joel Katoro³, Golda Caesar¹, Acaga Taban², Lee Hundley⁵

¹South Sudan Ministry of Hlth, Juba, South Sudan, ²IntraHlth Intl, Juba, South Sudan, ³CDC-South Sudan, Juba, South Sudan, ⁴IntraHlth Intl, Chapel Hill, NC, USA, ⁵Emory Univ, Atlanta, USA

915 "TEST AND TREAT" ANTIRETROVIRAL THERAPY AMONG FEMALE SEX WORKERS IN KAMPALA, UGANDA

Yunia Mayanja, Onesmus Kamacooko, Daniel Bagiire, Gertrude Namale, Janet Seeley

MRC/UVRI Uganda Rsr Unit on AIDS, Entebbe, Uganda

916 VALIDATING SELF-REPORTED USE OF ANTIRETROVIRAL THERAPY IN AGINCOURT, SOUTH AFRICA

Jennifer Manne-Goehler¹, Julia K Rohr², Livia Montana², Guy Harling², Xavier Gomez-Olive³, Pascal Geldsetzer², Ryan Wagner⁴, Stephen Tollman⁵, Kathleen Kahn⁵, Till Baernighausen⁶

¹Beth Israel Deaconess Med Cntr, Boston, MA, USA, ²Harvard Univ, Cambridge, MA, USA, ³Tintswalo Hosp, Acornhoek, South Africa, ⁴Univ of the Witwatersrand, Acornhoek, South Africa, ⁵Univ of the Witwatersrand, Johannesburg, South Africa, ⁶Heidelberg Univ, Heidelberg, Germany

917 REDUCING THE DEMAND FOR VIRAL-LOAD MONITORING IN THE CONTEXT OF TREATMENT FOR ALL

Denise Evans¹, Mouhamed Abdou Salam Mbengue¹, Dorina Onoya¹, Charles Chasela¹, Matthew Fox²

¹Univ of the Witwatersrand, Johannesburg, South Africa, ²Boston Univ, Boston, MA, USA

Poster P-U1 STRATEGIES TO INCREASE HIV TESTING

Poster Hall - 4 EF

2:30 PM - 4:00 PM

956 A PRAGMATIC RANDOMIZED CLINICAL TRIAL OF RAPID HIV SCREENING IN EMERGENCY DEPARTMENTS

Jason Haukoos¹, Michael S. Lyons², Douglas A. White³, Emily Hopkins¹, Meggan Bucossi¹, Sarah Pfeil³, Andrew Ruffner², Danielle Signer⁴, Richard Rothman⁴, for the HIV TESTED Trial Investigators

¹Denver Hlth Med Cntr, Denver, CO, USA, ²Univ of Cincinnati Coll of Med, Cincinnati, OH, USA, ³Highland Hosp, Oakland, CA, USA, ⁴Johns Hopkins Univ, Baltimore, MD, USA

957 OPT-OUT HIV/HCV TESTING AMONG JAIL INMATES

Carolina De La Flor¹, Esmaeil Porsa², Ank E. Nijhawan¹

¹Univ of Texas Southwestern Med Cntr, Dallas, TX, USA, ²Parkland Hlth and Hosp Systems, Dallas, TX, USA

958 STRENGTHENING MALE-PARTNER TESTING IN ANTENATAL CARE: FINDINGS FROM SOUTH AFRICA

Amy M. Medley¹, Nienke van Schaik², Carlos Toledo¹, Makungureyi Mlambo³, Sello Moremi², Kabelo Baloyi², Nompumelelo Khanyile³, Sphindile Magwaza³, Cila Kabongo⁴, John Tumbo⁴

¹CDC, Atlanta, GA, USA, ²Hlth Systems Trust, Durban, South Africa, ³US CDC, Pretoria, South Africa, ⁴Rustenburg Sub-District Office, Rustenburg, South Africa

959 HPTN 071 HOME-BASED TESTING IMPROVES UPTAKE OF HCT AMONG PREGNANT WOMEN IN ZAMBIA

Stable Besa¹, Ab Schaap¹, Mwate J. Chaila¹, S. Floyd², Richard Hayes², Sarah Fidler³, Kwame Shanaube¹, H. Ayles⁴, for the Zambart Study Group

¹Zambart, Lusaka, Zambia, ²London Sch of Hygiene and Trop Med, London, UK, ³Imperial Coll London, London, UK, ⁴London Sch of Hygiene and Trop Med, Lusaka, Zambia

960 DOES HIV TREATMENT AVAILABILITY ENCOURAGE PEOPLE TO LEARN THEIR HIV STATUS?

Ellen Moscoe¹, Jacob Bor², Frank Tanser³, Deenan Pillay⁴, Till Baernighausen⁵

¹Harvard Univ, Boston, MA, USA, ²Boston Univ, Boston, MA, USA, ³Africa Cntr for Pop Hlth, Mtubatuba, South Africa, ⁴Africa Hlth Rsr Inst, Mtubatuba, South Africa, ⁵Heidelberg Univ, Heidelberg, Germany

Poster P-W2 INTERVENTIONS TO IMPROVE THE CARE CASCADE

Poster Hall - 4 EF

2:30 PM - 4:00 PM

997 HIV TESTING, LINKAGE TO CARE, AND VIRAL SUPPRESSION AMONG GAY MEN IN NIGERIA

Habib R. Omari¹, Uchenna Ononaku², Rebecca G. Nowak¹, Ifeanyi Orazulike³, Trevor Crowell⁴, Nicaise Ndembu², Hongjie Liu⁵, Stefan Baral⁶, Man Charurat¹

¹Univ of Maryland, Baltimore, MD, USA, ²Inst of Human Virology Nigeria, Abuja, Nigeria, ³Intl Cntr on Advocacy and Rights to Hlth, Abuja, Nigeria, ⁴US Military HIV Rsr Prog, Bethesda, MD, USA, ⁵Univ of Maryland Coll Park, Coll Park, MD, USA, ⁶The Johns Hopkins Univ, Baltimore, MD, USA

998 ART INITIATION AND RETENTION IN AFTER-HOUR VERSUS DAILY MALE HEALTH CLINICS

Tali Cassidy¹, Amir Shroufi¹, Sarah Jane Steele¹, Morna Cornell², Virginia de Azevedo³, David Binza⁴, **Rodd Gerstenhaber**¹

¹Médecins Sans Frontières, Cape Town, South Africa, ²Univ of Cape Town, Cape Town, South Africa, ³City of Cape Town Dept of Hlth, Cape Town, South Africa, ⁴Western Cape Provincial Dept of Hlth, Cape Town, South Africa

999 THE IMPACT OF CARE NAVIGATORS ON ENGAGEMENT IN HIV CARE IN WESTERN KENYA

Becky L. Genberg¹, Violet Naanyu², Alfred Keter³, Anthony Ngeresa³, Juddy Wachira², Joseph Hogan⁴, Paula Braitstein⁴

¹Brown Univ, Providence, RI, USA, ²Moi Univ, Eldoret, Kenya, ³Academic Model Providing Access to Hlthcare, Eldoret, Kenya, ⁴Univ of Toronto, Toronto, Canada

1000 IMPROVED RETENTION WITH LONGER FOLLOW-UP INTERVALS FOR STABLE PATIENTS IN ZAMBIA

Aaloke Mody¹, Nancy Padian², Nancy Czaicki¹, Monika Roy¹, Carolyn Bolton Moore³, Charles Holmes⁴, Elvin Geng¹, Izukanji Sikazwe⁵

¹Univ of California San Francisco, San Francisco, CA, USA, ²Univ of California Berkeley, Berkeley, CA, USA, ³Univ of Alabama at Birmingham—CIDRZ, Lusaka, Zambia, ⁴The Johns Hopkins Univ—CIDRZ, Bethesda, MD, USA, ⁵Cntr for Infectious Disease Rsr in Zambia, Lusaka, Zambia

1001 EXPERIENCES WITH RETENTION IN CARE AND VIRAL SUPPRESSION IN A PHARMACY REFILL PROGRAM

Arvind Kaimal¹, Barbara Castelnuovo¹, Martha Atwiine¹, Rachel Musomba¹, Maria S. Nabaggala¹, Rosalind P. Ratanshi², Mohammed Lamerde¹

¹Makerere Univ, Kampala, Uganda, ²Univ of Cambridge, Cambridge, UK

1002 VIROLOGIC OUTCOMES WHEN ANTIRETROVIRAL THERAPY IS USED FOR PREVENTION: HPTN 052

Jessica M. Fogel¹, Xinyi C. Zhang², Estelle Piwowar-Manning¹, Nagalingeswaran Kumarasamy³, James G. Hakim⁴, Beatriz Grinsztejn⁵, Ying Q. Chen², Myron S. Cohen⁶, Susan H. Eshleman¹, for the HPTN 052 Study Team

¹The Johns Hopkins Univ Sch of Med, Baltimore, MD, USA, ²Fred Hutchinson Cancer Rsr Cntr, Seattle, WA, USA, ³YRG CARE, Chennai, India, ⁴Univ of Zimbabwe, Harare, Zimbabwe, ⁵Inst de Pesquisa Clinica Evandro Chagas, Rio de Janeiro, Brazil, ⁶Univ of North Carolina at Chapel Hill, Chapel Hill, NC, USA

1003 USERS MAY LACK CONFIDENCE IN ART FOR HIV PREVENTION: A QUALITATIVE ANALYSIS

Monique A. Wyatt¹, Emily E Pisarski¹, Jared Baeten², Renee Heffron², Edith Nakku-Joloba³, Timothy R. Muwonge⁴, Elly T Katabira³, Connie L. Celum², Norma C. Ware¹

¹Harvard Univ, Boston, MA, USA, ²Univ of Washington, Seattle, WA, USA,

³Makerere Univ, Kampala, Uganda, ⁴Infectious Diseases Inst, Kampala, Uganda

1004 UPTAKE AND ADAPTATION OF COMMUNITY ADHERENCE GROUPS IN ZAMBIA

Monika Roy¹, Mpande Mukumbwa-Mwenechanya², Emilie Efronson², Mwansa Lumpa², Anjali Sharma², Izukanji Sikazwe², Nancy Padian³, Carolyn Bolton Moore⁴, Elvin Geng¹, Charles Holmes⁵

¹Univ of California San Francisco, San Francisco, CA, USA, ²Cntr for Infectious Disease Rsr in Zambia, Lusaka, Zambia, ³Univ of California Berkeley, Berkeley, CA, USA, ⁴Cntr for Infectious Disease Rsr in Zambia, Lusaka, Zambia, ⁵Johns Hopkins Univ, Baltimore, MD, USA

1005 ASSESSING RETENTION IN A CLUSTER RANDOMIZED TRIAL TO ACCELERATE ART INITIATION

Richard Katuramu¹, Fred Semitala², Gideon Amanyire¹, Jennifer Namusobya¹, Leatitia Kampiire¹, Jeanna Wallenta³, David Glidden³, Moses R. Kanya², Diane V. Havlir³, Elvin Geng³

¹Makerere Univ Joint AIDS Prog, Kampala, Uganda, ²Makerere Univ Coll of Hlth Scis, Kampala, Uganda, ³Univ of California San Francisco, San Francisco, CA, USA

1006 LOWER RETENTION IN CARE WHEN ART IS INITIATED WITH CD4 $\geq$ 500 CELLS/ML

Isabelle A. Meyer-Andrieux¹, Jim Todd², Robert Keango³, Elisabeth Poulet⁴, Prince Nkhoma³, Elisabeth Szumilin⁴, David Maman⁵, Leon Salumu⁴

¹MSF, Geneva, Switzerland, ²London Sch of Hygiene & Trop Med, London, UK, ³MSF, Lilongwe, Malawi, ⁴MSF, Paris, France, ⁵Epicentre, Cape Town, South Africa

1007 ART INITIATION FOR NEWLY DIAGNOSED PLHIV: IMPLICATIONS FOR TEST & TREAT, SOUTH AFRICA

Anna Larsen¹, Mireille Cheyip¹, Abraham Tesfay², Peter Vranken¹, Henry Fomundam², Anthony Wutoh², Getahun Aynalem¹

¹US CDC, Pretoria, South Africa, ²Howard Univ, Pretoria, South Africa

1008 TREATMENT NEED AND FAST-TRACK ART IN THE BOTSWANA COMBINATION PREVENTION PROJECT

Refeletswe Lebelonyane¹, Lisa A. Mills², Joe Theu¹, Lisa Block³, Michael Kasonde², Tony Chebani¹, Shenaaz el-Halabi¹, Elliot Raizes³, Shahin Lockman⁴, Joseph N. Jarvis²

¹Botswana Ministry of Hlth, Gaborone, Botswana, ²CDC Botswana, Gaborone, Botswana, ³CDC Atlanta, Atlanta, USA, ⁴Harvard Univ, Boston, MA, USA

1009 LINKAGE TO CARE OUTCOMES IN THE BOTSWANA COMBINATION PREVENTION PROJECT

Mary Grace Alwano¹, **Pamela J. Bachanas**², Catherine Motswere¹, Tafireyi Marukutira¹, Baraedi W Sento³, Nokuthula Majingo⁴, Shahin Lockman⁵, Molly Pretorius Holme⁵, Huisheng Wang⁶, Janet Moore¹

¹US CDC, Gaborone, Botswana, ²CDC, Atlanta, GA, USA, ³Tebelopele HIV Testing and Counseling Cntr, Gaborone, Botswana, ⁴Ministry of Hlth, Gaborone, Botswana, ⁵Harvard Univ, Boston, MA, USA, ⁶Northrup Grumman, Atlanta, GA, USA

1010 ART COVERAGE AFTER 2 YEARS OF A UTT INTERVENTION IN ZAMBIA: FINDINGS FROM HPTN071

Sian Floyd¹, Mwelwa Phiri², Ab Schaap², David Macleod¹, Kwame Shanaube², Sam Griffith³, Nulda Beyers⁴, Richard Hayes¹, Sarah Fidler⁵, Helen Ayles⁶

¹London Sch of Hygiene and Trop Med, London, UK, ²Zambart, Lusaka, Zambia, ³FHI 360, Durham, NC, USA, ⁴Desmond Tutu TB Cntr, Western Cape, South Africa, ⁵Imperial Coll London, London, UK, ⁶London Sch of Hygiene and Trop Med, Lusaka, Zambia

1011 REACHING 90-90-90? FINDINGS AFTER 2 YEARS OF HPTN 071 (PopART) INTERVENTION IN ZAMBIA

Richard Hayes¹, S. Floyd¹, Ab Schaap², Kwame Shanaube², Peter Bock³, Sam Griffith⁴, Nulda Beyers³, H. Ayles⁵, Sarah Fidler⁶, for the HPTN 071 (PopART) Study Team

¹London Sch of Hygiene & Trop Med, London, UK, ²Zambart, Lusaka, Zambia, ³Desmond Tutu TB Cntr, Western Cape, South Africa, ⁴FHI 360, Durham, NC, USA, ⁵London Sch of Hygiene & Trop Med, Lusaka, Zambia, ⁶Imperial Coll London, London, UK

1012 HEALTH CARE COVERAGE AND VIRAL SUPPRESSION PRE- AND POST-ACA IMPLEMENTATION

Heather Bradley¹, Joseph Prejean¹, Lindsey Dawson², Antigone Dempsey³, Jennifer Kates², Pamela W. Klein³, R. L. Shouse¹

¹CDC, Atlanta, GA, USA, ²Kaiser Family Fndn, Washington, DC, USA, ³HRSA, HIV/AIDS Bureau, Rockville, MD, USA

1013 HOUSING STABILITY IS ASSOCIATED WITH HIV VIRAL SUPPRESSION IN A HOUSING PLACEMENT RCT

Yaoyu Zhong¹, Ellen Wiewel¹, Vivian L. Towe², Rachel Johnson¹, Laura McAllister-Hollod¹, Joanne Hsu¹, Sarah Braunstein¹, John Rojas¹

¹New York City DHMH, Long Island City, NY, USA, ²RAND Corporation, Arlington, VA, USA

1014 ADVANCING "TASP" USING A MEDICAL-CARE COORDINATION MODEL IN LOS ANGELES COUNTY

Wendy H. Garland, Sonali P. Kulkarni

Los Angeles County, Los Angeles, CA, USA

Poster P-W4 ADVANCED HIV AND LONG-TERM CARE

Poster Hall - 4 EF

2:30 PM - 4:00 PM

1019 FACTORS ASSOCIATED WITH LATE PRESENTATION FOR HIV CARE IN SOUTH AFRICA

Henry Fomundam¹, **Abraham Tesfay**¹, Shelter Mushipe¹, Myriam Mosina¹, Carol Boshie¹, Hanson Tebe¹, Anna Larsen², Mireille Cheyip², Getahun Aynalem², Yogan Pillay³

¹Howard Univ, Pretoria, South Africa, ²US CDC, Pretoria, South Africa, ³South African Natl Dept of Hlth, Pretoria, South Africa

1020 SOUTH AFRICA'S NATIONAL THIRD-LINE ART COHORT: DESCRIPTIVE ANALYSIS

Francesca Conradie¹, Matthew Fox², Michelle A. Moorhouse¹, Gary Maartens³, Willem D. Venter¹, Mahomed-Yunus Moosa⁴, Khadija Jamaloodien⁵

¹Univ of the Witwatersrand, Johannesburg, South Africa, ²Boston Univ, Boston, MA, ³Univ of Cape Town, Cape Town, South Africa, ⁴Univ of KwaZulu-Natal, Durban, South Africa, ⁵South African Natl Dept of Hlth, Pretoria, South Africa

1021 "I WON'T DIE WITH THE CAUSE OF AIDS": 10 YEARS ON ART IN SOUTH AFRICA'S HIV PROGRAM

Cheryl J. Hendrickson¹, Sophie Pascoe¹, Aneesa Moolla¹, Mhairi Maskew¹, Matthew Fox²

¹Univ of the Witwatersrand, Johannesburg, South Africa, ²Boston Univ, Boston, MA

1022 OUTCOMES OF AHI SCREENING AND IMMEDIATE ART INITIATION IN COASTAL KENYA

Edward Sanders¹, Oscar Chirro², Juma Mangi³, Elizabeth Wahome², Matt A. Price⁴, Huub C. Gelderblom⁴, Elisabeth M. van der Elst², Susan M. Graham⁵

¹Kenya Med Rsr Inst, Kilifi, Kenya, ²KEMRI Wellcome Trust Rsr Prog, Kilifi, Kenya, ³Malindi Sub-County Hosp, Malindi, Kenya, ⁴Intl AIDS Vaccine Initiative, New York, NY, USA, ⁵Univ of Washington, Seattle, WA, USA

1023 TEN YEARS OF SUPPORTING SCALE-UP OF HIV CARE AND EXPANSION OF ART IN 4 COUNTRIES

Chloe A. Teasdale, Chunhui Wang, Jessica E. Justman, David Hoos, Mark Hawken, Zenebe Melaku, Antonio Mussa, Wafaa M. El-Sadr, Elaine J. Abrams

ICAP at Columbia Univ, New York, NY, USA

Poster P-X2 COST-EFFECTIVENESS OF HIV TESTING AND SCREENING STRATEGIES**Poster Hall - 4 EF****2:30 PM - 4:00 PM****1028 EFFECTIVENESS AND COST-EFFECTIVENESS OF HIV SCREENING STRATEGIES ACROSS EUROPE**

Guillaume Mabileau¹, Julia Del Amo², Kristi Rüütel³, A. David Paltiel⁴, Liis Lemsalu³, Asunción Díaz², Jesús Martín Fernández⁵, Rochelle P. Walensky⁶, Kenneth Freedberg⁶, Yazdan Yazdanpanah¹

¹INSERM, Paris, France, ²Inst of Hlth Carlos III, Madrid, Spain, ³Natl Inst for Hlth Development, Tallinn, Estonia, ⁴Yale SPH, New Haven, CT, USA, ⁵Univ Rey Juan Carlos, Madrid, Spain, ⁶Massachusetts General Hosp, Boston, MA, USA

1029 COST-EFFECTIVENESS OF HIV SCREENING OF HETEROSEXUALS IN THE UNITED STATES

Angela B. Hutchinson¹, Katherine A. Hicks², Emine Yaylali¹, Emily Tucker³, Evin Jacobson¹, Stephanie L. Sansom¹

¹CDC, Atlanta, GA, USA, ²RTI Hlth Solutions, Rsr Triangle Park, NC, USA, ³Univ of Michigan, Ann Arbor, MI, USA

1030 COST-EFFECTIVENESS OF DIFFERENT DELIVERY APPROACHES FOR HIV SELF-TESTING

Valentina Cambiano¹, Cheryl Johnson², Carmen Figueroa², Paul Revill³, Rachel Baggailey², Elizabeth L. Corbett⁴, Tsitsi Apollo⁵, Karin Hatzold⁶, Frances Cowan⁷, Andrew Phillips¹

¹Univ Coll London, London, UK, ²WHO, Geneva, Switzerland, ³Univ of York, York, UK, ⁴London Sch of Hygiene & Trop Med, London, UK, ⁵Zimbabwe Ministry of Hlth and Child Care, Harare, Zimbabwe, ⁶Pop Services Intl, Harare, Zimbabwe, ⁷Cntr for Sexual Hlth and HIV/AIDS Rsr, Harare, Zimbabwe

1031 THE COST OF NOT RETESTING: HIV MISDIAGNOSIS IN THE ART "TEST-AND-OFFER" ERA

Jeffrey Eaton¹, Cheryl Johnson², Simon Gregson¹

¹Imperial Coll London, London, UK, ²WHO, Geneva, Switzerland

1032 MODELING THE COST-EFFECTIVENESS OF ASSISTED PARTNER NOTIFICATION FOR HIV IN KENYA

Monisha Sharma¹, Jennifer Smith², Carey Farquhar¹, Roger Ying³, Peter Cherutich⁴, Beatrice Wamuti⁵, Matthew R. Golden¹, Felix Abuna⁵, Ruanne V. Barnabas⁶

¹Univ of Washington, Seattle, WA, USA, ²Imperial Coll London, London, UK, ³Weill Cornell Med Coll, New York, NY, USA, ⁴Ministry of Hlth, Nairobi, Kenya, ⁵Kenyatta Natl Hosp, Nairobi, Kenya, ⁶Univ of Washington, Seattle, USA

Poster P-Y1 EMERGING VIRUSES: ZIKA VIRUS Poster Hall - 4 EF

2:30 PM - 4:00 PM

1054 CHARACTERIZATION OF MORE THAN 10,000 ZIKA VIRUS TEST RESULTS IN THE US

Joseph M. Volpe¹, Dajie Luo¹, Arren Fisher¹, Mindy Nye², Barbara Body², Marcia Eisenberg¹

¹LabCorp, Durham, NC, USA, ²LabCorp, Burlington, NC, USA

1055LB ZIKA VIRUS PERSISTENCE IN BODY FLUIDS

Gabriela Paz-Bailey¹, Eli Rosenberg², Katherine Doyle¹, Jorge Munoz-Jordan¹, Gilberto Santiago¹, Liore Klein³, Janice Perez¹, Stephen Waterman¹, Luisa Alvarado⁴, Tyler Sharp¹

¹CDC, Atlanta, GA, USA, ²Emory Univ, Atlanta, GA, USA, ³Caduceus Healthcare Inc, Ponce, PR, USA, ⁴Ponce Univ, Ponce, PR, USA

1056LB NEUROLOGIC CONSEQUENCES OF POSTNATAL ZIKA VIRUS INFECTION IN INFANTS

Maud Mavigner¹, Justin O'Neal², Siddhartha Bhaumik¹, Jakob Habib¹, Cameron Robinson¹, Maria Alvarado³, Xiaodong Zhang³, Jens Wrangert¹, Mehul Suthar², Ann Chahroudi¹

¹Emory Univ, Atlanta, GA, USA, ²Emory Vaccine Center, Atlanta, GA, USA, ³Yerkes Natl Primate Rsr Cntr, Atlanta, GA, USA

1057LB ZIKA VIRUS PROTECTION BY A SINGLE LOW-DOSE NUCLEOSIDE-MODIFIED mRNA VACCINATION

Michael J. Hogan¹, Norbert Pardi¹, Rebecca S. Pelc², Hanne Anderson³, Charles McGee⁴, Michael J. Hope⁵, Mark G. Lewis³, Theodore C. Pierson², Barton F. Haynes⁴, Drew Weissman¹

¹Univ of Pennsylvania, Philadelphia, PA, USA, ²NIAID, Bethesda, MD, USA, ³Bioqual, Inc, Rockville, MD, USA, ⁴Duke Univ, Durham, NC, USA, ⁵Acuitas Therapeutics, Vancouver, BC, Canada

Poster P-A2 VIRUS AND CELL RNA IN HIV REPLICATION**Poster Hall - 4 EF****2:30 PM - 4:00 PM****161 UBP43 (USP18) ABROGATES SAMHD1-MEDIATED RESTRICTION OF HIV-1****Edmund Osei-Kuffour**¹, Kerstin Schott², Dieter Häussinger¹, Philipp A Lang¹, Karl S. Lang³, Renate König⁴, Carsten Münk¹¹Heinrich Heine Univ Hosp, Düsseldorf, Germany, ²Paul Ehrlich Institut, Fed Inst for Vaccines and BioMeds, Düsseldorf, Germany, ³Univ Hosp, Essen, Düsseldorf, Germany, ⁴Paul Ehrlich Institut, Langen, Germany**162 LNCRNA DISCOVERY IN THE HIV REPLICATION CYCLE ADDS A NEW LAYER IN HIV-HOST INTERPLAY****Wim Trypsteen**¹, Pejman Mohammadi², Clarissa Van Hecke¹, Pieter Mestdagh¹, Steve Lefever¹, Pieter De Bleser³, Jo Vandesompele¹, Angela Ciuffi², Ward De Spiegelaere¹, Linos Vandekerckhove¹¹Ghent Univ, Ghent, Belgium, ²Univ of Lausanne, Lausanne, Switzerland, ³Inflammation Rsr Cntr, Flanders Inst of BioTech, Ghent, Belgium**163 SPLICING IN A PANEL OF HIV-1 TRANSMITTED/FOUNDER VIRUSES****Ann Emery**, Ronald Swanstrom

Univ of North Carolina at Chapel Hill, Chapel Hill, NC, USA

164 THE ROLES OF 5 CONSERVED LENTIVIRAL RNA STRUCTURES IN HIV-1 REPLICATION**Yang Liu**¹, Olga A. Nikolaitchik¹, Belete A. Desimmie¹, Vinay K. Pathak¹, Kevin M. Weeks², Wei-Shau Hu¹¹NCI, Frederick, MD, USA, ²Univ of North Carolina at Chapel Hill, Chapel Hill, NC, USA**165 EXPONENTIAL GROWTH OF HIV DEPENDENT ON BURST SIZE BREAKTHROUGH OF THE ALLEE THRESHOLD****Jason M. Hataye**¹, Joseph P. Casazza¹, David R. Ambrozak¹, Takuya Yamamoto², Daniel Douek³, Alan S. Perelson⁴, Richard A. Koup³¹NIH, Bethesda, MD, USA, ²Osaka Univ, Suita, Osaka, Japan, ³NIAID, Bethesda, MD, USA, ⁴Los Alamos Natl Lab, Los Alamos, NM, USA**Poster P-A4 HIV AND HOST DEFENSE****Poster Hall - 4 EF****2:30 PM - 4:00 PM****172 CHARACTERIZING APOBEC3H FUNCTION AND EVOLUTION IN AFRICAN GREEN MONKEYS****Erin I. Garcia**¹, Michael Emerman²¹Univ of Washington, Seattle, WA, USA, ²Fred Hutchinson Cancer Rsr Cntr, Seattle, WA, USA**173 MAPPING THE HIV-1 VIF-CBF β INTERACTION INTERFACE AND IDENTIFICATION OF DETERMINANTS****Belete A. Desimmie**¹, Jessica Smith¹, Hiroshi Matsuo², Wei-Shau Hu¹, Vinay K. Pathak¹¹NCI, Frederick, MD, USA, ²Univ of Minnesota, Minneapolis, MN, USA**174 THE ABILITY OF HIV-1 TO EVADE SAMHD1-MEDIATED RESTRICTION IN MACROPHAGE****Timothy Plitnik**, Mark Sharkey, Mario Stevenson

Univ of Miami, Miami, FL, USA

175 MHC DOWN-MODULATION IN HIV-INFECTED CELLS OCCURS LATE IN THE VIRUS REPLICATIVE CYCLE

Rodrigo Matus Nicodemos, Daniel Douek, Richard A. Koup
Vaccine Rsr Cntr, NIAID, Bethesda, MD, USA

Poster P-B2 VIRAL DIVERSITY

Poster Hall - 4 EF

2:30 PM - 4:00 PM

191 ESTIMATING THE HERITABILITY OF AN HIV-1 TRAIT IN A CLINICAL SETTING

Nadine Bachmann¹, Teja Turk¹, Alex Marzel², Claus Kadelka², Thomas Klimkait³, Vincent Aubert⁴, Jürg Böni², Huldrych F. Günthard², Roger Kouyos²

¹Univ Hosp Zurich, Zurich, Switzerland, ²Univ of Zurich, Zurich, Switzerland,

³Dept of Biomed, Basel, Switzerland, ⁴Univ Hosp Lausanne, Lausanne, Switzerland

192 NGS ANALYSIS OF HIV-1 GROUP O RT RESIDUE 181C PREVALENCE AND EVOLUTION OVER TIME

Marie Leoz¹, Myriam Vezain², Elodie Alessandri¹, Sophie Coutant², Guillemette Unal³, Isabelle Tournier², Francois Simon⁴, **Jean-Christophe Plantier**¹

¹Rouen Univ Hosp, Rouen, France, ²Normandie Univ, Rouen, France, ³COREVIH Haute-Normandie, Rouen, France, ⁴Saint Louis Hosp, Paris, France

193 ANALYSIS OF NEARLY FULL-GENOME HIV-1 SEQUENCES FROM UGANDA: RESULTS FROM PANGEA_HIV

Gonzalo Yebra¹, Deogratius Ssemwanga², Dan Frampton³, Brian Magambo², Nicholas Bbosa², Frederick Lyagoba², Rebecca N. Nsubuga², Pontiano Kaleebu², Andrew Leigh Brown¹, for the PANGEA_HIV Consortium

¹Univ of Edinburgh, Edinburgh, UK, ²MRC Uganda Virus Rsr Inst, Entebbe, Uganda, ³Farr Inst of Hlth Informatics Rsr, London, UK

194 LTR GENETIC DIVERSITY AMONG HIV-2 ARV-NAÏVE PATIENTS IN THE ANRS C05 HIV-2 COHORT

Quentin Le Hingrat¹, Benoit Visseaux¹, Mélanie Bertine¹, Fideline Collin², Florence Damond¹, Olivier Schwartz³, Sophie Matheron¹, Diane Descamps¹, **Charlotte Charpentier**¹, for the ANRS HIV-2 C05 Cohort

¹Bichat Hosp, Paris, France, ²INSERM, Bordeaux, France, ³Inst Pasteur, Paris, France

195 PHYLOGEOGRAPHIC STUDY OF HIV-2 GROUPS A AND B EARLY EPIDEMICS IN WESTERN AFRICA

Benoit Visseaux¹, Stéphane Hué², Florence Damond³, Fideline Collin⁴, Alexandre Storto¹, Genevieve Chene⁴, Sophie Matheron³, Charlotte Charpentier³, Diane Descamps¹, for the French ANRS C05 HIV-2 Cohort

¹Bichat Hosp, Paris, France, ²London Sch of Hygiene & Trop Med, London, UK, ³Bichat—Claude Bernard Hosp, Paris, France, ⁴INSERM, Bordeaux, France

Poster P-C1 PRIMARY HIV INFECTION AND SPREAD

Poster Hall - 4 EF

2:30 PM - 4:00 PM

202 FEW ACUTE HIV-1 SYMPTOMS AND HIGH SET-POINT VIRAL LOAD IN SUBTYPE-C INFECTIONS

Amin S. Hassan¹, Jonathan Hare², Matt A. Price³, Per Bjorkman⁴, Susan Allen⁵, Jill Gilmour², Thumbi Ndung'u⁶, Sarah Rowland-Jones⁷, Eduard Sanders⁸, Joakim Esbjörnsson⁷

¹KEMRI Wellcome Trust Rsr Prog, Kilifi, Kenya, ²Intl AIDS Vaccine Initiative Human Immunol Lab, London, UK, ³Intl AIDS Vaccine Initiative, New York, NY, USA, ⁴Lund Univ, Lund, Sweden, ⁵Emory Univ, Atlanta, GA, USA, ⁶KwaZulu-Natal Rsr Inst for TB and HIV, Durban, South Africa, ⁷Univ of Oxford, Oxford, UK, ⁸Kenya Med Rsr Inst, Kilifi, Kenya

203 GRANULOCYTIC MYELOID-DERIVED SUPPRESSOR CELLS IN PRIMARY HIV INFECTION

Nicola Tumino, Maria Teresa Bilotta, Adriana Ammassari, Annalisa Mondì, Casetti Rita, Veronica Bordoni, Eleonora Cimini, Federico Martini, Chiara Agrati, **Sacchi Alessandra**

Natl Inst for Infectious Diseases Lazzaro Spallanzani, Rome, Italy

204 HIV-1 EXPLOITS THE INTERPLAY BETWEEN EPITHELIAL AND TH17 CELLS FOR DISSEMINATION

Tomas Raul Wiche Salinas¹, Annie Gosselin¹, Dragos Vlad¹, Yuwei Zhang¹, Huicheng Chen¹, Cécile Tremblay¹, Jean-Pierre Routy², Petronela Ancuta¹

¹Cntr de Rsr du Cntr Hosp de l'Univ de Montréal, ²McGill Univ Hlth Cntr, Glen site, Montréal, Canada

205 PLASMA-SOLUBLE CD163 IS SUPPRESSED UPON EARLY ART INITIATION IN ACUTE HIV INFECTION

Michelle L. D'Antoni¹, Somporn Tipsuk², Shelly J. Krebs³, Thep Chalermchai², Duanghathai Suttichom², Nittaya Phanuphak², Victor Valcour⁴, Jintanat Ananworanich³, Lishomwa C. Ndhlovu¹, for the RV254/SEARCH 010, SEARCH013, and SEARCH011 Study Groups

¹Univ of Hawaii, Honolulu, HI, USA, ²SEARCH, South East Asia Rsr Collab with Hawaii, Bangkok, Thailand, ³US Military HIV Rsr Prog, Silver Spring, MD, USA, ⁴Univ of California San Francisco, San Francisco, CA, USA

206 CMV REPLICATION DURING PRIMARY HIV INFECTION IS ASSOCIATED WITH T-CELL DYSFUNCTION

Jennifer M. Dan¹, Antoine Chaillon², Masato Nakazawa¹, Davey M. Smith¹, Milenka Vargas², Rachel Schrier², Susan J. Little², Sara Gianella¹

¹Univ of California San Diego, La Jolla, CA, USA, ²Univ of California San Diego, San Diego, CA, USA

Poster P-C2 HOW DOES THE MICROBIOME AFFECT HIV INFECTION?

Poster Hall - 4 EF 2:30 PM - 4:00 PM

207 IMPACT OF MSM-ASSOCIATED MICROBIOTA ON IMMUNE ACTIVATION AND IN VITRO HIV INFECTION

Sam Li, Abigail Armstrong, Charles P. Neff, Catherine Lozupone, Brent E. Palmer

Univ of Colorado, Aurora, CO, USA

208 FECAL MICROBIOTA FROM HIV-INFECTED SUBJECTS INCREASES IMMUNE ACTIVATION AND INFECTION

Charles P. Neff, Sam Li, Abigail Armstrong, Catherine Lozupone, Brent E. Palmer

Univ of Colorado, Aurora, CO, USA

209 MARAVIROC INHIBITS HIV TARGET T-CELL TRAFFICKING INTO THE FEMALE GENITAL LUMEN

Alison S. Kohlmeier¹, Sean McMaster², Jessica Radzio¹, Mian-er Cong¹, Chuong Dinh¹, Amy Martin¹, Jacob E. Kohlmeier², Gerardo Garcia-Lerma¹
¹CDC, Atlanta, GA, USA, ²Emory Univ, Atlanta, GA, USA

210 INVESTIGATING THE EFFECT OF PH ON CERVICOVAGINAL MUCUS BARRIER PROPERTIES TO HIV

Julie K. Shade, Thuy Hoang, Kevin Delong, Justin Hanes, Richard Cone, Laura Ensign
 The Johns Hopkins Univ, Baltimore, MD, USA

Poster P-C3 HIV INFECTION AND THE MICROBIOME

Poster Hall - 4 EF

2:30 PM - 4:00 PM

211 INFLAMMATORY GUT ILCs ASSOCIATE WITH DYSBIOSIS DURING UNTREATED HIV-1 INFECTION

Stephanie Dillon¹, Daniel N. Frank¹, Gregory Austin¹, Sara Gianella², Moriah Castleman¹, Andrew Cogswell³, Alan Landay³, Edward Barker³, Cara Wilson¹

¹Univ of Colorado Anschutz Med Campus, Aurora, CO, USA, ²Univ of California San Diego, La Jolla, CA, USA, ³Rush Univ, Chicago, IL, USA

212 GUT-MICROBIOTA-RELATED METABOLIC PATHWAYS IN ELITE CONTROLLERS AND HIV PROGRESSORS

Piotr Nowak¹, Javier Rivera², Jan Vesterbacka¹, Marc Noguera-Julian², Kajsa Noyan¹, Maria L. Calle³, Roger Paredes², Anders Sönnernborg⁴

¹Karolinska Inst, Stockholm, Sweden, ²IrsiCaixa Inst for AIDS Rsr, Badalona, Spain, ³Univ of Vic-Central Univ of Catalonia, Barcelona, Spain, ⁴Karolinska Univ Hosp, Stockholm, Sweden

213 CHANGES IN THE ORAL MICROBIOME WITH ART INITIATION

Rachel Presti¹, Scott Handley², Lindsay Droit², Mahmoud Ghannoum³, Mark Jacobson⁴, Caroline H. Shiboski⁴, Jennifer Webster-Cyriaque⁵, Todd Brown⁶, Michael T. Yin⁷, Edgar T. Overton⁸

¹Washington Univ in St. Louis, St. Louis, MO, USA, ²Washington Univ, St. Louis, MO, USA, ³Case Western Reserve Univ, Cleveland, OH, USA, ⁴Univ of California San Francisco, San Francisco, CA, USA, ⁵Univ of North Carolina at Chapel Hill, NC, USA, ⁶The Johns Hopkins Univ, Baltimore, MD, USA, ⁷Columbia Univ, New York, NY, USA, ⁸Univ of Alabama at Birmingham, Birmingham, AL, USA

214 ACUTE HIV INFECTION AND HUMAN GUT MICROBIOME BEFORE AND AFTER ANTIRETROVIRAL THERAPY

Ornella Sortino¹, Nittaya Phanuphak², Nitiya Chomchey³, Yasmine Belkaid⁴, Jacquice Davis⁴, Mariam Quinones⁴, Suteeraporn Pinyakorn⁵, Jintanat Ananworanich², Jason Brenchley⁴, Irini Sereti⁴

¹Leidos Biomed Rsr, Inc, Frederick, MD, USA, ²SEARCH, Thai Red Cross AIDS Rsr Cntr, Bangkok, Thailand, ³SEARCH, Bangkok, Thailand, ⁴NIAID, Bethesda, MD, USA, ⁵Henry M. Jackson Fndn for the Advancement of Military Med, Bethesda, MD, USA

215 TWO-YEAR CART DOES NOT RESTORE PERIPHERAL BLOOD AND INTESTINAL HIV-RELATED DYSBIOSIS

Camilla Tincati, **Giuseppe Ancona**, Esther Merlini, Antonella d'Arminio Monforte, Giulia Marchetti
 Univ of Milan, Milan, Italy

Poster P-D4 CD8 T CELLS: WHERE AND HOW THEY KILL

Poster Hall - 4 EF

2:30 PM - 4:00 PM

266 LYMPH NODE HIV-SPECIFIC CXCR5+ CTLs ARE ASSOCIATED WITH ENHANCED VIRAL CONTROL

Zaza Ndhlovu¹, Funsho Ogunshola², Omolara Baiyegunhi², Nikoshia Mewala², Amber Moodley², Krista Dong¹, Thumbi Ndung'u², Bruce D. Walker¹

¹Ragon Inst of MGH, MIT and Harvard, Cambridge, MA, USA, ²Univ of KwaZulu Natal, Durban, South Africa

267 RESIDENT MEMORY CD8+ T CELLS FORM THE FRONT-LINE DEFENSE IN HIV-INFECTED LYMPH NODES

Marcus Buggert¹, Lalit Beura², Son Nguyen¹, David Canaday³, Ali Naji⁴, Constantinos Petrovas⁵, Gustavo Reyes-Terán⁶, Steven G. Deeks⁷, David Masopust², Michael R. Betts¹

¹Univ of Pennsylvania, Philadelphia, PA, USA, ²Univ of Minnesota, Minneapolis, MN, USA, ³Case Western Reserve Univ, Cleveland, OH, USA, ⁴Hosp of the Univ of Pennsylvania, Philadelphia, PA, USA, ⁵NIH, Bethesda, MD, USA, ⁶Rsr Cntr in Infectious Diseases, Mexico City, Mexico, ⁷Univ of California San Francisco, San Francisco, CA, USA

268 HIV-1 ESCAPE FROM CD8+ CYTOTOXIC T-LYMPHOCYTES DEFINED AT CLONAL RESOLUTION

Aleksandr Gorin, Yushen Du, Ren Sun, Otto Yang
Univ of California Los Angeles, Los Angeles, CA, USA

269 INVESTIGATING THE ROLE OF TCR STRUCTURE IN FUNCTIONAL ACTIVITY OF HIV-SPECIFIC CTLs

Nina C. Flerin¹, Tynisha Glover¹, Huabiao Chen², Jianhua Zheng¹, Harris Goldstein¹

¹Albert Einstein Coll of Med, Bronx, NY, USA, ²Ragon Inst of Massachusetts General Hosp, Cambridge, MA, USA

270 HIV-SPECIFIC CD8 T CELLS IN PERSONS TREATED IN FIEBIG I ACUTE INFECTION WHO STOP ART

Hiroshi Takata¹, Donn Colby², Eugene Kroon², Suteeraporn Pinyakorn¹, Nelson L. Michael³, Merlin L. Robb¹, Jintana Intasan², Jintanat Ananworanich⁴, Lydie Trautmann¹, for the RV411 and RV254/SEARCH010 Study Groups

¹Walter Reed Army Inst of Rsr, Silver Spring, MD, USA, ²SEARCH, The Thai Red Cross AIDS Rsr Cntr, Bangkok, Thailand, ³Walter Reed Army Inst of Rsr, Silver Spring, MD, USA, ⁴US Military HIV Rsr Prog, Silver Springs, MD, USA

271 EARLY CART OF HIV-1 INFECTED SUBJECTS PRESERVES ANTIVIRAL FUNCTION OF CD8+ T CELLS

Miriam Rosas Umbert¹, Beatriz Mothe², Gemma Hancock³, Hongbing Yang³, Christian Manzardo⁴, Josep Coll¹, Christian Brander¹, Lucy Dorrell³

¹IrsiCaixa AIDS Rsr Inst, Badalona, Spain, ²Hosp Germans Trias i Pujol, Badalona, Spain, ³Univ of Oxford, Oxford, UK, ⁴Univ of Barcelona, Barcelona, Spain

272 ROLE OF CTL IN PEDIATRIC HIV CURE STRATEGIES FOLLOWING EARLY WIDESPREAD VIRAL ESCAPE

Ellen M. Leitman¹, Christina F. Thobakgale², M. Azim Ansari¹, Jayna Raghwan¹, Emily Adland¹, Oliver Pybus¹, Paul Kellam³, Philippa C. Matthews⁴, Astrid Gall⁵, Philip J. Goulder¹

¹Univ of Oxford, Oxford, UK, ²Univ of KwaZulu-Natal, Durban, South Africa, ³Kymab Ltd, Babraham Rsr Campus, Cambridge, UK, ⁴Oxford Univ Hosps NGS Trust, John Radcliffe Hosp, Oxford, UK, ⁵Wellcome Trust Sanger Inst, Hinxton, UK

Poster P-D5 NK AND MAIT CELLS**Poster Hall - 4 EF****2:30 PM - 4:00 PM****273 TRAIL-SHORT REDUCES THE CYTOTOXIC CAPACITY OF NK CELLS****Fatma Aboulnasr**, Nathan Cummins, Zilin Nie, Stephen Burke, Andrew Badley*Mayo Clinic, Rochester, MN, USA***274 OF THE TB01 MOTIF KIR GENES, KIR3DS1 PLAYS ROLE IN HIV RESISTANCE & NK CELL FUNCTION****Zahra Kiani**¹, Elise Jackson¹, Xin Yu Zhang¹, Irene Lisovsky¹, Benjamin Tallon¹, Julie Bruneau², Jean-Pierre Routy³, Nicole Bernard⁴¹McGill Univ, Montreal, Quebec, ²Univ of Montreal, Montreal, Canada, ³McGill Univ Hlth Cntr, Glen site, Montréal, Canada, ⁴Rsr Inst, McGill Univ Hlth Cntr, Montreal, Canada**275 NO RECOVERY OF VA7.2 MAIT CELLS AFTER THERAPEUTIC IMMUNISATION PLUS IL-2/GM-CSF/RHGH****Louise Greathead**, Alexander Cocker, Anna Herasimtschuk, Sundhiya Mandalia, Peter Kelleher, Nesrina Imami*Imperial Coll London, London, UK***276 REDUCED CD161 EXPRESSION ON MAIT CELLS IN HIV-INFECTED SUBJECTS WITH IMMUNE FAILURE****Michael L. Freeman**, Michael M. Lederman*Case Western Reserve Univ, Cleveland, OH, USA***Poster P-E3 WHERE IS HIV HIDING?****Poster Hall - 4 EF****2:30 PM - 4:00 PM****288 CCR6+ RECTAL CD4+ T-CELLS ARE A SIGNIFICANT RESERVOIR ON ART****Jenny L. Anderson**¹, Gabriela Khoury¹, Rémi Fromentin², Nicolas Chomont², Ma Somsouk⁴, Wendy Hartogensis³, Peter Bacchetti³, Paul Cameron¹, Steven G. Deeks³, Sharon R. Lewin¹¹Univ of Melbourne, Melbourne, Australia, ²Univ de Montréal, Montréal, Canada, ³Univ of California San Francisco, San Francisco, CA, USA**289 BLOOD CXCR3+ CD4 T CELLS ARE ENRICHED IN INDUCIBLE REPLICATION-COMPETENT HIV****Riddhima Banga**, Francesco Procopio, Matthias Cavassini, Giuseppe Pantaleo, Matthieu Perreau*Lausanne Univ Hosp, Lausanne, Switzerland***290 SKEWED DISTRIBUTION OF HIV-2 RESERVOIR WITH LIMITED INPUT OF CENTRAL MEMORY T CELLS****Assia Samri**¹, Charlotte Charpentier², Mélanie Bertine², Mariama Diallo¹, Sophie Even¹, Sophie Matheron³, Rodolphe Thiébaud⁴, Brigitte Autran⁵, Françoise Brun-Vezinet³, for the ANRS C05 IMMUNOVIR-2 Study Group¹Pierre and Marie Curie Univ, Paris, France, ²INSERM, Paris, France, ³Bichat-Claude Bernard Hosp, Paris, France, ⁴INSERM, Bordeaux, France, ⁵Pitié-Salpêtrière Hosp, Paris, France

291 ALTERED STABILITY OF HIV-INFECTED MEMORY CELLS FOLLOWING VERY EARLY ART

Louise Leyre¹, Jintanat Ananworanich², Claire Vandergeeten³, Eugene Kroon⁴, Nitiya Chomchey⁵, Siriwat Akapirat⁶, Merlin L. Robb², Nittaya Phanuphak⁷, Nicolas Chomont⁸, for the RV254/SEARCH010 and RV304 Study Groups

¹Cntr de Rsr du Cntr Hosp de l'Univ de Montréal, Montréal, Québec, Canada ²US Military HIV Rsr Prog, Silver Spring, MD, USA, ³Vaccine and Gene Therapy Inst, Port St Lucie, FL, USA, ⁴SEARCH, The Thai Red Cross AIDS Rsr Cntr, Bangkok, Thailand, ⁵Armed Forces Rsr Inst of Med Scis, Bangkok, Thailand, ⁶Thai Red Cross AIDS Rsr Cntr, Bangkok, Thailand, ⁷Univ de Montréal, Montreal, QC, Canada

Poster P-E6 LATENCY REVERSAL

Poster Hall - 4 EF

2:30 PM - 4:00 PM

306 MURINE MODEL TO PREDICT VIRAL REBOUND IN HIV+ ALLOTRANSPLANTED SUBJECTS

Maria Salgado¹, Mi Kwon², Cristina Galvez Celada¹, Monique Nijhuis³, Cristina Vilaplana⁴, Alessandra Bandera⁵, Annemarie Wensing³, Jose Luis Diez², Javier Martinez-Picado¹, for the IciStem Consortium

¹IrsiCaixa AIDS Rsr Inst, Badalona, Spain, ²Gregorio Maranon Hosp, Madrid, Spain, ³Univ Med Cntr Utrecht, Utrecht, Netherlands, ⁴Inst for Hlth Sci Rsr Germans Trias i Pujol, Badalona, Spain, ⁵Univ of Milano-Bicocca, Milan, Italy

307 ROLE OF HIGH-MOBILITY GROUP A1 (HMGA1) GENE EXPRESSION IN REACTIVATION OF LATENT HIV

Hosiana Abewe¹, Amey Mukim², Savitha Deshmukh², Celsa A. Spina², Douglas D. Richman¹, Nadejda Beliakova-Bethell²

¹Univ of California San Diego, La Jolla, CA, USA, ²VA San Diego Hlthcare System, San Diego, CA, USA

308 INVESTIGATING THE MECHANISMS OF HIV-1 LATENCY BY HIGH-RESOLUTION MICROSCOPY

Luca Sardo¹, Angel Lin¹, Svetlana Khakhina¹, Lucas Beckman¹, Weam Elbezanti¹, Tara Jaison¹, Harshad D. Vishwasrao², Hari Shroff², Christopher J. Janetopoulos¹, Zachary A. Klase¹

¹Univ of the Scis, Philadelphia, PA, USA, ²NIH, Bethesda, MD, USA

309 CURRENT LATENCY REVERSING AGENTS REACTIVATE A SMALL FRACTION OF LATENT PROVIRUSES

Anthony R. Cillo¹, Joshua C. Cyktor¹, **Michele Sobolewski**¹, Taylor Buckley¹, Joseph Hesselgesser², Tomas Cihlar², Romas Geleziunas², Jeffrey Murry², John W. Mellors¹

¹Univ of Pittsburgh, Pittsburgh, PA, USA, ²Gilead Scis, Foster City, CA, USA

310 LATENCY REVERSAL USING SPECIFIC ANTIGENS INCLUDING THOSE OF HIV-1

Thomas Vollbrecht¹, Aaron Angerstein², John Guatelli²

¹Veterans Med Rsr Fndn, San Diego, CA, USA, ²Univ of California San Diego, La Jolla, CA, USA

311 IDENTIFICATION OF LRAS ACTIVE IN DIVERSE PRIMARY T-CELL MODELS OF HIV LATENCY

Richard Barnard¹, Jenny L. Anderson², Daria Hazuda¹, Sharon R. Lewin², Laura J. Martins³, Mauricio Montano⁴, Vicente Planelles³, Celsa A. Spina⁵, for the CARE Collaboratory

¹Merck & Co, Inc, West Point, PA, USA, ²The Univ of Melbourne, Melbourne, Australia, ³Univ of Utah, Salt Lake City, UT, USA, ⁴Univ of California San Francisco, San Francisco, CA, USA, ⁵VA San Diego Hlthcare System, San Diego, CA, USA

- 312 STIMULATING THE RIG-I PATHWAY TO KILL LATENT HIV-INFECTED CELLS USING ACITRETIN**
Peilin Li¹, Philipp Kaiser¹, Harry Lampiris¹, Peggy Kim², Steven A. Yukl¹, Diane V Havlir³, Warner C. Greene⁴, Joseph K. Wong¹
¹San Francisco VA Med Cntr/Univ of California San Francisco, San Francisco, CA, USA, ²San Francisco VA Med Cntr, San Francisco, CA, USA, ³San Francisco General Hosp, Univ of California San Francisco, San Francisco, CA, USA, ⁴Gladstone Inst of Virology and Immunol, San Francisco, CA, USA
- 313 TLR7 AGONIST GS-986 MARKEDLY ACTIVATES T & B CELLS FROM ART-SUPPRESSED DONORS**
Joshua C. Cyktor¹, Anthony R. Cillo¹, John Bui¹, Joseph Hesselgesser², Tomas Cihlar², Jeffrey Murry², John Mellors¹
¹Univ of Pittsburgh, Pittsburgh, PA, USA, ²Gilead Scis, Foster City, PA, USA
- 314 TLR9 AGONIST TRIGGERS POTENT INTESTINAL ANTIVIRAL RESPONSE IN HIV+ INDIVIDUALS ON ART**
Astrid R. Krarup¹, Mariane H. Schleimann¹, Line K. Vibholm¹, Mohamed Abdel Mohsen², Anders K. Dige¹, Lars Østergaard¹, Thomas Benfield³, Satish K. Pillai², Ole S. Søgaard¹, Paul W. Denton¹
¹Aarhus Univ Hosp, Aarhus, Denmark, ²Blood Systems Rsr Inst, San Francisco, CA, USA, ³Copenhagen Univ Hosp, Hvidovre, Denmark
- 315 SMALL-MOLECULE INHIBITION OF INTRINSIC STRESS PATHWAYS REDUCES HIV TRANSCRIPTION**
Andrew Timmons, Robert Siliciano, Cynthia K. Bullen
 The Johns Hopkins Hosp, Baltimore, MD, USA
- 316 NNRTIS DECREASE HIV-1 PRODUCTION FROM RCD4+ T CELLS FOLLOWING LATENCY REVERSAL**
Jennifer M. Zerbato¹, Gilda Tachedjian², Nicolas Sluis-Cremer¹
¹Univ of Pittsburgh, Pittsburgh, PA, USA, ²Burnet Inst, Melbourne, Australia

Poster P-E9 NEW TREATMENTS TO MODIFY THE HIV RESERVOIR

Poster Hall - 4 EF

2:30 PM - 4:00 PM

- 331 ENHANCEMENT OF THE CD4 CHIMERIC ANTIGEN RECEPTOR AGAINST HIV INFECTION**
 Anjie Zhen, **Mayra A. Carrillo**, Valerie Rezek, Scott G. Kitchen
 Univ of California Los Angeles, Los Angeles, CA, USA
- 332 HEMATOPOIETIC STEM-CELL-BASED CHIMERIC ANTIGEN RECEPTOR THERAPY FOR HIV INFECTION**
Anjie Zhen¹, Christopher Peterson², Mayra A. Carrillo¹, Valerie Rezek¹, Masakazu Kamata¹, Jerome Zack¹, Hans-Peter Kiem², Scott G. Kitchen¹
¹Univ of California Los Angeles, Los Angeles, CA, USA, ²Fred Hutchinson Cancer Rsr Cntr, Seattle, WA, USA
- 333 LENTIVIRAL DENDRITIC CELL VACCINE RAISES PROTECTIVE CTLs AND TARGETS LATENT HIV**
Thomas D. Norton¹, Anjie Zhen², Takuya Tada¹, Scott G. Kitchen², Nathaniel R. Landau¹
¹New York Univ, New York, NY, USA, ²Univ of California Los Angeles, Los Angeles, CA, USA

334 SELF-ACTIVATING VECTORS THAT EXPRESS VIF-RESISTANT APOBEC3G FOR HIV-1 GENE THERAPY

Krista Delviks-Frankenberry¹, Daniel Ackerman¹, Nina Timberlake², Maria Hamscher¹, Olga A Nikolaitchik¹, Wei-Shau Hu¹, Bruce E. Torbett², Vinay K. Pathak¹

¹NCI, Frederick, MD, USA, ²The Scripps Rsr Inst, La Jolla, CA, USA

335 ENGINEERING HIV-RESISTANT ANTI-HIV CHIMERIC ANTIGEN RECEPTOR (CAR) T CELLS

Malika Hale¹, Taylor Mesojednik¹, Guillermo Romano Ibarra¹, Jaya Sahni¹, Bryan Sands¹, Karen Sommer¹, Andrew M. Scharenberg², David J. Rawlings², Thor Wagner²

¹Seattle Children's Rsr Inst, Seattle, WA, USA, ²Univ of Washington, Seattle, WA, USA

336 VIRAL OUTCOMES AFTER ANALYTIC TREATMENT INTERRUPTIONS TO EVALUATE A FUNCTIONAL CURE

Lorna Leal¹, Constanza Lucero¹, Montserrat Plana¹, Nuria Climent¹, Esteban Martinez¹, Pedro Castro¹, Beatriz Mothe², Juan Carlos López-Bernaldo³, Jose M. Gatell¹, Felipe Garcia¹

¹IDIBAPS, Barcelona, Spain, ²IrsiCaixa Inst for AIDS Rsr, Badalona, Spain, ³Hosp Gregorio Marañón, Madrid, Spain

337 A BISPECIFIC APPROACH FOR TARGETING IMRS IN HIV-1 LATENCY

Debbie S. Ruelas¹, Yanyan Zheng¹, Fahimeh Raoufi¹, Laurence Fayadat-Dilman¹, Yuan Li², Julie Strizki², Richard Barnard², Mohammad Tabrizifard¹, Daniel Gorman¹

¹Merck & Co, Palo Alto, CA, USA, ²Merck & Co, Inc, West Point, PA, USA

338LB TLR7 AGONIST TREATMENT OF SIV+ MONKEYS ON ART CAN LEAD TO COMPLETE VIRAL REMISSION

So-Yon Lim¹, Christa Osuna¹, Joseph Hesselgesser², Alison Hill³, Michael D. Miller², Tomas Cihlar², Romas Geleziunas², William Lee², **James Whitney**¹

¹Beth Israel Deaconess Med Cntr, Boston, MA, USA, ²Gilead Scis, Inc, Foster City, PA, USA, ³Boston College, Chestnut Hill, MA, USA

Poster P-F2 CEREBROVASCULAR EVENTS AND HIV

Poster Hall - 4 EF

2:30 PM - 4:00 PM

346 THE ROLE OF PRESTROKE IMMUNE STATUS IN STROKE MECHANISMS IN HIV+ INDIVIDUALS

Jose Gutierrez¹, Camilla Ingrid Hatleberg², Henry W. Evans¹, Michael T. Yin¹

¹Columbia Univ, New York, NY, USA, ²CHIP, Copenhagen, Denmark

347 TYPES OF ISCHEMIC STROKES AMONG HIV-INFECTED INDIVIDUALS ACROSS THE UNITED STATES

Heidi M. Crane¹, Robin M. Nance¹, Felicia C. Chow², Christina Marra³, Joseph Zunt¹, Emily Ho¹, Richard D. Moore⁴, Daniel Drozd¹, Mari Kitahata¹, David Tirschwell¹

¹Univ of Washington, Seattle, WA, USA, ²Univ of California San Francisco, San Francisco, CA, USA, ³Harborview Med Cntr, Seattle, WA, USA, ⁴The Johns Hopkins Univ, Baltimore, MD, USA

348 ASSOCIATION OF HIV AND OPPORTUNISTIC INFECTIONS WITH INCIDENT STROKE

Yung-Feng Yen¹, I-An Jen², Yi-Ming A. Chen³

¹Taipei City Hosp, Taipei, Taiwan, ²Natl Yang-Ming Univ, Taipei, Taiwan, ³Kaohsiung Med Univ, Kaohsiung, Taiwan

Poster P-F4 CNS RESERVOIRS/ESCAPE**Poster Hall - 4 EF****2:30 PM - 4:00 PM**

- 363 CNS MONITORING OF CART INTERRUPTION IN INDIVIDUALS TREATED DURING FIEBIG I ACUTE HIV**
 Phillip Chan¹, Donn Colby¹, Victor Valcour², Napapon Sailasuta³, Shelly J. Krebs⁴, Linda Jagodzinski⁴, Robert Paul⁵, Jintanat Ananworanich⁴, **Serena Spudich**⁶, for the RV411 and RV254/SEARCH 010 Study Groups
¹SEARCH, The Thai Red Cross AIDS Rsr Cntr, Bangkok, Thailand, ²Univ of California San Francisco, San Francisco, USA, ³Univ of Hawaii, Honolulu, HI, USA, ⁴US Military HIV Rsr Prog, Silver Spring, MD, USA, ⁵Univ of Missouri—St. Louis, St. Louis, MO, USA, ⁶Yale Univ, New Haven, CT, USA
- 364 CSF HIV-1 COMPARTMENTALIZATION BY ENV DEEP SEQUENCING: RELATION TO NEURONAL INJURY**
Richard W. Price¹, Magnus Gisslén², Laura P. Kincer³, Ean Spielvogel³, Amy Lin¹, Jaser Eusuff⁴, Serena Spudich⁵, Ronald Swanstrom³, Sarah Beth Joseph³, for the THINC Study Group
¹Univ of California San Francisco, San Francisco, CA, USA, ²Sahlgrenska Academy at the Univ of Gothenburg, Gothenburg, Sweden, ³Univ of North Carolina at Chapel Hill, Chapel Hill, NC, USA, ⁴Univ of California Berkeley, Berkeley, CA, USA, ⁵Yale Univ, New Haven, CT, USA
- 365 EARLY EMERGENCE OF MAC-TROPIC HIV VARIANTS IN BRAIN OF PATIENTS WITH NORMAL NEUROLOGY**
Maria Paz Gonzalez-Perez, Paul P. Peters, Paul Clapham
 Univ of Massachusetts, Worcester, MA, USA
- 366 BLOOD BRAIN BARRIER FUNCTION, ART NEUROACTIVITY, AND RISK OF CSF HIV ESCAPE**
Carmela Pinnetti, Massimo Tempestilli, Patrizia Lorenzini, Valentina Fedele, Stefania Carta, Valentina Mazzotta, Chiara Agrati, Adriana Ammassari, Carlo F. Perno, Andrea Antinori
 Natl Inst for Infectious Diseases, Rome, Italy
- 367 SEX-BASED DIFFERENCES IN HIV RESERVOIRS IN BRAIN AND NEUROCOGNITION**
Michelli Faria de Oliveira¹, Masato Nakazawa¹, Andrej Vitomirov¹, Mitchell Zhao¹, Ben Gouaux², David Moore², Ronald J. Ellis², Davey M. Smith¹, Sara Gianella¹
¹Univ of California San Diego, La Jolla, CA, USA, ²Univ of California San Diego, San Diego, CA, USA
- 368 THE EFFECT OF CRYPTOCOCCAL MENINGITIS ON THE HIV RESERVOIR IN THE CNS**
Maura Manion¹, Camille Lange², Kathy Huppler Hullsiek³, Brandon Keele⁴, Helene Highbarger⁵, David Meya⁶, Frank Maldarelli⁴, David Boulware³, Irini Sereti¹
¹NIAID, Bethesda, MD, USA, ²NIH, Frederick, MD, USA, ³Univ of Minnesota, Minneapolis, MN, USA, ⁴NCI, Frederick, MD, USA, ⁵Leidos Biomed, Inc, Frederick, MD, USA, ⁶Makerere Univ, Kampala, Uganda
- 369 HIV CNS COMPARTMENTALIZATION AMONG SUBJECTS WITH HIV-1 SUBTYPES G AND CRF02_AG**
Olubusuyi M. Adewumi¹, Elena Dukhovlina², Nathan Shehu³, Shuntai Zhou², Maxwell Akanbi³, Babafemi Taiwo⁴, Adesola Ogunniyi¹, Kevin Robertson², Ronald Swanstrom²
¹Univ of Ibadan, Ibadan, Nigeria, ²Univ of North Carolina at Chapel Hill, Chapel Hill, NC, USA, ³Jos Univ Teaching Hosp, Jos, Nigeria, ⁴Northwestern Univ Feinberg Sch of Med, Chicago, IL, USA

- 370 EXPRESSION OF UNIQUE AND DIVERSE HIV VARIANTS IN CEREBROSPINAL FLUID DURING ART**
Jeffrey A. Johnson¹, Sarah Malik¹, Sam Nightingale², Jin-fen Li¹, Apostolos Beloukas², Tom Solomon², Saye Khoo³, Anna Maria Geretti²
¹CDC, Atlanta, GA, USA, ²Univ of Liverpool, Liverpool, UK, ³Univ of Liverpool Inst of Translational Med, Liverpool, UK

- 371 CSF ESCAPE IN TREATED HIV INFECTION SHOWS X4 TROPISM AND DEFECTIVE VIRAL SEQUENCES**
Bryan Smith¹, Guanhan Li¹, Hiromi Imamichi², Brad Sherman², Manori De Alwis¹, Govind Nair¹, Joseph Snow¹, Daniel S. Reich¹, H. Clifford Lane³, Avindra Nath¹
¹NIH, Bethesda, MD, USA, ²NIH, Frederick, MD, USA, ³NIAID, Bethesda, MD, USA

- 372 NEUROPSYCHIATRIC ADVERSE EVENTS ASSOCIATED WITH INTEGRASE STRAND TRANSFER INHIBITORS**
Prabha Viswanathan, Elande Baro, Guoxing Soon, Adam Sherwat, Kimberly Struble
 FDA, Silver Spring, MD, USA

Poster P-F8 NEUROIMAGING AND ASSOCIATED BIOMARKERS

Poster Hall - 4 EF

2:30 PM - 4:00 PM

- 394 MRS MEASURES ASSOCIATE WITH IMPAIRED NEUROPSYCHOLOGICAL PERFORMANCE IN ACUTE HIV**
Joanna Hellmuth¹, James L. Fletcher², Victor Valcour¹, Napapon Sailasuta³, Somporn Tipsuk², Jintanat Ananworanich⁴, Bonnie Slike⁴, Robert Paul⁵, Serena Spudich⁶, for the SEARCH 010/RV254 Study Group
¹Univ of California San Francisco, San Francisco, CA, USA, ²SEARCH, Bangkok, Thailand, ³Univ of Hawaii, Honolulu, HI, USA ⁴US Military HIV Rsr Prog, Silver Spring, MD, USA, ⁵Univ of Missouri-St. Louis, St. Louis, MO, USA, ⁶Yale Univ, New Haven, USA

- 395 CIRCULATING HIV DNA IS ASSOCIATED WITH WEAKER INTRINSIC BRAIN CONNECTIVITY**
Kalpna J. Kallianpur¹, Bruce Shiramizu¹, Melissa Agsalda-Garcia¹, Robert Paul², Cecilia Shikuma¹, Gregory Kirk³, Rasmus Birn³
¹Univ of Hawaii—Manoa, Honolulu, HI, USA, ²Univ of Missouri St. Louis, St. Louis, MO, USA, ³Univ of Wisconsin Madison, Madison, WI, USA

- 396 RETINAL LAYERS THICKNESS AS MARKER OF ACCELERATED NEUROCOGNITIVE DECAY IN HIV DISEASE**
Chiara Resnati¹, Alessandro Invernizzi¹, Alessandra Acquistapace¹, Marta Ferrari¹, Sara Boichicchio¹, Valentina Leta¹, Cristina Gervasoni², Stefano Rusconi¹, Simone Pomati², Agostino Riva²
¹Univ of Milan, Milano, Italy, ²Luigi Sacco Univ Hosp, Milano, Italy

- 397 LONGITUDINAL ASSESSMENT OF REGIONALLY SPECIFIC BRAIN VOLUMES IN TREATED HIV+ PATIENTS**
Ryan Sanford¹, Lesley K. Fellows¹, Louis Collins¹, Beau M. Ances²
¹Montreal Neuro Inst, Montreal, Canada, ²Washington Univ, St. Louis, MO, USA

- 398 BRAIN HIV LATENCY LEADS TO A COMPLEX PATTERN OF NEUROCHEMICAL DYSREGULATION**
 Lucette Cysique¹, Michael V. Tobia², **Thomas Gates**³, Lauriane Juge², Simon Jones⁴, Caroline Rae², Bruce Brew⁴
¹NeuroSci Rsr Australia, Randwick, Australia, ²Univ of New South Wales, Randwick, Australia, ³St. Vincent's Hosp, Sydney, Australia, ⁴Univ of New South Wales, Darlinghurst, Australia

- 399 CEREBRAL ENDOTHELIAL FUNCTION CORRELATES WITH PERFORMANCE ON COGNITIVE SCREENING TEST**
Natasha Mehta¹, Yanling Li², Yinghuan Hu², Huanling Wang², Weihai Xu², Taisheng Li², Felicia C Chow¹
¹Univ of California San Francisco, San Francisco, CA, USA, ²Peking Union Med Coll Hosp, Beijing, China
- 400 RANDOMIZED TRIAL OF BRAIN FUNCTION CHANGE AFTER STARTING TDF/FTC+ATV/R OR ABC/3TC+EFV**
Ignacio Pérez-Valero¹, Alicia Gonzalez-Baeza¹, Lucia Bailon¹, Belén Alejos², Rocio Montejano¹, Victor Hontanón¹, Helena Melero³, Marisa Montes¹, Carmen Bayón¹, Jose R. Arribas¹
¹Hosp Univ La Paz, Madrid, Spain, ²Instituto de Salud Carlos III, Madrid, Spain, ³Univ Rey Juan Carlos, Alcorcón, Spain
- 401 RESTING CEREBRAL BLOOD FLOW AND RISKY DECISION-MAKING IN HIV+ AND HIV- YOUNG ADULTS**
Robert S. Smith¹, Anika Guha², Aaron Tanenbaum¹, Florin Vaida³, Robert Paul⁴, Beau M. Ances¹
¹Washington Univ in Saint Louis, Saint Louis, MO, USA, ²Univ of California Los Angeles, Los Angeles, CA, USA, ³Univ of California San Diego, San Diego, USA, ⁴Univ of Missouri—St. Louis, St. Louis, MO, USA
- 402 MRI REVEALS ENLARGED INTRACRANIAL ARTERIES IN HIV- ASSOCIATED NEUROCOGNITIVE DISORDER**
Govind Nair, Angela Summers, Joseph Snow, Daniel S. Reich, Sally Steinbach, Paba M. DeAlwis, Bryan Smith, Avindra Nath
NIH, Bethesda, MD, USA
- 403 WORKING MEMORY IN HIV+ YOUNG ADULTS: FUNCTIONAL IMAGING USING MAGNETOENCEPHALOGRAPHY**
Sharon Nichols¹, Ashley R. Swan², Annemarie A. Quinto², Chris Fennema-Notestine², Mingxiong Huang²
¹Univ of California San Diego, La Jolla, CA, USA, ²Univ of California San Diego, San Diego, CA, USA

Poster P-G2 DRUG-DRUG INTERACTIONS

Poster Hall - 4 EF

2:30 PM - 4:00 PM

- 409 COBICISTAT, BUT NOT RITONAVIR, INCREASES DABIGATRAN EXPOSURE**
Kristina M. Brooks¹, Lori A. Gordon², Scott Penzak³, Anela Kellogg⁴, Maryellen McManus¹, Khanh Nghiem¹, Jay Lozier¹, Jomy M. George¹, Colleen Hadigan⁵, Parag Kumar¹
¹NIH, Bethesda, MD, USA, ²Xavier Univ of Louisiana, New Orleans, LA, USA, ³Univ of North Texas, Fort Worth, TX, USA, ⁴Leidos Biomed Rsr, Inc, Bethesda, MD, USA, ⁵NIAID, Bethesda, MD, USA
- 409a EARLY TERMINATION OF A PK STUDY BETWEEN DOLUTEGRAVIR AND WEEKLY ISONIAZID/RIFAPENTINE**
Kristina M. Brooks¹, Alice K. Pau², Jomy M. George¹, Raul Alfaro¹, Anela Kellogg³, Mary McLaughlin², Maryellen McManus¹, Colleen Hadigan², Joseph A. Kovacs¹, Parag Kumar¹
¹NIH Clinical Center, Bethesda, MD, USA, ²NIAID, NIH, Bethesda, MD, USA, ³Leidos Biomedical Research, Inc, Bethesda, MD, USA

- 410 INCREASED DOLUTEGRAVIR EXPOSURE IN HIV PATIENTS SWITCHED FROM RITONAVIR TO COBICISTAT**
Cristina Gervasoni, Agostino Riva, Amedeo Capetti, Valeria Cozzi, Giuliano Rizzardini, Massimo Galli, Emilio Clementi, Dario Cattaneo
Luigi Sacco Univ Hosp, Milan, Italy
- 411 EFFECT OF COBICISTAT ON TENOFOVIR PLASMA CONCENTRATION: A CROSS-SECTIONAL STUDY**
Cristina Gervasoni¹, Davide Minisci¹, Sara Baldelli¹, Cristina Mazzali², Andrea Giacomelli¹, Laura Milazzo¹, Paola Meraviglia¹, Emilio Clementi¹, Massimo Galli¹, Dario Cattaneo¹
¹*Luigi Sacco Univ Hosp, Milano, Italy*, ²*Politecnico di Milano, Italy, Milano, Italy*
- 412 MULTIPLE-DOSE TREATMENT WITH RITONAVIR INCREASES THE EXPOSURE OF DORAVIRINE**
Sauzanne Khalilieh¹, Matt Anderson¹, Tine Laethem², Kelly Yee¹, Rosa Sanchez¹, Li Fan¹, Monali Sura¹, Luc Van Bortel³, Greit Van Lancker³, Marian Iwamoto¹
¹*Merck & Co, Inc, Kenilworth, NJ, USA*, ²*MSD Belgium, Brussels, Belgium*, ³*Ghent Univ Hosp, Ghent, Belgium*
- 413 GLECAPREVIR AND PIBRENTASVIR INTERACTIONS WITH COMBINATION ANTIRETROVIRAL REGIMENS**
Matthew P. Kosloski, Sandeep Dutta, Rolando M. Viani, Xin Qi, Roger Trinh, Andrew Campbell, Wei Liu
AbbVie, North Chicago, IL, USA
- 414 EFFECT OF LOW-DOSE METHOTREXATE ON THE PHARMACOKINETICS OF TENOFOVIR**
David Gingich¹, Heather Ribaudo², Amy Kantor², James H. Stein³, Judith S. Carrier⁴, Priscilla Hsue¹, Francesca Aweeka¹
¹*Univ of California San Francisco, San Francisco, CA, USA*, ²*Harvard Univ, Boston, MA, USA*, ³*Univ of Wisconsin, Madison, WI, USA*, ⁴*Univ of California Los Angeles, Los Angeles, CA, USA*

Poster P-G4 EXPOSURE-RESPONSE RELATIONSHIPS OF ANTIRETROVIRAL DRUGS

Poster Hall - 4 EF

2:30 PM - 4:00 PM

- 423 AN IN VITRO—IN SILICO STUDY OF REDUCED-DOSE EFAVIRENZ INTERACTION WITH LEVONORGESTREL**
Owain Roberts¹, Paul Curley¹, Rajith Kumar Reddy Rajoli¹, Darren M. Moss¹, Mohammed Lamorde³, Andrew Owen¹, Kimberly K. Scarsi³, Marco Siccardi¹
¹*Univ of Liverpool, Liverpool, UK*, ²*Infectious Diseases Inst Ltd, Kampala, Uganda*, ³*Univ of Nebraska, Omaha, NE, USA*
- 424 PHARMACOKINETICS, SAFETY & EFFICACY OF E/C/F/TAF IN HIV-INFECTED CHILDREN (6-12 YRS)**
Aditya Gaur¹, Eva Natukunda², Pope Kosalarksa³, Jag Batra⁴, Natella Rakhmanina⁵, Amy Coluci⁶, Yongwu Shao⁶, Heather Zhang⁶, Cheryl Pikora⁶, Martin Rhee⁶
¹*St. Jude Children's Rsr Hosp, Memphis, TN, USA*, ²*Joint Clinical Rsr Cntr, Kampala, Uganda*, ³*Khon Kaen Univ, Khon Kaen, Thailand*, ⁴*Miller Children's Hosp, Long Beach, CA, USA*, ⁵*Children's Rsr Inst—Children's Natl Med Cntr, Washington, DC, USA*, ⁶*Gilead Scis, Inc, Foster City, CA, USA*

425 PHARMACOKINETICS, SAFETY, AND EFFICACY OF ATV OR DRV WITH COBI IN ADOLESCENTS

Elizabeth J. McFarland¹, Gloria P. Heresi², Jag Batra³, Torsak Bunupuradah⁴, Kulkanya Chokeyhaibulkit⁵, Pope Kosalaraksa⁶, Pamela Wong⁷, Heather Zhang⁷, Cheryl Pikora⁷, Martin Rhee⁷

¹Univ of Colorado, Aurora, CO, USA, ²Univ of Texas, Houston, TX, USA, ³Miller Children's Hosp, Long Beach, CA, USA, ⁴HIV-NAT, Thai Red Cross AIDS Rsr, Bangkok, Thailand, ⁵Mahidol Univ, Bangkok, Thailand, ⁶Khon Kaen Univ, Khon Kaen, Thailand, ⁷Gilead Scis, Inc, Foster City, CA, USA

426 EFFECT OF DOLUTEGRAVIR PLASMA CONCENTRATION ON CENTRAL NERVOUS SYSTEM SIDE EFFECTS

Hiroki Yagura¹, Dai Watanabe¹, Takao Nakauchi¹, Kosuke Tomishima¹, Daisuke Kasai¹, Yasuharu Nishida¹, Munehiro Yoshino², Tomoko Uehira¹, Kunio Yamazaki¹, Takuma Shirasaka¹

¹Natl Hosp, Osaka, Japan, ²Natl Hosp Org Osaka Minami Med Cntr, Osaka, Japan

427 EVALUATION OF RPV/FTC/TAF EXPOSURE-EFFICACY AND EXPOSURE-SAFETY RELATIONSHIPS

Sophia R. Majeed¹, Kavitha Bhasi¹, Yongwu Shao¹, William Garner¹, Jenna Scott¹, Carlos P. Ruixo², Devi SenGupta¹, Huyen Cao¹, Brian P. Kearney¹, Joseph M. Custodio¹

¹Gilead Scis, Foster City, CA, USA, ²Janssen Rsr and Development, Beerse, Belgium

Poster P-H1 I WANT A NEW DRUG**Poster Hall - 4 EF****2:30 PM - 4:00 PM****433 NOVEL HIV PI WITH HIGH RESISTANCE BARRIER AND POTENTIAL FOR UNBOOSTED QD ORAL DOSING**

John O. Link, Darryl Kato, Michael Moore, Andrew Mulato, Bernard Murray, Judy Mwangi, Nathan D. Shapiro, George Stepan, Yujin Wang, Zheng-Yu Yang

Gilead Scis, Inc, Foster City, CA, USA

434 NOVEL NON-CATALYTIC SITE INTEGRASE INHIBITOR WITH IMPROVED RESISTANCE PROFILE

Michael L. Mitchell, Mini Balakrishnan, Gediminas Brizgys, Ruby Cai, Eric Lansdon, Andrew Mulato, Mark Osier, Jianhong Wang, Helen Yu, Roman Sakowicz

Gilead Scis, Inc, Foster City, CA, USA

435 MK-8591 CONCENTRATIONS AT SITES OF HIV TRANSMISSION AND REPLICATION

Jay Grobler, Carolyn McHale, Carol Freddo, Dan Dreyer, Li Sun, Marissa Vavrek, Sheila Breidinger, Kerry Fillgrove, Daria Hazuda, Ming-Tain Lai

Merck & Co, Inc, West Point, PA, USA

436 GS-9131 IS A NOVEL NRTI WITH ACTIVITY AGAINST NRTI-RESISTANT HIV-1

Kirsten L. White, Nicolas Margot, Kirsten Stray, Helen Yu, George Stepan, Constantine Boojamra, Richard Mackman, Adrian Ray, Michael D. Miller, Tomas Cihlar

Gilead Scis, Inc, Foster City, CA, USA

437 PRO140 SINGLE-AGENT MAINTENANCE THERAPY FOR HIV-1 INFECTION: A 2-YEAR UPDATE

Jay Lalezari¹, **Kush Dhody**², Ula Kowalczyk¹, Kazem Kazempour², Nader Pourhassan³, Paul J. Maddon⁴

¹Quest Clinical Rsr, San Francisco, CA, USA, ²Amarex Clinical Rsr, LLC, Germantown, MD, USA, ³CytoDyn Inc, Vancouver, WA, USA, ⁴Maddon Advisors LLC, Scarsdale, NY, USA

438 INTRAMUSCULAR IBALIZUMAB: PHARMACOKINETICS, SAFETY, AND EFFICACY VS IV ADMINISTRATION

Hsi-Hsun Lin¹, Susan Shin-Jung Lee², Ning-Chi Wang³, YingAn Lai⁴, Kuei-Ling Kuo⁴, Steven Weinheimer⁵, **Stanley Lewis**⁵

¹E-Da Hosp, Kaohsiung City, Taiwan, ²Kaohsiung Veterans General Hosp, Kaohsiung, Taiwan, ³Tri-Service General Hosp, Taipei City, Taiwan, ⁴TaiMed Biologics, Taipei City, Taiwan, ⁵TaiMed Biologics USA, Irvine, CA, USA

439 A LONG-ACTING NANOFORMULATED CABOTEGRAVIR PRODRUG FOR IMPROVED ANTIRETROVIRAL THERAPY

Tian Zhou, Benson Edagwa, JoEllyn McMillan, Howard E. Gendelman
Univ of Nebraska, Omaha, NE, USA

440 ANTIVIRAL ACTIVITY OF EFDA AGAINST NRTI-SENSITIVE AND -RESISTANT STRAINS OF HIV-2

Vincent Wu¹, Robert Smith¹, Sara Masoum¹, Dana Raugi¹, Selly Ba², Moussa Seydi², Jay Grobler³, Geoffrey Gottlieb¹, for the University of Washington–Dakar HIV-2 Study Group

¹Univ of Washington, Seattle, WA, USA, ²CHU de Fann, Dakar, Senegal, ³Merck & Co, West Point, PA, USA

Poster P-13 ART: VIRAL RESPONSE OVER THE LONG TERM

Poster Hall - 4 EF

2:30 PM - 4:00 PM

461 VIROLOGICAL RESPONSE TO ANTIRETROVIRAL TREATMENT IN AN EASTERN EUROPEAN COHORT STUDY

Radko Avi, Merit Pauskar, Heli Rajasaar, Eveli Kallas, Ene-Ly Jõgeda, Pilleriin Soodla, Irja Lutsar, Kristi Huik, for the Estonian HIV Positive Patients Database

Univ of Tartu, Tartu, Estonia

462 DURABILITY OF NNRTI BASED REGIMENS AFTER 7 YEARS OF TREATMENT IN RURAL UGANDA

Mastula Nanfuka¹, Zishan Cui², Stephen Okoboi¹, Josephine Birungi¹, Pontiano Kaleebu³, Julia Zhu², Samuel Tibengana¹, David Moore⁴

¹The AIDS Support Organization, Kampala, Uganda, ²BC Cntr for Excellence in HIV/AIDS, Vancouver, British Columbia, Canada, ³Med Rsr Council, Entebbe, Uganda, ⁴Univ of British Columbia, Vancouver, British Columbia, Canada

463 LONG-TERM VIRAL SUPPRESSION DURING INITIAL ANTIRETROVIRAL THERAPY IN HANOI, VIETNAM

Junko Tanuma¹, Shoko Matsumoto¹, Sebastien Haneuze², Cuong Do Duy³, Thanh Thuy Pham Thi³, Dung T. Nguyen⁴, Kinh V. Nguyen⁴, Shinichi Oka¹

¹Natl Cntr for Global Hlth and Med, Tokyo, Japan, ²Harvard Univ, Boston, MA, USA, ³Bach Mai Hosp, Hanoi, Vietnam, ⁴Natl Hosp for Trop Diseases, Hanoi, Vietnam

464 OUTCOMES AND SIDE EFFECTS OF PATIENTS ON ART FOR MORE THAN 10 YEARS IN MALAWI

Sekai C. Mathabire¹, Alia Tayea¹, Joseph Bitilinyu-Bangoh², Elkin H. Bermudez¹, Leon Salumu³, Isabel A. Quiles⁴, Elisabeth Szumilin³, Zengani Chirwa⁵, Fernanda Rick¹, David Maman⁶

¹MSF France, Chiradzulu, Malawi, ²Queen Elizabeth Central Hosp, Blantyre, Malawi, ³MSF France, Paris, France, ⁴MSF France, Lilongwe, Malawi, ⁵Ministry of Hlth, Malawi, Lilongwe, Malawi, ⁶Epicentre, Cape Town, South Africa

465 INCREASED PERSISTENCE OF INITIAL ART WITH INSTI-CONTAINING REGIMENS

Thibaut Davy, Sonia Napravnik, Oksana Zakharova, Joseph J. Eron
Univ of North Carolina at Chapel Hill, Chapel Hill, NC, USA

466 DYNAMICS OF ULTRA-DEEP SUPPRESSED HIV VIREMIA (<5 CP/ML) IN CART-TREATED PATIENTS

Alessandra Amendola, Adriana Ammassari, Assunta Navarra, Giulia Bibbolino, Carmela Pinnetti, Isabella Abbate, Gabriella Rozera, Annalisa Mondì, Enrico Girardi, Maria R. Capobianchi
Natl Inst for Infectious Diseases Lazzaro Spallanzani, Rome, Italy

Poster P-I4 ART: PREDICTORS OF OUTCOMES

Poster Hall - 4 EF

2:30 PM - 4:00 PM

467 SUBOPTIMAL IMMUNE RECOVERY DESPITE SUPPRESSIVE ANTIRETROVIRAL THERAPY IN AFRICA

Stefanie Kroeze¹, Pascale Ondo¹, Cissy Kityo², Margaret Siwale³, Sonia Boender¹, Peter Reiss⁴, Ferdinand Wit⁴, Tobias F. Rinke de Wit¹, Raph L. Hamers¹, for the PASER Study Group

¹Amsterdam Inst for Global Hlth and Development, Amsterdam, Netherlands, ²Joint Clinical Rsr Cntr, Kampala, Uganda, ³Lusaka Trust Hosp, Lusaka, Zambia, ⁴Stichting HIV Monitoring and Academic Med Cntr Amsterdam, Amsterdam, Netherlands

468 CURRENT STATIN USE REDUCES RISK OF VIRAL REBOUND ON SUPPRESSIVE CART

Henning J. Drechsler¹, Colby Ayers², James Cutrell¹, Naim Maalouf³, Pablo Tebas⁴, Roger Bedimo¹

¹VA North Texas Hlth Care Cntr, Dallas, TX, USA, ²Univ of Texas Southwestern, Dallas, TX, USA, ³Univ of Texas Southwestern Med Cntr, Dallas, TX, USA, ⁴Univ of Pennsylvania, Philadelphia, PA, USA

469 HIV-RELATED PILL AVERSION: CHARACTERIZING A NOVEL BARRIER TO ADHERENCE

Robin Dorman, Sarah H. Sutton, **Lynn M. Yee**
Northwestern Univ, Chicago, IL, USA

Poster P-L4 HCV: THE RAINBOW AT THE END OF THE CASCADE

Poster Hall - 4 EF

2:30 PM - 4:00 PM

543 HEPATITIS C CASCADE OF CARE IN NON-BIRTH COHORT PATIENTS WITHIN A LARGE HEALTH SYSTEM

Chinyere Ukaegbu¹, Alexander Geboy¹, Whitney Nichols¹, Amanda E. Smart², Stephen Fernandez³, Peter Basch¹, Dawn Fishbein¹

¹MedStar Hlth Rsr Inst, Washington, DC, USA, ²Georgetown Univ, Washington, DC, USA, ³MedStar Hlth Rsr Inst, Hyattsville, MD, USA

544 STRATEGIES FOR UTILIZING EHR TO IMPROVE BIRTH COHORT TESTING IN THE HOSPITAL SETTING

Lorlette Moir, Shuchin Shukla, Uriel Felsen, Jeffrey Weiss, Kimberly Cartmill, Jonathan M. Schwartz, Paul Meissner, Kimberly Yu, Yuming Ning, Alain H. Litwin

Montefiore Med Cntr, Bronx, NY, USA

545 IMPLEMENTATION OF AN EHR PROMPT REVEALS LOW ADHERENCE TO HCV TESTING RECOMMENDATIONS

Alexander Geboy¹, Whitney Nichols¹, Chinyere Ukaegbu¹, Stephen Fernandez², Peter Basch³, Dawn Fishbein¹

¹MedStar Hlth Rsr Inst, Washington, DC, USA, ²MedStar Hlth Rsr Inst, Hyattsville, MD, USA, ³MedStar Hlth, Washington, DC, USA

546 DEVELOPMENT OF AN EMR-BASED ALGORITHM TO PLACE PATIENTS IN THE HCV CARE CASCADE

Jason Zucker, Justin Aaron, Henry W. Evans, Peter Gordon, Michael T. Yin
Columbia Univ, New York, NY, USA

547 COST-EFFECTIVENESS OF HCV SCREENING AND LINKAGE IN MMT: RELEVANCE OF HIV COINFECTION

Bruce R. Schackman¹, Jared A. Leff¹, Jake R. Morgan², Sarah Gutkind¹, Czarina N. Behrends¹, Kevin L. Delucchi³, Courtney McKnight⁴, David C. Perlman⁴, Carmen L. Masson³, Benjamin Linas⁵

¹Weill Cornell Med Coll, New York, NY, USA, ²Boston Med Cntr, Boston, MA, USA, ³Univ of California San Francisco, San Francisco, CA, USA, ⁴Icahn Sch of Med at Mt Sinai, New York, NY, USA, ⁵Boston Univ, Boston, MA, USA

548 PROVIDING HCV CURES IN THE MEDICAL HOME: TRAINING A NEW GENERATION OF PROVIDERS

Sarah Rojas, Christian B. Ramers, Stephanie Constantino
Family Hlth Cntrs of San Diego, San Diego, CA, USA

549 HCV RNA DETECTION IN SMALL VOLUME CAPILLARY BLOOD FOR POINT-OF-CARE APPLICATIONS

Mark Hopkins¹, Rachael Dagnall², Athanassios Papadimitropoulos², Paula Davies¹, Jillian William¹, Eimear Railton¹, Sarah Sarah Hau¹, **Apostolos Beloukas**², Anna Maria Geretti²

¹Royal Liverpool Univ Hosp, Liverpool, UK, ²Univ of Liverpool, Liverpool, UK

550 HIV/HCV COINFECTION IN THE DAA ERA: "EN ROUTE FOR ERADICATION"?

Laurent Cotte¹, Pascal Pugliese², Isabelle Poizot-Martin³, Marc-Antoine Valantin⁴, Lise Cuzin⁵, Jacques Reynes⁶, Eric Billaud⁷, Thomas Huleux⁸, Pierre Pradat¹, for the DatAIDS Study Group

¹Hospices Civils de Lyon, Lyon, France, ²CHU de Nice, Nice, France, ³Assistance Publique – Hôpitaux de Marseille, Marseille, France, ⁴Assistance Publique – Hôpitaux de Paris, Paris, France, ⁵CHU Toulouse, Toulouse, France, ⁶CHU de Montpellier, Montpellier, France, ⁷CHU de Nantes, Nantes, France, ⁸Cntr Hosp de Tourcoing, Tourcoing, France

- 551 SAME SAME BUT DIFFERENT? RISK OF DAA THERAPY FAILURE IN REAL-LIFE HCV/HIV COINFECTION**
Christoph Boesecke¹, Patrick Ingiliz², Florian Berger³, Thomas Lutz⁴, Knud Schewe⁵, Julian Schulze zur Wiesch⁶, Axel Baumgarten², Stefan Christensen⁷, Jürgen K. Rockstroh¹, Stefan Mauss³
¹Univ Hosp Bonn, Bonn, Germany, ²Cntr for Infectiology, Berlin, Germany, ³Cntr for HIV and Hepatogastroenterology, Duesseldorf, Germany, ⁴Infektiologikum, Frankfurt, Germany, ⁵daganae e.V., Berlin, Germany, ⁶Univ Med Cntr, Hamburg—Eppendorf, Hamburg, Germany, ⁷CIM Infectious Diseases, Münster, Germany
- 552 DIRECT-ACTING ANTIVIRALS IMPROVE ACCESS TO CARE AND CURE FOR PATIENTS WITH HIV-HCV**
Lauren F. Collins, Austin Chan, Jiayin Zheng, Shein-Chung Chow, Julius M. Wilder, Andrew J. Muir, Susanna Naggie
 Duke Univ, Durham, NC, USA
- 553 DIRECT ACTING ANTIVIRAL UPTAKE DISPARITIES IN HIV/HCV–COINFECTED POPULATIONS**
Sahar Saeed¹, Erin C. Strumpf¹, Sharon Walmsley², Curtis Cooper³, Brian Conway⁴, Valerie-Martel Laferriere⁵, Neora Pick⁶, Alexander Wong⁷, Marina Klein⁸, for the Canadian Co-Infection Cohort Study
¹McGill Univ, Montreal, Canada, ²Univ of Toronto, Toronto, Ontario, Canada, ³Ottawa General Rsr Inst, Ottawa, Ontario, Canada, ⁴Vancouver Infectious Diseases Cntr, Vancouver, Canada, ⁵Cntr Hosp de l'Univ de Montréal, Montreal, Canada, ⁶Oak Tree Clinic, Vancouver, Canada, ⁷Regina Qu'Appelle Hlth Region, Regina, Canada, ⁸McGill Univ Hlth Cntr Rsr Inst, Montreal, Ontario, Canada
- 554 HCV TREATMENT IN PEOPLE WHO INJECT DRUGS COLOCATED WITHIN NEEDLE AND SYRINGE PROGRAM**
Benjamin Eckhardt¹, Kristen M. Marks², Brian Edlin³
¹New York Univ, New York, NY, USA, ²Weill Cornell Med, New York, NY, USA, ³Natl Development and Rsr Insts, New York, NY, USA
- 555 HIGH EFFICACY OF IFN-FREE ANTI-HCV REGIMENS FOR INDIVIDUALS ON OPIATE AGONIST THERAPY**
Juan Macías¹, Luis E. Morano-Amado², Francisca Cuenca-Lopez³, Miriam Serrano⁴, Karin Neukam¹, Francisco Téllez⁵, Manuel Márquez⁶, Dolores Merino⁷, Juan A. Pineda¹
¹Hosp Univ de Valme, Sevilla, Spain, ²Hosp Univ Alvaro Cunqueiro, Vigo, Spain, ³Hosp Univ Reina Sofia, Cordoba, Spain, ⁴Hosp Univ de Gran Canaria Dr Negrín, Las Palmas, Gran Canaria, ⁵Hosp de La Línea, La Línea de la Concepción, Spain, ⁶Hosp Virgen de la Victoria, Málaga, Spain, ⁷Complejo Hospario Univ de Huelva, Huelva, Spain
- 556 SVR12 FOR PATIENTS WITH BEHAVIORAL HEALTH CONDITIONS TREATED FOR HEPATITIS C IN FQHCs**
Sophy S. Wong, Megan Crowley, Jan Diamond
 Alameda Hlth Consortium, San Leandro, CA, USA
- 557 REAL-WORLD OUTCOMES OF HCV TREATMENT IN HOMELESS AND MARGINALLY HOUSED ADULTS**
Joshua A. Barocas¹, Marguerite Beiser², Casey Leon², Molly Ingemi², Paul McCabe³, Lena Cardoso², Benjamin Linas⁴, James O'Connell²
¹Massachusetts General Hosp, Boston, MA, USA, ²Boston Hlth Care for the Homeless, Boston, MA, USA, ³Quinnipiac Univ, North Haven, CT, USA, ⁴Boston Univ, Boston, MA, USA

558 TREATMENT READINESS FOR HEPATITIS C INFECTION AMONG PWID IN CHENNAI, INDIA

Eshan U. Patel¹, Sunil S. Solomon², Allison M. McFall¹, Aylur K. Srikrishnan², Amrose Pradeep², Jungen Yi¹, Oliver Laeyendecker³, David Thomas¹, Mark Sulkowski¹, Shruti H. Mehta¹

¹Johns Hopkins Univ, Baltimore, MD, USA, ²YRG CARE, Chennai, India, ³NIAID, Baltimore, MD, USA

559 FIELD-BASED DELIVERY OF HCV THERAPY WITH MINIMAL MONITORING TO PWID IN CHENNAI, INDIA

Sunil S. Solomon¹, Amrose Pradeep², Mark Sulkowski¹, Aylur K. Srikrishnan², Nandagopal Paneerselvam², Shanmugam Saravanan², Santhanam Anand², Muniratnam S. Kumar², David Thomas¹, Shruti H. Mehta³

¹Johns Hopkins Univ Sch of Med, Baltimore, MD, USA, ²YR Gaitonde Cntr for AIDS Rsr and Educ, Chennai, India, ³Johns Hopkins Univ, Baltimore, USA

560 HIGH RATES OF HCV CURE AMONG URBAN BLACK AND NON-BLACK HIV-INFECTED PATIENTS

Oluwaseun Falade-Nwulia¹, Juhi Moon¹, Geetanjali Chander¹, Tanyaporn Wansom², Catherine Sutcliffe¹, Shruti H. Mehta¹, David Thomas¹, Richard D. Moore¹, Mark Sulkowski¹

¹Johns Hopkins Univ, Baltimore, MD, USA, ⁴US Military HIV Rsr Prog, Bethesda, MD, USA

Poster P-L5 HCV: RESISTANCE AND RETREATMENT**Poster Hall - 4 EF****2:30 PM - 4:00 PM****561 GLOBAL ORIGINS OF RESISTANCE-ASSOCIATED VARIANTS IN THE NS5A REGION OF HCV**

Bradley R. Jones¹, Jeffrey Joy²

¹BC Cntr for Excellence in HIV/AIDS, Vancouver, British Columbia, Canada, ²Univ of British Columbia, Vancouver, British Columbia, Canada

562 IMPACT OF HCV NS5A RESISTANCE ON TREATMENT RESPONSE IN HIV AND HIV/HCV PATIENTS

Itziar Carrasco Garcia¹, Ana Arias², Laura Benitez², Silvia Requena¹, Miriam Cuesta¹, Luis Otero³, Valentin Cuervas-Mons², Carmen de Mendoza Fernández², for the Internal Medicine Department

¹Puerta de Hierro Rsr Inst and Univ Hosp, Madrid, Spain, ²Hosp Puerta de Hierro, Madrid, Spain, ³Hosp de Cabueñes, Asturias, Spain

563 CATALOGING THE IMPACT OF Y93 SUBSTITUTIONS ON HCV NS5A INHIBITOR SUSCEPTIBILITY

Alicia Newton, Charity Ting, Arne Frantzell, Jennifer Cook, Christos Petropoulos, **Wei Huang**

Monogram BioScis, South San Francisco, CA, USA

564 NATURAL HCV RESISTANCE IS COMMON IN ITALY AND DIFFERENTLY ASSOCIATED TO GENOTYPES

Valeria Cento¹, Ada Bertoli¹, Giustino Parruti², Giuliano Rizzardini³, Gloria Taliani⁴, Caterina Pasquazzi⁴, Massimo Andreoni¹, Carlo F. Perno¹, **Francesca Ceccherini Silberstein**¹, for the Vironet Cohort

¹Univ of Rome Tor Vergata, Rome, Italy, ²Pescara Hosp, Pescara, Italy, ³Luigi Sacco Univ Hosp, Milan, Italy, ⁴Sapienza Univ of Rome, Rome, Italy

565 OPTIMAL EFFICACY OF HCV-RESISTANCE–BASED RETREATMENTS AFTER PI FAILURE

Valeria Cento¹, Silvia Barbaliscia¹, Stefano Bonora², Sergio Babudieri³, Alessia Ciancio⁴, Giuliano Rizzardini⁵, Mario Angelico⁶, Carlo F. Perno¹, Francesca Ceccherini Silberstein¹, for the Vironet Cohort

¹Univ of Rome Tor Vergata, Rome, Italy, ²Univ degli Studi di Torino, Torino, Italy, ³Univ of Sassari, Sassari, Italy, ⁴City of Hlth and Sci of Turin, Turin, Italy, ⁵Luigi Sacco Univ Hosp, Milano, Italy, ⁶Hosp of Rome Tor Vergata, Rome, Italy

566 RETREATMENT OPTIONS AFTER FAILING A FIRST LINE OF DAAs AGAINST HEPATITIS C VIRUS

Ana B. Perez¹, Natalia Chueca¹, Miguel García-Deltoro², Ana María Martínez-Sapiña³, Daniel Navarro⁴, Dolores Merino⁵, Miguel Jiménez⁶, Juan Manuel Pascasio⁷, Antonio Rivero⁸, **Federico García**¹

¹Complejo Hospario Univ de Granada, Granada, Spain, ²Hosp General de Valencia, Valencia, Spain, ³Hosp Univ Miguel Servet, Zaragoza, Spain, ⁴Complejo Hospario Univ de Santiago, Santiago de Compostela, Spain, ⁵Complejo Hospario Univ de Huelva, Huelva, Spain, ⁶Hosp Regional Carlos Haya, Málaga, Spain, ⁷Hosp Univ Virgen del Rocío, Sevilla, Spain, ⁸Hosp Univ Reina Sofia, Cordoba, Spain

567 HCV REINFECTION AFTER SUCCESSFUL DAA TREATMENT: A GECCO ANALYSIS

Patrick Ingiliz¹, Stefan Christensen², Florian Berger³, Torben Kimhofer⁴, Knud Schewe⁵, Christoph Boesecke⁶, Dietrich Hueppe⁷, Julian Schulze zur Wiesch⁸, Thomas Lutz⁹, Stefan Mauss³

¹Cntr for Infectiology, Berlin, Germany, ²CIM Infectious Diseases, Münster, Germany, ³Cntr for HIV and Hepatogastroenterology, Duesseldorf, Germany, ⁴Imperial Coll London, London, UK, ⁵dagnae e.V., Berlin, Germany, ⁶Univ Hosp Bonn, Bonn, Germany, ⁷Gastroenterology Practice, Herne, Germany, ⁸Univ Med Cntr, Hamburg-Eppendorf, Germany, Hamburg, Germany, ⁹Infektiologikum, Frankfurt, Germany

568LB LEDIPASVIR/SOFOSBUVIR±RIBAVIRIN IN HCV AND HCV/HIV PRIOR SOF-BASED VIROLOGIC FAILURES

Edward Tam¹, Robert S. Brown, Jr², Sanjaya Satapathy³, Gregory Camus⁴, Amanda Copans⁴, Lorenzo Rossaro⁴, William D. Guyer⁴, Richard Haubrich⁴, Minhee Kang⁵, Annie Luetkemeyer⁶

¹LAIR Cntr, Vancouver, Canada, ²Weill Cornell Med, New York, NY, USA, ³Univ of Tennessee, Memphis, TN, USA, ⁴Gilead Scis, Inc, Foster City, CA, USA, ⁵Harvard Univ, Boston, MA, USA, ⁶Univ of California San Francisco, San Francisco, CA

Poster P-L6 DAAs: TREATMENT AND ITS COMPLEXITIES

Poster Hall - 4 EF

2:30 PM - 4:00 PM

569 NINETY-SIX % SVR RATES USING IMPORTED GENERIC DAAs FOR PATIENTS WITH HEPATITIS C

Andrew Hill¹, Giten Khwairakpam², James Wang³, Sergey Golovin⁴, Julia Dragunova⁵, Rachel Smith⁶, Vicky Houghton-Price⁶, Roxanna S Korologou-Linden⁷, Anton Pozniak⁸, Greg Jefferys⁹

¹St Stephens Cntr, Chelsea and Westminster Hosp, London, UK, ²TREAT Asia/amfAR, Bangkok, Thailand, ³Ci Run Hlth Information Consulting Co Ltd, Kunming, China, ⁴Intl Treatment Preparedness Coalition, St. Petersburg, Russian Federation, ⁵Intl Treatment Preparedness Coalition and GEPATITKA Community, St. Petersburg, Russian Federation, ⁶Metavirology Ltd, London, UK, ⁷Imperial Coll London, London, UK, ⁸Chelsea and Westminster NHS Fdn Trust, London, UK, ⁹Univ of Tasmania, Tasmania, Australia

570 VIRAL KINETICS PREDICT RESPONSE TO ALL-ORAL THERAPY AGAINST HCV GENOTYPE 3 INFECTION

Juan A. Pineda¹, Luis E. Morano-Amado², Rafael Granados³, Juan Macías⁴, Francisco Téllez⁵, Miguel García-Deltoro⁶, Maria J. Rios-Villegas⁷, Antonio Collado⁸, Karin Neukam⁴, for the GEHEP-MONO/ HEPVIR-DAA, RIS-HEP07 and RIS-HEP13 Study Groups

¹Hosp Univ de Valme, Seville, Spain, ²Hosp Univ Alvaro Cunqueiro, Vigo, Spain, ³Hosp Univ de Gran Canaria Dr Negrín, Las Palmas de Gran Canaria, Spain, ⁴Hosp Univ de Valme, Sevilla, Spain, ⁵Hosp de La Línea, La Línea de la Concepción, Spain, ⁶Hosp General de Valencia, Valencia, Spain, ⁷Hosp Univ Virgen Macarena, Sevilla, Spain, ⁸Hosp Univ Torrecárdenas, Almeria, Spain

571 ALL ORAL DAA THERAPY IN HCV GENOTYPE 4 INFECTION WITH AND WITHOUT HIV COINFECTION

Juan A. Pineda¹, Luis E. Morano-Amado², Francisco Téllez³, Blanca Figueruela López⁴, Marcial Delgado-Fernández⁵, Antonio Rivero-Juárez⁶, Dolores Merino⁷, Montserrat Pérez-Pérez⁸, Karin Neukam¹, for the GEHEP-MONO/ HEPVIR-DAA, RIS-HEP07 and RIS-HEP13 Study Groups

¹Hosp Univ de Valme, Sevilla, Spain, ²Hosp Univ Alvaro Cunqueiro, Vigo, Spain, ³Hosp de La Línea, La Línea de la Concepción, Spain, ⁴Hosp Univ de Valme, Sevilla, Spain, ⁵Hosp Regional Univ de Málaga, Málaga, Spain, ⁶Hosp Univ Reina Sofía, Córdoba, Spain, ⁷Complejo Hospario Univ de Huelva, Huelva, Spain, ⁸Hosp La Línea, AGS Campo de Gibraltar, La Linea de la Concepcion, Spain

572 EFFECTIVENESS OF ALL-ORAL DAAs FOR HCV GENOTYPE 3 IN HIV/HCV-COINFECTED PATIENTS

Juan González-García¹, Ana Moreno², Encarnnacion Cruz³, Lourdes Domínguez-Domínguez⁴, Victoria Moreno¹, Jorge Vergas⁵, Jose Sanz⁶, Laura Benitez⁷, Beatriz Álvarez⁸, Juan Berenguer⁹

¹Hosp Univ La Paz, Madrid, Spain, ²Hosp Ramon y Cajal, Madrid, Spain, ³Subdireccion General de Farmacia, Madrid, Spain, ⁴Hosp Univ 12 de Octubre, Madrid, Spain, ⁵Hosp Clinico San Carlos, Madrid, Spain, ⁶Hosp Príncipe de Asturias, Alcalá de Henares (Madrid), Spain, ⁷Clinica Puerta de Hierro, Majadahonda (Madrid), Spain, ⁸Hosp Univ Fundación Jiménez Díaz, Madrid, Spain, ⁹Hosp General Univ Gregorio Marañón, Madrid, Spain

573 SOFOSBUVIR/LEDIPASVIR AS CHOLESTEROL-INCREASE RISK FACTOR IN HIV SUBJECTS

Mario Frías, Antonio Rivero-Juárez, Francisca Cuenca-Lopez, Angela Camacho-Espejo, Diego Rodriguez-Cano, Pedro Lopez-Lopez, Teresa Brieve, Antonio Rivero

Hosp Univ Reina Sofia, Cordoba, Spain

574 LIPID LEVELS AND THE RISK OF ACUTE MYOCARDIAL INFARCTION AMONG HCV+ AND HCV- PERSONS

Adeel A. Butt¹, Peng Yan², Kara Chew³, Judith S. Currier³, Kathleen Corey⁴, Raymond Chung⁴, Abdul-Badi Abou-Samra⁵, Javed Butler⁶, Matthew Freiberg⁷, for the ERCHIVES

¹Hamad Hlthcare Quality Inst and Hamad Med Corporation, Doha, Qatar, ²VA Pittsburgh Hlthcare System, Pittsburgh, PA, USA, ³Univ of California Los Angeles, Los Angeles, CA, USA, ⁴Massachusetts General Hosp, Boston, USA, ⁵Hamad Medica Corporation, Doha, Qatar, ⁶SUNY Stonybrook, Stony Brook, NY, USA, ⁷Vanderbilt Univ Sch of Med, Nashville, TN, USA

575 EFFECT OF INTERFERON-FREE TREATMENT ON LIPID AND GLUCOSE METABOLISM IN HEPATITIS C

Elisa Biliotti, Donatella Palazzo, Marco Serani, Rozenn Esvan, Paola Maida, Paola Perinelli, Martina Spaziante, Alessandro Maria Silvestri, Lorenzo Volpicelli, Gloria Taliani

Sapienza Univ of Rome, Rome, Italy

- 576 INFLUENCE OF DAA THERAPY ON ALT LEVELS IN HCV- AND HIV/ HCV-INFECTED PATIENTS (GECCO)**
Stefan Mauss¹, Christoph Boesecke², Florian Berger¹, Patrick Ingiliz³, Thomas Lutz⁴, Knud Schewe⁵, Malte Wehmeyer⁶, Axel Baumgarten³, Jürgen K Rockstroh⁷, Stefan Christensen⁸
¹Cntr for HIV and Hepatogastroenterology, Duesseldorf, Germany, ²Univ Hosp Bonn, Bonn, Germany, ³Cntr for Infectiology, Berlin, Germany, ⁴Infektiologikum, Frankfurt, Germany, ⁵agnae e. V., Berlin, Germany, ⁶I. Univ Hosp Hamburg–Eppendorf, Hamburg, Germany, ⁷Bonn Univ Hosp, Bonn, Germany, ⁸CIM Infectious Diseases, Münster, Germany

Poster P-M2 AIDS-RELATED CANCER: ART, RISK, INCIDENCE, AND BURDEN

Poster Hall - 4 EF

2:30 PM - 4:00 PM

- 598 EARLIER VERSUS DELAYED ANTIRETROVIRAL THERAPY INITIATION AND RISK OF CANCER**
Michael J. Silverberg¹, Wendy Leyden¹, Haiqun Lin², Li Qin², Chad J. Achenbach³, Gysamber D'Souza⁴, Eric A. Engels⁵, Charles Rabkin⁵, Keri N. Althoff⁴, Romain Neugebauer¹
¹Kaiser Permanente, Oakland, CA, USA, ²Yale Univ, New Haven, CT, USA, ³Northwestern Univ, Chicago, IL, USA, ⁴Johns Hopkins Univ, Baltimore, MD, USA, ⁵NCI, Rockville, MD, USA
- 599 TIMING OF CART INITIATION INFLUENCES CANCER RISK AMONG WOMEN LIVING WITH HIV**
Kate Salters¹, Monica Ye², Neora Pick³, Angela Kaida¹, Sam Wiseman⁴, Shahab Jabbari², Mark Hull², Jean A. Shoveller², Julio S. Montaner², Robert S. Hogg²
¹Simon Fraser Univ, Burnaby, British Columbia, Canada, ²BC Cntr for Excellence in HIV/AIDS, Vancouver, British Columbia, Canada, ³Oak Tree Clinic, Vancouver, British Columbia, Canada, ⁴St. Paul's Hosp, Vancouver, British Columbia, Canada
- 600 CANCER RISK AMONG HIV-INFECTED PEOPLE IN THE US DURING THE MODERN TREATMENT ERA**
Raul Ulises Hernandez-Ramirez¹, Meredith S. Shiels², Robert Dubrow¹, Eric A. Engels²
¹Yale Univ, New Haven, CT, USA, ²NCI, Rockville, MD, USA
- 601 CANCER INCIDENCE AMONG PERSONS ON MODERN SUPPRESSIVE ART, 2000–2012**
Ann N. Burchell¹, Kate Salters², Oghenowede Eyawo³, Joanne Lindsay⁴, Jason Chia⁵, Michelle Cotterchio⁶, Mark Hull³, Monica Ye³, Janet M. Raboud¹, Robert S. Hogg¹
¹St. Michael's Hosp, Toronto, Ontario, Canada, ²Simon Fraser Univ, Vancouver, British Columbia, Canada, ³BC Cntr for Excellence in HIV/AIDS, Vancouver, British Columbia, Canada, ⁴St. Michael's Hosp, Toronto, Canada, ⁵Cancer Care Ontario, Toronto, Canada, ⁶Univ of Toronto, Toronto, Ontario, Canada
- 602 CANCER BURDEN AMONG HIV+ INDIVIDUALS ON ART IN MALAWI: A RECORD LINKAGE STUDY**
Marie-Jospehe Horner¹, Steady Chasimpha², Adrian Spoerri³, Julia Bohlius³, Hannock Tweya⁴, Eddie Moffo Phiri⁵, Sam Phiri⁶, Kennedy Malisita⁵, Charles Dzamalala², Satish Gopal⁷
¹Univ of North Carolina at Chapel Hill, Chapel Hill, NC, USA, ²Malawi Cancer Registry, Blantyre, Malawi, ³Univ of Bern, Bern, Switzerland, ⁴Lighthouse Trust Clinic, Lilongwe, Malawi, ⁵Queen Elizabeth Hosp ART Clinic, Blantyre, Malawi, ⁶Lighthouse Trust, Lilongwe, Malawi, ⁷Univ of North Carolina Proj–Malawi, Lilongwe, Malawi

Poster P-N1 CARDIOVASCULAR RISK AND ART EFFECTS

Poster Hall - 4 EF

2:30 PM - 4:00 PM

608 THE EFFECT OF ART ON INFLAMMATION, COAGULATION, AND VASCULAR INJURY IN START

Jason Baker, Shweta Sharma, Birgit Grund, for the INSIGHT START (Strategic Timing of AntiRetroviral Treatment) Study Group

Univ of Minnesota, Minneapolis, MN, USA

609 PROTHROMBOTIC EFFECTS OF ABACAVIR IN AN IN VIVO MODEL

Isabel Andujar¹, Victor Collado-Diaz², Samuel Orden¹, Ainhoa Sanchez-Lopez², Maria Angeles Martinez-Cuesta², **Angeles Alvarez**², Juan V. Esplugues²

¹FISABIO, Valencia, Spain, ²Univ of Valencia, Valencia, Spain

610 A SWITCH TO RALTEGRAVIR DOES NOT LOWER PLATELET REACTIVITY IN HIV-INFECTED ADULTS

Wouter A. van der Heijden, Marjolein Bosch, Reinout van Crevel, Monique Keuter, André van der Ven, Quirijn de Mast

Radboud Univ Med Cntr, Nijmegen, Netherlands

Poster P-N2 DYSLIPIDEMIA AND HDL FUNCTION

Poster Hall - 4 EF

2:30 PM - 4:00 PM

611 DYSFUNCTIONAL HDL FROM HIV+ INDIVIDUALS PROMOTES FOAM-CELL FORMATION IN VITRO

Thomas A. Angelovich¹, Anna Hearps¹, Margaret D. Shi¹, Theodoros Kelesidis², Anthony Jaworowski¹

¹Burnet Inst, Melbourne, Australia, ²Univ of California Los Angeles, Los Angeles, CA, USA

612 HDL CHOLESTEROL EFFLUX CAPACITY IS INVERSELY RELATED TO CLASSICAL MONOCYTE NUMBER

Santhosh R. Mannem¹, **Dominic Chow**¹, Martin Playford Playford², Beau K. Nakamoto¹, Kalpana J. Kallianpur¹, Mary Margaret Byron¹, Brooks I. Mitchell¹, Cecilia Shikuma¹, Nehal N. Mehta²

¹Univ of Hawaii, Honolulu, HI, USA, ²Natl Heart, Lung and Blood Inst, Bethesda, MD, USA

613 EFFECT OF ART INITIATION ON MONOCYTE AND HDL FUNCTION

Jane A. O'Halloran¹, Theodoros Kelesidis², Luke O'Brien¹, Therese Herlihy³, Louise Rainford³, John Lambert⁴, Gerard Sheehan⁴, Niall Mahon⁴, Leo Lawler⁴, Patrick W. Mallon³

¹Univ Coll Dublin, Dublin, Ireland, ²Univ of California Los Angeles, Los Angeles, CA, USA, ³Mater Misericordiae Univ Hosp, Dublin, Ireland

614 CHOLESTEROL EFFLUX RESPONDS TO THE IMMUNE STATUS IN PROGRESSION OF HIV INFECTION

Olivia Tort¹, Roque Pastor¹, Felipe Garcia², Esteban Martinez², Montserrat Plana², Tuixent Escribà¹, Montserrat Cofán¹, Emma Fernández², Jose M. Gatell², **Mireia Arnedo**¹

¹IDIBAPS, Barcelona, Spain, ²Hosp Clinic of Barcelona, Barcelona, Spain

Poster P-N3 INTERVENTIONS TO PREVENT AND TREAT CARDIOVASCULAR DISEASE

Poster Hall - 4 EF

2:30 PM - 4:00 PM

615 LOWER RATES OF CVD PROCEDURES IN HIV-INFECTED PATIENTS WITH ACUTE CORONARY SYNDROME

Meredith Clement¹, Li Lin², Ann M. Navar¹, Nwora L. Okeke¹, Susanna Naggie¹, Pamela Douglas¹

¹Duke Univ, Durham, NC, USA, ²Duke Clinical Rsr Inst, Durham, NC, USA

616 EXERCISE, OXIDATIVE STRESS, AND FIBRINOLYTIC FUNCTION IN HIV-1 INFECTED ADULTS

Elizabeth Connick¹, Jared Greiner², Caitlin Dow², Kyle Diehl², Brian Stauffer³, Christopher DeSouza²

¹Univ of Arizona, Tucson, AZ, USA, ²Univ of Colorado Boulder, Boulder, CO, USA,

³Univ of Colorado Denver, Aurora, CO, USA

617 VITAMIN D DEFICIENCY IMPAIRS THE BENEFICIAL EFFECTS OF STATIN IN TREATED HIV

Corrilynn O. Hileman¹, Vin Tangpricha², Abdus Sattar¹, Grace A. McComsey¹

¹Case Western Reserve Univ, Cleveland, OH, USA, ²Emory Univ, Atlanta, GA, USA

618 EFFECT OF STATIN ON ARGININE METABOLITES IN TREATED HIV INFECTION

Sahera Dirajlal-Fargo¹, **Vanessa El Kamari**², Abdus Sattar², Nicholas Funderburg³, W. H. Wilson Tang⁴, Grace A. McComsey²

¹Rainbow Babies and Children's Hosp—Case Western Sch of Med, Cleveland, OH, USA, ²Case Western Reserve Univ, Cleveland, OH, USA, ³Ohio State Univ, Columbus, OH, USA, ⁴Cleveland Clinic, Cleveland, OH, USA

619 THE LARGE GAP BETWEEN STATIN ELIGIBILITY AND PRESCRIPTION AMONG HIV+ IN NORTH AMERICA

Keri N. Althoff¹, Micheal A. Horberg², Joseph J. Eron³, Stephen J. Gange¹, Heidi M. Crane⁴, Amy Justice⁵, Mari Kitahata⁴, Joseph B. Margolick¹, Oghenowede Eyawo⁶, Richard D. Moore¹

¹The Johns Hopkins Univ, Baltimore, MD, USA, ²Kaiser Permanente Mid-Atlantic States, Rockville, MD, USA, ³Univ of North Carolina at Chapel Hill, Chapel Hill, NC, USA, ⁴Univ of Washington, Seattle, WA, USA, ⁵VA Connecticut Hlthcare System, West Haven, CT, USA, ⁶BC Cntr for Excellence in HIV/AIDS, Vancouver, British Columbia, Canada

Poster P-N4 VASCULAR, CARDIAC, AND PULMONARY EVENTS

Poster Hall - 4 EF

2:30 PM - 4:00 PM

620 FIRST AND RECURRENT VENOUS THROMBOSIS IN HIV PATIENTS OF THE DUTCH ATHENA COHORT

Casper Rokx¹, Jaime Borjas Howard², Colette Smit³, Ferdinand Wit³, Elise D Pieterman¹, Karina Meijer², Wouter Bierman², Vladimir Tichelaar², Bart Rijnders¹

¹Erasmus Univ Med Cntr, Rotterdam, Netherlands, ²Univ Med Cntr Groningen, Groningen, Netherlands, ³Stichting HIV Monitoring, Amsterdam, Netherlands

621 PREVALENCE AND PROGNOSTIC IMPACT OF PULMONARY HYPERTENSION IN HIV-INFECTED ADULTS

Courtney Zola, John R. Koethe, Meng Xu, Quinn S. Wells, Eric Farber-Eger, Evan L. Brittain

Vanderbilt Univ, Nashville, TN, USA

622 BODY-MASS INDEX AND ADJUDICATED HEART FAILURE IN A LARGE ELECTRONIC HIV COHORT

Matthew J. Feinstein, Alexandra B. Steverson, Anna Pawlowski, Daniel Schneider, Prasanth Nannapaneni, Sadiya S. Khan, Mercedes Carnethon, Chad J. Achenbach, Sanjiv J. Shah, Donald M Lloyd-Jones
Northwestern Univ, Chicago, IL, USA

Poster P-03 PULMONARY COMPLICATIONS

Poster Hall - 4 EF

2:30 PM - 4:00 PM

654 HIV AS A RISK FACTOR OF AIRWAY OBSTRUCTIVE DISEASE

Alain Makinson¹, Sabrina Eymard-Duvernay², Céline Ribet³, Lucie Marchand⁴, Maurice Hayot¹, Gilles Pialoux⁵, Jacques Reynes⁶, Marie Zins³, Vincent Le Moing¹, for the ANRS EP48 HIVCHEST Study Team

¹Univ Hosp Montpellier, Montpellier, France, ²INSERM, Montpellier, France, ³INSERM, Villejuif, France, ⁴France Recherche Nord et Sud Sida-HIV et Hépatites, Paris, France, ⁵Tenon Hosp, Paris, France, ⁶CHU de Montpellier, Montpellier, France

655 CHRONIC HIV PULMONARY DISEASE (CHPD) IN NEVER-SMOKING HIV PATIENTS

Antonella Santoro¹, Riccardo Scaglioni¹, Giulia Besutti¹, Andrea Malagoli¹, Jonathon Leipsic², Janice Leung², Gabriella Orlando¹, Stefano Zona¹, Guido Ligabue¹, Giovanni Guaraldi¹

¹Univ of Modena and Reggio Emilia, Modena, Italy, ²Univ of British Columbia, Vancouver, British Columbia, Canada

656 THE INFLUENCE OF HIV INFECTION ON PULMONARY FUNCTION IN A RURAL AFRICAN POPULATION

Alinda Vos¹, Meri Varkila¹, Hugo Tempelman², Walter Devillé², Roos Barth¹, Diederick Grobbee¹, Roel Coutinho¹, Kerstin Klipstein-Grobusch¹, for the Ndlovu Research Group

¹Univ Med Cntr Utrecht, Utrecht, Netherlands, ²Ndlovu Care Group, Groblersdal, South Africa

657 FACTORS ASSOCIATED WITH PULMONARY IMPAIRMENT IN HIV-INFECTED SOUTH AFRICAN ADULTS

Akshay Gupte¹, Michelle Wong², Reginah Msandiwa³, Grace Barnes¹, Jonathan Golub¹, Richard Chaisson¹, Chris Hoffmann¹, Neil Martinson³

¹The Johns Hopkins Univ, Baltimore, MD, USA, ²Univ of the Witwatersrand, Soweto, South Africa, ³Perinatal HIV Rsr Unit, Soweto, South Africa

658 CHRONIC OBSTRUCTIVE PULMONARY DISEASE AND MORTALITY IN HIV

Matthew Triplette¹, Sheldon T. Brown², Matthew B. Goetz³, Joon W. Kim⁴, Maria Rodriguez-Barradas⁵, Guy W. Soo Hoo³, Cherry Wongtrakool⁶, Kathleen Akgün⁷, Amy Justice⁸, Kristina Crothers¹

¹Univ of Washington, Seattle, WA, USA, ²James J. Peters VA Med Cntr, Bronx, NY, USA, ³VA Greater Los Angeles Hlth Care System, Los Angeles, CA, USA, ⁴James J. Peters VA Med Cntr, Bronx, NY, USA, ⁵Baylor Coll of Med, Houston, TX, USA, ⁶Emory Univ, Atlanta, GA, USA, ⁷Yale Univ, New Haven, CT, USA, ⁸VA Connecticut Hlthcare System, West Haven, CT, USA

659 SPIROMETRIC AND RADIOLOGICAL PREDICTORS OF INCIDENT COPD IN A SPANISH COHORT

Francisco Fanjul, Gloria Sampérez, Javier Verdú, Helem Haydee Vilchez, Antoni Campins, Luisa Martin, María Peñaranda, Maria Angeles Ribas, María Leyes, Melchor Riera

Hosp Univ Son Espases, Palma de Mallorca, Spain

660 EFFECT OF HIV INFECTION ON ALPHA-1 ANTITRYPSIN FUNCTION: ROLE IN EMPHYSEMA?

Sarah E. Stephenson¹, **Engi F. Attia**², Carole L. Wilson¹, Cherry Wongtrakool³, Kristina Crothers², Irina Petrache⁴, Lynn M. Schnapp¹

¹Med Univ of South Carolina, Charleston, SC, USA, ²Univ of Washington, Seattle, WA, USA, ³Emory Univ, Atlanta, GA, USA, ⁴Natl Jewish Hlth, Univ of Colorado, Denver, CO, USA

661 HIV AND CIRCULATING LEVELS OF PRO-SURFACTANT PROTEIN B AND SURFACTANT PROTEIN D

Meredith S. Shiels¹, Gregory D. Kirk², M. Brad Drummond³, Dilsher Dhillon⁴, Samir Hanash⁴, Ayumu Taguchi⁴, Eric A. Engels¹

¹NCI, Rockville, MD, USA, ²Johns Hopkins Univ, Baltimore, MD, USA, ³Univ of North Carolina at Chapel Hill, Chapel Hill, NC, USA, ⁴MD Anderson Cancer Cntr, Houston, TX, USA

Poster P-04 FRAILTY AND MULTIMORBIDITY

Poster Hall - 4 EF

2:30 PM - 4:00 PM

662 TREND IN MULTIMORBIDITY AMONG HIV+ ADULTS IN CLINICAL CARE IN THE US

Cherise Wong¹, Stephen J. Gange¹, Richard D. Moore², Amy Justice³, Alison Abraham⁴, Kelly Gebo¹, John Gill⁵, Jeffrey N. Martin⁴, Angel Mayor⁵, Keri N. Althoff¹

¹The Johns Hopkins Univ, Baltimore, MD, USA, ²VA Connecticut Hlthcare System, West Haven, CT, USA, ³Univ of Calgary, Calgary, Canada, ⁴Univ of California San Francisco, San Francisco, CA, USA, ⁵Univ Central del Caribe, Bayamon, Puerto Rico

663 NON-AIDS ILLNESS BURDEN DIFFERS BY SEX, RACE, AND INSURANCE TYPE IN AGING HIV+ ADULTS

Frank J. Palella¹, Rachel Hart², Carl Armon², Ellen Tedaldi³, Bienvenido Yangco⁴, Richard Novak⁵, Linda Battalora⁶, Douglas Ward⁷, Bonnie Dean², Kate Buchacz⁸

¹Northwestern Univ, Chicago, IL, USA, ²Cerner Corporation, Kansas City, MO, USA, ³Temple Univ, Philadelphia, PA, USA, ⁴Infectious Disease Rsr Inst, Tampa, FL, USA, ⁵Univ of Illinois, Chicago, IL, USA, ⁶Colorado Sch of Mines, Golden, CO, USA, ⁷Dupont Circle Physicians Group, Washington, DC, USA, ⁸CDC, Atlanta, GA, USA

664 PSYCHIATRIC DISORDERS OBSERVED IN HIV+ PATIENTS USING 6 COMMON THIRD AGENTS IN OPERA

Ricky Hsu¹, Jennifer Fusco², Cassidy Henegar², Felix Carpio³, Karam Mounzer⁴, Michael Wohlfeiler⁵, Vani Vannappagari⁶, Michael Aboud⁷, Lloyd Curtis⁸, Gregory Fusco²

¹New York Univ, New York, NY, USA, ²Epididian, Durham, NC, USA, ³Altamed Hlth Services, Los Angeles, CA, USA, ⁴Philadelphia FIGHT, Philadelphia, PA, USA, ⁵AIDS Hlthcare Fndn, Los Angeles, CA, USA, ⁶ViiV Hlthcare, Rsr Triangle Park, NC, USA, ⁷ViiV Hlthcare, Brentford, UK, ⁸GlaxoSmithKline, Uxbridge, UK

665 FRAILTY HAS A STRONGER ASSOCIATION THAN NEUROCOGNITIVE IMPAIRMENT WITH POOR OUTCOMES

Kristine Erlandson¹, Mona Abdo², Kevin Robertson³, Susan L. Koletar⁴, Robert Kalayjian⁵, Babafemi Taiwo⁶, Frank J. Palella⁶, Katherine Tassiopoulos², for the A5322 Study Team

¹Univ of Colorado, Aurora, CO, USA, ²Harvard Univ, Boston, USA, ³Univ of North Carolina at Chapel Hill, Chapel Hill, NC, USA, ⁴Ohio State Univ, Columbus, OH, USA, ⁵MetroHlth Med Cntr, Cleveland, OH, USA, ⁶Northwestern Univ, Chicago, IL, USA

666 FRAILTY STATUS AND RISK OF FALLS IN HIV-INFECTED OLDER ADULTS IN THE ACTG A5322 STUDY

Katherine Tassiopoulos¹, **Mona Abdo**¹, Susan L. Koletar², Frank J. Palella³, Babafemi Taiwo³, Kristine Erlandson⁴, for the A5322 Study Team

¹Harvard Univ, Boston, MA, USA, ²Ohio State Univ, Columbus, OH, USA,

³Northwestern Univ, Chicago, IL, USA, ⁴Univ of Colorado, Aurora, CO, USA

667 PHYSICAL FUNCTION AND INFLAMMATION IN OLDER HIV-INFECTED MEN

Hillary McClintic¹, Matthew Freiberg², Stephen Crystal³, David Leaf⁴, Julie A. Womack⁵, Karen Nieves-Lugo⁶, Janet Tate⁷, Kristina Crothers⁸, Amy Justice⁷, Krisann Oursler⁹

¹Virginia Tech, Roanoke, VA, USA, ²Vanderbilt Univ, Nashville, TN, USA,

³Rutgers, The State Univ of New Jersey, New Brunswick, NJ, USA, ⁴VA Greater Los Angeles Hlthcare System, Los Angeles, CA, USA, ⁵VA Connecticut Hlthcare System, Branford, CT, USA, ⁶The George Washington Univ, Washington, DC, USA, ⁷VA Connecticut Hlthcare System, West Haven, CT, USA, ⁸Univ of Washington, Seattle, WA, USA, ⁹Salem VA Med Cntr, Salem, VA, USA

668 VACS INDEX AS A PREDICTOR FOR NON-AIDS DEFINING CONDITIONS IN A LONGITUDINAL COHORT

Brian K. Agan¹, Seung Hyun Won¹, Christina Schofield², Anuradha Ganesan¹, Margaret Glancey¹, Jason Okulicz³, Edmund C. Tramont⁴, Julie Pavlin¹, for the IDCRP HIV Working Group

¹Uniformed Services Univ of the Hlth Scis, Bethesda, MD, USA, ²Madigan Army Med Cntr, Tacoma, WA, USA, ³San Antonio Military Med Cntr, Fort Sam Houston, TX, USA, ⁴NIAID, Bethesda, MD, USA

669 AMERICAN GINSENG FOR THE TREATMENT OF HIV FATIGUE: A RANDOMIZED CLINICAL TRIAL

Adriana Andrade¹, Jeff Sloan², Chun-Su Yuan³, Brent Bauer², Paul Novotny², Judith Rabkin⁴, Jeffrey Hsu¹, Adrian Dobs¹, Todd Brown¹

¹The Johns Hopkins Univ, Baltimore, MD, USA, ²Mayo Clinic, Rochester, MN, USA, ³Univ of Chicago Med, Chicago, IL, USA, ⁴Columbia Univ, New York, NY, USA

670 APPLES—THE AUSTRALIAN POSITIVE & PEERS LONGEVITY EVALUATION STUDY

Kathy Petoumenos¹, Robin Huang¹, Jennifer Hoy², Mark Bloch³, David J. Templeton⁴, David Baker⁵, Michelle Giles⁶, Matthew Law¹, David A. Cooper¹

¹Kirby Inst, Sydney, Australia, ²The Alfred Hosp and Monash Univ, Melbourne, Australia, ³Holdsworth House Med Practice, Sydney, Australia, ⁴RPA Sexual Hlth, Camperdown, Australia, ⁵East Sydney Doctors, Darlinghurst, Australia, ⁶Monash Hlth, Melbourne, Australia

671 PATIENTS' BELIEFS ABOUT THEIR HAART IN COMPARISON WITH THEIR CHRONIC COTREATMENTS

Susan Kamal¹, Olivier Bugnon¹, Matthias Cavassini¹, Marie-Paule Schneider², for the Swiss HIV Cohort Study

¹Univ of Lausanne, Lausanne, Switzerland, ²Univ of Geneva, Univ of Lausanne, Lausanne, Switzerland

Poster P-P4 TB EPIDEMIOLOGY AND BURDEN OF DISEASE**Poster Hall - 4 EF****2:30 PM - 4:00 PM****725 TUBERCULOSIS IN SOUTH AFRICA IS MORE CONCENTRATED BY RACE THAN POVERTY****Eran Bendavid**, Lea Prince, Douglas K. Owens, Jeremy D. Goldhaber-Fiebert, Jason R. Andrews*Stanford Univ, Stanford, CA, USA***726 HIGH TB INFECTION RATE IN CHILDREN & YOUNG ADULTS IN RURAL UGANDA IN THE SEARCH TRIAL****Carina Marquez**¹, Atukunda Mucunguzi², Gabriel Chamie¹, Dalsone Kwariisima³, Theodore Ruel¹, Laura B. Balzer⁴, Tamara D. Clark¹, Edwin D. Charlebois¹, Maya L. Petersen⁵, Diane V. Havlir¹¹*Univ of California San Francisco, San Francisco, CA, USA*, ²*Infectious Diseases Rsr Collab, Kampala, Uganda*, ³*Makerere Univ Joint AIDS Prog, Kampala, Uganda*, ⁴*Harvard Univ, Boston, MA, USA*, ⁵*Univ of California Berkeley, Berkeley, CA, USA***727 THE HIV-ASSOCIATED BURDEN OF RECURRENT TB DISEASE IN CAPE TOWN, SOUTH AFRICA****Sabine Hermans**¹, Nesbert Zinyakatira², Judy Caldwell³, Frank Cobelens⁴, Andrew Boule², Robin Wood²¹*Amsterdam Inst for Global Hlth and Development, Amsterdam, Netherlands*, ²*Univ of Cape Town, Cape Town, South Africa*, ³*City Hlth, Cape Town, South Africa*, ⁴*Univ of Amsterdam, Amsterdam Zuidoost, Netherlands***728 HIV TESTING UPTAKE AMONG HOUSEHOLD CONTACTS OF MDR-TB INDEX CASES IN 8 COUNTRIES****Valarie S. Opollo**¹, Xingye Wu², Richard Lando³, Susan Swindells⁴, Amita Gupta⁵, Anneke Hesselings⁶, Rodney Dawson⁷, Michael D. Hughes⁸, N. Sarita Shah⁸, for the A5300/I2003 Study Team¹*Kenya Med Rsr Inst, Kisumu, Nyanza, Kenya*, ²*Harvard Univ, Boston, MA, USA*, ³*Kenya Med Rsr Inst, Kisumu, Kenya*, ⁴*Univ of Nebraska, Omaha, NE, USA*, ⁵*The Johns Hopkins Univ, Baltimore, MD, USA*, ⁶*Stellenbosch Univ, Tygerberg, South Africa*, ⁷*Univ of Cape Town, Mowbray, South Africa*, ⁸*CDC, Atlanta, GA, USA***Poster P-P5 TB AND CONTINUUM OF CARE****Poster Hall - 4 EF****2:30 PM - 4:00 PM****729 HIV CONTINUUM AND EXPEDITED TB DIAGNOSIS IN TB/HIV COINFECTED PATIENTS IN BOTSWANA****Diane Gu**¹, Sanghyuk S Shin¹, Chawangwa Modongo², Cynthia Caiphus³, Othusitse Fane², Matsiri Ogopotse², Mbatshi Dima², Nicola M Zetola⁴¹*Univ of California Los Angeles, Los Angeles, CA, USA*, ²*Botswana-UPenn Partnership, Gaborone, Botswana*, ³*Princess Marina Hosp, Gaborone, Botswana*, ⁴*Univ of Pennsylvania, Gaborone, Botswana***730 IMPROVEMENT OF HIV/TB CARE: TIME-SERIES ANALYSIS OF HEALTH FACILITY DATA****Nehaben Ramanlal**¹, Dulce Bila¹, Orvalho Augusto², Nello Macuacua¹, Victorino Chavane¹, Leonel Zevo¹, Chadreque Muluana³, Esmeralda Karajeane¹, Paula Vaz¹¹*Fundação Ariel Glaser Contra o Sida Pediátrico, Maputo, Mozambique*, ²*Univ Eduardo Mondlane, Maputo, Mozambique*, ³*Direcção Provincial de Saude de Maputo, Maputo Provincia, Mozambique*

Poster P-P6 TB AND OI IRIS**Poster Hall - 4 EF****2:30 PM - 4:00 PM****731 INTEGRASE INHIBITORS ARE AN INDEPENDENT RISK FACTOR FOR IRIS: AN ATHENA COHORT STUDY**

Ingeborg Wijting¹, Casper Rokx¹, Ferdinand Wit², Anneloes Postma¹, Andy Hoepelman³, Ineke van der Ende¹, Peter Reiss², Bart Rijnders¹

¹Erasmus Univ Med Cntr, Rotterdam, Netherlands, ²Stichting HIV Monitoring, Amsterdam, Netherlands, ³Univ Med Cntr Utrecht, Utrecht, Netherlands

732 INITIATION OF ART BASED ON INTEGRASE INHIBITORS INCREASES THE RISK OF IRIS

Marine Dutertre¹, **Lise Cuzin**², Pascal Puglièse³, Veronique Joly⁴, Marc-Antoine Valantin⁵, Laurent Cotte⁶, Thomas Huleux⁷, Pierre Delobel², Guillaume Martin-Blondel¹, for the Dat'AIDS

¹Toulouse Univ Hosp, Toulouse, France, ²CHU Toulouse, Toulouse, France, ³CHU de Nice, Nice, France, ⁴Bichat Hosp, Paris, France, ⁵AP-HP, Paris, France, ⁶Hospices Civils de Lyon, Lyon, France, ⁷Cntr Hosp de Tourcoing, Tourcoing, France

733 INFLAMMASOMES PLAY A MAJOR ROLE IN TB IRIS PATHOGENESIS

Denise C. Hsu¹, Daniel Sturdevant², Eleanor Wilson¹, Virginia Sheikh¹, Ornella Sortino³, Silvia Lage¹, Timothy G. Myers¹, Stephen Porcella², Irini Sereti¹

¹NIAID, Bethesda, MD, USA, ²NIAID, Hamilton, MT, USA, ³Leidos Biomed Rsr Inc, Frederick, MD, USA

Poster P-P7 TB COMORBIDITIES**Poster Hall - 4 EF****2:30 PM - 4:00 PM****734 THE DIABETES-TUBERCULOSIS COMORBIDITY AMONG PERSONS WITH HIV**

Monica Sane Schepisi¹, Jalal Miah², Anna Kaluzhenina³, Katerina Manika Manika⁴, Emanuele Pontali⁵, Monica Rios Prego⁶, María Nieves Altet Altet⁷, Diana Sanchez Mellado Sanchez Mellado⁸, **Enrico Girardi**¹, for the TB NET

¹Natl Inst for Infectious Diseases L. Spallanzani, Rome, Italy, ²Newham Univ Hosp Barts NHS Trust, London, UK, ³Volgograd State Med Univ, Volgograd, Russian Federation, ⁴Aristotle Univ of Thessaloniki, Thessaloniki, Greece, ⁵Galliera Hosp, Genova, Italy, ⁶EComplejo Hospario Univ de Pontevedra, Pontevedra, Spain, ⁷Unidad de Prevención y Control de la TB de Barcelona, Barcelona, Spain, ⁸IIS-Fundacion Jimenez Diaz, UAM, Madrid, Spain

735 RISK PROFILES IN MONOINFECTED TB PATIENTS AND THOSE COINFECTED WITH HCV AND/OR HIV

David Roth¹, James Johnston¹, Jason Wong¹, Mel Krajden¹, Zahid A. Butt², Nabin Shrestha¹, Mark Gilbert¹, Victoria Cook¹, Naveed Z. Janjua¹

¹BC Cntr for Disease Control, Vancouver, British Columbia, Canada, ²Univ of British Columbia, Vancouver, British Columbia, Canada

736 PROBLEM DRUG USE PREDICTS HIGHER HIV PREVALENCE IN UK TUBERCULOSIS CASES, 2010–2014

Joanne R. Winter¹, Helen R. Stagg¹, Colette J. Smith¹, Maeve K. Lalor², Alison E. Brown², H. L. Thomas², Valerie Delpech², Ibrahim Abubakar¹

¹Univ Coll London, London, UK, ²Pub Hlth England, London, UK

Poster P-Q5 HIV DIAGNOSIS IN NEWBORNS AND INFANTS**Poster Hall - 4 EF****2:30 PM - 4:00 PM**

- 788 EVALUATION OF MATERNAL AND INFANT HIV POINT-OF-CARE DIAGNOSTICS AT BIRTH IN TANZANIA**
Issa Sabi¹, Hellen Mahiga¹, Jimson Mgaya¹, Otto Geisenberger², John France³, Michael Hoelscher², **Arne Kroidl**²
¹NIMR—Mbeya Med Rsr Cntr (MMRC), Mbeya, Tanzania, ²Univ of Munich, Munich, Germany, ³Mbeya Referral Hosp, Mbeya, Tanzania
- 789 EVALUATION OF THE CEPHEID HIV-1 QUAL POINT-OF-CARE TEST FOR HIV DIAGNOSIS AT BIRTH**
Maryanne R. Ibrahim¹, Sikhulile Moyo², Terence Mohammed², Kenneth Maswabi², Gbolahan Ajibola², Rebecca Gelman³, Chloe Auletta-Young¹, Shahn Lockman¹, Joseph Makhema², Roger L. Shapiro¹
¹Doris Duke Intl Clinical Rsr Fellowship, Los Angeles, CA, USA, ²Botswana Harvard AIDS Rsr Inst Partnership, Gaborone, Botswana, ³Dana—Farber Cancer Inst, Boston, MA, USA
- 790 TARGETED HIV SCREENING AT BIRTH CAN IDENTIFY THE MAJORITY OF IN UTERO TRANSMISSIONS**
Maryanne R. Ibrahim¹, Kenneth Maswabi², Gbolahan Ajibola², Sikhulile Moyo², Michael D. Hughes³, Chloe Auletta-Young³, Daniel R. Kuritzkes⁴, Mathias Lichterfeld⁵, Joseph Makhema², Roger L. Shapiro³
¹Doris Duke Intl Clinical Rsr Fellowship, Los Angeles, CA, USA, ²Botswana Harvard AIDS Inst Partnership, Gaborone, Botswana, ³Harvard Univ, Boston, MA, USA, ⁴Brigham and Women's Hosp, Boston, MA, USA, ⁵Massachusetts General Hosp, Boston, MA, USA
- 791 IMPACT OF BIRTH PCR ON RETENTION IN CARE OF HIV-EXPOSED INFANTS IN PRIMARY CARE**
Aurelie Nelson¹, Laura Trivino Duran¹, Tali Cassidy¹, Gilles van Cutsem², Sarah Jane Steele², Mark Cotton³, Janet Giddy⁴, Jean Maritz³
¹MSF, Khayelitsha, South Africa, ²MSF, Cape Town, South Africa, ³Stellenbosch Univ, Cape Town, South Africa, ⁴KES, Cape Town, South Africa
- 792 IMPACT OF EXPANDED SCREENING AND POC ON INFANT DIAGNOSIS AND ART INITIATION**
Alliance Nikuze¹, Stephen Wanjala², Jihane Ben-Farhat¹, Willis Omwoyo³, Laura Oyiengo⁴, Elisabeth Szumilin⁵, Leon Salumu⁵, Alexandra Vandenbulcke⁵, Valarie S. Opollo⁶, **David Maman**⁷
¹Epicentre, Paris, France, ²MSF, Nairobi, Kenya, ³Ministry of Hlth, Homa bay, Kenya, ⁴Natl AIDS/STI Control Prog, Nairobi, Kenya, ⁵MSF France, Paris, France, ⁶Kenya Med Rsr Inst, Kisumu, Nyanza, ⁷Epicentre, Cape Town, South Africa
- 793 DELAYED HIV DNA PCR DETECTION AMONG INFANTS WHO RECEIVED COMBINATION ART PROPHYLAXIS**
Thanyawee Puthanakit¹, Archawin Rojanawiwat², Tanawan Samleerat³, Hansa Thaisri², Jiratchaya Sophonphan⁴, Sarawut Boonsuk⁵, Sumet Ongwandee⁵, Varunee Jinarat², for the Thailand ACC Program
¹Chulalongkorn Univ, Bangkok, Thailand, ²Ministry of Pub Hlth, Nonthaburi, Thailand, ³Chiang Mai Univ, Chiang Mai, Thailand, ⁴HIV Netherlands Australia Thailand Rsr Collab, Thai Red Cross AIDS Rsr, Bangkok, Thailand, ⁵Ministry of Pub Hlth, Nonthaburi, Thailand
- 794 HIV VIRAL-LOAD TRENDS WITHIN SOUTH AFRICA'S EARLY INFANT DIAGNOSIS PROGRAM, 2010–2015**
Ahmad Haeri Mazanderani¹, Faith Moyo¹, Tendesayi Kufa-Chakezha¹, Gayle G. Sherman²
¹NCID, Johannesburg, South Africa, ²Univ of the Witwatersrand, Johannesburg, South Africa

Poster P-R1 HIV DETECTION AND LATENT RESERVOIR IN CHILDREN

Poster Hall - 4 EF

2:30 PM - 4:00 PM

795 DETECTION OF INDUCIBLE HIV IN CHILDREN ON ART DESPITE LOW HIV-1 DNA

Shalena Naidoo¹, Michele Sobolewski², Taylor Buckley², Joshua C. Cyktor², Melissa Tosiano², Mary Grace K. Katusiime¹, Gert U. van Zyl³, Mark Cotton¹, Richard Glashoff¹, John Mellors³

¹Stellenbosch Univ, Cape Town, South Africa, ²Univ of Pittsburgh, Pittsburgh, PA, USA, ³Stellenbosch Univ, Parow, South Africa

796 HIV RESERVOIR SIZE IS NOT INCREASED BY SHORT ART INTERRUPTION IN KENYAN INFANTS

Mark D. Pankau¹, Dalton Wamalwa², Sarah Benki-Nugent³, Agnes Langat⁴, Ken Tapia³, Elizabeth Maleche-Obimbo⁵, Julie Overbaugh¹, Grace John-Stewart³, Dara Lehman¹

¹FRCHC, Seattle, WA, USA, ²Univ of Nairobi, Nairobi, Kenya, ³Univ of Washington, Seattle, WA, USA, ⁴US CDC, Nairobi, Kenya, ⁵Kenyatta Natl Hosp, Nairobi, Kenya

797 HIV SUBTYPE D IS ASSOCIATED WITH INCREASED LATENT RESERVOIR SIZE IN CHILDREN

Leila B. Giron¹, Jane Achan², Paul Bangirana³, Moses R. Kanya³, Diane V. Havlir⁴, Joseph K. Wong⁴, Theodore Ruel⁴, Satish K. Pillai⁵

¹Fed Univ of Sao Paulo/Blood Systems Rsr Inst, Sao Paulo, Brazil, ²Disease Control and Elimination Theme, Med Rsr Unit, Fajara, Gambia, ³Makerere Univ, Kampala, Uganda, ⁴Univ of San Francisco, San Francisco, USA, ⁵Blood Systems Rsr Inst/UCSF, San Francisco, CA, USA

Poster P-R2 IMMUNE RESPONSE AND ACTIVATION IN CHILDREN

Poster Hall - 4 EF

2:30 PM - 4:00 PM

798 B-CELL RESPONSES IN EARLY TREATED LONG TERM VIRAL SUPPRESSED SERONEG HIV+ CHILDREN

Paolo Palma¹, Paola Zangari¹, Nicola Cotugno², Eleni Nastouli³, Laura McCoy⁴, Salvatore Rocca², Bridget Ferns³, Savita Pahwa⁵, Paolo Rossi¹, for the EPIICAL Consortium

¹Children's Hosp Bambino Gesù, Rome, Italy, ²Univ of Rome Tor Vergata, Rome, Italy, ³Univ Coll London Hosps NHS Trust, London, UK, ⁴Univ Coll London, London, UK, ⁵Univ of Miami, Miami, FL, USA

799 RAPID RESTORATION OF EFFECTIVE ANTI-HIV CD4+ T-CELL ACTIVITY IN ART-TREATED CHILDREN

Emily Adland¹, Luisa Mori², Leana Laker², Alice Swordy², Anna Csala¹, Masahiko Mori¹, Philippa C. Matthews³, Pieter Jooste², Philip J. Goulder¹

¹Univ of Oxford, Oxford, UK, ²Kimberley Hosp Complex, Kimberley, South Africa, ³Oxford Univ Hosps NGS Trust, John Radcliffe Hosp, Oxford, UK

800 PD-1+ MEMORY CD4 T CELLS, PROLIFERATIVE CAPACITY, AND INFLAMMATION IN HIV+ CHILDREN

Julia Foldi¹, Lina Kozhaya¹, Max Kilberg¹, Mussa Mwamzuka², Fatma Marshad², Aabid Ahmed², William Borkowsky¹, Derya Unutmaz¹, **Alka Khaitan**¹

¹New York Univ, New York, NY, USA, ²Bomu Hosp, Mombasa, Kenya

801 MICROBIAL TRANSLOCATION DOES NOT DRIVE IMMUNE ACTIVATION IN UGANDAN CHILDREN WITH HIV

Felicity Fitzgerald¹, Edouard Lhomme², Kathryn Harris³, Julia Kenny¹, Ronan Doyle⁴, Cissy Kityo⁵, Sarah Walker⁴, Rodolphe Thiébaud², Nigel Klein⁴, for the CHAPAS-3 Trial Team

¹Univ Coll London Great Ormond Street Inst of Child Hlth, London, UK, ²INSERM, Bordeaux, France, ³Great Ormond Street NHS Fndn Trust, London, UK, ⁴Univ Coll London, London, UK, ⁵Joint Clinical Rsr Cntr, Kampala, Uganda

802 TARGETING IMMUNOACTIVATION IN HIV+ CHILDREN BY MODIFICATION OF THE GUT MICROBIOTA

Talía Sainz¹, Nuria Jiménez-Hernández², Laura Diaz³, Sergio Serrano-Villar⁴, Maria José Mellado¹, Luis Prieto⁵, Jose Tomas Ramos⁶, M. Ángeles Muñoz-Fernández³, María José Gosalbes², Maria Luisa Navarro³

¹Hosp La Paz Inst for Hlth Rsr, Madrid, Spain, ²FISABIO—Salud Pública, Valencia, Spain, ³Gregorio Marañon Hosp, Madrid, Spain, ⁴Hosp Univ Ramón y Cajal, Madrid, Spain, ⁵Hosp de Getafe, Madrid, Spain, ⁶Hosp Clínico San Carlos, Madrid, Spain

803 B- AND T-CELL SUBSETS AND IMMUNOGENICITY OF ROTAVIRUS VACCINE IN PHIV & PHEU INFANTS

Adriana Weinberg¹, Jane Lindsey², Ronald Bosch², Deborah Persaud³, Paul Sato⁴, Barbara Heckman⁵, Kelly Richardson¹, Amanda Zadzilka⁶, Margaret Nelson⁷, Myron Levin¹

¹Univ of Colorado, Aurora, CO, USA, ²Harvard Univ, Boston, MA, USA, ³The Johns Hopkins Univ, Baltimore, MD, USA, ⁴DAIDS, NIAID, Bethesda, MD, USA, ⁵Data Mgmt Cntr, Amherst, NY, USA, ⁶Frontier Sci and Tech Rsr Fndn, Amherst, NY, USA, ⁷Merck & Co, Inc, Upper Gwynedd, PA, USA

804 IMMUNOLOGICAL RESPONSE AFTER A BOOSTER DOSE OF HBV VACCINE IN HIV-INFECTED YOUTH

Vania Giacometti¹, Daria Trabattoni², Pilar Nannini², Michela Masetti², Federica Forlanini², Mario Clerici³, Gian Vincenzo Zuccotti⁴

¹L. Sacco Hosp, Milan, Italy, ²Univ of Milan, Milan, Italy, ³Univ of Milan, Segrate, Milan, Italy, ⁴Ospedale dei Bambini V. Buzzi, Milan, Italy

805 HPV4 VACCINE IMMUNOGENICITY/EFFECTIVENESS IN PERINATALLY HIV-INFECTED (PHIV) YOUTH

Anna-Barbara Moscicki¹, Brad Karalius², Katherine Tassiopoulos², Denise Jacobson², Kunjal Patel², Murli U. Purswani³, George R. Seage², Tzy-Jyun Yao²

¹Univ of California Los Angeles, Los Angeles, CA, USA, ²Harvard Univ, Boston, MA, USA, ³Bronx Lebanon Hosp, Bronx, NY, USA

Poster P-R6 APPROACHING 90:90:90 IN ADOLESCENTS AND YOUNG ADULTS

Poster Hall - 4 EF

2:30 PM - 4:00 PM

831 CURRENT TRENDS IN CHILDREN WITH HIV DIAGNOSED IN THE UK AND IRELAND

Helen Peters, Kate Francis, Intira J. Collins, Ali Judd, Claire Thorne
Univ Coll London, London, UK

832 BASELINE POPULATION HIV CASCADE AND 2-YR OUTCOME OF HIV+ CHILDREN IN THE SEARCH TRIAL

Laura B. Balzer¹, Norton Sang², Albert Plenty¹, Teri Liegler¹, Craig Cohen¹, Elizabeth A. Bukusi², Moses R. Kamya³, Maya L. Petersen⁴, Diane V. Havlir¹, Theodore Ruel¹

¹Univ of California San Francisco, San Francisco, CA, USA, ²Kenya Med Rsr Inst, Nairobi, Kenya, ³Makerere Univ, Kampala, Uganda, ⁴Univ of California Berkeley, Berkeley, CA, USA

833 COST-EFFECTIVENESS OF HIV SCREENING: US ADOLESCENTS AND YOUNG ADULTS (AYA) AGED 13–24

Anne M. Neilan¹, Richard Dunville², Cheryl B. Ocfemia², Joshua A. Salomon³, Li Yan Wang², Katherine K. Hsu⁴, Elizabeth DiNenno², Rochelle P. Walensky¹, Robert A. Parker¹, Andrea L. Ciaranello¹

¹Massachusetts General Hosp, Boston, MA, USA, ²CDC, Atlanta, GA, USA, ³Harvard SPH, Boston, MA, USA, ⁴Massachusetts Dept of Pub Hlth, Boston, MA, USA

834 COMMUNITY INTERVENTION IMPROVES ADOLESCENT HIV STATUS KNOWLEDGE: HPTN 071 STUDY ZAMBIA

Kwame Shanaube¹, Mwate J. Chaila¹, David Macleod², Ab Schaap¹, Sian Floyd², Conred Jani¹, Graeme Hoddinott³, Richard Hayes², Sarah Fidler⁴, Helen Ayles⁵

¹Zambart, Lusaka, Zambia, ²London Sch of Hygiene and Trop Med, London, UK, ³Univ of Stellenbosch, Cape Town, South Africa, ⁴Imperial Coll London, London, UK, ⁵London Sch of Hygiene and Trop Med, Lusaka, Zambia

835 A NOVEL MODEL OF COMMUNITY COHORT CARE FOR HIV-INFECTED ADOLESCENTS IMPROVES OUTCOMES

Lindsey Reif¹, Rachel Bertrand², Vanessa Rivera³, Bernadette Jospeh², Benedict Anglade², Jean W. Pape³, Daniel Fitzgerald³, Margaret McNairy³

¹Columbia Univ, New York, NY, USA, ²GHEKIO, Port-au-Prince, Haiti, ³Weill Cornell Med, New York, NY, USA

836 LOCAL SOCIAL NETWORKS PREDICT RETENTION & SUPPRESSION IN YOUNG WOMEN IN SEARCH TRIAL

Lillian Brown¹, Wenjing Zheng², James Ayieko³, Asiphas Owaraganise⁴, Florence Mwangwa⁴, Tamara D. Clark¹, Edwin D. Charlebois¹, Moses R. Kamya⁵, Diane V. Havlir¹, Maya L. Petersen²

¹Univ of California San Francisco, San Francisco, CA, USA, ²Univ of California Berkeley, Berkeley, CA, USA, ³Kenya Med Rsr Inst, Nairobi, Kenya, ⁴Infectious Diseases Rsr Collab, Kampala, Uganda, ⁵Makerere Univ, Kampala, Uganda

837 TEENAGE PREGNANCY: A CRITICAL BARRIER TO RETENTION ON ANTIRETROVIRAL THERAPY

Harriet Nuwagaba-Biribonwoha¹, Agnes Kiragga², Constantin Yiannoutsos³, Beverly Musick³, Kara K. Wools-Kaloustian³, Elaine J. Abrams¹, Batya Elul⁴, for the International Epidemiologic Databases to Evaluate AIDS (IeDEA) East Africa Collaboration

¹ICAP at Columbia Univ, New York, NY, USA, ²Makerere Univ, Kampala, Uganda, ³Indiana Univ, Indianapolis, IN, USA, ⁴Columbia Univ, New York, NY, USA

838 IMPACT OF SUBSTANCE USE, MENTAL HEALTH, AND AGE ON RETENTION AND VIRAL SUPPRESSION

Brian C. Zanoni¹, Sara Lammert¹, Jessica Haberer¹, Gregory K. Robbins¹, Heidi M. Crane², Michael J. Mugavero³, Katerina Christopoulos⁴, Kenneth H. Mayer⁵

¹Massachusetts General Hosp, Boston, MA, USA, ²Univ of Washington, Seattle, WA, USA, ³Univ of Alabama at Birmingham, Birmingham, AL, USA, ⁴Univ of California San Francisco, San Francisco, CA, USA, ⁵Fenway Hlth, Boston, MA, USA

839 THE MACARTI STUDY: CLOSING THE GAPS IN HIV CARE AMONG YOUTH IN ATLANTA, GA

Andres Camacho-Gonzalez¹, Scott Gillespie¹, Lateshia Thomas-Seaton², Krystal Frieson³, Sophia A. Hussen¹, Ashley Murray⁴, Zaneta Gaul⁶, Madeline Sutton⁴, Chanda Graves¹, Rana Chakraborty¹

¹Emory Univ, Atlanta, GA, USA, ²Children's Hlthcare of Atlanta, Atlanta, GA, USA, ³Atlanta VA Med Cntr, Decatur, GA, USA, ⁴Emory Univ, Atlanta, GA, USA, ⁵CDC, Atlanta, GA, USA, ⁶ICF Intl, Atlanta, GA, USA

840 RETENTION, ART USE, AND VIRAL SUPPRESSION AMONG YOUNG ADULTS NEWLY LINKED TO HIV CARE

Fidel A. Desir¹, Peter F. Rebeiro², Richard D. Moore¹, Heidi M. Crane³, Karyn Gabler⁴, Joseph B. Margolick¹, Ronald Bosch⁵, Michael A. Horberg⁶, Michael J. Silverberg⁷, Keri N. Althoff¹

¹The Johns Hopkins Univ, Baltimore, MD, USA, ²Vanderbilt Univ, Nashville, TN, USA, ³Univ of Washington, Seattle, WA, USA, ⁴BC Cntr for Excellence in HIV/AIDS, Vancouver, British Columbia, Canada, ⁵Harvard Univ, Boston, MA, USA, ⁶Kaiser Permanente Mid-Atlantic States, Rockville, MD, USA, ⁷Kaiser Permanente Northern California, Oakland, CA, USA

841LB WITHDRAWN**Poster P-S4 HIV AND SUBSTANCE USE: DOUBLE TROUBLE****Poster Hall - 4 EF****2:30 PM - 4:00 PM****869 "HOOKED ON PAINKILLERS" PRIOR TO FIRST INJECTION AMONG PWID IN 16 U.S. CITIES**

Dita Broz¹, Maria Zlotorzynska², Michael Spiller¹, Gabriela Paz-Bailey¹, for the NHBS Study Group

¹CDC, Atlanta, GA, USA, ²Emory Univ, Atlanta, GA, USA

870 OPIOID SUBSTITUTION THERAPY AND INITIATION INTO INJECTION DRUG USE IN SAN DIEGO, CA

Maria Luisa Mittal¹, Devesh Vashishtha¹, Xiaoying Sun¹, Sonia Jain¹, Richard S. Garfein², Steffanie A. Strathdee², Dan Werb¹

¹Univ of California San Diego, La Jolla, CA, USA, ²Univ of California San Diego, San Diego, CA, USA

871 CHANGES IN PRESCRIPTION OPIOID, METH, AND COCAINE USE AMONG MSM IN 20 US CITIES

Brooke Hoots, Dita Broz, Lina Nerlander, Gabriela Paz-Bailey
CDC, Atlanta, GA, USA

872 CHANGING PATTERN OF CRYSTAL METH USE IN BLACK & WHITE MSM, WASHINGTON, DC, 2008–2014

Irene Kuo¹, Rudy Patrick¹, Jenevieve Opoku², Anthony Rawls¹, Many Magnus¹, James Peterson¹, Michael Kharfen², Alan Greenberg¹

¹The George Washington Univ, Washington, DC, USA, ²District of Columbia Dept of Hlth, Washington, DC, USA

873 INCREASING METHAMPHETAMINE USE AMONG NON-MSM WHO INJECT DRUGS IN KING COUNTY, WA

Sara N. Glick¹, Richard Burt², Kim Kummer¹, Joe Tinsley², Caleb Banta-Green¹, Matthew R. Golden¹

¹Univ of Washington, Seattle, WA, USA, ²Pub Hlth - Seattle & King County, Seattle, WA, USA

874 REDUCING ALCOHOL CONSUMPTION IMPROVED HIV VIRAL SUPPRESSION IN WOMEN

Robert L. Cook¹, Zhi Zhou¹, Maria J. Miguez², Babette Brumback¹, John Lewis³, Luis Espinoza³, Kendall J. Bryant⁴

¹Univ of Florida, Gainesville, FL, USA, ²Florida Intl Univ, Miami, FL, USA,

³Univ of Miami, Miami, FL, USA, ⁴Natl Inst on Alcohol Abuse and Alcoholism, Bethesda, MD, USA

875 THE RELATIVE IMPACTS OF ART AND HARM REDUCTION ON HIV INCIDENCE IN BRITISH COLUMBIA

Bohdan Nosyk, Xiao Zang, Jeong E. Min, Emanuel Krebs, Viviane D. Lima, M-J Milloy, Jean A. Shoveller, Rolando Barrios, Evan Wood, Julio S. Montaner

BC Cntr for Excellence in HIV/AIDS, Vancouver, British Columbia, Canada

Poster P-T1 FERTILITY, CONTRACEPTION, PREGNANCY, AND REPRODUCTIVE HEALTH

Poster Hall - 4 EF

2:30 PM - 4:00 PM

934 PREP USED IN PREGNANCY DOES NOT INCREASE POOR BIRTH OUTCOMES

Renee Heffron¹, Nelly Mugo², Ting Hong¹, Elizabeth A. Bukusi², Elly T. Katabira³, Stephen Asiimwe⁴, Mark A. Marzinke⁵, Connie L. Celum¹, Jared Baeten¹, for the Partners Demonstration Project and Partners PrEP Study Teams

¹Univ of Washington, Seattle, WA, USA, ²Kenya Med Rsr Inst, Nairobi, Kenya,

³Makerere Univ, Kampala, Uganda, ⁴Kabwohe Clinical Rsr Cntr, Kabwohe, Uganda, ⁵The Johns Hopkins Univ, Baltimore, MD, USA

935 PREGNANCY INCIDENCE AND OUTCOMES AMONG WOMEN USING THE DAPIVIRINE VAGINAL RING

Bonus Makanani¹, Jennifer Balkus², Thesla Palanee-Phillips³, Yamikani Mbilizi¹, Jeanna Piper⁴, Kenneth Kintu⁵, Tchangani Tembo⁶, Lisa Noguchi⁷, Helen Rees³, Jared Baeten⁸

¹Malawi Coll of Med—Johns Hopkins Univ Rsr Proj, Blantyre, Malawi, ²Fred Hutchinson Cancer Rsr Cntr, Seattle, WA, USA, ³Wits Reproductive Hlth and HIV Inst, Johannesburg, South Africa, ⁴NIH, Bethesda, MD, USA, ⁵Makerere Univ—Johns Hopkins Univ Rsr Collab, Kampala, Uganda, ⁶Univ of North Carolina Proj—Malawi, Lilongwe, Malawi, ⁷The Johns Hopkins Univ, Baltimore, MD, USA, ⁸Univ of Washington, Seattle, WA, USA

- 936 PREFERENCE AND CHOICE OF MULTIPURPOSE PREVENTION TECHNOLOGIES IN YOUNG AFRICAN WOMEN**
Ariane van der Straten¹, Helen Cheng¹, Kawango Agot², Khatija Ahmed³, Rachel Weinrib¹, Kgahliso Manenzhe³, Fredrick Owino², Alexandra Minnis¹, for the Trio Study Team
¹RTI Intl, San Francisco, CA, USA, ²Impact Rsr and Development Org, Kisumu, Kenya, ³Setshaba Rsr Cntr, Pretoria, South Africa
- 937 MODERN CONTRACEPTIVE USE AND UNPROTECTED SEX IN HIGH-RISK HIV-POSITIVE WOMEN IN KENYA**
Diya Surie¹, Krista Yuhas¹, Kate Wilson¹, Linnet N. Masese¹, Juma Shafi², John Kinuthia³, Walter Jaoko², R. Scott McClelland¹
¹Univ of Washington, Seattle, WA, USA, ²Univ of Nairobi, Nairobi, Kenya, ³Kenyatta Natl Hosp, Nairobi, Kenya
- 938 INTERACTION BETWEEN ETONOGESTREL-RELEASING IMPLANT AND 3 ANTIRETROVIRAL REGIMENS**
Regis Kreitchmann¹, Alice Stek², Brookie Best³, Edmund Capparelli³, Jiajia Wang⁴, David E. Shapiro⁴, Nahida Chakhtoura⁵, Sandra Burchett⁶, Mark Mirochnick⁷, for the IMPAACT P1026s Protocol Team
¹Irmandade da Santa Casa de Misericórdia de Porto Alegre, Porto Alegre, Brazil, ²Univ of Southern California, Los Angeles, CA, USA, ³Univ of California San Diego, La Jolla, CA, USA, ⁴Harvard Univ, Boston, MA, USA, ⁵NICHD, Bethesda, MD, USA, ⁶Boston Children's Hosp, Boston, MA, USA, ⁷Boston Med Cntr, Boston, MA, USA
- 939 FERTILITY AND REPRODUCTIVE OUTCOMES OF HIV+ AND HIV- WOMEN IN THE CARMA COHORT STUDY**
Clara E. Van Ommen¹, Arianne Y. Albert², Ariel Nesbitt¹, Shanlea Gordon³, Evelyn J. Maan³, Helene C. Cote¹, Neora Pick¹, Deborah M. Money¹, Melanie C. Murray¹, for the CIHR Team on Cellular Aging and HIV Comorbidities in Women and Children (CARMA)
¹Univ of British Columbia, Vancouver, Canada, ²Women's Hlth Rsr Inst, Vancouver, Canada, ³Oak Tree Clinic, Vancouver, Canada
- 940 EARLY ONSET MENOPAUSE AMONG WOMEN LIVING WITH HIV IN CANADA**
Nisha Andany¹, Angela Kaida², Alexandra de Pokomandy³, Lu Wang⁴, V. Logan Kennedy¹, Mark Yudin⁵, Kath Webster⁶, Anita Benoit⁷, Mona Loutfy¹, for the CHIWOS Research Team
¹Women's Coll Rsr Inst, Toronto, Ontario, Canada, ²Simon Fraser Univ, Burnaby, British Columbia, Canada, ³McGill Univ, Montreal, Canada, ⁴BC Cntr for Excellence in HIV/AIDS, Vancouver, British Columbia, Canada, ⁵St. Michael's Hosp, Toronto, Ontario, Canada, ⁶CHIWOS Study, Vancouver, Canada, ⁷Univ of Toronto, Toronto, Ontario, Canada
- 941 COST-EFFECTIVENESS OF 2 METHODS TO TREAT CERVICAL DYSPLASIA IN HIV-POSITIVE WOMEN**
Naomi Lince-Deroche¹, Craig Van Rensburg¹, Jane Phiri¹, Pamela Michelow², Jennifer Smith³, **Cindy Firnhaber**⁴
¹Hlth Economics and Epi Rsr Office, Johannesburg, South Africa, ²NHLS, Johannesburg, South Africa, ³Univ of North Carolina at Chapel Hill, Chapel Hill, NC, USA, ⁴Right to Care, Johannesburg, South Africa
- 942 FERTILITY DESIRES OF HIV-POSITIVE MEN AND WOMEN IN THE US**
Susan E. Cohn¹, **Lisa B. Haddad**², Christina S. Hayford¹, Anandi N. Sheth², Justin A. Schmandt¹, Joan S. Chmiel¹
¹Northwestern Univ, Chicago, IL, USA, ²Emory Univ, Atlanta, GA, USA

Poster P-T2 HOT FLASHES: HORMONAL CONTRACEPTION AND HIV RISK
Poster Hall - 4 EF **2:30 PM - 4:00 PM**

943 CHANGES IN GENITAL-TRACT HIV TARGET CELLS WITH THREE PROGESTIN-BASED CONTRACEPTIVES

Lisa B. Haddad¹, Alison S. Kohlmeier², Richard Haaland², Nakita Brown¹, David Lupo², Christina Mehta¹, Anandi N. Sheth¹, Kehmia Titanji¹, Clyde Hart², Igbo Ofofokun¹

¹Emory Univ, Atlanta, GA, USA, ²CDC, Atlanta, GA, USA

944 DEPOT MEDROXYPROGESTERONE ACETATE INCREASES HIV-1 REPLICATION IN MUCOSAL TISSUE

Charlene S. Dezzutti¹, Seo Young Park¹, Ingrid Macio², Kenneth Marks³, Sidney Lawlor³, Catherine Chappell⁴, Katherine Bunge⁴

¹Univ of Pittsburgh, Pittsburgh, PA, USA, ²Univ of Pittsburgh Med Cntr, Pittsburgh, PA, USA, ³Magee-Womens Rsr Inst, Pittsburgh, PA, USA, ⁴Magee-Womens Hosp of UPMC, Pittsburgh, PA, USA

945 ZIM-CHIC: IMPACT OF CONTRACEPTIVE INITIATION ON IMMUNE CELLS IN THE CERVIX AND PBMCS

Sharon L. Achilles¹, Feliz Mhlanga², Leslie A. Meyn¹, Kevin A. Stoner³, Allen T. Matubu², Zvavahera M. Chirenje², Sharon L. Hillier¹

¹Univ of Pittsburgh, Pittsburgh, PA, USA, ²Univ of Zimbabwe, Harare, Zimbabwe, ³Magee-Womens Rsr Inst, Pittsburgh, PA, USA

946 HIV GENITAL-TRACT SHEDDING WHILE ON PROGESTIN CONTRACEPTION

Julie A. Nelson¹, Jeff Wiener², Jennifer H. Tang¹, Lameck Chinula³, Stacey Hurst², Gerald Tegha³, Albans Msika³, Mina C. Hosseinipour³, Lisa B. Haddad⁴, Athena Kourtis²

¹Univ of North Carolina at Chapel Hill, Chapel Hill, NC, USA ²CDC, Atlanta, GA, USA, ³Univ of North Carolina Proj—Malawi, Lilongwe, Malawi, ⁴Emory Univ, Atlanta, GA, USA

947 HORMONAL CONTRACEPTION DOES NOT AFFECT ART EFFECTIVENESS OR GENITAL HIV SHEDDING

Rena Patel¹, Jared Baeten¹, Renee Heffron¹, Ting Hong¹, Nicole Davis², Kavita Nanda³, Robert Coombs¹, Elizabeth A. Bukusi⁴, Athena Kourtis², Nelly Mugo⁵

¹Univ of Washington, Seattle, WA, USA, ²CDC, Atlanta, GA, USA, ³FHI 360, Durham, NC, USA, ⁴Kenya Med Rsr Inst, Nairobi, Kenya, ⁵KEMRI, Nairobi, Kenya

Poster P-T3 GENITAL INFECTIONS: MISHAPS AT THE MUCOSA
Poster Hall - 4 EF **2:30 PM - 4:00 PM**

948 ASYMPTOMATIC ANAL CHLAMYDIA AND GONORRHEA ARE ASSOCIATED WITH CD8+ T-CELL ACTIVATION

Vinícius A. Vieira¹, Natalia B. Cerqueira¹, Dayane A. Costa¹, Priscilla R. Costa¹, Vivian I. Avelino-Silva², Ricardo D. Vasconcelos², Jose Valdez Madruga², Valdilea Veloso³, Beatriz Grinsztejn³, Esper G. Kallas¹

¹Univ of Sao Paulo, Sao Paulo, Brazil, ²Centro de Referência e Treinamento DST/AIDS—SP, Sao Paulo, Brazil, ³Oswaldo Cruz Fndn—Fiocruz, Rio de Janeiro, Brazil

949 MUCOSAL INFLAMMATION ABROGATES TENOFOVIR-GEL-MEDIATED PROTECTION FROM HIV INFECTION

Lyle McKinnon¹, Lenine Liebenberg², Nonhlanhla Yende², Lindi Masson³, Angela Kashuba⁴, Derseree Archary², Quarraisha Abdool Karim², Salim Abdool Karim², Jo-Ann Passmore², for the CAPRISA Mucosal Immunology Collaboration

¹Univ of Manitoba, Winnipeg, Manitoba, Canada, ²CAPRISA, Durban, South Africa, ³Univ of Cape Town, Cape Town, South Africa, ⁴Univ of North Carolina at Chapel Hill, Chapel Hill, NC, USA

950 IS SYNDROMIC DIAGNOSIS OF REPRODUCTIVE TRACT INFECTIONS ANTIQUATED IN THE HIV ERA?

Harriet Nuwagaba-Biribonwoha¹, Hannah Chung¹, Asungushe Kayombo², Deodatha Mugisha¹, Kokuhumbya Kazaura³, Oscar Ernest¹, Gissenge J. Lija⁴, Deborah Kajoka⁴, Jessica E. Justman¹, Elaine J. Abrams¹

¹ICAP at Columbia Univ, New York, NY, USA, ²Natl Inst of Med Rsr, Mwanza, Tanzania, United Republic of, ³CDC Tanzania, Dar es Salaam, Tanzania, ⁴Tanzania Ministry of Hlth, Community Development, Gender, Elderly and Children, Dar es Salaam, Tanzania

Poster P-U2 PREP WITHOUT BORDERS: NEW DELIVERY OPTIONS

Poster Hall - 4 EF

2:30 PM - 4:00 PM

961 FEASIBILITY OF A PHARMACIST-RUN HIV PREP CLINIC IN A COMMUNITY PHARMACY SETTING

Elyse Tung¹, Annalisa Thomas¹, Allyson Eichner¹, Peter Shalit²

¹Kelley-Ross Pharm, Seattle, WA, USA, ²Univ of Washington, Seattle, WA, USA

962 ASSESSING THE EFFICACY AND FEASIBILITY OF A RETAIL PHARMACY-BASED HIV TESTING PROGRAM

Bryan C. Collins, Heather W. Bronson, Elaine G. Martin

Virginia Dept of Hlth, Richmond, VA, USA

963 MIDWEST PHARMACISTS' KNOWLEDGE OF & WILLINGNESS TO PROVIDE PREEXPOSURE PROPHYLAXIS

Jordan Broekhuis, Kimberly K. Scarsi, Harlan Sayles, Donald Klepser, Joshua Havens, Susan Swindells, Sara H. Bares

Univ of Nebraska, Omaha, NE, USA

964 TEXT MESSAGING IS ASSOCIATED WITH IMPROVED RETENTION IN A CLINIC-BASED PREP PROGRAM

Christine M. Khosropour¹, Richard T. Lester², Matthew R. Golden¹, Julia C. Dombrowski¹

¹Univ of Washington, Seattle, WA, USA, ²Univ of British Columbia, Vancouver, British Columbia, Canada

965 BRIEF BEHAVIORAL INTERVENTION INCREASES PREP DRUG LEVELS IN A REAL-WORLD SETTING

Sarit A. Golub¹, Stephanie Pena², Amy Hilley³, John Pachankis⁴, Asa Radix²

¹City Univ of New York, New York, NY, USA, ²Callen-Lorde Community Hlth Cntr, New York, NY, USA, ³Hunter HIV/AIDS Rsr Team, New York, NY, USA, ⁴Yale Univ, New Haven, CT, USA

Poster P-U3 PREP AWARENESS, TARGETING, AND UPTAKE

Poster Hall - 4 EF

2:30 PM - 4:00 PM

966 **FOUR-YEAR TRENDS IN AWARENESS AND USE OF HIV PREP AMONG GBMSM IN VANCOUVER, CANADA**

Moliehi Khaketla¹, Nathan J. Lachowsky², Heather L. Armstrong³, Zishan Cui³, Mark Hull³, Paul Sereda³, Robert S. Hogg³, Julio S. Montaner³, Eric Roth², David Moore¹

¹Univ of British Columbia, Vancouver, Canada, ²Univ of Victoria, Victoria, Canada, ³BC Cntr for Excellence in HIV/AIDS, Vancouver, British Columbia, Canada

967 **KNOWLEDGE ABOUT PREP AMONG MSM AND TRANS* METHAMPHETAMINE USERS IN SEATTLE**

Vanessa McMahan¹, Aleks Martin², Lindsay Garske², Jared Baeten¹, Caleb Banta-Green¹, Joanne Stekler¹

¹Univ of Washington, Seattle, WA, USA, ²Proj NEON, Seattle, WA, USA

968 **A CLINICAL HIV PREEXPOSURE PROPHYLAXIS EDUCATION INTERVENTION AMONG MSM**

Julia Raifman¹, Catherine E. Oldenburg², Amy Nunn³, Madeline C. Montgomery³, Alexi Almonte⁴, Allison Agwu¹, Renata Arrington-Sanders¹, Philip A. Chan⁴

¹The Johns Hopkins Univ, Baltimore, MD, ²Univ of California San Francisco, San Francisco, CA, USA, ³Brown Univ, Providence, RI, USA, ⁴Miriam Hosp, Providence, RI, USA

969 **PREP GUIDELINES HAVE LIMITED ACCURACY IDENTIFYING YOUNG MSM PRIOR TO SEROCONVERSION**

Nicola Lancki, Ellen Almirol, Leigh Alon, Moira McNulty, **John A. Schneider**

Univ of Chicago, Chicago, IL, USA

970 **IDENTIFYING PREGNANT WOMEN FOR PREP USING ROUTINE ANTENATAL CARE INDICATORS IN KENYA**

Jillian Pintye¹, Benson Singa², Kennedy Wanyonyi², Janet Itindi², John Kinuthia³, Lucy Ng'ang'a⁴, Agnes Langat⁴, Abraham Katana⁴, Christine J. McGrath⁵, Grace John-Stewart¹

¹Univ of Washington, Seattle, WA, USA, ²Kenya Med Rsr Inst, Nairobi, Kenya, ³Kenyatta Natl Hosp, Nairobi, Kenya, ⁴US CDC, Nairobi, Kenya, ⁵Univ of Texas Med Branch, Galveston, TX, USA

971 **PREP UPTAKE DISPARITIES IN A DIVERSE ON-LINE SAMPLE OF US MEN WHO HAVE SEX WITH MEN**

Kenneth H. Mayer¹, Katie Biello², David S. Novak³, Douglas Krakower⁴, Matthew J. Mimiaga²

¹Fenway Hlth, Boston, MA, USA, ²Brown Univ, Providence, RI, USA, ³On-Line Buddies, Inc, Cambridge, MA, USA, ⁴Beth Israel Deaconess Med Cntr, Boston, MA, USA

Poster P-U4 PREP PERSISTENCE, ADHERENCE, AND OUTCOMES**Poster Hall - 4 EF****2:30 PM - 4:00 PM****972 IMPACT OF INSURANCE COVERAGE ON PREEXPOSURE PROPHYLAXIS FOR HIV PREVENTION****Rupa R. Patel**¹, Leandro Mena², Amy Nunn³, Timothy McBride¹, Laura C. Harrison¹, Catherine E. Oldenburg⁴, Jingxia Liu¹, Kenneth H. Mayer⁵, Philip A. Chan⁶¹Washington Univ in St. Louis, St. Louis, MO, USA, ²Univ of Mississippi, Jackson, MS, USA, ³Brown Univ, Providence, RI, USA, ⁴Univ of California San Francisco, San Francisco, USA, ⁵Fenway Hlth, Boston, USA, ⁶The Miriam Hosp, Providence, RI, USA**973 CONCORDANT POPULATION-LEVEL INCREASES IN PREP FOUND WITH NOVEL PUBLIC HEALTH METHODS****Susan Buskin**¹, Julia Hood¹, Sara N. Glick², Warren Dinges³, Matthew R. Golden²¹Pub Hlth—Seattle & King County, Seattle, WA, USA, ²Univ of Washington, Seattle, WA, USA, ³Seattle Infectious Disease Clinic, Seattle, WA, USA**974 RACIAL/ETHNIC DISPARITIES IN PERSISTENCE AMONG PREP USERS IN SAN FRANCISCO****Hyman Scott**¹, Miranda Nordell¹, Anne Hirozawa¹, Monica Gandhi², Catherine James¹, Hali Hammer¹, Susan Buchbinder¹, Susan Scheer¹¹San Francisco Dept of Pub Hlth, San Francisco, CA, USA, ²Univ of California San Francisco, San Francisco, CA, USA**975 URINE TENOFOVIR TESTING TO MEASURE PREP ADHERENCE AMONG YOUTH IN A REAL WORLD SETTING**Linden Lalley-Chareczko¹, Devon Clark¹, Ganesh S. Moorthy², Athena Zuppa³, Caitlin Conyngham¹, Karam Mounzer¹, Pablo Tebas², **Helen C. Koenig**²¹Philadelphia FIGHT, Philadelphia, PA, USA, ²Univ of Pennsylvania, Philadelphia, PA, USA, ³Children's Hosp of Philadelphia, Philadelphia, PA, USA**976 COMBINING MEASURES OF ADHERENCE CAN ASSESS PATTERNS OF PREP DRUG-TAKING****Andrew M. Abaasa**¹, Craig Hendrix², Monica Gandhi³, Peter Anderson⁴, Anatoli Kamali⁵, Eduard Sanders⁶, Gaudensia Mutua⁷, Frances Priddy⁵, Haberer Jessica⁸¹MRC/UVRI Uganda Rsr Unit on AIDS, Entebbe, Uganda, ²The Johns Hopkins Univ, Baltimore, MD, USA, ³Univ of California San Francisco, San Francisco, CA, USA, ⁴Univ of Colorado, Aurora, CO, USA, ⁵Intl AIDS Vaccine Initiative, New York, NY, USA, ⁶Kenya Med Rsr Inst, Kilifi, Kenya, ⁷Univ of Nairobi, Nairobi, Kenya, ⁸Cntr for Global Hlth, Massachusetts General Hosp, Boston, MA, USA**977 SUBSTANCE-USING MSM ON HIV PREEXPOSURE PROPHYLAXIS HAVE BETTER ADHERENCE****Martin Hoenigl**¹, Sonia Jain², David J Moore¹, Deborah Collins³, Xiaoying Sun², Peter L. Anderson⁴, Katya Calvo⁵, Michael Dube⁶, Sheldon Morris¹, for the California Collaborative Treatment Group (CCTG) 595 Team¹Univ of California San Diego, San Diego, CA, USA, ²Univ of California San Diego, La Jolla, CA, USA, ³Long Beach HHS, Long Beach, CA, USA, ⁴Univ of Colorado Denver, Aurora, CO, USA, ⁵Los Angeles Biomed Rsr Inst at Harbor—UCLA Med Cntr, Torrance, CA, USA, ⁶Univ of Southern California, Los Angeles, CA, USA

978 OLDER AGE ASSOCIATED WITH BOTH ADHERENCE AND RENAL DECLINE IN THE PREP DEMO PROJECT

Monica Gandhi¹, Peter Bacchetti¹, Catherine A. Koss¹, Chengshi Jin¹, Howard Horng¹, Richard Elion², Michael Kolber³, Stephanie E. Cohen⁴, Susan Buchbinder⁴, Albert Y. Liu⁴

¹Univ of California San Francisco, San Francisco, CA, USA, ²The George Washington Univ, Washington, DC, USA, ³Univ of Miami, Miami, FL, USA, ⁴San Francisco Dept of Pub Hlth, San Francisco, CA, USA

979 CHANGES IN SEXUAL BEHAVIOR AND STI DIAGNOSES AMONG MSM USING PREP IN SEATTLE, WA

Michalina A. Montano, Julia C. Dombrowski, Lindley A. Barbee, Matthew R. Golden, Christine M. Khosropour

Univ of Washington, Seattle, WA, USA

980 LABORATORY TESTING OF A US COHORT OF PRIVATELY INSURED USERS OF HIV PREP, 2011–2014

Ya-Lin A. Huang, Guoyu Tao, Taraz Samandari, Karen W. Hoover
CDC, Atlanta, GA, USA

981 BONE CHANGES WITH TDF-CONTAINING AND NON-TDF-CONTAINING PREP IN US MEN AND WOMEN

Todd Brown¹, Timothy Wilkin², Kenneth H. Mayer³, Raphael J. Landovitz⁴, Ying Q. Chen⁵, Alicia Young⁶, Mark A. Marzinke¹, Wairimu Chege⁷, Marybeth McCauley⁸, Roy M. Gulick²

¹The Johns Hopkins Univ, Baltimore, MD, USA, ²Weill Cornell Med, New York, NY, USA, ³Fenway Hlth, Boston, MA, USA, ⁴Univ of California Los Angeles Cntr for Clinical AIDS Rsr & Educ, Los Angeles, CA, USA, ⁵Fred Hutchinson Cancer Rsr Cntr, Seattle, WA, USA, ⁶Statistical Cntr for HIV/AIDS Rsr and Prevention, Seattle, WA, USA, ⁷NIAID, Bethesda, MD, USA, ⁸FHI 360, Washington, DC, USA

Poster P-W1 MEASURING THE GLOBAL HIV CARE CASCADE**Poster Hall - 4 EF****2:30 PM - 4:00 PM****988 BOTSWANA'S PROGRESS TOWARDS THE THIRD "90": VIRAL SUPPRESSION IN THE MASA PROGRAM**

Madisa Mine¹, Julia Ngidi¹, Lesego Gabaititi², Joseph N. Jarvis³, Modiri Tau¹, Ava Avalos¹, Tendani Gaolathe⁴, Dinah Ramabyaa⁵, Bornaparte Nkomo⁵

¹Natl Hlth Lab, Gaborone, Botswana, ²Univ of Botswana, Gaborone, Botswana, ³CDC Botswana, Gaborone, Botswana, ⁴Botswana Harvard AIDS Inst Partnership, Gaborone, Botswana, ⁵Ministry of Hlth, Gaborone, Botswana

989 POPULATION-LEVEL VIRAL-LOAD MONITORING TO MEASURE PROGRESS TOWARDS THE "THIRD 90"

Maia Lesosky¹, Nei-Yuan M. Hsiao¹, Wolfgang Preiser², Jean Maritz³, Landon Myer¹

¹Univ of Cape Town, Cape Town, South Africa, ²Stellenbosch Univ, Cape Town, South Africa, ³NHLS, Cape Town, South Africa

990 CONTEMPORARY DISENGAGEMENT FROM ANTIRETROVIRAL THERAPY IN KHAYELITSHA, SOUTH AFRICA

Samantha Kaplan¹, Christa Oosthuizen², Kathryn Stinson², Francesca Little², Jonathan Euvrard², Meg Osler², Katherine Hilderbrand², Andrew Boule², Graeme Meintjes²

¹Yale Univ Sch of Med, New Haven, CT, USA, ²Univ of Cape Town, Cape Town, South Africa

991 SELF-REPORTED AND BIOMARKER HIV TREATMENT CASCADES FOR OLDER SOUTH AFRICAN ADULTS

Julia K. Rohr¹, Jennifer Manne-Goehler², Xavier Gomez-Olive³, Joshua A. Salomon⁴, Pascal Geldsetzer⁵, Ryan Wagner⁶, Molly Rosenberg⁷, Chodziwadziwa Kabudula⁴, Kathleen Kahn⁴, Till Baernighausen⁷

¹Harvard Univ, Cambridge, MA, USA, ²Beth Israel Deaconess Med Cntr, Boston, MA, USA, ³Tintswalo Hosp, Acornhoek, South Africa, ⁴Univ of the Witwatersrand, Acornhoek, South Africa, ⁵Indiana Univ, Bloomington, IN, USA, ⁶Univ of the Witwatersrand, Johannesburg, South Africa, ⁷Heidelberg Univ, Heidelberg, Germany

992 MISDIAGNOSED HIV INFECTION IN PREGNANT WOMEN INITIATING UNIVERSAL ART IN SOUTH AFRICA

Allison Zerbe¹, Nei-yuan Hsiao², Tamsin Phillips³, Kirsty Brittain³, Elaine J. Abrams¹, Landon Myer³, for the Maternal Child Health - Antiretroviral Therapy (MCH-ART) Study

¹ICAP at Columbia Univ, New York, NY, USA, ²Div of Med Virology, Cape Town, South Africa, ³Univ of Cape Town, Cape Town, South Africa

993 ACCURACY OF HIV AND CD4 FIELD TESTING IN THE BOTSWANA COMBINATION PREVENTION PROJECT

Ebi Bile¹, **Pamela J. Bachanas**², Fiona Maurice¹, Sylvia Modise¹, Liziwe Chebani³, Vongai Makovore¹, Peter Fonjongo², Mary Grace Alwano¹, William Bapati⁴, Joseph N. Jarvis¹

¹US CDC Botswana, Gaborone, Botswana, ²CDC, Atlanta, GA, USA, ³Botswana Ministry of Hlth, Gaborone, Botswana, ⁴Tebelopele Voluntary Counseling and Testing Cntr, Gaborone, Botswana

994 PATIENTS' OUT-OF-POCKET EXPENDITURES FOR ART IN SWAZILAND

Maria Vaikath¹, **Shaukat Khan**², Emma Mafara², Ndimiso Dlamini², Phiwayinkhosi Dlamini², Nothando Ndzinisa², Njabulo Simelane², Velephi Okello³, Till Baernighausen⁴, Pascal Geldsetzer¹

¹Harvard Univ, Boston, MA, ²Clinton Hlth Access Initiative, Mbabane, Swaziland, ³Swaziland Ministry of Hlth, Mbabane, Swaziland, ⁴Heidelberg Univ, Heidelberg, Germany

995 MARKED MORTALITY AND RETENTION UNDER-REPORTING IN A LARGE HIV PROGRAM IN ZAMBIA

Charles Holmes¹, Izukanji Sikazwe¹, Ingrid Eshun-Wilson², Nancy Czaicki³, Kombatende Sikombe¹, Sandra Simbeza¹, Carolyn Bolton Moore⁴, Cardinal Hantuba¹, Nancy Padian³, Elvin Geng⁵

¹Cntr for Infectious Disease Rsr in Zambia, Lusaka, Zambia, ²Stellenbosch Univ, Cape Town, South Africa, ³Univ of California Berkeley, Berkeley, USA, ⁴Univ of Alabama at Birmingham in Lusaka, Zambia, ⁵Univ of California San Francisco, San Francisco, CA, USA

996 DIFFERENTIAL UPTAKE OF HIV CARE AND TREATMENT BY SEXUAL RISK BEHAVIORS

Veena G. Billioux¹, Larry W. Chang¹, Kate Grabowski¹, Steven Reynolds², Gertrude Nakigozi³, Joseph Ssekasanvu¹, Robert Ssekubugu³, Ronald H. Gray¹, Maria Wawer¹, for the Rakai Health Sciences Program

¹The Johns Hopkins Univ, Baltimore, MD, USA, ²NIAID, Washington, DC, USA, ³Rakai Hlth Scis Prog, Kalisizo, Uganda

Poster P-W3 HIV, MIGRATION, AND ACCESS TO CARE**Poster Hall - 4 EF****2:30 PM - 4:00 PM****1015 MIGRATION, GENDER, AND HIV INCIDENCE IN RAKAI, UGANDA**

Oluwasolape M. Olawore¹, Aaron Tobian², Fred Nalugoda², Ronald H. Gray¹, Maria Wawer¹, Robert Ssekubugu², John Santelli³, Larry W. Chang², David Serwadda⁴, Kate Grabowski¹

¹The Johns Hopkins Univ, Baltimore, MD, USA, ²Rakai Hlth Scis Prog, Kalisizo, Uganda, ³Columbia Univ, New York, NY, USA, ⁴Makerere Univ, Kampala, Uganda

1016 OUTCOMES ALONG THE HIV CARE CONTINUUM AMONG UNDOCUMENTED IMMIGRANTS IN CLINICAL CARE

Jonathan Ross, Uriel Felsen, Chinazo Cunningham, Viraj V. Patel, David B. Hanna

Albert Einstein Coll of Med, Bronx, NY, USA

1017 IMMIGRANTS AND BOTSWANA'S ART PROGRAM: POTENTIAL BARRIERS TO EPIDEMIC CONTROL

Tafireyi Marukutira¹, Mary Grace Alwano¹, Stephanie Behel², Joseph N. Jarvis¹, Unoda Chakalisa³, Kathleen Powis⁴, William Bapati⁵, Gene Ussery⁶, Refeletswe Lebelonyane⁷, Pamela J. Bachanas²

¹US CDC, Gaborone, Botswana, ²CDC, Atlanta, GA, USA, ³Botswana Harvard Partnership, Gaborone, Botswana, ⁴Harvard Univ, Boston, MA, USA, ⁵Tebelopele Voluntary Counseling and Testing Cntr, Gaborone, Botswana, ⁶Northrop Grumman Corporation, Atlanta, GA, USA, ⁷Botswana Ministry of Hlth, Gaborone, Botswana

1018 CASCADE OF CARE OF HIV SEROCONVERTERS IN THE CONTEXT OF UNIVERSAL "TEST AND TREAT"

Joseph Larmarange¹, Mamadou H. Diallo¹, Collins C. Iwuji², Joanna Orne-Gliemann³, Nuala McGrath⁴, Mélanie Plazy³, Frank Tanser⁵, Rodolphe Thiébaud⁶, Deenan Pillay⁵, François Dabis⁶

¹IRD, Paris, France, ²Univ Coll London, UK, London, UK, ³INSERM, Bordeaux, France, ⁴Univ of Southampton, Southampton, UK, ⁵Africa Hlth Rsr Inst, Mtubatuba, South Africa, ⁶Univ de Bordeaux, Bordeaux, France

Poster P-X3 IMPROVING THE EFFECTIVENESS AND COST EFFECTIVENESS OF PREP AND OTHER PREVENTION APPROACHES**Poster Hall - 4 EF****2:30 PM - 4:00 PM****1033 PREP TARGETING STRATEGIES FOR US ADOLESCENT SEXUAL MINORITY MALES: A MODELING STUDY**

Steven M. Goodreau¹, Deven T. Hamilton¹, Patrick Sullivan², Samuel Jenness², Rachel A. Kearns², Li Yan Wang³, Richard Dunville³, Lisa C. Barrios³, Eli Rosenberg²

¹Univ of Washington, Seattle, WA, USA, ²Emory Univ, Atlanta, GA, USA, ³CDC, Atlanta, GA, USA

1034 STI INCIDENCE AMONG MSM FOLLOWING HIV PREEXPOSURE PROPHYLAXIS: A MODELING STUDY

Samuel Jenness¹, Kevin Weiss¹, Steven M. Goodreau², Thomas Gift³, Harrell Chesson³, Karen W. Hoover³, Dawn K. Smith³, Patrick Sullivan¹, Eli Rosenberg¹

¹Emory Univ, Atlanta, GA, USA, ²Univ of Washington, Seattle, WA, USA, ³CDC, Atlanta, GA, USA

1035 ANTICIPATED ADHERENCE, EFFICACY, AND IMPACT OF WEEKLY ORAL PREEXPOSURE PROPHYLAXIS

Christian Selinger¹, Ameya Kirtane², Omar Abouzid², Robert Langer², Carlo G. Traverso³, Anna Bershteyn¹

¹*Inst for Disease Modeling, Bellevue, WA, USA*, ²*Massachusetts Inst of Tech, Cambridge, MA, USA*, ³*Brigham and Women's Hosp, Boston, MA, USA*

1036 POPULATION-LEVEL IMPACT AND COST-EFFECTIVENESS OF AN HIV VACCINE IN SOUTH AFRICA

Christian Selinger¹, Anna Bershteyn¹, Dobromir Dimitrov², Timothy B. Hallett³, Linda-Gail Bekker⁴, Helen Rees⁵, Glenda Gray⁶, for the Pox-Protein Public-Private Partnership Global Access Committee

¹*Inst for Disease Modeling, Bellevue, WA, USA*, ²*Fred Hutchinson Cancer Rsr Cntr, Seattle, WA, USA*, ³*Imperial Coll London, London, UK*, ⁴*Univ of Cape Town, Cape Town, South Africa*, ⁵*Wits Reproductive Hlth and HIV Inst, Johannesburg, South Africa*, ⁶*Perinatal HIV Rsr Unit, Soweto, South Africa*

1037 COST-EFFECTIVENESS OF PREEXPOSURE PROPHYLAXIS ACROSS COUNTIES IN WESTERN KENYA

Anna Bershteyn¹, Daniel J. Klein¹, Adam N. Akullian¹, Zindoga Mukandavire², Graham F. Medley², Wanjiru Mukoma³, Michael K. Kiragu³, Kennedy Mutai⁴, Katharine Kripke⁵, for the OPTIONS Consortium

¹*Inst for Disease Modeling, Bellevue, WA, USA*, ²*London Sch of Hygiene and Trop Med, London, United Kingdom*, ³*LVCT Hlth, Nairobi, Kenya*, ⁴*National AIDS Control Council, Ministry of Hlth, Nairobi, Kenya*, ⁵*Avenir Hlth, Washington, DC, USA*

1038 THE POTENTIAL IMPACT AND COST-EFFECTIVENESS OF MULTIPURPOSE PREVENTION TECHNOLOGIES

Ide Cremin¹, Jennifer Smith¹, Rebecca Geary², Timothy B. Hallett¹

¹*Imperial Coll London, London, UK*, ³*London Sch of Hygiene & Trop Med, London, UK*

1039 THE IMPORTANCE OF A LOCAL PERSPECTIVE IN MONITORING THE SUCCESS OF HIV PREVENTION

Sarah-Jane Anderson¹, Joanne Enstone², Geoff P. Garnett³, Timothy B. Hallett¹

¹*Imperial Coll London, London, UK*, ²*Univ of Nottingham, Nottingham, UK*, ³*Bill and Melinda Gates Fndn, Seattle, WA, USA*

Poster P-A3 HIV CELL INTERACTION

Poster Hall - 4 EF

2:30 PM - 4:00 PM

166 DETECTION AND CHARACTERIZATION OF CELLS EXPRESSING HIV RNA BY FLOW CYTOMETRY

Aaron Christensen-Quick¹, Amey Mukim², Celsa A. Spina², Sara Gianella³, Davey M. Smith³

¹Univ of California San Diego, San Diego, CA, USA, ²VA San Diego Hlthcare System, San Diego, CA, USA, ³Univ of California San Diego, La Jolla, CA, USA

167 INFLAMMASOME-REGULATED CYTOKINE IL-37 INHIBITS HIV-1 REPLICATION IN PRIMARY HUMAN CD4

Neel Sangal, Guido Massaccesi, Jeffrey Quinn, Andrea Cox, Matthew Winter, **Michael Chattergoon**

Johns Hopkins Univ, Baltimore, MD, USA

168 BCA2 INTERFERES WITH HIV-1 TRANSCRIPTION BY ENHANCING THE SUMOYLATION OF IKBA

Marta Colomer-Lluch, **Ruth Serra-Moreno**

Texas Tech Univ, Lubbock, TX, USA

169 RHO FAMILY GTPASES ENHANCE HIV-1 INFECTION

Mark Lucera¹, Zach Fleissner², Caroline Tabler², Daniela Schlatter², Zach Troyer², **John Tilton**²

¹Univ of Colorado, Aurora, CO, USA, ²Case Western Reserve Univ, Cleveland, OH, USA

170 SEMEN FACTORS ASSOCIATED WITH SEMEN VIRAL LOAD AND INFECTION-ENHANCING ACTIVITY

Christopher D. Pilcher¹, Kara Marson¹, Peter Bacchetti¹, Sheila Keating², Wendy Hartogensis¹, Teri Liegler¹, H. Ewa Witkowska¹, Satish K. Pillai², Frederick M. Hecht¹, Nadia R. Roan³

¹Univ of California San Francisco, San Francisco, CA, USA, ²Blood Systems Rsr Inst, San Francisco, CA, USA, ³Gladstone Inst of Virology, San Francisco, CA, USA

171LB STRUCTURAL BASIS FOR INHIBITOR-INDUCED AGGREGATION OF HIV INTEGRASE

Kushol Gupta¹, Vesa Turkki¹, Scott Sherrill-Mix¹, Young Hwang¹, Grant Eilers¹, Robert T. Nolte², Emile Velthuisen², Jerry Jeffrey², Gregory Van Duyn¹, Frederic Bushman¹

¹Univ of Pennsylvania, Philadelphia, PA, USA, ²Glaxosmithkline, Rsr Triangle Park, NC, USA

Poster P-A5 VIRUS ADAPTATION TO IMMUNITY

Poster Hall - 4 EF

2:30 PM - 4:00 PM

176 HLA-B27—RESTRICTED CTL-ESCAPE MUTATIONS INCREASE SENSITIVITY OF HIV-1 TO INTERFERON ?

Philipp Schommers¹, Christopher Ford², Angelique Hölzemer², Gerd Fätkenheuer¹, Marcus Atlfeld²

¹Univ of Cologne, Cologne, Germany, ²Heinrich Pette Inst, Hamburg, Germany

177 CXCR4 VARIANTS ARE NEUTRALIZATION-RESISTANT COMPARED TO CCR5-USING VIRUSES IN HIV-1B

Ludy Registre¹, Yvetane Moreau², Sila Ataca¹, Manish Sagar¹

¹Boston Univ, Boston, MA, USA, ²Boston Med Cntr, Boston, MA, USA

- 178 MEASURING FITNESS OF IN VIVO ESCAPE MUTATIONS IN SIV ENV BY FITSEQ**
Sergio Ita¹, Alison Hill², Evan Lam², Ismael B. Fofana², Welkin E. Johnson²
¹Univ of California San Diego, La Jolla, CA, USA, ²Boston Coll, Chestnut Hill, MA, USA
- 179 SIV ESCAPE FROM A VACCINE TARGETING CLEAVAGE SITES IS ASSOCIATED WITH A FITNESS LOSS**
So-Yon Lim¹, David Tang², David La², Shaun Tyler², Ben Liang², Francis Plummer², Ma Luo², James Whitney¹
¹Beth Israel Deaconess Med Cntr, Boston, MA, USA, ²Natl MicroBio Lab, Winnipeg, Canada
- 180 MUTATIONS IN HIV-1 ENV RESCUE REPLICATION DEFECTS DESPITE POOR CELL-FREE INFECTIVITY**
Rachel Van Duyne, Lillian Kuo, Ken Fujii, Eric O. Freed
 NCI, Frederick, MD, USA
- 181LB RESISTANCE TO TYPE I INTERFERONS IS A MAJOR DETERMINANT OF HIV-1 TRANSMISSION FITNESS**
Shilpa S. Iyer¹, Frederic Bibollet-Ruche¹, Scott Sherill-Mix¹, Gerald H. Learn¹, Lindsey J. Plenderleith², Andrew G. Smith¹, Ronnie M. Russell¹, Paul M. Sharp², Persephone Borrow³, Beatrice H. Hahn¹
¹Univ of Pennsylvania, Philadelphia, PA, USA, ²Univ of Edinburgh, Edinburgh, UK, ³Univ of Oxford, Oxford, UK

Poster P-B3 TIMING INFECTION AND DEFINING FOUNDER SEQUENCES AND DUAL INFECTIONS

Poster Hall - 4 EF

2:30 PM - 4:00 PM

- 196 BLIND DATING: PHYLOGENETIC DETERMINATION OF LATENT HIV SEQUENCE AGES WITHIN HOST**
Bradley R. Jones¹, Joshua Horacsek¹, Jeffrey Joy², Zabrina Brumme¹, Art Poon²
¹Simon Fraser Univ, Burnaby, British Columbia, Canada, ²Univ of British Columbia, Vancouver, British Columbia, Canada
- 197 HIV-1 SEQUENCES FROM EARLY INFECTION PREDICT THE AGE OF THE INFECTION**
Morgane Rolland¹, Christopher L. Owen¹, Sodsai Tovanabutra¹, Eric Sanders-Buell¹, Lucas Maganga², Hannah Kibuuka³, Sorachai Nitayaphan⁴, Fredrick Sawe⁵, Merlin L. Robb¹, Nelson L. Michael¹
¹US Military HIV Rsr Prog, Silver Spring, MD, USA, ²MMRP, Mbeya, Tanzania, United Republic of, ³Makerere Univ Walter Reed Proj, Kampala, Uganda, ⁴AFRIMS, Bangkok, Thailand, ⁵Kenya Med Reseach Inst/Walter Reed Proj, Kericho, Kenya
- 198 USING PRIMER ID DEEP SEQUENCING TO IDENTIFY RECENT HIV INFECTION IN NORTH CAROLINA**
Shuntai Zhou¹, Christopher Sellers¹, Marc Potempa¹, Scott J. Zimmerman², Erkia Samoff³, William C. Miller⁴, Joseph J. Eron¹, Myron S. Cohen¹, Ronald Swanstrom¹, Ann M. Dennis¹
¹Univ of North Carolina at Chapel Hill, Chapel, NC, USA, ²North Carolina State Lab of Pub Hlth, Raleigh, NC, USA, ³North Carolina Div of Pub Hlth, Raleigh, NC, USA, ⁴Ohio State Univ, Columbus, OH, USA

199 CHARACTERIZATION OF RECTAL TRANSMISSION BOTTLENECK USING SIV-MACAQUE MODEL

Zhe Yuan¹, Fangrui Ma¹, Andrew J. Demers¹, Dong Wang², Jianqing Xu³, Mark G. Lewis⁴, Qingsheng Li¹

¹Univ of Nebraska—Lincoln, Lincoln, NE, USA, ²Dow AgroScis, LLC, Indianapolis, IN, USA, ³Fudan Univ, Shanghai, China, ⁴BIOQUAL, Inc, Rockville, MD, USA

200 HIV-1 SUPERINFECTION AFTER RECENT INFECTION IS UNCOMMON IN SUB-SAHARAN AFRICA

Gabriel A. Wagner¹, Parris S. Jordan¹, Sergei L. Kosakovsky Pond², Matt A. Price³, Eric Hunter⁴, Susan Allen⁴, William Kilembe⁵, Douglas D. Richman¹, Antoine Chaillon¹, for the IAVI

¹Univ of California San Diego, La Jolla, CA, USA, ²Temple Univ, Philadelphia, PA, USA, ³Intl AIDS Vaccine Initiative, New York, NY, USA, ⁴Emory Univ, Atlanta, GA, USA, ⁵Zambia—Emory HIV Rsr Proj, Atlanta, GA, USA

201 FREQUENT INTRASUBTYPE HIV DUAL INFECTION IN TREATED CHRONICALLY INFECTED INDIVIDUALS

Gabriel A. Wagner¹, Antoine Chaillon¹, Gemma Caballero², Donald Franklin¹, Sergei L. Kosakovsky Pond³, Robert K. Heaton¹, Douglas D. Richman¹, Davey M. Smith¹, for the CHARTER

¹Univ of California San Diego, La Jolla, CA, USA, ²VA San Diego Hlthcare System, La Jolla, CA, USA, ³Temple Univ, Philadelphia, PA, USA

Poster P-C6 CORRELATES OF HIV DISEASE

Poster Hall - 4 EF

2:30 PM - 4:00 PM

228 GENOME-WIDE METHYLATION IS ASSOCIATED WITH HIV-1 INFECTION AND DISEASE PROGRESSION

Sara Moron-Lopez¹, Judith Dalmau¹, Victor Urrea¹, Miguel Lopez², Maria C. Puertas¹, Beatriz Mothe¹, Christian Brander¹, Manel Esteller², Maria Berdasco², Javier Martinez-Picado¹

¹IrsiCaixa Inst for AIDS Rsr, Badalona, Spain, ²Bellvitge Biomed Rsr Inst, L'Hosp de Llobregat, Spain

229 MITOCHONDRIAL HAPLOGROUP AND HLA-B MAY JOINTLY INFLUENCE HIV VIRAL LOAD AND CD4 COUNT

Samuel Bailin, Mark Pilkinton, David C. Samuels, Silvana Gaudieri, Spyros Kalams, Todd Hulan

Vanderbilt Univ, Nashville, TN, USA

230 T-CELL PHENOTYPE AND RECEPTOR DIVERSITY IN BLOOD & ADIPOSE TISSUE FROM HIV+ PERSONS

John R. Koethe, Arion Kennedy, Wyatt J. McDonnell, Ian Setliff, Chike O. Abana, Mark Pilkinton, Cindy Hager, Spyros Kalams, Alyssa Hasty, Simon Mallal

Vanderbilt Univ, Nashville, TN, USA

231 REDUCED APOPTOSIS CONTRIBUTES TO GASTROINTESTINAL NEUTROPHIL INFILTRATION IN HIV

Tiffany Hensley-McBain¹, Jennifer Manuzak¹, Charlene Miller¹, Alexander S. Zevin¹, Eric Lee², Cara Wilson², Thomas Hope³, Adam Burgener⁴, Nichole Klatt¹

¹Univ of Washington, Seattle, WA, USA, ²Univ of Colorado Anschutz Med Campus, Aurora, CO, USA, ³Northwestern Univ, Evanston, IL, USA, ⁴Pub Hlth Agency of Canada, Winnipeg, Canada

- 232 HIV INDUCES LIPID ACCUMULATION IN ALVEOLAR MACROPHAGES IN VITRO**
Amy K. Dickey¹, Bjorn Corleis², Abigail Schiff³, Antonella Lisante², Benjamin Medoff¹, Josalyn Cho¹, Douglas Kwon²
¹Massachusetts General Hosp, Boston, MA, USA, ²Ragon Inst of MGH, MIT, and Harvard, Cambridge, MA, USA, ³Harvard Univ, Boston, MA, USA
- 233 TIM-3 IS A MARKER OF PDC DYSFUNCTION IN HIV INFECTION**
Jordan A. Schwartz¹, Kiera L. Clayton¹, Shariq Mujib¹, Hongliang Zhang¹, Nur-ur Rahman¹, Jun Liu¹, Feng Yun Yue¹, Erika Benko², Colin Kovacs¹, Mario Ostrowski¹
¹Univ of Toronto, Toronto, Canada, ²Maple Leaf Med Clinic, Toronto, Canada
- 234 IMMUNE CHECKPOINT MOLECULES IN HIV AND AGING**
Lesley R. de Armas, Suresh Pallikkuth, Sidney Lane, Rajendra Pahwa, Varghese George, Stefano Rinaldi, Margaret Fischl, Gordon Dickinson, Allan Rodriguez, Savita Pahwa
 Univ of Miami, Miami, FL, USA
- 235 SOLUBLE UPAR PREDICTS ALL-CAUSE MORTALITY FROM HIV-1 INFECTION**
 Ditte M Kirkegaard-Klitbo, Anne Langkilde, Niels Mejer, Ove Andersen, Jesper Eugen-Olsen, Thomas Benfield
 Hvidovre Hosp, Hvidovre, Denmark
- 236 R5-TROPIC HIV RESISTANCE IN A SUBSET OF ELITE AND VIREMIC CONTROLLERS**
Elena Gonzalo-Gil, Patrick Rapuano, Jimmy Auer, Zach Porterfield, Uchenna Ikediobi, Ayse Coskun, Richard Sutton
 Yale Univ, New Haven, CT, USA
- 237LB MULTI-ANCESTRY GWAS IDENTIFIES NOVEL VARIANTS ASSOCIATED WITH HIV-1 VIRAL LOAD**
Eric O. Johnson¹, Dana B. Hancock¹, Nathan C. Gaddis¹, Christina A Markunas¹, Yuelong Guo¹, Elizabeth T. Golub², Mardge H. Cohen³, Kathryn Anastos⁴, Ruth Greenblatt⁵, Bradley E. Aouizerat⁶
¹RTI Intl, Rsr Triangle Park, NC, USA, ²Johns Hopkins Univ, Baltimore, MD, USA, ³Stroger Hosp, Chicago, IL, USA, ⁴Albert Einstein Coll of Med, Bronx, NY, USA, ⁵Univ of California San Francisco, San Francisco, CA, USA, ⁶New York Univ, New York, NY, USA

Poster P-C7 INTERACTIONS OF HIV WITH OTHER INFECTIONS

Poster Hall - 4 EF

2:30 PM - 4:00 PM

- 238 18F-FDG-PET/CT ABNORMALITIES ARE ASSOCIATED WITH HIGHER RISK OF IRIS IN HIV**
 Dima A. Hammoud¹, Georgios Z. Papadakis¹, **Afroditi Boulougoura**², Virginia Sheikh³, Lori E. Dodd⁴, Jing Wang⁵, Angela Kibiy⁶, JoAnn Mican², Corina Millo¹, Irini Sereti²
¹NIH, Bethesda, MD, USA, ²NIAID, Bethesda, MD, USA, ³FDA, Silver Spring, MD, USA, ⁴NIAID, Rockville, MD, USA, ⁵Leidos Biomed Rsr, Rockville, MD, USA, ⁶Leidos Biomed Rsr, Bethesda, MD, USA
- 239 MAIT CELLS, MICROBIAL TRANSLOCATION AND THE MICROBIOME IN HIV/HCV CHRONIC INFECTIONS**
Esther Merlini¹, Maddalena Cerrone¹, Bonnie van Wilgenburg², Leo Swadling², Camilla Tincati¹, Elvira S. Cannizzo¹, Antonella d'Arminio Monforte¹, Paul Klenerman², Giulia Marchetti¹
¹Univ of Milan, Milan, Italy, ²Univ of Oxford, Oxford, UK

240 IMPACT OF MUCOSAL CMV AND EBV REPLICATION ON ENTERIC MICROBIOME DURING HIV INFECTION

Antoine Chaillon¹, Sara Gianella², Ece A. Mutlu³, Phillip A. Engen³, Robin M. Voigt³, Ali Keshavarzian³, John Losurdo³, Steven Lada², Masato Nakazawa², Alan Landay³

¹Univ of California San Diego, San Diego, CA, USA, ²Univ of California San Diego, La Jolla, CA, ³Rush Univ Med Cntr, Chicago, IL, USA

241 EFFECT OF HIV STATUS, CMV, AND EBV REPLICATION ON MUCOSAL GENE EXPRESSION IN THE GUT

Sara Gianella¹, Antoine Chaillon², Ece A. Mutlu³, Phillip A. Engen³, Robin M. Voigt³, Ali Keshavarzian³, John Losurdo³, Steven Lada¹, Masato Nakazawa¹, Alan Landay³

¹Univ of California San Diego, La Jolla, CA, USA, ²Univ of California San Diego, San Diego, CA, USA, ³Rush Univ, Chicago, IL, USA

Poster P-D2 INFLAMMATION AND IMMUNITY

Poster Hall - 4 EF

2:30 PM - 4:00 PM

251 TELMISARTAN DOES NOT IMPROVE LYMPH NODE OR FAT FIBROSIS IN TREATED HIV INFECTION

Netanya S. Utay¹, Douglas Kitch², Carl Fichtenbaum³, Michael M. Lederman⁴, Jacob D. Estes⁵, Clara Magyar⁶, Karin Klingman⁷, Judith S. Currier⁶, Jordan E. Lake¹, for the A5317 Team

¹Univ of Texas, Galveston, TX, USA, ²Harvard Univ, Boston, MA, USA, ³Univ of Cincinnati, Cincinnati, OH, USA, ⁴Case Western Reserve Univ, Cleveland, OH, USA, ⁵Frederick Natl Lab for Cancer Rsr, Frederick, MD, USA, ⁶Univ of California Los Angeles, Los Angeles, CA, USA, ⁷DAIDS, NIAID, Bethesda, MD, USA

252 PHARMACOLOGIC INHIBITION OF IDO BLUNTS FEATURES OF SIV-RELATED CHRONIC INFLAMMATION

Richard M. Dunham¹, Kevin W. Brown¹, James M. Billingsley², Zhong-Min Ma³, Gregory K. Tharp², Christopher J. Miller³, Steven E. Bosinger², Brian A. Johns¹, David Favre¹

¹GlaxoSmithKline, Durham, NC, USA, ²Yerkes Natl Primate Rsr Cntr, Atlanta, GA, USA, ³Univ of California Davis, Davis, CA, USA

253 HIV-SPECIFIC ANTIBODIES ENHANCE TYPE I INTERFERON PRODUCTION FROM PLASMACYTOID DCS

Rebecca Veenhuis¹, Zachary Freeman¹, Jack Korleski¹, Alessandra Tomasi¹, Austin Boesch², Margaret Ackerman², Joseph B. Margolick¹, Joel Blankson¹, Michael Chattergoon¹, Andrea Cox¹

¹The Johns Hopkins Univ, Baltimore, MD, USA, ²Dartmouth Coll, Hanover, NH, USA

254 TARGETING TYPE I INTERFERON-MEDIATED IMMUNE ACTIVATION TO CONTROL HIV INFECTION

Anjie Zhen¹, Mayra A. Carrillo¹, Valerie Rezek¹, David Brooks², **Scott G. Kitchen**¹

¹Univ of California Los Angeles, Los Angeles, CA, USA, ²Princess Margaret Cancer Cntr, Toronto, Ontario, Canada

255 METFORMIN REDUCES T-CELL EXHAUSTION IN A CLINICAL TRIAL OF HIV-INFECTED ADULTS ON ART

Glen Chew¹, Dominic Chow¹, Scott A. Souza¹, Lindsay Kohorn¹, Richard M. Watanabe², Ivo Sah Bandar¹, Eun-Young Park¹, Mary Margaret Byron¹, Lishomwa C. Ndhlovu¹, Cecilia Shikuma¹

¹Univ of Hawaii, Honolulu, HI, USA, ²Univ of Southern California, Los Angeles, CA, USA

- 256 P2X PURINERGIC RECEPTORS AS THERAPEUTIC TARGETS OF HIV-1 INFECTION AND INFLAMMATION**
Talia Swartz¹, Natasha Durham², Alexandra Soare¹, Meagan O'Brien¹, Nina Bhardwaj¹, Benjamin K. Chen¹
¹Icahn Sch of Med at Mt Sinai, New York, NY, USA, ²Tufts Univ, Boston, MA, USA
- 257 AGE AND HIV DO NOT SYNERGISTICALLY IMPACT T-CELL MATURATION OR ACTIVATION**
Shelli Farhadian¹, Emilie Jalbert², Yanhong Deng³, Matthew B. Goetz⁴, Lesley Park⁵, Amy Justice³, Robert Dubrow³, Brinda Emu¹, for the VACS Project Team
¹Yale Univ, New Haven, CT, USA, ²Univ of Colorado, Aurora, CO, USA, ³VA Greater Los Angeles Hlth Care System, Los Angeles, CA, USA, ⁴Stanford Med, Stanford, CA, USA, ⁵VA Connecticut Hlthcare System, West Haven, CT, USA
- 258 CELLULAR IMMUNE ACTIVATION IN THE ERA OF CART AND AN AGING HIV+ POPULATION**
Lesley R. de Armas, Suresh Pallikkuth, Rajendra Pahwa, Stefano Rinaldi, Varghese George, Li Pan, Allan Rodriguez, Margaret Fischl, Gordon Dickinson, Savita Pahwa
 Univ of Miami, Miami, FL, USA
- 259 ADAR1, A TARGET TO BOOST HIV-1 IMMUNE RESPONSE**
Maria Pujantell, Ester Ballana, Eva Riveira-Muñoz, Bonaventura Clotet, Jose A. Este
 IrsiCaixa Inst for AIDS Rsr, Badalona, Spain
- 260LB LIVER INFLAMMATION CORRELATES WITH SIV LEVELS AND IS ONLY PARTLY REVERSED WITH CART**
Bridget Fisher¹, Rachel Brown¹, Matthew Wood¹, Richard Green², Cole Fisher¹, Michael Gale², Guido Silvestri³, Ann Chahroudi³, Nichole Klatt², Donald Sodora¹
¹Cntr for Infectious Disease Rsr, Seattle, WA, USA, ²Univ of Washington, Seattle, WA, USA, ³Emory Univ, Atlanta, GA, USA

Poster P-D3 CD4 T CELLS: MORE THAN JUST HELP

Poster Hall - 4 EF

2:30 PM - 4:00 PM

- 261 CD57+ CYTOTOXIC CD4+ EFFECTOR T CELLS INCREASE IN CHRONIC HIV INFECTION**
Chansavath Phetsouphanh¹, Jodi Meyerowitz¹, Lyle Murray¹, Dominique Goedhals², Cloete Van Vuuren², Sarah Fidler³, Paul Klennerman¹, John Frater¹
¹Univ of Oxford, Oxford, UK, ²Univ of Free State Med Sch, Bloemfontein, South Africa, ³Imperial Coll London, London, UK
- 262 TARGETING LC WITH ANTI-LANGERIN HIV FUSION MONOCLONAL AB PROMOTES TFH DIFFERENTIATION**
Jérôme Kervevan¹, Aurélie Chaigneau¹, Sandy Zurawski², Marion Bonnet³, Romain Marlin⁴, Marie-Thérèse Nugeyre⁴, Elisabeth Menu⁴, Gerard Zurawski², Yves Levy¹, Sylvain Cardinaud¹
¹INSERM, Créteil, France, ²Baylor Inst for Immunol Rsr, Dallas, TX, USA, ³Univ of Cardiff, Cardiff, UK, ⁴Inst Pasteur, Paris, France
- 263 HIV-1-INFECTION—ASSOCIATED CHANGES IN THE HUMAN CD4+ T-CELL PROTEOME**
Johannes Nemeth¹, Valentina Vongrad², Karin Metzner², Victoria P. Strouville², Rainer Weber², Patrick Pedrioli³, Ruedi Aebersold³, Huldrych F. Günthard², Ben Collins³
¹Cntr for Infectious Disease Rsr, Seattle, WA, USA, ²Univ of Zürich, Zürich, Switzerland, ³ETH Zürich, Zürich, Switzerland

264 CHARACTERIZATION OF PREEXISTING HIV-SPECIFIC CD4 T CELLS IN UNINFECTED INDIVIDUALS

Audrey Daigneault¹, Nathalie Brassard², Amy E. Baxter¹, Lucie Barblu¹, Colin Havenar-Daughton³, Roxanne Charlebois², Jean-Pierre Routy³, Shane Crotty³, **Daniel E. Kaufmann**¹

¹Cntr de Rsr du Cntr Hosp de l'Univ de Montréal, ²La Jolla Inst for Allergy and Immunol, La Jolla, CA, USA, ³McGill Univ Hlth Cntr, Glen site, Montréal, Canada

265LB TFH CELLS FUNCTIONAL PROFILE DRIVES ABNORMAL B CELL MATURATION IN HIV INFECTION

Giuseppe Pantaleo¹, Alessandra Noto¹, Andrew McDavid², Phu Van², Agostino Riva³, Guy Cavet⁴, Song Ding⁵, Raphael Gottardo², Craig Fenwick¹

¹Univ Hosp of Lausanne, Lausanne, Switzerland, ²FRCHC, Seattle, WA, USA, ³Luigi Sacco Univ Hosp, Milan, Italy, ⁴Milano, Italy, ⁵Atreca, Redwood City, CA, USA, ⁶Eurovacc Foundation, Amsterdam, Netherlands

Poster P-E2 CHARACTERIZING THE HIV RESERVOIR

Poster Hall - 4 EF

2:30 PM - 4:00 PM

282 SOLUBLE BIOMARKERS IN ACUTE HIV INFECTION REVEAL INSIGHT INTO HIV RESERVOIR

Jeffrey E. Teigler¹, Bonnie Slike¹, Nicolas Chomont², Eugene Kroon³, Merlin L. Robb¹, Jintanat Ananworanich¹, Nelson L. Michael¹, Hendrik Streeck⁴, Shelly J. Krebs¹, for the RV254/RV217 Study Groups

¹US Military HIV Rsr Prog, Silver Spring, MD, USA, ²Univ de Montréal, Montreal, QC, Canada, ³SEARCH, The Thai Red Cross AIDS Rsr Cntr, Bangkok, Thailand, ⁴Inst for HIV Rsr, Essen, Germany

283 FAST VALIDATION TO STUDY THE BASELINE AND INDUCIBLE HIV RESERVOIR

Marilia R. Pinzone¹, Xiaohe Liu², Lidia Sambucetti², Giuseppe Nunnari³, Una O'Doherty¹

¹Univ of Pennsylvania, Philadelphia, PA, USA, ²SRI Intl, Menlo Park, USA, ³Univ of Messina, Messina, Italy

284 HOST TRANSCRIPTOMIC DETERMINANTS OF HIV PERSISTENCE IN VIVO

Mohamed Abdel Mohsen¹, Xutao Deng¹, Sheila Keating¹, Andrew Worlock², Christopher D. Pilcher³, Michael P. Busch¹, Steven G. Deeks³, Satish K. Pillai¹

¹Blood Systems Rsr Inst, San Francisco, CA, USA, ²Hologic Corporation, Bedford, MA, USA, ³Univ of California, San Francisco, San Francisco, CA, USA

285 LOW INDUCIBILITY OF THE HIV RESERVOIR IN EARLY ART-TREATED THAI CHILDREN

Marta Massanella¹, Jintanat Ananworanich², Louise Leyre³, Thidarat Jupimai⁴, Mark de Souza⁵, Piyarat Suntarattiwong⁶, Pope Kosalaraksa⁷, Thanyawee Puthanakit⁸, Nicolas Chomont⁹, for the HIVNAT209 and HIVNAT194 Study Groups

¹Cntr de Rsr du Cntr Hosp de l'Univ de Montréal, Montréal, Canada, ²Henry M. Jackson Fndn for the Advancement of Military Med, Bethesda, MD, USA, ³HIV-NAT Rsr Collab, Thai Red Cross AIDS Rsr Cntr, Bangkok, Thailand, ⁴SEARCH, Thai Red Cross AIDS Rsr Cntr, Bangkok, Thailand, ⁵Queen Sirikit Natl Inst of Child Hlth, Bangkok, Thailand, ⁶Khon Kaen Univ, Khon Kaen, Thailand, ⁷Chulalongkorn Univ, Bangkok, Thailand

286 CELL-ASSOCIATED HIV RNA PREDICTS POSTTREATMENT HIV CONTROL AND CD4+ T-CELL LOSS

Alexander Pasternak, Jan Prins, Ben Berkhout
Univ of Amsterdam, Amsterdam, Netherlands

287 PRE-ART TUBERCULOSIS AND TB-IRIS AFFECT THE HIV-1 RESERVOIR

Camille Lange¹, Maura Manion², Gregg Roby³, Rob Gorelick⁴, Virginia Sheikh⁵, Joseph Adelsberger⁶, Frank Maldarelli¹, Irini Sereti²

¹NCI, Frederick, MD, USA, ²NIAID, Bethesda, MD, USA, ³NIH, Rockville, MD, USA,

⁴AIDS and Cancer Virus Prog, Frederick, MD, USA, ⁵FDA, Silver Spring, MD, USA,

⁶Leidos Biomed Rsr, Inc, Frederick, MD, USA

Poster P-E4 HIV PERSISTENCE: SEND IN THE CLONES

Poster Hall - 4 EF

2:30 PM - 4:00 PM

292 CLONAL EXPANSION OF GENOME-INTACT HIV-1 IN FUNCTIONALLY POLARIZED T-CELL SUBSETS

Guinevere Q. Lee¹, Nina Orlova¹, Erik Serrao², Xiaoming Sun¹, Navin F. Chowdhury¹, Eric Rosenberg³, Alan N. Engelman², Xu G. Yu¹, Mathias Lichterfeld⁴

¹Ragon Inst of MGH, MIT and Harvard, Cambridge, MA, USA, ²Dana-Farber Cancer Inst, Boston, MA, USA, ³Massachusetts General Hosp, Boston, MA, USA,

⁴Brigham and Women's Hosp, Boston, MA, USA

293 INTACT PROVIRUSES ARE UNEQUALLY DISTRIBUTED IN T CELL SUBSETS DURING ART

Bonnie Hiener¹, Bethany A. Horsburgh¹, John-Sebastian Eden², Kirston Barton¹, Eunok Lee¹, Steven G. Deeks³, Jeffery Milush³, Nicolas Chomont⁴, Rémi Fromentin⁴, Sarah Palmer¹

¹The Westmead Inst for Med Rsr, Westmead, Australia, ²The Univ of Sydney, Sydney, Australia, ³Univ of California San Francisco, San Francisco, CA, USA,

⁴Univ de Montréal, Montreal, QC, Canada

294 A SMALL FRACTION OF PROVIRUSES IN EXPANDED CLONES EXPRESS UNSPLICED HIV RNA IN VIVO

Andrew Musick¹, Jonathan Spindler¹, Brandon Keele², Michael J. Bale¹, Wei Shao², Ann Wiegand¹, John Mellors³, John Coffin⁴, Frank Maldarelli¹, Mary F. Kearney¹

¹NCI, Frederick, MD, USA, ²Leidos Biomed, Inc, Frederick, MD, USA, ³Univ of Pittsburgh, Pittsburgh, PA, USA, ⁴Tufts Univ, Boston, MA, USA

295 PROLIFERATION OF CD4+ T CELLS CONTAINING REPLICATION-COMPETENT HIV-1

Zheng Wang, Ya-Chi Ho, Janet Siliciano, Robert Siliciano

Johns Hopkins Univ, Baltimore, MD, USA

296 CYTOTOXIC LYMPHOCYTES MAY SHAPE THE HIV-1 PROVIRAL LANDSCAPE

R. Brad Jones¹, Mihaela Pertea², Katherine Bruner², Ross Pollack², Adam Capoferri², Robert Siliciano², **Ya-Chi Ho**²

¹The George Washington Univ, Washington, DC, USA, ²The Johns Hopkins Univ, Baltimore, MD, USA

297 DYNAMICS OF HIV CLONAL EXPANSION AND PERSISTENCE DURING ART

Elizabeth M Anderson¹, Shawn Hill¹, Jennifer Bell¹, Francesco R. Simonetti², Cathy Rehm³, Sara Jones⁴, Rob Gorelick⁴, John Coffin⁵, Frank Maldarelli¹

¹NCI, Frederick, MD, USA, ²The Johns Hopkins Univ, Baltimore, MD, USA, ³NIAID, Bethesda, MD, USA, ⁴Leidos Biomed Rsr, Inc, Frederick, MD, USA, ⁵Tufts Univ, Boston, MA, USA

298 CLONES OF HIV-INFECTED CELLS ARISE IN VIVO IN THE FIRST FEW WEEKS FOLLOWING INFECTION

David Wells¹, Jennifer M. Zerbato², Joann D. Kuruc³, Joseph J. Eron³, Mary F. Kearney⁴, John Coffin⁵, Frank Maldarelli⁴, Xiaolin Wu¹, John W. Mellors², **Stephen H. Hughes⁴**

¹Liedos Biomed Rsr, Inc, Frederick, MD, USA, ²Univ of Pittsburgh, Pittsburgh, PA, USA, ³Univ of North Carolina at Chapel Hill, Chapel Hill, NC, USA, ⁴NCI, Frederick, MD, USA, ⁵Tufts Univ, Boston, MA, USA

299LB RESURGENCE OF HIV-1 FOUNDER VIRUSES FOLLOWING ANTIRETROVIRAL TREATMENT INTERRUPTION

Morgane Rolland¹, Eric Sanders-Buell¹, Meera Bose¹, Nittaya Phanuphak², Mark de Souza³, Nelson L. Michael¹, Merlin L. Robb¹, Jintanat Ananworanich¹, Sodsai Tovanabutra¹, for the RV254/SEARCH 010 Study Groups

¹US Military HIV Rsr Prog, Silver Spring, MD, USA, ²Thai Red Cross AIDS Rsr Cntr, Bangkok, Thailand, ³SEARCH, Thai Red Cross AIDS Rsr Cntr, Bangkok, Thailand

Poster P-E8 MODIFYING THE RESERVOIR: CLINICAL STUDIES

Poster Hall - 4 EF

2:30 PM - 4:00 PM

323 HIV-1 DNA BLOOD RESERVOIRS ARE NOT ALTERED BY HIGH-DOSE CHEMOTHERAPY FOR LYMPHOMA

Heloise M. Delagreverie¹, Antoine Chaillon², Laurence Gerard¹, Marie-Laure Néré¹, Romain Palich³, Sylvain Chawki¹, Lionel Galicier¹, Eric Oksenhendler¹, Marie-Laure Chaix Baudier¹, Constance Delaugerre¹

¹Saint Louis Hosp, Paris, France, ²Univ of California San Diego, San Diego, CA, USA, ³Pitié-Salpêtrière Hosp, Paris, France

324 THE IMPACT OF IMMUNOGLOBULIN IN PRIMARY HIV INFECTION ON THE HIV RESERVOIR

Juan Tiraboschi¹, Prabhjeet Phalora², Nicola Robinson², Emily Hopkins², Steve Kaye³, Jeremy Sanderson¹, Sarah Fidler³, Paul Klenerman², John Frater², **Julie Fox⁴**

¹Guy's and St Thomas' NHS Fndn Trust, London, UK, ²Univ of Oxford, Oxford, UK, ³Imperial Coll London, London, UK, ⁴King's Coll London, London, UK

325 RATES OF VIRAL DECAY IN HIV-1 CONTROLLERS INITIATING ANTIRETROVIRAL THERAPY

Jonathan Li¹, Heloise M. Delagreverie², Rachel Getz¹, Christina Lalama³, Ronald Bosch³, Daniel R. Kuritzkes¹, Alan Landay⁴, Florencia Pereyra¹, Paul E. Sax¹, for the AIDS Clinical Trials Group A5308 Study Team

¹Brigham and Women's Hosp, Harvard Med Sch, Boston, MA, USA, ²Saint Louis Hosp, Paris, France, ³Harvard Univ, Boston, MA, USA, ⁴Rush Univ Med Cntr, Chicago, IL, USA

326 PEGYLATED IFN-ALPHA-2B DECREASES LATENT HIV MEASURES IN ART-SUPPRESSED SUBJECTS

Livio Azzoni¹, Emmanouil Papasavvas¹, Nicolas Chomont², Qingsheng Li³, Bonnie J. Howell⁴, Douglas D. Richman⁵, Pablo Tebas⁶, Karam Mounzer⁷, Jay Kostman⁸, Luis Montaner¹

¹Wistar Inst, Philadelphia, PA, USA, ²Univ de Montréal, Montreal, QC, Canada, ³Univ of Nebraska, Lincoln, NE, USA, ⁴Merck & Co, Inc, West Point, PA, USA, ⁵Univ of California San Diego, La Jolla, CA, USA, ⁶Univ of Pennsylvania, Philadelphia, PA, USA, ⁷Philadelphia FIGHT, Philadelphia, PA, USA, ⁸Philadelphia FIGHT Community Hlth Cntrs, Philadelphia, PA, USA

- 327 EFFECTS OF PEG-IFN α ON THE HIV-1 DNA LEVELS IN HIV-1/HCV COINFECTED INDIVIDUALS**
Victoria P. Strouvelle, Valentina Vongrad, Dominique L. Braun, Yik Lim Kok, Roger Kouyos, Karin Metzner, Huldrych F. Günthard, for the Swiss HIV Cohort Study
Univ of Zürich, Zürich, Switzerland
- 328 IN VIVO CONTROL OF HIV INFECTION BY AN ENGINEERED BI-SPECIFIC ANTI-HIV FUSION PROTEIN**
Ariola Bardhi¹, Weizao Chen², Yanping Wang², Jennifer Jones³, John C. Kappes³, Christina Ochsenbauer³, Dimitar S. Dimitrov², Harris Goldstein¹
¹Albert Einstein Coll of Med, Bronx, NY, USA, ²NIH, Frederick, MD, USA, ³Univ of Alabama at Birmingham, Birmingham, AL, USA
- 329 PGT121 ANTIBODY ENGINEERING: ENHANCED INFECTED CELL KILLING AND DRUG-LIKE PROPERTIES**
Mini Balakrishnan, Nathan D. Thomsen, Craig S. Pace, Xue Zhang, Magdeleine Hung, Mark R. Nagel, Brian A. Carr, Y. E. Hu, Helen Yu, John A. Corbin
Gilead Scis, Inc, Foster City, CA, USA
- 330LB VRC01 INFUSION HAS NO EFFECT ON HIV-1 PERSISTENCE IN ART-SUPPRESSED CHRONIC INFECTION**
Sharon Riddler¹, Christine Durand², Lu Zheng³, Justin Ritz³, Richard A. Koup⁴, Julie Ledgerwood⁴, Bernard Macatangay¹, Joshua C. Cyktor¹, John W. Mellors¹, for the ACTG A5342 Protocol Team
¹Univ of Pittsburgh, Pittsburgh, PA, USA, ²Johns Hopkins Univ, Baltimore, MD, USA, ³Harvard Univ, Boston, MA, USA, ⁴NIAID, Bethesda, MD, USA

Poster P-F1 THE CNS AND SYSTEMATIC IMMUNE ACTIVATION

Poster Hall - 4 EF

2:30 PM - 4:00 PM

- 339 HEIGHTENED SYSTEMIC AND CNS IMMUNE ACTIVATION IN ACUTE HIV INFECTION WITH SYPHILIS**
Phillip Chan¹, Donn Colby¹, Eugene Kroon¹, Victor Valcour², Napapon Sailasuta³, Joanna Hellmuth⁴, Shelly J. Krebs⁵, Jintanat Ananworanich⁵, Serena Spudich⁶, for the RV254/SEARCH 010 Study Group
¹SEARCH, The Thai Red Cross AIDS Rsr Cntr, Bangkok, Thailand, ²Univ of California San Francisco, San Francisco, USA, ³Univ of Hawaii, Honolulu, HI, USA, ⁵US Military HIV Rsr Prog, Silver Spring, MD, USA, ⁶Yale Univ, New Haven, CT, USA
- 340 CNS INFLAMMATION STILL PRESENT AFTER >10 YEARS OF EFFECTIVE ANTIRETROVIRAL THERAPY**
Gustaf O. Hammarlund¹, Arvid Edén¹, Åsa Mellgren², Dietmar Fuchs³, Henrik Zetterberg¹, Lars Hagberg¹, Staffan Nilsson⁴, Aylin Yilmaz¹, Magnus Gisslén¹
¹Univ of Gothenburg, Gothenburg, Sweden, ²South Älvsborgs Hosp, Borås, Sweden, ³Innsbruck Med Univ, Innsbruck, Austria, ⁴Chalmers Univ of Tech, Gothenburg, Sweden
- 341 MONOCYTE ACTIVATION IS ASSOCIATED WITH COGNITION IN SUPPRESSED HIV-INFECTED WOMEN**
Brandon M. Imp¹, Leah H. Rubin², Phyllis Tien³, Michael Plankey⁴, Elizabeth T. Golub⁵, Audrey French⁶, Victor Valcour³, for the Women's Interagency HIV Study (WIHS)
¹Rutgers Robert Wood Johnson Med Sch, Piscataway, NJ, USA, ²Univ of Illinois at Chicago, Chicago, IL, USA, ³Univ of California San Francisco, San Francisco, CA, USA, ⁴Georgetown Univ, Washington, DC, ⁵The Johns Hopkins Univ, Baltimore, MD, USA, ⁶Rush Univ, Chicago, IL, USA

342 SYSTEMIC INFLAMMATORY AND IMMUNE BIOMARKERS IN NEUROCOGNITIVE CHANGE WITH INITIAL ART

Kevin Robertson¹, Sachiko Miyahara², Alan Landay³, Todd Brown⁴, Carl Fichtenbaum⁵, Joseph J. Eron⁶, Athe Tsibris⁷, Babafemi Taiwo⁸, for the ACTG 5303 team

¹Univ of North Carolina at Chapel Hill, Chapel Hill, NC, USA, ²Harvard Univ, Boston, MA, USA, ³Rush Univ, Chicago, IL, USA, ⁴The Johns Hopkins Univ, Baltimore, MD, USA, ⁵Univ of Cincinnati, Cincinnati, OH, USA, ⁶Massachusetts General Hosp, Cambridge, MA, USA, ⁷Northwestern Univ, Chicago, IL, USA

343 IMPACT OF ADVANCING AGE ON COGNITION IN HIV+ PERSONS ON A FIRST SUPPRESSIVE REGIMEN

Hamza Coban¹, Kevin Robertson², Kunling Wu³, Ronald Bosch³, **Ronald J. Ellis⁴**

¹Univ of California San Diego, La Jolla, CA, USA, ²Univ of North Carolina at Chapel Hill, Chapel Hill, NC, USA, ³Harvard Univ, Boston, MA, USA, ⁴Univ of California, San Diego, CA, USA

344 CNS IMMUNE ACTIVATION PERSISTS IN ACUTE AND CHRONIC HIV DESPITE EXTENDED CART

Joanna Hellmuth¹, John Best², Carlo Sacdalan³, Shelly J. Krebs⁴, Duanghathai Suttichom⁵, Serena Spudich⁶, Nisakorn Ratnaratorn³, Jintanat Ananworanich⁴, Victor Valcour¹, for the SEARCH 010/RV254 Study Group

¹Univ of California San Francisco, San Francisco, CA, USA, ²Univ of Pennsylvania, Philadelphia, PA, USA, ³SEARCH, Thai Red Cross AIDS Rsr Cntr, Bangkok, Thailand, ⁴US Military HIV Rsr Prog, Silver Spring, MD, USA, ⁵SEARCH, South East Asia Rsr Collab with Hawaii, Bangkok, Thailand, ⁶Yale Univ, New Haven, CT, USA

345 IMMUNE MARKERS OF CRYPTOCOCCAL REACTIVATION IN HIV INFECTION

Admire Hlupeni¹, Kathryn F. Boyd², Azure T. Makadzange³, Chiratidzo E. Ndhlovu¹

¹Univ of Zimbabwe, Harare, Zimbabwe, ²Infectious Disease Rsr Lab, Harare, Zimbabwe, ³Massachusetts General Hosp, Cambridge, MA, USA

Poster P-F3 NEUROCOGNITIVE FUNCTIONING, VIRAL SUPPRESSION, AND ASSOCIATED RISKS

Poster Hall - 4 EF

2:30 PM - 4:00 PM

349 HIV NEUROLOGICAL DISORDERS CAN OCCUR IN PATIENTS WITH SUPPRESSED HIV-1 VL IN PLASMA

Cathia Soulie¹, Maxime Grudé², Corinne Amiel³, Laurence Morand-Joubert⁴, Stephanie Raymond⁵, Coralie Pallier⁶, Pantxika Bellecave⁷, Diane Descamps⁸, Anne-Geneviève Marcelin¹, for the ANRS Resistance AC11 Group

¹Pitié Salpêtrière Hosp, Paris, France, ²INSERM, Paris, France, ³Tenon Hosp, Paris, France, ⁴Saint Antoine Hosp, Paris, France, ⁵Toulouse Univ Hosp, Toulouse, France, ⁶Paul Brousse Hosp, Villejuif, France, ⁷Pellegrin Hosp, Bordeaux, France, ⁸Bichat Hosp, Paris, France

350 COGNITIVE TRAJECTORIES OVER 4 YEARS AMONG HIV+ WOMEN WITH OPTIMAL VIRAL SUPPRESSION

Leah H. Rubin¹, Gayle Springer², Pauline M. Maki¹, Kathryn Anastos³, Deborah Gustafson⁴, Maria Villacres⁵, Drenna Waldrop-Valverde⁶, David Vance⁷, Hector Bolivar⁸, Victor Valcour⁹

¹Univ of Illinois at Chicago, Chicago, IL, USA, ²The Johns Hopkins Univ, Baltimore, MD, USA, ³Albert Einstein Coll of Med, Bronx, NY, USA, ⁴SUNY Downstate Med Cntr, Brooklyn, NY, USA, ⁵Univ of Southern California, Los Angeles, CA, USA, ⁶Emory Univ, Atlanta, GA, USA, ⁷Univ of Alabama at Birmingham, Birmingham, AL, USA, ⁸Univ of Miami, Miami, FL, USA, ⁹Univ of California San Francisco, San Francisco, CA USA

351 COGNITIVE TRAJECTORIES IN SUPPRESSED HIV INFECTION INDICATE EVOLVING DISEASE ACTIVITY

Chloe Gott¹, **Thomas Gates**², Nadene Dermody¹, Bruce Brew³, Lucette Cysique⁴

¹Macquarie Univ, North Ryde, NSW, Australia, ²St Vincent's Hosp, Sydney, Darlinghurst, NSW, Australia, ³Univ of New South Wales, Darlinghurst, NSW, Australia, ⁴NeuroSci Rsr Australia, Randwick, NSW, Australia

352LB LONGITUDINAL ANALYSIS SHOWS NO EVIDENCE FOR ACCELERATED BRAIN AGEING IN TREATED HIV

James H. Cole¹, Matthan W. Caan², Jonathan Underwood¹, **Rosan van Zoest**³, Davide De Francesco⁴, Alan Winston¹, Caroline Sabin⁴, David J. Sharp¹, Peter Reiss⁵, for the CO-morBidity in Relation to AIDS (COBRA) Collaboration

¹Imperial College London, London, United Kingdom, ²Academic Medical Center Amsterdam, Amsterdam, Netherlands, ³Amsterdam Institute for Global Health and Development, Amsterdam, Netherlands, ⁴UCL, London, UK, ⁵Stichting HIV Monitoring and Academic Medical Center Amsterdam, Amsterdam, Netherlands

353 DECREASE IN EXECUTIVE FUNCTION IS ASSOCIATED WITH DETECTABLE PLASMA HIV DURING CART

Albert Anderson¹, Josue Perez-Santiago², Andrea Knezevic¹, Xiaohu Yang¹, Eugene Huang¹, Jennifer Iudicello³, David Moore², Ronald J. Ellis², Robert K. Heaton³, Scott Letendre²

¹Emory Univ, Atlanta, GA, USA, ²Univ of California San Diego, San Diego, CA, USA, ³Univ of California at San Diego, La Jolla, CA, USA

354 DAAs IMPROVE VACS BUT DO NOT INFLUENCE COGNITIVE IMPAIRMENT IN HIV/HCV COINFECTED

Ilaria Mastroianni, Patrizia Lorenzini, Martina Ricottini, Gabriele Fabbri, Pietro Balestra, Alessandra Vergori, Carmela Pinnetti, Mauro Zaccarelli, Adriana Ammassari, Andrea Antinori

Natl Inst for Infectious Diseases, Rome, Italy

355 LIMITATIONS OF THE INTERNATIONAL HIV DEMENTIA SCALE IN THE CURRENT ERA

Benedetta Milanini¹, Emmanuel Bahemana², Babajide Keshinro Keshinro³, Francis Kiweewa⁴, Rither Langat⁵, Winnie Rehema⁶, Isabel E. Allen¹, Christina Polyak⁷, Julie Ake⁷, Victor Valcour¹

¹Univ of California San Francisco, San Francisco, CA, USA, ²Walter Reed Prog-Tanzania, Mbeya, Tanzania, United Republic of, ³Walter Reed Prog-Nigeria, Abuja, Nigeria, ⁴Makerere Univ Walter Reed Proj, Kampala, Uganda, ⁵KEMRI/Walter Reed Proj, Kericho, Kenya, ⁶KEMRI/Walter Reed Proj, Kisumu, Kenya, ⁷US Military HIV Rsr Prog, Bethesda, MD, USA

356 EFFECTS OF AGE AND OBESITY ON NEUROCOGNITIVE PERFORMANCE IN THE MACS COHORT

Kristine Erlandson¹, Long Zhang², Lisa Jacobson², James T. Becker³, Cynthia Munro², Jordan E. Lake⁴, Eileen Martin⁵, Andrew Levine⁶, Todd Brown², Ned Sacktor²

¹Univ of Colorado, Aurora, CO, USA, ²The Johns Hopkins Univ, Baltimore, MD, USA, ³Univ of Pittsburgh, Pittsburgh, PA, USA, ⁴Univ Texas Houston, Houston, USA, ⁵Rush Univ, Chicago, USA, ⁶Univ of California Los Angeles, Los Angeles, CA, USA

357 CSF TO PLASMA HIV-RNA RATIO ≥ 1 IS ASSOCIATED WITH HAND IN UNTREATED HIV PATIENTS

Francesca Bai, Francesca Iannuzzi, Esther Merlini, Lidia Borghi, Teresa Bini, Giulia Marchetti, Antonella d'Arminio Monforte
Univ of Milan, Milan, Italy

358 POST-TRAUMATIC STRESS AND NEUROCOGNITIVE IMPAIRMENT IN A US MILITARY COHORT

Robert Deiss¹, Raeanne Moore², Nancy Crum-Cianflone¹, Scott Letendre², Anuradha Ganesan¹, Jason Okulicz³, Mary F. Bavaro⁴, David J. Moore², Brian K. Agan¹

¹Uniformed Services Univ of the Hlth Scis, Rockville, MD, USA, ²Univ of California San Diego, San Diego, CA, USA, ³Infectious Disease Service, San Antonio, TX, USA, ⁴Naval Med Cntr of San Diego, San Diego, CA, USA

359 ANTIRETROVIRALS IMPROVE HAND STAGE IN HIV+ PATIENTS WITH SUBTYPE D AND A IN UGANDA

Ned Sacktor¹, Deanna Saylor¹, Gertrude Nakigozi², Kevin Robertson³, Noeline Nakasujja⁴, Ronald H. Gray¹, Maria Wawer¹

¹The Johns Hopkins Univ, Baltimore, MD, USA, ²Rakai Hlth Scis Prog, Kalisizo, Uganda, ³Univ of North Carolina at Chapel Hill, Chapel Hill, NC, USA, ⁴Makarere Univ, Kampala, Uganda

360 ADDITIONAL SCREENING TESTS FOR HIV-ASSOCIATED NEUROCOGNITIVE DISORDERS

Mattia Trunfio¹, Chiara Montrucchio¹, Daniela Vai², Daniele Imperiale², Alessandro Livelli², Giancarlo Orofino³, Alice Trentalange¹, Stefano Bonora¹, Giovanni Di Perri¹, Andrea Calcagno¹

¹Univ of Torino, Torino, Italy, ²Maria Vittoria Hosp, Torino, Italy, ³Amedeo di Savoia Hosp, Torino, Italy

361 COGNITIVE COMPLAINTS AND DEVELOPMENT OF FALLS AMONG HIV+ AND HIV- WOMEN

Anjali Sharma¹, Donald R. Hoover², Qiuhi Shi³, Michael Plankey⁴, Phyllis Tien⁵, Kathleen M. Weber⁶, Michelle Floris-Moore⁷, Hector Bolivar⁸, Marica M. Holstad⁹, Michael T. Yin¹⁰

¹Albert Einstein Coll of Med, Bronx, NY, USA, ²Rutgers, the State Univ of New Jersey, Piscataway, NJ, USA, ³New York Med Coll, Valhalla, NY, USA, ⁴Georgetown Univ, Washington DC, USA, ⁵Univ of California San Francisco, San Francisco, CA, USA, ⁶Cook County Hlth & Hosps System, Chicago, IL, USA, ⁷Univ of North Carolina at Chapel Hill, Chapel Hill, NC, USA, ⁸Univ of Miami, Miami, FL, USA, ⁹Emory Univ, Atlanta, GA, USA, ¹⁰Columbia Univ, New York, NY, USA

362 PREVALENCE OF NEUROCOGNITIVE DISORDERS IN A WELL-TREATED AND AGING SWISS HIV-COHORT

Melanie Metral¹, Isabella Locatelli¹, Peter Brugger², Klemens Gutbrod³, Ursula Kunze⁴, Isaure Nadin⁵, Marc Schwind⁶, Riccardo Pignatti⁷, Matthias Cavassini¹, Renaud Du Pasquier¹

¹Univ of Lausanne, Lausanne, Switzerland, ²Univ Hosp of Zürich, Zürich, Switzerland, ³Univ Hosp of Bern, Bern, Switzerland, ⁴Felix Platter Hosp, Basel, Switzerland, ⁵Univ Hosps of Geneva, Geneva, Switzerland, ⁶Klinik für Neuro, St. Gallen, Switzerland, ⁷Servizio di Malattie Infettive, Lugano, Switzerland

Poster P-G5 ANTIRETROVIRAL PHARMACOKINETICS: SPECIAL PROBLEMS AND POPULATIONS

Poster Hall - 4 EF

2:30 PM - 4:00 PM

428 EFFECT OF SORBITOL ON 3TC PK AFTER ADMINISTRATION OF LAMIVUDINE SOLUTION IN ADULTS

Kimberly K. Adkison¹, Cynthia McCoig², Allen Wolstenholme³, Yu Lou⁴, Zhiping Zhang⁴, Amy Eld³, Katy Hayward⁵, Mark Shaefer¹

¹ViiV Hlthcare, Rsr Triangle Park, NC, USA, ²ViiV Hlthcare, Tres Cantos, Madrid, Spain, ³GlaxoSmithKline, Collville, PA, USA, ⁴PAREXEL Intl, Durham, NC, USA, ⁵ViiV Hlthcare, Brentford, UK

429 CRUSHING OF DOLUTEGRAVIR COMBINATION TABLETS INCREASES DOLUTEGRAVIR EXPOSURE

Marieke Roskam-Kwint¹, **Pauline Bollen**¹, Angela Colbers¹, Marjolijn Duisenberg-van Essen², Veroniek Harbers¹, Reinout van Crevel¹, David M. Burger¹

¹Radboud Univ Med Cntr, Nijmegen, Netherlands, ²Elisabeth—TweeSteden Ziekenhuis, Tilburg, Netherlands

430 EFFECT OF SEVERE RENAL IMPAIRMENT ON DORAVIRINE PHARMACOKINETICS

Wendy Ankrom¹, Kelly Yee¹, Rosa Sanchez¹, Adedayo Adedoyin¹, Li Fan¹, Thomas Marbury², Richard A. Preston³, Sauzanne Khalilieh¹, Marian Iwamoto¹

¹Merck & Co, Inc, Kenilworth, NJ, USA, ²Orlando Clinical Rsr Cntr, Orlando, FL, USA, ³Univ of Miami, Miami, FL, USA

431 HIGHER PLASMA LEVELS AND MORE SIDE EFFECTS IN ELDERLY DARUNAVIR-TREATED PATIENTS

Erika Ahlgren¹, Arvid Edén¹, Jaran Eriksen², Staffan Nilsson³, Carl Johan Treutiger², Anders Thalme⁴, Anders Blaxhult⁵, Åsa Mellgren⁶, Magnus Gisslén¹, Lars-Magnus Andersson¹

¹Univ of Gothenburg, Gothenburg, Sweden, ²Karolinska Inst, Stockholm, Sweden, ³Chalmers Univ of Tech, Gothenburg, Sweden, ⁴Karolinska Univ Hosp, Stockholm, Sweden, ⁵Sodersjukhuset, Stockholm, Sweden, ⁶South Älvsborgs Hosp, Borås, Sweden

432 PHARMACOKINETICS OF DOLUTEGRAVIR IN PEOPLE LIVING WITH HIV OVER THE AGE OF 60

Emilie Elliot¹, Xinzhu Wang², Nicole Pagani¹, Alison Jenkin¹, Jaime Vera-Rojas³, Isaac Day-Weber², Graeme Moyle⁴, Myra McClure², Marta Boffito¹

¹St. Stephen's AIDS Trust—Chelsea and Westminster Hosp, London, UK, ²Imperial Coll, London, UK, ³Brighton and Sussex Med Sch, Brighton, UK, ⁴Chelsea and Westminster Hosp, London, UK

Poster P-15 IMMEDIATE VS DELAYED ART**Poster Hall - 4 EF****2:30 PM - 4:00 PM****470 LONG-TERM EFFECTS OF IMMEDIATE VERSUS DEFERRED C-ART IN PRIMARY HIV INFECTION (PHI)****Kees Brinkman**, Sebastian Tawil, Guido van den Berk, Daoud Ait Moha, Willem Blok*OLVG, Amsterdam, Netherlands***471 IL-6 AND D-DIMER PREDICT MORTALITY AND ARE ELEVATED AFTER DELAYED HIV TREATMENT****Ashita S. Batavia**¹, Myung Hee Lee¹, Patrice Severe², Julie Reust¹, Yuan-Shan Zhu¹, Marc Antoine Jean Juste², Kathryn Dupnik¹, Jean W. Pape¹, Daniel Fitzgerald¹¹Weill Cornell Med Coll, New York, NY, USA, ²GHEKIO, Port-au-Prince, Haiti**472 EARLY TREATMENT IS LIKELY MORE IMPORTANT THAN PREVIOUSLY THOUGHT****Katherine E. Schlusser**¹, Shweta Sharma², Julia A. Metcalf³, Angie N. Pinto⁴, Rika Draenert⁵, Pola de la Torre⁶, Giuseppe Tambussi⁷, James Neaton², Oliver Laeyendecker⁸¹The Johns Hopkins Univ, Baltimore, MD, USA, ²Univ of Minnesota, Minneapolis, MN, USA, ³NIAID, Bethesda, MD, USA, ⁴Kirby Inst, Sydney, Australia, ⁵Klinikum der Univ Munich, Munich, Germany, ⁶Cooper Univ Hosp, Camden, NJ, USA, ⁷Ospedale San Raffaele, Milano, Italy, ⁸NIAID, Bethesda, MD, USA**473 ART IN HIV PERSONS WITH PRETREATMENT VIREMIA ≤3000 C/ML: THE START STUDY****Irin Sereti**¹, Roy M. Gulick², Sonya Krishnan¹, Stephen A. Migueles¹, Adrian Palfreeman³, Veronique Touzeau-Römer⁴, Waldo Belloso⁵, Sean Emery⁶, Matthew Law⁶¹NIAID, Bethesda, MD, USA, ²Weill Cornell Med, New York, NY, USA, ³Leicester Royal Infirmary, Leicester, UK, ⁴Med Univ of Vienna, Vienna, Austria, ⁵Hosp Italiano de Buenos Aires, Buenos Aires, Argentina, ⁶Kirby Inst, Sydney, Australia**474 BENEFIT OF CONTINUOUS/IMMEDIATE ART ON DISEASE RISK: SMART & START COMBINED ANALYSIS****Álvaro H. Borges**¹, Jacqueline Neuhaus², Shweta Sharma², James Neaton², Keith Henry³, Olga Anagnostou⁴, Therese Staub⁵, Sean Emery⁶, Jens D. Lundgren¹, for the INSIGHT SMART & START Study Groups¹RigsHosp, Copenhagen, Denmark, ²Univ of Minnesota, Minneapolis, MN, USA, ³Hennepin County Med Cntr, Minneapolis, MN, USA, ⁴Univ of Athens, Athens, Greece, ⁵Cntr Hosp de Luxembourg, Luxembourg, Luxembourg, ⁶Kirby Inst, Sydney, Australia**475 NO PER-PATIENT COST INCREASE UNDER IMMEDIATE ART FOR ALL: EVIDENCE FROM SWAZILAND****Shaukat Khan**¹, Emma Mafara¹, Pascal Geldsetzer², Salinda Phanitsiri³, Cebele Wong¹, Charlotte Lejeune¹, Fiona Walsh³, Velephi Okello⁴, Till Baernighausen⁵¹Clinton Hlth Access Initiative, Mbabane, Swaziland, ²Harvard Univ, Boston, MA, USA, ³Clinton Hlth Access Initiative, Boston, MA, USA, ⁴Swaziland Ministry of Hlth, Mbabane, Swaziland, ⁵Heidelberg Univ, Heidelberg, Germany

476 COST-EFFECTIVENESS AND BUDGET IMPACT OF IMMEDIATE ART INITIATION IN CÔTE D'IVOIRE

Eric N. Ouattara¹, Rachel L. MacLean², Christine Danel³, Ethan D. Borre², Delphine Gabillard³, Mingshu Huang², A. David Paltiel⁴, Xavier Anglaret³, Serge Eholie⁵, Kenneth Freedberg²

¹Prog PAC-CI, ANRS Rsr site, Abidjan, Cote d'Ivoire, ²Massachusetts General Hosp, Boston, MA, USA, ³INSERM, Bordeaux, France, ⁴Yale Univ, New Haven, CT, USA, ⁵Service des Maladies Infectieuses et Tropes, Abidjan, Côte d'Ivoire

Poster P-J1 PREVALENCE AND INCIDENCE OF HIV DRUG RESISTANCE Poster Hall - 4 EF

2:30 PM - 4:00 PM

477 CORRELATES OF DRUG RESISTANCE MUTATIONS IN ART-NAIVE INDIVIDUALS WITH HIV INFECTION

Sarah E. Porter¹, Ellsworth Campbell¹, Emily Westheimer², Cynthia L. Gay³, Stephanie E. Cohen⁴, Anupama Shankar¹, Jin-Fen Li¹, Jeffrey A. Johnson¹, William M. Switzer¹, Philip J. Peters¹

¹CDC, Atlanta, GA, USA, ²New York City DHMH, New York, NY, USA, ³Univ of North Carolina at Chapel Hill, Chapel Hill, NC, USA, ⁴San Francisco Dept of Pub Hlth, San Francisco, CA, USA

478 HIV INTEGRASE GENOTYPIC TESTING AND RESISTANCE IN THE UNITED STATES—9 JURISDICTIONS

Angela L. Hernandez¹, M. Cheryl B. Ocfemia¹, Neeraja Saduvala², Alexandra Oster¹, Walid Heneine¹, Jeffrey A. Johnson¹, Irene Hall¹

¹CDC, Atlanta, GA, USA, ²ICF Intl, Atlanta, GA, USA

479 PREDICTORS OF HIV GENOTYPE TESTING AMONG NEW DIAGNOSES LINKED TO CARE IN PHILADELPHIA

Melissa Miller, Tanner Nassau, Makeda Carroll, Coleman Terrell, Kathleen Brady

Philadelphia Dept of Pub Hlth, Philadelphia, PA, USA

480 PRETREATMENT DRUG-RESISTANCE INCREASE IN 3 FOCAL POINTS OF MEXICO, 2012–2015

Claudia García-Morales¹, Santiago Avila-Rios¹, Daniela Tapia-Trejo¹, Verónica S. Quiroz-Morales¹, Samuel Navarro², Carlos A. Barrera-Arellano³, Jesús Casillas-Rodríguez⁴, Akio Murakami-Ogasawara¹, Gustavo Reyes-Terán¹, for the HIV MexNet Group

¹Natl Inst of Respiratory Diseases, Mexico City, Mexico, ²Hosp General Tijuana, Tijuana, Baja California, USA, ³Capasits Cancún, Cancún, Quintana Roo, Mexico, ⁴Clínica Especializada Condesa, Mexico City, Mexico

481 HIV DRUG RESISTANCE: A UNIQUE PERSPECTIVE ACROSS 4 AFRICAN COUNTRIES

Brook Danboise¹, Christina Polyak¹, Alex Kasembeli², Samoel Khamadi³, Babajide Keshinro Keshinro⁴, Hannah Kibuuka⁵, John Owuoth⁶, Sheila A. Peel¹, Julie Ake¹, Trevor Crowell¹

¹US Military HIV Rsr Prog, Bethesda, MD, USA, ²Walter Reed Proj—Kericho, Kericho, Kenya, ³Walter Reed Proj—Tanzania, Mbeya, Tanzania, ⁴Walter Reed Proj—Nigeria, Abuja, Nigeria, ⁵Makerere Univ Walter Reed Proj, Kampala, Uganda, ⁶Walter Reed Proj, Kisumu, Kenya

482 HIV PRETREATMENT DRUG RESISTANCE IN CAMEROON: FIRST NATIONWIDE STUDY

Gaëlle F. Tchouwa¹, Jenny Domyeum¹, Sabrina Eymard-Duvernay², Amandine Cournil², Eric Delaporte², Martine Peeters², Elliot Raizes³, Eitel Mpoudi-Ngole¹, Avelin F. Aghokeng⁴

¹CREMER, Yaoundé, Cameroon, ²Univ de Montpellier, Montpellier, France, Montpellier, France, ³CDC, Atlanta, GA, USA, ⁴IRD, Yaoundé, Cameroon

483 LOW PREVALENCE OF HIV DRUG RESISTANCE WITH MODERN AGENTS

Thibaut Davy, Laurence Brunet, Sonia Napravnik, Oksana Zakharova, Ann M. Dennis, Joseph J. Eron

Univ of North Carolina at Chapel Hill, Chapel Hill, NC, USA

484 LOW PREVALENCE OF NRTI, NNRTI, AND PI DRUG RESISTANCE MUTATIONS IN BOTSWANA

Sikhulile Moyo¹, Simani Gaseitsiwe¹, Melissa Zahralban-Steele², Dorcas Maruapula¹, Phillimon P. Sebogodi¹, Madisa Mine³, Elliot Raizes⁴, Shahin Lockman², Max Essex², Vlad Novitsky²

¹Botswana Harvard AIDS Institute Partnership, Gaborone, Botswana, ²Harvard Univ, Boston, MA, ³Natl Hlth Lab, Gaborone, Botswana, ⁴CDC, Atlanta, GA, USA

485 ARV RESISTANCE MUTATIONS IN PATIENTS RECEIVING A WHO TDF-CONTAINING 1ST-LINE REGIMEN

Soo-Yon Rhee¹, John Gregson², Ravindra K. Gupta³, Robert Shafer¹, for the TenoRes Study Group

¹Stanford Univ, Stanford, CA, USA, ²London Sch of Hygiene and Trop Med, London, UK, ³Univ Coll London, London, UK

486 VIRAL SUPPRESSION AND ACQUIRED HIV DRUG RESISTANCE IN CAMEROON: A NATIONWIDE STUDY

Gaëlle F. Tchouwa¹, Jenny Domyeum¹, Sabrina Eymard-Duvernay², Amandine Cournil², Eric Delaporte², Martine Peeters², Eitel Mpoudi-Ngole¹, Elliot Raizes³, Avelin F. Aghokeng⁴

¹CREMER, Yaoundé, Cameroon, ²Univ de Montpellier, Montpellier, France, ³CDC, Atlanta, GA, USA, ⁴IRD, Yaoundé, Cameroon

487 HIGH HIV DRUG RESISTANCE OF FIRST-LINE ART TREATMENT IN BENIN PEDIATRIC POPULATION

Djeneba Bocar Fofana¹, Marcelline d'Almeida², Pierre-Marie Girard¹, Bernabé Lafia³, Sidonie Lambert¹, Lutecia Zohoun-Guidigbi², Rene Keke⁴, Cathia Soulie⁵, Anne-Geneviève Marcelin⁵, Laurence Morand-Joubert¹

¹Saint-Antoine Hosp, Paris, France, ²Univ d'Abomey-Calavi, Benin, ³CNHU-HKM, Cotonou, Benin, ⁴Reference Lab of the Natl Cntr for the Treatment of HIV, Cotonou, Benin, ⁵Pitie-Salpetriere Hosp, Paris, France

488 DRUG-RESISTANT HIV-1 DURING LONG-TERM SECOND-LINE ANTIRETROVIRAL TREATMENT IN KENYA

Seth Inzaule¹, Raph L. Hamers¹, Irene Mukui², Kennedy Were³, Preston Owiti³, Daniel Kwaro³, Tobias R. de Wit¹, Clement Zeh⁴

¹Academic Med Cntr of the Univ of Amsterdam, Amsterdam, Netherlands, ²Natl AIDS and STI Control Prog, Nairobi, Kenya, ³Kenya Med Rsr Inst, Kisumu, Kenya, ⁴US CDC, Kisumu, Kenya

489 ELIMINATING DRUG RESISTANCE IN SOUTH AFRICA BY USING DOLUTEGRAVIR

Katie Sharp¹, Thibault Mesplede², Mark A. Wainberg², Sally Blower¹

¹Univ of California Los Angeles, Los Angeles, CA, USA, ²McGill Univ, Montreal, Quebec, Canada

Poster P-J2 IMPACT OF RESISTANCE ON RESPONSE TO ART**Poster Hall - 4 EF****2:30 PM - 4:00 PM****490 IMPACT OF PRETREATMENT HIV-DRUG RESISTANCE ON VIROLOGIC OUTCOME OF FIRST-LINE ART**

Ingrid A. Beck¹, Molly Levine¹, Ross Milne¹, Isaac So¹, Nina Andersen¹, Michael Watling², Michael H. Chung², James Munyao³, Catherine Kiptinness², Lisa Frenkel²

¹Seattle Children's Rsr Inst, Seattle, WA, USA, ²Univ of Washington, Seattle, WA, USA, ³Coptic Hope Cntr, Nairobi, Kenya

491 RESPONSE TO FIRST-LINE ART IN ADULTS WITH DRUG RESISTANT HIV, ANRS 12249 TASP TRIAL

Collins C. Iwuji¹, Anne Derache², Kathy Baisley³, Siva Danaviah⁴, Tulio de Oliveira⁵, François Dabis⁶, Kholoud Porter¹, Deenan Pillay², for the ANRS 12249 TasP Study Group

¹Univ Coll London, London, UK, ²Africa Hlth Rsr Inst, Mtubatuba, South Africa, ³London Sch of Hygiene and Trop Med, London, UK, ⁴Africa Cntr for Pop Health, Mtubatuba, South Africa, ⁵Univ of KwaZulu-Natal, Durban, South Africa, ⁶Univ de Bordeaux, Bordeaux, France

492 ASSOCIATION BETWEEN HIV DRUG RESISTANCE AND BASELINE FAILURE IN THE ACTG PEARLS STUDY

Rami Kantor¹, Saran Vardhanabhuti², Srikanth Tripathy³, Mariza Morgado⁴, Shanmugam Saravanan⁵, Carole Wallis⁶, Sarah E. Hudelson⁷, Susan H. Eshleman⁷, Thomas Campbell⁸

¹Brown Univ, Providence, RI, USA, ²Harvard Univ, Cambridge, MA, USA, ³Natl Inst for Rsr in TB, Chennai, India, ⁴Oswaldo Cruz Inst, Rio de Janeiro, Brazil, ⁵YRG CARE, Chennai, Tamilnadu, ⁶Lancet Labs and BARC-SA, Johannesburg, South Africa, ⁷The Johns Hopkins Univ, Baltimore, MD, USA, ⁸Univ of Colorado Denver, Aurora, CO, USA

493 SHOULD WE BE TESTING FOR BASELINE INTEGRASE RESISTANCE?

Yiannis Koullias¹, Paul E. Sax¹, Rochelle P. Walensky², Emily P. Hyle²

¹Brigham and Women's Hosp, Boston, MA, USA, ²Massachusetts General Hosp, Boston, MA, USA

494 COST-EFFECTIVENESS ANALYSIS OF PRE-ART HIV DRUG RESISTANCE TESTING IN KENYA

Horacio A. Duarte¹, Joseph Babigumira², David Stauffer³, Robert Shafer³, Ingrid Beck⁴, Louis Garrison², Michael H Chung², Lisa Frenkel¹, Eran Bendavid³

¹Univ of Washington/Seattle Children's Rsr Inst, Seattle, WA, USA, ²Univ of Washington, Seattle, WA, USA, ³Stanford Univ, Stanford, CA, USA, ⁴Seattle Children's Rsr Inst, Seattle, WA, USA

Poster P-L7 HEPATITIS IS NOT ALL C**Poster Hall - 4 EF****2:30 PM - 4:00 PM****577 HIGH PREVALENCE OF HEPATITIS DELTA VIRUS AMONG CAMEROONIAN HBSAG-POSITIVE SPECIMENS**

Mary Rodgers¹, Kelly Collier¹, Ka-Cheung Luk¹, Emily Butler¹, Jill Fuhrman¹, Elizabeth Krilich², Devin Barnaby², Nicaise Ndembu³, Lazare Kaptue⁴, Gavin Cloherty¹

¹Abbott Labs, Abbott Park, IL, USA, ²Franciscan Univ of Steubenville, Steubenville, OH, USA, ³Inst for Human Virology, Abuja, Nigeria, ⁴Univ of Montagnes, Bangangté, Cameroon

578 DECLINE AND CHANGING PROFILE OF HEPATITIS DELTA AMONG INJECTION DRUG USERS IN SPAIN

Antonio Aguilera¹, **Vincent Soriano**², Pablo Barreiro², Jose M. Peña², Rocio Trastoy¹, Jose J. Costa¹

¹Complejo Hospario Univ Santiago, Santiago, Spain, ²La Paz Univ Hosp, Madrid, Spain

579 UNCONVENTIONAL T CELLS IN A PEG-INF-2α ADD-ON STRATEGY FOR SUPPRESSED HBV INFECTION

Camilla Tincati¹, **Elvira S. Cannizzo**¹, Francesca Binda², Paola Ronzi², Federico A. Cazzaniga¹, Antonella d'Arminio Monforte¹, Giulia Marchetti¹, Laura Milazzo²

¹Univ of Milan, Milan, Italy, ²Luigi Sacco Univ Hosp, Milan, Italy

580 INCREASED RATES OF HBV SEROCONVERSION UNDER LONG-TERM HBV ACTIVE THERAPY IN HBV/HIV

Christoph Boesecke¹, Fabian Busch¹, Clara Lehmann², Carolynne Schwarze-Zander¹, Jakob Malin¹, Joerg Janne Vehreschild², Jan-Christian Wasmuth¹, Gerd Fätkenheuer², Jürgen K. Rockstroh¹, for the Cologne Bonn Cohort

¹Bonn Univ Hosp, Bonn, Germany, ²Cologne Univ Hosp, Cologne, Germany

581 MORTALITY OF HIV/HBV COINFECTED PATIENTS ON ART IN URBAN AND RURAL SOUTHERN AFRICA

Jonas Hector¹, Michael J. Vinikoor², Kalo Musukuma², Roma Chilengi², Laura Jefferys³, Michael A. Hobbins¹, Mary-Ann Davies⁴, Matthias Egger⁵, Gilles Wandeler⁵

¹SolidarMed, Luzern, Switzerland, ²Cntr for Infectious Disease Rsr in Zambia, Lusaka, Zambia, ³SolidarMed, Pemba, Mozambique, ⁴Univ of Cape Town, Cape Town, South Africa, ⁵Univ of Bern, Bern, Switzerland

582 EFFECTIVENESS OF HAV VACCINATION AMONG HIV-POSITIVE PATIENTS DURING AN HAV OUTBREAK

Kuan-Yin Lin¹, Szu-Min Hsieh¹, Hsin-Yun Sun¹, Yi-Chun Lo², Wang-Huei Sheng¹, Yu-Chung Chuang¹, Sung-Ching Pan¹, Chien-Ching Hung¹, Shan-Chwen Chang¹

¹Natl Taiwan Univ Hosp, Taipei, Taiwan, ²Taiwan Cntrs for Disease Control, Taipei, Taiwan

583 ACTIVE HPGV-2 INFECTION IS RESTRICTED TO COCIRCULATING HCV INFECTION

Kelly Collier, Michael Berg, Matthew Frankel, Kenn Forberg, John Hackett, Gavin Cloherty, George Dawson

Abbott Labs, Abbott Park, IL, USA

584LB TDF TO PREVENT PERINATAL HEPATITIS B VIRUS TRANSMISSION: A RANDOMIZED TRIAL (ITAP)

Gonzague Jourdain¹, Nicole Ngo-Giang-Huong¹, Linda J. Harrison², Luc Decker¹, Camlin Tierney², Tim R. Cressey³, Jullapong Achalapong⁴, George K. Siberry⁵, Noele Nelson⁶, Nantasak Chotivanich⁷

¹IRD, Chiang Mai, Thailand, ²Harvard Univ, Boston, MA, USA, ³Prog for HIV Prevention and Treatment, Chiang Mai, Thailand, ⁴Chiangrai Prachanukroh Hosp, Chiang Rai, Thailand, ⁵NIH, Bethesda, MD, USA, ⁶CDC, Atlanta, GA, USA, ⁷Chonburi Hospital, Chonburi, Thailand

Poster P-L8 PATHOGENESIS OF HCV INFECTION**Poster Hall - 4 EF****2:30 PM - 4:00 PM****585 EFFECTS OF TREATMENT WITH MARAVIROC—A CCR5 INHIBITOR ON HUMAN HEPATIC STELLATE CELLS**

Salvatore Martini¹, Angelica Perna¹, Angela Lucariello¹, Margherita Macera¹, Maria Aurora Carleo², Germano Guerra³, Vincenzo Esposito², Antonio De Luca¹, Nicola Coppola¹

¹Second Univ of Naples, Naples, Italy, ²AORN dei Colli, Naples, Italy, ³Univ of Molise, Campobasso, Italy

586 CORRELATION OF BLOOD TRANSCRIPTOME WITH OUTCOME AFTER DAA TREATMENT FOR HCV INFECTION

Cody Orr¹, Paul Nietert¹, Shyam Kotttilil², Gary Hardiman¹, **Eric G. Meissner**¹

¹Med Univ of South Carolina, Charleston, SC, USA, ²Univ of Maryland, Baltimore, MD, USA

587 DO MAIT CELLS IMPACT FIBROSIS IN HCV AND HIV/HCV COINFECTED PATIENTS?

Boris J. Beudeker¹, Gertine van Oord¹, Joop Arends², Julian Schulze zur Wiesch³, Marieke van Heide - Mulder¹, Robert de Knecht¹, Annelies Verbon¹, Andre Boonstra¹, **Mark Claassen**⁴

¹Erasmus Univ Med Cntr, Rotterdam, Netherlands, ²Univ Med Cntr Utrecht, Utrecht, Netherlands, ³Univ Med Cntr Hamburg-Eppendorf, Hamburg, Germany, ⁴Rijnstate Hosp, Arnhem, Netherlands

588 PATHOGENESIS OF HIV-INDUCED LIVER DISEASE IN DUAL IMMUNE AND LIVER HUMANIZED MICE

Raghubendra S. Dagur, Weimin Wang, Yan Cheng, Weizhe Li, Edward Makarov, Natalia Osna, Santhi Gorantla, Larisa Y. Poluektova

Univ of Nebraska, Omaha, NE, USA

589 PERIPHERAL ENDOTHELIAL FUNCTION IS SUBOPTIMAL IN HCV-UNTREATED, HIV-SUPPRESSED ADULTS

Kara W. Chew¹, Eric Daar², Jordan E. Lake³, Chrisandra L. Shufelt⁴, Zhaoping Li¹, Diana Liao¹, Wilbert Jordan⁵, C. Noel Bairey Merz⁴, Judith S. Currier¹, Debika Bhattacharya¹

¹Univ of California Los Angeles, Los Angeles, CA, USA, ²Los Angeles Biomed Rsr Inst at Harbor-UCLA Med Cntr, Torrance, CA, USA, ³Univ Texas Houston, Houston, TX, USA, ⁴Cedars-Sinai Med Cntr, Los Angeles, CA, USA, ⁵Charles R. Drew Univ of Med and Sci, Los Angeles, CA, USA

590 LEUKOCYTE TELOMERE ATTRITION IS RAPID FOLLOWING HIV BUT NOT HCV SEROCONVERSION

Alejandro Gonzalez-Serna¹, **Abhinav Ajaykumar**², Izabelle Gadawski², M. Ángeles Muñoz-Fernández³, Kanna Hayashi¹, M.J. Milloy¹, P. Richard Harrigan¹, Helene C. Cote²

¹BC Cntr for Excellence in HIV/AIDS, Vancouver, British Columbia, Canada, ²Univ of British Columbia, Vancouver, British Columbia, Canada, ³General Univ Hosp Gregorio Marañón, Madrid, Spain

Poster P-M3 AIDS-RELATED CANCER: LYMPHOMA, KAPOSI SARCOMA, LUNG, AND LIVER

Poster Hall - 4 EF

2:30 PM - 4:00 PM

603 LYMPHOMA IN HIV-2–INFECTED PATIENTS IN CART ERA: A 15-PATIENT SINGLE-CENTER SERIES

Anne-Marie Ronchetti¹, Sophie Matheron², Lionel Galicier¹, Florence Damond², Nadia Mahjoub¹, Amel Besseghir³, Veronique Meignin¹, Francois Simon¹, Eric Oksenhendler¹, **Laurence Gerard¹**

¹Saint Louis Hosp, Paris, France, ²Bichat-Claude Bernard Hosp, Paris, France, ³INSERM, Bordeaux, France

604 EPSTEIN-BARR VIRUS DNA LOAD: A POSSIBLE PREDICTOR OF AIDS-RELATED LYMPHOMA

Simone H. Hijlkema, Jeroen J. van Kampen, David van de Vijver, Ineke van der Ende

Erasmus Univ Med Cntr, Rotterdam, Netherlands

605 THE IMMUNE ACTIVATION PROFILE LINKED TO KAPOSI SARCOMA IN HIV-1–POSITIVE ADULTS

Christina Psomas¹, Mehwish Younas², Jacques Reynes¹, Pierre Portales², Jean-François Eliaou², Pierre Corbeau²

¹Univ Hosp of Montpellier, Montpellier, France, ²Inst of Human Genetics, Montpellier, France

606 TREATMENT AND OUTCOMES OF NON–SMALL-CELL LUNG CANCER IN LATER ART-ERA HIV INFECTION

Keith M. Sigel¹, Kristina Crothers², Sheldon T. Brown³, Cynthia L. Gibert⁴, Matthew B. Goetz⁵, Roger Bedimo⁶, Roxanne Wadia⁷, Maria Rodriguez-Barradas⁸, Fatma Shebl⁹, Lesley Park¹⁰

¹Icahn Sch of Med at Mt Sinai, New York, NY, USA, ²Univ of Washington, Seattle, WA, USA, ³James J. Peters VA Med Cntr, Bronx, NY, USA, ⁴Washington, DC, VA Med Cntr, Washington, DC, USA, ⁵VA Greater Los Angeles Hlth Care System, Los Angeles, CA, USA, ⁶VA North Texas Hlth Care Cntr, Dallas, TX, USA, ⁷VA Connecticut Hlthcare System, West Haven, CT, USA, ⁸Baylor Coll of Med, Houston, TX, USA, ⁹Yale Univ, New Haven, CT, USA, ¹⁰Stanford Med, Stanford, CA, USA

607 ETIOLOGY OF HEPATOCELLULAR CARCINOMA IN WEST AFRICA: THE HIV CONTRIBUTION

Antoine Jaquet¹, Boris Tchounga², Aristophane Tanon², Aklesso Bagny³, Didier K. Ekouevi⁴, Hamar A. Traore⁵, Annie J. Sasco¹, Moussa Maiga⁶, François Dabis¹, for the leDEA West Africa Collaboration

¹Univ de Bordeaux, Bordeaux, France, ²CHU de Treichville, Abidjan, Cote d'Ivoire, ³CHU Campus, Lomé, Togo, ⁴Univ de Lomé, Lomé, Togo, ⁵CHU du Point G, Bamako, Mali, ⁶Hôpital Gabriel Touré, Bamako, Mali

Poster P-010 ORGAN TRANSPLANTATION

Poster Hall - 4 EF

2:30 PM - 4:00 PM

688 KIDNEY TRANSPLANT OUTCOMES IN HIV-POSITIVE AND HIV-NEGATIVE RECIPIENT PAIRS

Esther Gathogo¹, Frank Post²

¹King's Coll London, London, UK, ²King's Coll Hosp NHS Fndn Trust, London, UK

689 PLANNED PRACTICE OF HIV POSITIVE-TO-POSITIVE TRANSPLANTS IN US TRANSPLANT CENTERS

Sarah Rasmussen, Mary Grace Bowring, Ashton Shaffer, Allan Massie, Aaron Tobian, Dorry Segev, Christine Durand

The Johns Hopkins Univ, Baltimore, MD, USA

Poster P-011 METABOLIC COMPLICATIONS**Poster Hall - 4 EF****2:30 PM - 4:00 PM****690 FOOD INSECURITY IS ASSOCIATED WITH POOR DIABETES CONTROL IN THE WIHS**

Kartika Palar¹, Edward A. Frongillo², Tracey Wilson³, Mardge Cohen⁴, Eryka Wentz⁵, Adaora Adimora⁶, Daniel Merenstein⁷, Janet M. Turan⁸, Phyllis Tien¹, Sheri Weiser¹

¹Univ of California at San Francisco, San Francisco, CA, USA, ²Univ of South Carolina, Columbia, SC, USA, ³SUNY Downstate Med Cntr, Brooklyn, NY, USA, ⁴Stroger Hosp, Chicago, IL, USA, ⁵The Johns Hopkins Univ, Baltimore, MD, USA, ⁶Univ of North Carolina at Chapel Hill, Chapel Hill, NC, USA, ⁷Georgetown Univ, Washington, DC, USA, ⁸Univ of Alabama at Birmingham, Birmingham, AL, USA

691 ADIPOSE MITOCHONDRIAL FUNCTION, ADIPONECTIN, AND INSULIN RESISTANCE IN ACTG A5224S

Todd Hulan¹, Benjamin Ramsey², John R. Koethe¹, David C. Samuels¹, Mariana Gerschenson³, Daniel Libutti³, Grace A. McComsey⁴, Paul E. Sax⁵, Todd Brown⁶, for the AIDS Clinical Trials Group Study A5224s Team

¹Vanderbilt Univ, Nashville, TN, USA, ²Univ of South Carolina, Greenville, SC, USA, ³Univ. of Hawaii-Manoa, Honolulu, HI, USA, ⁴Case Western Reserve Univ, Cleveland, OH, USA, ⁵Brigham and Women's Hosp, Boston, MA, USA, ⁶The Johns Hopkins Univ, Baltimore, MD, USA

692 PLASMINOGEN ACTIVATOR INHIBITOR-1 PREDICTS REDUCED INSULIN SENSITIVITY IN HIV

Kamonkiat Wirunsawanya¹, Dominic Chow¹, Loni Belyea¹, Cecilia Shikuma¹, Richard M Watanabe², Lindsay Kohorn¹, Bruce Shiramizu¹, Brooks Mitchell¹, Scott A. Souza¹, Lishomwa Ndhlovu¹

¹Univ of Hawaii, Honolulu, HI, USA, ²Univ of Southern California, Los Angeles, CA, USA

Poster P-012 OBESITY AND FATTY LIVER DISEASE**Poster Hall - 4 EF****2:30 PM - 4:00 PM****693 BODY MASS INDEX AND THE RISK OF SERIOUS NON-AIDS EVENTS: THE D:A:D STUDY**

Amit C. Achhra¹, Caroline Sabin², Lene Ryom³, Antonella d'Arminio Monforte⁴, Stephane de Wit⁵, Andrew Phillips², Christian Pradier⁶, Jens D. Lundgren⁷, Matthew Law¹, for the the DAD Study Group

¹Kirby Inst, Sydney, Australia, ²Univ Coll London, London, UK, ³CHIP, Copenhagen, Denmark, ⁴Univ of Milan, Milan, Italy, ⁵Univ Libre de Bruxelles, Brussels, Belgium, ⁶Nice Univ Hosp, Nice, France, ⁷Univ of Copenhagen, Copenhagen, Denmark

694 RANDOMIZED TRIAL OF BEHAVIORAL WEIGHT LOSS FOR HIV-INFECTED PATIENTS

Katie Becofsky¹, Edward J. Wing², Jeanne McCaffery³, Matthew Boudreau³, Rena R. Wing³

¹Univ of Massachusetts Amherst, Amherst, MA, USA, ²Brown Univ, Providence, RI, USA, ³The Miriam Hosp, Providence, RI, USA

695 PREDICTORS OF SEVERE WEIGHT/BODY MASS INDEX GAIN FOLLOWING ANTIRETROVIRAL INITIATION

Priya Bhagwat¹, Igbo Ofotokun², Grace A. McComsey³, Todd Brown⁴, Carlee Moser⁵, Catherine A. Sugar¹, Judith S. Currier¹

¹Univ of California Los Angeles, Los Angeles, CA, USA, ²Emory Univ, Atlanta, GA, USA, ³Case Western Reserve Univ, Cleveland, OH, USA, ⁴The Johns Hopkins Univ, Baltimore, MD, USA, ⁵Harvard Univ, Boston, MA, USA

696 RALTEGRAVIR SWITCH AND BIOMARKERS OF LIVER STEATOSIS AND METABOLIC SYNDROME IN WOMEN

David Reynoso¹, Anoma Somasunderam¹, Maitreyee Nigalye¹, Judith S. Currier², Netanya S. Uday¹, **Jordan E. Lake**³

¹Univ of Texas Med Branch at Galveston, Galveston, TX, USA, ²Univ of California Los Angeles, Los Angeles, CA, USA, ³Univ Texas Houston, Houston, TX, USA

697 CHANGES IN LIVER STEATOSIS AFTER SWITCHING EFVIRENZ TO RALTEGRAVIR: THE STERAL STUDY

Juan Macías¹, Dolores Merino², Francisco Téllez³, Federico Pulido⁴, Juan González-García⁵, Manuel Márquez⁶, Antonio Rivero⁷, María Mancebo¹, Juan A. Pineda¹, for the RIS-HEP09

¹Hosp Univ de Valme, Sevilla, Spain, ²Complejo Hospario Univ de Huelva, Huelva, Spain, ³Hosp Univ de Puerto Real, Cádiz, Spain, ⁴Hosp 12 de Octubre, Madrid, Spain, ⁵Hosp Univ La Paz, Madrid, Spain, ⁶Hosp Virgen de la Victoria, Málaga, Spain, ⁷Hosp Univ Reina Sofía, Córdoba, Spain

698 OBESITY IN ANTIRETROVIRAL-TREATED HIV-INFECTED ADULTS: PREDICTORS AND COMORBIDITIES

Anchalee Avihingsanon¹, Sivaporn Gatechompol¹, Opass Putcharoen², Jiratchaya Sophonphan¹, Supalak Phonphithak¹, Sasiwimol Ubolyam¹, Stephen J. Kerr¹, Kiat Ruxrungtham², Praphan Phanunphak¹, for the HIV-NAT 006 Study Group

¹HIV-NAT, Thai Red Cross AIDS Rsr Cntr, Bangkok, Thailand, ²Chulalongkorn Univ, Bangkok, Thailand

699 WOMEN GAIN MORE WEIGHT THAN MEN FOLLOWING INITIATION OF ANTIRETROVIRAL THERAPY

Sara H. Bares¹, Laura M. Smeaton², Ai Xu², Catherine Godfrey³, Grace A. McComsey⁴

¹Univ of Nebraska, Omaha, NE, USA, ²Harvard Univ, Cambridge, MA, USA, ³DAIDS, NIAID, Bethesda, MD, USA, ⁴Case Western Reserve Univ, Cleveland, OH, USA

700 CT FAT DENSITY REFLECTS HISTOLOGIC FAT QUALITY IN ART-TREATED, HIV-1-INFECTED ADULTS

Jordan E. Lake¹, Carlee Moser², Liz Johnston², Clara Magyar³, Scott D. Nelson³, Kristine Erlandson⁴, Todd Brown⁵, Grace A. McComsey⁶

¹Univ of Texas, Houston, TX, USA, ²Harvard Univ, Boston, MA, USA, ³Univ of California Los Angeles, Los Angeles, CA, USA, ⁴Univ of Colorado, Aurora, CO, USA, ⁵The Johns Hopkins Univ, Baltimore, MD, USA, ⁶Case Western Reserve Univ, Cleveland, OH, USA

701 ASSOCIATION OF NAFLD WITH ADIPOKINE AND INFLAMMATORY MARKERS DIFFERS BY HIV STATUS

Jennifer Price¹, Ruibin Wang², Eric Seaberg², Matthew Budoff³, Lawrence Kingsley⁴, Frank J. Palella⁵, Mallory Witt⁶, Wendy Post², Chloe Thio²

¹Univ California San Francisco, San Francisco, CA, USA, ²The Johns Hopkins Univ, Baltimore, MD, USA, ³Harbor—UCLA Med Cntr, Torrance, CA, USA, ⁴Univ of Pittsburgh, Pittsburgh, PA, USA, ⁵Northwestern Univ, Chicago, IL, USA, ⁶Los Angeles Biomed Rsr Inst, Harbor—UCLA Med Cntr, Torrance, CA, USA

702 PREVALENCE AND RISK FACTORS FOR HEPATIC STEATOSIS IN HIV+ PERSONS

Jessie Torgersen¹, Kaku So-Armah², Matthew Freiberg³, Matthew Budoff⁴, Joseph Lim⁵, Adeel Butt⁶, Maria Rodriguez-Barradas⁷, Amy Justice⁸, Jay Kostman⁹, Vincent Lo Re¹

¹Univ of Pennsylvania, Philadelphia, PA, USA, ²Boston Univ, Boston, MA, USA, ³Vanderbilt Univ, Nashville, TN, USA, ⁴Harbor—UCLA Med Cntr, Torrance, CA, USA, ⁵Yale Univ, New Haven, CT, USA, ⁶Univ of Pittsburgh, Pittsburgh, PA, USA, ⁷Baylor Coll of Med, Houston, TX, USA, ⁸VA Connecticut Hlthcare System, West Haven, CT, USA, ⁹Philadelphia FIGHT Community Hlth Cntrs, Philadelphia, PA, USA

703 LIVER STEATOSIS AND FIBROSIS IN AT-RISK EUROPEAN HIV-MONOINFECTED PATIENTS

Maud Lemoine¹, Lambert Assoumou², **Patrick Ingiliz**³, Pierre-Marie Girard⁴, Stephane de Wit⁵, Marc-Antoine Valantin⁶, Anja Huefner⁷, Jacqueline Capeau⁸, Dominique Costagliola⁹, Georg Behrens¹⁰

¹Imperial Coll London, London, UK, ²Inst Pierre Louis d'Epidémiologie et de Santé Publique, Paris, France, ³Cntr for Infectiology, Berlin, Germany, ⁴Hôpital Saint-Antoine, Paris, France, ⁵Univ Libre de Bruxelles, Brussels, Belgium, ⁶AP—HP, Paris, France, ⁷Universitätsklinikum Hamburg, Hamburg, Germany, ⁸Univ Pierre & Marie Curie, Paris, France, ⁹Medizinische Hochschule Hannover, Hannover, Germany

704 CHANGES IN LIVER FIBROSIS AND STEATOSIS IN HIV MONOINFECTED PATIENTS OVER 24 MONTHS

Raphael Mohr, Christoph Boesecke, Carolynne Schwarze-Zander, Jan-Christian Wasmuth, Jonel Trebicka, Jürgen K. Rockstroh
Univ Hosp Bonn, Bonn, Germany

Poster P-05 PREDATORS OF INFLAMMATION OR ART

Poster Hall - 4 EF

2:30 PM - 4:00 PM

672 BIOMARKERS OF AGING IN HIV-POSITIVE INDIVIDUALS AND MATCHED CONTROLS

Davide De Francesco¹, Sebastian Oehlke², Alexander Bürkle², Ferdinand Wit³, Claudio Franceschi⁴, Neeltje A. Kootstra⁵, Claude Libert⁶, Peter Reiss³, Caroline Sabin¹, for the Co-morbidity in Relation to AIDS (COBRA) Collaboration

¹Univ Coll London, London, UK, ²Univ of Konstanz, Konstanz, Germany, ³Stichting HIV Monitoring and Academic Med Cntr, Amsterdam, Netherlands, ⁴Alma Mater Studiorum Univ di Bologna, Bologna, Italy, ⁵Academic Med Cntr, Amsterdam, Netherlands, ⁶VIB, Ghent, Belgium

673 LONGITUDINAL ASSOCIATION BETWEEN ALCOHOL USE AND INFLAMMATORY BIOMARKERS

Kaku So-Armah¹, Matthew Freiberg², Debbie Cheng¹, Gregory Patts¹, Russell Tracy³, Margaret Doyle³, Natalia Gnatenko⁴, Kendall J. Bryant⁵, Evgeny Krupitsky⁶, Jeffrey H. Samet¹

¹Boston Univ, Boston, MA, USA, ²Vanderbilt Univ, Nashville, TN, USA, ³Univ of Vermont, Colchester, VT, USA, ⁴Boston Med Cntr, Boston, MA, USA, ⁵Natl Inst on Alcohol Abuse and Alcoholism, Bethesda, MD, USA, ⁶St. Petersburg Pavlov State Med Univ, St. Petersburg, Russia

674 ASSOCIATION OF ANISOCYTOSIS WITH MARKERS OF INFLAMMATION AND IMMUNE EXHAUSTION IN HIV

Sadeer Al-Kindi, David A. Zidar, Grace A. McComsey, **Chris T. Longenecker**
Case Western Reserve Univ, Cleveland, OH, USA

675 GREATER ART ADHERENCE IS ASSOCIATED WITH LESS INFLAMMATION IN HIV-SUPPRESSED UGANDANS

Jose Castillo-Mancilla¹, Mary Morrow², Yap Boum³, Jessica E. Haberer⁴, Jeffrey N. Martin⁵, David Bangsberg⁶, Samantha MaWhinney¹, Nicholas Musinguzi⁷, Peter W. Hunt⁵, Mark J. Siedner⁴

¹Univ of Colorado Denver, Aurora, CO, USA, ²Colorado SPH, Aurora, CO, USA,

³Epicentre, MSF, Mbarara, Uganda, ⁴Massachusetts General Hosp, MA, USA,

⁵Univ of California San Francisco, San Francisco, CA, USA, ⁶MGH-Ragon Inst, Boston, MA, USA, ⁷Mbarara Univ of Sci and Tech, Mbarara, Uganda

676 IMMUNOLOGICAL EFFECTS OF SYNBIOTIC SUPPLEMENTATION IN ADVANCED HIV DISEASE

Sergio Serrano-Villar¹, Maria Lagarde², Jose I. Bernardino³, Mariano Matarranz², Alfonso Cabello⁴, Judit Villar⁵, Jose Ramón Blanco⁶, Otilia Bisbal², Alberto Díaz de Santiago⁷, Vicente Estrada⁸

¹Hosp Univ Ramón y Cajal, Madrid, Spain, ²Hosp 12 de Octubre, Madrid, Spain,

³Hosp Univ La Paz—IdiPAZ, Madrid, Spain, ⁴Hosp Univ Fdn Jiménez Díaz,

Madrid, Spain, ⁵Hosp del Mar, Barcelona, Spain, ⁶Hosp San Pedro, La Rioja,

Spain, ⁷Hosp Puerta de Hierro, Madrid, Spain, ⁸Hosp Univ Clínico San Carlos,

Madrid, Spain

Poster P-06 BONE DISEASE: RISK PREDICTION

Poster Hall - 4 EF

2:30 PM - 4:00 PM

677 BONE MICROARCHITECTURAL CHANGES AND FRACTURE-RISK PREDICTION IN HIV AND HCV

Roger Bedimo¹, Beverley Adams-Huet², John Poindexter², Irfan Farukhi³, Rosinda Castanon³, Geri Brown³, Diana Turner³, Teresa Moore³, Pablo Tebas⁴, Naim Maalouf²

¹VA North Texas Hlth Care Cntr, Dallas, TX, ²Univ of Texas Southwestern

Med Cntr, Dallas, TX, ³VA North Texas Hlthcare System, Dallas, TX, ⁴Univ of Pennsylvania, Philadelphia, PA

678 FRAX-TOOL FRACTURE-RISK COMPARISON: HAVE A LITTLE BACKBONE!

Linda Battalora¹, Carl Armon², Kate Buchacz³, John Hammer⁴, John Spear¹, John T. Brooks³, Benjamin Young⁵, Edgar T. Overton⁶

¹Colorado Sch of Mines, Golden, CO, USA, ²Cerner Corporation, Kansas City,

MO, USA, ³CDC, Atlanta, GA, USA, ⁴Denver Infectious Disease Consultants,

Denver, CO, USA, ⁵APEX Family Med, Denver, CO, USA, ⁶Univ of Alabama at

Birmingham, Birmingham, AL, USA

679 FRACTURE-RISK ESTIMATES IN HIV-POSITIVE AND -NEGATIVE SUBJECTS: DATA FROM HIV UPBEAT

Aoife G. Cotter¹, Dylan Shannon¹, Tara McGinty¹, Alan Macken¹, Eoin Kavanagh², Geraldine McCarthy², Jennifer J. Brady², Juliet Compston³, Caroline Sabin⁴, Patrick W. Mallon¹

¹Univ Coll Dublin, Dublin, Ireland, ²Mater Misericordiae Univ Hosp, Dublin,

Ireland, ³Cambridge, Cambridge, UK, ⁴Univ Coll London, London, UK

Poster P-07 BONE DISEASE: MECHANISMS**Poster Hall - 4 EF****2:30 PM - 4:00 PM****680 SOCS-1/TRAF-6 UP-REGULATION IN BONE IMPAIRMENT IN HIV+ PATIENTS ON EFFECTIVE CART**

Elvira S. Cannizzo, Federico A. Cazzaniga, Esther Merlini, Camilla Tincati, Lidia Gazzola, Nathalie Iannotti, Angelo Del Sole, Antonella d'Arminio Monforte, Giulia Marchetti

Univ of Milan, Milan, Italy

681 BONE DENSITY, MICROARCHITECTURE, AND BONE STRENGTH AFTER 1 YEAR OF TDF

Robert Güerri-Fernández¹, Hernando Knobel¹, Judit Villar¹, Alicia González-Mena¹, Ana Guelar¹, Ludovic Humbert², Elisabet Lerma-Chipirraz¹, Marta Trenchs-Rodríguez³, Adolfo Díez-Pérez¹

¹Hosp del Mar, Barcelona, Spain, ²Galgo Med, Inc, Barcelona, Spain, ³CAP Passeig de Sant Joan, Barcelona, Spain

Poster P-08 BONE DISEASE: INTERVENTIONS**Poster Hall - 4 EF****2:30 PM - 4:00 PM****682 A RANDOMIZED TRIAL OF VITAMIN D3 (3000 VERSUS 1000 IU) IN HIV+ POSTMENOPAUSAL WOMEN**

Michael T. Yin¹, Chengchen Zhang¹, Mariana Bucovsky¹, David Ferris², Susan Olender¹, Arindam Roy Choudhury¹, Anjali Sharma³, Cosmina Zeana⁴, Barry S. Zingman⁵, Elizabeth Shane¹

¹Columbia Univ, New York, NY, USA, ²Columbia Univ, New York, NY, USA, ³Icahn Sch of Med at Mt Sinai, New York, NY, USA, ⁴Albert Einstein Coll of Med, Bronx, NY, USA, ⁵Bronx Lebanon Hosp Cntr, Bronx, NY, USA, ⁶Montefiore Med Cntr, Bronx, NY, USA

683 SWITCHING FROM TDF TO TAF IN HIV-INFECTED ADULTS WITH LOW BMD: A POOLED ANALYSIS

Todd Brown¹, Michael T. Yin², Samir Gupta³, Christine Katlama⁴, Adriano Lazzarin⁵, Kathy Melbourne⁶, Calvin Cohen⁶, YaPei Liu⁶, Thai Nguyen-Cleary⁶, Scott McCallister⁶

¹The Johns Hopkins Univ, Baltimore, MD, USA, ²Columbia Univ, New York, NY, USA, ³Indiana Univ, Indianapolis, IN, USA, ⁴Pierre and Marie Curie Univ, Paris, France, ⁵Vita-Salute San Raffaele Univ, Milan, Italy, ⁶Gilead Scis, Inc, Foster City, CA, USA

684 ANTIRETROVIRAL BONE LOSS IS DURABLY SUPPRESSED BY A DOSE OF ZOLEDRONIC ACID

Igho Ofotokun, Kehmia Titanji, Aswani Vunnava, Antonina Foster, Anandi N. Sheth, Cecile D. Lahiri, Jeffrey J. Lennox, Andrea Knezevic, Kirk A. Easley, M. N. Weitzmann

Emory Univ, Atlanta, GA, USA

685LB HIGH DOSE VITAMIN D3 INCREASES SPINE BONE DENSITY IN HIV+ YOUTH ON TENOFOVIR (TDF)

Peter L. Havens¹, Charles Stephensen², Marta Van Loan², Brandy Rutledge³, Bob Harris³, Patricia M. Flynn⁴, Catherine Gordon⁵, Bill Kapogiannis⁶, Kathleen Mulligan⁷, for the Adolescent Medicine Trials Network for HIV/AIDS Interventions (ATN) 109 Study Team

¹Med Coll of Wisconsin, Wauwatosa, WI, USA, ²USDA, Davis, CA, USA, ³Westat, Rockville, MD, USA, ⁴St. Jude Children's Rsr Hosp, Memphis, TN, USA, ⁵Univ of Cincinnati, Cincinnati, OH, USA, ⁶NICHD, Bethesda, MD, USA, ⁷Univ of California San Francisco, San Francisco, CA, USA

Poster P-09 RENAL DISEASE

Poster Hall - 4 EF

2:30 PM - 4:00 PM

686 PREVALENCE AND RISK FACTORS OF RENAL INJURY IN OPTION B+ DURING THE FIRST 6 MONTHS

Caroline Melhado, Jacob Phulusa, Mathius John, Allan Jumbe, Bryna Harrington, Bryan Mthiko, Mina C. Hosseinipour, for the S4 Team
Univ of North Carolina Proj—Malawi, Lilongwe, Malawi

687 PREDICTORS OF CKD AND UTILITY OF RISK-PREDICTION SCORES IN HIV-POSITIVE INDIVIDUALS

Emily Woolnough¹, Jennifer Hoy¹, Allen Cheng¹, Rowan G. Walker¹, Anastasia Chrystostomou¹, Ian Woolley¹, Freya Langham¹, Michael Moso¹, Achini Weeraratne², Janine M. Trevillyan¹
¹Alfred Hosp, Melbourne, Australia, ²Monash Univ, Melbourne, Australia

Poster P-P10 NEUROSYPHILIS

Poster Hall - 4 EF

2:30 PM - 4:00 PM

749 HOW WELL DO NEUROLOGIC SYMPTOMS IDENTIFY HIV-INFECTED INDIVIDUALS WITH NEUROSYPHILIS?

Arielle P. Davis¹, Joshua Stern², Shelia Dunaway¹, Lauren Tantalo¹, Sharon Sahi¹, Abigail Crooks¹, Claire Stevens¹, Sarah Holte³, Christina Marra¹
¹Harborview Med Cntr, Seattle, WA, USA, ²Univ of Washington, Seattle, WA, USA, ³FRCHC, Seattle, WA, USA

750 TREATMENT OF NEUROSYPHILIS: IV PENICILLIN G VS IM PROCAINE PENICILLIN/ORAL PROBENECID

Shelia Dunaway¹, Claire Maxwell², Lauren Tantalo¹, Sharon Sahi¹, Arielle P. Davis¹, Claire Stevens¹, Abigail Crooks¹, Christina Marra¹
¹Harborview Med Cntr, Seattle, WA, USA, ²Univ of Washington, Seattle, WA, USA

Poster P-P11 PROTOZOAL OIs

Poster Hall - 4 EF

2:30 PM - 4:00 PM

751 STOPPING SECONDARY TE PROPHYLAXIS IN SUPPRESSED PATIENTS WITH CD4 100-200 IS NOT SAFE

Jose M. Miro, for the Opportunistic Infection Team of the COHERE in EuroCoord
IDIBAPS, Barcelona, Spain

752 ASYMPTOMATIC INFECTION IN AN HIV COHORT: LEISHMANIASIS OUTBREAK IN FUENLABRADA, SPAIN

Alicia Castro¹, Eugenia Carrillo², **Juan V. San Martin**¹, Laura Botana², Laura Molina¹, Laura Fernandez², Belen Matia¹, Carmen Sanchez², Jose Manuel Ruiz-Giardin¹, Javier Moreno²
¹Hosp Univ de Fuenlabrada, Fuenlabrada, Madrid, Spain, ²Inst de Salud Carlos III, Majadahonda, Spain

Poster P-P8 OI EPIDEMIOLOGY AND PATHOGENESIS**Poster Hall - 4 EF****2:30 PM - 4:00 PM****737 OPPORTUNISTIC INFECTIONS AMONG US HIV-INFECTED ADULTS IN CARE, 2009–2014****Alejandro Pérez**, John Weiser, Heather Bradley*CDC, Atlanta, GA, USA***738 SIGNIFICANT HIGHER CMV-REACTIVATION IN PJP PATIENTS WITH ADJUNCTIVE CORTICOSTEROIDS****Gundolf Schuettfort**, Sarah Tomasini, H.R. Brodt, Philipp De Leuw, Siri Goepel, Gerrit Kann, Annette E. Haberl, Eva Herrmann, Timo Wolf, Christoph Stephan*Univ Hosp Frankfurt, Frankfurt, Germany***739 HIV COINFECTION HAS A SIGNIFICANT IMPACT ON TRANSCRIPTIONAL RESPONSE TO TUBERCULOSIS****Hanif Esmail**¹, Rachel Lai², Christine Graham², Anne O'Garra², Robert Wilkinson³¹*Univ of Oxford, Oxford, UK*, ²*The Francis Crick Inst, London, UK*, ³*Imperial Coll London, London, UK***Poster P-P9 CRYPTOCOCCAL MENINGITIS AND OTHER FUNGAL OIs****Poster Hall - 4 EF****2:30 PM - 4:00 PM****740 PREVALENCE OF ADVANCED HIV DISEASE AND CRYPTOCOCCAL INFECTION IN GABORONE, BOTSWANA****Kwana Lechiile**¹, Hannah K. Mitchell¹, Fredah Mulenga², Irene Goercke³, Martin S. Azama², Mooketsi Molefi³, Tshepo B. Leeme¹, Mark W. Tenforde⁴, Madisa Mine⁵, Joseph N. Jarvis⁶¹*Botswana–UPenn Partnership, Gaborone, Botswana*, ²*Ministry of Hlth, Gaborone, Botswana*, ³*Univ of Botswana, Gaborone, Botswana*, ⁴*Univ of Washington, Seattle, WA, USA*, ⁵*Natl Hlth Lab, Gaborone, Botswana*, ⁶*US CDC, Gaborone, Botswana***741 CRYPTOCOCCAL ANTIGEN SCREENING AMONG PATIENTS WITH ADVANCED HIV INFECTION IN VIETNAM****Dat Q. Vu**¹, Kinh V. Nguyen², Dung T. Nguyen², Moses Bateganya³, Sheryl Lyss³, Anh T. Ho⁴, Jonathan Kaplan³, Presented by Hanzhu Qian, for the CRICS Team¹*Hanoi Med Univ, Hanoi, Vietnam*, ²*Natl Hosp for Trop Diseases, Hanoi, Vietnam*, ³*CDC, Atlanta, GA, USA*, ⁴*CDC, Hanoi, Vietnam***742 CHANGES IN CRAG TITERS AMONG ASYMPTOMATIC HIV-POSITIVE PATIENTS****Agnes Kiragga**¹, Francis Kakooza¹, Bozena M. Morawski², Elizabeth Nalintya¹, Radha Rajasingham², David Boulware², David Meya³, Yukari C. Manabe⁴¹*Infectious Diseases Inst, Kampala, Uganda*, ²*Univ of Minnesota, Minneapolis, MN, USA*, ³*Makerere Univ, Kampala, Uganda*, ⁴*The Johns Hopkins Univ, Baltimore, MD, USA***743 HIGH PREVALENCE OF CNS DISSEMINATION WITH ASYMPTOMATIC CRYPTOCOCCAL ANTIGENEMIA****Azure T. Makadzange**¹, Admire Hlupeni², Kathryn F. Boyd³, Takudzwa Chagumaira², Christine Ross⁴, Snigdha Vallabhaneni⁴, Shirish Balachandra⁴, Moses Bateganya⁴, Chiratidzo E. Ndhlovu²¹*Massachusetts General Hosp, Cambridge, MA, USA*, ²*Univ of Zimbabwe, Harare, Zimbabwe*, ³*Infectious Disease Rsr Lab, Harare, Zimbabwe*, ⁴*CDC, Atlanta, GA, USA*

744 SERTRALINE AND HIGH-DOSE FLUCONAZOLE TREATMENT OF CRYPTOCOCCAL MENINGITIS IN TANZANIA

Katende Andrew¹, Gladys Mbwangi¹, Diana Faini¹, Aneth Kalinjuma¹, Katherine Hullsiek², Josh Rhein², Maja Weisser¹, David Meya³, David Boulware², Emilio Letang¹

¹Ifakara Hlth Inst, Morogoro, Tanzania, ²Univ of Minnesota, Minneapolis, MN, USA, ³Infectious Disease Inst, Kampala, Uganda

745 MORTALITY DUE TO HIV-ASSOCIATED CRYPTOCOCCAL MENINGITIS IN BOTSWANA IN THE ART ERA

Tshepo B. Leeme¹, Raju K. Patel¹, Caitlin Azzo², Nametso Lekwape¹, Katlego Tsholo¹, Ephraim Tawanana³, Mooketsi Molefi⁴, Margaret Mokomane³, Mark W. Tenforde⁵, Joe N. Jarvis⁶

¹Botswana–UPenn Partnership, Gaborone, Botswana, ²Univ of Pennsylvania, Philadelphia, USA, ³Botswana Ministry of Hlth, Gaborone, Botswana, ⁴Univ of Botswana, Gaborone, Botswana, ⁵Univ of Washington, Seattle, WA, USA, ⁶US CDC, Gaborone, Botswana

746 CSF IMMUNE RESPONSES ASSOCIATED WITH DEPRESSION FOLLOWING CRYPTOCOCCAL MENINGITIS

Sarah Lofgren¹, Kathy Huppler Hullsiek¹, Bozena M. Morawski¹, Josh Rhein¹, David Meya², Mahsa Abassi¹, Noeline Nakasujja³, Abdu Musubire³, David Boulware¹, for the Adjunctive Sertraline for the Treatment of HIV-Associated Cryptococcal Meningitis (ASTRO-CM) Study Group

¹Univ of Minnesota, Minneapolis, MN, USA, ²Infectious Disease Inst, Kampala, Uganda, ³Makarere Univ, Kampala, Uganda

747 CLINICAL PERFORMANCE OF THE MP1P IMMUNOASSAY FOR RAPID DIAGNOSIS OF TALAROMYCOSIS

Thu T. Nguyen¹, Jasper F. Chan², Hien T. Ha¹, Nguyen Le Nhu Tung³, Jeremy Day¹, Chau V. Nguyen³, Guy Thwaites¹, Patrick C. Woo², Kwok-Yung Yuen², Thuy Le¹

¹Oxford Univ Clinical Rsr Unit, Ho Chi Minh, Vietnam, ²Univ of Hong Kong, Hong Kong, ³Hosp for Trop Diseases, Ho Chi Minh City, Vietnam

748 PREDICTING THE RISK OF DEATH IN HIV-ASSOCIATED TALAROMYCES MARNEFFI INFECTION

Thanh T. Nguyen¹, Thu T. Nguyen¹, Nguyen Le Nhu Tung², Jeremy Day¹, Cecilia Shikuma³, Chau V. Nguyen², Guy Thwaites¹, Thuy Le¹

¹Oxford Univ Vietnam Collaboration, Ho Chi Minh City, Vietnam, ²Hosp for Trop Diseases, Ho Chi Minh City, Vietnam, ³Univ of Hawaii, Honolulu, HI, USA

Poster P-Q1 PK AND SAFETY OF ARVs AND MONOCLONAL ANTIBODIES FOR PMTCT

Poster Hall - 4 EF

2:30 PM - 4:00 PM

753 DOSING FOR TWO: PLACENTAL TRANSFER OF DARUNAVIR AND SIMULATION OF FETAL EXPOSURE

Stein Schalkwijk, Aaron O. Buaben, Angela Colbers, David M. Burger, Rick Greupink, Frans G. Russel

Radboud Univ Med Cntr, Nijmegen, Netherlands

754 SUBSTANTIALLY LOWER RILPIVIRINE PLASMA CONCENTRATIONS DURING PREGNANCY

Angela Colbers¹, **Stein Schalkwijk**¹, Deborah Konopnicki², Andrea Ginkelmaier³, John Lambert⁴, Ineke van der Ende⁵, José Moltó⁶, David M. Burger¹, for the PANNA Network

¹Radboud Univ Med Cntr, Nijmegen, Netherlands, ²Saint-Pierre Univ Hosp, Brussels, Belgium, ³Klinikum der Univ München, München, Germany, ⁴Mater Misericordiae Univ Hosp Dublin, Dublin, Ireland, ⁵Erasmus Univ Med Cntr, Rotterdam, Netherlands, ⁶Fundació Lluita Contra la Sida, Badalona, Spain

755 ELVITEGRAVIR/COBICISTAT PHARMACOKINETICS IN PREGNANCY AND POSTPARTUM

Brookie Best¹, Edmund Capparelli¹, Alice Stek², Edward Acosta³, Elizabeth Smith⁴, Nahida Chakhtoura⁵, Jiajia Wang⁶, Adriane Hernandez⁷, Mark Mirochnick⁸, for the IMPAACT P1026s Protocol Team

¹Univ of California San Diego, La Jolla, CA, USA, ²Univ of Southern California, Los Angeles, CA, USA, ³Univ of Alabama at Birmingham, Birmingham, AL, USA, ⁴DAIDS, NIAID, Rockville, MD, USA, ⁵NICHD, Bethesda, MD, USA, ⁶Harvard Univ, Boston, MA, USA, ⁷Frontier Sci & Tech Rsr, Amherst, NY, USA, ⁸Boston Med Cntr, Boston, MA, USA

756 PROTEASE-INHIBITOR–BASED CART IS ASSOCIATED WITH HIGH ESTRADIOL LEVELS IN PREGNANCY

Kayode Balogun¹, Monica Guzman¹, Eszter Papp¹, Mona Loutfy², Mark Yudin³, Jay MacGillivray⁴, Kellie Murphy⁵, Sharon Walmsley⁶, Michael Silverman⁶, Lena Serghides¹

¹Univ Hlth Network, Toronto, Ontario, Canada, ²Women's Coll Rsr Inst, Toronto, Ontario, Canada, ³St. Michael's Hosp, Toronto, Ontario, Canada, ⁴Mt Sinai Hosp, Toronto, Ontario, Canada, ⁵Univ of Toronto, Toronto, Ontario, Canada, ⁶Univ of Western Ontario, London, Ontario, Canada

757 RALTEGRAVIR PHARMACOKINETICS AND SAFETY IN HIV-1 EXPOSED NEONATES: DOSE-FINDING STUDY

Diana F. Clarke¹, Edward Acosta², Anne Chain³, Mae Cababasay⁴, Jiajia Wang⁵, Hedy Teppler⁶, Elizabeth Smith⁷, Rohan Hazra⁸, Mark Mirochnick⁸, for the IMPAACT P1110 Protocol Team

¹Boston Med Cntr, Boston, MA, USA, ²Univ of Alabama at Birmingham, Birmingham, AL, USA, ³Merck Rsr Labs, Rahway, NJ, USA, ⁴Harvard Univ, Boston, MA, USA, ⁵Merck Rsr Labs, North Wales, PA, USA, ⁶DAIDS, NIAID, Rockville, MD, USA, ⁷NICHD, Bethesda, MD, USA, ⁸Boston Univ, Boston, MA, USA

758 PHARMACOKINETICS OF NEVIRAPINE PROPHYLAXIS IN HIV-EXPOSED LOW BIRTH WEIGHT INFANTS

Adrie Bekker¹, Avy Violari², Mae Cababasay³, Jiajia Wang³, Lubbe Wiesner⁴, Edmund Capparelli⁵, Mark Cotton¹, Firdose Nakwa², Mark Mirochnick⁶, for the IMPAACT P1106 Team

¹Stellenbosch Univ, Cape Town, South Africa, ²Univ of Witwatersrand, Johannesburg, South Africa, ³Harvard Univ, Boston, MA, USA, ⁴Univ of Cape Town, Cape Town, South Africa, ⁵Univ of California San Diego, La Jolla, CA, USA, ⁶Boston Med Cntr, Boston, MA, USA

759 SAFETY OF 6-WEEK TRIPLE ANTIRETROVIRAL PROPHYLAXIS IN HIGH-RISK HIV-EXPOSED INFANTS

Suvaporn Anugulruengkitt¹, Piyarat Suntarattiwong², Pradthana Ounchanum³, Ussanee Srirompotong⁴, Watsamon Jantarabenjakul¹, Jiratchaya Sophonphan⁵, Tim R. Cressey⁶, Chitsanu Pancharoen¹, Thanyawee Puthanakit¹, for the CIPHER_AEPEP Study Team

¹Chulalongkorn Univ, Bangkok, Thailand, ²Queen Sirikit Natl Inst of Child Hlth, Bangkok, Thailand, ³Chiang Rai Prachanukroh Hosp, Chiang Rai, Thailand, ⁴Khon Kaen Hosp, Khon Kaen, Thailand, ⁵HIV Netherlands Australia Thailand Rsr Collab, Thai Red Cross AIDS Rsr, Bangkok, Thailand, ⁶Prog for HIV Prevention and Treatment, Chiang Mai, Thailand

760 SAFETY & PHARMACOKINETICS OF THE MONOCLONAL ANTIBODY, VRC01, IN HIV-EXPOSED NEWBORNS

Coleen K. Cunningham¹, Elizabeth J. McFarland², Edmund V. Capparelli³, Petronella Muresan⁴, Charlotte Perlowski⁵, Megan Valentine⁵, Elizabeth Smith⁶, John R. Mascola⁷, Barney S. Graham⁷, for the IMPAACT P1112 Team

¹Duke Univ, Durham, NC, USA, ²Univ of Colorado, Aurora, CO, USA, ³Univ of California San Diego, La Jolla, CA, USA, ⁴Harvard Univ, Boston, MA, USA, ⁵FHI360, Durham, NC, USA, ⁶DAIDS, NIAID, Rockville, MD, USA, ⁷Vaccine Rsr Cntr, NIAID, Bethesda, MD, USA

Poster P-Q3 PREGNANCY AND PREGNANCY OUTCOMES

Poster Hall - 4 EF

2:30 PM - 4:00 PM

772 SUBSEQUENT PREGNANCY OUTCOMES IN WOMEN DURING FOLLOW-UP IN PROMISE 1077HS

Jose H. Pilotto¹, Sean Brummel², Risa M. Hoffman³, Paula Britto², Gaerolwe Masheto⁴, Linda Aupibul⁵, Nahida Chakhtoura⁶, Karin Klingman⁷, Judith S. Currier³, for the 1077HS Team

¹Fiocruz, Rio de Janeiro, Brazil, ²Harvard Univ, Boston, MA, USA, ³Univ of California Los Angeles, Los Angeles, CA, USA, ⁴Harvard Univ-Botswana Collaboration, Gaborone, Botswana, ⁵Chiang Mai Univ, Chiang Mai, Thailand, ⁶NICHD, Bethesda, MD, USA, ⁷DAIDS, NIAID, Bethesda, MD, USA

773 HIV AND RISK OF POSTPARTUM INFECTION, COMPLICATIONS, AND MORTALITY IN RURAL UGANDA

Lisa Bebell¹, Joseph Ngonzi², Mark J. Siedner³, Winnie Muyindike⁴, Bosco M. Bwana², Laura E. Riley¹, Yap Boum⁵, David Bangsberg⁶, Ingrid V. Bassett¹

¹Massachusetts General Hosp, Boston, MA, USA, ²Mbarara Univ of Sci and Tech, Mbarara, Uganda, ³Epicentre, MSF, Mbarara, Uganda, ⁴MGH-Ragon Inst, Boston, MA, USA

774 CMV VIREMIA IN HIV-POSITIVE AND -NEGATIVE PREGNANT WOMEN IN BOTSWANA

Natasha O. Moraka¹, Maryanne R. Ibrahim², Sikhulile Moyo¹, Prisca Thami¹, Gloria Mayondi¹, Christiana Smith³, Adriana Weinberg⁴, Rosemary Musonda¹, Simani Gaseitsiwe¹, Shahin Lockman⁵

¹Botswana Harvard AIDS Inst Partnership, Gaborone, Botswana, ²Doris Duke Intl Clinical Rsr Fellowship, Los Angeles, CA, USA, ³Univ of Colorado, Denver, CO, USA, ⁴Univ of Colorado, Aurora, CO, USA, ⁵Harvard Univ, Boston, MA, USA

775 PREGNANCIES IN WOMEN WHO ACQUIRED HIV PERINATALLY

Mira Hleyhel¹, Catherine Dollfus², Roland Tubiana³, Christine Rouzioux⁴, Pierre Frange⁴, Stephane Blanche⁴, Jérôme Le Chenadec¹, Albert Faye⁵, Laurent Mandelbrot⁶, **Josiane Warszawski**¹

¹INSERM, Le Kremlin-Bicêtre, Paris, France, ²Trousseau Hosp, Paris, France,

³Pitié-Salpêtrière Hosp, Paris, France, ⁴Necker Hosp, Paris, France, ⁵Univ Paris Diderot, Paris, France, ⁶Univ Paris Diderot, Colombes, France

776 ANTENATAL ANTIRETROVIRAL THERAPY AND ADVERSE BIRTH OUTCOMES: THE PROMISE TRIAL

Benjamin H. Chi¹, Mona Farhad², Maxensia Owor³, Tsungai Chipato⁴, Min Qin², Sufia Dadabha⁵, Devasena Gnanashanmugam⁶, Nahida Chakhtoura⁷, Mary Glenn Fowler⁵, Jeffrey S. Stringer¹

¹Univ of North Carolina at Chapel Hill, Chapel Hill, NC, USA, ²Harvard Univ, Boston, MA, USA, ³Makerere Univ—Johns Hopkins Univ Rsr Collab, Kampala, Uganda, ⁴Univ of Zimbabwe, Harare, Zimbabwe, ⁵The Johns Hopkins Univ, Baltimore, MD, USA, ⁶DAIDS, NIAID, Rockville, MD, USA, ⁷NICHD, Bethesda, MD, USA

777 RISK FACTORS FOR LOW BIRTH WEIGHT AND PRETERM DELIVERY IN THE PROMISE TRIAL

Dorothy Sebikari¹, Min Qin², Maxensia Owor¹, Jeffrey S. Stringer³, Mona Farhad², Nahida Chakhtoura⁴, Benjamin H. Chi³, Karin Klingman⁵, Gerhard Theron⁶, Mary Glenn Fowler⁷

¹Makerere Univ—Johns Hopkins Univ Rsr Collab, Kampala, Uganda, ²Harvard Univ, Boston, MA, USA, ³Univ of North Carolina at Chapel Hill, Chapel Hill, NC, USA, ⁴NICHD, Bethesda, MD, USA, ⁵DAIDS, NIAID, Bethesda, MD, USA, ⁶Stellenbosch Univ, Cape Town, South Africa, ⁷The Johns Hopkins Univ, Baltimore, MD, USA

778 DO HIV+ WOMEN ON PROTEASE INHIBITORS DELIVER PRETERM? FINDINGS FROM A UK STUDY

Graziella Favarato, Claire Townsend, Heather Bailey, Claire Thorne, for the UK and Ireland National Study of HIV in Pregnancy and Childhood (NSHPC)

Univ Coll London, London, UK

779 TDF/FTC IN PREGNANCY SHOWS NO INCREASE IN ADVERSE INFANT BIRTH OUTCOMES IN US COHORTS

Kathryn Rough¹, George R. Seage¹, Paige L. Williams¹, Sonia Hernandez-Diaz¹, Yanling Huo¹, Ellen G. Chadwick², Risa M. Hoffman³, Emily Barr⁴, David E. Shapiro¹, Kunjal Patel¹

¹Harvard Univ, Boston, MA, USA, ²Ann & Robert H. Lurie Children's Hosp of Chicago, Chicago, IL, USA, ³Univ of California Los Angeles, Los Angeles, CA, USA, ⁴Children's Hosp Colorado, Aurora, CO, USA

Poster P-R3 PHARMACOKINETICS AND DOSING OF ARVs AND COTREATMENTS IN CHILDREN AND YOUTH

Poster Hall - 4 EF

2:30 PM - 4:00 PM

806 DOLUTEGRAVIR PHARMACOKINETICS, SAFETY AND EFFICACY IN HIV+ CHILDREN 2 TO <6 YEARS OLD

Theodore Ruel¹, Edward Acosta², Rajendra P. Singh³, Carmelita Alvero⁴, Kathleen George⁵, Stephanie Popson⁶, Cindy Vavro⁷, Rohan Hazra⁸, Andrew Wiznia⁹, for the P1093 Team

¹Univ of California, San Francisco, San Francisco, CA, USA, ²Univ of Alabama at Birmingham, Birmingham, AL, USA, ³GlaxoSmithKline, King of Prussia, PA, USA, ⁴Harvard Univ, Boston, MA, USA, ⁵FHI 360, Durham, NC, USA, ⁶Frontier Sci & Tech Rsr Fndn, Inc., Amherst, NY, USA, ⁷ViiV Hlthcare, Rsr Triangle Park, NC, USA, ⁸NICHD, Bethesda, MD, USA, ⁹Albert Einstein Coll of Med, Bronx, NY, USA

807 PHARMACOKINETICS OF RILPIVIRINE AFTER SWITCHING FROM EFAVIRENZ IN ADOLESCENTS

Watsamon Jantarabenjakul¹, Narukjaporn Thammajaruk², Torsak Bunupuradah², Jiratchaya Sophonphan², Tim R. Cressey³, Angela Colbers⁴, David M. Burger⁴, Wanatpreeya Phongsamart⁵, Thanyawee Puthanakit¹, Chitsanu Pancharoen¹

¹Chulalongkorn Univ, Bangkok, Thailand, ²HIV Netherlands Australia Thailand Rsr Collab, Thai Red Cross AIDS Rsr, Bangkok, Thailand, ³Prog for HIV Prevention and Treatment, Chiang Mai, Thailand, ⁴Radboud Univ, Nijmegen, Netherlands, ⁵Mahidol Univ, Bangkok, Thailand

808 NEVIRAPINE PK, VIROLOGICAL OUTCOME, AND AEs IN AFRICAN CHILDREN ON PAEDIATRIC FDCs

Andrzej Bieniczak¹, Paolo Denti¹, Adrian Cook², Lubbe Wiesner¹, Diana Gibb², David M. Burger³, Sarah Walker², Helen McIlleron¹, for the CHAPAS-3 Study Team

¹Univ of Cape Town, Cape Town, South Africa, ²Univ Coll London, London, UK, ³Radboud Univ Med Cntr, Nijmegen, Netherlands

809 AN EASY-TO-USE PAEDIATRIC DOSING TOOL: ONE MG/KG DOSE DOES NOT FIT ALL

Paolo Denti¹, Nandita Sugandhi², Tim R. Cressey³, Mark Mirochnick⁴, Edmund V. Capparelli⁵, Martina Penazzato⁶, for the Paediatric ARV Working Group

¹Univ of Cape Town, Cape Town, South Africa, ²Clinton Hlth Access Initiative, New York, NY, USA, ³Prog for HIV Prevention and Treatment, Chiang Mai, Thailand, ⁴Boston Med Cntr, Boston, MA, USA, ⁵Univ of California San Diego, La Jolla, CA, USA, ⁶WHO, Geneva, Switzerland

810 SERTRALINE PHARMACOKINETICS IN HIV-INFECTED ON ARV AND UNINFECTED YOUTH

Nathan Hanan¹, Mary Paul², Yanling Huo³, Edmund Capparelli¹, Suad Kapetanovic⁴, J. L. Ariansen⁵, Elizabeth Smith⁶, Pim Brouwers⁴, Brookie Best¹, for the IMPAACT P1080 Protocol Team

¹Univ of California San Diego, La Jolla, CA, USA, ²Baylor Coll of Med, Houston, TX, USA, ³Harvard Univ, Boston, MA, USA, ⁴NIMH, Rockville, MD, USA, ⁵FHI 360, Durham, NC, USA, ⁶NIAID, Rockville, MD, USA

811 SUBOPTIMAL COTRIMOXAZOLE PROPHYLACTIC CONCENTRATIONS IN CHILDREN

Claire Pressiat¹, Véronique Mea-Assande², Caroline Yonaba³, Jean-Marc Treluyer⁴, Désiré Lucien Dahourou⁵, Madeleine Amorissani-Folquet⁶, Stéphane Blanche⁷, Valeriane Leroy⁸, Déborah Hirt⁹, for the MONOD Study Group

¹Paris Descartes Univ, Paris, France, ²PACCI Prog, Abidjan, Cote d'Ivoire, ³CHU Yalgado Ouédraogo, Ouagadougou, Burkina Faso, ⁴Paris Cntr Hosp Group, Paris, France, ⁵Cntr de Rsr Intl Pour la Santé, Ouagadougou, Burkina Faso, ⁶CHU of Cocody, Abidjan, Cote d'Ivoire, ⁷Necker Hosp, Paris, France, ⁸INSERM, Toulouse, France, ⁹Paris Cntr Hosp Group, Paris, France

Poster P-R4 ART STRATEGIES AND OUTCOMES IN CHILDREN AND YOUTH

Poster Hall - 4 EF

2:30 PM - 4:00 PM

- 812 DOLUTEGRAVIR-BASED CART IN VERTICALLY HIV-1-INFECTED ADOLESCENTS, REAL-WORLD SETTING**
 Coralie Briand¹, Catherine Dollfus², Marion Caseris³, Elie Kantor⁴, Veronique Avettand-Fenoel¹, Diane Descamps⁴, Veronique Schneider⁵, Marie-Dominique Tabone², Stephane Blanche¹, **Pierre Frange**¹
¹Necker Hosp, Paris, France, ²Trousseau Hosp, Paris, France, ³Robert Debre Hosp, Paris, France, ⁴Bichat Hosp, Paris, France, ⁵Tenon Hosp, Paris, France
- 813 LONG-TERM EFFECTS OF WEEKENDS OFF ART IN HIV-1 INFECTED YOUNG PEOPLE ON EFV+2NRTI**
Anna Turkova, for the BREATHER (PENTA 16) Trial Group
 Univ Coll London, London, UK
- 814 COST-EFFECTIVENESS OF PREEMPTIVE SWITCH TO EFAVIRENZ (EFV) IN HIV-INFECTED CHILDREN**
Sophie Desmonde¹, Simone C. Frank², Ashraf Coovadia³, Désiré Lucien Dahourou⁴, Elaine J. Abrams⁵, Rochelle P. Walensky², Kenneth Freedberg², Louise Kuhn⁶, Valeriane Leroy⁷, Andrea L. Ciaranello²
¹Univ of Bordeaux, Bordeaux, France, ²Massachusetts General Hosp, Boston, MA, USA, ³Empilweni Service and Rsr Unit, Johannesburg, South Africa, ⁴Cntr de Rsr Intl Pour la Santé, Ouagadougou, Burkina Faso, ⁵ICAP at Columbia Univ, New York, NY, USA, ⁶Columbia Univ, New York, NY, USA, ⁷INSERM, Toulouse, France
- 815 PREDICTORS OF SWITCH TO SECOND-LINE ART IN HIV-POSITIVE CHILDREN: A GLOBAL ANALYSIS**
Kara K. Wools-Kaloustian¹, Colette J. Smith², Ruth Goodall², Intira J. Collins², Elaine J. Abrams³, Mary-Ann Davies⁴, Mary Paul⁵, Jorge Pinto⁶, Russell B. Van Dyke⁷, for the CIPHER Durability of First Line Project Team
¹Indiana Univ, Indianapolis, IN, USA, ²Univ Coll London, London, UK, ³ICAP at Columbia Univ, New York, NY, USA, ⁴Univ of Cape Town, Cape Town, South Africa, ⁵Baylor Coll of Med, Houston, TX, USA, ⁶Univ Fed de Minas Gerais, Belo Horizonte, Brazil, ⁷Tulane Univ, New Orleans, LA, USA
- 816 FREQUENT FAILURE AFTER SECOND-LINE ART IN HIV-POSITIVE CHILDREN FROM LATIN AMERICA**
 Bryan E. Shepherd¹, Cathy Jenkins¹, Regina Succi², Daisy Machado², Jorge Pinto³, Vanessa Rouzier⁴, Marco Luque⁵, Sten Vermund¹, **Catherine McGowan**¹, for the Caribbean, Central and South America Network for HIV Epidemiology (CCASAnet)
¹Vanderbilt Univ, Nashville, TN, USA, ²Univ Fed de Sao Paulo, São Paulo, Brazil, ³Univ Fed de Minas Gerais, Belo Horizonte, Brazil, ⁴Les Cntrs GHESKIO, Port-au-Prince, Haiti, ⁵Hosp Escuela Univ, Tegucigalpa, Honduras
- 817LB HIV-INFECTED CHILDREN WITH SEVERE ACUTE MALNUTRITION: EARLY VS DELAYED ART INITIATION**
Moherndran Archary¹, Benn Sartorius¹, Philip La Russa², Thobekile Sibaya¹, Micheal Healy², Raziya Bobat¹
¹Univ of KwaZulu-Natal, Durban, South Africa, ²Columbia Univ, New York, NY, USA

Poster P-S1 NETWORKS OF HIV RISK
Poster Hall - 4 EF

2:30 PM - 4:00 PM

842 RACIAL DISPARITIES IN HIV PREVALENCE AND COMPOSITION OF RISK NETWORKS, HPTN 037

Florence Momplaisir¹, Mustafa Hussein², Danielle Fiore³, Laramie Smith⁴, David Bennett⁵, Carl Latkin⁶, David Metzger³

¹Drexel Coll of Med, Philadelphia, PA, USA, ²Univ of Wisconsin-Milwaukee, Milwaukee, WI, USA, ³Univ of Pennsylvania, Philadelphia, PA, USA, ⁴Univ of California San Diego, La Jolla, CA, USA, ⁵Drexel Univ, Philadelphia, PA, USA, ⁶The Johns Hopkins Univ, Baltimore, MD, USA

843 CONCURRENCY IN THE SEXUAL NETWORKS OF RACIALLY DIVERSE YMSM

Patrick Janulis, Gregory Phillips, Brian Mustanski, Michelle Birkett
Northwestern Univ, Chicago, IL, USA

844 HIV TRANSMISSION IN TIJUANA, MEXICO: REAL-TIME IDENTIFICATION OF A NEW CLUSTER

Antoine Chaillon¹, Patricia Gonzalez-Zuniga¹, Tommi O. Gaines¹, Horacio Almanza², Jose R. Chavez², Jesus Vera¹, Thomas L. Patterson¹, Davey M. Smith³, Steffanie A. Strathdee¹, **Sanjay R. Mehta**¹

¹Univ of California San Diego, San Diego, CA, USA, ²Autonomous Univ of Baja California, Tijuana, Mexico, ³Univ of California San Diego, La Jolla, CA, USA

845LB IDENTIFYING AND INVESTIGATING A RAPIDLY GROWING HIV TRANSMISSION CLUSTER IN TEXAS

Analise C. Monterosso¹, Sydney Minnerly¹, Samuel Goings¹, Allyson Morris¹, Anne Marie France², Sharoda Dasgupta², Alexandra Oster², Miranda Fanning¹

¹Texas Dept of State Hlth Services, Austin, TX, USA, ²CDC, Atlanta, GA, USA

846 SEXUAL NETWORKS OF CIS AND TRANSGENDER PEOPLE WITH & AT-RISK FOR HIV, KING COUNTY, WA

Julia Hood¹, David A. Katz², Lindley A. Barbee², Sara N. Glick², Amy Bennett¹, Susan Buskin¹

¹Pub Hlth—Seattle & King County, Seattle, WA, USA, ²Univ of Washington, Seattle, WA, USA

847 SPATIAL CLUSTERING OF HIV IN KENYA MAY NOT MATCH WELL-KNOWN EPIDEMIC PATTERN

Anthony Waruru¹, Thomas Achia¹, James Nganga², Joyce Wamicwe³, **James Tobias**⁴, Mary Mwangi¹, Evelyn Muthama¹, Emily Zielinski-Gutierrez¹, Tom Oluoch⁴, Thorkild Tylleskär⁵

¹US CDC, Nairobi, Kenya, ²Natl Bureau of Statistics, Nairobi, Kenya, ³Natl AIDS and STI Control Prog (NASCO), Nairobi, Kenya, ⁴US CDC, Atlanta, GA, ⁵Univ of Bergen, Bergen, Norway

848 A FRAMEWORK FOR PREDICTING PHYLOGENETIC CLUSTERS OF HIV AT HIGH RISK FOR GROWTH

David McVea¹, Richard Liang², Jeffrey Joy², P. Richard Harrigan², Art Poon³

¹Univ of British Columbia, Vancouver, Canada, ²BC Cntr for Excellence in HIV/AIDS, Vancouver, British Columbia, Canada, ³Western Univ, London, Ontario, Canada

849 NETWORK VIRAL LOAD: A CRITICAL METRIC FOR HIV ELIMINATION

Britt Skaathun¹, Aditya Khanna¹, Ethan Morgan¹, Samuel R. Friedman²,
John A. Schneider¹

¹Univ of Chicago, Chicago, IL, USA, ²Natl Development & Rsr Insts, New York, NY, USA

850 IDENTIFYING A GEOSPATIAL RELATIONSHIP BETWEEN COMMUNITY-LEVEL RISK AND HIV PREVALENCE

Laurence Palk, Sally Blower

Univ of California Los Angeles, Los Angeles, CA, USA

Poster P-S10 STIGMA, MENTAL HEALTH, AND SEXUAL VIOLENCE

Poster Hall - 4 EF

2:30 PM - 4:00 PM

918 STIGMA ASSOCIATED WITH HIV/STI INCIDENCE AMONG NIGERIAN MEN WHO HAVE SEX WITH MEN

Cristina Rodriguez-Hart¹, Rebecca G. Nowak², Rashelle Musci¹, Danielle German¹, Ifeanyi Orazulike³, Uchenna Ononaku⁴, Hongjie Liu⁵, Trevor Crowell⁶, Stefan Baral¹, Man Charurat²

¹The Johns Hopkins Univ, Baltimore, MD, USA, ²Univ of Maryland, Baltimore, MD, USA, ³Intl Cntr on Advocacy and Rights to Hlth, Abuja, Nigeria, ⁴Inst of Human Virology Nigeria, Abuja, Nigeria, ⁵Univ of Maryland, Coll Park, Coll Park, MD, USA, ⁶US Military HIV Rsr Prog, Bethesda, MD, USA

919 POPULATION TRENDS IN HIV STIGMA IN LUSAKA, ZAMBIA, 2004–2011

Margaret P. Kasaro¹, Marie Stoner², Sujit Rathod³, Tessa Roberts³, Jennifer Winston², Richard Banda⁴, Thankian Kusanthan⁵, Jeffrey S. Stringer², Benjamin H. Chi²

¹Univ of North Carolina-Zambia Collaboration, Lusaka, Zambia, ²Univ of North Carolina at Chapel Hill, Chapel Hill, NC, USA, ³London Sch of Hygiene & Trop Med, London, UK, ⁴Central Statistical Office, Lusaka, Zambia, ⁵Univ of Zambia, Lusaka, Zambia

920 DEPRESSION AND ART INITIATION AMONG HIGH-RISK HIV SERODISCORDANT COUPLES IN AFRICA

Jennifer Velloza¹, Connie L. Celum¹, Haberer Jessica², Kenneth Ngunjiri³, Elizabeth Irungu³, Nelly Mugo³, Jared Baeten¹, Renee Heffron¹, for the Partners Demonstration Project Team

¹Univ of Washington, Seattle, WA, USA, ²Cntr for Global Hlth, Massachusetts General Hosp, Boston, MA, USA, ³Kenya Med Rsr Inst, Nairobi, Kenya

921 HIV STIGMA, DEPRESSION, ADHERENCE, AND VIRAL LOAD AMONG HIV+ AFRICAN-AMERICAN WOMEN

Lauren Lipira¹, Emily C. Williams¹, David Huh¹, Patrick J. Heagerty¹, Audrey French², Susan E. Cohn³, Janet M. Turan⁴, Michael J. Mugavero⁴, Deepa Rao¹

¹Univ of Washington, Seattle, WA, USA, ²Ruth M. Rothstein CORE Cntr, Chicago, IL, USA, ³Northwestern Univ, Chicago, IL, USA, ⁴Univ of Alabama at Birmingham, Birmingham, AL, USA

922 THE CAUSAL EFFECT OF DEPRESSION ON VIRAL SUPPRESSION AMONG ADULTS IN HIV CARE

Alison Hughes, Susan Scheer

San Francisco Dept of Pub Hlth, San Francisco, CA, USA

- 923 SOCIAL ECOLOGICAL FACTORS ASSOCIATED WITH SEX WORK AMONG TRANSGENDER WOMEN IN JAMAICA**
Carmen H. Logie¹, Ying Wang¹, Nicolette Jones², Uzma Ahmed¹, Kandasi Levermore², Tyrone Ellis², Ava Neil², Anneka Marshall³, Ashley A. Lacombe-Duncan¹, Peter A. Newman¹
¹Univ of Toronto, Toronto, Canada, ²Jamaica AIDS Support for Life, Kingston, Jamaica, ³Univ of the West Indies, Mona Campus, Kingston, Jamaica
- 924 SEXUAL ORIENTATION DIFFERENCES IN HEALTH AND WELLBEING AMONG WOMEN WITH HIV IN CANADA**
Carmen H. Logie¹, Ashley A. Lacombe-Duncan¹, Ying Wang¹, Angela Kaida², Alexandra de Pokomandy³, Kath Webster², Tracey Conway⁴, Mona Loutfy⁴
¹Univ of Toronto, Toronto, Canada, ²Simon Frasier Univ, Vancouver, Canada, ³McGill Univ, Montreal, Canada, ⁴Women's Coll Rsr Inst, Toronto, Canada
- 925 HEALTH OUTCOMES ASSOCIATED WITH GENDER-BASED VIOLENCE AMONG WOMEN WITH HIV IN CANADA**
Carmen H. Logie¹, Angela Kaida², Alexandra de Pokomandy³, Erin Ding⁴, Nadia O'Brien³, Uzma Ahmed¹, Tracey Conway⁵, Val Nicholson², Mona Loutfy⁵
¹Univ of Toronto, Toronto, Canada, ²Simon Frasier Univ, Vancouver, Canada, ³McGill Univ, Montreal, Canada, ⁴BC Cntr for Excellence in HIV Rsr, Vancouver, Canada, ⁵Women's Coll Rsr Inst, Toronto, Ontario
- 926 TRANS WOMEN WITH HIV IN CANADA: RESULTS OF A NATIONAL COMMUNITY-BASED COHORT STUDY**
 Ashley A. Lacombe-Duncan¹, **Yasmeen Persad**², Greta R. Bauer³, Carmen H. Logie¹, Angela Kaida⁴, Alexandra de Pokomandy⁵, Nadia O'Brien⁵, Mona Loutfy⁶, for the CHIWOS Research Team
¹Univ of Toronto, Toronto, ON, Canada, ²The 519, Toronto, ON, Canada, ³Western Univ, London, Ontario, Canada, ⁴Simon Fraser Univ, Vancouver, Canada, ⁵McGill Univ, Montreal, Canada, ⁶Women's Coll Rsr Inst, Toronto, Ontario, Canada
- 927 THE HEALTH IMPACT OF SEXUAL VIOLENCE AMONG WOMEN IN A PLATINUM MINING BELT**
Meiwen Zhang¹, Sarah Jane Steele¹, Amir Shroufi¹, Gilles van Cutsem¹, Junaid Khan², Garret Barnwell², Julia Hill¹, Kristal Duncan¹
¹MSF, Cape Town, South Africa, ²MSF, Rustenburg, South Africa

Poster P-S11 MORBIDITY, MORTALITY, AND VIRAL DYNAMICS

Poster Hall - 4 EF

2:30 PM - 4:00 PM

- 928 ASSOCIATION OF SEX AND RACE WITH HIV-/NON-HIV-RELATED DEATH IN TREATED HIV INFECTION**
David B. Hanna¹, Donald R. Hoover², Qihu Shi³, Uriel Felsen¹, Mark H. Kuniholm⁴, Mindy S. Ginsberg¹, Howard D. Strickler¹, Kathryn Anastos¹
¹Albert Einstein Coll of Med, Bronx, NY, USA, ²Rutgers, the State Univ of New Jersey, New Brunswick, NJ, USA, ³New York Med Coll, Valhalla, NY, USA, ⁴State Univ of New York at Albany, Rensselaer, NY, USA
- 929 IMPACT OF INJECTION DRUG USE AND SELECTED COMORBIDITIES ON HEALTHY LIFE EXPECTANCY**
Robert S. Hogg, Oghenowede Eyawo, Wendy Zhang, Paul Serada, Mark Hull, Jean A. Shoveller, Karyn Gabler, Viviane D. Lima, Julio S. Montaner, for the Comparative Outcomes And Service Utilization Trends (COAST) study
 BC Cntr for Excellence in HIV/AIDS, Vancouver, British Columbia, Canada

930 LONGITUDINAL ASSOCIATION BETWEEN HIV STATUS AND MEDICALLY SIGNIFICANT FALLS

Julie A. Womack¹, Terrence E. Murphy², Harini Bathulapalli¹, Jonathan Bates², Cynthia L. Gibert³, Maria Rodriguez-Barradas⁴, Phyllis Tien⁵, Michael T. Yin⁶, Cynthia A. Brandt¹, Amy Justice¹

¹VA Connecticut Hlthcare System, West Haven, CT, USA, ²Yale Univ, New Haven, CT, USA, ³Washington, DC, VA Med Cntr, Washington, DC, USA, ⁴Baylor Coll of Med, Houston, TX, USA, ⁵Univ of California San Francisco, San Francisco, CA, USA, ⁶Columbia Univ, New York, NY, USA

931 VIREMIA COPY-YEARS & MORTALITY IN HIV+ MEN STARTING ART: HOW MUCH HISTORY IS NEEDED?

Ruibin Wang¹, Sabina Haberlen¹, Frank J. Palella², Joseph B. Margolick¹, Bernard Macatangay³, Otoniel Martínez-Maza⁴, Lisa Jacobson¹, Alison Abraham¹

¹The Johns Hopkins Univ, Baltimore, MD, USA, ²Northwestern Univ, Chicago, IL, USA, ³Univ of Pittsburgh, Pittsburgh, PA, USA, ⁴Univ of California, Los Angeles, Los Angeles, CA, USA

932 LOW-LEVEL VIREMIA IS ASSOCIATED WITH VIROLOGIC FAILURE IN A LARGE MILITARY COHORT

Christie Joya¹, Seung Hyun Won², Karl Kronmann³, Jason Okulicz⁴, Timothy Whitman¹, Robert Deiss⁵, Christina Schofield⁶, Julie Pavlin⁵, Brian K. Agan⁵, Anuradha Ganesan⁵

¹Walter Reed Natl Military Med Cntr, Bethesda, MD, USA, ²Henry M. Jackson Fndn for Advancement of Military Med, Bethesda, MD, USA, ³Naval Med Cntr Portsmouth, Portsmouth, VA, USA, ⁴Brooke Army Med Cntr, San Antonio, TX, USA, ⁵Uniformed Services Univ of the Hlth Scis, Rockville, MD, USA, ⁶Madigan Army Med Cntr, Tacoma, WA, USA

933 LONGITUDINAL VIRAL TRAJECTORY AMONG WOMEN IN THE WOMEN'S INTERAGENCY HIV STUDY

Seble Kassaye¹, Cuiwei Wang¹, Jeff Collmann¹, Tracey Wilson², Kathryn Anastos³, Mardge H. Cohen⁴, Ruth Greenblatt⁵, Joel Milam⁶, Steven Gange⁷, Michael Plankey¹

¹Georgetown Univ, Washington, DC, USA, ²SUNY Downstate Med Cntr, Brooklyn, NY, USA, ³Albert Einstein Coll of Med, Bronx, NY, USA, ⁴John H. Stroger Jr. Hosp of Cook County, Chicago, IL, USA, ⁵Univ of California San Francisco, San Francisco, CA, USA, ⁶Univ of Southern California, Los Angeles, CA, USA, ⁷The Johns Hopkins Univ, Baltimore, MD, USA

Poster P-S2 RISK FACTORS FOR HIV INFECTION

Poster Hall - 4 EF

2:30 PM - 4:00 PM

851 THE EPIDEMIOLOGY OF HIV IN PEOPLE BORN OUTSIDE THE UNITED STATES, 2010–2014

Roxanne P. Kerani¹, Anna S. Johnson², Susan Buskin³, Deepa Rao¹, Matthew R. Golden¹, Xiaohong Hu², Irene Hall²

¹Univ of Washington, Seattle, WA, USA, ²CDC, Atlanta, GA, USA, ³Pub Hlth–Seattle & King County, Seattle, WA, USA

852 CHANGES IN HIV RISK FACTORS AMONG MEN WHO HAVE SEX WITH MEN AND WOMEN, 2008–2014

Wade Ivy¹, Thema Chapple², Gabriela Paz-Bailey¹, for the NHBS Study Group

¹CDC, Atlanta, GA, USA, ²Morehouse Coll, Atlanta, GA, USA

853 ASSOCIATION BETWEEN HOUSING STABILITY AND NEW HIV DIAGNOSIS IN SEEK AND TEST STUDIES

Bridget Whitney¹, Bridget Kruska¹, Jennifer Lorvick², Gregory M. Lucas³, Wendee Wechsberg⁴, Irene Kuo⁵, William E. Cunningham⁶, Asa Clemenzi-Allen⁷, Julie Franks⁸, Heidi M. Crane¹

¹Univ of Washington, Seattle, WA, USA, ²RTI Intl, Berkeley, CA, USA, ³The Johns Hopkins Univ, Baltimore, MD, USA, ⁴RTI Intl, Rsr Triangle Park, NC, USA, ⁵George Washington Univ, Washington, DC, USA, ⁶Univ of California Los Angeles, Los Angeles, CA, USA, ⁷Univ of California San Francisco, San Francisco, CA, USA, ⁸Columbia Univ, New York, NY, USA

854 HIV INCIDENCE AND RISK BEHAVIORS IN THE BANGKOK MSM COHORT STUDY, THAILAND, 2006–2015

Timothy H. Holtz¹, Anchalee Varangrat², Philip Mock², Warunee Thienkrua², Wannee Chonwattana², Wipas Wimonasate², Wichuda Sukwicha², Marcel Curlin³, Eileen Dunne⁴, Anupong Chitwarakorn⁵

¹CDC, Atlanta, GA, USA, ²Thailand Ministry of Pub Hlth—US CDC Collab, Nonthaburi, Thailand, ³Oregon Hlth and Scis Univ, Portland, OR, USA, ⁴US CDC, Nonthaburi, Thailand, ⁵Thailand Ministry of Pub Hlth, Nonthaburi, Thailand

855 CHANGES IN RISK BEHAVIORS AFTER HIV SEROCONVERSION, BANGKOK MSM COHORT STUDY

Wipas Wimonasate¹, Sarika Pattanasin¹, Pikunchai Luechai¹, Jaray Tongtoyai¹, Wichuda Sukwicha¹, Chaiwat Ungsedhapand¹, Anupong Chitwarakorn², Michael Thigpen³, Eileen Dunne³, Timothy Holtz³

¹Thailand Ministry of Pub Hlth—US CDC Collab, Nonthaburi, Thailand, ²Thailand Ministry of Pub Hlth, Nonthaburi, Thailand, ³US CDC, Nonthaburi, Thailand

856 AN EMPIRIC RISK SCORE TO GUIDE PREP UPTAKE IN MSM IN COASTAL KENYA

Elizabeth Wahome¹, Alexander N. Thiong'o¹, Oscar Chirro¹, Evans Gichuru¹, John Mwambi¹, Matt A. Price², Susan M. Graham³, Eduard Sanders⁴

¹KEMRI Wellcome Trust Rsr Prog, Kilifi, Kenya, ²Intl AIDS Vaccine Initiative, New York, NY, USA, ³Univ of Washington, Seattle, WA, USA, ⁴Kenya Med Rsr Inst, Kilifi, Kenya

857 VALIDATION OF A RISK SCORE FOR HIV ACQUISITION IN YOUNG AFRICAN WOMEN WITH FACTS 001

Emma K. Burgess¹, Sinead Delany-Moretlwe², Pedro Pisa², Khatija Ahmed³, Sydney Sibiya⁴, Cynthia Gama⁵, Busiswe Nkala⁶, Gustavo Doncel⁷, Glenda Gray⁶, Helen Rees²

¹Global Hlth Fellows Internship at USAID, Arlington, VA, USA, ²Wits Reproductive Hlth and HIV Inst, Johannesburg, South Africa, ³Setshaba Rsr Cntr, Pretoria, South Africa, ⁴Qhakaza Mbokodo Rsr Clinic, Ladysmith, South Africa, ⁵MatCH, Durban, South Africa, ⁶Perinatal HIV Rsr Unit, Soweto, South Africa, ⁷CONRAD, Arlington, VA, USA

858 SELF-ASSESSED HIV RISK 3 YEARS AFTER HIV “TEST AND TREAT” IMPLEMENTED IN SEARCH

James Ayieko¹, Dalsone Kwariisima², Catherine A. Koss³, Craig Cohen³, Elizabeth A. Bukusi¹, Tamara D. Clark³, Edwin D. Charlebois³, Moses R. Kanya⁴, Maya L. Petersen⁵, Diane V. Havlir³

¹Kenya Med Rsr Inst, Nairobi, Kenya, ²Makerere Univ Joint AIDS Prog, Kampala, Uganda, ³Univ of California San Francisco, San Francisco, CA, USA, ⁴Makerere Univ, Kampala, Uganda, ⁵Univ of California Berkeley, Berkeley, CA, USA

859 HIV RISK FACTORS AND RISK PERCEPTION AMONG ADOLESCENT GIRLS AND YOUNG WOMEN IN MALAWI

Joan T. Price¹, Nora E. Rosenberg¹, Bertha Maseko², Savvy Brar², Twambilile Phanga², Audrey Pettifor¹, Linda-Gail Bekker³

¹Univ of North Carolina at Chapel Hill, Chapel Hill, NC, USA, ²Univ of North Carolina Proj—Malawi, Lilongwe, Malawi, ³Univ of Cape Town, Cape Town, South Africa

860 GENDERED PATTERNS OF MOBILITY PREDICT HIV PREVALENCE IN UGANDA/KENYA IN SEARCH STUDY

Carol S. Camlin¹, Tor Neilands¹, Jane Kabami², Gabriel Chamie¹, Elizabeth A. Bukusi³, Tamara D. Clark¹, Moses R. Kamya⁴, Maya L. Petersen⁵, Diane V. Havlir¹, Edwin D. Charlebois¹

¹Univ of California San Francisco, San Francisco, CA, USA, ²Infectious Diseases Rsr Collab, Kampala, Uganda, ³Kenya Med Rsr Inst, Nairobi, Kenya, ⁴Makerere Univ, Kampala, Uganda, ⁵Univ of California Berkeley, Berkeley, CA, USA

861 HIGH RISK BEHAVIOR IN MARRIED PEOPLE LIVING WITH HIV: IMPLICATIONS FOR PREVENTION

Zachary A. Kwenya¹, Catherine K. Makokha¹, David O. Ang'awa¹, Elizabeth A. Bukusi²

¹Kenya Med Rsr Inst, Kisumu, Kenya, ²Kenya Med Rsr Inst, Nairobi, Kenya

Poster P-S3 HIV AND STIs: BACK TO THE FUTURE

Poster Hall - 4 EF

2:30 PM - 4:00 PM

862 HIV AND SYPHILIS COINFECTION IN MEN WHO HAVE SEX WITH MEN, BANGKOK, 2005–2016

Chaiwat Ungsedhapand¹, Kanokpan Panchroen¹, Anuwat Sriporn¹, Wichuda Sukwicha¹, Wipas Wimonasate¹, Nutthawoot Promda¹, Santi Winaitam¹, Anupong Chitwarakorn², Eileen F. Dunne³, Michael Thigpen³

¹Thailand MOPH—US CDC Collab, Nonthaburi, Thailand, ²Thailand MOPH, Nonthaburi, Thailand, ³US CDC, Nonthaburi, Thailand

863 SUBSEQUENT AND RECURRENT STI AMONG THAI MSM AND TG IN TEST AND TREAT COHORT

Akarin Hiransuthikul¹, Supanit Pattanachaiwit¹, Nipat Teeratakulpisarn¹, Parinya Chamnan², Panita Pathipvanich³, Suchart Thongpaen⁴, Supabhorn Pengnonyang¹, Deondara Trachunthong¹, Nittaya Phanuphak¹, for the Thai MSM/TG Test and Treat Study Group

¹The Thai Red Cross AIDS Rsr Cntr, Bangkok, Thailand, ²Sanpasitthiprasong Hosp, Ubonratchathani, Thailand, ³Lampang Hosp, Lampang, Thailand, ⁴Maharakham Hosp, Maharakham, Thailand

864 RISK FACTORS AND INCIDENCE OF SYPHILIS IN HIV-INFECTED PERSONS, THE HOPS, 1999–2015

Richard Novak¹, Abdelhamid Ghanem¹, Rachel Hart², Douglas Ward³, Carl Armon³, Kate Buchacz⁴

¹Univ of Illinois at Chicago, Chicago, IL, USA, ²Cerner Corp, Kansas City, MO, USA, ³Dupont Circle Physicians Group, Washington, DC, USA, ⁴CDC, Atlanta, GA, USA

865 INCIDENT SYPHILIS INFECTIONS DECLINED IN WELL-CHARACTERIZED COHORT OF HIV+ PERSONS

Anuradha Ganesan¹, Xun Wang², Robert Deiss³, Julie Pavlin³, Tomas Ferguson⁴, Thomas O'Bryan⁵, Jason Okulicz⁶, Ryan Maves⁷, Karl Kronmann⁸, Grace Macalino³

¹Uniformed Services Univ of the Hlth Scis, Rockville, MD, USA, ²Henry M. Jackson Fndn for the Advancement of Military Med, Rockville, MD, USA, ³Tripler Army Med Cntr, Honolulu, HI, USA ⁴Uniformed Services Univ of the Hlth Scis, San Antonio, TX, USA, ⁵San Antonio Military Med Cntr, San Antonio, TX, USA, ⁶Naval Med Cntr San Diego, San Diego, CA, USA, ⁷Naval Med Cntr Portsmouth, Portsmouth, VA, USA

866 INCIDENT SYPHILIS INFECTIONS IN HIV-POSITIVE PATIENTS IN CARE

Raynell Lang¹, Ron Read², Soheil Ramazani³, John Gill²

¹Alberta Hlth Services, Calgary, Canada, ²Univ of Calgary, Calgary, Canada, ³Southern Alberta Clinic, Calgary, Canada

867 SCREENING FOR EXTRAGENITAL CT/GC AMONG HIV-INFECTED MSM: A COMPARISON OF 4 NAATs

Jodie Dionne-Odom, Kristal Aaron, Mary Banasiewicz, Sarah Dougherty, Brice Daniels, James Raper, Edward Hook, Barbara Van Der Pol
Univ of Alabama at Birmingham, Birmingham, AL, USA

868LB NALTREXONE IMPLANT IMPROVES HIV TX OUTCOMES VS ORAL NTX IN OPIATE ADDICTED PATIENTS

Evgeny Krupitsky¹, Edwina Zvartau¹, E. Blokhina¹, Elena Verbitskaya¹, D. Lioznov¹, T. Yaroslavltsseva¹, Sabrina Poole², **Robert Gross**², George Woody²

¹First Pavlov State Med Univ of St. Petersburg, St. Petersburg, Russian Federation, ²Univ of Pennsylvania, Philadelphia, PA, USA

Poster P-S6 ACUTE AND EARLY HIV INFECTION

Poster Hall - 4 EF

2:30 PM - 4:00 PM

886 RISK- AND SYMPTOM-BASED SCREENING IMPROVES IDENTIFICATION OF ACUTE HIV INFECTION

Maartje Dijkstra¹, Godelieve J. de Bree², Ineke Stolte¹, Udi Davidovich¹, Eduard Sanders³, Maria Prins¹, Maarten F. Schim van der Loeff¹

¹Pub Hlth Service Amsterdam, Netherlands, ²Academic Med Cntr, Amsterdam, Netherlands, ³Kenya Med Rsr Inst, Kilifi, Kenya

887 IMPLEMENTATION OF A RAPID TRAJECTORY TO IDENTIFY ACUTE HIV INFECTION IN AMSTERDAM

Maartje Dijkstra¹, Elske Hoornenborg¹, Udi Davidovich¹, Arjan Hogewoning¹, Henry J.C. de Vries¹, Sylvia Bruisten¹, Maria Prins¹, Maarten F. Schim van der Loeff¹, Godelieve J. de Bree²

¹Pub Hlth Service Amsterdam, Netherlands, ²Academic Med Cntr, Amsterdam, Netherlands

888 COMPARISON OF SELF-REPORT TO BIOMARKERS OF RECENT INFECTION

Katherine E. Schlusser¹, Shweta Sharma², Pola de la Torre³, Giuseppe Tambussi⁴, Rika Draenert⁵, Angie N. Pinto⁶, Julia A. Metcalf⁷, Danielle German¹, James Neaton², Oliver Laeyendecker⁷

¹The Johns Hopkins Univ, Baltimore, MD, USA, ²Univ of Minnesota, Minneapolis, MN, USA, ³Cooper Univ Hosp, Camden, NJ, USA, ⁴Ospedale San Raffaele, Milano, Italy, ⁵Klinikum der Univ Munich, Munich, Germany, ⁶Kirby Inst, Sydney, Australia, ⁷NIAID, Bethesda, MD, USA

889 USE OF TESTING HISTORY TO IDENTIFY HIV-INFECTED PEOPLE AT HIGH RISK OF TRANSMISSION

Laurie Linley¹, Richard M. Selik¹, Xiaona Qian², Alexandra Oster¹

¹CDC, Atlanta, GA, USA, ²ICF Intl, Atlanta, GA, USA

890 VIRAL LOADS NEAR HIV DIAGNOSIS: VARIATION WITH STAGE (0, 1, 2, OR 3) AT DIAGNOSIS

Richard M. Selik, **Laurie Linley**, Mi Chen

CDC, Atlanta, GA, USA

Poster P-T4 LESSONS FROM SEROCONVERSION ON PREP AND MICROBICIDES

Poster Hall - 4 EF

2:30 PM - 4:00 PM

951 DOES THE E138A MUTATION IN ASPIRE SEROCONVERTERS AFFECT SUSCEPTIBILITY TO DAPIVIRINE?

Kerri Penrose¹, Breanna J. Goetz¹, Kelley C. Gordon¹, Daniel W. Szydlo², Marla J. Husnik², Thesla Palanee-Phillips³, Jared Baeten⁴, John Mellors¹, Urvi Parikh¹, for the MTN020/ASPIRE Study Team

¹Univ of Pittsburgh, Pittsburgh, PA, USA, ²Statistical Cntr for HIV/AIDS Rsr and Prevention (SCHARP), Seattle, WA, USA, ³Wits Reproductive Hlth and HIV Inst, Johannesburg, South Africa, ⁴Univ of Washington, Seattle, WA, USA

952 NNRTI-CONTAINING ART IS EFFECTIVE FOR DAPIVIRINE RING BREAKTHROUGH HIV-1 INFECTION

Sharon Riddler¹, Jennifer Balkus², John Mellors¹, Urvi Parikh¹, Carolyne Akello³, Sufia Dadabhai⁴, Felix Mhlanga⁵, Colin O'Rourke², Jared Baeten⁶, for the MTN-015 and MTN-020/ASPIRE Study Teams

¹Univ of Pittsburgh, Pittsburgh, PA, USA, ²Fred Hutchinson Cancer Rsr Cntr, Seattle, WA, USA, ³Makerere Univ-Johns Hopkins Univ Rsr Collab, Kampala, Uganda, ⁴The Johns Hopkins Univ, Baltimore, MD, USA, ⁵Univ of Zimbabwe, Harare, Zimbabwe, ⁶Univ of Washington, Seattle, WA, USA

953 ACUTE INFECTION WITH A WILD-TYPE HIV-1 VIRUS IN PREP USER WITH HIGH TDF LEVELS

Elske Hoornenborg¹, Godelieve J. de Bree², for the Amsterdam PrEP Project in the HIV Transmission Elimination Amsterdam Consortium (H-TEAM)

¹Pub Hlth Service Amsterdam, Amsterdam, Netherlands, ²Academic Med Cntr, Amsterdam, Netherlands

954 HIV GENETIC DIVERSITY TO INFER PREP ADHERENCE AT THE ESTIMATED TIME OF INFECTION

Olivia Council¹, Susan Ruone¹, Philip Mock², George Khalil¹, Marcel Curlin³, Walid Heneine¹, Kachit Choopanya⁴, Michael Martin², **Gerardo Garcia-Lerma**¹

¹CDC, Atlanta, GA, USA, ²Thailand MOPH-US CDC Collab, Nonthaburi, Thailand, ³Oregon Hlth and Scis Univ, Portland, OR, USA, ⁴Bangkok Tenofovir Study Group, Bangkok, Thailand

955 CHARACTERIZATION OF HIV SEROCONVERTERS IN A TDF/FTC PREP STUDY: HPTN 067

Mariya V. Sivay¹, Yinfeng Zhang¹, Sarah E. Hudelson¹, Maoji Li², Estelle Piwowar-Manning¹, Mark A. Marzinke¹, Kevin Bokoch³, Robert Grant⁴, Susan H. Eshleman¹, for the HPTN 067 Study Team

¹The Johns Hopkins Univ, Baltimore, MD, USA, ²Fred Hutchinson Cancer Rsr Cntr, Seattle, WA, USA, ³FHI 360, Durham, NC, USA, ⁴Univ of California San Francisco Gladstone Insts, San Francisco, CA, USA

Poster P-U5 VOLUNTARY MEDICAL CIRCUMCISION

Poster Hall - 4 EF

2:30 PM - 4:00 PM

982 PREDICTORS OF MEDICAL MALE CIRCUMCISION UPTAKE BY MEN AGED 25-39 YEARS IN NYANZA

Donath Emusu¹, **Kawango Agot**², Jonathan Grund³, Paul K Musingila⁴, Frankline Onchiri⁵, Edward Mboya², Jacob Onyango², Eunice Omanga², Elijah Odoyo-June¹, Boaz Otieno-Nyunya¹

¹US CDC, Nairobi, Kenya, ²Impact Rsr and Development Org, Kisumu, Kenya, ³CDC, Atlanta, GA, USA ⁴US CDC, Kisumu, Kenya, ⁵Seattle Children's Rsr Inst, Seattle, WA, USA

983 MALE CIRCUMCISION AND RISK COMPENSATION IN KWAZULU-NATAL, SOUTH AFRICA

Katrina F. Ortblad¹, Guy Harling¹, Joshua A. Salomon¹, Frank Tanser², Deenan Pillay³, Tinofa Mutevedzi³, Till Baernighausen⁴

¹Harvard Univ, Boston, MA, USA, ²Africa Cntr for Pop Hlth, Mtubatuba, South Africa, ³Africa Hlth Rsr Inst, Mtubatuba, South Africa, ⁴Heidelberg Univ, Heidelberg, Germany

984 RISK COMPENSATION OVER 2 YEARS AMONG MEN IN A NATIONAL VMMC ROLL-OUT IN ZIMBABWE

Daniel E. Montano¹, Danuta Kasprzyk¹, Deven T. Hamilton¹, Mufuta Tshimanga²

¹Univ of Washington, Seattle, WA, USA, ²Univ of Zimbabwe, Harare, Zimbabwe

985 WITHDRAWN

986 AGREEMENT OF SELF-REPORTED AND PHYSICALLY VERIFIED MALE CIRCUMCISION STATUS IN KENYA

Elijah Odoyo-June¹, Kawango Agot², Edward Mboya², Jonathan Grund³, Paul K. Musingila¹, Donath Emusu¹, Leonard Soo¹, Boaz Otieno-Nyunya¹

¹US CDC, Nairobi, Kenya, ²Impact Rsr and Development Org, Kisumu City, Kenya, ³CDC, Atlanta, GA, USA

987 VOLUNTARY MEDICAL MALE CIRCUMCISION FOR NONCOMMUNICABLE DISEASE CASE FINDING, NAMIBIA

Nikki Soboil¹, Shawn J. Rooinasie², Catherine Laube³, Abubakari Mwinyi¹, Amir Shaker²

¹Jhpiego, Swakopmund, Republic of Namibia, ²Ministry of Hlth and Social Services, Erongo Regional Directorate, Swakopmund, Republic of Namibia, ³Jhpiego, Baltimore, MD, USA

Poster P-X1 MODELLING HIV TRANSMISSION**Poster Hall - 4 EF****2:30 PM - 4:00 PM****1024 DISTRIBUTION OF HIV TRANSMISSION BY NETWORK AND CLINICAL FACTORS AMONG US MSM****Johanna Chapin-Bardales¹**, Samuel Jenness¹, Eli Rosenberg¹, Patrick Sullivan¹, Steven M. Goodreau²¹Emory Univ, Atlanta, GA, USA, ²Univ of Washington, Seattle, WA, USA**1025 HIV TRANSMISSION IN GENERALIZED, CONCENTRATED, AND MIXED EPIDEMICS IN WESTERN KENYA****Anna Bershteyn¹**, Vibhuti Hate², Daniel J. Klein¹, Zindoga Mukandavire³, Graham F. Medley³, Wanjiru Mukoma⁴, Michael K. Kiragu⁴, Kristine Torjesen⁵, Nduku Kilonzo⁶, Katharine Kripke⁷, for the OPTIONS Consortium¹Inst for Disease Modeling, Bellevue, WA, USA, ²The George Washington Univ, Washington, DC, USA, ³London Sch of Hygiene and Trop Med, London, United Kingdom, ⁴LVCT Hlth, Nairobi, Kenya, ⁵FHI 360, Durham, NC, USA, ⁶Natl AIDS Control Council, Ministry of Hlth, Nairobi, Kenya, ⁷Avenir Hlth, Washington, DC, USA**1026 ANALYZING "MISSING MEN" IN THE UK HETEROSEXUAL HIV EPIDEMIC BY DSPS-HIV SIMULATIONS****Emma B. Hodcroft¹**, Manon Ragonnet-Cronin², Joel O. Wertheim³, Samantha Lycett⁴, Sergei L. Kosakovsky Pond⁵, Andrew Leigh Brown⁶¹Univ of Edinburgh, Edinburgh, Scotland, ²Univ of Edinburgh, Midlothian, Scotland, ³Univ of California San Diego, San Diego, CA, ⁴Temple Univ, Philadelphia, PA, USA**1027 TEMPORAL EVOLUTION OF HIV SERODISCORDANCY AMONG STABLE COUPLES IN SUB-SAHARAN AFRICA**Susanne Awad, Hiam Chemaitelly, **Laith J. Abu-Raddad**
Weill Cornell Med Coll in Qatar, Doha, Qatar**Poster P-X4 MODELLING TO GUIDE IMPROVEMENTS IN THE CARE CASCADE****Poster Hall - 4 EF****2:30 PM - 4:00 PM****1040 PAST AND FUTURE IMPACT OF ART SCALE-UP IN BRAZIL: PROGRAMME DATA ANALYSIS 1996–2014****Juan F. Vesga¹**, Ana R. Pati Pascom², Tara Mangal¹, Marcelo Freitas², Juliana M. Givisiez², Ronaldo de Almeida Coelho², Mariana Veloso Meirelles², Clarissa Habckost Dutra de Barros², Adele Benzaken², Timothy B. Hallett¹¹Imperial Coll London, London, UK, ²Ministry of Hlth, Brasilia (DF), Brazil**1041 EARLIER DIAGNOSIS AND TREATMENT REDUCES HIV TRANSMISSION IN MSM IN THE NETHERLANDS****Ard van Sighem¹**, Daniela Bezemer¹, Eline Op de Coul², Judith Branger³, Mark de Boer⁴, Peter Reiss⁵, for the ATHENA National Observational HIV Cohort¹Stichting HIV Monitoring, Amsterdam, Netherlands, ²Natl Inst for Pub Hlth and the Environment, Bilthoven, Netherlands, ³Flevoziekenhuis, Almere, Netherlands, ⁴Leiden Univ Med Cntr, Leiden, Netherlands, ⁵Stichting HIV Monitoring and Academic Med Cntr Amsterdam, Amsterdam, Netherlands**1042 ACHIEVING THE 90-90-90 TARGET BY 2020: THE EXPERIENCE IN BRITISH COLUMBIA, CANADA**Viviane D. Lima, **Martin St-Jean**, Jean A. Shoveller, P. Richard Harrigan, Bohdan Nosyk, Robert S Hogg, Paul Sereda, Rolando Barrios, Julio S. Montaner

BC Cntr for Excellence in HIV/AIDS, Vancouver, British Columbia, Canada

1043 THE CLINICAL AND ECONOMIC IMPACT OF ATTAINING NHAS TREATMENT TARGETS IN THE US

Ethan D. Borre¹, Emily P. Hyle¹, Paul E Sax², A. David Paltiel³, Anne M. Neilan¹, Kenneth Freedberg¹, Rochelle P. Walensky¹

¹Massachusetts General Hosp, Boston, MA, USA, ²Brigham and Women's Hosp, Boston, MA, USA, ³Yale Univ, New Haven, CT, USA

1044 IMPROVING THE PRISON CARE CONTINUUM REDUCES RACIAL HIV DISPARITIES: A MODELING STUDY

Brandon D. Marshall¹, Maximilian King¹, Alexandria Macmadu², Lauren Brinkley-Rubinstein³, M.-J. Milloy⁴, Curt G. Beckwith¹, Frederick Altice⁵, Josiah D. Rich¹

¹Brown Univ, Providence, RI, USA, ²The Miriam Hosp, Providence, RI, USA, ³Univ of North Carolina at Chapel Hill, Chapel Hill, NC, USA, ⁴Univ of British Columbia, Vancouver, British Columbia, Canada, ⁵Yale Univ, New Haven, CT, USA

1045 THE COST-EFFECTIVENESS OF FINANCIAL INCENTIVES FOR VIRAL SUPPRESSION IN HPTN 065

Blythe J. Adamson¹, Deborah J. Donnell², Dobromir Dimitrov², Louis Garrison¹, Geetha Beauchamp², Theresa Gamble³, Wafaa M. El-Sadr⁴

¹Univ of Washington, Seattle, WA, USA, ²Fred Hutchinson Cancer Rsr Cntr, Seattle, WA, USA, ³FHI 360, Durham, NC, USA, ⁴ICAP at Columbia Univ, New York, NY, USA

1046 OPTIMIZING INTERVENTION MODALITIES TO IMPROVE 90-90-90 CONTINUUM IN SOUTH AFRICA

David Wilson¹, Andrew Shattock², Nicole Fraser³, Zara Shubber³, Marelize Gorgens³, Richard Gray², Yogan Pillay⁴

¹Monash Univ, Melbourne, Australia, ²Univ of New South Wales, Sydney, Australia, ³World Bank, Washington, DC, USA, ⁴South African Natl Dept of Hlth, Pretoria, South Africa

1047 POPULATION-LEVEL IMPACT OF REACHING UNAIDS HIV PREVENTION TARGETS IN CÔTE D'IVOIRE

Mathieu Maheu-Giroux¹, Juan F. Vesga², Souleymane Dabate³, Michel Alary³, Stefan Baral⁴, Douada Diouf⁵, Kouame Abo⁶, **Marie-Claude Boily**²

¹Imperial Coll London, London, UK, ²Laval Univ, Quebec, Canada, ³The Johns Hopkins Univ, Baltimore, MD, USA, ⁵Enda Santé, Dakar, Senegal, ⁶Ministère de la Santé et de l'Hygiène Pub, Abidjan, Cote d'Ivoire

1048 ART RETENTION AND VIRAL SUPPRESSION KEY TO MAXIMISING TREATMENT AS PREVENTION IMPACT

Nicky McCreesh¹, Ioannis Andrianakis¹, Mark Strong², Rebecca N. Nsubuga³, Ian Vernon⁴, Trevelyan J. McKinley⁵, Jeremy E. Oakley², Michael Goldstein⁴, Richard Hayes¹, Richard G. White¹

¹London Sch of Hygiene and Trop Med, London, UK, ²Sheffield Univ, Sheffield, UK, ³MRC/UVRI Rsr Unit on AIDS, Entebbe, Uganda, ⁴Durham Univ, Durham, UK, ⁵Exeter Univ, Exeter, UK

1049LB COST-EFFECTIVENESS OF A COMBINATION STRATEGY FOR THE HIV CARE CASCADE IN SWAZILAND

Elizabeth Stevens¹, Kimberly Nucifora¹, Qinlian Zhou¹, Lingfeng Li¹, Scott Braithwaite¹, Margaret McNairy², Averie B. Gachuhi², Matthew R. Lamb³, Velephi Okello⁴, Wafaa M. El-Sadr²

¹New York Univ, New York City, NY, USA, ²ICAP Columbia Univ, New York, NY, USA, ³Columbia Univ, New York, NY, USA, ⁴Swaziland Ministry of Hlth, Mbabane, Swaziland

1050 COST-EFFECTIVENESS OF SAME-DAY TREATMENT INITIATION IN SOUTH AFRICA

Lawrence Long¹, Mhairi Maskew¹, Alana Brennan², Constance Mongwenyana¹, Cynthia Nyoni¹, Given Malete¹, **Ian Sanne**¹, Matthew Fox², Sydney Rosen²

¹Univ of the Witwatersrand, Johannesburg, South Africa, ²Boston Univ, Boston, MA, USA

1051 COST OF STREAMLINED HIV CARE IN RURAL KENYAN AND UGANDAN CLINICS IN THE SEARCH STUDY

Starley B. Shade¹, Thomas Osmand¹, Florence Mwangwa², Asiphas Owaraganise², Tamara D. Clark¹, Edwin D. Charlebois¹, Moses R. Kanya³, Maya L. Petersen⁴, Diane V. Havlir¹, Vivek Jain¹

¹Univ of California San Francisco, San Francisco, CA, USA, ²Infectious Diseases Rsr Collab, Kampala, Uganda, ³Makerere Univ Coll of Hlth Scis, Kampala, Uganda, ⁴Univ of California Berkeley, Berkeley, CA, USA

1052 DIFFERENTIATED HIV RNA VIRAL-LOAD MONITORING IN UGANDA: A COST-EFFECTIVENESS ANALYSIS

Diana M. Negoescu¹, Zhenhuan Zhang¹, **Heiner C. Bucher**², Eran Bendavid³, for the Swiss HIV Cohort Study

¹Univ of Minnesota, Minneapolis, MN, USA, ²Basel Inst for Clinical Epi and Biostatistics, Basel, Switzerland, ³Stanford Univ, Stanford, CA, USA

1053 PROJECTING FUTURE DONOR ASSISTANCE FOR HIV/AIDS GLOBAL FUNCTION SUPPORT

Eran Bendavid¹, Marco Marco Schäferhoff², Jessica Kraus², Dean Jamison³, Sebastian Martinez²

¹Stanford Univ, Stanford, CA, USA, ²SEEK Development, Berlin, Germany, ³Univ of California San Francisco, San Francisco, CA, USA

POSTER SESSIONS, BY CATEGORY

All poster sessions will be held in Poster Hall in Room 4 EF from 2:30 PM to 4:00 PM on the scheduled day (listed in parenthesis below).

A. VIROLOGY

- P-A1 VIROLOGY TRAFFICKING (Tuesday)
- P-A2 VIRUS AND CELL RNA IN HIV REPLICATION (Wednesday)
- P-A3 HIV CELL INTERACTION (Thursday)
- P-A4 HIV AND HOST DEFENSE (Wednesday)
- P-A5 VIRUS ADAPTATION TO IMMUNITY (Thursday)

B. MOLECULAR EPIDEMIOLOGY AND HIV/SIV EVOLUTION

- P-B1 UNDERSTANDING NETWORKS AND LINKED INFECTIONS: FROM LOCAL TO GLOBAL (Tuesday)
- P-B2 VIRAL DIVERSITY (Wednesday)
- P-B3 TIMING INFECTION AND DEFINING FOUNDER SEQUENCES AND DUAL INFECTIONS (Thursday)

C. PATHOGENESIS: HUMAN STUDIES AND ANIMAL MODELS

- P-C1 PRIMARY HIV INFECTION AND SPREAD (Wednesday)
- P-C2 HOW DOES THE MICROBIOME AFFECT HIV INFECTION? (Wednesday)
- P-C3 HIV INFECTION AND THE MICROBIOME (Wednesday)
- P-C4 ANIMAL MODELS OF HIV INFECTION (Tuesday)
- P-C5 EFFECT OF ANTIRETROVIRAL THERAPY ON HIV DISEASE AND RECOVERY (Tuesday)
- P-C6 CORRELATES OF HIV DISEASE (Thursday)
- P-C7 INTERACTIONS OF HIV WITH OTHER INFECTIONS (Thursday)

D. HOST IMMUNE RESPONSES TO INFECTION, VACCINES, AND IMMUNOTHERAPY

- P-D1 HIV-SPECIFIC ANTIBODIES AND HOW TO INDUCE THEM (Tuesday)
- P-D2 INFLAMMATION AND IMMUNITY (Thursday)
- P-D3 CD4 T CELLS: MORE THAN JUST HELP (Thursday)
- P-D4 CD8 T CELLS: WHERE AND HOW THEY KILL (Wednesday)
- P-D5 NK AND MAIT CELLS (Wednesday)

E. HIV RESERVOIRS, LATENCY, AND ALL CURATIVE STRATEGIES INCLUDING THERAPEUTIC VACCINES AND GENE THERAPY

- P-E1 PERSISTENT VIREMIA AND IMMUNITY ON ART (Tuesday)
- P-E2 CHARACTERIZING THE HIV RESERVOIR (Thursday)
- P-E3 WHERE IS HIV HIDING? (Wednesday)
- P-E4 HIV PERSISTENCE: SEND IN THE CLONES (Thursday)
- P-E5 PARSING PERSISTENT PROVIRUSES (Tuesday)
- P-E6 LATENCY REVERSAL (Wednesday)
- P-E7 EFFECT OF TRANSPLANTATION ON THE HIV RESERVOIR (Tuesday)
- P-E8 MODIFYING THE RESERVOIR: CLINICAL STUDIES (Thursday)
- P-E9 NEW TREATMENTS TO MODIFY THE HIV RESERVOIR (Wednesday)

F. NEUROPATHOGENESIS AND CNS HIV COMPLICATIONS

- P-F1 THE CNS AND SYSTEMATIC IMMUNE ACTIVATION (Thursday)
- P-F2 CEREBROVASCULAR EVENTS AND HIV (Wednesday)
- P-F3 NEUROCOGNITIVE FUNCTIONING, VIRAL SUPPRESSION, AND ASSOCIATED RISKS (Thursday)
- P-F4 CNS RESERVOIRS/ESCAPE (Wednesday)
- P-F5 VIROLOGY/BASIC NEUROSCIENCE (Tuesday)
- P-F6 INTERVENTION-FOCUSED (Tuesday)
- P-F7 HOST AND VIRAL BIOMARKERS (Tuesday)
- P-F8 NEUROIMAGING AND ASSOCIATED BIOMARKERS (Wednesday)

G. CLINICAL PHARMACOLOGY

- P-G1 INTRACELLULAR AND TISSUE PHARMACOLOGY (Tuesday)
- P-G2 DRUG - DRUG INTERACTIONS (Wednesday)
- P-G3 PHARMACOKINETICS AND PHARMACOGENETICS: NEW AND EXISTING DRUGS AND FORMULATIONS (Tuesday)
- P-G4 EXPOSURE-RESPONSE RELATIONSHIPS OF ANTIRETROVIRAL DRUGS (Wednesday)
- P-G5 ANTIRETROVIRAL PHARMACOKINETICS: SPECIAL PROBLEMS AND POPULATIONS (Thursday)

H. ANTIRETROVIRAL THERAPY: PRE-CLINICAL AND RANDOMIZED TRIALS

- P-H1 I WANT A NEW DRUG (Wednesday)
- P-H2 ANTIRETROVIRAL CLINICAL TRIALS (Tuesday)

I. ANTIRETROVIRAL THERAPY: EFFICACY AND EFFECTIVENESS STUDIES

- P-I1 ART: SAFETY AND PRESCRIBING OVER THE LONG TERM (Tuesday)
- P-I2 MAINTENANCE: SECOND- AND THIRD-LINE THERAPY (Tuesday)
- P-I3 ART: VIRAL RESPONSE OVER THE LONG TERM (Wednesday)
- P-I4 ART: PREDICTORS OF OUTCOMES (Wednesday)
- P-I5 IMMEDIATE VS DELAYED ART (Thursday)

J. HIV DRUG RESISTANCE

- P-J1 PREVALENCE AND INCIDENCE OF HIV DRUG RESISTANCE (Thursday)
- P-J2 IMPACT OF RESISTANCE ON RESPONSE TO ART (Thursday)
- P-J3 INTEGRASE STRAND TRANSFER INHIBITOR RESISTANCE (Tuesday)
- P-J4 REVERSE TRANSCRIPTASE INHIBITOR RESISTANCE (Tuesday)
- P-J5 RESISTANCE TO PROTEASE AND MATURATION INHIBITORS (Tuesday)

K. HIV DIAGNOSTICS

- P-K1 HIV DETECTION AND REGENCY METHODS (Tuesday)

L. HEPATITIS VIRUSES AND LIVER COMPLICATIONS

- P-L1 HCV TRANSMISSION: THE CASCADE IS NOT RUNNING DRY (Tuesday)
- P-L2 PROGRESSION OF LIVER DISEASE IN THE HCV-INFECTED POPULATION (Tuesday)
- P-L3 HCV: PROGRESSION TO CIRRHOSIS AND HEPATOCELLULAR CARCINOMA (Tuesday)
- P-L4 HCV: THE RAINBOW AT THE END OF THE CASCADE (Wednesday)
- P-L5 HCV: RESISTANCE AND RETREATMENT (Wednesday)
- P-L6 DAAs: TREATMENT AND ITS COMPLEXITIES (Wednesday)
- P-L7 HEPATITIS IS NOT ALL C (Thursday)
- P-L8 PATHOGENESIS OF HCV INFECTION (Thursday)

M. MALIGNANCIES

- P-M1 ANAL CANCER: SCREENING AND HPV (Tuesday)
- P-M2 AIDS-RELATED CANCER: ART, RISK, INCIDENCE, AND BURDEN (Wednesday)
- P-M3 AIDS-RELATED CANCER: LYMPHOMA, KAPOSI SARCOMA, LUNG, AND LIVER (Thursday)

N. CARDIOVASCULAR COMPLICATIONS OF HIV INFECTION AND ANTIRETROVIRAL THERAPY

- P-N1 CARDIOVASCULAR RISK AND ART EFFECTS (Wednesday)
- P-N2 DYSLIPIDEMIA AND HDL FUNCTION (Wednesday)
- P-N3 INTERVENTIONS TO PREVENT AND TREAT CARDIOVASCULAR DISEASE (Wednesday)
- P-N4 VASCULAR, CARDIAC, AND PULMONARY EVENTS (Wednesday)
- P-N5 INFLAMMATION, BIOMARKERS, AND RISK FACTORS FOR VASCULAR DISEASE (Tuesday)
- P-N6 INTEGRATION OF SCREENING AND TREATMENT OF NCD INTO HIV CARE IN RESOURCE-LIMITED SETTINGS (Tuesday)

O. OTHER COMPLICATIONS OF HIV INFECTION AND ANTIRETROVIRAL THERAPY

- P-O1 IMMUNOLOGIC PREDICTORS OF MORBIDITY AND MORTALITY (Tuesday)
- P-O2 ART TOXICITY (Tuesday)
- P-O3 PULMONARY COMPLICATIONS (Wednesday)
- P-O4 FRAILITY AND MULTIMORBIDITY (Wednesday)
- P-O5 PREDATORS OF INFLAMMATION OR ART (Thursday)
- P-O6 BONE DISEASE: RISK PREDICTION (Thursday)
- P-O7 BONE DISEASE: MECHANISMS (Thursday)
- P-O8 BONE DISEASE: INTERVENTIONS (Thursday)
- P-O9 RENAL DISEASE (Thursday)
- P-O10 ORGAN TRANSPLANTATION (Thursday)
- P-O11 METABOLIC COMPLICATIONS (Thursday)
- P-O12 OBESITY AND FATTY LIVER DISEASE (Thursday)

P. TUBERCULOSIS AND OTHER OPPORTUNISTIC INFECTIONS

- P-P1 TB PREVENTION (Tuesday)
- P-P2 TB PATHOGENESIS AND DIAGNOSIS (Tuesday)
- P-P3 TB TREATMENT, OUTCOMES, AND MORTALITY (Tuesday)
- P-P4 TB EPIDEMIOLOGY AND BURDEN OF DISEASE (Wednesday)
- P-P5 TB AND CONTINUUM OF CARE (Wednesday)
- P-P6 TB AND OI IRIS (Wednesday)
- P-P7 TB COMORBIDITIES (Wednesday)
- P-P8 OI EPIDEMIOLOGY AND PATHOGENESIS (Thursday)
- P-P9 CRYPTOCOCCAL MENINGITIS AND OTHER FUNGAL OIs (Thursday)
- P-P10 NEUROSYPHILIS (Thursday)
- P-P11 PROTOZOAL OIs (Thursday)

Q. MATERNAL/FETAL HIV

- P-Q1 PK AND SAFETY OF ARVs AND MONOCLONAL ANTIBODIES FOR PMTCT (Thursday)
- P-Q2 THE PMTCT CASCADE: TRANSMISSION, TESTING, AND VIRAL SUPPRESSION (Tuesday)
- P-Q3 PREGNANCY AND PREGNANCY OUTCOMES (Thursday)
- P-Q4 OUTCOMES OF HIV AND ARV-EXPOSED INFANTS (Tuesday)
- P-Q5 HIV DIAGNOSIS IN NEWBORNS AND INFANTS (Wednesday)

R. PEDIATRICS AND ADOLESCENTS

- P-R1 HIV DETECTION AND LATENT RESERVOIR IN CHILDREN (Wednesday)
- P-R2 IMMUNE RESPONSE AND ACTIVATION IN CHILDREN (Wednesday)
- P-R3 PHARMACOKINETICS AND DOSING OF ARVs AND COTREATMENTS IN CHILDREN AND YOUTH (Thursday)
- P-R4 ART STRATEGIES AND OUTCOMES IN CHILDREN AND YOUTH (Thursday)
- P-R5 COMORBIDITIES AND COMPLICATIONS IN CHILDREN AND YOUTH (Tuesday)
- P-R6 APPROACHING 90:90:90 IN ADOLESCENTS AND YOUNG ADULTS (Wednesday)

S. EPIDEMIOLOGY

- P-S1 NETWORKS OF HIV RISK (Thursday)
- P-S2 RISK FACTORS FOR HIV INFECTION (Thursday)
- P-S3 HIV AND STIs: BACK TO THE FUTURE (Thursday)
- P-S4 HIV AND SUBSTANCE USE: DOUBLE TROUBLE (Wednesday)
- P-S5 MEASURING HIV INCIDENCE AND PREVALENCE (Tuesday)
- P-S6 ACUTE AND EARLY HIV INFECTION (Thursday)
- P-S7 HIV SELF TESTING: KNOW YOURSELF (Tuesday)
- P-S8 MEASURING THE US HIV EPIDEMIC (Tuesday)
- P-S9 FACTORS INFLUENCING HIV OUTCOMES (Tuesday)
- P-S10 STIGMA, MENTAL HEALTH, AND SEXUAL VIOLENCE (Thursday)
- P-S11 MORBIDITY, MORTALITY, AND VIRAL DYNAMICS (Thursday)

T. PREVENTION INTERVENTIONS

- P-T1 FERTILITY, CONTRACEPTION, PREGNANCY, AND REPRODUCTIVE HEALTH (Wednesday)
- P-T2 HOT FLASHES: HORMONAL CONTRACEPTION AND HIV RISK (Wednesday)
- P-T3 GENITAL INFECTIONS: MISHAPS AT THE MUCOSA (Wednesday)
- P-T4 LESSONS FROM SEROCONVERSION ON PREP AND MICROBICIDES (Thursday)

U. PREVENTION SCALE-UP

- P-U1 STRATEGIES TO INCREASE HIV TESTING (Tuesday)
- P-U2 PREP WITHOUT BORDERS: NEW DELIVERY OPTIONS (Wednesday)
- P-U3 PREP AWARENESS, TARGETING, AND UPTAKE (Wednesday)
- P-U4 PREP PERSISTENCE, ADHERENCE, AND OUTCOMES (Wednesday)
- P-U5 VOLUNTARY MEDICAL CIRCUMCISION (Thursday)

W. IMPLEMENTATION AND SCALE-UP OF TREATMENT AND CARE

- P-W1 MEASURING THE GLOBAL HIV CARE CASCADE (Wednesday)
- P-W2 INTERVENTIONS TO IMPROVE THE CARE CASCADE (Tuesday)
- P-W3 HIV, MIGRATION, AND ACCESS TO CARE (Wednesday)
- P-W4 ADVANCED HIV, AND LONG-TERM CARE (Tuesday)

X. POPULATION AND COST MODELING

- P-X1 MODELLING HIV TRANSMISSION (Thursday)
- P-X2 COST-EFFECTIVENESS OF HIV TESTING AND SCREENING STRATEGIES (Tuesday)
- P-X3 IMPROVING THE EFFECTIVENESS AND COST EFFECTIVENESS OF PREP AND OTHER PREVENTION APPROACHES (Wednesday)
- P-X4 MODELLING TO GUIDE IMPROVEMENTS IN THE CARE CASCADE (Thursday)

Y. EMERGING VIRUSES: ZIKA VIRUS

- P-Y1 EMERGING VIRUSES: ZIKA VIRUS (Tuesday)

Please refer to the Index of Studies Related to Women for presentations that include, among others, studies on contraceptive and reproductive health in women (Category V).

DISCLOSURE OF FINANCIAL RELATIONSHIPS WITH COMMERCIAL CONCERNS

Disclosure information is presented generally as submitted by the corresponding presenting abstract author or invited speaker. The authors and speakers below provided their relevant disclosures of financial relationships with commercial entities for themselves and their spouses or partners, as well as funding provided to their

Abu-Raddad, Laith, J.

For self, paid to my institution:

Research grant recipient from the Qatar National Research Fund

Achhra, Amit, C.

Self: Employee of NCBH Hosp and JJP VA Med Ctr, Bronx, NY

Achilles, Sharon, L.

Self: Consultant of Merck & Co, Inc

Adkison, Kimberly, K.

Self: Employee of ViiV Healthcare

Althoff, Keri, N.

Self: Consultant Gilead Sciences, Inc

Ananworanich, Jintanat

Self: Honoraria from ViiV Healthcare and Merck & Co, Inc

For self, paid to my institution:

Research grant recipient from Cooperative agreements between The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., and the U.S. Department of the Army

Anderson, Jenny, L.

For self, paid to my institution:

Contracted researcher Merck & Co, Inc

Anderson, Peter, L.

For self, paid to my institution:

Research grant recipient from for contract work and study drug donation from Gilead Sciences, Inc

Anderson, Sarah-Jane

Self: Consultant for Bill and Melinda Gates Foundation and consultant for Avenir Health

Andrade, Adriana

Self: Board member of Ginseng Board of Wisconsin and research grant recipient Gilead Sciences, Inc

Andrew, Katende

Self: Employee of IFAKARA Health Institute

Ankrom, Wendy

Self: Employee of Merck & Co., Inc
Spouse or Partner: Contracted researcher for Certara

Anugulruengkitt, Suvaporn

Self: Research grant recipient from The Collaborative Initiative for Paediatric HIV Education and Research (CIPHER) Grant Programme

Arribas, Jose, R.

Self: Research grant recipient from and speaker's bureau for ViiV Healthcare, JanssenTherapeutics, AbbVie, Bristol-Myers Squibb, and Gilead Sciences, Inc

Barber, Tristan

Self: Consultant and speaker's bureau for Gilead Sciences, Inc, Janssen Therapeutics, and ViiV Healthcare

Bares, Sara, H.

Self: Research grant recipient from Gilead Sciences, Inc.

Barnard, Richard

Self: Employee of Merck and Co., Inc

Bauer, Wolfgang

Self: Consultant of GlaxoSmithKline and Pharma GmbH

Bedimo, Roger

Self: Research grant recipient from and consultant for Merck & Co, Inc and Bristol-Myers Squibb

Bekker, Linda-Gail

For self, paid to my institution:

Research grant recipient from The Desmond Tutu HIV Centre

Berenguer, Juan

For self, paid to my institution:

Research grant recipient from ABBVIE, Gilead Sciences, Inc, Merck & Co, Inc, ViiV Healthcare

Self: Speaker's bureau for ABBVIE, Bristol-Myers Squibb, Gilead Sciences, Inc, Merck & Co, Inc, Janssen Therapeutics, and ViiV Healthcare

Bhattacharya, Debika

For self, paid to my institution:

Research grant recipient from AbbVie, Bristol Myers Squibb, and Merck & Co, Inc

Boesecke, Christoph

Self: Consultant and speaker's bureau AbbVie, Bristol-Myers Squibb, Gilead Sciences, Inc, Merck & Co, Inc, and ViiV Healthcare

For self, paid to my institution:

Research grant recipient from Deutsches Zentrum für Infektionsforschung (DZIF), Deutsche Leberstiftung, and NEAT ID

Boffito, Marta

Self: Consultant and speaker's bureau for Gilead Sciences, Inc, ViiV Healthcare, Bristol-Myers Squibb, Janssen Therapeutics, Mylan, Inc, and Teva

Self, For self, paid to my institution:

Research grant recipient from Gilead Sciences, Inc, ViiV Healthcare, Bristol-Myers Squibb, Janssen Therapeutics, Mylan, Inc, and Teva

Bollen, Pauline

For self, paid to my institution: Grant from ViiV Healthcare

Brehm, Jessica

Self: Employee of GlaxoSmithKline

Brinkman, Kees

Self: Consultant for Merck & Co, Inc, Gilead Sciences, Inc, ViiV Healthcare, Roche Diagnostics, Bristol-Myers Squibb, and Janssen Therapeutics

Brockmeyer, Norbert, H.

Self: Consultant Merck & Co, Inc

For self, paid to my institution:

Research grant recipient from ViiV Healthcare, Bristol-Myers Squibb, and Janssen Therapeutics

Brown, Kimberley

Self: Janssen Therapeutics

Brown, Todd

Self: Consultant for Gilead Sciences, Bristol-Myers Squibb, Merck & Co, Inc, EMD-Serono, and Theratechnologies

Bucher, Heiner, C.**For self, paid to my institution:**

Research grant recipient from Gilead Sciences, Bristol-Myers Squibb, and ViiV Health Care

Butt, Adeel, A.

Self: Research grant recipient from Gilead Sciences, Inc, Merck & Co, Inc, and AbbVie

Cai, Suqin

Self: Employee of Monogram Biosciences

Calcagno, Andrea

Self: Consultant of Abbvie, Bristol-Myers Squibb, Gilead Sciences, Inc, Janssen-Cilag, Merck & Co, Inc, ViiV Healthcare

For self, paid to my institution:

Research grant recipient from Gilead Sciences, Inc, Bristol-Myers Squibb, ViiV Healthcare

Cambiano, Valentina

Self: Other for Merck & Co, Inc

Ceccherini Silberstein, Francesca

Self: Research grant recipient from consultant, and speaker's bureau for AbbVie, Abbott Molecular, Bristol-Myers Squibb, Gilead Sciences, Inc, Janssen Therapeutics, Merck & Co, Inc, Roche Diagnostics, ViiV Healthcare

Cento, Valeria

Self: Speaker's bureau for Abbvie, Bristol-Myers Squibb, Merck Sharp & Dohme, and Janssen Therapeutics

Chew, Kara, W.**Self, For self, paid to my institution:**

Research grant recipient from Merck & Co, Inc

Christopoulos, Katerina

Self: Other for Roche Diagnostics and Gilead Sciences, Inc

Clarke, Diana, F.

Self: Consultant for Merck & Co, Inc

Clement, Meredith

Spouse or Partner: Royalty holder (company not stated)

Cloherly, Gavin

Self: Employee of Abbott Laboratories

Coller, Kelly

Self: Employee of Abbott Laboratories

Corbin, John, A.

Self: Employee of Gilead Sciences, Inc

Costagliola, Dominique

Self: Consultant for Gilead Sciences, Inc and Innativax

For self, paid to my institution:

Research grant recipient from ViiV Healthcare, Janssen-Cilag, Merck & Co, Inc.

Cotte, Laurent**For self, paid to my institution:**

Research grant recipient from Merck & Co, Inc, ViiV

Custodio, Joseph, M.

Self: Employee of Gilead Sciences, Inc

Dean, Bonnie

Self: Research grant recipient from Cerner, Inc

DeJesus, Edwin

Self: Consultant of Bristol-Myers Squibb, Gilead Sciences, Inc, Janssen Therapeutics, Merck & Co, Inc, and Vertex, Inc

For self, paid to my institution:

Research grant recipient from Abbott Laboratories, Achillion Pharmaceuticals, Avexa, Boehringer Ingelheim, Bristol-Myers Squibb, Gilead Sciences, Inc, GlaxoSmithKline, LaRoche Diagnostics, Idenix, Janssen Therapeutics, Merck & Co, Inc, Pfizer, Sangamo, Taimed, Tobira, and Vertex, Inc

Devillé, Walter**For self, paid to my institution:**

Research grant recipient from Orasure Company

Dolci, Giovanni,

Self: Consultant of Gilead Sciences, Inc

Self, For self, paid to my institution:

Research grant recipient from Gilead Sciences, Inc

Dunham, Richard, M.

Self: Employee of GlaxoSmithKline

Durand, Christine

Self: Consultant Gilead Sciences
Research grant recipient from Merck Pharmaceuticals
Consultant Bristol-Myers Squibb

Durham, Phillip, G.**Self:** Employee of RTI International**Eaton, Ellen, F.****For self, paid to my institution:**

Research grant recipient from Other Bristol Myers Squibb Virology Fellowship Recipient, Analyst on Merck-funded project

Eckard, Allison, R.**Self:** Consultant Gilead Sciences**For self, paid to my institution:**

Research grant recipient from Bristol-Myers Squibb, Cubist Pharmaceuticals, and GlaxoSmithKline

Eckhardt, Benjamin,**Self:** Research grant recipient from and consultant Gilead Sciences, Inc**Ellis, Ronald, J.****Spouse or Partner:** Stockholder of Merck & Co, Inc, Abbott, and Johnson and Johnson**Emu, Brinda****Self:** Consultant for Taimed and 3V Biosciences**Erlandson, Kristine****Self:** Research grant recipient from and consultant for Gilead Sciences, Inc and Theratechnologies**Esser, Stefan****Self, For self, paid to my institution:**

Research grant recipient from Consultant Abbvie, BMS, Gilead, Merck & Co, Inc, Janssen, ViiV

Evans, Ceri**Self:** Other for GlaxoSmithKline**Fleisher, Ilan****Self:** Employee of MedStar Health Research**Flexner, Charles, W.****Self:** Consultant for Merck & Co, Inc, Mylan, Inc, and ViiV Healthcare**For self, paid to my institution:**

Research grant recipient from Gilead Sciences, Inc

Frangé, Pierre**Self:** Consultant for Merck & Co, Inc, ViiV Healthcare, Bristol-Myers Squibb, Janssen Therapeutics, and Gilead Sciences, Inc**Gandhi, Rajesh, T.****For self, paid to my institution:** Grants from EBSCO Information Services, Gilead Sciences, Inc, Merck & Co, Inc, and ViiV Healthcare**Gatell, Jose, M.****Self:** Consultant of Gilead Sciences, Inc, Merck & Co, Inc, ViiV Healthcare, and Janssen Therapeutics**For self, paid to my institution:**

Research grant recipient from ViiV Healthcare, Merck & Co, Inc, Gilead Sciences, Inc, and Janssen Therapeutics

Gaur, Aditya**For self, paid to my institution:**

Research grant recipient from Gilead Sciences, Inc

Gerstenhaber, Rodd**Self:** Employee of Medecins Sans Frontieres**Girardi, Enrico****Self:** Speaker's bureau for Janssen Therapeutics, Gilead Sciences, Inc, Otsuka, and Angelini. Research grant recipient from Gilead Sciences, Inc**Golub, Sarit, A.****Self:** Gilead provides free study drug to project participants and covers the cost of some testing**González-García, Juan****Self:** Consultant and speaker's bureau for ViiV Healthcare, Gilead Sciences, Inc, Abbvie, and Merck Sharp Dohme**For self, paid to my institution:**

Research grant from ViiV Healthcare, Gilead Sciences, Inc, Merck Sharp Dohme, Abbvie, Bristol-Myers Squibb, and Janssen-Cilag

Gonzalez-Perez, Maria Paz**Self:** Employee of (company not indicated)**Grattoni, Alessandro****Self:** Stockholder of NanoMedical Systems**Grimwood, Ashraf****Self:** Employee of Kheth'Impilo**Grinsztejn, Beatriz****Self:** Employee of Fundação Oswaldo Cruz**Guaraldi, Giovanni****Self:** Consultant and speaker's bureau for Gilead Sciences, Inc., Janssen Therapeutics, Bristol-Myers Squibb, GlaxoSmithKline. Grant recipient from ViiV Healthcare and Merck & Co, Inc**Gupta, Ravindra, K.****Self:** Speaker's bureau for Janssen Therapeutics**Hagins, Debbie****For self, paid to my institution:**

Research grant recipient from Gilead Sciences, Inc

Hamzah, Lisa**Self:** Other from Gilead Sciences, Inc**Hayes, Richard****Self:** Royalty holder from Chapman and Hall**Hileman, Corri Lynn, O.****Self:** Consultant for Gilead Sciences, Inc**Hill, Andrew****Self:** Consultant for Merck & Co, Inc and Janssen Therapeutics**Hillier, Sharon, L.****Self:** Consultant for Merck & Co, Inc, Cepheid, and Symbiomix, LLC**Hodder, Sally****Self:** Consultant for Bristol-Myers Squibb, ViiV Healthcare, Gilead Sciences, Inc, and Janssen Therapeutics**Spouse or Partner:** Consultant for Sanofi, Novartis, and Johnson & Johnson**Hogan, Michael, J.****Self:** Recipient of Intellectual Property Rights from University of Pennsylvania

Holzmayer, Vera

Self: Employee of and stockholder of Abbott Laboratories

Hsu, Ricky,

Self: Research grant recipient from consultant, speaker's bureau, and contracted researcher for Gilead Sciences, Inc. Consultant and speaker's bureau for Janssen Therapeutics, and Bristol-Myers Squibb. Consultant for ViiV Healthcare. Speaker's bureau for Merck & Co, Inc

Huang, Wei

Self: Employee of Monogram Biosciences

Hultquist, Judd, F.

Self: Contracted researcher for Roche Diagnostics and consultant for BlueCatBio Ltd.

Imaz, Arkaitz

Self: Research grant recipient from consultant, and speaker's bureau for Gilead Sciences, Inc, ViiV Healthcare, Bristol-Myers Squibb, Janssen Therapeutics, Merck & Co, Inc, and Abbvie

Iwuji, Collins, C.

Self: Speaker's bureau for Gilead Sciences, Inc

Jarvis, Joseph, N.

For self, paid to my institution: Research grant recipient from for an investigator initiated award from Gilead Sciences, Inc

Keating, Sheila

Self: Other for Ortho Clinical Diagnostics

Khalilieh, Sauzanne

Self: Employee of Merck & Co., Inc.

Kosloski, Matthew, P.

Self: Employee of and stockholder of AbbVie

Koss, Catherine, A.

For self, paid to my institution: I am involved with a study for which Gilead Sciences, Inc awarded study drug to my institution.

Lansdon, Eric

Self: Employee of and stockholder of Gilead Sciences, Inc

Lathouwers, Erkki

Self: Employee of Janssen Therapeutics

Leal, Lorna

Self: Other for Gilead Sciences, Inc

Letendre, Scott

Self: Consultant for ViiV Healthcare, Gilead Sciences, Inc., Merck & Co, Inc, and Janssen Therapeutics

Levy, Itzhak

Self: Speaker's bureau for Gilead Sciences, Inc and Merck & Co, Inc

For self, paid to my institution:

Research grant recipient from Gilead Sciences, Inc

Lewis, Stanley

Self: Employee of TaiMed Biologics

Li, Jonathan

Self: Research grant recipient and consultant for Gilead Sciences, Inc and Merck & Co, Inc

Link, John, O.

Self: Employee and stockholder of Gilead Sciences, Inc

Longenecker, Chris, T.

Self: Consultant for Gilead Sciences, Inc

Macías, Juan

Self: Investigator in clinical trials supported by Roche Diagnostics, Bristol-Myers Squibb and Abbott Pharmaceuticals. Lectures fees from Roche Diagnostics, Gilead Sciences, Inc, Boehringer Ingelheim, and Bristol-Myers Squibb. Consulting fees from Boehringer Ingelheim

Maddon, Paul, J.

Self: Consultant and stockholder of CytoDyn Inc. Stockholder of Progenics Pharmaceuticals, Inc.

Majeed, Sophia, R.

Self: Employee and stockholder for Gilead Sciences

Makadzange, Azure, T.

Self: Consultant GSK

Self: Speaker's bureau Janssen Therapeutics

Maleche Obimbo, Elizabeth

Self: Stockholder Nairobi Securities Exchange

Mangia, Alessandra

Self: Research grant recipient from Gilead Sciences, Janssen-Cilag, Bristol-Myers Squibb, and Merck & Co, Inc

Marconi, Vincent, C.

Self: Research grant recipient from ViiV Healthcare

Margolis, David, A.

Self: Employee and stockholder for ViiV Healthcare

Martinez, Esteban

Self: Research grant recipient from Gilead Sciences, Inc, Janssen Therapeutics, Merck & Co, Inc, and ViiV Healthcare

Matheron, Sophie

For self, paid to my institution: Research grant recipient from Merck & Co, Inc

Mauss, Stefan

Self: Consultant, speaker's bureau and advisory board for: AbbVie, Bristol-Myers Squibb, Gilead Sciences, Inc, Janssen Therapeutics, and ViiV Healthcare

McClelland, R. Scott

For self, paid to my institution: Research grant recipient from Hologic Corporation

McFarland, Elizabeth, J.

For self, paid to my institution: Research grant recipient from Gilead Sciences, Inc

Meintjes, Graeme

Self: Other relationship with Gilead Sciences, Inc

Meissner, Eric, G.**For self, paid to my institution:**

Research grant recipient from Gilead Sciences, Inc

Mills, Lisa, A.

Spouse or Partner: Employee of Leidos Biomedical

Mitchell, Michael, L.

Self: Employee of Gilead Sciences, Inc

Molina, Jean-Michel

Self: Consultant and speaker's bureau Gilead Sciences, Inc. Consultant for Merck & Co, Inc and ViiV Healthcare

For self, paid to my institution:

Research grant recipient from Gilead Sciences

Morris, Sheldon

Self: Research grant recipient from Gilead Sciences

Moscicki, Anna-Barbara

Self: Other Merck & Co, Inc

Mothe, Beatriz

Self: Consultant Aelix Therapeutics, AlbaJuna Therapeutics

Murry, Jeffrey

Self: Employee of Gilead Sciences, Inc

Nijhawan, Ank, E.

Self: Research grant recipient from Gilead Sciences, Inc

Novak, Richard

Self: Consultant for Gilead Sciences, Inc. Contracted researcher for Merck & Co, Inc and GlaxoSmithKline

Ofotokun, Igbo

Self: Consultant for Accordant

Owen, Andrew

Self: Consultant Merck & Co, Inc and Norgine

For self, paid to my institution:

Research grant recipient from Merck & Co, Inc, ViiV Healthcare, and AstraZeneca, Inc

Palella, Frank, J.

Self: Consultant and speaker's bureau Gilead Sciences, Inc, Janssen Therapeutics, Merck & Co, Inc, Bristol-Myers Squibb

Palma, Paolo**For self, paid to my institution:**

Research grant recipient from ViiV Healthcare

Pérez-Valero, Ignacio

Self: Other relationship with ViiV Healthcare, Gilead Sciences, Inc, and Bristol-Myers Squibb

Petoumenos, Kathy

Self: Research grant from Merck Sharp & Dohme; Gilead Sciences, Inc, Bristol-Myers Squibb, Boehringer Ingelheim, Janssen-Cilag and ViiV Healthcare

Picker, Louis, J.

Self: Consultant Vir Biotechnology

Price, Richard, W.

Self: Consultant with Merck & Co., Inc

Riddler, Sharon

For self, paid to my institution: Research grant recipient from Gilead Sciences, Inc and GlaxoSmithKline

Rijnders, Bart

Self: Research grant recipient from Merck & Co, Inc and Gilead Sciences, Inc. Consultant for GL-pharmaceuticals, Bristol-Myers Squibb, Merck & Co, Inc, Gilead Sciences, Inc, Janssen-Cilag, ViiV Healthcare. Contracted researcher for Gilead Sciences, Inc and ViiV Healthcare

Rodgers, Mary

Self: Employee and stockholder for Abbott Laboratories

Rose, Rebecca

Self: Consultant for BioInfoExperts

Rough, Kathryn

Self: Consultant for Bayer Pharmaceuticals

Ruelas, Debbie, S.

Self: Employee of Merck & Co, Inc

Sabin, Caroline

Self: Speaker's bureau for Gilead Sciences, Inc. Other relationship with ViiV Healthcare and Janssen-Cilag

Sax, Paul, E.

Self: Research grant recipient from AbbVie, Bristol-Myers Squibb, Gilead Sciences, Inc, GlaxoSmithKline, Merck & Co, Inc, and Janssen Therapeutics

Schalkwijk, Stein**For self, paid to my institution:**

Research grant from Bristol-Myers Squibb, Merck & Co, Inc, ViiV Healthcare and Janssen Therapeutics

Seydi, Moussa**For self, paid to my institution:**

Research grant recipient from Gilead Sciences, Inc

Silverberg, Michael, J.**For self, paid to my institution:**

Research grant from Merck & Co, Inc and Pfizer, Inc

Soriano, Vincent

Self: Consultant and speaker's bureau for Gilead Sciences, Inc, Merck & Co, Inc, Janssen Therapeutics, Bristol-Myers Squibb

Squillace, Nicola

Self: Consultant for ViiV Healthcare. speaker's bureau for Merck & Co, Inc and Bristol-Myers Squibb. Other relationship with Janssen Therapeutics and Gilead Sciences, Inc

Squires, Kathleen

Self: Consultant for Bristol Myers Squibb, Gilead Sciences, Inc, Janssen Therapeutics, Merck & Co, Inc, and ViiV Healthcare

For self, paid to my institution:

Research grant recipient from Clinical trials research grants to Thomas Jefferson University from Gilead Sciences, Inc

Tam, Edward

Self: Consultant and speaker's bureau for AbbVie, Bristol-Myers Squibb, Gilead Sciences, Inc, Janssen Pharmaceutica, Merck & Co, Inc, and Pendopharm

For self, paid to my institution:

Research grant recipient from AbbVie

Tan, Darrell, H.S.**For self, paid to my institution:**

Research grant recipient from ViiV Healthcare and Gilead Sciences, Inc

Telisinghe, L

For self, paid to my institution: Other QIAGEN provided non-financial support by providing the QuantiFERON®-TB Gold Plus kits free of charge to use in the study.

Thomsen, Nathan, D.

Self: Employee of Gilead Sciences, Inc

Thorne, Claire**For self, paid to my institution:**

Research grant recipient from AbbVie and ViiV Healthcare

Tieu, Hong Van

Self: Research grant recipient from Merck & Co, Inc

Todesco, Eve

Self: Speaker's bureau for Bristol-Myers Squibb

Tort, Olivia**For self, paid to my institution:**

Research grant recipient from Gilead Sciences, Inc

Tse, Winston, C.

Self: Employee of Gilead Sciences

Tung, Elyse

Self: Other relationship with Gilead Sciences, Inc

Ukaegbu, Chinyere

Self: Research grant recipient from Gilead Sciences, Inc

Utay, Netanya, S.

Self: Consultant for Gilead Sciences, Inc. Consultant and contracted researcher for Tobira Therapeutics, Inc and Entera Health, Inc

van der Heijden, Wouter, A.**For self, paid to my institution:**

Research grant recipient from Merck Sharp & Dohme, Merck & Co, Inc

van Sighem, Ard**For self, paid to my institution:**

Research grant from Janssen-Cilag and ViiV Healthcare

van Zoest, Rosan**For self, paid to my institution:**

Research grant from Gilead Sciences, Inc

Vannappagari, Vani

Self: Employee of ViiV Healthcare and stockholder of GlaxoSmithKline

Volpe, Joseph, M.

Self: Employee of LabCorp

Vos, Alinda,

Self: Employee of University Medical Center Utrecht, The Netherlands, Departmetn Julius Center.

Vourvahis, Manoli

Self: Employee and stockholder Pfizer, Inc

Wagner, Thor

Self: Research grant from Gilead Sciences, Inc

Wandeler, Gilles

Self: Research grant from Gilead Sciences, Inc

Warszawski, Josiane**For self, paid to my institution:**

Research grant from ViiV Healthcare and Parexel

Weinberg, Adriana

Self: Research grant recipient from GlaxoSmithKline and Medimmune

Spouse or Partner: Research grant recipient from and royalty holder from Merck & Co, Inc

Weinheimer, Steven

Self: Employee of TaiMed Biologics USA

White, Douglas, A. E.

Self: Research grant recipient from Gilead Sciences, Inc

White, Kirsten, L.

Self: Employee and stockholder of Gilead

Wiley, Dorothy, J.

Self: Research grant recipient from Merck Sharp & Dohme Corp, Merck & Co., Inc

Wong, Wingwai**For self, paid to my institution:**

Research grant recipient from United BioPharma

Self, For self, paid to my institution:

Research grant from Gilead Sciences, Inc, ViiV Healthcare, Merck 7 Co, Inc, and Bristol-Myers Squibb

Yin, Michael, T.

Self: Consultant for Gilead Sciences, Inc

Zhang, Heather

Self: Employee and stockholder of Gilead Sciences, Inc

DISCLOSURE INFORMATION

The following have no relevant financial relationships to disclose. Any updates will be reflected in the Mobile App.

Aamer, Hadeqa	Belaunzaran-Zamudio, Pablo, F.	Chaila, Mwate, J.
Abaasa, Andrew, M.	Beloukas, Apostolos	Chaillon, Antoine
Abdel Mohsen, Mohamed	Bendavid, Eran	Chaix Baudier, Marie-Laure
Abdo, Mona	Bengtson, Angela	Chan, Austin, W.
Abewe, Hosiana	Bershteyn, Anna	Chan, Phillip
Aboulnasr, Fatma	Bertoli, Ada	Chang, Ming
Abutaima, Rana	Bhagwat, Priya	Chapin-Bardales, Johanna
Adamson, Blythe, J.	Bieniczak, Andrzej	Chattergoon, Michael
Adewumi, Olubusuyi, M.	Biliotti, Elisa	Chen, Mi
Adland, Emily	Billioux, Veena, G.	Cheng, Shu-Hsing
Agan, Brian, K.	Birnbaum, Jeanette	Chew, Glen
Aghokeng, Avelin, F.	Bisson, Gregory	Chi, Benjamin, H.
Agot, Kawango	Blanco, José, L.	Chow, Dominic
Agrati, Chiara	Blokhuys, Charlotte	Christ, Frauke
Ahlgren, Erika	Boehme, Catharina, C.	Christensen-Quick, Aaron
Ajibola, Gbolahan	Boerekamps, Anne	Ciaranello, Andrea, L.
Akay-Espinoza, Caglia	Boivin, Michael, J.	Cillo, Anthony, R.
Alcaide, Maria, L.	Bonar, Michał	Claassen, Mark
Aldámiz-Echevarría, Teresa	Bordoni, Veronica	Coban, Hamza
Alessandra, Sacchi	Borges, Alvaro, H.	Cocker, Alexander
Almirol, Ellen	Borre, Ethan, D.	Collins, Bryan, C.
Alvarez, Angeles	Bosman, Kobus	Collins, Lauren, F.
Alwano, Mary Grace	Boulougoura, Afroditi	Collins, Pamela
Amodo, Faizana	Bowen-Test, Kevin, W.	Connick, Elizabeth
An, Qian	Bozzi, Giorgio	Conradie, Francesca
Ancona, Giuseppe	Bracchi, Margherita	Cote, Helene, C.F.
Andany, Nisha	Bradley, Heather	Cotugno, Nicola
Anderson, Albert	Brenner, Bluma	Courtney, Colleen, R.
Anderson, Elizabeth, M.	Brittain, Kirsty	Crabtree- Ramirez, Brenda
Angelovich, Thomas, A.	Broekhuis, Jordan	Crane, Heidi, M.
Araújo, Marília, L.	Brooks, Kristina, M.	Cremin, Ide
Archary, Moherndran	Brown, Lillian	Crepaz, Nicole
Armstrong, Heather, L.	Broz, Dita	Cummins, Nathan
Arnedo, Mireia	Bruce, Veronica	Cunningham, Coleen, K.
Arpadi, Stephen, M.	Brühl, Maria, C.	Curtis, Kelly
Attia, Engi, F.	Brunet, Laurence	Cuzin, Lise
Avi, Radko	Buchacz, Kate	Cyktor, Joshua, C.
Avihingsanon, Anchalee	Buggert, Marcus	Dabydeen, Sarah
Avila-Rios, Santiago	Bull, Marta, E.	Dagur, Raghubendra, S.
Ayieko, James	Buranapraditkun, Supranee	Dan, Jennifer, M.
Azzoni, Livio	Burchell, Ann, N.	Danboise, Brook
Bachanas, Pamela, J.	Burdick, Ryan, C.	D'Antoni, Michelle, L.
Bachmann, Nadine	Burgener, Adam	D'arc, Mirela
Badje, Anani, D.	Burgess, Emma, K.	Dasgupta, Sharoda
Bai, Francesca	Burke, Mark, W.	Daskalakis, Demetre, C.
Bailin, Samuel	Buseyne, Florence	Davis, Arielle, P.
Baker, Jason	Bush, William, S.	Davis, Nicole
Balkus, Jennifer	Buskin, Susan	Davy, Thibaut
Balogun, Kayode	Butt, Zahid, A.	de Armas, Lesley, R.
Banga, Riddhima	Cachay, Edward, R.	De Francesco, Davide
Bangham, Charles, R.M.	Camacho-Gonzalez, Andres	De La Flor, Carolina
Bardhi, Ariola	Camlin, Carol, S.	Debyser, Zeger
Barnabas, Ruanne, V.	Campbell, Ellsworth	Del Amo, Julia
Barocas, Joshua, A.	Cannizzo, Elvira, S.	Delagreverie, Heloise, M.
Batavia, Ashita, S.	Capoferri, Adam	Delaney, Kevin, P.
Battalora, Linda	Carrillo, Mayra, A.	Delelis, Olivier
Baxter, Amy, E.	Carroll, Makeda	Delviks-Frankenberry, Krista
Bearde, David	Carryl, Heather	Derache, Anne
Bebell, Lisa	Casazza, Joseph, P.	Desimie, Belete, A.
Beck, Ingrid, A	Castagna, Antonella	Desir, Fidel, A.
Becker, James, T.	Castel, Amanda, D.	Desmonde, Sophie
Becofsky, Katie	Castelli, Francesco	Dezzutti, Charlene, S.
Bekker, Adrie	Castillo-Mancilla, Jose, R.	Dhody, Kush

Dickey, Amy, K.	Giacomet, Vania	Hsu, Hilary, K.
Dickinson, Laura	Gianella, Sara	Hsu, Ling
Dijkstra, Maartje	Gilada, Trupti, I.	Huang, Suzhan
Dillon, Stephanie	Gill, Alexander, J.	Huang, Yunda
Dingens, Adam	Gill, John	Hubbard, Mark
Dionne-Odom, Jodie	Gingich, David	Hughes, Alison
Dirajlal-Fargo, Sahera	Giron, Leila, B.	Hughes, Stephen, H.
Donnell, Deborah, J.	Gisslén, Magnus	Huik, Kristi
Drake, Alison, L.	Glick, Sara, N.	Hulgan, Todd
Drechsler, Henning, J.	Golden, Matthew, R.	Hussen, Sophia, A.
Dryden-Peterson, Scott	Gonzalo-Gil, Elena	Hutchinson, Angela, B.
Duarte, Horacio, A.	Goodreau, Steven, M.	Ibrahim, Maryanne, R.
Duenas Decamp, Maria Jose	Gorin, Aleksandr	Imamichi, Hiromi
Duerr, Ralf	Graham, Susan, M.	Imp, Brandon, M.
Dumchev, Kostyantyn	Greathead, Louise	Indravudh, Pitchaya
Dumond, Julie, B.	Greene, Sharon, A.	Ingiliz, Patrick
Dunaway, Shelia	Grund, Jonathan	Innes, Steve
Eaton, Jeffrey	Gu, Diane	Inzaule, Seth
Edelstein, Zoe, R.	Güerri-Fernández, Robert	Ita, Sergio
Egger, Matthias	Gupta, Amita	Iyer, Shilpa, S.
El Kamari, Vanessa	Gupta, Kushol	Izopet, Jacques
Elliot, Emilie	Gupte, Akshay	Jagodzinski, Linda
Emery, Ann	Gutierrez, Jose	Jani, Ilesh
Eshun-Wilson, Ingrid	Haaland, Richard	Janjua, Naveed, Z.
Esmail, Hanif	Haas, Andreas	Jantarabenjakul, Watsamon
Evans, Henry, W.	Haberlen, Sabina	Janulis, Patrick
Fabbri, Gabriele	Hachiya, Atsuko	Jao, Jennifer
Falade-Nwulia, Oluwaseun	Haddad, Lisa, B.	Jaquet, Antoine
Fanjul, Francisco	Hader, Shannon, L.	Jarrin, Inma
Farhadian, Shelli	Hakim, Avi	Jenness, Samuel
Faria de Oliveira, Michelli	Hale, Malika	Jiamsakul, Awachana
Favarato, Graziella	Hammarlund, Gustaf, O.	Johnson, Anna, S.
Feinstein, Matthew, J.	Hanan, Nathan	Johnson, Eric, O.
Fenner, Lukas	Hanna, David, B.	Johnson, Erica, L.
Fernández McPhee, Carolina	Harada, Shigeyoshi	Johnson, Jeffrey, A.
Fielding, Katherine	Hassan, Amin, S.	Joly, Veronique
Firnhaber, Cindy	Hassan, Jaythoon	Jones, Bradley, R.
Fisher, Bridget	Hassounah, Said	Jones, Mathew, L.
Fitch, Kathleen, V.	Havens, Peter, L.	Joseph, Sarah Beth
Flerin, Nina, C.	Haworth, Kevin, G.	Jourdain, Gonzague
Floyd, S	Hecht, Frederick, M.	Joya, Christie
Fogel, Jessica, M.	Hector, Jonas	Justman, Jessica, E.
Fox, Julie	Heffron, Renee	Kadelka, Claus
Franco, Sandra	Hellmuth, Joanna	Kahn, James
Freeman, Michael, L.	Hendrickson, Cheryl, J.	Kaida, Angela
Freiman, J. Morgan	Hensley-McBain, Tiffany	Kakkar, Fatima
Frías, Mario	Hermans, Lucas, E.	Kallianpur, Asha, R.
Fulcher, Jennifer, A.	Hermansson, Linn	Kallianpur, Kalpana, J.
Galvez Celada, Cristina	Hernandez-Ramirez, Raul	Kalmin, Mariah, M.
Gandhi, Monica	Ulises	Kamal, Susan
Ganesan, Anuradha	Hessol, Nancy, A.	Kane, Melissa
Ganser-Pornillos, Barbie, K.	Hiener, Bonnie	Kantor, Rami
Gantner, Pierre	Hijlkema, Simone, H.	Kapito-Tembo, Atupele, P.
Garcia, Erin, I.	Hikichi, Yuta	Kaplan, Justin, A.
García, Federico	Hiransuthikul, Akarin	Kaplan, Samantha
Garcia-Lerma, Gerardo	Hlupeni, Admire	Karajeanes, Esmeralda
García-Morales, Claudia	Ho, Ya-Chi	Kasaro, Margaret, P.
Garland, Wendy, H.	Hodcroft, Emma, B.	Kassaye, Seble
Gaseitsiwe, Simani	Hoenigl, Martin	Katuramu, Richard
Gatechompol, Sivaporn	Hoepelman, Andy	Katz, David, A
Gates, Thomas	Hof, Malon, Van den	Kaufmann, Daniel, E
Gathogo, Esther	Hofstra, Laura Marije	Kaur, Harpreet
Gavegnano, Christina	Hogg, Robert, S.	Kearney, Mary, F
Geboy, Alexander	Holtz, Timothy, H.	Keiser, Olivia
Gelman, Benjamin, B.	Hood, Julia	Kelly, Christine
Genberg, Becky, L.	Hoornenborg, Elske	Kerani, Roxanne, P.
George, Varghese	Hoots, Brooke	Kervevan, Jérôme
Gerard, Laurence	Horner, Marie-Josephe	Khaitan, Alka
Gervasoni, Cristina	Howard, Andrea	Khaketla, Moliehi
Giacobbi, Nicholas, S.	Hoyte, Ashley, C.	Khan, Shaukat
	Hsu, Denise, C.	

Khosropour, Christine, M.	Makinson, Alain	Moreno, Ana
Kiani, Zahra	Mallard, Jaclyn	Moron-Lopez, Sara
Kinuthia, John	Maman, David	Morse, Caryn, G.
Kiragga, Agnes	Mamede, João, I.	Moscoe, Ellen
Kirkegaard-Klitbo, Ditte, M.	Manasa, Justen	Mosepele, Mosepele
Kitchen, Scott, G.	Manion, Maura	Moyo, Sikhulile
Kityo, Cissy	Mankowski, Madeleine, C.	Msukwa, Malango, T.
Kiweewa, Francis	Manne-Goehler, Jennifer	Mukui, Irene
Koethe, John, R.	Manzardo, Christian	Murphy, Gary
Koullias, Yiannis	Martin, Alyssa, R.	Murphy, Robert
Kouyos, Roger	Martin, Natasha	Musick, Andrew
Krurup, Astrid, R.	Martin-Blondel, Guillaume	Mutenda, Nicholas
Krebs, Shelly, J.	Martin-Gayo, Enrique	Mwangi, Mary
Kroeze, Stefanie	Martini, Salvatore	Myer, Landon
Ku, Wen-Wei	Marukutira, Tafireyi	Myers, Julie
Kuhn, Louise	Masciotra, Silvina	Nagot, Nicolas
Kujawski, Stephanie	Masetti, Michela	Naidoo, Shalena
Kuo, Irene	Masia, Mar	Nakanyala, Tuli
Kutluay, Sebla, B.	Massanella, Marta	Nakazawa, Masato
Kvaratskhelia, Mamuka	Mathabire, Sekai, C.	Nakiyingi, Lydia
Kwariisima, Dalsone	Mattingly, Aviva	Nanfack, Aubin, J.
Kwena, Zachary, A.	Matus Nicodemos, Rodrigo	Nanfuka, Mastula
Lada, Steven	Mavigner, Maud	Navarro, Jordi
Laeyendecker, Oliver	Mayanja, Yunia	Navarro, Samuel
Lahuerta, Maria	Mayer, Kenneth, H.	Ndembi, Nicaise
Lake, Jordan, E.	Mayor, Angel	Ndhlovu, Lishomwa, C.
Lamb, Matthew, R.	McClintic, Hillary	Ndhlovu, Zaza
Lang, Raynell	McCreesh, Nicky	Neary, Megan
Lange, Camille	McFall, Allison, M.	Neff, Charles, P.
Larmarange, Joseph	McFaul, Katie	Negoescu, Diana, M.
Larsen, Anna	McGowan, Catherine	Neilan, Anne, M.
Latkin, Carl, A.	McKibben, Rebecca	Nelson, Aurelie
Le, Leah, T.	McKinnon, Lyle	Nelson, Julie, A.E.
Le, Thuy	McMahan, Vanessa	Nelson, Kristin, N.
Lebelonyane, Refeletswe	McVea, David	Nemeth, Johannes
Lechiile, Kwana	Medrano, Luz, M.	Neukam, Karin
Lee, Guinevere, Q.	Mehta, Natasha	Newell, Evan William
Lee, Hana	Mehta, Sanjay, R.	Newman, Peter, A.
Lee, Sulggi	Melhado, Caroline	Ng'ang'a, Lucy
Leitman, Ellen, M.	Menego, Geoffrey	Nganou Makamdop, Krystelle
Lesosky, Maia	Menzaghi, Barbara	Ngongondo, McNeil
Levy, Yves	Merchante, Nicolás	Nguyen, Nam, H.
Leyre, Louise	Merli, Marco	Nguyen, Son
Li, Sam	Merlini, Esther	Nguyen, Thanh, T.
Li, Taisheng	Mesplede, Thibault	Nguyen, Thu, T.
Liberatore, Rachel, A.	Metcalfe, John, Z.	Nikuzce, Alliance
Lifson, Jeffrey, D.	Metcalfe, Rebecca	Norton, Thomas, D.
Lim, So-Yon	Meyer, Laurence	Novikova, Mariia
Lin, Kuan-Yin	Meyer-Andrieux, Isabelle, A.	Novitsky, Vlad
Lince-Deroche, Naomi	Michel, Kate	Nowak, Piotr
Linley, Laurie	Milam, Joel	Nowak, Rebecca, G.
Lipira, Lauren	Milanini, Benedetta	Nussenzweig, Michel
Lisco, Andrea	Miller, Melissa	O'Brien, Meagan
Liu, Cindy, M.	Miller, Shannon	Odoyo-June, Elijah
Liu, Qingbo	Minami, Rumi	Ohainle, Molly
Llibre, Josep, M.	Miro, Jose M	O'Halloran, Jane, A.
Loarec, Anne	Mitchell, Brooks, I.	Olaiya, Oluwatosin
Lofgren, Sarah	Mitchell, Julie	Olawore, Oluwasolape, M.
Logie, Carmen, H.	Mittal, Maria Luisa	Olney, Jack
Lombardi, Francesca	Mmalane, Mompoti	Omari, Habib, R.
Long, Lawrence	Mody, Aaloke	Onorato, Lorenzo
López-Bernaldo, Juan Carlos	Mohr, Erika, K.	Onoya, Dorina
Luong Nguyen, Liem Binh	Moir, Lorlette	Opoku, Jenevieve
Lynch, Briana	Montano, Daniel, E.	Opello, Valarie, S.
Mabileau, Guillaume	Montano, Michalina, A.	Ortblad, Katrina, F.
MacBrayne, Christine, E.	Montejano, Rocio	Osei-Kuffour, Edmund
Macera, Margherita	Monterosso, Analise, C.	Osman, Nathan
Maeda, Kenji	Moraka, Natasha, O.	Ostrowski, Mario
Maher, Andrew, D.	Moran, Caitlin, A.	Quattara, Eric, N.
Makanani, Bonus	Morand-Joubert, Laurence	Palar, Kartika

Palk, Laurence	Rogers, Anna Joy	Soboil, Nikki
Panchroen, Kanokpan	Rohr, Julia, K.	Sobolewski, Michele
Paneerselvam, Nandagopal	Rokx, Casper	Solomon, Sunil, S.
Panneer, Nivedha	Rolland, Morgane	Sortino, Ornella
Pantaleo, Giuseppe	Rolle, Charlotte-Paige, M.	Soulie, Cathia
Pasipamire, Munyaradzi	Rosas Umbert, Miriam	Spinner, Christoph, D.
Pasternak, Alexander	Rosen, Sydney	Spudich, Serena
Patel, Eshan, U.	Rosenbloom, Daniel, I.S.	Srinivasa, Suman
Patel, Rena	Ross, Jonathan	Stekler, Joanne
Patel, Rupa, R.	Rossi, Fiorella, P.	Stevens, Elizabeth
Patel, Viraj, V.	Roth, David	Steward, Wayne, T.
Paul, Robert	Rouskin, Silvi	Strouvelle, Victoria, P.
Pavlin, Julie	Rowan, Sarah, E.	Su, Hang
Paz-Bailey, Gabriela	Roy, Monika	Sudjaritruk, Tavitiya
Peeling, Rosanna, W.	Rubin, Leah, H.	Surie, Diya
Penazzato, Martina	Ruel, Theodore	Sutton, Madeline
Penrose, Kerri	Rusconi, Stefano	Swartz, Talia
Pérez, Alejandro	Ryom, Lene	Swathirajan, Chinnambedu
Perez-Santiago, Josue	Sacktor, Ned	Ravichandran
Persad, Yasmeen	Saeed, Sahar	Tadesse, Mulualem
Persaud, Deborah	Sagnelli, Caterina	Takata, Hiroshi
Peters, Helen	Salazar-Austin, Nicole	Tanuma, Junko
Peterson, Christopher	Salcuni, Paul, M.	Tassiopoulos, Katherine
Phetsouphanh, Chansavath	Salgado, Maria	Tchouwa, Gaëlle, F.
Phillips, Andrew	Salters, Kate	Teasdale, Chloe, A.
Phillips, Gregory	Samri, Assia	Teigler, Jeffrey, E.
Piggott, Damani, A.	Sanders, Eduard	Telesnitsky, Alice
Pilcher, Christopher, D.	Sanford, Ryan	Tenthani, Lyson
Pilotto, Jose, H.	Sanne, Ian	Tesfay, Abraham
Pineda, Juan A.	Santoro, Antonella	Thiébaud, Rodolphe
Pintye, Jillian	Saravanan, Shanmugam	Thrift, Aaron, P.
Pinzone, Marilia, R.	Sardo, Luca	Tilton, John
Plantier, Jean-Christophe	Saylor, Deanna	Timmons, Andrew
Plitnik, Timothy	Schaaf, H. Simon	Tobias, James
Podany, Anthony	Schackman, Bruce, R.	Torgersen, Jessie
Poongulali, Selvamuthu	Schaffer, Elisabeth	Toribio, Mabel
Porter, Sarah, E.	Schlusser, Katherine, E.	Torres, Thiago, S.
Pressiat, Claire	Schneider, John, A.	Trunfo, Mattia
Presti, Rachel	Schommers, Philipp	Trypsteen, Wim
Price, Jennifer	Schuettfort, Gundolf	Turan, Janet, M.
Price, Joan, T.	Schwartz, Jordan, A.	Vaikath, Maria
Psomas, Christina	Scott, Hyman	van der Straten, Ariane
Pujantell, Maria	Scott, John, D.	Van Duyn, Rachel
Puthanakit, Thanyawee	Scully, Eileen	Van Ommen, Clara, E.
Rabkin, Miriam	Sebikari, Dorothy	VanBelzen, Jake
Rahmberg, Andrew, R.	Selik, Richard, M.	Vandekerckhove, Linos
Raifman, Julia	Sereti, Irini	Vasan, Sandhya
Rajoli, Rajith Kumar Reddy	Serra-Moreno, Ruth	Veenhuis, Rebecca
Ramanlal, Nehaben	Serrano-Villar, Sergio	Veldsman, Kirsten, A.
Ramogola-Masire, Doreen	Shade, Julie, K.	Velloza, Jennifer
Rao, Deepa	Shade, Starley, B.	Vesga, Juan, F.
Rasmussen, Sarah	Shaffer, Ashton	Viard, Jean-Paul
Rasmussen, Thomas, A.	Shanaube, Kwame	Vieira, Vinícius, A.
Raymond Marchand,	Shapiro, Roger, L.	Virlogeu, Victor
Laurence	Sharma, Anjali	Visseaux, Benoit
Real, Luis M.	Sharma, Monisha	Viswanathan, Prabha
Rebeiro, Peter, F.	Sharp, Katie	Vollbrecht, Thomas
Redd, Andrew, D.	Shiboski, Caroline, H.	von Groote-Bidlingmaier,
Registre, Ludy	Shiels, Meredith, S.	Florian
Reid, Michael, J.A.	Sigel, Keith, M.	Votteler, Joerg
Reif, Lindsey	Sikazwe, Izukanji	Vu, Dat, Q.
Rentsch, Christopher	Sikombe, Kombatende	Wagner, Gabriel, A.
Requena, Silvia	Simonetti, Francesco, R.	Wahome, Elizabeth
Resnati, Chiara	Singh, Kumud, K.	Wainberg, Mark
Reynolds, Steven, J.	Singh, Sonia	Wainberg, Mark A.
Rhee, Soo-Yon	Sirijatuphat, Rujipas	Wang, Ruibin
Rheinemann, Lara	Sivay, Mariya, V.	Wang, Zheng
Roberts, Owain	Smart, Amanda, E.	Wansom, Tanyaporn
Robertson, Kevin	Smith, Bryan	Ward, Andrew, B.
Robichaux, Spencer	Smith, Robert, S.	Waruru, Anthony
Rodriguez-Hart, Cristina	So-Armah, Kaku	Weber, Kathleen, M.

Weiser, Sheri	Wong, Sophy, S.	Zangerle, Robert
Weiss, Kevin	Woolnough, Emily	Zanoni, Brian, C.
Wertheim, Joel, O.	Wools-Kaloustian, Kara, K.	Zash, Rebecca
Whitney, Bridget	Wray, Tyler, B.	Zerbato, Jennifer, M.
Whitney, James	Wu, Vincent	Zerbe, Allison
Wiche Salinas, Tomas Raul	Wyatt, Monique, A.	Zhang, Meiwen
Wijting, Ingeborg	Yagura, Hiroki	Zhang, Yinfeng
Wimonsate, Wipas	Yang, Jingyan	Zhang, Yuwei
Winckelmann, Anni	Yebra, Gonzalo	Zhen, Anjie
Winston, Alan	Yee, Lynn, M.	Zheng, Wenjing
Winter, Joanne, R.	Yen, Yung-Feng	Zhong, Yaoyu
Wirunsawanya, Kamonkiat	Yonga, Gerald	Zhou, Shuntai
Wong, Cherise	Yuan, Zhe	Zola, Courtney
Wong, Chun-Shu	Zaccarelli, Mauro	Zucker, Jason

INDEX OF STUDIES RELATED TO WOMEN

The following index lists abstracts that noted women or women's issues as the focus of the study. This index was developed for attendees with an interest in these issues. We encourage you to refer to the full program for other presentations that may address this subject.

TUESDAY, FEBRUARY 14, 2017

- 22** **RANDOMIZED TRIAL OF LEEP VS CRYOTHERAPY TO TREAT CIN2/3 IN HIV-INFECTED WOMEN** (Oral Abstract Session 0-2)
- 23** **NATURAL HISTORY OF CERVICAL INTRAEPITHELIAL NEOPLASIA-2 AMONG HIV-INFECTED WOMEN** (Oral Abstract Session 0-2)
- 24** **INTEGRATION OF POSTNATAL SERVICES IMPROVES MCH AND ART OUTCOMES: A RANDOMISED TRIAL** (Oral Abstract Session 0-2)
- 242** **A BROAD POLYCLONAL RESPONSE IS MEDIATED BY SUPERINFECTION WITH 2 DISTINCT VIRUSES** (Poster Session P-D1)
- 25** **ADVERSE BIRTH OUTCOMES DIFFER BY ART REGIMEN FROM CONCEPTION IN BOTSWANA** (Oral Abstract Session 0-2)
- 266** **LYMPH NODE HIV-SPECIFIC CXCR5+ CTLs ARE ASSOCIATED WITH ENHANCED VIRAL CONTROL** (Themed Discussion TD-1)
- 281** **SEX-BASED DIFFERENCES IN HIV RESERVOIR ACTIVITY AND RESIDUAL IMMUNE ACTIVATION** (Poster Session P-E1)
- 376** **IFN- β REDUCES MACROPHAGE HEME OXYGENASE-1 EXPRESSION: ROLE IN HIV NEUROPATHOGENESIS** (Poster Session P-F5)
- 421LB** **HPTN 076: TMC278 LA SAFE, TOLERABLE AND ACCEPTABLE FOR HIV PREEXPOSURE PROPHYLAXIS** (Poster Session P-G3)
- 443** **EFFICACY & SAFETY OF SWITCHING TO EVG/COBI/FTC/TAF IN VIROLOGICALLY SUPPRESSED WOMEN** (Poster Session P-H2)
- 502** **DRUG RESISTANCE AFTER CESSATION OF EFAVIRENZ-BASED ANTIRETROVIRAL TREATMENT** (Poster Session P-J4)
- 526** **GUT EPITHELIAL DAMAGE, IMMUNE ACTIVATION & LIVER FIBROSIS IN HIV AND HCV INFECTION** (Poster Session P-L2)
- 591** **MULTIPLE-TEST SCREENING STRATEGIES IMPROVE BIOPSY-PROVEN HSIL-DETECTION IN HIV+ WOMEN** (Poster Session P-M1)
- 627** **EPICARDIAL FAT, IMMUNE ACTIVATION, AND CORONARY PLAQUE AMONG HIV+ AND HIV- WOMEN** (Poster Session P-N5)
- 629** **CRP PREDICTS SUBCLINICAL CVD PROGRESSION IN HIV- BUT NOT HIV+ WOMEN** (Poster Session P-N5)
- 634** **IMPAIRED ANTIVASCULAR CONTRACTION OF PERIVASCULAR ADIPOSE TISSUE IN HIV INDIVIDUALS** (Poster Session P-N5)
- 646** **LONGITUDINAL HIV VIRAL TRAJECTORIES AND COMORBIDITIES IN THE WIHS** (Poster Session P-O1)
- 696** **RALTEGRAVIR SWITCH AND BIOMARKERS OF LIVER STEATOSIS AND METABOLIC SYNDROME IN WOMEN** (Themed Discussion TD-4)
- 762** **MISSED OPPORTUNITIES FOR REPEAT HIV TESTING AND EARLY ART INITIATION IN PREGNANCY** (Poster Session P-Q2)

- 763 LOW HIV INCIDENCE IN SOUTH AFRICAN PREGNANT WOMEN RECEIVING A PREVENTION INTERVENTION** (Poster Session P-Q2)
- 764 HIV INCIDENCE, CASCADE, AND TESTING AMONG MOTHERS IN WESTERN KENYA** (Poster Session P-Q2)
- 765 DETECTION OF HIV IN BREAST MILK AMONG PREGNANT/POSTPARTUM WOMEN WITH RECENT HIV** (Poster Session P-Q2)
- 766 UPTAKE AND RETENTION IN CARE OF PREGNANT WOMEN STARTING OPTION B+ IN MAPUTO PROVINC** (Poster Session P-Q2)
- 767 STRATEGIES FOR VIRAL-LOAD MONITORING DURING PREGNANCY IN RESOURCE-LIMITED SETTINGS** (Poster Session P-Q2)
- 768 VIRAL SUPPRESSION AMONG HIV+ PREGNANT WOMEN ENTERING ANTENATAL CARE ON ART IN UGANDA** (Poster Session P-Q2)
- 769 MEASURES OF ENGAGEMENT IN ROUTINE HIV CARE TO PREDICT ELEVATED VIRAL LOAD ON ART** (Poster Session P-Q2)
- 770 SELF-REPORT AND DRY BLOOD SPOTS AS MARKERS OF ANTIRETROVIRAL ADHERENCE IN PREGNANCY** (Poster Session P-Q2)
- 771 UNINTENDED PREGNANCY PREDICTS SUBSEQUENT RAISED VIRAL LOAD IN THE POSTNATAL PERIOD** (Poster Session P-Q2)
- 879 IDENTIFICATION AND VALIDATION OF AN INCIDENCE-TESTING ALGORITHM FOR HIV-1 SUBTYPE C** (Poster Session P-S5)
- 913 FOOD INSECURITY AND HIV TREATMENT OUTCOMES IN THE WOMEN'S INTERAGENCY HIV STUDY** (Poster Session P-S9)
- 914 HIV STATUS AWARENESS AND ART COVERAGE AMONG FEMALE SEX WORKERS IN JUBA, SOUTH SUDAN** (Poster Session P-S9)
- 915 "TEST AND TREAT" ANTIRETROVIRAL THERAPY AMONG FEMALE SEX WORKERS IN KAMPALA, UGANDA** (Poster Session P-S9)
- 958 STRENGTHENING MALE-PARTNER TESTING IN ANTENATAL CARE: FINDINGS FROM SOUTH AFRICA** (Poster Session P-U1)
- 959 HPTN 071 HOME-BASED TESTING IMPROVES UPTAKE OF HCT AMONG PREGNANT WOMEN IN ZAMBIA** (Poster Session P-U1)
- 1006 LOWER RETENTION IN CARE WHEN ART IS INITIATED WITH CD4 $\geq$ 500CELLS/ML** (Poster Session P-W2)

WEDNESDAY, FEBRUARY 15, 2017

- 85 DAILY ORAL PREP IS EFFECTIVE AMONG WOMEN WITH ABNORMAL VAGINAL MICROBIOTA** (Oral Abstract Session O-8)
- 86LB IMPACT OF VAGINAL MICROBIOTA ON GENITAL TISSUE AND PLASMA CONCENTRATIONS OF TENOFOVIR** (Oral Abstract Session O-8)
- 88 DAPIVIRINE RING USE DOES NOT DIMINISH THE EFFECTIVENESS OF HORMONAL CONTRACEPTION** (Oral Abstract Session O-8)
- 209 MARAVIROC INHIBITS HIV TARGET T-CELL TRAFFICKING INTO THE FEMALE GENITAL LUMEN** (Poster Session P-C2)
- 210 INVESTIGATING THE EFFECT OF PH ON CERVICOVAGINAL MUCUS BARRIER PROPERTIES TO HIV** (Poster Session P-C2)
- 266 LYMPH NODE HIV-SPECIFIC CXCR5+ CTLs ARE ASSOCIATED WITH ENHANCED VIRAL CONTROL** (Poster Session P-D4)

- 350 COGNITIVE TRAJECTORIES OVER 4 YEARS AMONG HIV+ WOMEN WITH OPTIMAL VIRAL SUPPRESSION** (Themed Discussion TD-7)
- 423 AN IN VITRO–IN SILICO STUDY OF REDUCED-DOSE EFAVIRENZ INTERACTION WITH LEVONORGESTREL** (Poster Session P-G4)
- 599 TIMING OF CART INITIATION INFLUENCES CANCER RISK AMONG WOMEN LIVING WITH HIV** (Poster Session P-M2)
- 657 FACTORS ASSOCIATED WITH PULMONARY IMPAIRMENT IN HIV-INFECTED SOUTH AFRICAN ADULTS** (Poster Session P-O3)
- 790 TARGETED HIV SCREENING AT BIRTH CAN IDENTIFY THE MAJORITY OF IN UTERO TRANSMISSIONS** (Poster Session P-Q5)
- 793 DELAYED HIV DNA PCR DETECTION AMONG INFANTS WHO RECEIVED COMBINATION ART PROPHYLAXIS** (Poster Session P-Q5)
- 836 LOCAL SOCIAL NETWORKS PREDICT RETENTION & SUPPRESSION IN YOUNG WOMEN IN SEARCH TRIAL** (Poster Session P-R6)
- 874 REDUCING ALCOHOL CONSUMPTION IMPROVED HIV VIRAL SUPPRESSION IN WOMEN** (Poster Session P-S4)
- 934 PREP USED IN PREGNANCY DOES NOT INCREASE POOR BIRTH OUTCOMES** (Poster Session P-T1)
- 935 PREGNANCY INCIDENCE AND OUTCOMES AMONG WOMEN USING THE DAPIVIRINE VAGINAL RING** (Poster Session P-T1)
- 936 PREFERENCE AND CHOICE OF MULTIPURPOSE PREVENTION TECHNOLOGIES IN YOUNG AFRICAN WOMEN** (Poster Session P-T1)
- 937 MODERN CONTRACEPTIVE USE AND UNPROTECTED SEX IN HIGH-RISK HIV-POSITIVE WOMEN IN KENYA** (Poster Session P-T1)
- 938 INTERACTION BETWEEN ETONOGESTREL-RELEASING IMPLANT AND 3 ANTIRETROVIRAL REGIMENS** (Poster Session P-T1)
- 939 FERTILITY AND REPRODUCTIVE OUTCOMES OF HIV+ AND HIV- WOMEN IN THE CARMA COHORT STUDY** (Poster Session P-T1)
- 940 EARLY ONSET MENOPAUSE AMONG WOMEN LIVING WITH HIV IN CANADA** (Poster Session P-T1)
- 941 COST-EFFECTIVENESS OF 2 METHODS TO TREAT CERVICAL DYSPLASIA IN HIV-POSITIVE WOMEN** (Poster Session P-T1)
- 944 DEPOT MEDROXYPROGESTERONE ACETATE INCREASES HIV-1 REPLICATION IN MUCOSAL TISSUE** (Poster Session P-T2)
- 945 ZIM-CHIC: IMPACT OF CONTRACEPTIVE INITIATION ON IMMUNE CELLS IN THE CERVIX AND PBMCS** (Poster Session P-T2)
- 946 HIV GENITAL-TRACT SHEDDING WHILE ON PROGESTIN CONTRACEPTION** (Poster Session P-T2)
- 947 HORMONAL CONTRACEPTION DOES NOT AFFECT ART EFFECTIVENESS OR GENITAL HIV SHEDDING** (Poster Session P-T2)
- 949 MUCOSAL INFLAMMATION ABROGATES TENOFOVIR-GEL–MEDIATED PROTECTION FROM HIV INFECTION** (Poster Session P-T3)
- 950 IS SYNDROMIC DIAGNOSIS OF REPRODUCTIVE TRACT INFECTIONS ANTIQUATED IN THE HIV ERA?** (Poster Session P-T3)
- 970 IDENTIFYING PREGNANT WOMEN FOR PREP USING ROUTINE ANTENATAL CARE INDICATORS IN KENYA** (Poster Session P-U3)
- 992 MISDIAGNOSED HIV INFECTION IN PREGNANT WOMEN INITIATING UNIVERSAL ART IN SOUTH AFRICA** (Poster Session P-W1)

- 995 MARKED MORTALITY AND RETENTION UNDER-REPORTING IN A LARGE HIV PROGRAM IN ZAMBIA** (Poster Session P-W1)
- 1037 COST-EFFECTIVENESS OF PREEXPOSURE PROPHYLAXIS ACROSS COUNTIES IN WESTERN KENYA** (Poster Session P-X3)
- 1038 THE POTENTIAL IMPACT AND COST-EFFECTIVENESS OF MULTIPURPOSE PREVENTION TECHNOLOGIES** (Poster Session P-X3)

THURSDAY, FEBRUARY 16, 2017

- 132 BONE DENSITY AND TRABECULAR BONE SCORE IMPROVE FRACTURE PREDICTION IN HIV+ WOMEN** (Oral Abstract Session 0-12)
- 197 HIV-1 SEQUENCES FROM EARLY INFECTION PREDICT THE AGE OF THE INFECTION** (Poster Session P-B3)
- 209 MARAVIROC INHIBITS HIV TARGET T-CELL TRAFFICKING INTO THE FEMALE GENITAL LUMEN** (Themed Discussion TD-16)
- 210 INVESTIGATING THE EFFECT OF PH ON CERVICOVAGINAL MUCUS BARRIER PROPERTIES TO HIV** (Themed Discussion TD-16)
- 341 MONOCYTE ACTIVATION IS ASSOCIATED WITH COGNITION IN SUPPRESSED HIV-INFECTED WOMEN** (Poster Session P-F1)
- 350 COGNITIVE TRAJECTORIES OVER 4 YEARS AMONG HIV+ WOMEN WITH OPTIMAL VIRAL SUPPRESSION** (Poster Session P-F3)
- 361 COGNITIVE COMPLAINTS AND DEVELOPMENT OF FALLS AMONG HIV+ AND HIV- WOMEN** (Poster Session P-F3)
- 584LB TDF TO PREVENT PERINATAL HEPATITIS B VIRUS TRANSMISSION: A RANDOMIZED TRIAL (ITAP)** (Poster Session P-L7)
- 682 A RANDOMIZED TRIAL OF VITAMIN D3 (3000 VERSUS 1000 IU) IN HIV+ POSTMENOPAUSAL WOMEN** (Poster Session P-08)
- 686 PREVALENCE AND RISK FACTORS OF RENAL INJURY IN OPTION B+ DURING THE FIRST 6 MONTHS** (Poster Session P-09)
- 690 FOOD INSECURITY IS ASSOCIATED WITH POOR DIABETES CONTROL IN THE WIHS** (Poster Session P-011)
- 696 RALTEGRAVIR SWITCH AND BIOMARKERS OF LIVER STEATOSIS AND METABOLIC SYNDROME IN WOMEN** (Poster Session P-012)
- 699 WOMEN GAIN MORE WEIGHT THAN MEN FOLLOWING INITIATION OF ANTIRETROVIRAL THERAPY** (Poster Session P-012)
- 753 DOSING FOR TWO: PLACENTAL TRANSFER OF DARUNAVIR AND SIMULATION OF FETAL EXPOSURE** (Poster Session P-Q1)
- 754 SUBSTANTIALLY LOWER RILPIVIRINE PLASMA CONCENTRATIONS DURING PREGNANCY** (Poster Session P-Q1)
- 755 ELVITEGRAVIR/COBICISTAT PHARMACOKINETICS IN PREGNANCY AND POSTPARTUM** (Poster Session P-Q1)
- 756 PROTEASE-INHIBITOR-BASED CART IS ASSOCIATED WITH HIGH ESTRADIOL LEVELS IN PREGNANCY** (Poster Session P-Q1)
- 772 SUBSEQUENT PREGNANCY OUTCOMES IN WOMEN DURING FOLLOW-UP IN PROMISE 1077HS** (Poster Session P-Q3)
- 773 HIV AND RISK OF POSTPARTUM INFECTION, COMPLICATIONS, AND MORTALITY IN RURAL UGANDA** (Poster Session P-Q3)

- 774 CMV VIREMIA IN HIV-POSITIVE AND -NEGATIVE PREGNANT WOMEN IN BOTSWANA** (Poster Session P-Q3)
- 775 PREGNANCIES IN WOMEN WHO ACQUIRED HIV PERINATALLY** (Poster Session P-Q3)
- 776 ANTENATAL ANTIRETROVIRAL THERAPY AND ADVERSE BIRTH OUTCOMES: THE PROMISE TRIAL** (Poster Session P-Q3)
- 778 DO HIV+ WOMEN ON PROTEASE INHIBITORS DELIVER PRETERM? FINDINGS FROM A UK STUDY** (Poster Session P-Q3)
- 779 TDF/FTC IN PREGNANCY SHOWS NO INCREASE IN ADVERSE INFANT BIRTH OUTCOMES IN US COHORTS** (Poster Session P-Q3)
- 836 LOCAL SOCIAL NETWORKS PREDICT RETENTION & SUPPRESSION IN YOUNG WOMEN IN SEARCH TRIAL** (Themed Discussion TD-12)
- 857 VALIDATION OF A RISK SCORE FOR HIV ACQUISITION IN YOUNG AFRICAN WOMEN WITH FACTS 001** (Poster Session P-S2)
- 921 HIV STIGMA, DEPRESSION, ADHERENCE, AND VIRAL LOAD AMONG HIV+ AFRICAN-AMERICAN WOMEN** (Poster Session P-S10)
- 924 SEXUAL ORIENTATION DIFFERENCES IN HEALTH AND WELLBEING AMONG WOMEN WITH HIV IN CANADA** (Poster Session P-S10)
- 925 HEALTH OUTCOMES ASSOCIATED WITH GENDER-BASED VIOLENCE AMONG WOMEN WITH HIV IN CANADA** (Poster Session P-S10)
- 927 THE HEALTH IMPACT OF SEXUAL VIOLENCE AMONG WOMEN IN A PLATINUM MINING BELT** (Poster Session P-S10)
- 928 ASSOCIATION OF SEX AND RACE WITH HIV-/NON-HIV-RELATED DEATH IN TREATED HIV INFECTION** (Poster Session P-S11)
- 933 LONGITUDINAL VIRAL TRAJECTORY AMONG WOMEN IN THE WOMEN'S INTERAGENCY HIV STUDY** (Poster Session P-S11)
- 944 DEPOT MEDROXYPROGESTERONE ACETATE INCREASES HIV-1 REPLICATION IN MUCOSAL TISSUE** (Themed Discussion TD-13)
- 945 ZIM-CHIC: IMPACT OF CONTRACEPTIVE INITIATION ON IMMUNE CELLS IN THE CERVIX AND PBMCS** (Themed Discussion TD-13)
- 946 HIV GENITAL-TRACT SHEDDING WHILE ON PROGESTIN CONTRACEPTION** (Themed Discussion TD-13)
- 947 HORMONAL CONTRACEPTION DOES NOT AFFECT ART EFFECTIVENESS OR GENITAL HIV SHEDDING** (Themed Discussion TD-13)
- 951 DOES THE E138A MUTATION IN ASPIRE SEROCONVERTERS AFFECT SUSCEPTIBILITY TO DAPIVIRINE?** (Poster Session P-T4)
- 952 NNRTI-CONTAINING ART IS EFFECTIVE FOR DAPIVIRINE RING BREAKTHROUGH HIV-1 INFECTION** (Poster Session P-T4)
- 1025 HIV TRANSMISSION IN GENERALIZED, CONCENTRATED, AND MIXED EPIDEMICS IN WESTERN KENYA** (Poster Session P-X1)

AUTHOR INDEX

—A—

- Aamer, Hadega 304
 Aaron, Justin 546
 Aaron, Kristal 867
 Abaasa, Andrew Max. 976
 Abacassamo, Fatima 110
 Abana, Chike O. 230
 Abassi, Mahsa 746
 Abbas, Zaheer 418
 Abbate, Isabella 466
 Abdel Mohsen, Mohamed 284, 314
 Abdo, Mona 665, 666
 Abdool Karim, Quarraisha 879, 949
 Abdool Karim, Salim 949
 Abewe, Hosiana 307
 Ablan, Sherimay 507
 Abo, Kouame 1047
 Abou-Samra, Abdul-Badi 574
 Aboud, Michael 44LB, 664
 Aboulnasr, Fatma 273
 Abouzid, Omar 1035
 Abraham, Alison 87, 624, 645, 662, 931
 Abrams, Elaine J. 24, 27, 767, 769, 771, 780, 814, 815, 837, 950, 992, 1023
 Abu-Raddad, Laith J. 1027
 Abubakar, Ibrahim 736
 Abuna, Felix 1032
 Abutaima, Rana 416
 Achalapong, Jullapong 584LB
 Achan, Jane 797
 Acharya, Priyamvada 14LB
 Achenbach, Chad J. 598, 622
 Achhra, Amit C. 693
 Achia, Thomas 847
 Achilles, Sharon L. 945
 Achterbergh, Roel CA 519
 Achut, Victoria 914
 Ackerman, Daniel 334
 Ackerman, Margaret 253
 Ackers, Marta 882
 Acosta, Edward 755, 757, 806
 Acquistapace, Alessandra 396
 Adams-Huet, Beverley 677
 Adamson, Blythe J. 1045
 Adedoyin, Adedayo 430
 Adelsberger, Joseph 159, 287
 Adewumi, Olubusuyi M. 369
 Adeyeye, Adeola 421LB
 Adimora, Adaora 690, 913
 Adkison, Kimberly Kalp. 428
 Adland, Emily 272, 799
 Aebersold, Ruedi 263
 Afzal, Saira 302
 Agaba, Tifu 712
 Agan, Brian K. 358, 668, 932
 Aghokeng, Avelin F. 482, 486
 Agnew, Emily 111
 Agot, Kawango 894, 936, 982, 986
 Agrati, Chiara 203, 366
 Aqsalda-Garcia, Melissa 395
 Aguilera, Antonio 578
 Aguilera, Victoria 540
 Agwu, Allison 827, 828, 968
 Ahlgren, Erika 431
 Ahmed, Aabid 800
 Ahmed, Khatija 857, 936
 Ahmed, Uzma 923, 925
 Ahoua, Laurence 110
 Aid, Malika 304
 Ait Moha, Daoud 470
 Aitken, Celia 185
 Ajaykumar, Abhinav 590
 Ajibola, Gbolahan 502, 789, 790
 Akama, Eliud 762
 Akanbi, Maxwell 369
 Akapirat, Siriwat 291
 Akay-Espinoza, Cagla 74, 378
 Ake, Julie 355, 481
 Akello, Carolynne 952
 Akgün, Kathleen 658
 Akullian, Adam N. 1037
 Al-Kindi, Sadeer 674
 Alary, Michel 1047
 Albert, Arianne Y.K. 939
 Alcaide, Maria L. 770
 Aldámiz-Echevarria, Teresa 530, 534
 Aldrovandi, Grace M. 27
 Alejos, Belén 400
 Alessandra, Sacchi 203
 Alessandri-Gradt, Elodie 192
 Alfaro, Raul 409a
 Alfaro, Ricardo 446
 Allana, Salim 77
 Alland, David 76LB
 Allen, Isabel Elaine. 355
 Allen, Susan 200, 202
 Allender, Christopher 715LB
 Allice, Tiziano 379
 Almanza, Horacio 844
 Almirol, Ellen 969
 Almonte, Alexi 968
 Alon, Leigh 969
 Altet, María Nieves Altet 734
 Althoff, Keri N. 130, 598, 619, 662, 840
 Altice, Frederick 1044
 Alvarado, Luisa 1055LB
 Alvarado, Maria 1056LB
 Alvarez, Angeles 609
 Álvarez, Beatriz 572
 Alvero, Carmelita 806
 Alwano, Mary Grace 993, 1009, 1017
 Amanyire, Gideon 1005
 Amasio, Maria Enrica 379
 Ambegaokar, Suren A. 375
 Ambinder, Richard 318
 Ambrozak, David R. 61, 165
 Amedee, Angela M. 217
 Amendola, Alessandra 466
 Amiel, Corinne 349, 520
 Ammassari, Adriana 203, 354, 366, 466
 Amodo, Faizana 818
 Amofa-Sekyi, M. 711
 Amorissani-Folquet, Madeleine 811
 An, Qian 902
 Anagnostou, Olga 474
 Anand, Santhanam 559, 883
 Ananworanich, Jintanat 12, 124, 125, 205, 214, 249, 270, 282, 285, 291, 299LB, 339, 344, 363, 387, 394, 71
 Anastos, Kathryn 132, 237LB, 350, 514, 636LB, 646, 928, 933
 Ances, Beau M. 397, 401
 Ancona, Giuseppe 215
 Ancuta, Petronela 204
 Andaluz, Adriana 898
 Andany, Nisha 940

- Andersen, Nina 490
 Andersen, Ove 235
 Anderson, Albert 353
 Anderson, Christy M. 134
 Anderson, Elizabeth Marion. 297, 303
 Anderson, Hanne 1057LB
 Anderson, Jason 157
 Anderson, Jenny L. 288, 311
 Anderson, Matt 412
 Anderson, Meegan R. 15
 Anderson, Peter L. 404, 405, 419, 422LB, 976, 977
 Anderson, Sarah-Jane 1039
 Andersson, Lars-Magnus 431
 Andrade, Adriana 669
 Andrasik, Michele 897
 Andreoni, Massimo 564
 Andrew, Katende 744
 Andrews, Jason R. 725
 Andrianakis, Ioannis 1048
 Andrieux-Meyer, Isabelle 523
 Andrinopoulou, Elrozy 451LB
 Andujar, Isabel 609
 Ang'awa, David Odhiambo. 861
 Angelico, Mario 565
 Angelovich, Thomas A. 611
 Angerstein, Aaron 310
 Anglade, Benedict 835
 Anglaret, Xavier 78, 476
 Ankrom, Wendy 430
 Ansari, M. Azim 272
 Antinori, Andrea 354, 366
 Anuglueng Kitt, Suvaporn 759
 Aouizerat, Bradley E. 237LB
 Aplenc, Richard 384
 Apollo, Tsitsi 1030
 Appelmans, Eline 380
 Aragaw, Dossegaw 713
 Araújo, Marília Ladeira. 388
 Archary, Dersere 949
 Archary, Moherndran 817LB
 Archin, Nancie 123
 Arduino, Roberto 422LB
 Arends, Joop 136, 137LB, 587
 Arendt, Marina 633
 Arezes, Elisa 821
 Ariansen, J.L. 810
 Arias, Ana 562
 Arkangelo, Golda Caesar. 914
 Armon, Carl 32, 663, 678, 864
 Armstrong, Abigail 207, 208
 Armstrong, Heather L. 966
 Arnedo, Mireia 614
 Arpadi, Stephen M. 819
 Arribas, Jose R. 148, 400, 453, 652
 Arrington-Sanders, Renata 968
 Arrivé, Elise 821
 Arthos, James 64LB
 Aschheim, Joshua 132
 Asher Prince, Heather M. 406
 Asimwe, Stephen 934
 Assoumou, Lambert 441, 703
 Ataca, Sila 177
 Atkins, Elizabeth 248
 Atifeld, Marcus 176
 Attia, Engi Farouk. 660
 Atwiine, Martha 1001
 Aubert, Vincent 191
 Auer, Jim 236
 Augusto, Orvalho 730, 766, 818
 Auld, Sara C. 77
 Auletta-Young, Chloe 789, 790, 885
 Aurpibul, Linda 772, 820
 Austin, Gregory 211
 Austin, Michele 86LB
 Autran, Brigitte 290
 Avalos, Ava 988
 Avelino-Silva, Vivian Iida. 948
 Avettand-Fenoel, Veronique 812
 Avi, Radko 461
 Avihingsanon, Anchalee 443, 698
 Avila-Rios, Santiago 182, 480
 Awad, Susanne 1027
 Aweeka, Francesca 414
 Axelsson, Markus 383
 Ayat, Ferial 821
 Ayers, Colby 468
 Ayieko, James 638, 836, 858
 Ayles, Helen 711, 834, 959, 1010, 1011
 Aynalem, Getahun 1007, 1019
 Ayoub, Ahidjo 218
 Azama, Martin S. 740
 Aznar, Esther 441
 Azzo, Caitlin 745
 Azzoni, Livio 326
-B-
 Ba, Selly 440, 508
 Babigumira, Joseph 494
 Babudieri, Sergio 565
 Bacchetti, Peter 170, 281, 288, 632, 978
 Bachanas, Pamela J. 993, 1009, 1017
 Bachmann, Nadine 191
 Badje, Anani D. 78
 Badley, Andrew 273, 319
 Baernighausen, Till 475, 639, 916, 960, 983, 991, 994
 Baeten, Jared 85, 88, 920, 934, 935, 947, 951, 952, 967, 1003
 Baggaley, Rachel 1030
 Bagiere, Daniel 915
 Bagny, Aklesso 607
 Bahemana, Emmanuel 355
 Bai, Francesca 357
 Bailey, Heather 778
 Bailey, Justin R. 141
 Bailey, S.L. 711
 Bailin, Samuel 229
 Bailon, Lucia 400
 Bailor, Robert 415
 Bairey Merz, C. Noel 589
 Baisley, Kathy 491
 Baiyegunhi, Omolara 266
 Baker, David 670
 Baker, Jason 319, 608, 623
 Balachandra, Shirish 743
 Balagopal, Ashwin 648
 Balakrishnan, Mini 329, 434
 Baldelli, Sara 411
 Bale, Michael J. 294
 Balestra, Pietro 354
 Balkan, Suna 523
 Balkus, Jennifer 85, 88, 935, 952
 Ballana, Ester 259
 Ballif, Marie 714
 Balogun, Kayode 756
 Balotta, Claudia 227, 303
 Baloyi, Kabelo 958
 Balzer, Laura B. 36, 726, 832
 Banasiewicz, Mary 867
 Banda, Karen M. 35
 Banda, Richard 919

- Bandason, Tsitsi 841LB
 Bandeen-Roche, Karen 133
 Bandera, Alessandra 222, 306
 Bandermann, Silke 716LB
 Banga, Riddhima 289
 Bangham, Charles R.M. 109
 Bangirana, Paul 797
 Bangsberg, David 675, 773
 Banta-Green, Caleb 873, 967
 Bao, Jing 717
 Bapat, William 993, 1017
 Baral, Stefan 918, 997, 1047
 Barbaliscia, Silvia 565
 Barbee, Lindley A. 846, 979
 Barber, Tristan 382
 Barber, Xavier 647
 Barblu, Lucie 264
 Bardhi, Ariola 328
 Bares, Sara H. 408, 699, 963
 Barin, Francis 278
 Barker, Edward 211
 Barlow-Mosha, Linda 826
 Barnabas, Ruanne V. 107, 1032
 Barnaby, Devin 577
 Barnard, Richard 311, 337
 Barnes, Grace 657, 707
 Barnhart, Scott 111
 Barnwell, Garret 927
 Baro, Elande 372
 Barocas, Joshua A. 557
 Baron, Deborah 2
 Barr, Emily 779
 Barreiro, Pablo 578
 Barrera-Arellano, Carlos Arturo 480
 Barrios, Lisa C. 1033
 Barrios, Rolando 875, 1042
 Barth, Roos 656
 Bartlett, Jeffrey S. 322
 Barton, Kirston 293, 305
 Barton, Simon 447
 Basch, Peter 517, 543, 545
 Bassett, Ingrid Valerie. 773
 Batavia, Ashita S. 471
 Bateganya, Moses 741, 743
 Bates, Jonathan 930
 Bathulapalli, Harini 930
 Batra, Jag 424, 425
 Battalora, Linda 663, 678
 Bauer, Brent 669
 Bauer, Greta R. 926
 Bauer, Wolfgang 716LB
 Bauleni, Andy 783
 Baumgarten, Axel 551, 576
 Bavaro, Mary F. 358
 Baxter, Amy E. 264
 Bayon, Carmen 400
 Bbosa, Nicholas 193
 Bearden, David 827, 828
 Beauchamp, Geetha 1045
 Bebawy, Sally S. 644, 912
 Bebell, Lisa 773
 Beck, Ingrid A. 490, 494
 Beck-Wirth, Geneviève 495
 Becker, James T. 356
 Beckman, Lucas 308
 Beckwith, Curt G. 1044
 Becofsky, Katie 694
 Bedimo, Roger 468, 606, 677
 Beg, Subul 318
 Behel, Stephanie 1017
 Behrends, Czarina N. 547
 Behrens, Georg 703
 Beiser, Marguerite 557
 Bekele, Alemayehu 713
 Bekker, Adrie 758
 Bekker, Linda-Gail 1036, 421LB, 859
 Belaunzaran-Zamudio, Pablo Francisco. 225
 Beliakova-Bethell, Nadejda 307
 Belkaid, Yasmine 214
 Bell, Jennifer 297
 Bell, Teal 89
 Bellamy, Scarlett 384
 Bellecave, Pantxika 349
 Bellini, Giulia 531
 Bellón, José M. 533
 Belloso, Waldo 473
 Belmonti, Simone 445
 Belnap, David M. 21
 Beloukas, Apostolos 370, 549
 Belyea, Loni 692
 Ben-Farhat, Jihane 764, 792
 Benalycherif, Aida 458
 Bendavid, Eran 494, 725, 1052, 1053
 Bender Ignacio, Rachel Ann. 446
 Benfield, Thomas 235, 314
 Bengtson, Angela 454
 Béniguel, Lydie 441
 Benitez, Laura 562, 572
 Benjapornpong, Khunthalee 125, 387
 Benki-Nugent, Sarah 796
 Benko, Erika 122, 233
 Benne, Clarisse 321
 Bennett, Amy 846
 Bennett, David 842
 Bennett, Kara 502, 640
 Benoit, Anita 940
 Benson, Paul 41
 Benzaken, Adele 1040
 Benzekri, Noelle A. 642
 Berdasco, Maria 228
 Berenguer, Juan 530, 533, 534, 572
 Berg, Michael 583
 Berger, Florian 551, 567, 576
 Berkhout, Ben 286
 Berkley, Jay 117
 Berlacher, Kathryn 624
 Bermudez, Elkin Hernan. 464
 Bernard, Nicole 274
 Bernardino, Jose I. 652, 676
 Bershteyn, Anna 1025, 1035, 1036, 1037
 Bertagnolio, Silvia 112
 Bertero, Luca 379
 Bertine, Mélanie 194, 290
 Bertisch, Barbara 596
 Bertoli, Ada 564
 Bertrand, Rachel 722, 835
 Besa, Stable 959
 Besseghir, Amel 448, 603
 Best, Brookie 755, 810, 938
 Best, John 344
 Besutti, Giulia 655
 Betsem, Edouard 190
 Betts, Michael R. 65, 267
 Beudeker, Boris J.B. 587
 Beura, Lalit 267
 Beyers, Nulda 1010, 1011
 Bezemer, Daniela 1041
 Bhagani, Sanjay 9
 Bhagwat, Priya 695
 Bhardwaj, Nina 256
 Bharti, Ajay 74, 390
 Bhasi, Kavitha 427

- Bhattacharya, Debika 9, 589
 Bhattacharya, Jayantha 245
 Bhaumik, Siddhartha 1056LB
 Biasin, Mara 222
 Bibbolino, Giulia 466
 Bibollet-Ruche, Frederic 181LB
 Bichko, Vadim 452LB
 Bidwell, Gabriella 82
 Biello, Katie 971
 Bieniczak, Andrzej 808
 Bieniasz, Paul 1, 160LB, 220
 Bierman, Wouter 451LB, 620
 Bila, Dulce 730, 766, 818
 Bile, Ebi 993
 Biliotti, Elisa 575
 Billaud, Eric 135, 550
 Billingsley, James M. 252, 62LB
 Billioux, Veena Goud. 996
 Bilotta, Maria Teresa 203
 Binda, Francesca 579
 Bini, Teresa 357
 Binza, David 998
 Birkett, Michelle 843
 Birn, Rasmus 395
 Birnbaum, Jeanette 900
 Birungi, Josephine 462
 Bisbal, Otilia 676
 Bishai, William 79
 Bismut, Gilad 880
 Bisson, Gregory 384, 710, 717, 720
 Bitchong, Raymond Aristide. 637
 Bitilinyu-Bangoh, Joseph 464
 Bjorkman, Per 202
 Blackburn, Justin 762
 Blair, Elizabeth 44LB
 Blanche, Stephane 775, 781, 811, 812
 Blanco, José L. 42
 Blanco, Jose Ramón 676
 Blankson, Joel 253
 Blaser, Nello 596
 Blaxhult, Anders 431
 Blennow, Kaj 383, 389
 Bloch, Mark 670
 Block, Lisa 1008
 Blok, Willem 470
 Blokhina, E 868LB
 Blokhuis, Charlotte 825, 830
 Bloom, Jesse 243
 Blosser, Sara J. 878
 Blower, Sally 489, 850
 Blumenthal, Liz 81LB
 Bobat, Raziya 817LB
 Bochicchio, Sara 396
 Bock, Peter 1011
 Bocour, Angelica 903
 Body, Barbara 1054
 Boehme, Catharina C. 52, 76LB
 Boender, T. Sonia 467
 Boerekamps, Anne 136, 137LB
 Boesch, Austin 253
 Boescke, Christoph 551, 567, 576, 580, 704
 Boffito, Marta 39, 382, 416, 418, 432
 Bofill, Carmen E. 644
 Bohlius, Julia 602
 Boily, Marie-Claude 1047
 Boivin, Michael Joseph. 826
 Bokoch, Kevin 955
 Bolivar, Hector 350, 361
 Bollen, Pauline 429
 Bolo, Alex 914
 Bolon, Dan 246
 Bolton Moore, Carolyn 995, 1000, 1004
 Boltz, Valerie F. 120
 Bonar, Michał 154
 Bonfanti, Paolo 542LB
 Bongomin, Pido 637
 Böni, Jürg 191, 521
 Bonnet, Fabrice 131, 630
 Bonnet, Marion 262
 Bonora, Stefano 360, 379, 565
 Booramra, Constantine 436
 Boon, Denali 516
 Boonstra, Andre 587
 Boonsuk, Sarawut 793
 Bor, Jacob 960
 Bordoni, Veronica 203
 Borges, Álvaro H. 474
 Borghi, Lidia 357
 Boritz, Eli 61
 Borjas Howard, Jaime 620
 Borkowsky, William 800
 Borre, Ethan Daniel. 476, 1043
 Borrow, Persephone 181LB
 Bosch, Marjolein 610
 Bosch, Ronald 277, 279, 280, 325, 343, 803, 840
 Bose, Meera 299LB
 Boshelio, Carol 1019
 Bosinger, Steven E. 252
 Bosman, Kobus 320
 Botana, Laura 752
 Boucher, Charles 137LB, 451LB
 Boucher, Marc 785
 Boudreau, Matthew 694
 Boule, Andrew 727, 769, 990
 Boulougoura, Afroditi 221, 238
 Boulware, David 368, 742, 744, 746
 Boum, Yap 675, 773
 Bowman, Natalie M. 73
 Bowring, Mary Grace 689
 Boyd, Kathryn Fortunate. 345, 743
 Bozzi, Giorgio 227
 Bracchi, Margherita 418
 Bradley, Heather 737, 907, 1012
 Bradley-Stewart, Amanda 185
 Brady, Jennifer J. 679
 Brady, Kathleen 479, 911
 Braithwaite, Scott 1049LB
 Brander, Christian 119LB, 228, 271, 541
 Brandes, Peter 380
 Brandt, Cynthia A. 930
 Brandt, Mary-Grace 187
 Branger, Judith 1041
 Brar, Savvy 859
 Brassard, Nathalie 264
 Braun, Dominique Laurent 327, 521
 Braunstein, Sarah 1013
 Breen, Elizabeth 593
 Brehm, Jessica 123
 Breidinger, Sheila 435
 Brenchley, Jason 214
 Brennan, Alana 1050
 Brenner, Bluma 42
 Brew, Bruce 351, 398
 Briand, Coralie 812
 Bridgforth, Bob F. 903
 Brieve, Teresa 573
 Brinkley-Rubinstein, Lauren 912, 1044
 Brinkman, Kees 136, 470
 Brinson, Cynthia 442, 44LB
 Brittain, Evan L. 621
 Brittain, Kirsty 24, 771, 992

- Britto, Paula 772
 Brizgys, Gediminas 434
 Brockmeyer, Norbert H. 633
 Brodt, H.-R. 738
 Broekhuis, Jordan 963
 Bronson, Heather W. 962
 Brook, Jenny 592
 Brookmeyer, Ronald 879
 Brooks, David 254
 Brooks, John T. 597, 678
 Brooks, Kristina M. 409, 409a
 Brophy, Jason 226
 Brosens, Lodewijk 320
 Brouwers, Pim 810
 Brown, Alison E. 186, 736
 Brown, Diane M. 317
 Brown, Geri 677
 Brown, Kevin W. 252
 Brown, Kimberley 505
 Brown, Lillian 836
 Brown, Nakita 943
 Brown, Rachel 260LB
 Brown, Sheldon T. 606, 658
 Brown, Todd 133, 213, 342, 356, 593, 624, 632, 645, 669, 683, 691, 695, 700, 981
 Brown, Jr, Robert S. 568LB
 Browne, Sara H. 823, 824
 Broz, Dita 869, 871
 Bruce, Veronica 516
 Brugger, Peter 362
 Brühl, Maria Carlson. 389
 Bruisten, Sylvia 887
 Brumback, Babette 874
 Brumme, Zabrina 196
 Brummel, Sean 772
 Brun-Vezinet, Francoise 290, 448
 Bruneau, Julie 274
 Bruner, Katherine 296
 Brunet, Laurence 483
 Bruns, Anke 320
 Brust, James CM. 77
 Bryant, Kendall J. 673, 874
 Buaben, Aaron Ohene. 753
 Buchacz, Kate 32, 663, 678, 864, 907
 Buchbinder, Susan P. 419, 974, 978
 Bucher, Heiner C. 1052
 Buckley, Taylor 121, 309, 795
 Bucossi, Meggan 956
 Bucovsky, Mariana 682
 Budoff, Matthew 624, 626, 701, 702
 Buggert, Marcus 65, 267
 Bugnon, Olivier 671
 Bui, John 121, 313
 Bukusi, Elizabeth A. 85, 762, 832, 858, 860, 861, 934, 947
 Bull, Marta Eileen. 224
 Bullen, Cynthia Korin. 315
 Bunge, Katherine 86LB, 944
 Bunupuradah, Torsak 425, 807, 820
 Buranapraditkun, Supranee 249
 Burbelo, Peter 391
 Burchell, Ann N. 601
 Burchett, Sandra 938
 Burdet, Charles 458
 Burdick, Ryan C. 17, 227
 Burdo, Tricia H. 627, 635LB
 Burgener, Adam 231
 Burger, David M. 429, 753, 754, 807, 808
 Burger, Divan 724LB
 Burgess, Emma Karolina. 857
 Burk, Robert 636LB
 Burke, Bryan P. 322
 Burke, Mark William. 373
 Burke, Stephen 273
 Bürkle, Alexander 672
 Burt, Richard 873
 Busch, Fabian 580
 Busch, Michael P. 279, 284, 511, 512, 876
 Buseyne, Florence 190
 Bush, Tim 597
 Bush, William S. 377, 392, 393
 Bushman, Frederic 171LB
 Bushman, Lane R. 404, 405, 419
 Buskin, Susan 846, 851, 973
 Busza, Joanna 841LB
 Butler, Emily 577
 Butler, Javed 574
 Butt, Adeel Ajwad. 127, 574, 626, 702
 Butt, Zahid Ahmad. 524, 735
 Buyze, Jozefien 81LB
 Bwakura-Dangarembizi, Mutsa 826
 Bwana, Bosco Mwebesa. 773
 Byron, Mary Margaret 255, 385, 612
- C—
 Caan, Matthan WA. 352LB
 Cababasay, Mae 757, 758
 Caballero, Gemma 201
 Cabello, Alfonso 676
 Cabié, André 458
 Cachay, Edward Rafael. 134
 Cachomba, Yolanda 818
 Cahn, Pedro 447, 451LB
 Cai, Ruby 434
 Cai, Suqin 140
 Caiphus, Cynthia 729
 Cairó, Mireia 535
 Calado, Rodrigo 388
 Calcagno, Andrea 360, 379, 416
 Caldwell, Judy 727
 Calle, Maria Luz. 212
 Calnan, Marianne 708
 Calvez, Vincent 43, 499
 Calvo, Katya 977
 Calvo-Pulido, Jorge 540
 Camacho-Espejo, Angela 573
 Camacho-Gonzalez, Andres 839
 Cambiano, Valentina 112, 1030
 Cameron, Paul 288
 Camlin, Carol S. 860
 Campbell, Andrew 413
 Campbell, Angela 77
 Campbell, Ellsworth 189, 477, 877, 878
 Campbell, Thomas 492, 648
 Campins, Antoni 659
 Camus, Gregory 568LB
 Canaday, David 267
 Canales Santos, Raissa 525
 Canestri, Ana 75
 Cannizzo, Elvira Stefania. 239, 579, 680
 Cantor, Scott B. 591
 Cao, Huyen 427, 443
 Capeau, Jacqueline 703
 Capetti, Amedeo 410
 Capitant, Catherine 91LB
 Capobianchi, Maria Rosaria. 466
 Capoferri, Adam 296, 318
 Capparelli, Edmund V. 755, 758, 760, 809, 810, 938
 Cardinaud, Sylvain 262
 Cardoso, Lena 557
 Cardoso, Sandra Wagner. 457, 648

- Carleo, Maria Aurora 585
Carmona, Sergio 113
Carnethon, Mercedes 622
Carnimeo, Valentina 523
Caro-Vega, Yanink 225
Carpio, Felix 664
Carr, Andrew 444
Carr, Brian A. 329
Carr, Jason 900
Carragher, Bridget 14LB
Carrasco Garcia, Itziar 562
Carrere, Nicolas 223
Carrillo, Eugenia 752
Carrillo, Mayra A. 254, 331, 332
Carrion, Jose Antonio. 535
Carroll, Makeda 479, 911
Carryl, Heather 373
Carta, Stefania 366
Cartmill, Kimberly 544
Casazza, Joseph P. 61, 165
Caseris, Marion 812
Casillas-Rodríguez, Jesús 480
Casseb, Jorge 388
Cassella, Elena 220
Cassels, Susan 901
Cassidy, Adam R. 784
Cassidy, Tali 791, 998
Cassoni, Paola 379
Castagna, Antonella 460
Castanon, Rosinda 677
Castel, Amanda Derryck. 905, 909
Castelli, Francesco 44LB
Castells, LLuis 540
Castelnuovo, Barbara 1001
Castilho, Jessica L. 644
Castillo-Mancilla, Jose R. 405, 419, 675
Castleman, Moriah 211
Castro, Alicia 752
Castro, Pedro 336
Cattaneo, Dario 410, 411
Cattaneo, Paolo 303
Cauda, Roberto 445
Cavassini, Matthias 289, 362, 596, 671
Cavet, Guy 265LB
Cazabat, Michelle 223
Cazzaniga, Federico Angelo. 579, 680
Ceccherini Silberstein, Francesca 564, 565
Celentano, David D. 883
Celum, Connie L. 85, 879, 920, 934, 1003
Cenderello, Giovanni 460, 542LB
Cento, Valeria 564, 565
Cercamondi, Colin 721
Cerqueira, Natalia Barros. 948
Cerrone, Maddalena 239
Chabalala, Bongani 718
Chadwick, David 650
Chadwick, Ellen G. 779
Chagumaira, Takudzwa 743
Chahroudi, Ann 1056LB, 260LB, 822
Chaigneau, Aurélie 262
Chaila, Mwate Joseph. 834, 959
Chaillon, Antoine 134, 182, 183, 200, 201, 206, 240, 241, 323, 844
Chain, Anne 757
Chaisson, Richard E. 657, 707
Chaiwarith, Romanee 705
Chaix Baudier, Marie-Laure 323
Chakalisa, Unoda 885, 1017
Chakhtoura, Nahida 755, 772, 776, 777, 938
Chakrabarti, Bimal K. 245
Chakraborty, Rana 829, 839
Chalermchai, Thep 205, 387
Chamie, Gabriel 33, 36, 726, 860
Chammudzi, Mishek 641
Chamnan, Parinya 863
Chan, Austin Wei-Hong. 138, 552
Chan, Dora 122
Chan, Jasper F.W. 747
Chan, Philip A. 892, 968, 972
Chan, Phillip 339, 363
Chan, Shanna 226
Chander, Geetanjali 560
Chang, Larry W. 1015, 34LB, 996
Chang, Ming 508
Chang, Shan-Chwen 582
Chapin-Bardales, Johanna 1024
Chappell, Catherine 88, 944
Chapple, Thema 852
Charlebois, Edwin D. 36, 638, 726, 768, 836, 858, 860, 1051
Charlebois, Roxanne 264
Charpentier, Charlotte 194, 195, 290, 499
Charreau, Isabelle 91LB
Charurat, Man 918, 997
Chasekwa, Bernard 786
Chasela, Charles 917
Chasimpha, Steady 602
Chattergoon, Michael 167, 253
Chavane, Victorino 730, 766
Chavez, Jose R. 844
Chawki, Sylvain 323
Chebani, Liziwe 993
Chebani, Tony 1008
Cheeba-Lengwe, M 711
Chege, Wairimu 981
Chemaitelly, Hiam 1027
Chen, Benjamin K. 256
Chen, Huabiao 269
Chen, Huicheng 204
Chen, Jianbo 17
Chen, Jingxian 406
Chen, Mi 890
Chen, Weizao 328
Chen, Yen-Hsu 450LB
Chen, Yi-Ming Arthur. 348
Chen, Ying Q. 981, 1002
Chenal, Henri 714
Chene, Genevieve 195, 448
Cheng, Allen 687
Cheng, Andrew 41, 443
Cheng, Chien-Yu 594
Cheng, Debbie 673
Cheng, Helen 936
Cheng, Shu-Hsing 594
Cheng, Yan 588
Cheng, Yao 39
Chernoff, Miriam 826
Cherutich, Peter 1032
Chesang, Kipruto 985
Chesson, Harrell 1034
Cheu, Ryan 216
Chew, Glen 255, 385
Chew, Kara W. 574, 589
Cheyip, Mireille 1007, 1019
Chi, Benjamin H. 776, 777, 919
Chia, Jason 601
Chiao, Elizabeth 539, 591
Chidiac, Christian 91LB
Chilengi, Roma 581
Chilisa, Florence 502
Chimbwandira, Frank M. 782
Chinula, Lameck 946

- Chipato, Tsungai 776
 Chirenje, Zvavahera M. 945
 Chirro, Oscar 856, 893, 1022
 Chirwa, Zengani 464
 Chisunkha, Blessings 896
 Chitwarakorn, Anupong 854, 855, 862
 Chiwele, K 711
 Chmiel, Joan Sander. 942
 Cho, Josalyn 232
 Chofle, Awilly Aden. 82
 Chohan, Vrasa 765
 Chokephaibulkit, Kulkanya 425
 Choko, Augustine 895
 Chomchey, Nitiya 214, 291
 Chomont, Nicolas 1, 124, 281, 282, 285, 288, 291, 293, 319, 326
 Chonwattana, Wannee 854
 Chonzi, Prosper 841LB
 Choopanya, Kachit 954
 Chotecharoentanan, Tawalchaya 820
 Chotivanich, Nantasak 584LB
 Chow, Dominic 255, 385, 612, 692
 Chow, Felicia C. 347, 399
 Chow, Shein-Chung 552
 Chowdary Koneru, Pratibha 16, 157
 Chowdhury, Navin Fatema. 292
 Christ, Frauke 155
 Christensen, Stefan 551, 567, 576
 Christensen-Quick, Aaron 166
 Christopoulos, Katerina 838
 Chrystostomou, Anastasia 687
 Chu, Fang-Yeh 594
 Chuang, Yu-Chung 582
 Chueca, Natalia 566
 Chun, Tae-Wook 319
 Chung, Hannah 950
 Chung, Michael H. 22, 490, 494
 Chung, Raymond T. 404, 574
 Cianci, Gianguido C. 15
 Ciano, Alessia 565
 Ciaranello, Andrea L. 814, 833
 Cicala, Claudia 64LB
 Cifuentes, Carmen 535
 Cihlar, Tomas 118, 309, 313, 338LB, 436
 Cillo, Anthony R. 121, 309, 313
 Cimini, Eleonora 203
 Ciuffi, Angela 162
 Claassen, Mark 137LB, 587
 Clapham, Paul 246, 365
 Clark, Andrew 417
 Clark, Devon 975
 Clark, Tamara D. 36, 638, 726, 768, 836, 858, 860, 1051
 Clarke, Amanda 447, 453
 Clarke, Diana F. 757
 Clarke, William 904
 Clayton, Kiera L. 233
 Clement, Meredith 615
 Clementi, Emilio 410, 411
 Clemenzi-Allen, Angelo Asa. 853
 Clerici, Mario 222, 804
 Climent, Nuria 336
 Clish, Clary 636LB
 Cloherty, Gavin 510, 522, 577, 583
 Clotet, Bonaventura 119LB, 259
 Coban, Hamza 343
 Cobelens, Frank 727
 Cocker, Alexander 275
 Cofán, Montserrat 614
 Coffin, John 294, 297, 298
 Cogswell, Andrew 211
 Cohan, Deborah 768
 Cohen, Calvin 683
 Cohen, Craig 36, 85, 762, 832, 858
 Cohen, Mardge H. 132, 237LB, 514, 646, 690, 933
 Cohen, Myron S. 198, 406, 1002
 Cohen, Sophie 825, 830
 Cohen, Stephanie E. 189, 477, 978
 Cohn, Silvia 707
 Cohn, Susan E. 921, 942
 Colbers, Angela 429, 753, 754, 807
 Colby, Donn 124, 249, 270, 339, 363
 Cole, James H. 352LB
 Cole, Stephen R. 908
 Colella, Elisa 222
 Colie, Christine 23
 Coll, Josep 119LB, 271
 Collado, Antonio 570
 Collado-Diaz, Victor 609
 Coller, Kelly 510, 577, 583
 Collier, Ann 280, 457
 Collin, Fideline 194, 195, 448
 Collin, Gilles 499
 Collins, Ben 263
 Collins, Bryan C. 962
 Collins, Deborah 977
 Collins, Intira Jeannie. 815, 831
 Collins, Lauren Frances. 138, 552
 Collins, Louis 397
 Collins, Pamela 153
 Collmann, Jeff 646, 933
 Colman, Rebecca 715LB
 Colomer-Lluch, Marta 168
 Coluci, Amy 424
 Comi, Laura 460
 Comins, Kyla 80LB
 Compston, Juliet 679
 Cone, Richard 210
 Cong, Mian-er 84, 209
 Conley, Lois 597
 Connick, Elizabeth 63, 616
 Connor, James R. 377
 Conradie, Almari 724LB
 Conradie, Francesca 51, 1020, 80LB
 Constantino, Stephanie 548
 Conway, Brian 553
 Conway, Tracey 924, 925
 Conyngham, Caitlin 975
 Cook, Adrian 808
 Cook, Jennifer 563
 Cook, Robert L. 874
 Cook, Ryan 770
 Cook, Victoria 735
 Cookson, Debralee 390
 Coombs, Robert 224, 446, 508, 947
 Cooper, Curtis 138, 553
 Cooper, David A. 670
 Coovadia, Ashraf 27, 29LB, 814, 819
 Copans, Amanda 568LB
 Cope, Fred 635LB
 Coppola, Nicola 531, 537, 585
 Corbeau, Pierre 605
 Corbett, Amanda 783
 Corbett, Elizabeth L. 1030
 Corbett, Liz 895, 896
 Corbin, John A. 329
 Cordero, Elisa 541
 Corey, Kathleen 574
 Corey, Larry 415
 Corleis, Bjorn 232
 Cornell, Morna 998

- Cortes, Claudia P. 719
Cortez, Valerie 242
Coskun, Ayse 236
Costa, Dayane Alves. 948
Costa, Jose J. 578
Costa, Priscilla Ramos. 948
Costagliola, Dominique 75, 441, 703
Cote, Helene C.F. 590, 780, 785, 939
Cotte, Laurent 135, 550, 732
Cotter, Aoife G. 679
Cotterchio, Michelle 601
Cotton, Mark 120, 28, 29LB, 758, 791, 795, 823, 824, 826
Cottrell, Mackenzie L. 407
Cotugno, Nicola 798
Council, Olivia 84, 954
Cournil, Amandine 482, 486
Courtney, Colleen R. 881
Coutant, Sophie 192
Coutinho, Roel 656
Cowan, Frances 1030
Cox, Andrea 167, 253, 516, 518
Coyle, Ryan P. 405
Cozzi, Valeria 410
Crabtree-Ramírez, Brenda 719
Crane, Heidi M. 347, 619, 625, 838, 840, 853
Cremin, Ide 1038
Crepaz, Nicole 31
Crespo, Manuel 533, 535
Cressey, Tim R. 584LB, 759, 807, 809
Crofoot, Gordon 41
Crooks, Abigail 749, 750
Crothers, Kristina 606, 658, 660, 667
Crotty, Shane 264
Crowe, James E. 141
Crowell, Trevor 481, 918, 997
Crowley, Megan 556
Crum-Cianflone, Nancy 358
Cruz, Encarnación 572
Crystal, Stephen 667
Csala, Anna 799
Cua, Eric 91LB
Cuenca-Lopez, Francisca 536, 555, 573
Cuervas-Mons, Valentin 562
Cuesta, Miriam 562
Cui, Zishan 462, 966
Cummins, Nathan 273, 319
Cunningham, Chinazo 1016
Cunningham, Coleen K. 760
Cunningham, William E. 853
Curley, Paul 423
Curlin, Marcel 854, 954
Curran, Adrià 651
Currier, Judith S. 1, 251, 414, 574, 589, 695, 696, 772
Curtis, Kelly 877, 878
Curtis, Lloyd 664
Cusato, Jessica 416
Custodio, Joseph M. 40, 427
Cutrell, James 468
Cutro, Scott R. 90
Cuzin, Lise 135, 550, 732
Cyktor, Joshua Charles. 121, 277, 279, 280, 309, 313, 330LB, 795
Cysique, Lucette 351, 398
Czaicki, Nancy 995, 1000
d'Arminio Monforte, Antonella 131, 215, 239, 357, 579, 680, 693
D'Avolio, Antonio 416
D'Elbee, Marc 895
D'Souza, Gysamber 23, 593, 598
da Silva, Zacarias J. 37
Daar, Eric 589
Dabis, François 43, 491, 607, 1018
Dabydeen, Sarah 374
Dadabhai, Sufia 952
Dadabhaia, Sufia 776
Dagnall, Rachael 549
Dagur, Raghubendra Singh. 588
Dahourou, Désiré Lucien 811, 814
Daigneault, Audrey 264
Dalmau, Judith 228
Damond, Florence 194, 195, 448, 603
Dan, Jennifer Marie. 206
Danaviah, Siva 43, 491
Danboise, Brook 481
Danel, Christine 78, 476
Daniels, Brice 867
Daniels, Johnny 718
Darko, Sam 61
Darragh, Teresa 597
Das, Debananda 503
Das, Moupali 453
Dasgupta, Sharoda 187, 845LB
Dash, Prasanta 219
Daskalakis, Demetre C. 108, 891, 898
Dauya, Ethel 841LB
Davidovich, Udi 519, 886, 887
Davidson, Arthur 528
Davies, Mary-Ann 581, 815
Davies, Nicholas 382
Davies, Paula 549
Davis, Arielle Patricia. 749, 750
Davis, Jacquice 214
Davis, Jeremy 221
Davis, Nicole 947
Davy, Thibaut 465, 483
Dawson, George 583
Dawson, Lindsey 1012
Dawson, Rodney 724LB, 728, 79
Day, Jeremy 83, 747, 748
Day, Nesrine 520
Day-Weber, Isaac 432
de Almeida, Sergio Monteiro. 386
de Almeida Coelho, Ronaldo 1040
De Alwis, Manori 371
de Armas, Lesley R. 234, 258
de Azevedo, Virginia 718, 998
de Benito, Amparo 595
De Bleser, Pieter 162
de Boer, Mark 1041
de Bree, Godelieve J. 886, 887, 953
de Bruyn, Elize 787
De Cock, Kevin 761
De Francesco, Davide 352LB, 672
De Gascun, Cillian 513
De Kort, Jaclyn 504LB
De La Flor, Carolina 957
de la Torre, Pola 472, 888
De Leuw, Philipp 738
De Luca, Andrea 445
De Luca, Antonio 585
de Mast, Quirijn 610
de Mendoza Fernández, Carmen 562
De Meyer, Sandra 505
de Oliveira, Tulio 43, 491, 504LB
De Paris, Kristina 373

—D—

D'Antoni, Michelle L. 205, 381
D'arc, Mirela 218

- de Pokomandy, Alexandra 924, 925, 926, 940
- de Souza, Mark 125, 285, 299LB
- De Spiegelaere, Ward 162, 302
- de Stefano, Giorgio 537
- de Vries - Sluijs, Theodora 451LB
- De Vuyst, Hugo 22
- de Wit, Stephane 693, 703
- DeAlwis, Paba M. 402
- Dean, Bonnie 663
- Debyser, Zeger 155
- Decker, Luc 584LB
- Deeks, Steven G. 65, 126, 267, 281, 284, 288, 293, 391, 407, 512
- DeHovitz, Jack 514
- Deiss, Robert 358, 865, 932
- DeJesus, Edwin 41, 453, 45LB
- DeKadt, Julia 111
- Del Amo, Julia 1028
- Del Campo, Santos 541
- del Rio, Carlos 90
- Del Río-Estrada, Perla 65
- Del Sole, Angelo 680
- Delagreverie, Heloise M. 278, 323, 325
- Delaney, Kevin Payton. 509
- Delany-Moretlwe, Sinead 857
- Delaporte, Eric 482, 486
- Delaugerre, Constance 278, 323, 441, 91LB
- Deleage, Claire 70, 226
- Delelis, Olivier 499
- Delgado-Fernández, Marcial 139, 571
- Delobel, Pierre 223, 732
- DeLong, Kevin 210
- Delpech, Valerie 736
- Delucchi, Kevin L. 547
- Delviks-Frankenberry, Krista 334
- Demers, Andrew J. 199
- Dempsey, Antigone 1012
- Deng, Wenjie 304
- Deng, Xutao 284
- Deng, Yanhong 257
- Denkinger, Claudia M. 76LB
- Dennis, Ann M. 182, 198, 483
- Denti, Paolo 29LB, 808, 809
- Denton, Paul W. 314
- Derache, Anne 43, 491
- Dermody, Nadene 351
- DeRosa, Stephen 321
- Desai, Tejal 420
- Descamps, Diane 194, 195, 349, 448, 458, 499, 812
- Deshmukh, Ashish A. 591
- Deshmukh, Savitha 307
- Desimmie, Belete A. 164, 173, 227
- Desir, Fidel A. 840
- Desmonde, Sophie 814
- DeSouza, Christopher 616
- Deulina, Marina 452LB
- Devillé, Walter 656
- Dewar, Robin L. 227
- Dezzutti, Charlene S. 86LB, 944
- Dhillon, Dilsher 661
- Dhody, Kush 437
- Di Perri, Giovanni 360, 379
- Diabaté, Souleymane 1047
- Diacon, Andreas Henri. 79, 80LB
- Diallo, Mamadou Hassimiou. 1018
- Diallo, Mariama 290
- Diamond, Jan 556
- Díaz, Asunción 1028
- Díaz, Carmen 527
- Díaz, Laura 802
- Díaz de Santiago, Alberto 676
- Dickey, Amy Kathryn. 232
- Dickinson, Gordon 234, 258
- Dickinson, Laura 39
- Diehl, Kyle 616
- Dieterich, Douglas 138
- Diez, Cristina 530
- Diez, Jose Luis 306
- Díez-Pérez, Adolfo 681
- Dige, Anders Kirch. 314
- Dijkstra, Maartje 886, 887
- Dillon, Stephanie 211
- Dima, Mbatshi 729
- Dimitrov, Dimiter S. 328
- Dimitrov, Dobromir 1036, 1045
- DiNunno, Elizabeth 833
- Ding, Erin 925
- Ding, Song 265LB
- Dingens, Adam 243
- Dinges, Warren 973
- Dinh, Chuong 209
- Dionne-Odom, Jodie 867
- Diouf, Douada 1047
- Dirajlal-Fargo, Sahera 618
- Dirksen, Suzanne 528
- Dirix, Lieve 155
- Diseko, Modiegi 25
- Dlamini, Ndimiso 994
- Dlamini, Phiwayinkhosi 994
- Do Duy, Cuong 463
- Dobs, Adrian 669
- Dodd, Lori E. 238
- Doherty, Meg 112
- Dolan, Michael 14LB
- Dolci, Giovanni 532
- Dollfus, Catherine 775, 812
- Domanico, Paul 39
- Dombrowski, Julia C. 89, 964, 979
- Domínguez-Domínguez, Lourdes 534, 572
- Domyeum, Jenny 482, 486
- Doncel, Gustavo 857
- Dong, Krista 266
- Donnell, Deborah J. 3, 85, 1045
- Doria-Rose, Nicole 244
- Dorman, Robin 469
- Dorman, Susan E. 76LB
- Dorrell, Lucy 271
- Douek, Daniel 60, 61, 165, 175
- Dougherty, Sarah 867
- Douglas, Pamela 615
- Douglas, Steven D. 827, 828
- Dow, Caitlin 616
- Downhour, Diane 20
- Doyle, Katherine 1055LB
- Doyle, Margaret 673
- Doyle, Ronan 801
- Draenert, Rika 472, 888
- Dragavon, Joan 224
- Dragunova, Julia 569
- Drake, Alison L. 765
- Drechsler, Henning J. 468
- Dreyer, Dan 435
- Droit, Lindsay 213
- Droz, Daniel 347, 625
- Drummond, M. Brad 661
- Druz, Aliaksandr 14LB
- Dryden-Peterson, Scott 787
- Du, Yushen 268, 500LB
- Du Pasquier, Renaud 362
- Duarte, Horacio A. 494

Duarte, Wellington 388
Dube, Michael 977
Dube, Queen 783
Dubrow, Robert 257, 600
Duenas Decamp, Maria Jose 246
Duerr, Ann 380, 446
Duerr, Ralf 881
Duisenberg-van Essenberg, Marjolijn 429
Dukhovlinova, Elena 369
Dumchev, Kostyantyn 884
Dumond, Julie B. 406
Dunaway, Shelia 749, 750
Duncan, Kristal 927
Dunham, Richard M. 252
Dunn, David 186
Dunne, Eileen F. 854, 855, 862
Dunville, Richard 833, 1033
Dupnik, Kathryn 471
Dupon, Michel 630
Durand, Christine 317, 318, 330LB, 689
Durfee, Joshua 528
Durham, Natasha 256
Durham, Phillip G. 420
Dutertre, Marine 732
Dutta, Sandeep 413
Duwve, Joan 878
Dyavar Shetty, Ravi 408
Dzamalala, Charles Patrick. 602
d'Almeida, Marcelline 487

–E–

Easley, Kirk A. 684
Eaton, Ellen F. 454, 455
Eaton, Jeffrey 115, 1031
Ebner, Hanna 66, 67
Eckard, Allison Ross. 822
Eckhardt, Benjamin 554
Edagwa, Benson 439
Edelstein, Zoe R. 891, 898
Edén, Arvid 340, 431
Eden, John-Sebastian 293
Edlefsen, Paul 304
Edlin, Brian 554
Edwards, Jessie K. 454
Efronson, Emilie 1004
Egbujie, Bon 763
Egger, Matthias 581, 596, 714
Eholie, Serge 78, 476
Eichner, Allyson 961
Eilers, Grant 171LB
Eisenberg, Anna 515
Eisenberg, Marcia 1054
Ekouevi, Didier Koumavi. 607
El Kamari, Vanessa 618
El-Fakhri, Georges 635LB
El-Halabi, Shenaaz 1008
El-Sadr, Wafaa M. 1023, 1045, 1049LB,
128LB, 637, 706
Elashoff, David 592, 593
Elbezanti, Weam 308
Eld, Amy 428
Elde, Nels 20
Eley, Brian 763
Eliaou, Jean-François 605
Elion, Richard 978
Elliot, Emilie 432
Elliott, Jennifer 16
Ellis, Ronald J. 343, 353, 367, 377, 386,
392, 393
Ellis, Shanon 84
Ellis, Tyrone 923

Ellison, Lucas 405
Ellner, Jerrold 709, 76LB
Else, Laura 416, 418
Elul, Batya 110, 837
Emerman, Michael 19, 172
Emery, Ann 163
Emery, Sandy 765
Emery, Sean 473, 474
Emiliozzi, Arianna 445
Emperador, Devy 33
Emu, Brinda 257, 449LB, 72
Emusu, Donath 982, 985, 986
Engelbrecht, Susan 120
Engelman, Alan N. 157, 292
Engels, Eric A. 598, 600, 661
Engelthaler, David M. 715LB
Engen, Phillip A. 240, 241
Ensign, Laura 210
Enstone, Joanne 1039
Epie, Fanny 780
Eriksen, Jaran 431
Erlandson, Kristine 356, 665, 666, 700
Ernest, Oscar 950
Eron, Joseph J. 73, 198, 277, 279, 280, 298,
342, 442, 454, 465, 483, 619
Esbjörnsson, Joakim 37, 202
Escota, Jerome 597
Escribà, Tuixent 614
Eshleman, Susan H. 492, 879, 955, 1002
Eshun-Wilson, Ingrid 995
Esmail, Hanif 739
Espinoza, Luis 874
Esplugues, Juan V. 609
Esposito, Vincenzo 585
Esser, Stefan 633
Essex, Max 25, 184, 484
Este, Jose A. 259
Esteller, Manel 228
Estes, Jacob D. 70, 226, 251
Esteve, Anna 651
Estill, Janne 596, 782
Estrada, Vicente 676
Esvan, Rozenn 575
Ethridge, Steven 509
Eugen-Olsen, Jesper 235
Eusuff, Jasur 364
Euvrard, Jonathan 990
Evans, Ceri 786
Evans, David 2
Evans, Denise 917
Evans, Henry W. 346, 546
Even, Sophie 290
Everitt, Daniel 80LB
Eyawo, Oghenowede 601, 619, 929
Eymard-Duvernay, Sabrina 482, 486, 654

–F–

Fabbiani, Massimiliano 222, 445
Fabbri, Gabriele 354
Fabre, Roxane 72
Facente, Shelley 511, 876
Fafi-Kremer, Samira 495
Faini, Diana 744
Falade-Nwulia, Oluwaseun 560
Faller, Jean-Pierre 495
Fan, Li 412, 430
Fane, Othusitse 729
Fang, Annie 417
Fanjul, Francisco 659
Fanning, Miranda 845LB
Farber-Eger, Eric 621

- Farella, Nunzia 537
 Farhad, Mona 776, 777
 Farhadian, Shelli 257
 Faria de Oliveira, Michelli 367
 Farquhar, Carey 1032
 Farrior, Jennifer Hanna. 421LB
 Farukhi, Irfan 677
 Fate, Gwendolyn 417
 Fätkenheuer, Gerd 176, 183, 580
 Fatti, Geoffrey 763
 Fauci, Anthony S. 64LB
 Favarato, Graziella 778
 Favre, David 123, 252
 Fawcett, Tracy 186
 Fayadat-Dilman, Laurence 337
 Faye, Albert 775
 Fedele, Valentina 366
 Fehr, Jan Sven. 521
 Feinstein, Matthew J. 622
 Fellows, Lesley K. 397
 Felsen, Uriel 544, 903, 928, 1016
 Fennema-Notestine, Chris 403
 Fenner, Lukas 714, 721
 Fenwick, Craig 265LB
 Ferguson, Tomas 865
 Ferlazzo, Gabriella 718
 Fernández, Emma 614
 Fernandez, Jose Ramon. 540
 Fernandez, Laura 752
 Fernández, Marta 647
 Fernandez, Stephen 517, 543, 545
 Fernández McPhee, Carolina 527
 Fernández-Rodríguez, Amanda 530
 Ferns, Bridget 798
 Ferrand, Rashida 841LB
 Ferrara, Micol 460
 Ferrari, Marta 396
 Ferris, David 682
 Ferris, Robert 123
 Fessel, Jeffry 449LB, 506
 Fey, Jordan M. 405
 Fichtenbaum, Carl 251, 342
 Fidler, Sarah 261, 324, 834, 959, 1010, 1011
 Fielding, Katherine 723LB
 Fierer, Daniel S. 404
 Figueroa, Carmen 1030
 Figueruela López, Blanca 571
 Fillgrove, Kerry 435
 Finlayson, Teresa 902
 Fiore, Danielle 842
 Fiore, Vito 542LB
 Firnhaber, Cindy 941
 Fischer, Laurent 381
 Fischl, Margaret 234, 258
 Fishbein, Dawn 517, 543, 545
 Fisher, Arren 1054
 Fisher, Bridget 260LB
 Fisher, Cole 260LB
 Fitch, Kathleen V. 627
 Fitzgerald, Daniel 471, 722, 835
 Fitzgerald, Felicity 801
 Fleisher, Ilan 517
 Fleissner, Zach 169
 Fleming, Ira 897
 Flerin, Nina Campbell. 269
 Fletcher, Courtney V. 79, 408
 Fletcher, James LK. 71, 394
 Flexner, Charles W. 147
 Floris-Moore, Michelle 361
 Floyd, Sian 711, 834, 959, 1010, 1011
 Flyak, Andrew I. 141
 Flynn, Colin 904
 Flynn, Patricia M. 685LB
 Focà, Emanuele 460
 Fofana, Djeneba Bocar 487
 Fofana, Ismael Ben 178
 Fogel, Jessica M. 1002
 Foldi, Julia 800
 Folkvord, Joy 63
 Fomundam, Henry 1007, 1019
 Fonjuno, Peter 993
 Fonseca, Luiz Augusto. 388
 Forberg, Kenn 583
 Force, Luis 535, 651
 Ford, Christopher 176
 Forgione, Lisa A. 903
 Forlanini, Federica 804
 Fortuny, Rosa 382
 Foster, Antonina 684
 Foucat, Emile 630
 Fourati, Slim 60
 Fowler, Mary Glenn 776, 777
 Fox, Julie 324
 Fox, Matthew 459, 917, 1020, 1021, 1050
 Frampton, Dan 193
 France, Anne Marie 187, 188, 845LB
 France, John 788
 Franceschi, Claudio 672
 Francis, Kate 831
 Franco, Sandra 541
 Frange, Pierre 775, 812
 Frank, Daniel N. 211
 Frank, Simone C. 814
 Frankel, Matthew 583
 Franklin, Donald 74, 201, 392, 393
 Franks, Julie 853
 Frantzell, Arne 563
 Fraser, Nicole 1046
 Frater, John 261, 301, 324
 Fredo, Carol 435
 Freed, Eric O. 156, 158, 180, 507
 Freedberg, Kenneth 116, 456, 476, 814, 1028, 1043
 Freeman, Michael L. 276
 Freeman, Zachary 253
 Freiberg, Matthew 127, 574, 626, 667, 673, 702
 Freiman, J. Morgan 709
 Freitas, Marcelo 1040
 French, Audrey 341, 526, 921
 Frenkel, Lisa 224, 304, 490, 494
 Frías, Mario 532, 573
 Fried, Michael 522
 Friedman, Samuel R. 849
 Frieson, Krystal 839
 Fromentin, Rémi 288, 293
 Frongillo, Edward A. 690, 913
 Fronza, Raffaele 302
 Frost, Eric H. 522
 Fuchs, Dietmar 340, 383, 389
 Fuchs, James R. 16, 157
 Fuhrman, Jill 510, 577
 Fujii, Ken 180
 Fulcher, Jennifer A. 500LB
 Funderburg, Nicholas 618
 Furtado, Carolina 218
 Fusco, Gregory 664
 Fusco, Jennifer 664
 Fux, Christoph A. 653
 Fwamba, Franck 522

-G-

- Gabaitiri, Lesego 988
 Gabillard, Delphine 78, 476
 Gabler, Karyn 840, 929
 Gachuhi, Averie B. 1049LB, 637
 Gadawski, Izabelle 590
 Gaddis, Nathan C. 237LB
 Gadisa, Tsigereda 706
 Gaines, Tommi O. 844
 Gale, Michael 260LB
 Galicier, Lionel 323, 603
 Galindo, Maria J. 139
 Gall, Astrid 272
 Galli, Laura 460
 Galli, Massimo 303, 410, 411
 Gallien, Sébastien 448
 Galvez Celada, Cristina 306
 Gama, Cynthia 857
 Gamble, Theresa 1045
 Gandhi, Monica 277, 281, 974, 976, 978
 Gandhi, Neel R. 77
 Gandhi, Rajesh T. 277, 279, 280
 Ganesan, Anuradha 358, 668, 865, 932
 Gange, Stephen J. 130, 619, 646, 662, 933
 Ganoza, Carmela 446
 Ganser, Martha 592
 Ganser-Pornillos, Barbie K. 95
 Gantner, Pierre 495
 Ganz, Peter 126, 625
 Gaolathe, Tendani 885, 988
 Garcia, Erin I. 172
 García, Federico 566
 Garcia, Felipe 336, 614
 García-Deltoro, Miguel 538, 566, 570
 Garcia-Lerma, Gerardo 84, 209, 954
 García-Morales, Claudia 182, 480
 Gardner, Lytt 32
 Garfein, Richard S. 134, 870
 Garland, Wendy Hayward. 1014
 Garner, William 427
 Garnett, Geoff P. 1039
 Garrison, Louis 494, 1045
 Garske, Lindsay 967
 Garza, Rolando 376
 Gascón, Maria Rita Polo. 388
 Gaseitsiwe, Simani 184, 484, 774
 Gaspar, Gabriel 534
 Gastonguay, Marc 384
 Gatechompol, Sivaporn 698
 Gatell, Jose Maria. 336, 614
 Gates, Thomas 351, 398
 Gathogo, Esther 688
 Gatto, Greg 420
 Gaudieri, Silvana 229
 Gaul, Zaneta 839
 Gaur, Aditya 424
 Gaur, Ritu 507
 Gavegnano, Christina 829
 Gay, Cynthia L. 189, 406, 477
 Gaziano, Thomas 639
 Gazzard, Brian 382
 Gazzola, Lidia 680
 Geary, Rebecca 1038
 Gebo, Kelly 130, 662
 Geboy, Alexander 517, 543, 545
 Geffner, Mitchell 780
 Geisenberger, Otto 788
 Geit, Maria 631
 Gelderblom, Huub C. 1022
 Geldsetzer, Pascal 475, 916, 991, 994
 Gelezianas, Romas 309, 338LB
 Gelman, Benjamin B. 68, 375
 Gelman, Rebecca 789
 Genberg, Becky L. 908, 999
 Gendelman, Howard E. 219, 439
 Geng, Elvin 995, 1000, 1004, 1005
 George, Jomy M. 409, 409a
 George, Kathleen 806
 George, Varghese 234, 258
 Gerard, Laurence 323, 603
 Geretti, Anna Maria 370, 549
 German, Danielle 888, 904, 918
 Gerschenson, Mariana 691
 Gerstenhaber, Rodd 998
 Gervasoni, Cristina 396, 410, 411
 Gessain, Antoine 190
 Getz, Rachel 325
 Ghanem, Abdelhamid 864
 Ghannoum, Mahmoud 213
 Ghisetti, Valeria 379
 Ghova, Margaret 786
 Giacobbi, Nicholas Scott. 501
 Giacomelli, Andrea 411
 Giacomet, Vania 804
 Gianella, Sara 166, 206, 211, 240, 241, 367, 390
 Giardiello, Marco 39
 Gibb, Diana 117, 808
 Gibert, Cynthia L. 606, 930
 Gichuru, Evans 856
 Giddy, Janet 791
 Gift, Thomas 1034
 Gil-Martin, Ángela 534
 Gilada, Trupti Ishwar. 446
 Gilbert, Mark 735
 Gilbert, Peter 415
 Giles, Michelle 670
 Gilkeson, Robert 628
 Gill, Alexander J. 68, 375, 376, 827, 828
 Gill, John 662, 866
 Gill, Surinder P. 62LB
 Gillespie, Scott 839
 Gilmore, Hailey 111
 Gilmour, Jill 202
 Gingelmaier, Andrea 754
 Gingich, David 414
 Ginsberg, Mindy S. 928
 Girard, Pierre-Marie 44LB, 487, 703
 Girardi, Enrico 466, 734
 Giron, Leila Bertoni. 797
 Gisslén, Magnus 72, 73, 340, 364, 383, 389, 391, 431
 Givisiez, Juliana Machado. 1040
 Glancey, Margaret 668
 Glashoff, Richard 795, 824
 Glick, Sara Nelson. 846, 873, 973
 Glidden, David 1005
 Glover, Tynisha 269
 Gnanashanmugam, Devasena 776
 Gnatienco, Natalia 673
 Gocke, Christopher 318
 Godfrey, Catherine 699
 Godin, Ophélie 75
 Goedhals, Dominique 261
 Goepel, Siri 738
 Goercke, Irene 740
 Goetz, Breanna J. 951
 Goetz, Matthew Bidwell. 127, 257, 606, 626, 658
 Goggins, Kathryn 912
 Goh, Shih Lin 18
 Goings, Samuel 845LB

- Goldberg, David 185
 Golden, Matthew R. 56, 89, 851, 873, 964, 973, 979, 1032
 Goldhaber-Fiebert, Jeremy D. 725
 Goldstein, Harris 269, 328
 Goldstein, Michael 1048
 Golovin, Sergey 569
 Golub, Elizabeth T. 132, 237LB, 341, 514, 629, 632
 Golub, Jonathan 657
 Golub, Sarit A. 965
 Gomez-Olive, Xavier 639, 916, 991
 Gonzalez-Baeza, Alicia 400
 González-García, Juan 533, 534, 572, 697
 González-Mena, Alicia 681
 Gonzalez-Perez, Maria Paz 365
 Gonzalez-Serna, Alejandro 590
 González-Tomé, María Isabel 527
 Gonzalez-Zuniga, Patricia 844
 Gonzalo-Gil, Elena 236
 Goodall, Ruth 815
 Goodreau, Steven M. 1024, 1033, 1034
 Gopal, Satish 602
 Gorantla, Santhi 219, 588
 Gordon, Catherine 685LB
 Gordon, Kelley C. 951
 Gordon, Lori A. 409
 Gordon, Peter 546
 Gordon, Shanlea 939
 Gorelick, Rob 281, 287, 297
 Gorgens, Marelize 1046
 Gori, Andrea 222
 Gorin, Aleksandr 268
 Gorman, Daniel 337
 Gosalbes, María José 802
 Gosselin, Annie 204
 Gott, Chloe 351
 Gottardo, Raphael 265LB
 Gottlieb, Geoffrey 440, 508, 642
 Gotuzzo, Eduardo 719
 Gouaux, Ben 367
 Goujard, Cécile 278
 Goulder, Philip J.R. 272, 799
 Gouzil, Julie 190
 Goyal, Rajat 245
 Grabowski, Kate 880, 996, 1015
 Grabowski, Mary K. 34LB
 Graham, Barney S. 59, 760
 Graham, Christine 739
 Graham, Susan M. 856, 893, 1022
 Granados, Rafael 570
 Grant, Igor 74, 390
 Grant, Robert M. 955
 Grattoni, Alessandro 422LB
 Gravel, Catherine 785
 Graves, Chanda 839
 Gray, Glenda 857, 1036
 Gray, Richard 1046
 Gray, Ronald H. 1015, 34LB, 359, 87, 880, 996
 Greathead, Louise 275
 Grebe, Eduard 511, 876
 Grech, Christine 61
 Green, Richard 260LB
 Greenberg, Alan 872, 909
 Greenblatt, Ruth 237LB, 632, 646, 933
 Greene, Sharon A. 22
 Greene, Stephen A. 406
 Greene, Warner C. 312
 Gregson, John 485
 Gregson, Simon 1031
 Greiner, Jared 616
 Gres, Anna 18
 Greupink, Rick 753
 Griffith, Sam 1010, 1011
 Grignon, Jessica 111
 Grimwood, Ashraf 763
 Grinspoon, Steven K. 627, 635LB
 Grinsztejn, Beatriz 149, 447, 714, 948, 1002
 Grobbee, Diederick 113, 656
 Grobler, Jay 435, 440
 Gross, Robert 384, 868LB
 Grube, Christina 521
 Grudé, Maxime 278, 349
 Grund, Birgit 608, 623
 Grund, Jonathan 982, 986
 Grunenberg, Nicole 415
 Grunfeld, Carl 526
 Gu, Diane 729
 Guaraldi, Giovanni 532, 655
 Guardiola, Josep Maria. 535
 Guatelli, John 310
 Guehi, Calixte 78
 Guelar, Ana 681
 Guerra, Germano 585
 Güerri-Fernández, Robert 681
 Guha, Anika 401
 Gulick, Roy M. 473, 981
 Gulminetti, Roberto 542LB
 Günthard, Huldrych F. 66, 67, 191, 263, 327, 521
 Guo, Jia 248
 Guo, Yuelong 237LB
 Gupta, Amita 648, 710, 717, 720, 728
 Gupta, Kushol 171LB
 Gupta, Ravindra K. 146, 485
 Gupta, Samir 683
 Gupte, Akshay 657
 Gupte, Nikhil 648
 Gussio, Maria 542LB
 Gustafson, Deborah 132, 350
 Gutbrod, Klemens 362
 Gutiérrez, Félix 647
 Gutierrez, Jose 346
 Gutkind, Sarah 547
 Guy, Rebecca J. 57
 Guyer, William D. 568LB
 Guzman, Monica 756
 Guzzo, Christina 64LB
- H—
 Ha, Hien Thuc Ai. 747
 Haaland, Richard 943
 Haas, Andreas 782
 Haas, Bernhard 453, 631
 Habckost Dutra de Barros, Clarissa 1040
 Haberer, Jessica E. 675, 838, 920, 976
 Haberl, Annette Elisabeth. 738
 Haberlen, Sabina 624, 632, 645, 931
 Habib, Jakob 1056LB
 Hachiya, Atsuko 496
 Hackett, John 583
 Hader, Shannon L. 58
 Haddad, Lisa B. 942, 943, 946
 Haddox, Hugh 243
 Hadigan, Colleen 409, 409a, 525, 649
 Haeri Mazanderani, Ahmad 794
 Hafeez, Maria 517
 Hafner, Richard 79
 Hagberg, Lars 340, 383, 389, 391
 Hager, Cindy 230
 Hagins, Debbie 443

- Hahn, Beatrice H. 181LB
Hahn, Judith 709
Hakim, Avi 914
Hakim, James G. 11, 1002
Hale, Malika 335
Hall, Irene 30, 31, 478, 851, 899
Hall, Jake 511
Hallett, Timothy B. 115, 129, 1036, 1038, 1039, 1040
Hallett, Travis R. 627
Halvas, Elias K. 120
Hamers, Raph L. 467, 488
Hamilton, Deven T. 984, 1033
Hammarlund, Gustaf Olof. 340
Hammer, Hali 974
Hammer, John 678
Hammoud, Dima A. 238
Hampel, Benjamin Hans. 521
Hamscher, Maria 334
Hamunime, Ndapewa 35
Hamzah, Lisa 650
Han, Xiaoyan 384
Hanan, Nathan 810
Hanash, Samir 661
Hancock, Dana B. 237LB
Hancock, Gemma 271
Handley, Scott 213
Hanes, Justin 210
Haneuze, Sebastian 463
Hanh, Doan Thi Hong. 83
Hanke, Tomas 119LB
Hanna, David B. 1016, 632, 636LB, 928
Hanna, Debra 723LB
Hanna, George 45LB
Hannah, Stacey 2
Hanson, Debra 878
Hantuba, Cardinal 995
Harada, Shigeyoshi 247
Harb, Socorro Michel. 446
Harbers, Veroniek 429
Hardiman, Gary 586
Hare, Jonathan 202
Hargreaves, James R. 4
Harkoo, Ishana 88
Harling, Guy 639, 916, 983
Harrigan, P. Richard 590, 848, 1042
Harrington, Bryna 686
Harris, Bob 685LB
Harris, Kathryn 801
Harris, Kendra 724LB
Harrison, Laura C. 972
Harrison, Linda J. 457, 584LB
Harrison, Thomas S. 82
Hart, Clyde 943
Hart, Rachel 663, 864
Hartman, Christine 539
Hartogensis, Wendy 170, 288
Hassan, Amin S. 202
Hassan, Jaythoon 513
Hasson, Hamid 531
Hassounah, Said 498
Hasty, Alyssa 230
Hatano, Hiroyu 407
Hataye, Jason M. 165
Hate, Vibhuti 1025
Hatleberg, Camilla Ingrid 131, 346
Hattori, Shinichiro 503
Hatzioannou, Theodora 220
Hatzold, Karin 895, 896, 1030
Haubrich, Richard 568LB
Haukoos, Jason 956
Haumba, Samson 708
Häussinger, Dieter 161
Havenar-Daughton, Colin 264
Havens, Joshua 408, 963
Havens, Peter Lucas. 685LB
Havli, Diane V. 33, 36, 312, 638, 726, 768, 797, 832, 836, 858, 860, 1005, 1051
Havranek, Edward 528
Hawes, Stephen E. 642
Hawken, Mark 1023
Hawkins, David 418
Haworth, Kevin G. 322
Hayashi, Hironori 503
Hayashi, Kanna 590
Hayes, Richard 1010, 1011, 1048, 834, 841LB, 959
Hayford, Christina Sage. 942
Haynes, Barton F. 1057LB
Hayot, Maurice 654
Hayward, Katy 428
Hazen, Stanley 625
Hazra, Rohan 649, 757, 806
Hazuda, Daria 311, 435
Heagerty, Patrick J. 921
Healy, Micheal 817LB
Hearps, Anna 611
Heaton, Robert K. 74, 201, 353, 377, 390, 392, 393
Hecht, Frederick M. 170
Heckman, Barbara 803
Hector, Jonas 581
Heera, Jayvant 417
Heffron, Renee 85, 920, 934, 947, 1003
Heide - Mulder, Marieke van der. 587
Hella, Jerry 721
Heller, Theo 525
Hellmuth, Joanna 339, 344, 394
Hemphill, Linda C. 640
Hendrickson, Cheryl Jane. 1021
Hendrix, Craig 86LB, 976
Hendrix, Jelle 155
Henegar, Cassidy 664
Heneine, Walid 84, 478, 954
Hennequin, William 116
Henry, Amy R. 61
Henry, Keith 474, 597
Hensley-McBain, Tiffany 216, 231
Herasimtschuk, Anna 275
Herdman, Bruce 911
Heresi, Gloria P. 425
Herlihy, Therese 613
Hermann, David 723LB
Hermans, Lucas Etienne. 113
Hermans, Sabine 727
Hermansson, Linn 383
Hernandez, Adriane 755
Hernandez, Angela L. 187, 478
Hernandez-Diaz, Sonia 779
Hernández-Novoa, Beatriz 595
Hernandez-Ramirez, Raul Ulises 600
Herrmann, Eva 738
Hesselgesser, Joseph 309, 313, 338LB
Hesseling, Anneke 728
Hessol, Nancy A. 910
Heyderman, Rob 641
Hicks, Katherine A. 1029
Hiener, Bonnie 293, 305
Hierro, Loreto 527
Higgs, Chris 416
Highbarger, Helene 368
Hijlkema, Simone Hélène. 604

- Hikichi, Yuta 247
 Hilderbrand, Katherine 990
 Hileman, Corri Lynn O. 617, 628
 Hill, Alison 178, 338LB
 Hill, Andrew 569
 Hill, Julia 927
 Hill, Shawn 297
 Hilley, Amy 965
 Hillier, Sharon L. 86LB, 945
 Hiransuthikul, Akarin 863
 Hirasen, Kamban 459
 Hirozawa, Anne 974
 Hirsch-Moverman, Yael 706
 Hirt, Deborah 811
 Hleyhel, Mira 775
 Hlupeni, Admire 345, 743
 Ho, Anh Thi Van. 741
 Ho, Emily 347
 Ho, Ya-Chi 122, 295, 296
 Hoang, Thuy 210
 Hobbins, Michael A. 581
 Hodcroft, Emma B. 1026
 Hodder, Sally 443
 Hoddinott, Graeme 834
 Hoelscher, Michael 788
 Hoenigl, Martin 183, 977
 Hoepelman, Andy 731
 Hof, Malon Van den. 830
 Hofer, Cristina Barroso. 782
 Hoffman, Heather 909
 Hoffman, Risa M. 772, 779
 Hoffmann, Chris 657
 Hoffmann, Udo 627, 635LB
 Hofkens, Johan 155
 Hofstra, Laura Marije 113, 504LB
 Hogan, Joseph 908
 Hogan, Michael J. 1057LB
 Hogewoning, Arjan 519, 887
 Hogg, Evelyn 79
 Hogg, Robert S. 599, 601, 929, 966, 1042
 Holding, Penny 784
 Hollabaugh, Kimberly M. 404
 Holmes, Charles B. 995, 1000, 1004
 Holstad, Marica McDonnell. 361
 Holte, Sarah 749
 Holtz, Timothy H. 854, 855
 Hölzemer, Angélique 176
 Holzendorf, Volker 633
 Holzmayer, Vera 510, 522
 Homar, Francesc 651
 Hong, Ting 934, 947
 Hontanon, Victor 400
 Hood, Julia 846, 973
 Hoofnagle, Andrew 645
 Hook, Edward 867
 Hoornenborg, Elske 519, 887, 953
 Hoos, David 114LB
 Hoos, David 1023
 Hoots, Brooke 871
 Hoover, Donald R. 361, 928
 Hoover, Karen W. 980, 1034
 Hope, Michael J. 1057LB
 Hope, Thomas 15, 231
 Hopkins, Emily 956
 Hopkins, Emily 324
 Hopkins, Mark 549
 Horacek, Joshua 196
 Horberg, Micheal A. 130, 619, 840
 Horner, Marie-Joséphé 602
 Horng, Howard 277, 978
 Horsburgh, Bethany A. 293
 Horsburgh, C. Robert 709
 Hosseinipour, Mina C. 686, 710, 717, 720, 783, 946
 Houghton-Price, Vicky 569
 Howard, Andrea 706
 Howell, Bonnie J. 326
 Howell, Pauline 80LB
 Hower, Martin 633
 Hoy, Jennifer 670, 687
 Hoyte, Ashley Christopher. 157
 Hsia, Yang 21
 Hsiao, Nei-Yuan M. 767, 769, 771, 989, 992
 Hsieh, Szu-Min 582
 Hsu, Denise C. 70, 733
 Hsu, Hilary K. 592, 593
 Hsu, Jeffrey 669
 Hsu, Joanne 1013
 Hsu, Katherine K. 833
 Hsu, Ling 906, 910
 Hsu, Ricky 664
 Hsue, Priscilla 126, 414, 625
 Hsueh, Yu-Mei 594
 Hu, Jianfei 60, 61
 Hu, Ming 422LB
 Hu, Shiu-Lok 321, 322
 Hu, Wei-Shau 17, 164, 173, 334
 Hu, Xiaohong 851
 Hu, Y. Eric. 329
 Hu, Yinghuan 399
 Hua, Simin 636LB
 Huang, Eugene 353
 Huang, Mingshu 456, 476
 Huang, Mingxiong 403
 Huang, Robin 670
 Huang, Suzhan 122
 Huang, Wei 84, 140, 563
 Huang, Ya-Lin A. 980
 Huang, Yunda 415
 Hubbard, Johnathan 905
 Hubbard, Mark 2
 Hudelson, Sarah E. 492, 955
 Hue, Sophie 630
 Hue, Stéphane 186, 195, 520
 Huefner, Anja 703
 Hueppe, Dietrich 567
 Hughes, Alison 922
 Hughes, Jennifer 718
 Hughes, Michael D. 404, 457, 710, 728, 790
 Hughes, Stephen H. 298
 Huh, David 921
 Huik, Kristi 461
 Huleux, Thomas 135, 550, 732
 Hulgán, Todd 229, 377, 392, 393, 691
 Hull, Mark 599, 601, 929, 966
 Hullsiek, Katherine 744
 Hultquist, Judd F. 6
 Humbert, Ludovic 681
 Humphrey, Jean 786
 Hundley, Lee 914
 Hung, Chien-Ching 44LB, 582
 Hung, Magdeleine 329
 Hunt, Peter W. 407, 625, 675
 Hunter, Eric 200
 Huo, Yanling 779, 810
 Huppler Hullsiek, Kathy 368, 746
 Hur, Sophia 126
 Hurst, Jacob 301
 Hurst, Stacey 946
 Husnik, Marla J. 951

Hussein, Mustafa 842
Hussen, Sophia A. 839
Hutchinson, Angela B. 1029
Hütter, Gero 320
Hwang, Carey 45LB
Hwang, Young 171LB
Hyle, Emily P. 493, 1043

—I—

Iannotti, Nathalie 680
Iannuzzi, Francesca 357
Ibarra, Sofia 538
Ibrahim, Fauz 893
Ibrahim, Maryanne Rose. 774, 789, 790
Ichikawa, David 64LB
Ido, Yoko 496
Ignacio, Caroline 300
Igoe, Derval 513
Ikediobi, Uchenna 236
Imami, Nesrina 275
Imamichi, Hiromi 159, 371
Imamura, Junji 496
Imaz, Arkaitz 382
Imp, Brandon M. 341
Imperial, Marjorie 723LB
Imperiale, Daniele 360, 379
Indravudh, Pitchaya 895, 896
Ingemi, Molly 557
Ingiliz, Patrick 551, 567, 576, 703
Innes, Steve 823, 824
Intasan, Jintana 270
Invernizzi, Alessandro 396
Inwoley, André 78
Inzaule, Seth 488
Iodice, Valentina 537
Iribarren, Jose A. 647
Irlbeck, David 123
Irrinki, Alivelu 118
Irungu, Elizabeth 920
Isaacs, Abby 415
Isaacs, Shahieda 28
Iscache, Anne Laure 223
Ishai, Amorina Eliana. 126
Ismail, Nazir 77
Ita, Sergio 178
Itindi, Janet 970
Iudicello, Jennifer 353
Ivanauskas, Emma N. 157
Ivy, Wade 852
Iwamoto, Marian 412, 430
Iwatani, Yasumasa 496
Iwuji, Collins Chika. 43, 491, 1018
Iyer, Shilpa S. 181LB
Izopet, Jacques 223

—J—

Jabbari, Shahab 599
Jackson, Akil 39
Jackson, Celia 185
Jackson, Debra 763
Jackson, Elise 274
Jacobson, Denise 25, 805
Jacobson, Evin 1029
Jacobson, Karen 709
Jacobson, Lisa 356, 624, 645, 931
Jacobson, Mark 213
Jagodzinski, Linda 363
Jain, Priya 422LB
Jain, Sonia 870, 977
Jain, Vivek 1051
Jaison, Tara 308
Jalbert, Emilie 257

Jamaloodien, Khadija 1020
James, Catherine 974
Jamin, Augusta V. 157
Jamison, Dean 1053
Janetopoulos, Christopher J. 308
Jang, Karen S. 506
Jani, Conred 834
Jani, Ilesh 26, 110
Janjua, Naveed Zafar. 524, 735
Janse van Rensburg, Anita 28
Jansson, Marianne 37
Jantarabenjakul, Watsamon 759, 807
Janulis, Patrick 843
Jao, Jennifer 780
Jaoko, Walter 937
Jaquet, Antoine 607
Jara, Paloma 527
Jarrin, Inma 534
Jarvis, Joseph N. 82, 740, 745, 988, 993, 1008, 1017
Jaworowski, Anthony 611
Jayathilake, Karu 719
Jean Juste, Marc Antoine 471
Jefferys, Greg 569
Jefferys, Laura 581
Jeffrey, Jerry 171LB
Jen, I-An 348
Jenkin, Alison 432
Jenkins, Cathy 719, 816
Jenness, Samuel 1024, 1033, 1034
Jerome, Keith 321
Jia, Hongwei 509
Jia, Peilin 74
Jiamsakul, Awachana 705
Jiang, Li 246
Jiang, Shuping 443
Jibril, Haruna 787
Jiménez, Miguel 566
Jiménez-Hernández, Nuria 802
Jimenez-Sousa, María Ángeles. 530
Jin, Chengshi 978
Jin, Haolun 497
Jinarat, Varunee 793
Jōgeda, Ene-Ly 461
John, Mathius 686
John-Stewart, Grace 22, 761, 765, 796, 970
Johns, Brian A. 252
Johnson, Anna Satcher. 30, 851, 899
Johnson, Cheryl 895, 896, 1030, 1031
Johnson, Eric Otto. 237LB
Johnson, Erica L. 829
Johnson, Jeffrey A. 189, 370, 477, 478
Johnson, Leah 420
Johnson, R. Paul 62LB
Johnson, Rachel 1013
Johnson, Welkin E. 178
Johnston, James 735
Johnston, Liz 700
Johnston, Rowena 281
Joloba, Moses L. 712
Joly, Veronique 458, 732
Jonas, Anna 35
Jones, Bradley Robert. 196, 561
Jones, Deborah 770
Jones, Jennifer 328
Jones, Mathew Lee. 301
Jones, Nicolette 923
Jones, R. Brad 122, 296
Jones, Rachael 650
Jones, Rena R. 905
Jones, Sara 227, 297, 649

Jones, Simon 398
 Jooste, Pieter 799
 Jordan, Michael 112
 Jordan, Parris S. 200
 Jordan, Wilbert 589
 Jordan-Sciutto, Kelly L. 74, 378
 Jose, Sophie 650
 Joseph, Sarah Beth 73, 364
 Joshi, Kedar 705
 Joseph, Bernadette 835
 Joste, Nancy 593
 Jourdain, Gonzague 584LB
 Joy, Jeffrey 196, 561, 848
 Joya, Christie 932
 Judd, Ali 831
 Juge, Lauriane 398
 Julma, Pierrot 722
 Jumbe, Allan 686
 June, Carl H. 13
 Jupimai, Thidarat 285
 Justice, Amy 127, 257, 619, 626, 658, 662, 667, 702, 930
 Justman, Jessica E. 1023, 114LB, 421LB, 950

—K—

Kabami, Jane 860
 Kabongo, Cila 958
 Kabran, Mathieu 78
 Kabudula, Chodziwadziwa 991
 Kabwigu, Samuel 88
 Kadelka, Claus 66, 67, 191
 Kadima, Etienne 885
 Kahl, Lesley 44LB
 Kahn, James 33
 Kahn, Kathleen 916, 991
 Kaida, Angela 599, 924, 925, 926, 940
 Kaimal, Arvind 1001
 Kaiser, Philipp 312
 Kaiser, Rolf 183
 Kajoka, Deborah 950
 Kakkar, Fatima 785
 Kakooza, Francis 742
 Kalams, Spyros 229, 230
 Kalayjian, Robert 665
 Kaleebu, Pontiano 193, 462
 Kalinjuma, Aneth 744
 Kallas, Esper Georges. 948
 Kallas, Eveli 461
 Kallianpur, Asha R. 74, 377, 392, 393
 Kallianpur, Kalpana Juliet. 381, 385, 387, 395, 612
 Kalmin, Mariah M. 909
 Kalton, Graham 114LB
 Kalua, Thokozani 895, 896
 Kaluba-Milimo, D 711
 Kaluzhenina, Anna 734
 Kamacooko, Onesmus 915
 Kamal, Susan 671
 Kamali, Anatoli 976
 Kamata, Masakazu 332
 Kammerer, Betsy 784, 787
 Kamng'ona, Raphael 641
 Kampiire, Leatitia 1005
 Kamthunzi, Portia 826
 Kanya, Moses R. 33, 36, 638, 768, 797, 832, 836, 858, 860, 1005, 1051
 Kane, Melissa 160LB
 Kang, Minhee 568LB
 Kanjanavanit, Suparat 820
 Kankasa, Chipepo 781
 Kanke, Matt 123
 Kann, Gerrit 738
 Kantor, Amy 414
 Kantor, Elie 812
 Kantor, Rami 492
 Kapetanovic, Suad 810
 Kapito-Tembo, Atupele Patience. 783
 Kaplan, Jonathan 741
 Kaplan, Justin Allan. 507
 Kaplan, Robert C. 629, 632, 636LB
 Kaplan, Samantha 990
 Kapogiannis, Bill 685LB
 Kappes, John C. 328
 Kaptue, Lazare 577
 Karajeane, Esmeralda 730, 766
 Karalius, Brad 805
 Karandish, Sara 122
 Karn, Jonathan 281
 Karris, Maile 824
 Kasai, Daisuke 426
 Kasaro, Margaret Phiri. 919
 Kasembeli, Alex 481
 Kashuba, Angela 406, 407, 949
 Kasonde, Michael 1008
 Kasprzyk, Danuta 984
 Kassanjee, Reshma 876
 Kassay, Seble 634
 Kassaye, Seble 23, 646, 933
 Kasteren, Marjo 137LB
 Katabira, Elly T. 934, 1003
 Katana, Abraham 761, 970
 Kates, Jennifer 1012
 Katlama, Christine 278, 458, 520, 683
 Kato, Darryl 433
 Katoro, Joel 914
 Katuramu, Richard 1005
 Katusiime, Mary Grace K. 28, 120, 795
 Katz, David A. 89, 846, 898, 901
 Katzenstein, David 506
 Kaufmann, Daniel E. 46, 264
 Kaufmann, Stefan 716LB
 Kaul, Rupert 87
 Kaur, Harpreet 377
 Kaur, Jasmine 118
 Kavanagh, Eoin 679
 Kaye, Steve 324
 Kayombo, Asungushe 950
 Kazaura, Kokuhumbya 950
 Kazempour, Kazem 437
 Keango, Robert 1006
 Kearney, Brian P. 40, 427
 Kearney, Mary F. 47, 120, 294, 298
 Kearns, Rachel Ann. 1033
 Keating, Sheila 170, 279, 284, 511, 876
 Keele, Brandon 294, 322, 368
 Kehrl, John 64LB
 Keiser, Olivia 596, 782
 Keke, Rene 487
 Kelesidis, Theodoros 611, 613
 Kellam, Paul 272
 Kelleher, Peter 248, 275
 Kelley, Colleen F. 90
 Kellogg, Anela 409, 409a
 Kelly, Christine 641
 Kelly, Karina 504LB
 Kennedy, Arion 230
 Kennedy, V. Logan 940
 Kennedy, Patrick 96
 Kenny, Julia 801
 Kerani, Roxanne Pieper. 851
 Kerr, Stephen J. 444, 698
 Kervevan, Jérôme 262

- Keshavarzian, Ali 240, 241
 Keshinro, Babajide Keshinro 355, 481
 Keuter, Monique 610
 KewalRamani, Vineet 18
 Khaitan, Alka 800
 Khaketla, Molihi 966
 Khakhina, Svetlana 308
 Khalil, George 954
 Khalilieh, Sauzanne 412, 430
 Khamadi, Samoel 481
 Khan, Junaid 927
 Khan, Nealia 885
 Khan, Sadiya S. 622
 Khan, Shaukat 475, 994
 Khanna, Aditya 849
 Khanyile, Nompumelelo 958
 Kharfen, Michael 872
 Khoo, Saye 370, 416, 418, 641
 Khosropour, Christine M. 964, 979
 Khoury, Gabriela 288
 Khwairakpam, Giten 569
 Kiani, Zahra 274
 Kibiy, Angela 221, 238
 Kibuuka, Hannah 197, 481
 Kiem, Hans-Peter 321, 322, 332
 Kiertiburanakul, Sasisopin 705, 714
 Kigozi, Godfrey 34LB, 87
 Kijak, Gustavo 71
 Kilberg, Max 800
 Kilembe, William 200
 Kilonzo, Nduku 1025
 Kim, Dhohyung 250
 Kim, Joon W. 658
 Kim, Peggy 312
 Kimata, Jason T. 422LB
 Kimhofer, Torben 567
 Kincer, Laura P. 73, 364
 Kindandi, Kikanda 708
 King, Maximilian 1044
 King, Neil P. 21
 Kingsley, Lawrence 645, 701
 Kinh, Nguyen Van. 83
 Kinloch-de Loes, Sabine 302
 Kintu, Kenneth 935
 Kinuthia, John 761, 765, 937, 970
 Kiptinness, Catherine 22, 490
 Kiragga, Agnes 742, 837
 Kiragu, Michael K. 1025, 1037
 Kirk, Gregory D. 133, 244, 661
 Kirk, Gregory 395
 Kirk, Ole 128LB, 653
 Kirkegaard-Klitbo, Ditte Marie. 235
 Kirmse, Brian 780
 Kirtane, Ameya 1035
 Kiser, Jennifer J. 404, 405, 419
 Kisia, Cristine 985
 Kitahata, Mari 130, 347, 619
 Kitch, Douglas 251
 Kitchen, Scott G. 254, 331, 332, 333
 Kityo, Cissy 443, 467, 801
 Kiweewa, Francis 355
 Klase, Zachary A. 308
 Klatt, Nichole 216, 231, 260LB, 321
 Klein, Daniel J. 1025, 1037
 Klein, Daniel B. 130
 Klein, Liore 1055LB
 Klein, Marina 553
 Klein, Nigel 641, 801
 Klein, Pamela W. 1012
 Kleiner, David E. 525
 Klenerman, Paul 239, 261, 324
 Klepser, Donald 963
 Klimkait, Thomas 191
 Klingman, Karin 251, 772, 777
 Klipstein-Grobusch, Kerstin 656
 Knegt, Robert de. 587
 Knezevic, Andrea 353, 684
 Knobel, Hernando 681
 Kobe, Matthew 157
 Kober, Kord 514
 Koblin, Beryl A. 897
 Kobrak, Paul 898
 Koenig, Helen C. 975
 Koenig, Serena 722
 Koethe, John R. 230, 621, 644, 691
 Koga, Yasunori 643
 Kohgo, Satoru 503
 Kohlmeier, Alison Swaims. 209, 943
 Kohlmeier, Jacob E. 209
 Kohorn, Lindsay 255, 692
 Kojic, Erna M. 597
 Kok, Yik Lim 327
 Kolb, Kellie E. 250
 Kolber, Michael 978
 Koletar, Susan L. 665, 666
 Koller, Manuel 596
 Kolson, Dennis L. 68, 375, 376, 827, 828
 Kombo, Bernadette 893
 König, Renate 161
 Konikoff, Jacob 516, 879
 Konopnicki, Deborah 754
 Kootstra, Neeltje A. 672, 825, 830
 Kopp, Jeffrey 649
 Korleski, Jack 253
 Korologou-Linden, Roxanna Stephanie. 569
 Kosakovsky Pond, Sergei L. 200, 201, 1026
 Kosalarksa, Pope 285, 424, 425
 Kosloff, B. 711
 Kosloski, Matthew P. 413
 Koss, Catherine A. 768, 858, 978
 Kostman, Jay 326, 702
 Kottlil, Shyam 586
 Koullias, Yiannis 493
 Koup, Richard A. 1b, 165, 175, 330LB, 61
 Kourtis, Athena 946, 947
 Kouyos, Roger 66, 67, 191, 327, 521, 596
 Kovacs, Colin 122, 233
 Kovacs, Joseph A. 409a, 525
 Kovacsics, Colleen E. 68, 375
 Kowalczyk, Ula 437
 Kozhaya, Lina 800
 Kozirev, Oleg 452LB
 Kräusslich, Hans-Georg 93
 Krajden, Mel 735
 Krakora, Rebecca 525
 Krakower, Douglas 971
 Kramer, Jennifer R. 539
 Kranzer, Katharina 841LB
 Krarup, Astrid Raaby. 314
 Kraus, Jessica 1053
 Kravchenko, Alexey V. 452LB
 Krebs, Emanuel 875
 Krebs, Shelly J. 205, 282, 339, 344, 363, 387
 Kreitchmann, Regis 938
 Kreplak, Georges 520
 Krilich, Elizabeth 577
 Kripalani, Sunil 912
 Kripke, Katharine 1025, 1037
 Krishnan, Sonya 473
 Kroeze, Stefanie 467
 Kroidl, Arne 788
 Kronmann, Karl 865, 932

- Kroon, Eugene 124, 125, 270, 282, 291, 339, 387
- Krupitsky, Evgeny 673, 868LB
- Kruszka, Bridget 853
- Ku, Wen-Wei 705
- Kuball, Jürgen 320
- Kufa-Chakezha, Tendesayi 794
- Kuhn, Louise 27, 814, 819
- Kujawski, Stephanie 110
- Kukolj, George 118
- Kulkarni, Rima 443
- Kulkarni, Sonali P. 1014
- Kumar, Muniratnam S. 559, 883
- Kumar, Parag 409, 409a
- Kumar, Princy 449LB, 905
- Kumar, Sudeep 512
- Kumarasamy, Nagalingeswaran 456, 1002
- Kummer, Kim 873
- Kumwenda, Johnstone 710, 717, 720
- Kumwenda, Moses 895, 896
- Kuniholm, Mark H. 928
- Kunze, Ursula 362
- Kuo, Irene 853, 872
- Kuo, Kuei-Ling 438
- Kuo, Lillian 180
- Kuritzkes, Daniel R. 325, 790
- Kurland, Irwin J. 780
- Kuruc, Joann D. 298
- Kuruppu, Nishani 507
- Kusanthan, Thankian 919
- Kutluay, Sebla B. 16
- Kutscher, Eric 722
- Kvaratskhelia, Mamuka 94, 157, 16, 160LB
- Kvaratskhelia, Nina 525
- Kvist, Anders 37
- Kwariisima, Dalsone 638, 726, 858
- Kwariisima, Dalsone 33
- Kwaro, Daniel 488
- Kwena, Zachary Arochi. 762, 861
- Kwon, Douglas 232
- Kwon, Mi 306
- Kwong, Peter D. 14LB
- L-**
- La, David 179
- La Grange, Heleen 28
- La Rosa, Alberto M. 224, 457
- La Russa, Philip 817LB
- Laar, Thijs JW van de. 519
- Labbato, Danielle 822
- Laboune, Farida 60, 61
- Lacabarat, Christine 630
- Lachowsky, Nathan J. 966
- Lacombe-Duncan, Ashley A. 923, 924, 926
- Lada, Steven 240, 241, 300
- Laethem, Tine 412
- Laeyendecker, Oliver 244, 472, 515, 516, 518, 558, 879, 880, 881, 888, 904
- Laferriere, Valerie-Martel 553
- Lafia, Bernabé 487
- Lagarde, Maria 676
- Lage, Silvia 733
- Laguno, Montse 535
- Lahiri, Cecile Delille. 684
- Lahuerta, Maria 110
- Lai, Alessia 303
- Lai, Ming-Tain 435
- Lai, Rachel 739
- Lai, YingAn 438
- Lain, Maria 766
- Laird, Gregory 317
- Lake, Jordan E. 251, 356, 589, 696, 700
- Laker, Leana 799
- Lalama, Christina 279, 280, 325
- Lalezari, Jay 118, 126, 437
- Lallemant, Marc 29LB
- Lalley-Chareczko, Linden 975
- Lalor, Maeve K. 736
- Lam, Evan 178
- Lama, Javier R. 380, 446
- Lamarre, Valerie 785
- Lamb, Matthew R. 1049LB, 110
- Lambert, Caroline 190
- Lambert, John 613, 754
- Lambert, Sidonie 278, 487
- Lamers, Susanna 518
- Lamirel, Cédric 75
- Lammert, Sara 838
- Lamorde, Mohammed 423, 1001
- Lampiris, Harry 312
- Lancar, Rémi 441
- Lancki, Nicola 969
- Landau, Nathaniel R. 333
- Landay, Alan 211, 240, 241, 325, 342
- Landman, Roland 458
- Lando, Richard 728
- Landovitz, Raphael J. 500LB, 981
- Lane, H. Clifford 159, 371
- Lane, Sidney 234
- Lang, Karl Sebastian. 161
- Lang, Philipp A. 161
- Lang, Raynell 866
- Langat, Agnes 761, 796, 970
- Langat, Deborah 720
- Langat, Rither 355
- Lange, Camille 287, 368
- Langer, Robert 1035
- Langham, Freya 687
- Langkilde, Anne 235
- Lansdon, Eric 434
- Lapointe, Normand 785
- Larmarange, Joseph 1018
- Larsen, Anna 1007, 1019
- Lathouwers, Erkki 505
- Latini, Alessandra 445
- Latkin, Carl A. 5, 842, 904
- Lau, Bryan 908
- Laube, Catherine 987
- Laufs, Stephanie 302
- Laughton, Barbara 28, 120, 823, 824, 826
- Lauw, Fanny 137LB
- Law, Matthew 473, 653, 670, 693
- Lawler, Leo 613
- Lawlor, Sidney 944
- Lawson, Dana Quinn. 16
- Lazar, Jason 636LB
- Lazerwith, Scott E. 497
- Lazzarin, Adriano 460, 531, 683
- Le, Leah T. 72
- Le, Phong Thanh. 882
- Le, Thuy 83, 747, 748
- Le Champion, Armelle 785
- Le Chenadec, Jérôme 775
- Le Hingrat, Quentin 194
- Le Moing, Vincent 654
- Le Roux, Stanzi M. 24
- Leaf, David 667
- Leal, Lorna 336
- Learn, Gerald H. 181LB
- Lebelonyane, Refeletswe 1008, 1017
- LeBlanc, Roger P. 442
- Lechiile, Kwana 740

- Ledergerber, Bruno 631
 Lederman, Michael M. 225, 251, 276
 Ledgerwood, Julie 330LB, 415
 Lee, Eric 231
 Lee, Eunok 293
 Lee, Guinevere Q. 292, 495
 Lee, Ha Youn 514
 Lee, Hana 908
 Lee, Janice 29LB
 Lee, Jeanette 591
 Lee, Kelly K. 242
 Lee, KyeongEun 18
 Lee, Myung Hee 471
 Lee, Sarah 408
 Lee, Sulggi 407
 Lee, Susan Shin-Jung 438
 Lee, William 338LB
 Leeme, Tshepo Botho. 82, 740, 745
 Lefebvre, Eric 381
 Lefever, Steve 162
 Leff, Jared A. 547
 Lehman, Dara 796
 Lehmann, Clara 183, 580
 Leidner, Jean 502, 784, 787
 Leierer, Gisela 631
 Leigh Brown, Andrew 185, 186, 193, 1026
 Leipsic, Jonathon 655
 Leitman, Ellen M. 272
 Lejeune, Charlotte 475
 Lekwape, Nametso 82, 745
 Lelievre, Jean Daniel 441, 630
 LeMarec, Fabien 630
 Lemmens, Veerle 155
 Lemmer, Darrin 715LB
 Lemoine, Maud 703
 Lemos, Maria 897
 Lemsalu, Liis 1028
 Leng, Sean X. 133
 Lennox, Jeffrey J. 684
 Leon, Casey 557
 Leoz, Marie 192
 Leport, Catherine 278
 Lerma-Chipirraz, Elisabet 681
 LeRoith, Derek 780
 Leroy, Valeriane 811, 814
 Lescure, François-Xavier 75
 Lesosky, Maia 767, 989
 Lester, Richard T. 106, 964
 Leta, Valentina 396
 Letang, Emilio 744
 Letendre, Scott 74, 353, 358, 377, 386, 390, 392, 393
 Leung, Janice 655
 Levermore, Kandasi 923
 Levin, Myron 803
 Levine, Andrew 356
 Levine, Molly 490
 Levy, David N. 63
 Levy, Itzhak 226
 Levy, Yves 262, 441, 630
 Lewin, Sharon R. 125, 281, 288, 311
 Lewis, John 874
 Lewis, Mark G. 1057LB, 199
 Lewis, Stanley 438, 449LB
 Leyden, Wendy 598
 Leyes, María 659
 Leyre, Louise 124, 285, 291
 Leyten, Eliane 137LB
 Lhomme, Edouard 801
 Li, Danny 126
 Li, Guanhan 371
 Li, Jian 378
 Li, Jin-fen 189, 370, 477
 Li, Jonathan 325
 Li, Lingfeng 1049LB
 Li, Maoji 955
 Li, Peilin 312
 Li, Qingsheng 199, 326
 Li, Sam 207, 208
 Li, Shuying Sue. 421LB
 Li, Taisheng 399
 Li, Weizhe 588
 Li, Yanling 399
 Li, Yuan 337
 Li, Zhaoping 589
 Liang, Ben 179
 Liang, Richard 848
 Liao, Diana 589
 Liao, Mei-June 450LB
 Liberatore, Rachel A. 220
 Libert, Claude 672
 Liberty, Afaaf 29LB
 Libutti, Daniel 691
 Lichterfeld, Mathias 292, 319, 790
 Liebenberg, Lenine 949
 Liechti, Thomas 66, 67
 Liegler, Teri 170, 407, 832
 Lienhardt, Christian 723LB
 Lifson, Jeffrey D. 10, 281
 Ligabue, Guido 655
 Lija, Gissenge Jackson. 950
 Lim, Joseph 127, 702
 Lim, So-Yon 179, 338LB
 Lima, Viviane Dias. 875, 929, 1042
 Lin, Amy 364
 Lin, Angel 308
 Lin, Haiqun 598
 Lin, Hsi-Hsun 438
 Lin, Kuan-Yin 582
 Lin, Li 615
 Linas, Benjamin 547, 557, 709
 Lince-Deroche, Naomi 941
 Lindman, Jacob 37
 Lindsay, Joanne 601
 Lindsey, Jane 803
 Ling, John 40
 Link, John O. 38, 433
 Linley, Laurie 889, 890
 Lioznov, D 868LB
 Lipira, Lauren 921
 Lippman, Sheri A. 111
 Lisante, Antonella 232
 Lisco, Andrea 221, 226
 Lisinicchia, Joshua G. 68
 Lisovsky, Irene 274
 Little, Francesca 990
 Little, Susan J. 134, 206
 Litwin, Alain H. 544
 Liu, Albert Y. 419, 978
 Liu, Chenglong 514, 634
 Liu, Cindy M. 87
 Liu, Hongjie 918, 997
 Liu, Jingxia 972
 Liu, Jun 233
 Liu, Qingbo 14LB
 Liu, Wei 413
 Liu, Xiaohu 283
 Liu, Yang 164
 Liu, YaPei 683
 Livelli, Alessandro 360
 Llibre, Josep M. 44LB, 651
 Lloyd-Jones, Donald M. 622

- Lo, Janet 627
 Lo, Yi-Chun 582
 Lo Re, Vincent 127, 702
 Loarec, Anne 523
 Locatelli, Isabella 362
 Lockman, Shahin 25, 484, 502, 640, 774, 784, 787, 789, 1008, 1009
 Lofgren, Sarah 746
 Logie, Carmen H. 923, 924, 925, 926
 Loiseau, Claire 223
 Lombaard, Johan 45LB
 Lombardi, Francesca 445
 Londoño, Maria Carlota 540
 Long, Lawrence 459, 1050
 Longenecker, Chris T. 628, 674, 822
 Looby, Sara E. 627
 Loomba, Rohit 99
 López, Alondra 225
 Lopez, Miguel 228
 López-Bernaldo, Juan Carlos 336
 Lopez-Lopez, Pedro 573
 Loquiha, Osvaldo 26
 Lorenzini, Patrizia 354, 366
 Lorvick, Jennifer 853
 Losurdo, John 240, 241
 Lou, Yu 428
 Loutfy, Mona 756, 924, 925, 926, 940
 Love, Tanzy 514
 Lowrance, David W. 35
 Lozier, Jay 409
 Lozupone, Catherine 207, 208
 Lu, Michael T. 627, 635LB
 Lu, Xiang 593
 Luban, Jeremy 18
 Lucariello, Angela 585
 Lucas, Gregory M. 853, 883
 Lucera, Mark 169
 Lucero, Constanza 336
 Lucy, Debbie 897
 Luechai, Pikunchai 855
 Luetkemeyer, Annie 568LB
 Luisi, Nicole 90
 Luk, Ka-Cheung 577
 Lumpa, Mwansa 1004
 Lundgren, Jens D. 128LB, 131, 474, 653, 693
 Luo, Dajie 1054
 Luo, Donghan 505
 Luo, Ma 179
 Luong Nguyen, Liem Binh 116
 Lupo, David 943
 Luque, Marco 816
 Lusso, Paolo 14LB, 64LB
 Lutsar, Irja 461
 Lutz, Thomas 551, 567, 576
 Lyagoba, Frederick 193
 Lycett, Samantha 1026
 Lycke, Jan 383
 Lynch, Briana 881
 Lynen, Lutgarde 81LB
 Lynn, Shugene 450LB
 Lyons, Michael S. 956
 Lyss, Sheryl 741
 —M—
 Ma, Fangrui 199
 Ma, Yifei 526, 625
 Ma, Zhong-Min 252
 Maalouf, Naim 468, 677
 Maan, Evelyn J. 939
 Maartens, Gary 1020, 81LB
 Maas, Brian 406
 Mabileau, Guillaume 1028
 Mabunda, Nedio 26
 Macalino, Grace 865
 Macatangay, Bernard 280, 330LB, 931
 MacBrayne, Christine E. 404
 Macera, Margherita 585
 MacGillivray, Jay 756
 Machado, Daisy 816
 Macías, Juan 532, 536, 555, 570, 697
 Macio, Ingrid 944
 Mack, Wendy 514
 Macken, Alan 679
 Mackman, Richard 436
 Maclean, Rachel L. 476
 Macleod, David 834, 1010
 Macmadu, Alexandria 1044
 Macuacua, Nello 730, 766
 Maddon, Paul J. 437
 Madhi, Shabir 787
 Madison, Michaela 16
 Maeda, Kenji 503
 Mafara, Emma 475, 994
 Mafukidze, Arnold 708
 Magambo, Brian 193
 Maganga, Lucas 197
 Magni, Carlo 542LB
 Magnus, Many 872
 Magwaza, Sphindile 958
 Magyar, Clara 251, 700
 Maher, Andrew D. 35
 Maheu-Giroux, Mathieu 1047
 Mahiga, Hellen 788
 Mahjoub, Nadia 603
 Mahon, Niall 613
 Maida, Paola 575
 Maiga, Moussa 607
 Majeed, Sophia R. 427
 Majingo, Nokuthula 1009
 Makadzange, Azure Tariro. 345, 743
 Makanani, Bonus 935
 Makarov, Edward 588
 Makhema, Joseph 25, 502, 784, 789, 790
 Maki, Pauline M. 350
 Makinson, Alain 654
 Makokha, Catherine K. 861
 Makovore, Vongai 993
 Malagoli, Andrea 655
 Malatinkova, Eva 302
 Maldarelli, Frank 227, 287, 294, 297, 298, 303, 368
 Maleche Obimbo, Elizabeth 103, 796
 Malet, Isabelle 499
 Malette, Given 1050
 Malik, Sarah 370
 Malin, Jakob 580
 Malisita, Kennedy 602
 Mallal, Simon 230
 Mallard, Jaclyn 69
 Mallewa, Jane Edith. 117, 641
 Mallolas, Josep 42
 Mallon, Patrick W.G. 613, 679
 Maluzi, K 711
 Maman, David 116, 464, 523, 764, 792, 1006
 Mamede, João I. 15
 Manabe, Yukari C. 712, 742
 Manasa, Justen 506
 Mancebo, María 532, 697
 Mandalia, Sundhiya 275, 382
 Mandelbrot, Laurent 775
 Manenzhe, Kgahliso 936

- Mangal, Tara 1040
Mangi, Juma 1022
Mangia, Alessandra 9
Manika, Katerina Manika 734
Manion, Maura 221, 287, 368
Mankowski, Madeleine Clare Percy. 141
Manne-Goehler, Jennifer 639, 916, 991
Mannem, Santhosh R. 612
Månsson, Fredrik 37
Manuzak, Jennifer A. 216, 231
Manzardo, Christian 119LB, 271, 540, 541
Marbury, Thomas 430
Marcelin, Anne-Geneviève 43, 349, 487, 499, 520
Marchand, Lucie 654
Marchetti, Giulia 215, 239, 357, 579, 680
Marchi, Emanuele 301
Marchou, Bruno 223
Marco Schäferhoff, Marco 1053
Marconi, Vincent C. 127, 626
Margolick, Joseph B. 253, 619, 645, 840, 931
Margolis, David M. 123
Margolis, David A. 442
Margot, Nicolas 436
Maritz, Jean 28, 791, 989
Marks, Gary 31
Marks, Kenneth 944
Marks, Kristen M. 404, 554
Markunas, Christina A. 237LB
Marlin, Romain 262
Marquez, Carina 726
Márquez, Manuel 536, 555, 697
Marra, Christina 347, 749, 750
Marshall, Annecka 923
Marshall, Brandon David Lewis. 1044
Marshall, Jean-Claude 417
Marshed, Fatma 800
Marsolais, Christian 449LB
Marson, Kara 170, 511, 512
Martin, Aleks A. 967
Martin, Alyssa R. 317
Martin, Amy 209
Martin, David 507
Martin, Eileen 356
Martin, Elaine G. 962
Martin, Hal 40, 41
Martin, Jeffrey N. 625, 662, 675
Martin, Luisa 659
Martin, Michael 954
Martin, Natasha 134
Martin, Thomas CS. 134
Martín Fernández, Jesús 1028
Martin-Blondel, Guillaume 732
Martin-Gayo, Enrique 250
Martinez, Esteban 42, 336, 614
Martinez, Sebastian 1053
Martinez-Cuesta, Maria Angeles 609
Martínez-Maza, Otoniel 592, 931
Martínez-Picado, Javier 119LB, 228, 306, 320
Martínez-Sapiña, Ana María 566
Martini, Federico 203
Martini, Salvatore 585
Martinot, Martin 495
Martins, Laura J. 311
Martinson, Neil 657, 707
Maruapula, Dorcas 184, 484
Marukutira, Tafireyi 1009, 1017
Marzel, Alex 67, 191
Marzinke, Mark A. 420, 421LB, 86LB, 934, 955, 981
Masango, Mhleli 29LB
Masciotra, Silvana 509
Mascola, John R. 244, 760
Maseko, Bertha 859
Masese, Linnet N. 937
Masetti, Michela 222, 804
Masheto, Gaerolwe 772
Masia, Mar 595, 647
Maskew, Mhairi 1021, 1050
Masopust, David 267
Masoum, Sara 440
Massaccesi, Guido 167, 518
Massad, L. Stewart 23
Massanella, Marta 285
Massie, Allan 689
Masson, Carmen L. 547
Masson, Lindi 949
Mastrocola, Emily J. 220
Mastrososa, Ilaria 354
Maswabi, Kenneth 789, 790
Matano, Tetsuro 247
Matarranz, Mariano 676
Matemo, Daniel 765
Mateo, Gracia 651
Mathabire, Sekai Chenai. 464
Mathanga, Don 783
Mathema, Barun 77
Matheron, Sophie 194, 195, 290, 448, 603, 821
Mathews, W. Christopher. 454
Mathot, Ron 830
Matia, Belen 752
Matlhaoleng, Katlego 707
Matoga, Mitch 720
Matsuda, Kouki 503
Matsuda, Masakazu 496
Matsumoto, Shoko 463
Matsuo, Hiroshi 173
Matthews, Philippa C. 272, 799
Mattingly, Aviva 649
Matubu, Allen T. 945
Matus Nicodemos, Rodrigo 175
Maurice, Fiona 993
Mauss, Stefan 551, 567, 576
Maves, Ryan 865
Mavigner, Maud 1056LB
MaWhinney, Samantha 63, 419, 675
Maxwell, Claire 750
Mayanja, Yunia 915
Mayer, Kenneth H. 415, 456, 838, 971, 972, 981
Mayondi, Gloria 25, 774, 784, 787
Mayor, Angel 662
Mazzali, Cristina 411
Mazzotta, Valentina 366
Mbengue, Mouhamed Abdou Salam 917
Mbetse, Ndileka 819
Mbilizi, Yamikani 935
Mboya, Edward 982, 986
Mbwangi, Gladys 744
McAllister-Hollod, Laura 1013
McAuley, Andrew 185
McBride, Timothy 972
McCabe, Paul 557
McCaffery, Jeanne 694
McCallister, Scott 453, 683
McCarter, Martin 63
McCarthy, Geraldine 679
McCauley, Marybeth 981
McClelland, R. Scott 54, 85, 242, 937
McClintic, Hillary 667

- McClure, Myra 432
 McCoig, Cynthia 428
 McComsey, Grace A. 617, 618, 628, 674, 691, 695, 699, 700, 822
 McCoy, Laura 798
 McCray, Eugene 30
 McCreesh, Nicky 1048
 McCullough, John 20
 McDavid, Andrew 265LB
 McDonald, Cheryl 453
 McDonnell, Wyatt James. 230
 McElrath, Julie 897
 McFall, Allison Marie. 558, 883
 McFarland, Elizabeth J. 425, 760
 McFarland, Willi 35
 McFaul, Katie 248
 McGee, Charles 1057LB
 McGinty, Tara 679
 McGowan, Catherine 719, 816
 McGowan, Ian 420
 McGrath, Christine J. 761, 970
 McGrath, Nuala 1018
 McHale, Carolyn 435
 McHugh, Cricket 419
 McHugh, Grace 841LB
 McIlleron, Helen 29LB, 808
 McIntyre, James A. 1, 24, 769, 771
 McKenney, Jennie 901
 McKeown, Alesia 20
 McKibben, Rebecca 632
 McKinley, Trevelyan J. 1048
 McKinnon, Lyle 949
 McKnight, Courtney 547
 McLane, Mary Fran. 184
 McLaughlin, Mary 409a, 525
 McLaughlin, Sherry 304
 McMahan, Vanessa 967
 McMahon, Deborah 277, 279, 280
 McManus, Maryellen 409, 409a
 McMaster, Sean 209
 McMillan, JoEllyn 439
 McNairy, Margaret 1049LB, 637, 722, 835
 McNulty, Moira 969
 McPherson, Tristan 912
 McRobie, Ellen 115
 McVea, David 848
 Mdululi, Charlotte 784
 Mea-Assande, Véronique 811
 Meda, Nicolas 781
 Meditz, Amie 63
 Medley, Amy Michelle. 958
 Medley, Graham F. 1025, 1037
 Medoff, Benjamin 232
 Medrano, Luz M. 530
 Medstrand, Patrik 37
 Meggi, Bindiya 26
 Mehta, Christina 629, 943
 Mehta, Natasha 399
 Mehta, Nehal N. 612
 Mehta, Sanjay R. 182, 183, 844
 Mehta, Shruti H. 133, 244, 516, 558, 559, 560, 883
 Meignin, Veronique 603
 Meijer, Karina 620
 Meijers, Joost CM. 825
 Meintjes, Graeme 990
 Meintjes, Graeme 81LB
 Meissner, Eric G. 586
 Meissner, Paul 544
 Mejer, Niels 235
 Mejía-Villatoro, Carlos 182
 Melaku, Zenebe 706, 1023
 Melbourne, Kathy 683
 Melchers, Fritz 716LB
 Melero, Helena 400
 Melhado, Caroline 686
 Mellado, Maria José 527, 802
 Mellgren, Åsa 340, 431
 Mellins, Claude A. 24
 Mellors, John W. 120, 121, 277, 279, 28, 280, 294, 298, 303, 309, 313, 330LB, 795, 951, 952
 Mena, Leandro 972
 Menan, Hervé 78
 Mendel, Carl 724LB, 80LB
 Mendiharat, Pierre 116
 Mendoza, Maria 32
 Menego, Geoffrey 985
 Menu, Elisabeth 262
 Menzaghi, Barbara 542LB
 Meraviglia, Paola 411
 Mercenne, Gaele 20
 Merchante, Nicolás 139, 538
 Merenstein, Daniel 132, 690
 Merino, Dolores 532, 536, 555, 566, 571, 697
 Merino, Esperanza 139, 538
 Merli, Marco 531
 Merlini, Esther 215, 239, 357, 680
 Meshnick, Steven R. 522
 Mesojednik, Taylor 335
 Mesplede, Thibault 489, 495, 498
 Mestdag, Pieter 162
 Metcalf, Julia A. 472, 888
 Metcalfe, John Z. 715LB
 Metcalfe, Rebecca 529
 Metral, Melanie 362
 Metsch, Lisa 913
 Metzger, David 842
 Metzner, Karin 263, 327
 Mewalal, Nikoshia 266
 Meya, David 368, 742, 744, 746
 Meyer, Laurence 91LB
 Meyer-Andrieux, Isabelle Anne. 1006
 Meyerowitz, Jodi 261
 Meyn, Leslie A. 86LB, 945
 Mgaya, Jimson 788
 Mgodli, Nyaradzo 421LB
 Mhimbira, Francis 721
 Mhlanga, Felix 945, 952
 Miah, Jalal 734
 Mican, JoAnn 221, 238
 Michael, Denna 714
 Michael, Nelson L. 124, 197, 249, 270, 282, 299LB, 70, 71
 Michel, Kate 23
 Michelow, Pamela 941
 Migueles, Stephen A. 473
 Miguez, Maria Jose. 874
 Milam, Joel 646, 933
 Milanini, Benedetta 355
 Milazzo, Laura 411, 579
 Miles, Brodie 63
 Miller, Charlene 216, 231
 Miller, Christopher J. 252
 Miller, Melissa 479, 911
 Miller, Michael D. 338LB, 436, 497
 Miller, Shannon 63
 Miller, William 198
 Millo, Corina 238
 Milloy, M. J. 590, 875, 1044
 Mills, Lisa A. 184, 1008

- Milne, Ross 490
 Milosevic, Catriona 185
 Milush, Jeffery 293
 Mimiaga, Matthew J. 971
 Min, Jeong Eun. 875
 Minami, Rumi 643
 Mine, Madisa 484, 740, 988
 Mingorance, Jesus 652
 Minichini, Carmine 537
 Minisci, Davide 411
 Minkoff, Howard 23
 Minnerly, Sydney 845LB
 Minnis, Alexandra 936
 Miro, Jose M 540, 541, 651, 751
 Mirochnick, Mark 755, 757, 758, 809, 938
 Mitchell, Brooks I. 385, 612, 692
 Mitchell, Caroline 224
 Mitchell, Hannah K. 740
 Mitchell, James 84
 Mitchell, Julie 125
 Mitchell, Michael Lloyd. 434
 Mitsuya, Hiroaki 503
 Mitsuyasu, Ronald T. 592
 Mittal, Maria Luisa 870
 Miyahara, Sachiko 79, 342, 710, 717, 720
 Mlambo, Makungureyi 958
 Mmalane, Mompoti 25
 Mock, Philip 854, 954
 Moccroft, Amanda 128LB, 131, 653
 Modesitt, Jacob 216
 Modise, Sylvia 993
 Modongo, Chawangwa 729
 Mody, Aaloke 1000
 Moh, Raoul 78
 Mohammadi, Pejman 162
 Mohammed, Terence 789
 Mohr, Erika K. 718
 Mohr, Raphael 704
 Moir, Lorette 544
 Mokale, Baitshapi 184
 Mokomane, Margaret 745
 Molefi, Mooketsi 82, 740, 745
 Molfino, Lucas 523
 Molina, Jean-Michel 55, 45LB, 91LB
 Molina, Laura 752
 Mollan, Katie 454
 Molloy, Sile 82
 Moltó, José 119LB, 754
 Momplaisir, Florence 842
 Moncla, Bernard John. 86LB
 Mond, Annalisa 203, 466
 Money, Deborah M. 939
 Monge, Susana 652
 Mongwenyana, Constance 1050
 Montana, Livia 639, 916
 Montaner, Julio SG. 599, 875, 929, 966, 1042
 Montaner, Luis 326
 Montano, Daniel E. 984
 Montano, Mauricio 311
 Montano, Michalina A. 979
 Montejano, Rocio 400, 652
 Montero, Marta 139, 527, 533
 Monterosso, Analise Castellanos. 845LB
 Montes, Marisa 400, 533, 652
 Montgomery, Madeline C. 968
 Montrucchio, Chiara 360
 Moodley, Amber 266
 Moodley, Pravi 77
 Moolla, Aneesa 1021
 Moon, Jui 560
 Moore, David 462, 966
 Moore, David J. 353, 358, 367, 977
 Moore, Janet 1009
 Moore, Michael 433
 Moore, Penny 142
 Moore, Raeanne 358
 Moore, Richard D. 130, 347, 454, 560, 619, 662, 840
 Moore, Teresa 677
 Moorhouse, Michelle Anne. 113, 1020
 Moorthy, Ganesh S. 975
 Moosa, Mahomed-Yunus 1020
 Moraka, Natasha Onalenna. 774
 Moran, Caitlin A. 629
 Moran, Joanne 513
 Moran, Matthew G. 592
 Morand-Joubert, Laurence 349, 487
 Morano-Amado, Luis E. 536, 555, 570, 571
 Morawski, Bozena M. 742, 746
 Moreau, Yvetane 177
 Moremi, Sello 958
 Moreno, Ana 540, 572
 Moreno, Javier 752
 Moreno, Santiago 647
 Moreno, Victoria 572
 Morgado, Mariza 492
 Morgan, Ethan 849
 Morgan, Jake R. 547
 Mori, Luisa 799
 Mori, Masahiko 799
 Morlat, Philippe 653
 Moron-Lopez, Sara 228
 Morris, Allyson 845LB
 Morris, David 592
 Morris, Martina 900
 Morris, Sheldon 977
 Morrison, Charles S. 879
 Morrison, Douglas 879
 Morrison, Justin T. 628
 Morrow, Mary 675
 Morse, Caryn Gee. 226, 525
 Moscicki, Anna-Barbara 805
 Moscoe, Ellen 960
 Mosepele, Mosepele 384, 640
 Moser, Carlee 695, 700
 Mosina, Myriam 1019
 Moso, Michael 687
 Moss, Darren Michael. 423
 Mothe, Beatriz 119LB, 228, 271, 336
 Mothibi, Eula 763
 Motswere, Catherine 1009
 Moulignier, Antoine 75
 Mounzer, Karam 326, 664, 975
 Moyle, Graeme 418, 432
 Moyo, Crispin 114LB
 Moyo, Faith 794
 Moyo, Sikhulile 184, 484, 502, 774, 789, 790
 Mpoudi-Ngole, Eitel 482, 486
 Msandiwa, Reginah 657
 Msika, Albans 946
 Msukwa, Malango T. 782
 Mthiko, Bryan 686
 Mubiru, Frank 712
 Mucunguzi, Atukunda 726
 Mudenyanga, Chishamiso 26
 Mudrikova, Tania 504LB
 Mugavero, Michael J. 454, 455, 838, 908, 921
 Mugenyi, Mark 712
 Mugisha, Deodatha 950
 Mugo, Nelly 22, 85, 920, 934, 947
 Mugurungi, Owen 114LB
 Mugenyi, Peter 117

Muianga, Basilio 766
 Muir, Andrew J. 552
 Mujib, Shariq 233
 Mukandavire, Zindoga 1025, 1037
 Mukim, Amey 166, 307
 Mukoma, Wanjiru 1025, 1037
 Mukui, Irene 488
 Mukumbwa-Mwenechanya, Mpande 1004
 Mulato, Andrew 38, 433, 434
 Mulenga, Fredah 740
 Muller, Odelia 718
 Mulligan, Kathleen 685LB
 Mullins, James 304
 Muluana, Chadreque 730, 766
 Münk, Carsten 161
 Muñoz-Fernández, M Ángeles 590, 802
 Munoz-Jordan, Jorge 1055LB
 Munro, Cynthia 356
 Munyao, James 490
 Murakami-Ogasawara, Akio 480
 Muresan, Petronella 760
 Murphy, Gary 511, 512, 513, 876
 Murphy, Kellie 756
 Murphy, Robert 452LB
 Murphy, Terrence E. 930
 Murray, Ashley 839
 Murray, Bernard 433
 Murray, Lyle 261
 Murray, Melanie C.M. 939
 Murray, Stephen 724LB
 Murry, Jeffrey 118, 309, 313
 Murugavel, Kailapuri G. 245
 Muscatello, Antonio 222
 Musci, Rashelle 918
 Mushipe, Shelter 1019
 Musick, Andrew 294
 Musick, Beverly 837
 Musingila, Paul Kithikii. 982, 986
 Musinguzi, Nicholas 675
 Musomba, Rachel 1001
 Musonda, Rosemary 774
 Mussa, Antonio 1023
 Mustanski, Brian 843
 Musubire, Abdu 746
 Musukuma, Kalo 581
 Musuruana, Martin 897
 Mutai, Kennedy 1037
 Mutasa, Kuda 786
 Mutenda, Nicholas 35
 Mutevedzi, Tinofa 983
 Muthama, Evelyn 847
 Muthoga, Charles 82
 Mutlu, Ece A. 240, 241
 Mutsaerts, Henk-Jan MM. 825
 Mutsaka, Dadirayi 26
 Mutua, Gaudensia 976
 Muwanga, Jérémie 522
 Muwonge, Timothy R. 1003
 Muyindike, Winnie 523, 709, 773
 Mwambi, John 856
 Mwamzuka, Mussa 800
 Mwandumba, Henry 641
 Mwanga-Amumpaire, Juliet 523
 Mwangi, Judy 433
 Mwangi, Mary 847
 Mwangwa, Florence 638, 836, 1051
 Mwapasa, Victor 783
 Mwinyi, Abubakari 987
 Myer, Landon 24, 767, 769, 771, 989, 992
 Myers, Julie 891, 898
 Myers, Timothy G. 733

–N–

Nabaggala, Maria Sarah. 1001
 Nabeta, Pamela 76LB
 Nadin, Isaure 362
 Nagel, Mark R. 329
 Naggie, Susanna 138, 404, 552, 615
 Nagimova, Firaya 452LB
 Nagot, Nicolas 781
 Naidoo, Shalena 795, 824
 Nair, Gonasangrie 88
 Nair, Govind 371, 402
 Naji, Ali 65, 267
 Nakabiito, Clemensia 88
 Nakagawa, Fumiyo 112
 Nakalembe, Miriam 768
 Nakamoto, Beau K. 381, 385, 612
 Nakanwagi, Prossy 712
 Nakanyala, Tuli 35
 Nakashima, Masaaki 496
 Nakasujja, Noeline 359, 746
 Nakauchi, Takao 426
 Nakazawa, Masato 206, 240, 241, 367
 Nakigozi, Gertrude 34LB, 359, 996
 Nakiyingi, Lydia 712
 Nakku-Joloba, Edith 1003
 Nakwa, Firdose 758
 Nalintya, Elizabeth 742
 Nalugoda, Fred 1015, 34LB, 87
 Namale, Gertrude 915
 Namusobya, Jennifer 1005
 Nance, Robin M. 347
 Nanda, Kavita 947
 Nandi, Vijay 897
 Nanfack, Aubin J. 881
 Nanfuka, Mastula 462
 Nannapaneni, Prasanth 622
 Nannini, Pilar 804
 Napravnik, Sonia 465, 483
 Nara, Rebecca L. 378
 Narumi, Tetsuo 247
 Nassau, Tanner 479, 911
 Nastouli, Eleni 798
 Nath, Avindra 371, 402
 Nattermann, Una 21
 Natukunda, Eva 424
 Natureeba, Paul 768
 Navar, Ann Marie. 615
 Navarra, Assunta 466
 Navarro, Daniel 566
 Navarro, Jordi 535
 Navarro, Maria Luisa 527, 802
 Navarro, Samuel 480
 Ndambi, Nicaise 577, 997
 Ndhlovu, Chiratidzo Ellen. 345, 743
 Ndhlovu, Lishomwa C. 205, 255, 381, 385, 387, 692
 Ndhlovu, Zaza 266
 Ndung'u, Thumbi 202, 266
 Ndyabakira, Alex 33
 Ndyanabo, Anthony 880
 Ndzinisa, Nothando 994
 Neary, Megan 418
 Neaton, James 472, 474, 888
 Neff, Charles P. 207, 208
 Negoescu, Diana Maria. 1052
 Neil, Ava 923
 Neilan, Anne M. 833, 1043
 Neilands, Tor 860
 Nelson, Aurelie 791
 Nelson, Julie AE. 946
 Nelson, Kristin Nicole. 77

- Nelson, Margaret 803
 Nelson, Noele 584LB
 Nelson, Scott D. 700
 Nemeth, Johannes 263
 Nepal, Sunil 417
 Néré, Marie-Laure 323
 Nerlander, Lina 871
 Nesbitt, Ariel 939
 Neugebauer, Romain 598
 Neuhaus, Jacqueline 474
 Neukam, Karin 536, 555, 570, 571
 Neuman, Melissa 896
 Neumann, Till 633
 Newell, Evan William 7
 Newman, Peter A. 923
 Newsum, Astrid 136
 Newton, Alicia 140, 563
 Ng'ang'a, Lucy 761, 970
 Nganga, James 847
 Nganou Makamdop, Krystelle 60
 Nghiem, Khanh 409
 Ngidi, Julia 988
 Ngo-Giang-Huong, Nicole 584LB
 Ngongondo, McNeil 457, 710
 Ngonzi, Joseph 773
 Ngure, Kenneth 920
 Nguyen, Bach-Yen T. 45LB
 Nguyen, Chau Van Vinh. 747, 748
 Nguyen, Dung Thi Hoai. 463, 741
 Nguyen, Kinh Van. 463, 741
 Nguyen, Mindie H. 97
 Nguyen, Nam Hoang. 882
 Nguyen, Son 65, 267
 Nguyen, Tam Van. 882
 Nguyen, Thanh Tat. 748
 Nguyen, Thu Thi Mai. 747, 748
 Nguyen-Cleary, Thai 683
 Nichols, Brooke 129
 Nichols, Sharon 403
 Nichols, Whitney 517, 543, 545
 Nicholson, Val 925
 Nicolini, Laura Ambra. 542LB
 Nie, Zilin 273
 Niedziela-Majka, Anita 38, 497
 Nietert, Paul 586
 Nieves-Lugo, Karen 667
 Nigalye, Maitreyee 696
 Nightingale, Sam 370
 Nijhawan, Ank E. 957
 Nijhuis, Monique 306, 320, 504LB
 Nikolaitchik, Olga A. 164, 334
 Nikuze, Alliance 764, 792
 Nilsson, Staffan 340, 431
 Ning, Yuming 544
 Nishida, Yasuharu 426
 Nitayaphan, Sorachai 197
 Nitz, T.J. 507
 Niubo, Jordi 382
 Nkala, Busiswe 857
 Nkele, Isaac 640
 Nkhoma, Chiwawa 896
 Nkhoma, Prince 1006
 Nkomani, Sanele 117
 Nkomo, Bornaparte 988
 Noggle, Arianna 69
 Noguchi, Lisa 935
 Noguera-Julian, Antoni 527
 Noguera-Julian, Marc 212
 Nolan, David J. 69
 Nolte, Robert T. 171LB
 Nordell, Miranda 974
 Norrgren, Hans 37
 Norton, Thomas D. 333
 Nosyk, Bohdan 875, 1042
 Noto, Alessandra 265LB
 Novak, David S. 971
 Novak, Richard 32, 663, 864
 Novikov, Nikolai 497
 Novikova, Mariia 158
 Novitsky, Vlad 184, 484
 Novotny, Paul 669
 Nowak, Piotr 212
 Nowak, Rebecca G. 918, 997
 Noyan, Kajsa 212
 Nsubuga, Rebecca N. 193, 1048
 Ntema, Charity 35
 Ntozini, Robert 786
 Nucifora, Kimberly 1049LB
 Nugeyre, Marie-Thérèse 262
 Nunn, Amy 968, 972
 Nunnari, Giuseppe 283
 Nussenzweig, Michel 145
 Nuwagaba-Biribonwoha, Harriet 637, 837, 950
 Nyambi, Hanson Tebe. 1019
 Nyambi, Phillipe N. 881
 Nye, Mindy 1054
 Nyirenda, Rose 114LB
 Nyongesa-Malava, Evans 22
 Nyoni, Cynthia 1050
 Nzomukunda, Yvonne 523
- 0-
 O'Brein, Luke 613
 O'Brien, Meagan 256
 O'Brien, Nadia 925, 926
 O'Bryan, Thomas 865
 O'Connell, James 557
 O'Connell, Robert J. 70
 O'Doherty, Una 283, 300
 O'Donnell, James 628
 O'Donnell, Kate 513
 O'Garra, Anne 739
 O'Halloran, Jane A. 613
 O'Neal, Justin 1056LB
 O'Neill, Jennifer 408
 O'Riordan, Mary Ann 822
 O'Rourke, Colin 952
 Oakley, Jeremy E. 1048
 Ocampo, Antonio 595
 Ocfemia, Cheryl Banez. 187, 478, 833
 Ochieng, Teddy 768
 Ochsenauber, Christina 328
 Odek, James 985
 Odhiambo, Jacob 985
 Odoyo-June, Elijah 982, 985, 986
 Oduor, Clifford 893, 1022
 Oehlke, Sebastian 672
 Ofotokun, Igbo 629, 684, 695, 913, 943
 Ogata-Arakaki, Debra 381
 Ogihara, Kasumi 247
 Ogohara, Cassie 21
 Ogopotse, Matsiri 729
 Ogunniyi, Adesola 369
 Ogunshola, Funsho 266
 Ohainle, Molly 19
 Oka, Shinichi 463
 Okazaki, Reiko 496
 Okeke, Nwora Lance. 615
 Okello, Velephi 1049LB, 475, 637, 994
 Okiria, Alfred Geoffrey. 914
 Okoboi, Stephen 462

- Oksenhendler, Eric 323, 603
 Okulicz, Jason 358, 668, 865, 932
 Olaiya, Oluwatosin 907
 Olawore, Oluwasolape M. 1015
 Oldenbuettel, Celia 42
 Oldenburg, Catherine E. 968, 972
 Olender, Susan 682
 Oliveira, Augusto César Penalva. 388
 Olmedo Reneaum, Rodrigo Alejandro 225
 Olney, Jack 115
 Oluoch, Tom 847
 Omanga, Eunice 982
 Omari, Habib R. 997
 Omwoyo, Willis 764, 792
 Onchiri, Frankline 982
 Ondoa, Pascale 467
 Ongubo, Dennis 783
 Ongwande, Sumet 793
 Ononaku, Uchenna 918, 997
 Onorato, Lorenzo 537
 Onoya, Dorina 459, 917
 Onyango, Jacob 982
 Onyango, Mathews 985
 Oord, Gertine van. 587
 Oosthuizen, Christa 990
 Op de Coul, Eline 1041
 Operario, Don 892
 Opoku, Jenevieve 872, 905
 Opollo, Valarie Sarah. 728, 764, 792
 Orazulike, Ifeanyi 918, 997
 Orden, Samuel 609
 Orlando, Gabriella 655
 Orlova, Nina 292
 Orlova-Morozova, Elena 452LB
 Orne-Gliemann, Joanna 1018
 Orofino, Giancarlo 360
 Orr, Cody 586
 Ortblad, Katrina F. 983
 Ortega, Jose 508
 Ortiz, Geneva 897
 Osburn, William 518
 Osei-Kuffour, Edmund 161
 Osier, Mark 434
 Osler, Meg 990
 Osman, Nathan 498
 Osmand, Thomas 1051
 Osna, Natalia 588
 Oster, Alexandra 187, 188, 478, 845LB, 889
 Ostrander, Darin 317
 Ostrowski, Mario 233
 Osuna, Christa 338LB
 Otero, Luis 562
 Otieno-Nyunya, Boaz 982, 986
 Otworld, Kennedy N. 823, 824
 Ouattara, Eric Nindougou. 476
 Ounchanum, Pradthana 759, 820
 Oursler, Krisann 667
 Ouyang, Zhengyu 250
 Overbaugh, Julie 242, 243, 765, 796
 Overton, Edgar Turner. 213, 678
 Owaraganise, Asiphas 638, 836, 1051
 Owen, Andrew 39, 416, 418, 423
 Owen, Christopher Leigh. 197
 Owens, Douglas K. 725
 Owino, Fredrick 936
 Owino, George 762
 Owiti, Preston 488
 Owor, Maxensia 776, 777
 Owuoth, John 481
 Oyaró, Patrick 762
 Oyiengo, Laura 764, 792
 Ozanturk, Ayse Naz. 16
 O'Clairigh, Connall 454
- P—
 Pace, Craig S. 329
 Pachankis, John 965
 Padgett, Denis 719
 Padian, Nancy 995, 1000, 1004
 Padilla, Sergio 647
 Pagani, Nicole 418, 432
 Page, Kimberly 516
 Pahwa, Rajendra 234, 258
 Pahwa, Savita 234, 258, 798
 Paiardini, Mirko 48
 Paiva, Raquel 388
 Pajkrt, Dasja 825, 830
 Palai, Tommy 640
 Palanee-Phillips, Thesla 88, 935, 951
 Palar, Kartika 690, 913
 Palazzo, Donatella 575
 Palefsky, Joel 23, 591, 597
 Palella, Frank Joseph. 32, 130, 624, 632, 645, 663, 665, 666, 701, 931
 Palfreeman, Adrian 473
 Palich, Romain 323
 Palk, Laurence 850
 Pallier, Coralie 349
 Pallikkuth, Suresh 234, 258
 Palm, Angelica 37
 Palma, Anton M. 637
 Palma, Paolo 798
 Palmateer, Norah 185
 Palmer, Brent E. 207, 208
 Palmer, Sarah 293, 305
 Palou, Elsa Y. 182
 Paltiel, A. David 456, 476, 1028, 1043
 Palumbo, Paul 826
 Pan, Li 258
 Pan, Sung-Ching 582
 Panchareon, Chitsanu 759, 807
 Panchroen, Kanokpan 862
 Paneerselvam, Nandagopal 245, 559
 Pankau, Mark David. 796
 Panneer, Nivedha 187, 188
 Pantaleo, Giuseppe 265LB, 289
 Panvelker, Nina 378
 Papadakis, Georgios Z. 238
 Papadimitropoulos, Athanasios 549
 Papasavvas, Emmanouil 326
 Papazian, Emily 69
 Pape, Jean W. 471, 722, 835
 Papp, Eszter 756
 Pardi, Norbert 1057LB
 Paredes, Roger 212
 Parikh, Urvi 951, 952
 Park, Chung 64LB
 Park, Eun-Young 255
 Park, Lawrence 138
 Park, Lesley 257, 606
 Park, Seo Young 944
 Park, Sung Yong 514
 Parker, Robert A. 116, 833
 Parr, Jonathan 522
 Parruti, Giustino 564
 Partisani, Marialuisa 495
 Pascasio, Juan Manuel 566
 Pascoe, Sophie 1021
 Pasipamire, Munyaradzi 708
 Pasquazzi, Caterina 564
 Passmore, Jo-Ann 949
 Pasternak, Alexander 286

- Pastor, Roque 614
Patel, Eshan Uday 515, 516, 558, 881
Patel, Faezaz 27, 819
Patel, Hetal 114LB
Patel, Kunjal 779, 805
Patel, Pragna 150, 597
Patel, Raju KK. 745
Patel, Rena 947
Patel, Rupa Rajesh. 972
Patel, Sadhna V. 35
Patel, Vipulkumar N. 68
Patel, Viraj V. 1016
Pathak, Vinay K. 17, 164, 173, 227, 334
Pathipvanich, Panita 863
Pati Pascom, Ana Roberta. 1040
Patrick, Rudy 872
Pattamasavin, Suwanna 249
Pattanachaiwit, Supanit 863
Pattanasin, Sarika 855
Patterson, Thomas L. 844
Patton, Stephanie M. 377
Patts, Gregory 673
Pau, Alice K. 409a
Paul, Mary 810, 815
Paul, Robert 363, 381, 385, 394, 395, 401
Pauskar, Merit 461
Pavlin, Julie 668, 865, 932
Pawlowski, Anna 622
Paz-Bailey, Gabriela 1055LB, 852, 869, 871, 902
Pedrioli, Patrick 263
Peel, Sheila A. 481
Peeling, Rosanna W. 105
Peeters, Martine 218, 482, 486
Pelc, Rebecca S. 1057LB
Pellegrin, Isabelle 630
Peltzer, Karl 770
Peña, Alejandro 647
Peña, Jose M. 578
Pena, Stephanie 965
Peñafiel, Judith 540, 541
Peñaranda, María 659
Penazzato, Martina 101, 809
Pence, Brian W. 454
Pendergast, Louisa 19
Pengnonyang, Supabhorn 863
Penrose, Kerri 951
Penzak, Scott 409
Pepin, Jacques 522
Perelson, Alan S. 165
Pereyra, Florencia 325
Pérez, Alejandro 737
Perez, Ana Belen. 566
Perez, Idene 517
Perez, Janice 1055LB
Pérez Latorre, Leire 533
Pérez-Martínez, Laura 595
Pérez-Molina, José A. 595
Pérez-Pérez, Montserrat 571
Perez-Santiago, Josue 353, 390
Pérez-Valero, Ignacio 400, 652
Periès, Marianne 781
Perinelli, Paola 575
Perlman, David C. 547
Perlowski, Charlotte 760
Perna, Angelica 585
Perno, Carlo F. 366, 564, 565
Perona, Rosario 652
Perreau, Matthieu 289
Persad, Yasmeen 926
Persaud, Deborah 803
Person, Anna K. 912
Perte, Mihaela 296
Peter, Trevor 26
Peters, Helen 831
Peters, Paul J. 365
Peters, Philip J. 189, 477, 878
Petersen, Maya L. 36, 638, 726, 832, 836, 858, 860, 1051
Peterson, Christopher 321, 322, 332
Peterson, James 872
Peterson, Scott N. 390
Petlo, Chipo 25, 784
Petoumenos, Kathy 131, 670
Petrache, Irina 660
Petro, Greg 769, 771
Petropoulos, Christos 563
Petrovas, Constantinos 267
Pettifor, Audrey 859, 879
Pettit, April C. 714, 912
Peytavin, Gilles 458
Pfeil, Sarah 956
Phalora, Prabhjeet 324
Pham Thi, Thanh Thuy 83, 463
Phanga, Twambilile 859
Phanitsiri, Salinda 475
Phanunphak, Praphan 125, 698
Phanuphak, Nittaya 124, 205, 214, 291, 299LB, 863
Phetsouphanh, Chansavath 261
Phillips, Andrew 1030, 112, 128LB, 650, 693
Phillips, Gregory 843
Phillips, Patrick 723LB
Phillips, Tamsin 24, 769, 771, 992
Phiri, Eddie Moffo 602
Phiri, Jane 941
Phiri, Mwelwa 1010
Phiri, Sam 602, 783
Phongsamart, Wanatpreeya 807
Phonphithak, Supalak 698
Phuc, Pham Thi Hanh. 83
Phulusa, Jacob 686
Pialoux, Gilles 654, 91LB
Picarelli, Chiara 445
Pick, Neora 553, 599, 939
Picker, Louis J. 49
Pierson, Theodore C. 1057LB
Pieterman, Elise D. 620
Piggott, Damani A. 133
Pignatti, Riccardo 362
Pikora, Cheryl 424, 425
Pilcher, Christopher D. 170, 284, 380, 511, 512, 876
Pilkinton, Mark 229, 230
Pillai, Satish K. 170, 284, 314, 797
Pillay, Deenan 43, 491, 960, 983, 1018
Pillay, Sandy 29LB, 648
Pillay, Yogan 1019, 1046
Pilotto, Jose H. 772
Pineda, Juan A. 139, 532, 536, 538, 555, 570, 571, 697
Pinnetti, Carmela 354, 366, 466
Pintado, Laura 652
Pinto, Angie Natalie. 472, 888
Pinto, Jorge 815, 816
Pintye, Jillian 761, 970
Pinyakorn, Suteeraporn 124, 125, 214, 249, 270
Pinzone, Marilia Rita. 283
Piovesan, Mauro 386
Piper, Jeanna 935
Pipkin, Sharon 910

Pisa, Pedro 857
 Pisarski, Emily E. 1003
 Pistorius, Marcel 830
 Pittaluga, Stefania 221
 Piwowar-Manning, Estelle 955, 1002
 Plana, Montserrat 336, 614
 Planelles, Vicente 311
 Plankey, Michael 341, 361, 526, 629, 646, 933
 Plantier, Jean-Christophe 192
 Playford, Martin Playford 612
 Plazy, Mélanie 1018
 Plenderleith, Lindsey J. 181LB
 Plenty, Albert 832
 Plessis, Lorraine 278
 Plitnik, Timothy 174
 Plotnikova, Yulia 443
 Plummer, Francis 179
 Podany, Anthony 408
 Podzamczar, Daniel 382, 651
 Poerio, Cody 911
 Poindexter, John 677
 Poizot-Martin, Isabelle 135, 550
 Polacino, Patricia 321, 322
 Pollack, Ross 296
 Poluektova, Larisa Y. 219, 588
 Polyak, Christina 355, 481
 Pomati, Simone 396
 Pontali, Emanuele 734
 Pontones, Pam 878
 Poole, Sabrina 868LB
 Poon, Art 196, 848
 Poongulali, Selvamuthu 457
 Popson, Stephanie 806
 Porcella, Stephen 244, 733
 Porco, Travis C. 876
 Porsa, Esmaeil 957
 Portales, Pierre 605
 Porter, Kholoud 491
 Porter, Laura 114LB
 Porter, Sarah E. 477
 Porterfield, Zach 236
 Portilla, Joaquin 647
 Portu, Joseba 538
 Post, Frank 650, 688
 Post, Wendy 624, 632, 636LB, 701
 Postma, Annelees 731
 Potempa, Marc 198
 Potenza, Nicoletta 537
 Potter, Clinton 14LB
 Poulet, Elisabeth 1006
 Pourhassan, Nader 437
 Powis, Kathleen M. 502, 780, 1017
 Pozniak, Anton 186, 382, 569
 Pradat, Pierre 550
 Pradeep, Amrose 558, 559
 Pradier, Christian 72, 693
 Preiser, Wolfgang 989
 Prejean, Joseph 1012
 Prendergast, Andrew 117, 786
 Pressiat, Claire 811
 Presti, Rachel 213
 Preston, Richard A. 430
 Pretorius Holme, Molly 1009
 Price, Jennifer 526, 701
 Price, Joan T. 859
 Price, Krystin A. 877, 878
 Price, Lance 87
 Price, Matt A. 200, 202, 856, 876, 1022
 Price, Richard W. 72, 73, 364, 389, 391
 Priddy, Frances 976

Prieto, Luis 802
 Prince, Lea 725
 Prins, Jan 286
 Prins, Maria 519, 886, 887
 Procopio, Francesco 289
 Proctor, Gordon 529
 Prodger, Jessica 87
 Promda, Nutthawoot 862
 Psomas, Christina 605
 Puertas, Maria Carmen. 119LB, 228
 Puglièse, Pascal 135, 550, 732
 Pujantell, Maria 259
 Pulido, Federico 441, 697
 Purdy, Julia 649
 Purswani, Murli U. 805
 Putcharoen, Opass 698
 Puthanakit, Thanyawee 285, 759, 793, 807, 820
 Pybus, Oliver 272

–Q–

Qi, Qibin 636LB
 Qi, Xin 413
 Qian, Xiaona 889
 Qin, Li 598
 Qin, Min 776, 777
 Quereda, Carmen 533, 534
 Quiles, Isabel Amoros. 464
 Quinn, Jeffrey 167, 515
 Quinn, Thomas 244, 317, 34LB, 515, 516, 880, 881, 904
 Quinones, Mariam 214
 Quinto, Annemarie Angeles. 403
 Quirk, Erin 40, 41
 Quiros-Roldan, Eugenia 445
 Quiroz-Morales, Verónica Sonia. 480
 Quyyumi, Arshed 629

–R–

Rabie, Helena 29LB
 Rabkin, Charles 130, 598
 Rabkin, Judith 669
 Rabkin, Miriam 637
 Raboni, Sonia Mara. 386
 Raboud, Janet M. 447, 601
 Radix, Asa 965
 Radzio, Jessica 84, 209
 Rae, Caroline 398
 Rafecas, Antonio 541
 Raffanti, Stephen P. 644
 Raffi, François 278, 458
 Raggi, Paolo 822
 Raghwan, Jayna 272
 Ragonnet-Cronin, Manon 185, 186, 1026
 Rahman, A. K. M. Nur ur 233
 Rahmberg, Andrew R. 62LB
 Raifman, Julia 968
 Railton, Eimear 549
 Rainford, Louise 613
 Raizes, Elliot 112, 482, 484, 486, 1008
 Rajakumar, Premeela A. 62LB
 Rajasaar, Heli 461
 Rajasingham, Radha 742
 Rajoli, Rajith Kumar Reddy 423
 Rakhmanina, Natella 424
 Ramabyaa, Dinah 988
 Ramanlal, Nehaben 730
 Ramazani, Soheil 866
 Ramchandani, Ritesh 717
 Ramers, Christian B. 548
 Ramirez, Roberto 318
 Ramlagan, Shandir 770

- Ramogola-Masire, Doreen 152
Ramos, Jose Tomas 802
Ramsey, Benjamin 691
Rannard, Steve 39
Ransier, Amy 60
Rao, Deepa 851, 921
Raoufi, Fahimeh 337
Raper, James 867
Rappold, Michaela 631
Rapuano, Patrick Burns. 236
Rasmussen, Sarah 689
Rasmussen, Thomas Aagaard. 305
Ratanshi, Rosalind Parkes. 1001
Rathod, Sujit 919
Ratlhagana, Mary-Jane 111
Ratnaratorn, Nisakorn 344
Raugi, Dana 440, 508
Rawlings, David J. 335
Rawls, Anthony 872
Ray, Adrian 436
Ray, Stuart C 141, 518
Raymond, Stephanie 349
Raymond Marchand, Laurence 785
Read, Ron 866
Real, Luis M. 532
Rebeiro, Peter F. 840, 912
Rebensburg, Stephanie 157, 160LB
Redd, Andrew D. 244, 317, 318, 881
Reece, Stephen 716LB
Rees, Helen 857, 935, 1036
Registre, Ludy 177
Rego, Dalila 818
Rehema, Winnie 355
Rehm, Cathy 297, 64LB
Reich, Daniel S. 371, 402
Reid, Michael J A. 526
Reif, Lindsey 722, 835
Reinsch, Nico 633
Reiss, Peter 1041, 128LB, 129, 131, 136, 352LB, 467, 653, 672, 731, 825
Reliquet, Véronique 821
Remien, Robert 24
Rentsch, Christopher 626
Requena, Mary 223
Requena, Silvia 562
Resino, Salvador 530
Resnati, Chiara 396
Reust, Julie 471
Revill, Paul 112, 1030
Revollo, Boris 139, 538
Rewari, Bharat Bhushan 456
Rey, David 495
Reyes-Terán, Gustavo 65, 182, 267, 480
Reynes, Jacques 135, 550, 605, 654
Reynolds, James 649
Reynolds, Steven J. 104, 34LB, 880, 996
Reynoso, David 696
Rezek, Valerie 254, 331, 332
Rhee, Martin 424, 425
Rhee, Soo-Yon 485, 506
Rhein, Josh 744, 746
Rheinemann, Lara 20
Ribas, Maria Angeles 659
Ribauda, Heather 414
Ribeiro, Clea Elisa. 386
Ribet, Céline 654
Rice, William 14LB
Rich, Josiah D. 1044
Richard, Léa 190
Richardson, Barbra A. 22, 765
Richardson, Kelly 803
Richman, Douglas D. 113, 200, 201, 300, 307, 319, 326
Richmond, Gary J. 442, 449LB
Richter, Clemens 136
Rick, Fernanda 464
Ricottini, Martina 354
Riddler, Sharon 330LB, 952
Rieger, Armin 631
Riera, Melchor 651, 659
Rife, Brittany 69
Rijnders, Bart 136, 137LB, 451LB, 620, 731
Riley, Laura Elizabeth. 773
Rimland, David 626
Rimola, Antoni 540, 541
Rinaldi, Stefano 234, 258
Rinaldo, Charles 280
Rinke de Wit, Tobias F. 467, 488
Rios, Jessica 380
Rios Prego, Monica 734
Rios-Villegas, Maria J. 139, 536, 570
Risch, Lorenz 721
Rita, Casetti 203
Ritz, Justin 330LB
Riva, Agostino 265LB, 396, 410
Riveira-Muñoz, Eva 259
Rivera, Javier 212
Rivera, Vanessa 722, 835
Rivero, Antonio 566, 573, 697
Rivero-Juárez, Antonio 139, 532, 571, 573
Riviere, Cynthia 648, 720
Rizza, Stacey 319
Rizzardini, Giuliano 410, 564, 565
Roan, Nadia R. 170
Robb, Merlin L. 124, 197, 249, 270, 282, 291, 299LB
Robbins, Gregory K. 838
Roberts, Owain 423
Roberts, Tessa 919
Robertson, Kevin 72, 73, 342, 343, 359, 369, 380, 665
Robichaux, Spencer 217
Robinson, Cameron 1056LB
Robinson, Nicola 301, 324
Roby, Gregg 287
Rocca, Salvatore 798
Rocha, Susana 155
Rockstroh, Jürgen K. 551, 576, 580, 704
Rodgers, Mary 510, 577
Rodriguez, Allan 234, 258
Rodriguez, Violeta 770
Rodriguez-Arrondo, Francisco 139, 538
Rodriguez-Barradas, Maria 127, 606, 626, 658, 702, 930
Rodriguez-Cano, Diego 573
Rodriguez-Hart, Cristina 918
Rogers, Anna Joy 762
Rohan, Lisa C. 86LB
Rohr, Julia K. 639, 916, 991
Rojanawiwat, Archawin 793
Rojas, John 1013
Rojas, Sarah 548
Rojas-Castro, Daniela 91LB
Rokx, Casper 451LB, 620, 731
Rolland, Morgane 197, 299LB
Rolle, Charlotte-Paige Melanie. 90
Romano Ibarra, Guillermo 335
Romero, Jorge 595
Romero, Klaus 723LB
Romero-Palacios, Alberto 538
Ronan, Agnes 769, 771
Roncadori, Andrea 460

- Ronchetti, Anne-Marie 603
 Ronzi, Paola 579
 Rooinasie, Shawn Jarroth. 987
 Roon, Laura 405
 Rosas Umbert, Miriam 271
 Rose, Charles 32
 Rose, Herbert 903
 Rose, Rebecca 518
 Rosebush, Julia C. 822
 Rosen, Sydney 1050
 Rosenberg, Eli 1024, 1033, 1034, 1055LB, 90
 Rosenberg, Eric 292
 Rosenberg, Molly 991
 Rosenberg, Nora E. 859
 Rosenbloom, Daniel I.S. 318
 Roskam-Kwint, Marieke 429
 Ross, Christine 743
 Ross, Jonathan 1016
 Ross, Michael 653
 Rossaro, Lorenzo 568LB
 Rossi, Fiorella Patricia. 376
 Rossi, Francesca 531
 Rossi, Paolo 798
 Roth, David 735
 Roth, Eric 966
 Rothman, Richard 956
 Rothrock, Ginger 420
 Rotta, Indianara 386
 Roudière, Laurent 520
 Rough, Kathryn 779
 Rouskin, Silvi 8
 Routy, Jean-Pierre 123, 204, 264, 274
 Rouzier, Vanessa 816
 Rouzioux, Christine 775
 Rowan, Sarah E. 528
 Rowe, William 38
 Rowland-Jones, Sarah 202
 Rowley, Christopher 502
 Roy, Daisy 512
 Roy, Monika 1000, 1004
 RoyChoudhury, Arindam 682
 Royse, Kathryn E. 539
 Rozera, Gabriella 466
 Rua, Réjane 190
 Rubin, Leah H. 341, 350
 Rude, Eric 903
 Ruel, Theodore 726, 768, 797, 806, 832
 Ruelas, Debbie Sophia. 337
 Ruff, Joshua H. 822
 Ruffner, Andrew 956
 Ruixo, Carlos Pérez. 427
 Ruiz, Eduardo 380
 Ruiz-Giardin, Jose Manuel 752
 Rukobo, Sandra 786
 Ruone, Susan 954
 Rupert, Adam 126, 225, 226
 Rusconi, Stefano 303, 396
 Rusert, Peter 66, 67
 Russel, Frans G.M. 753
 Russell, Ronnie M. 181LB
 Russo, Aniello 537
 Rutledge, Brandy 685LB
 Rüütel, Kristi 1028
 Ruxrungtham, Kiat 698, 705
 Ryan, Pablo 534
 Ryom, Lene 128LB, 131, 653, 693
- 679, 693
 Sacdalan, Carlo 344
 Sacktor, Ned 356, 359
 Saduvala, Neeraja 478
 Saeed, Sahar 553
 Sagar, Manish 177
 Sagnelli, Caterina 531
 Sagnelli, Evangelista 531, 537
 Sah Bandar, Ivo 255
 Sahi, Sharon 749, 750
 Sahni, Jaya 335
 Sahoo, Debashis 374
 Sailasuta, Napapon 339, 363, 394
 Sainz, Talía 527, 802
 Saito, Suzue 706
 Sakala, Doreen 895
 Sakowicz, Roman 434
 Sakr, Sameh 22
 Salanave, Benoit 821
 Salazar-Austin, Nicole 707
 Salcuni, Paul M. 891, 898
 Salemi, Marco 69
 Salgado, Maria 306, 320
 Salomon, Joshua A. 833, 983, 991
 Salters, Kate 599, 601
 Salumu, Leon 464, 764, 792, 1006
 Samandari, Taraz 980
 Sambucetti, Lidia 283
 Samet, Jeffrey H. 673
 Samleerat, Tanawan 793
 Samoff, Erkia 198
 Sampéris, Gloria 659
 Samri, Assia 290
 Samuels, David C. 229, 377, 392, 393, 691
 San Martin, Juan Victor. 752
 Sanchez, Carmen 752
 Sanchez, Rosa 412, 430
 Sanchez, Travis 90
 Sanchez Mellado, Diana Sanchez
 Mellado 734
 Sánchez Rivas, Elena 504LB
 Sanchez-Lopez, Ainhoa 609
 Sanders, Eduard 202, 856, 886, 893, 976,
 1022
 Sanders-Buell, Eric 197, 299LB, 71
 Sanderson, Jeremy 324
 Sands, Bryan 335
 Sane Schepisi, Monica 734
 Sanford, Ryan 397
 Sang, Norton 36, 832
 Sangal, Neel 167
 Sanne, Ian 225, 1050
 Sansom, Stephanie L. 1029
 Santana, Bárbara 388
 Santelli, John 1015
 Santiago, Gilberto 1055LB
 Santiago, Mario 63
 Santoro, Antonella 655
 Santos, Ignacio 534
 Sanz, Gonzalo 595
 Sanz, Jose 572
 Sarafianos, Stefan G. 18, 503
 Sarah Hau, Sarah 549
 Saravanan, Shanmugam 492, 559
 Sarcletti, Mario 631
 Sardo, Luca 308
 Sartorius, Benn 817LB
 Sasco, Annie Jeanne. 607
 Sastri, Jaya 17
 Sastry, Jagannadha 422LB
 Satapathy, Sanjaya 568LB

—S—

- Saag, Michael 138
 Sabi, Issa 788
 Sabin, Caroline 128LB, 352LB, 650, 672,

- Sato, Paul 803
Sattar, Abdus 617, 618
Savatovsky, Julien 75
Savic, Radojka M. 407, 723LB
Sawe, Fredrick 197
Sax, Paul E. 1043, 325, 41, 453, 45LB, 493, 691
Sayles, Harlan 963
Saylor, Deanna 359
Sazonova, Yana 884
Scaglioni, Riccardo 655
Scarsi, Kimberly K. 408, 423, 963
Schaaf, H. Simon 53
Schaap, Ab 834, 959, 1010, 1011
Schacker, Timothy 319
Schackman, Bruce R. 547
Schaffer, Elisabeth 33, 894
Schalkwijk, Stein 753, 754
Schankel, Laura 827, 828
Schanz, Merle 67
Scharenberg, Andrew M. 335
Schauer, Amanda 406
Scheer, Susan 906, 910, 922, 974
Schellenberg, Gerard D. 74
Scherpbier, Henriëtte J. 825, 830
Scherzer, Rebecca 526
Schewe, Knud 551, 567, 576
Schief, William R. 143
Schiff, Abigail 232
Schim van der Loeff, Maarten F. 519, 886, 887
Schinazi, Raymond F. 829
Schinkel, Janke 519
Schlatzer, Daniela 169
Schleimann, Mariane H. 314
Schlub, Timothy E. 305
Schlusser, Katherine E. 472, 888
Schmandt, Justin A. 942
Schmidt, Fabian 220
Schmidt, Manfred 302
Schmidt, Stephen 244
Schmied, Brigitte 631
Schmitz, Mary 761
Schnapp, Lynn M. 660
Schneider, Daniel 622
Schneider, John A. 849, 969
Schneider, Marie-Paule 671
Schneider, Veronique 520, 812
Schofield, Christina 668, 932
Schofield, Joe 529
Schommers, Philipp 176
Schott, Kerstin 161
Schrader, Shannon 449LB
Schrier, Rachel 206
Schuettfort, Gundolf 738
Schulze, Christina 633
Schulze zur Wiesch, Julian 551, 567, 587
Schumacher, Samuel G. 76LB
Schurink, Karin 451LB
Schutz, Charlotte 81LB
Schuurman, Rob 504LB
Schwarcz, Sandy 906
Schwartz, Jill 86LB
Schwartz, Jonathan M. 544
Schwartz, Jordan Ari. 233
Schwartz, Olivier 194
Schwarze-Zander, Carolynne 580, 704
Schwind, Marc 362
Scott, Hyman 974
Scott, Jenna 427
Scott, John D. 9
Scully, Eileen 281
Seaberg, Eric 701
Seage, George R. 779, 805
Seaton, Kelly 415
Sebikari, Dorothy 777
Sebogodi, Phillimon P. 484
Seeley, Janet 915
Segev, Dorry 317, 689
Seifert, Sharon 419
Seivers, Matthew 244
Sekaly, Rafick-Pierre 60, 304, 321
Selik, Richard M. 889, 890
Selinger, Christian 1035, 1036
Sellers, Christopher 198
Semba, Richard 648
Semitala, Fred 1005
Sendagorta, Elena 595
SenGupta, Devi 427
Sento, Baraedi Winnie. 1009
Serada, Paul 929
Serani, Marco 575
Sereda, Paul 966, 1042
Sereti, Irini 214, 221, 225, 226, 238, 287, 368, 473, 733
Serghides, Lena 756
Serra-Moreno, Ruth 168
Serrano, Miriam 555
Serrano-Villar, Sergio 595, 676, 802
Serrao, Eric 292
Serwadda, David 1015, 34LB, 87, 880
Setliff, Ian 230
Severe, Patrice 471
Seydi, Moussa 440, 508, 642
Seyedkazemi, Sareh 505
Seyedkazemi, Star 381
Shade, Julie Kristin. 210
Shade, Starley B. 111, 1051
Shaefer, Mark 428
Shafer, Robert 485, 494, 506
Shaffer, Ashton 689
Shafi, Juma 937
Shah, N. Sarita 50, 77, 728
Shah, Sanjiv J. 622
Shaikh, Najma 763
Shaker, Amir 987
Shalek, Alex K. 250
Shalit, Peter 961
Shally, Mahmoud 893
Shanaube, Kwame 834, 959, 1010, 1011
Shane, Elizabeth 682
Shankar, Anupama 189, 477
Shannon, Dylan 679
Shao, Wei 227, 294, 305
Shao, Yongwu 424, 427
Shapiro, David E. 779, 938
Shapiro, Nathan D. 433
Shapiro, Roger L. 25, 100, 502, 787, 789, 790
Sharkey, Mark 174
Sharma, Anjali 132, 361, 682
Sharma, Anjali 1004
Sharma, Monisha 1032
Sharma, Shweta 472, 474, 608, 623, 888
Sharp, David J. 352LB
Sharp, Katie 489
Sharp, Paul M. 181LB
Sharp, Tyler 1055LB
Shattock, Andrew 1046
Shearer, Kate 904
Shebl, Fatma 606
Sheehan, Gerard 613
Sheha, Irene 641

- Shehu, Nathan 369
 Sheikh, Virginia 221, 238, 287, 733
 Sheira, Lila Aziz. 913
 Sheng, Wang-Huei 582
 Shepherd, Bryan E. 644, 719, 816
 Shepherd, Leah 131
 Sherill-Mix, Scott 181LB
 Sherman, Brad 371
 Sherman, Gayle Gillian. 27, 794
 Sherrill-Mix, Scott 171LB
 Sherwat, Adam 372
 Sheth, Anandi N. 629, 684, 942, 943
 Shi, Margaret D. 611
 Shi, Qiuhu 361, 928
 Shiau, Stephanie 27, 819
 Shiboski, Caroline H. 213
 Shiels, Meredith S. 600, 661
 Shigemi, Urara 496
 Shikuma, Cecilia 255, 381, 385, 395, 612, 692, 748
 Shimonava, Tatyana 452LB
 Shin, Sanghyuk S. 729
 Shiramizu, Bruce 395, 692
 Shirasaka, Takuma 426
 Shivakoti, Rupak 648
 Shouse, R. Luke. 907, 1012
 Shoveller, Jean A. 599, 875, 929, 1042
 Shrestha, Nabin 524, 735
 Shroff, Hari 308
 Shroufi, Amir 718, 927, 998
 Shubber, Zara 1046
 Shufelt, Chrisandra L. 589
 Shukla, Shuchin 544
 Sibaya, Thobekile 817LB
 Siberry, George K. 584LB
 Sibiya, Sydney 857
 Sibley, Thomas R. 304
 Siccardi, Marco 39, 416, 423
 Siedner, Mark J. 675, 773
 Siegler, Aaron S. 90
 Sierra-Madero, Juan 225
 Sigel, Keith M. 606
 Signer, Danielle 956
 Siika, Abraham 117
 Sikazwe, Izukanji 995, 1000, 1004
 Sikombe, Kombatende 995
 Silberman, Evan Jonas. 304
 Siliciano, Janet 295
 Siliciano, Robert 295, 296, 315, 317, 318
 Silva Arrieta, Sandra 541
 Silverberg, Michael J. 598, 840
 Silverman, Michael 756
 Silvestri, Alessandro Maria 575
 Silvestri, Guido 260LB
 Simbeza, Sandra 995
 Simelane, Batsabile 708
 Simelane, Njabulo 994
 Simelane, Samkelo 637
 Simms, Victoria 841LB
 Simon, Francois 192, 603
 Simonetti, Francesco Roberto. 297, 303
 Simpanen, Erik 892
 Sineath, Robert Craig. 901
 Singa, Benson 970
 Singata, Mandisa 781
 Singh, Kumud K. 374
 Singh, Lalita D. 68
 Singh, Rajendra P. 806
 Singh, Sonia 30
 Sinha, Arjun 625
 Siqueira, Juliana D. 218
 Sirijatuphat, Rujipas 71
 Sista, Nirupama 421LB
 Siva, Samantha 88
 Sivay, Mariya V. 955
 Siwale, Margaret 467
 Skaathun, Britt 849
 Slike, Bonnie 282, 394
 Sloan, Derek D. 118
 Sloan, Jeff 669
 Sluis-Cremer, Nicolas 316, 501
 Smart, Amanda Elizabeth. 517, 543
 Smeaton, Laura M. 699
 Smedley, Jeremy 216
 Smieszek, Sandra Paulina. 392, 393
 Smit, Colette 129, 136, 620
 Smit, Mikaela 129
 Smith, Andrew G. 181LB
 Smith, Bryan 371, 402
 Smith, Christiana 774
 Smith, Colette J. 736, 815
 Smith, Davey M. 134, 166, 201, 206, 367, 844
 Smith, Dawn K. 1034
 Smith, Elizabeth 755, 757, 760, 810
 Smith, Graham HR. 442
 Smith, Jennifer 941
 Smith, Jennifer 1032, 1038
 Smith, Jessica 173
 Smith, Laramie 842
 Smith, Rachel 569
 Smith, Robert 440, 508
 Smith, Robert S. 401
 Smyrnov, Pavlo 884
 Snow, Joseph 371, 402
 So, Isaac 490
 So-Armah, Kaku 127, 673, 702
 Soare, Alexandra 256
 Soares, Marcelo A. 218
 Soboil, Nikki 987
 Sobolewski, Michele 121, 309, 795
 Sodora, Donald 260LB
 Solomon, Sunil S. 245, 558, 559, 883
 Solomon, Tom 370
 Somasunderam, Anoma 696
 Sommer, Karen 335
 Somoza, John R. 38
 Somsouk, Ma 288, 407
 Song, Riuguang 902
 Song, Ruiguang 30, 899
 Sönnnerborg, Anders 212
 Soo, Leonard 986
 Soo Hoo, Guy W. 658
 Soodla, Pilleriin 461
 Soon, Guoxing 372
 Sophonphan, Jiratchaya 698, 759, 793, 807
 Soria, Jaime 224
 Soriano, Vincent 578
 Sortino, Ornella 214, 733
 Soto-Torres, Lydia 88
 Soudeyns, Hugo 785
 Soulie, Cathia 349, 487
 Souza, Scott A. 255, 385, 692
 Sow, Papa Salif 642
 Spaziante, Martina 575
 Spear, John 678
 Spielvogel, Ean 364
 Spigelman, Mel 724LB, 80LB
 Spiller, Michael 869
 Spina, Celsa A. 166, 307, 311
 Spindler, Jonathan 294
 Spinner, Christoph D. 42

- Spira, Bonnie 498
 Spoerri, Adrian 602, 782
 Spreen, William 84, 442
 Springer, Gayle 350
 Spudich, Serena 1, 70, 71, 72, 73, 339, 344, 363, 364, 380, 387, 391, 394
 Squillace, Nicola 222
 Squires, Kathleen 443, 45LB
 Srikrishnan, Aylur K. 245, 558, 559, 883
 Srinivasa, Suman 627
 Sriporn, Anuwat 862
 Srirompotong, Ussanee 759
 Ssekasanvu, Joseph 880, 996
 Ssekubugu, Robert 996, 1015
 Ssemwanga, Deogratius 193
 St-Jean, Martin 1042
 Stagg, Helen R. 736
 Stancil, Britt S. 442
 Starace, Mario 537
 Staub, Therese 474
 Stauffer, Brian 616
 Stauffer, David 494
 Stecher, Melanie 183
 Steele, Sarah Jane 718, 791, 927, 998
 Stefanescu, Andrei 277
 Stein, James H. 414
 Steinbach, Sally 402
 Stek, Alice 755, 938
 Stek, Cari 81LB
 Stekler, Joanne 901, 967
 Stella-Ascariz, Natalia 652
 Stengelin, Martin 512
 Stepan, George 433, 436
 Stephan, Christoph 738
 Stephensen, Charles 685LB
 Stephenson, Sarah E. 660
 Stephenson, Sophie 407
 Sterling, Timothy R. 644, 719, 912
 Sterman, Felicia 126
 Stern, Anna L. 378
 Stern, Joshua 749
 Sterrantino, Gaetana 460
 Stevens, Claire 749, 750
 Stevens, Elizabeth 1049LB
 Stevenson, Mario 174
 Steverson, Alexandra B. 622
 Steward, Wayne T. 111
 Stier, Elizabeth A. 591
 Stingl, Georg 716LB
 Stinson, Kathryn 990
 Stoeckle, Marcel 596
 Stoffel, Nicole 721
 Stolte, Ineke 886
 Stoner, Kevin A. 945
 Stoner, Marie 919
 Storto, Alexandre 195
 Strain, Matthew 300
 Strathdee, Steffanie A. 844, 870
 Stray, Kirsten 436
 Streeck, Hendrik 282
 Strehlau, Renate 27, 819
 Streicher, Elizabeth 715LB
 Strickler, Howard D. 23, 928
 Stringer, Jeffrey S. 776, 777, 919
 Strizki, Julie 337
 Strong, Mark 1048
 Strouville, Victoria Pamela. 263, 327
 Struble, Kimberly 372
 Strumpf, Erin C. 553
 Sturdevant, Daniel 733
 Su, Hang 219
 Subra, Frédéric 499
 Suc, Bertrand 223
 Succi, Regina 816
 Sudjaritruk, Tavitiya 820
 Sugandhi, Nandita 809
 Sugar, Catherine Ann. 695
 Sukwicha, Wichuda 854, 855, 862
 Sulkowski, Mark 138, 558, 559, 560
 Sullivan, Claire E. 628
 Sullivan, Patrick 90, 901, 1024, 1033, 1034
 Summers, Angela 402
 Sun, Hsin-Yun 582
 Sun, Li 435
 Sun, Ly Penh 705
 Sun, Philena 634
 Sun, Ren 268, 500LB
 Sun, Xiaoming 292
 Sun, Xiaoying 870, 977
 Sun, Xin 79, 710, 717, 720
 Sundquist, Wes 20, 21
 Suntarattiwong, Piyaarat 285, 759, 820
 Sunyakumthorn, Piyanate 70
 Sura, Monali 412
 Surie, Diya 937
 Sutcliffe, Catherine 560
 Suthar, Mehul 1056LB
 Suttichom, Duanghathai 205, 344
 Sutton, Kenneth 442
 Sutton, Madeline 839
 Sutton, Richard 236
 Sutton, Sarah H. 469
 Swadling, Leo 239
 Swaminathan, Shobha 421LB
 Swan, Ashley Robb. 403
 Swanstrom, Ronald 73, 163, 198, 364, 369
 Swarner, Stephanie 420
 Swartz, Talia 256
 Swathirajan, Chinnambedu
 Ravichandran 245
 Swieboda, Dominika 829
 Swindells, Susan 79, 408, 728, 963
 Switzer, William M. 189, 477, 877, 878
 Swordy, Alice 799
 Sykes, Craig 406
 Symonds, Geoff P. 322
 Szadkowski, Leah 447
 Szubert, Alexander J. 117
 Szumilin, Elisabeth 116, 464, 764, 792, 1006
 Szydlo, Daniel W. 951
 Søgaard, Ole Schmeltz. 305, 314
 -T-
 Taban, Acaga 914
 Tabano, David C. 528
 Tabler, Caroline 169
 Tabone, Marie-Dominique 812
 Tabrizifard, Mohammad 337
 Tachedjian, Gilda 316
 Tada, Takuya 333
 Tadesse, Mulualem 713
 Taegtmeier, Miriam 896
 Taejaroenkul, Sineenart 820
 Taguchi, Ayumu 661
 Tai, Vincent 123
 Taiwo, Babafemi 342, 369, 665, 666
 Takahama, Soichiro 643
 Takamatsu, Yuki 503
 Takata, Hiroshi 270
 Takata, Matthew 160LB
 Taliani, Gloria 564, 575
 Tallon, Benjamin 274

- Tam, Edward 568LB
 Tambussi, Giuseppe 441, 472, 888
 Tamhane, Ashutosh 455
 Tan, Darrell H.S. 447
 Tanenbaum, Aaron 401
 Tang, Bin 386
 Tang, David 179
 Tang, Jennifer H. 946
 Tang, Jun 123
 Tang, Tian 31
 Tang, W.H Wilson 618
 Tangpricha, Vin 617, 822
 Tanon, Aristophane 607
 Tanser, Frank 960, 983, 1018
 Tantalo, Lauren 749, 750
 Tanuma, Junko 463
 Tao, Guoyu 980
 Tapia, Ken 796
 Tapia-Trejo, Daniela 480
 Tassiopoulos, Katherine 665, 666, 805
 Tate, Janet 127, 626, 667
 Tau, Modiri 988
 Tawakol, Ahmed 126
 Tawanana, Ephraim 745
 Tawil, Sebastian 470
 Tayea, Alia 464
 Taylor, Ninon 631
 Tchetgen Tchetgen, Eric 885
 Tchounga, Boris 607
 Tchouwa, Gaëlle F. 482, 486
 Team, Research 535
 Teasdale, Chloe A. 1023
 Tebas, Pablo 326, 468, 677, 975
 Technau, Karl 27
 Tedaldi, Ellen 32, 663
 Tedbury, Philip R. 156, 158
 Teeratakulpisarn, Nipat 863
 Tegha, Gerald 946
 Teigler, Jeffrey E. 282
 Tejerina, Francisco 530
 Telesnitsky, Alice 92
 Telisinghe, L. 711
 Téllez, Francisco 532, 536, 538, 555, 570, 571, 697
 Téllez, María J. 533
 Tembo, Tchangani 935
 Tempelman, Hugo 113, 656
 Tempestilli, Massimo 366
 Templeton, David J. 670
 Tenforde, Mark W. 740, 745
 Tenthani, Lyson 782
 Teppler, Hedy 757
 Terrell, Coleman 479, 911
 Terris-Prestholt, Fern 895
 Terzian, Arpi 905
 Tesfay, Abraham 1007, 1019
 Teunissen, Charlotte E. 825, 830
 Thaisri, Hansa 793
 Thalme, Anders 431
 Thami, Prisca 774
 Thammajaruk, Narukjaporn 807
 Tharp, Gregory K. 252
 Theron, Gerhard 777
 Theron, Grant 715LB
 Theu, Joe 1008
 Thiébaud, Rodolphe 290, 630, 801, 1018
 Thienemann, Friedrich 81LB
 Thienkrua, Warunee 854
 Thigpen, Michael 855, 862
 Thio, Chloe 701
 Thiong'o, Alexander N. 856
 Thirumurthy, Harsha 33, 894
 Thobakgale, Christina F. 272
 Thomas, Allison S. 122
 Thomas, Annalisa 961
 Thomas, David 516, 558, 559, 560
 Thomas, H Lucy. 736
 Thomas, Réjean 42
 Thomas-Seaton, Lateshia 839
 Thompson, Melanie 453
 Thomsen, Nathan D 329
 Thomson, Emma 529
 Thongpaen, Suchart 863
 Thorne, Claire 102, 778, 831
 Thorne, Jennifer E. 130
 Thrift, Aaron Peter 539
 Thwaites, Guy 83, 747, 748
 Tibengana, Samuel 462
 Tichelaar, Vladimir 620
 Ticona, Eduardo 224
 Tie, Yunfeng 907
 Tiemessen, Caroline 27
 Tien, Phyllis 132, 341, 361, 526, 629, 690, 913, 930
 Tierney, Camlin 584LB
 Tieu, Hong Van 897
 Tilton, John 154, 169
 Timberlake, Nina 334
 Timmons, Andrew 315, 318
 Tincati, Camilla 215, 239, 579, 680
 Ting, Charity 563
 Tinsley, Joe 873
 Tipsuk, Somporn 205, 394
 Tiraboschi, Juan 324
 Tirschwell, David 347
 Titanji, Kehmia 684, 943
 Tladi, Molefi 707
 Tobaiwa, Ocean 26
 Tobia, Michael V. 398
 Tobian, Aaron 87, 317, 515, 689, 1015
 Tobias, James 847
 Todd, Jim 1006
 Todesco, Eve 520
 Toledo, Carlos 958
 Tolley, Betsy 421LB
 Tollman, Stephen 639, 916
 Tolstrup, Martin 305
 Tomasi, Alessandra 253
 Tomasini, Sarah 738
 Tomishima, Kosuke 426
 Tomo, Maria 110
 Tongtoyai, Jaray 855
 Torbett, Bruce E. 334
 Torgersen, Jessie 702
 Torian, Lucia VanOgle. 903
 Toribio, Mabel 635LB
 Torjesen, Kristine 1025
 Tornack, Julia 716LB
 Torres, Thiago Silva. 457, 710
 Tort, Olivia 614
 Tosiano, Melissa 303, 795
 Tostevin, Anna 186
 Tournier, Isabelle 192
 Touzeau-Römer, Veronique 473
 Tovanabutra, Sodjai 197, 299LB, 71
 Towe, Vivian L. 1013
 Townsend, Claire 778
 Trabattoni, Daria 222, 804
 Trachunthong, Deondara 863
 Tracy, Russell 673
 Tramont, Edmund C. 668
 Traore, Hamar Alassane. 607

Trastoy, Rocio 578
 Trautmann, Lydie 125, 249, 270
 Traverso, Carlo Giovanni. 1035
 Trebicka, Jonel 704
 Treluyer, Jean-Marc 811
 Tremblay, Cécile 204
 Trenchs-Rodríguez, Marta 681
 Trentalange, Alice 360
 Treutiger, Carl Johan 431
 Trevillyan, Janine M. 687
 Triant, Virginia 640
 Trichaviroj, Rapee 249
 Trinh, Roger 413
 Tripathy, Srikanth 492
 Triplette, Matthew 658
 Trivino Duran, Laura 718, 791
 Trkola, Alexandra 66, 67
 Troyer, Zach 169
 Truesdale, Aimee 528
 Trunfio, Mattia 360, 379
 Trypsteen, Wim 162
 Tsai, Angela 118
 Tsai, Hung-Chin 450LB
 Tse, Winston C. 38
 Tshetu, Anto 522
 Tshimanga, Mufuta 984
 Tsholo, Katlego 82, 745
 Tsiang, Manuel 497
 Tsibris, Athe 342
 Tsoi, Benjamin 898
 Tubiana, Roland 75, 448, 775
 Tucker, Emily 1029
 Tumbo, John 111, 958
 Tumino, Nicola 203
 Tumwine, James 781
 Tung, Elyse 961
 Tung, Nguyen Le Nhu 83, 747, 748
 Turan, Janet M. 690, 762, 921
 Turk, Teja 191
 Turkki, Vesa 171LB
 Turkova, Anna 813
 Turner, Diana 677
 Turner, Megan M. 644, 912
 Tweya, Hannock 602
 Tyler, Shaun 179
 Tylleskär, Thorkild 781, 847

–U–

Uberti-Foppa, Caterina 531
 Ubolyam, Sasiwimol 698
 Uehira, Tomoko 426
 Ukaegbu, Chinyere 543, 545
 Ulrich, Angela K. 446
 Unal, Guillemette 192
 Underwood, Jonathan 352LB
 Unger, Elizabeth 597
 Ungos Pasayan, Mark Kristoffer 705
 Ungsedhapand, Chaiwat 855, 862
 Unsal, Aylin 649
 Unutmaz, Derya 800
 Urano, Emiko 507
 Urrea, Victor 228
 Ussery, Gene 1017
 Utay, Netanya Sandler. 251, 696

–V–

Vaartjes, Ilonca 129
 Vai, Daniela 360
 Vaida, Florin 386, 401
 Vaikath, Maria 994
 Valantin, Marc-Antoine 135, 520, 550, 703, 732

Valcours, Victor 70, 71, 205, 339, 341, 344, 350, 355, 363, 387, 394
 Valdez, Rogelio Miguel. 446
 Valdez Madruga, Jose 447, 948
 Valentine, Megan 760
 Valin, Nadia 75
 Vallabhaneni, Snigdha 743
 Van, Phu 265LB
 Van Bortel, Luc 412
 Van Crevel, Reinout 429, 610
 Van Cutsem, Gilles 791, 927
 Van de Perre, Philippe 781
 Van de Vijver, David 604
 Van den Berk, Guido 137LB, 470
 Van der Elst, Elisabeth Maria. 893, 1022
 Van der Ende, Ineke 604, 731, 754
 Van der Heijden, Wouter Anton. 610
 Van Der Pol, Barbara 867
 Van der Straten, Ariane 420, 936
 Van der Valk, Marc 129, 136
 Van der Ven, André 610
 Van Duyne, Gregory 171LB
 Van Duyne, Rachel 156, 180
 Van Dyke, Russell B. 815, 827, 828
 Van Gorp, Eric 451LB
 Van Hecke, Clarissa 162
 Van Kampen, Jeroen Jacob Alexander. 604
 Van Lancker, Greit 412
 Van Loan, Marta 685LB
 Van Niekerk, Christo 80LB
 Van Ommen, Clara E. 939
 Van Oosterhout, Joep J. 782
 Van Rensburg, Craig 941
 Van Rompay, Koen 373
 Van Schaik, Nienke 958
 Van Sighem, Ard 1041
 Van Vuuren, Cloete 261
 Van Wilgenburg, Bonnie 239
 Van Zoest, Rosan 129, 352LB
 Van Zyl, Gert U. 28, 120, 795
 VanBelzen, Jake 300
 Vance, David 350
 Vandekerckhove, Lino 162, 302
 Vandenbulcke, Alexandra 116, 764, 792
 Vandergeeten, Claire 291
 Vandermeulen, Kati 44LB
 Vandesompele, Jo 162
 Vangala, Sitram 593
 Vannappagari, Vani 664
 VanWidenfelt, Erik 885
 Varangrat, Anchalee 854
 Vardhanabhuti, Saran 492
 Varetska, Olga 884
 Vargas, Milenka 206
 Varghese, Vici 506
 Varkila, Meri 656
 Vasan, Sandhya 70
 Vasconcelos, Ricardo de Paula. 948
 Vashishtha, Devesh 870
 Vassallo, Matteo 72
 Vasudevan, Canjeevaram K. 883
 Vavrek, Marissa 435
 Vavro, Cindy 806
 Vaz, Paula 730, 766, 818
 Veenhuis, Rebecca 253
 Vehreschild, Joerg Janne 183, 580
 Veldsman, Kirsten Abigail. 28
 Velloza, Jennifer 920
 Veloso, Valdilea 719, 948
 Veloso Meirelles, Mariana 1040
 Velthuisen, Emile 171LB

- Venter, Willem Daniel. 113, 1020
 Vera, Jesus 844
 Vera-Rojas, Jaime 432
 Verbesey, Jennifer 634
 Verbitskaya, Elena 868LB
 Verbon, Annelies 587
 Verdú, Javier 659
 Vergas, Jorge 572
 Vergori, Alessandra 354
 Vermeire, Jolien 19
 Vermund, Sten 816
 Vernon, Ian 1048
 Vesga, Juan Fernando. 1040, 1047
 Vesterbacka, Jan 212
 Vezain, Myriam 192
 Viani, Rolando M. 413
 Viard, Jean-Paul 821
 Vibholm, Line Khalidan. 314
 Vichi, Francesca 542LB
 Vidal, Francesc 647
 Vieira, Vinícius Adriano. 948
 Vigón, Lorena 530
 Vigouroux, Corinne 821
 Vilaplana, Cristina 306
 Vilchez, Helem Haydee 535, 659
 Villacres, Maria 350
 Villar, Judit 676, 681
 Villaseñor, Armando G. 38
 Vinikoor, Michael J. 581
 Violari, Avy 758, 826
 Virlogeu, Victor 135
 Vishwasrao, Harshad D. 308
 Visseaux, Benoît 194, 195
 Viswanathan, Prabha 372
 Vitomirov, Andrej 367
 Vitoria, Marco 112
 Vlad, Dragos 204
 Voetsch, Andrew 114LB
 Vogelzang, Alexis 716LB
 Voigt, Robin M. 240, 241
 Vojnov, Lara 26
 Vollbrecht, Thomas 310
 Volpe, Joseph M. 1054
 Volpicelli, Lorenzo 575
 Von Groote-Bidlingmaier, Florian 79
 Von Wichmann, Miguel A. 533
 Vongrad, Valentina 263, 327
 Voronin, Dennis 220
 Vos, Alinda 656
 Vostokova, Natalia 452LB
 Votteler, Joerg 21
 Vourvahis, Manoli 417
 Vranken, Peter 1007
 Vries, Henry JC de. 519, 887
 Vu, Amanda 40
 Vu, Dat Quoc. 741
 Vubil, Adolfo 26
 Vujkovic, Marijana 384
 Vunnava, Aswani 629, 684
- W–
 Wade, Alisha 639
 Wadia, Roxanne 606
 Wafula, Rose 761
 Wagner, Gabriel A. 200, 201
 Wagner, Ryan 639, 916, 991
 Wagner, Theresa 419
 Wagner, Thor 335
 Wahome, Elizabeth 856, 1022
 Wainberg, Mark 495
 Wainberg, Mark A. 42, 489, 498
 Waldrop-Valverde, Drenna 350
 Walensky, Rochelle P. 456, 493, 814, 833, 1028, 1043
 Walker, Bruce D. 250, 266
 Walker, Rowan G. 687
 Walker, Sarah 117, 641, 801, 808
 Wallenta, Jeanna 638, 1005
 Wallis, Carole 492
 Walmsley, Sharon 447, 553, 756
 Walsh, Fiona 475
 Walston, Jeremy D. 133
 Walter, Kizito 523
 Wamalwa, Dalton 796
 Wamicwe, Joyce 847
 Wamuti, Beatrice 1032
 Wandeler, Gilles 581
 Wang, Bingjie 242
 Wang, Chang-Yi 450LB
 Wang, Cheng 634
 Wang, Chi-Chao 594
 Wang, Chunhui 1023
 Wang, Cuiwei 23, 634, 646, 933
 Wang, Dan 634
 Wang, Dong 199
 Wang, Huanling 399
 Wang, Hui 40
 Wang, Huisheng 1009
 Wang, James 569
 Wang, Jiajia 755, 757, 758, 938
 Wang, Jianhong 434
 Wang, Jing 238
 Wang, Jing 879
 Wang, Li Yan 833, 1033
 Wang, Linbo 885
 Wang, Lu 940
 Wang, Ning-Chi 438
 Wang, Ruibin 624, 701, 931
 Wang, Wei 302
 Wang, Weimin 588
 Wang, Xinzhong 432
 Wang, Xun 865
 Wang, Yanping 328
 Wang, Ying 923, 924
 Wang, Yujin 433
 Wang, Zheng 295
 Wanjala, Stephen 116, 764, 792
 Wansom, Tanyaporn 560
 Wanyonyi, Kennedy 970
 Ward, Adam 122
 Ward, Andrew B. 144
 Ward, Douglas 41, 663, 864
 Ward, John W. 98
 Ware, Norma C. 1003
 Warren, Rob 715LB
 Warszawski, Josiane 775, 821
 Waruru, Anthony 847
 Washington, Ida 420
 Wasmuth, Jan-Christian 580, 704
 Watanabe, Dai 426
 Watanabe, Richard M. 255, 692
 Waterman, Stephen 1055LB
 Watkins, Melynda 39
 Watling, Michael 490
 Wawer, Maria 1015, 34LB, 359, 880, 996
 Weber, Kathleen M. 361
 Weber, Rainer 128LB, 263
 Webster, Kath 924, 940
 Webster-Cyriaque, Jennifer 213
 Wechsberg, Wendee 853
 Weeks, Kevin M. 164
 Weeraratne, Achini 687

- Wegner, Matthew 70
Wehmeyer, Malte 576
Wei, Xuelian 40, 41
Weinberg, Adriana 774, 803
Weinheimer, Steven 438, 449LB
Weinrib, Rachel 936
Weiser, John 737
Weiser, Sheri 690, 913
Weiss, Helen 841LB
Weiss, Jeffrey 544
Weiss, Kevin 1034
Weiss, Stephen 770
Weisser, Maja 744
Weissman, Drew 1057LB
Weitzmann, M Neale. 684
Wejnert, Cyprian 902
Weke, Elly 762
Wells, David 298
Wells, Quinn S. 621
Welte, Alex 511, 876
Wensing, Annemarie 113, 306, 320, 504LB
Wentz, Eryka 690, 913
Werb, Dan 870
Were, Kennedy 488
Wertheim, Joel O. 182, 188, 1026
Wesevich, Austin 783
Wesolowski, Laura 509
Wesson, Jennifer 914
Westheimer, Emily 189, 477
Whitcomb, Jeannette 140
White, Douglas A. E. 956
White, Elizabeth 506
White, Kirsten Lofgren. 41, 436, 497
White, Richard G. 1048
Whiteside, Y. Omar. 188
Whitman, Timothy 932
Whitney, Bridget 853
Whitney, James 179, 338LB
Wiche Salinas, Tomas Raul 204
Widhani, Alvina 705
Wiegand, Ann 120, 294
Wiener, Jeff 946
Wiesner, Lubbe 758, 808
Wiewel, Ellen 1013
Wijting, Ingeborg 451LB, 731
Wilcox, Christopher 634
Wild, Carl 507
Wilder, Julius M. 552
Wiley, Dorothy Joann. 591, 592, 593
Wilkin, Timothy 981
Wilkinson, Eduan 504LB
Wilkinson, Robert 739, 81LB
Wilks, Moses Q. 635LB
Willen, Jessie 220
William, Jillian 549
Williams, Corey 224
Williams, Deborah 650
Williams, Emily C. 921
Williams, Gary J. 903
Williams, James A. 242
Williams, Katherine L. 242
Williams, Kenneth C. 635LB, 69
Williams, Paige L. 779, 784, 827, 828
Williams, Peter E. 442
Wilson, Cara 211, 231
Wilson, Carole L. 660
Wilson, David 1046
Wilson, David 1046
Wilson, Eleanor 733
Wilson, Kate 937
Wilson, Tracey 646, 690, 913, 933
Wimonsate, Wipas 854, 855, 862
Winaitham, Santi 862
Winckelmann, Anni 305
Wing, Edward J. 694
Wing, Rena R. 694
Winston, Alan 352LB
Winston, Jennifer 919
Winter, Joanne R. 736
Winter, Matthew 167
Wirth, Kathleen 184, 885
Wirunsawanya, Kamonkiat 692
Wiseman, Sam 599
Wit, Ferdinand 129, 467, 620, 672, 731, 825, 830
Witkowska, H. Ewa 170
Witt, Mallory 624, 645, 701
Wiznia, Andrew 806
Wohl, David 453
Wohlfeiler, Michael 664
Wolbers, Marcel 83
Wolf, Eva 42
Wolf, Timo 738
Wolstenholme, Allen 428
Womack, Julie A. 667, 930
Won, Seung Hyun 668, 932
Wong, Alexander 553
Wong, Audrey J. 508
Wong, Cebele 475
Wong, Cherise 662
Wong, Chun-Shu 221, 226
Wong, Eric Y. 505
Wong, Jason 735
Wong, Joseph K. 312, 797
Wong, Michelle 657
Wong, Pamela 425
Wong, Sophy S. 556
Wong, Wingwai 450LB, 705
Wongtrakool, Cherry 658, 660
Woo, Patrick C.Y. 747
Wood, Evan 875
Wood, Linda S. 417
Wood, Matthew 260LB
Wood, Robin 727
Woody, George 868LB
Woolley, Ian 687
Woolnough, Emily 687
Wools-Kaloustian, Kara Kay. 815, 837
Worlock, Andrew 284
Wrammert, Jens 1056LB
Wray, Tyler B. 892
Wright, Mary E. 227
Wu, Kunling 343
Wu, Ning 302
Wu, Vincent 440
Wu, Xiaolin 298
Wu, Xiaotian 908
Wu, Xingye 728
Wutoh, Anthony 1007
Wyatt, Monique A. 1003
Wyles, David L. 134
Wynn, Brian 44LB

-X-

- Xia, Qiang 903
Xu, Ai 699
Xu, Jianqing 199
Xu, Meng 621
Xu, Weihai 399
Xu, Xia 45LB
Xu, Xiao-Ning 248
Xuan Chua, Corrine 422LB

Xue, Guangai 18

-Y-

Yagura, Hiroki 426
 Yamamoto, Masahiro 643
 Yamamoto, Takuya 165
 Yamashita, Masahiro 160LB
 Yamazaki, Kunio 426
 Yan, Peng 574
 Yang, Hongbing 271
 Yang, Huanle 133
 Yang, Jingyan 132
 Yang, Otto 268
 Yang, Xiaohu 353
 Yang, Z npanah, Yazdan 116, 458, 1028
 Ye, Monica 599, 601
 Yebra, Gonzalo 193
 Yee, Kelly 412, 430
 Yee, Lynn M. 469
 Yen, Yung-Feng 348
 Yende, Nonhlanhla 949
 Yi, Jungen 558
 Yi, Sue 21
 Yiannoutsos, Constantin 837
 Yilmaz, Aylin 340, 389
 Yin, Michael T. 132, 213, 346, 361, 546, 682, 683, 819, 930
 Ying, Roger 1032
 Yokomaku, Yoshiyuki 496
 Yonaba, Caroline 811
 Yonga, Gerald 151
 Yoshimura, Kazuhisa 247
 Yoshino, Munehiro 426
 Yotebieng, Marcel 714
 Younas, Mehwish 605
 Younes, Naji 905
 Young, Alicia 981
 Young, Benjamin 678
 Young, Heather 909
 Young, Mary 634
 Young, Stephen 592, 593
 Yu, Chunli 780
 Yu, Helen 329, 434, 436
 Yu, Hyun Jae 18
 Yu, Kimberly 544
 Yu, Xu G. 250, 292
 Yuan, Chun-Su 669
 Yuan, Zhe 199
 Yudin, Mark 756, 940
 Yue, Feng Yun 233
 Yuen, Kwok-Yung 747
 Yuengling, Katharine 706
 Yuhas, Krista 937
 Yukl, Steven A. 312

-Z-

Zaccarelli, Mauro 354, 460
 Zack, Jerome 332
 Zadzilka, Amanda 803
 Zahralban-Steele, Melissa 184, 484
 Zakharova, Oksana 465, 483
 Zang, Trinity 160LB, 220
 Zang, Xiao 875
 Zangari, Paola 798
 Zangerle, Robert 631
 Zanni, Markella V. 627, 635LB
 Zannoni, Brian C. 838
 Zash, Rebecca 25
 Zeana, Cosmina 682
 Zedler, Ulrike 716LB
 Zeh, Clement 488
 Zellman, Hannah 911

Zerbato, Jennifer M. 298, 316
 Zerbe, Allison 24, 769, 771, 992
 Zetola, Nicola M. 729
 Zetterberg, Henrik 72, 73, 340, 383, 389
 Zevin, Alexander Simon. 216, 231
 Zevo, Leonel 730
 Zeymo, Alexander 517
 Zhang, Chengchen 682
 Zhang, Heather 40, 424, 425
 Zhang, Hongliang 233
 Zhang, Jennifer R. 38
 Zhang, Lily 415
 Zhang, Long 356, 645
 Zhang, Meiwen 927
 Zhang, Peng 14LB
 Zhang, Tianchi 187
 Zhang, Wendy 929
 Zhang, Xiaodong 1056LB
 Zhang, Xin Yu 274
 Zhang, Xinyi C. 1002
 Zhang, Xue 329
 Zhang, Yinfeng 955
 Zhang, Yuwei 204
 Zhang, Zhenhuan 1052
 Zhang, Zhiping 428
 Zhao, Mitchell 367
 Zhen, Anjie 254, 331, 332, 333
 Zheng, Amy 456
 Zheng, Jia-Hua 405
 Zheng, Jianhua 269
 Zheng, Jiayin 552
 Zheng, Jim 38
 Zheng, Lu 330LB, 457
 Zheng, Wenjing 36, 836
 Zheng, Yanyan 337
 Zhong, Yaoyu 1013
 Zhou, Qinlian 1049LB
 Zhou, Shuntai 198, 369
 Zhou, Tian 439
 Zhou, Zhi 874
 Zhu, Julia 462
 Zhu, Yuan-Shan 471
 Zidar, David A. 628, 674
 Zielinski-Gutierrez, Emily 847
 Zimmerman, Scott J. 198
 Zingman, Barry S. 682, 903
 Zins, Marie 654
 Zinyakatira, Nesbert 727
 Zlotorzynska, Maria 869, 901
 Zohoun-Guidigbi, Lutecia 487
 Zola, Courtney 621
 Zona, Stefano 655
 Zozulya, Olga 452LB
 Zubyk, Wendy 447
 Zuccotti, GianVincenzo 804
 Zucker, Jason 546
 Zunt, Joseph 347
 Zuppa, Athena 384, 975
 Zurawski, Gerard 262
 Zurawski, Sandy 262
 Zürcher, Kathrin 714
 Zurnic, Irena 155
 Zvartau, Edwina 868LB
 Zwahlen, Marcel 721
 Østergaard, Lars 305, 314

NOTES

[illegible]

Conference Schedule Overview

	Monday, February 13, 2017	Tuesday, February 14, 2017	Wednesday, February 15, 2017	Thursday, February 16, 2017
8:30 AM		Plenary Session Auditorium 4 AB 8:30 AM THE EMERGING POTENTIAL FOR HIV CURE FOR INFANTS CHILDREN, AND ADULTS 9:00 AM ADVANCES IN CELLULAR THERAPY IN CANCER AND HIV	Plenary Session Auditorium 4 AB 8:30 AM (PREVENTING) THE COMING EPIDEMIC: HIV IN YOUTH 9:00 AM ANTIVIRAL VACCINE DEVELOPMENT FROM A (AIDS) TO Z (ZIKA)	Plenary Session Auditorium 4 AB 8:30 AM IF YOU CAN MAKE IT THERE: ENDING THE HIV EPIDEMIC IN NEW YORK 9:00 AM HTLV-1: THE OTHER HUMAN RETROVIRUS
9:00 AM	PROGRAM COMMITTEE WORKSHOP FOR NEW INVESTIGATORS AND TRAINEES <i>Room 6 AB</i>			
9:30 AM				
10:00 AM		CONCURRENT ORAL ABSTRACT SESSIONS 0-1 GETTING HIV THROUGH THE CELL <i>Room 611-614</i> 0-2 CRITICAL ISSUES IN WOMEN'S HEALTH, MTCT, AND HIV TREATMENT IN CHILDREN <i>Room 606-609</i> 0-3 HIDING IN PLAIN SIGHT: DISCOVERING THE UNDIAGNOSED AND UNDERTREATED HIV EPIDEMIC <i>Room 6 E</i> 0-4 NEW HIV DRUGS, FORMULATIONS, COMBINATIONS, AND RESISTANCE <i>Room 6 AB</i>	CONCURRENT ORAL ABSTRACT SESSIONS 0-5 ROLE OF HOST AND IMMUNE FACTORS IN HIV INFECTION <i>Room 611-614</i> 0-6 CNS RESERVOIRS, NEUROPATHOGENESIS, AND HOST FACTORS <i>Room 606-609</i> 0-7 TB AND OTHER OPPORTUNISTIC INFECTIONS <i>Room 6 C</i> 0-8 COMMON BEDFELLOWS: PREP, STIs, AND THE MICROBIOME <i>Room 6 AB</i>	CONCURRENT ORAL ABSTRACT SESSIONS 0-9 HEPATITIS C: PROBLEMS AND PROGRESS <i>Room 606-609</i> 0-10 IMPROVING THE HIV CARE CASCADE <i>Room 6 C</i> 0-11 HIV PERSISTENCE AND REACTIVATION <i>Room 6 E</i> 0-12 INFLAMMATION AND AGE-RELATED COMPLICATIONS <i>Room 6 AB</i>
12:00 PM	LUNCH AND MARTIN DELANEY PRESENTATION FROM LAB TO LICENSURE: THE IMPORTANCE OF GOOD PARTICIPATORY PRACTICE IN RESEARCH <i>Room 6 AB</i>	LUNCH 12:00 PM - 1:30 PM	LUNCH 12:00 PM - 1:30 PM	LUNCH 12:00 PM - 1:30 PM
1:30 PM		CONCURRENT THEMED DISCUSSIONS TD-1 CD8 T CELLS: WHERE AND HOW THEY KILL <i>Room 615-617</i> TD-2 VIRUS AND CELL RNA IN HIV REPLICATION <i>Room 611-614</i> TD-3 HIV, MIGRATION, AND ACCESS TO CARE <i>Room 606-609</i> TD-4 OBESITY AND FATTY LIVER DISEASE <i>Room 6 C</i> TD-5 PREP WITHOUT BORDERS: NEW DELIVERY OPTIONS <i>Room 6 E</i>	CONCURRENT THEMED DISCUSSIONS TD-6 INTRACELLULAR AND TISSUE PHARMACOLOGY <i>Room 615-617</i> TD-7 CNS TREATMENT STRATEGIES: RISK AND BENEFITS <i>Room 611-614</i> TD-8 SCREENING FOR HSIL: ALTERNATIVES TO CYTOLOGY <i>Room 606-609</i> TD-9 HIV SELF-TESTING: KNOW YOURSELF <i>Room 6 C</i> TD-10 HIV PERSISTENCE: CLONES, CLONES, AND MORE CLONES <i>Room 6 AB</i> TD-11 INTEGRATION OF SCREENING AND TREATMENT OF NCD INTO HIV CARE IN RESOURCE LIMITED SETTINGS <i>Room 6 E</i>	CONCURRENT THEMED DISCUSSIONS TD-12 THE IMPOSSIBLE DREAM: POPULATION PERSPECTIVES ON 90:90:90 IN ADOLESCENTS AND YOUNG ADULTS <i>Room 615-617</i> TD-13 HOT FLASHES: HORMONAL CONTRACEPTION AND HIV RISK <i>Room 611-614</i> TD-14 HIV AND SUBSTANCE ABUSE: DOUBLE TROUBLE <i>Room 606-609</i> TD-15 I WANT A NEW DRUG <i>Room 6 C</i> TD-16 HOW DOES THE MICROBIOME AFFECT HIV INFECTION? <i>Room 6 E</i> TD-17 EMERGING VIRUSES: THE ZIKA VIRUS <i>Room 6 AB</i>
2:00 PM	CONCURRENT WORKSHOPS 2:15 PM TO 4:00 PM CLINICAL TRIAL DESIGN AND ANALYSIS <i>Room 6 C</i> FRONTIERS IN LABORATORY SCIENCE <i>Room 611-614</i>			
2:30 PM	INTERACTIVE CASE-BASED WORKSHOP ON HEPATITIS C <i>Room 6 E</i>	POSTER SESSIONS 2:30 PM TO 4:00 PM <i>POSTER HALL 4 EF</i>	POSTER SESSIONS 2:30 PM TO 4:00 PM <i>POSTER HALL 4 EF</i>	POSTER SESSIONS 2:30 PM TO 4:00 PM <i>POSTER HALL 4 EF</i>
4:00 PM		CONCURRENT SYMPOSIA S-1 VISIONS OF HIV CURE <i>Room 6 E</i> S-2 MULTIDRUG-RESISTANT TB (MDR-TB): THE GOOD THE BAD, AND THE UGLY <i>Room 606-609</i> S-3 STRANGERS IN THE NIGHT: CHALLENGES AND OPPORTUNITIES IN STI CONTROL <i>Room 6 C</i>	CONCURRENT SYMPOSIA S-4 CREATING AND DESTROYING HIV CAPSIDS <i>Room 611-614</i> S-5 HEPATITIS/LIVER <i>Room 6 E</i> S-6 THE FIRST AGE: INFANTS ON THE WORLD STAGE <i>Room 606-609</i> S-7 GETTING TO THE THIRD 90 <i>Room 6 C</i>	CONCURRENT SYMPOSIA S-8 PATHS INTERTWINED: BROADLY NEUTRALIZING ANTIBODIES AND THE HIV-1 ENVELOPE TRIMER <i>Room 606-609</i> S-9 MODERN ART <i>Room 6 E</i> S-10 LEVERAGING THE PLATFORM: RESPONDING TO NONCOMMUNICABLE DISEASES <i>Room 6 C</i>
5:00 PM	OPENING SESSION Auditorium - 4 AB Bernard Fields Lecture N'Galy-Mann Lecture CROI Foundation Special Event			
7:00 PM	Welcome Reception 7:00 - 9:00 PM			




24th Conference on
Retroviruses and
Opportunistic Infections
February 13–16, 2017

4th Floor Meeting Rooms



6th Floor Meeting Rooms



KEY

4th FLOOR

Opening Session and Plenary Sessions.....**4AB**
Poster Hall.....**4EF**
Registration.....**4C**
Simultaneous Overflow.....**Atrium Lobby**
Cyber Cafe.....**4D**
New Mother's Room.....**416**

5th FLOOR

Personal Considerations Room.....**508**

6th FLOOR

Oral Abstract, Themed Discussion, and
Symposia Breakout Rooms.....**6AB, 6C, 6E**
606-609, 611-614
615-617
Speaker Ready Room.....**618-620**
IAS—USA Office.....**603**

WiFi Hotspot + First Aid Station
AED Device FE Fire Exit
MW Restrooms Food/Beverage